Back to HOME

Vitamin D

(total 699)
Download Data as Excel Download All Images
No Structure COMMON NAME NAME DATA No INFORMANT SYMBOL FORMULA MOL.WT(ave) Download BIOOGICAL ACTIVITY PHYSICAL AND CHEMICAL PROPERTIES SPECTRAL DATA CHROMATOGRAM DATA SOURCE CHEMICAL SYNTHESIS METABOLISM GENETIC INFORMATION NOTE REFERENCES
MELTING POINT BOILING POINT DENSITY REFRACTIVE INDEX OPTICAL ROTATION SOLUBILITY UV SPECTRA IR SPECTRA NMR SPECTRA MASS SPECTRA OTHER SPECTRA
1
1a-hydroxy-20-oxo-19,22,23,24,25,26,27-heptanorvitamin D3 / 1a-hydroxy-20-oxo-19,22,23,24,25,26,27-heptanorcholecalciferol
(7E)-(1R,3R)-1,3-dihydroxy-19-nor-9,10-seco-5,7-pregnadien-20-one
VVD0001
Sachiko Yamada
1a-OH-20-oxo-19,22,23,24,25,26,27-heptanor-D3
C20H30O3 318.450 Download ChemDraw structure file
Had no affinity for progesterone receptor in MCF-7. (Ref. 0304)
lmax (EtOH) (nm) 243, 251.5, 261 (Ref. 0304)
1H-NMR (d, CDCl3) 0.51 (3H, s, 18-CH3), 2.14 (3H, s, 21-CH3), 4.06 (1H, m, 3a-H), 4.13 (1H, m, 1b-H), 5.88 (1H, d, J = 11.3 Hz, 7-H), 6.29 (1H, d, J = 11.3 Hz, 6-H) (Ref. 0304)
m/z 318 (M+, 85), 300 (5), 282 (2), 275 (35) 239 (41), 133 (100), 95 (100) (Ref. 0304)



From corresponding C-22 aldehyde via oxidative decarbonylation. (Ref. 0304)



2
20-oxo-22,23,24,25,26,27-hexanorvitamin D3 / 20-oxo-22,23,24,25,26,27-hexanorcholecalciferol
(5Z,7E)-(3S)-3-dihydroxy-9,10-seco-5,7,10(19)-pregnatrien-20-one
VVD0002
Sachiko Yamada
20-oxo-22,23,24,25,26,27-hexanor-D3
C21H30O2 314.462 Download ChemDraw structure file
Had significant affinity for progesterone receptor in MCF-7. (Ref. 0304)
lmax (EtOH) (nm) 264, lmin (nm) 228 (Ref. 0304)
1H-NMR (d, CDCl3) 0.51 (3H, s, 18-CH3), 2.13 (3H, s, 21-CH3), 4.20 (1H, m, 3a-H), 4.45 (1H, m, 1b-H), 4.98 (1H, br s, 19E-H), 5.33 (1H, br s, 19Z-H), 6.04 (1H, d, J = 11.3 Hz, 7-H), 6.36 (1H, d, J = 11.3 Hz, 6-H) (Ref. 0304)
m/z 330 (M+, 31), 312 (21), 183 (95), 134 (100) (Ref. 0304)



From corresponding C-22 aldehyde via oxidative decarbonylation. (Ref. 0304)



3
1a-hydroxy-20-oxo-22,23,24,25,26,27-hexanorvitamin D3 / 1a-hydroxy-20-oxo-22,23,24,25,26,27-hexanorcholecalciferol
(5Z,7E)-(1S,3R)-1,3-dihydroxy-9,10-seco-5,7,10(19)-pregnatrien-20-one
VVD0003
Sachiko Yamada
1a-OH-20-oxo-22,23,24,25,26,27-hexanor-D3
C21H30O3 330.461 Download ChemDraw structure file
Had no affinity for progesterone receptor in MCF-7. (Ref. 0304)
Effects of the compound given at the doses of 0.2 or 1.0mg/kg on the primary immune response in BALB/C mice immunized with 1 times 107 sheep red blood cells were shown in comparison with 1a-hydroxyvitamin D3 (0.2mg/kg). The binding affinity with chick intestinal cytosolic receptor was 1/10,000 compared to 1a,25-(OH)2D3. no calcemic activity of the compound (125mg/kg, times 5, i.v.) was observed. (Ref. 0211)
[a]d-23 9.20 deg (c = 1.00 in EtOH) (Ref. 0211)
lmax (EtOH) (nm) 264, lmin (nm) 228 (Ref. 0304)
1H-NMR (d, CDCl3) 0.51 (3H, s, 18-CH3), 2.13 (3H, s, 21-CH3), 3.95 (1H, m, 3a-H), 4.81 (1H, br s, 19E-H), 5.06 (1H, br s, 19Z-H), 6.06 (1H, d, J = 11.2 Hz, 7-H), 6.22 (1H, d, J = 11.2 Hz, 6-H) (Ref. 0304)
1H-NMR (d, CDCl3) 0.51 (3H, s), 2.13 (3H, s), 2.23-2.37 (1H, m), 2.52-2.73 (3H, m), 2.84 (1H, br d, J = 12.8 Hz), 3.26 (2H, br s), 4.15-4.28 (1H, br), 4.36-4.47 (1H, br), 4.99 (1H, t, J = 1.4 Hz), 5.33 (1H, t, J = 1.4 Hz), 6.04 (1H, d, J = 11.4 Hz), 6.36 (1H, d, J = 11.4 Hz) (Ref. 0211)
m/z 314 (M+, 23), 296 (2.4), 281 (15), 271 (1.5) 253 (4.6), 136 (33), 118 (73), 43 (100) (Ref. 0304)
HRMS Calcd 330.2195, Found 330.2176 (Ref. 0211)


From corresponding C-22 aldehyde via oxidative decarbonylation. (Ref. 0304)
Synthesis from dehydroepiandrostertone via 5,7-diene compound by photochemical method. (Ref. 0211)



4
1a,21-dihydroxy-20-oxo-22,23,24,25,26,27-hexanorvitamin D3 / 1a,21-dihydroxy-20-oxo-22,23,24,25,26,27-hexanorcholecalciferol
(5Z,7E)-(1S,3R)-1,3,21-trihydroxy-9,10-seco-5,7,10(19)-pregnatrien-20-one
VVD0005
Sachiko Yamada
1a,21-(OH)2-20-oxo-22,23,24,25,26,27-hexanor-D3
C21H30O4 346.460 Download ChemDraw structure file
The binding affinity for chick intestinal cytosolic receptor was less than 1/100,000 compared to 1a,25-(OH)2D3. (Ref. 0211)
[a]d-23 2.81 deg (c = 0.07 in EtOH) (Ref. 0211)
lmax (EtOH) (nm) 262 (Ref. 0211)
1H-NMR (d, CDCl3) 0.53 (3H, s), 2.52-2.68 (2H, m), 2.87 (1H, d, J = 12.0 Hz), 3.26 (2H, br s), 4.12-4.34 (3H, m), 4.38-4.49 (1H, m), 4.98 (1H, t, J = 1.7 Hz), 5.33 (1H, t, J = 1.7 Hz), 6.05 (1H, d, J = 10.8 Hz), 6.34 (1H, d, J = 10.8 Hz) (Ref. 0211)
m/z 346 (M+), 134 (100%) (Ref. 0211)
HRMS Calcd 346.2144, Found 346.2146 (Ref. 0211)


Synthesis from dehydroepiandrostertone via 5,7-diene compound by photochemical method. (Ref. 0211)



5
1a,17a,21-trihydroxy-20-oxo-22,23,24,25,26,27-hexanorvitamin D3 / 1a,17a,21-trihydroxy-20-oxo-22,23,24,25,26,27-hexanorcholecalciferol
(5Z,7E)-(1S,3R,17R)-1,3,17,21-tetrahydroxy-9,10-seco-5,7,10(19)-pregnatrien-20-one
VVD0006
Sachiko Yamada
1a,17a,21-(OH)3-20-oxo-22,23,24,25,26,27-hexanor-D3
C21H30O5 362.460 Download ChemDraw structure file
The binding affinity for chick intestinal cytosolic receptor was less than 1/100,000 compared to 1a,25-(OH)2D3. (Ref. 0211)
lmax (EtOH) (nm) 264 (Ref. 0211)
1H-NMR (d, CDCl3) 0.58 (3H, s), 2.35 (1H, dd, J = 12.5 and 6.3 Hz), 2.55-2.96 (4H, m), 3.10 (1H, t, J = 4.9 Hz), 4.21-4.31 (1H, m), 4.35 (1H, dd, J = 20.0 and 4.9 Hz), 4.38-4.51 (1H, m), 4.66 (1H, t, J = 20.0 and 4.9 Hz), 5.01 (1H, t, J = 1.5 Hz), 5.35 (1H, t, J = 1.5 Hz), 6.09 (1H, d, J = 11.4 Hz), 6.38 (1H, d, J = 11.4 Hz) (Ref. 0211)




Synthesis from dehydroepiandrostertone via 5,7-diene compound by photochemical method. (Ref. 0211)



6
(20S)-1a,20-dihydroxy-22,23,24,25,26,27-hexanorvitamin D3 / (20S)-1a,20-dihydroxy-22,23,24,25,26,27-hexanorcholecalciferol
(5Z,7E)-(1S,3R,20S)-9,10-seco-5,7,10(19)-pregnatriene-1,3,20-triol
VVD0007
Sachiko Yamada
1a,20S-(OH)2-22,23,24,25,26,27-hexanor-D3
C21H32O3 332.477 Download ChemDraw structure file
The antiproliferation activity towards HL-60 was <1/217 of 22-oxacalcitriol (OCT). The binding affinity for bovine thymus vitamin D receptor was 1/929 of OCT. (Ref. 0213)
[a]d-20 55.10 deg (c = 0.01 in EtOH) (Ref. 0212)
lmax (EtOH) (nm) 263, lmin (nm) 227 (Ref. 0212)
(neat) 3375, 2920, 2865, 1050 cm-1 (Ref. 0212)
1H-NMR (d, CDCl3) 0.55 (3H, s), 1.23 (3H, d, J = 6.6 Hz), 2.33 (1H, dd, J = 6.0 and 13.1 Hz), 2.61 (1H, dd, J = 2.9 and 13.1 Hz), 2.85 (1H, dd, J = 2.9 and 10.8 Hz), 3.25-3.57 (4H, m), 3.62-3.76 (1H, m), 4.17-4.31 (1H, m), 4.37-4.51 (1H, m), 5.00 (1H, s), 5.33 (1H, s), 6.04 (1H, d, J = 11.7 Hz), 6.37 (1H, d, J = 11.7Hz) (Ref. 0212)
m/z 332 (M+), 134 (100%) (Ref. 0212)
Colorless foam. (Ref. 0213)
HRMS Calcd 332.2351, Found 332.2369 (Ref. 0212)
1)Flash column chromatography with CH2Cl2-EtOH (10 : 1). 2)Fash column chromatography with AcOEt. 3)Flash column chromatography with CH2Cl2-EtOH (10 : 1). (Ref. 0213)

Synthesis from dehydroepiandrostertone via the 5,7-diene by photochemical method. (Ref. 0212/0213)



7
1a-hydroxy-22-oxo-23,24,25,26,27-pentanorvitamin D3 / 1a-hydroxy-22-oxo-23,24,25,26,27-pentanorcholecalciferol
(5Z,7E)-(1S,3R)-1,3-dihydroxy-9,10-seco-23,24-dinor-5,7,10(19)-cholatrien-22-one
VVD0008
Sachiko Yamada
1a-OH-22-oxo-pentanor-D3
C22H32O3 344.488 Download ChemDraw structure file
HL-60 human promyelocytes differentiation: ED50 in nitro blue tetrazplium reduction, phagocytic activity, and nonspecific acid esterase activity are 7.5 times 10-7 M, 8.2 times 10-7 M and 8.5 times 10-7 M, respectively, when 1,25-(OH)2D3 shows the respective ED50 values of 1.0 times 10-8 M, 1.0 times 10-8 M and 1.1 times 10-8 M, respectively. (Ref. 0228)





From C(22) ester precursor. (Ref. 0228)



8
(6RS)-22-oxo-23,24,25,26,27-pentanorvitamin D3 6,19-sulfur dioxide adduct / (6RS)-22-oxo-23,24,25,26,27-pentanorcholecalciferol 6,19-sulfur dioxide adduct
(7E)-(3S,6RS)-3-hydroxy-6,19-epithio-23,24-dinor-9,10-seco-5(10),7-choladien-22-al S,S-dioxide
VVD0009
Sachiko Yamada
22-oxo-23,24,25,26,27-pentanor-D3 6,19-sulfur dioxide adduct
C22H32O4S 392.553 Download ChemDraw structure file

1H-NMR (d, CDCl3) (a 1:1 mixture of C6) epimers) 0.62 and 0.70 (1:1, 3 H, s, H-18), 1.14 and 1.15 (1:1, 3 H, d, J = 6.9 Hz, H-21), 3.68 (2 H, br, H-19), 4.09 (1 H, m, H-3), 4.57 and 4.66 (1:1, 1 H, d, J = 9.9 Hz, H-6), 4.76 and 4.79 (1:1, 1 H, d, J = 9.9 Hz, H-7), 9.58 and 9.60 (1:1, 1H, d, J = 3.0 Hz, CHO). (Ref. 0334)




From vitamin D2 sulfur dioxide adduct by ozonolysis. (Ref. 0334)



9
1a-hydroxy-23,24,25,26,27-pentanorvitamin D3 / 1a-hydroxy-23,24,25,26,27-pentanorcholecalciferol
(5Z,7E)-(1S,3R)-23,24-dinor-9,10-seco-5,7,10(19)-cholatriene-1,3-diol
VVD0010
Sachiko Yamada
1a-OH-23,24,25,26,27-pentanor-D3
C22H34O2 330.504 Download ChemDraw structure file
HL-60 human promyelocytes differentiation : ED50 in nitro blue tetrazolium reduction, phagocytic activity, and nonspecific acid esterase activity are 1.8 times 10-7 M, 1.9 times 10-7 M and 1.7 times 10-7 M, respectively, when 1,25-(OH)2D3 shows the respective ED50 values of 1.0 times 10-8 M, 1.0 times 10-8 M and 1.1 times 10-8 M, respectively. (Ref. 0228)





Prepared via 3,5-cyclovitamin D intermediate. (Ref. 0228)



10
22-hydroxy-23,24,25,26,27-pentanorvitmin D3 / 22-hydroxy-23,24,25,26,27-pentanorcholecalciferol
(5Z,7E)-(3S)-23,24-dinor-9,10-seco-5,7,10(19)-cholatrien-3-ol
VVD0011
Sachiko Yamada
22-OH-23,24,25,26,27-pentanor-D3
C22H34O2 330.504 Download ChemDraw structure file






From vitamin D2 via ozonolysis of its sulfur dioxide adduct. (Ref. 0334)



11
1a,22-dihydroxy-23,24,25,26,27-pentanorvitamin D3 / 1a,22-dihydroxy-23,24,25,26,27-pentanorcholecalciferol
(5Z,7E)-(1S,3R)-23,24-dinor-9,10-seco-5,7,10(19)-cholatriene-1,3,22-triol
VVD0012
Sachiko Yamada
1a,22-(OH)2-23,24,25,26,27-pentanor-D3
C22H34O3 346.504 Download ChemDraw structure file
HL-60 human promyelocytes differentiation : ED50 in nitro blue tetrazolium reduction, phagocytic activity, and nonspecific acid esterase activity are 1.4 times 10-6 M, 1.8 times 10-6 M and 2.0 times 10-6 M, respectively, when 1,25-(OH)2D3 shows the respective ED50 values of 1.0 times 10-8 M, 1.0 times 10-8 M and 1.1 times 10-8 M, respectively. (Ref. 0228)





From C(22) ester precursor. (Ref. 0228)



12
(6RS)-22-hydroxy-23,24,25,26,27-pentanorvitamin D3 6,19-sulfur dioxide adduct / (6RS)-22-hydroxy-23,24,25,26,27-pentanorcholecalciferol 6,19-sulfur dioxide adduct
(7E)-(3S,6RS)-6,19-epithio-23,24-dinor-9,10-seco-5(10),7-choladiene-3,22-diol S,S-dioxide
VVD0013
Sachiko Yamada
22-OH-23,24,25,26,27-pentanor-D3 6,19-sulfur dioxide adduct
C22H34O4S 394.569 Download ChemDraw structure file

1H-NMR (d, CDCl3, 270MHz) 0.59 and 0.68 (1:1) (3H, s, 18-H), 1.07 (3H, d, J = 6.4 Hz, 21-H), 3.67 (2H, m, 19-H), 4.11 (1H, m, 3-H) (Ref. 0334)




From vitamin D2 sulfur dioxide adduct by ozonolysis followed by reduction. (Ref. 0334)



13
1a-hydroxy-24,25,26,27-tetranorvitamin D3 23-carboxylic acid / calcitroic acid
(5Z,7E)-(1S,3R)-1,3-dihydroxy-24-nor- 9,10-seco-5,7,10(19)-cholatrien-23-oic acid
VVD0014
Sachiko Yamada
1a-OH-24,25,26,27-tetranor-D3 23-carboxylic acid
C23H34O4 374.514 Download ChemDraw structure file
Bone Mineral Mobilization and Intestinal Calcium Transport Activity of Calcitroic Acid. (Ref. 0072)
122-126 degC (Ref. 0074)
lmax (nm) (emax) 262 (18000), lmin (nm) (emin) 226 (10000) (Ref. 0074)
Me-ester : lmax (nm) (emax) 264 (18000) (Ref. 0071)
1H-NMR (d, CDCl3) 6.43, 6.06 (2H, ABq, J = 11 Hz, 6-, 7-H), 5.56 (1H, br s, 19E-H), 5.04 (1H, br s, 19Z-H), 4.46 (1H, m, 1b-H), 4.26 (1H, m, 3a-H), 2.80 (1H, m, 9b-H), 0.99 (3H, d, J = 6 Hz, 21-H), 0.59 (3H, s, 18-H) (Ref. 0074)
Me-ester : 1H-NMR (d, CDCl3) 0.58 (3H, s, 18-CH3), 0.99 (3H, d, J = 5.9 Hz, 21-CH3), 3.67 (3H, s, COOCH3), 4.23 (1H, m, 3a-H), 4.43 (1H, m, 1b-H), 5.00 (1H, s, 19(Z)-H), 5.33 (1H, s, 19(E)-H), 6.02 (1H, d, J = 11.0 Hz, 7-H), 6.38 (1H, d, J = 11.0 Hz, 6-H) (Ref. 0071)
Me-ester : m/z 388, 370, 352 , 152, 134, 287, 269, 251. Spectrum (Ref. 0070)

HPLC : (Ref. 0070/0073)
Isolation from rat liver. (Ref. 0070)
Isolation and identification from vitamin D supplemented rat kidney homogenates incubated with 24,25-(OH)2D3. (Ref. 0118)
From C(22)-steroid carboxylic acid via one-carbon homologation, conversion to tetranor-vitamin D3 23-carboxylic acid and 1a-hydroxylation of the corresponding 3,5-cyclovitamin D. (Ref. 0071)
From 3b-acetoxypregn-7-ene-22-carboxaldehyde. (Ref. 0074)
A final catabolite produced from the active vitamin D3 metabolite, 1,25-(OH)2D3, via 24-hydroxylation pathway.(Ref. 0034/0065/0066/0067/0068/0069/0070/0073)


14
1a-hydroxy-24,25,26,27-tetranorvitamin D3 / 1a-hydroxy-24,25,26,27-tetranorcholecalciferol
(5Z,7E)-(1S,3R)-24-nor-9,10-seco-5,7,10(19)-cholatriene-1,3-diol
VVD0015
Sachiko Yamada
1a-OH-23,24,25,26,27-tetranor-D3
C23H36O2 344.531 Download ChemDraw structure file
HL-60 human promyelocytes differentiation : ED50 in nitro blue tetrazolium reduction, phagocytic activity, and nonspecific acid esterase activity are 2.3 times 10-7 M, 2.5 times 10-7 M and 2.7 times 10-7 M, respectively, when 1,25-(OH)2D3 shows the respective ED50 values of 1.0 times 10-8 M, 1.0 times 10-8 M and 1.1 times 10-8 M, respectively. (Ref. 0228)





Prepared via 3,5-cyclovitamin D intermediate. (Ref. 0228)



15
(22R)-22-hydroxy-24,25,26,27-tetranorvitmin D3 / (22R)-22-hydroxy-24,25,26,27-tetranorcholecalciferol
(5Z,7E)-(3S,22R)- 24-nor-9,10-seco-5,7,10(19)-cholatriene-3,22-diol
VVD0016
Sachiko Yamada
22R-OH-24,25,26,27-tetranor-D3
C23H36O2 344.531 Download ChemDraw structure file

1H-NMR (d, CDCl3, 270MHz) 0.57 (3H, s, 18-H), 0.93 (3H, d, J = 6.6 Hz, 21-H), 1.04 (3H, d, J = 6.6 Hz, 23-H), 3.93 (2H, m, 3- and 22-H), 4.82 and 5.05 (each 1H, m, 19-H), 6.04 and 6.23 (each 1H, d, J = 11.5 Hz, 6- and 7-H) (Ref. 0334)




From vitamin D2 sulfur dioxide adduct via ozonolysis followed by Grignard reaction. (Ref. 0334)



16
(22S)-22-hydroxy-24,25,26,27-tetranorvitmin D3 / (22S)-22-hydroxy-23,24,25,26,27-pentanorcholecalciferol
(5Z,7E)-(3S,22S)- 24-nor-9,10-seco-5,7,10(19)-cholatriene-3,22-diol
VVD0017
Sachiko Yamada
22S-OH-24,25,26,27-tetranor-D3
C23H36O2 344.531 Download ChemDraw structure file

(EtOH) lmax (nm) 265, lmin (nm) 212 (Ref. 0334)
1H-NMR (d, CDCl3, 270MHz) 0.55 (3H, s, 18-H), 0.93 (3H, d, J = 6.9 Hz, 21-H), 1.16 (3H, d, J = 6.4 Hz, 23-H), 3.95 (2H, m, 3- and 22-H), 4.82 and 5.05 (each 1H, m, 19-H), 6.04 and 6.23 (each 2H, d, J = 11.4 Hz, 6- and 7-H) (Ref. 0334)
m/z 344 (M+, 75.7), 326 (93.7), 311 (23.6), 271 (15.6), 253 (41.1), 136 (96.7), 118 (100) (Ref. 0334)



From vitamin D2 sulfur dioxide adduct via ozonolysis followed by Grignard reaction. (Ref. 0334)



17
(5E)-(22R)-22-hydroxy-24,25,26,27-tetranorvitmin D3 / (5E)-(22R)-22-hydroxy-24,25,26,27-tetranorcholecalciferol
(5E,7E)-(3S,22R)- 24-nor-9,10-seco-5,7,10(19)-cholatriene-3,22-diol
VVD0018
Sachiko Yamada
(5E)-22R-OH-24,25,26,27-tetranor-D3
C23H36O2 344.531 Download ChemDraw structure file

1H-NMR (d, CDCl3, 270MHz) 0.59 (3H, s, 18-H), 0.93 (3H, d, J = 6.6 Hz, 21-H), 1.04 (3H, d, J = 6.3 Hz, 23-H), 3.89 (1H, m, 3-H), 3.93 (1H, m, 22-H), 4.69 and 4.98 (each 1H, s, 19-H), 5.88 and 6.54 (each 1H, d, J = 11.6 Hz, 6- and 7-H) (Ref. 0334)
m/z 344 (M+, 63.4), 326 (100), 308 (23.1), 271 (14.2), 253 (40.0), 251 (37.5) (Ref. 0334)



From vitamin D2 sulfur dioxide adduct via ozonolysis followed by Grignard reaction. (Ref. 0334)



18
(5E)-(22S)-22-hydroxy-24,25,26,27-tetranorvitmin D3 / (5E)-(22S)-22-hydroxy-24,25,26,27-tetranorcholecalciferol
(5E,7E)-(3S,22S)- 24-nor-9,10-seco-5,7,10(19)-cholatriene-3,22-diol
VVD0019
Sachiko Yamada
(5E)-22S-OH-24,25,26,27-tetranor-D3
C23H36O2 344.531 Download ChemDraw structure file

1H-NMR (d, CDCl3, 270MHz) 0.57 (3H, s, 18-H), 0.93 (3H, d, J = 6.8 Hz, 21-H), 1.17 (3H, d, J = 6.4 Hz, 23-H), 3.89 (1H, m, 3-H), 3.97 (1H, dq, J = 6.4 and 1.4 Hz, 22-H), 4.69 and 4.98 (each 1H, s, 19-H), 5.88 and 6.55 (each 1H, d, J = 11.6 Hz, 6- and 7-H) (Ref. 0334)
m/z 344 (M+, 63.4), 326 (100), 308 (23.1), 271 (14.2), 253 (40.0), 251 (37.5) (Ref. 0334)



From vitamin D2 sulfur dioxide adduct via ozonolysis followed by Grignard reaction. (Ref. 0334)



19
23-hydroxy-24,25,26,27-tetranorvitamin D3 / 23-hydroxy-24,25,26,27-tetranorcholecalciferol
(5Z,7E)-(3S)-24-nor-9,10-seco-5,7,10(19)-cholatriene-3,23-diol
VVD0020
Sachiko Yamada
23-OH-24,25,26,27-tetranor-D3
C23H36O2 344.531 Download ChemDraw structure file


m/z 344 (M+), 326, 311, 285, 271, 253, 211, 136, 118. Spectrum (Ref. 0105)

HPLC : (Ref. 0105)
Isolation and identification : By perfusing kidneys from vitamin D3 replete rats with 24,25-(OH)2D3. (Ref. 0105)
From 22-bromo-23,24-dinor-5,7-choladien-3-ol ether via one carbon homologation and photochemical transformation. (Ref. 0105)



20
1a,23-dihydroxy-24,25,26,27-tetranorvitamin D3 / 1a,23-dihydroxy-24,25,26,27-tetranorcholecalciferol
(5Z,7E)-(1S,3R)-24-nor-9,10-seco-5,7,10(19)-cholatriene-1,3,23-triol
VVD0021
Sachiko Yamada
1a,23-(OH)2-24,25,26,27-tetranor-D3
C23H36O3 360.530 Download ChemDraw structure file
HL-60 human promyelocytes differentiation : ED50 in nitro blue tetrazolium reduction, phagocytic activity, and nonspecific acid esterase activity are 3.0 times 10-6 M, 2.0 times 10-6 M and 2.0 times 10-6 M, respectively, when 1,25-(OH)2D3 shows the respective ED50 values of 1.0 times 10-8 M, 1.0 times 10-8 M and 1.1 times 10-8 M, respectively. (Ref. 0228)
lmax (nm) 265, lmin (nm) 228 (Ref. 0069)

tris-TMS-ether: Spectrum (Ref. 0069)

HPLC : (Ref. 0069)

From 1,23,25-(OH)3-24-oxo-D3, which was produced enzymatically from 1,24,25-(OH)3D3, by NaIO4 oxidation followed by NaBH4 reduction. (Ref. 0069)
1,23-(OH)2-Tetranor-D3 is metabolized to 1-OH-tetranor-D3 23-carboxylic acid (calcitroic acid). (Ref. 0070/0073)


21
cholacalcioic acid / 25,26,27-trinorvitamin D3 24-carboxylic acid / 25,26,27-trinorcholecalciferol 24-carboxylic acid
(5Z,7E)-(3S)-3-hydroxy-9,10-seco-5,7,10(19)-cholatrien-24-oic acid
VVD0022
Sachiko Yamada
25,26,27-trinor-D3 24-carboxylic acid
C24H36O3 372.541 Download ChemDraw structure file

Me-ester : lmax (nm) 264, lmin (nm) 229 (Ref. 0118)

Me-ester : m/z 386 (M+), 368, 327, 353, 271, 253, 136, 118 (Ref. 0118)


Isolation and identification from vitamin D supplemented rat kidney homogenates incubated with 24,25-(OH)2D3. (Ref. 0118)




22
1a-hydroxy-25,26,27-trinorvitamin D3 24-carboxylic acid
(5Z,7E)-(1S,3R)-1,3-dihydroxy-9,10-seco-5,7,10(19)-cholatrien-24-oic acid
VVD0023
Sachiko Yamada
1a-OH-25,26,27-trinor-D3 24-carboxylic acid
C24H36O4 388.540 Download ChemDraw structure file

117-120 degC (Ref. 0074)
lmax (nm) (e) 263 (18200) , lmin (nm) (e) 227 (10400) (Ref. 0074)
1H-NMR (d, CDCl3) 6.42, 6.04 (2H, ABq, J = 11.6 Hz, 6-, 7-H), 5.35 (1H, bs, 19E-H), 5.03 (1H, bs, 19Z-H), 4.46 (1H, m, 1b-H), 4.25 (1H, m, 3a-H), 2.80 (1H, m, 9b-H), 0.95 (3H, d, J = 5.5 Hz, 21-H), 0.55 (3H, s, 18-H) (Ref. 0074)




From methyl-3b-hydroxy-chola-1,5,7-triene-24-oate. (Ref. 0074)



23
1a,24-dihydroxy-25,26,27-trinorvitamin D3 / 1a,24-dihydroxy-25,26,27-trinorcholecalciferol
(5Z,7E)-(1S,3R)-9,10-seco-5,7,10(19)-cholatriene-1,3,24-triol
VVD0024
Sachiko Yamada
1a,24-(OH)2-25,26,27-trinor-D3
C24H38O3 374.557 Download ChemDraw structure file
HL-60 human promyelocytes differentiation : ED50 in nitro blue tetrazolium reduction, phagocytic activity, and nonspecific acid esterase activity are 7.0 times 10-7 M, 6.0 times 10-7 M and 1.0 times 10-6 M, respectively, when 1,25-(OH)2D3 shows the respective ED50 values of 1.0 times 10-8 M, 1.0 times 10-8 M and 1.1 times 10-8 M, respectively. (Ref. 0228)









24
26,26,26-trifluoro-25-hydroxy-27-norvitamin D3 / 26,26,26-trifluoro-25-hydroxy-27-norcholecalciferol
(5Z,7E)-(3S)-26,26,26-trifluoro-27-nor-9,10-seco-5,7,10(19)-cholestatriene-3,25-diol
VVD0025
Sachiko Yamada
26,26,26-F3-25-OH-27-nor-D3
C25H37F3O2 426.555 Download ChemDraw structure file

lmax (nm) 264, lmin (nm) 228 (Ref. 0201)

m/z 440 (M+), 425, 422, 408, 271, 253, 136, 118 (Ref. 0201)







25
1a-hydroxy-26,27-dinorvitamin D3 25-carboxylic acid / 1a-hydroxy-26,27-dinorcholecalciferol 25-carboxylic acid
(5Z,7E)-(1S,3R)-1,3-dihydroxy-25-homo-9,10-seco-5,7,10(19)-cholatrien-25-oic acid
VVD0026
Sachiko Yamada
1a-OH-26,27-dinor-D3 25-carboxylic acid
C25H38O4 402.567 Download ChemDraw structure file

97-101 degC (Ref. 0074)
lmax (nm) (e) 264 (18300) , lmin (nm) (e) 228 (10300) (Ref. 0074)
1H-NMR (d, CDCl3) 6.42, 6.04 (2H, ABq, J = 11.6 Hz, 6-, 7-H), 5.35 (1H, br s, 19E-H), 5.03 (1H, br s, 19Z-H), 4.45 (1H, m, 1b-H), 4.25 (1H, m, 3a-H), 2.81 (1H, m, 9b-H) (Ref. 0074)
m/z 416 (M+), 398 (M+-H2O), 380 (M+-2H2O), 269, 251, 134, 105 (Ref. 0074)



From methyl-3b-hydroxy-25-homo-chola-1,5,7-trien-25-oate. (Ref. 0074)



26
1a-hydroxy-21-nor-20-oxavitamin D3 / 1a-hydroxy-21-nor-20-oxacholecalciferol
(5Z,7E)-(1S,3R)-21-nor-20-oxa-9,10-seco-5,7,10(19)-cholestatriene-1,3-diol
VVD0027
Sachiko Yamada
1a-OH-20-oxa-21-nor-D3
C25H40O3 388.583 Download ChemDraw structure file

[a]d-24 -30.2 deg (c = 0.86 in EtOH) (Ref. 0207)
(EtOH) lmax (nm) 262, lmin (nm) 227 (Ref. 0207)
1H-NMR (d, CDCl3) 0.62 (3H, s), 0.86 (3H, d, J = 0.8 Hz), 0.89 (3H, d, J = 0.8 Hz), 3.35-3.56 (3H, m), 4.15-4.32 (1H, m), 4.38-4.51 (1H, m), 5.00 (1H, t, J = 1.6 Hz), 5.32 (1H, t, J = 1.6 Hz), 6.00 (1H, d, J = 12.0 Hz), 6.38 (1H, d, J = 12.0 Hz) (Ref. 0207)
m/z 388 (M+), 134 (100%) (Ref. 0207)
Colorless crystals (Ref. 0207)


Synthesis from dehydroepiandrostertone via 5,7-diene compound by photochemical method. (Ref. 0207)



27
1a,25-dihydroxy-23,24-dinorvitamin D3 / 1a,25-dihydroxy-23,24-dinorcholecalciferol
(5Z,7E)-(1S,3R)-23,24-dinor-9,10-seco-5,7,10(19)-cholestatriene-1,3,25-triol
VVD0028
Sachiko Yamada
1a,25-(OH)2-23,24-dinor-D3
C25H40O3 388.583 Download ChemDraw structure file
HL-60 human promyelocytes differentiation : ED50 in nitro blue tetrazolium reduction, phagocytic activity and nonspecific acid esterase activity are 2.4 times 10-6 M, 2.0 times 10-6 M and 2.1 times 10-6 M respectively, when 1,25-(OH)2D3 shows the respective ED50 values of 1.0 times 10-8 M, 1.0 times 10-8 M and 1.1 times 10-8 M respectively. (Ref. 0228)









28
1a,25-dihydroxy-26,27-dinorvitamin D3 / 1a,25-dihydroxy-26,27-dinorcholecalciferol
(5Z,7E)-(1S,3R)-26,27-dinor-9,10-seco-5,7,10(19)-cholestatriene-1,3,25-triol
VVD0029
Sachiko Yamada
1a,25-(OH)2-26,27-dinor-D3
C25H40O3 388.583 Download ChemDraw structure file
HL-60 human promyelocytes differentiation : ED50 in nitro blue tetrazolium reduction, phagocytic activity, and nonspecific acid esterase activity are 1.0 times 10-6 M, 1.2 times 10-6 M and 1.0 times 10-6 M, respectively, when 1,25-(OH)2D3 shows the respective ED50 values of 1.0 times 10-8 M, 1.0 times 10-8 M and 1.1 times 10-8 M, respectively. (Ref. 0228)









29
1a,25-dihydroxy-21-nor-20-oxavitamin D3 / 1a,25-dihydroxy-21-nor-20-oxacholecalciferol
(5Z,7E)-(1S,3R)-21-nor-20-oxa-9,10-seco-5,7,10(19)-cholestatriene-1,3,25-triol
VVD0030
Sachiko Yamada
1a,25-(OH)2-20-oxa-21-nor-D3
C25H40O4 404.583 Download ChemDraw structure file
Differentiation inducing activity of HL-60 (ED50): 4.0 times 10-8 M (1,25-(OH)2D3, 8.3 times 10-9 M); Binding affinity for chick intestinal receptor: 1/1000 of 1,25-(OH)2D3. Calcemic activity at a dose of 500mg/kg in normal mice, 8.96 pm 0.13 (1.25-(OH)2D3, 11.04 pm 0.12 at 10mg/kg). (Ref. 0209)
[a]d-24 -44.6 deg (c = 0.56 in EtOH) (Ref. 0207)
lmax (EtOH) (nm) 262, lmin (nm) 227 (Ref. 0207)
1H-NMR (d, CDCl3) 0.63 (3H, s), 1.23 (6H, s), 3.51 (3H, m), 4.17-4.29 (1H, m), 4.34-4.49 (1H, m), 4.98 (1H, t, J = 1.6 Hz), 5.31 (1H, t, J = 1.6 Hz), 5.99 (1H, d, J = 12.0 Hz), 6.36 (1H, d, J = 12.0 Hz) (Ref. 0207)
m/z 404 (M+), 83 (100%) (Ref. 0207)
Colorless crystals (Ref. 0207)


Synthesis from dehydroepiandrostertone via 5,7-diene compound by photochemical method. (Ref. 0209)



30
1a,25-dihydroxy-24-nor-22-oxavitamin D3 / 1a,25-dihydroxy-24-nor-22-oxacholecalciferol
(5Z,7E)-(1S,3R)-24-nor-22-oxa-9,10-seco-5,7,10(19)-cholestatriene-1,3,25-triol
VVD0031
Sachiko Yamada
1a,25-(OH)2-22-oxa-24-nor-D3
C25H40O4 404.583 Download ChemDraw structure file
The activity inducing differentiation of human myeloid leukemia cells (HL-60) into macrophases in vitro was compared with 1,25-(OH)2D3. Figure (Ref. 0203)
(EtOH) lmax (nm) 263, lmin (nm) 227(Ref. 0203)
1H-NMR (d, CDCl3) 0.53 (3H, s), 1.16 (3H, d, J = 6.2 Hz), 1.19 (6H, s), 3.04 (1H, d, J = 8.4 Hz), 3.24-3.48 (1H, br), 3.39 (1H, d, J = 8.4 Hz), 4.20-4.32 (1H, br), 4.40-4.52 (1H, br), 4.99 (1H, s), 5.33 (1H, s), 6.03 (1H, d, J = 11.4 Hz), 6.37 (1H, d, J = 11.4 Hz) (Ref. 0203)
m/z 404 (M+), 72 (100%) (Ref. 0203)
Colorless foam. (Ref. 0203)
1)Flash column chromatography with CH2Cl2/EtOH (12.5 : 1), 2)Flash column chromatography with AcOEt/n-hexane (6 : 1), 3)Preparative TLC developed four times with CH2Cl2/EtOH (12.5 : 1) (Ref. 0203)

Synthesis from dehydroepiandrostertone via 1a,3b-dihydroxy-20(S)-(2-hydroxy-2-methylpropyloxy)pregna-5,7-diene by photochemical method. (Ref. 0203)



31
1a-hydroxy-24-methylsulfonyl-25,26,27-trinorvitamin D3 / 1a-hydroxy-24-methylsulfonyl-25,26,27-trinorcholecalciferol
(5Z,7E)-(1S,3R)-24-methylsulfonyl-9,10-seco-5,7,10(19)-cholatriene-1,3-diol
VVD0032
Sachiko Yamada
24-methylsulfonyl-1a-OH-25,26,27-trinor-D3
C25H40O4S 436.649 Download ChemDraw structure file

1H-NMR (d, CD2Cl2) 6.34 and 5.98 (2H, AB pattern, J = 11.2 Hz, 6- and 7-H), 5.29 (1H, br s, 19E-H), 4.94 (1H, br s, 19Z-H), 4.35 (1H, m, 1-H), 4.15 (1H, m, 3-H), 2.88 - 2.97 (2H, m, 24-H), 2.84 (3H, s, SO2CH3), 0.94 (3H, d, J = 6.4 Hz, 21C-CH3), 0.53 (3H, s, 18C-CH3) (Ref. 0195)
13C-NMR (d, CD2Cl2) 148.6 (C), 143.2 (C), 134.1 (C), 125.0 (CH), 117.0 (CH), 111.8 (C-19), 71.2 (CH), 67.2 (CH), 56.7, 56.6, 55.7, 53.5, 46.3, 45.8, 43.4, 40.9, 36.2, 35.0, 29.4, 28.0, 23.9, 22.6, 19.7, 18.8, 12.1 (Ref. 0195)








32
1,25-dihydroxy-2,4-dinor-1,3-secovitamin D3 / 1,25-dihydroxy-2,4-dinor-1,3-secocholecalciferol
(5Z,7E)-A-dinor-(1,2)-(9,10)-diseco-5,7,10(19)-cholestatriene-1,2,25-triol
VVD0034
Sachiko Yamada
1,25-(OH)2-2,4-dinor-1,3-seco-D3
C25H42O3 390.599 Download ChemDraw structure file
Affinity for chick intestinal receptor: 2% of 1,25-(OH)2D3 effect. (Ref. 0359)









33
25,26-epoxy-1a-hydroxy-23,23,24,24-tetradehydro-19-norvitamin D3 / 25,26-epoxy-1a-hydroxy-23,23,24,24-tetradehydro-19-norcholecalciferol
(7E)-(1R,3R)-25,26-epoxy-19-nor-9,10-seco-5,7-cholestadien-23-yne-1,3-diol
VVD0035
Sachiko Yamada
25,26-epoxy-1a-OH-23,23,24,24-tetradehydro-19-nor-D3
C26H38O3 398.578 Download ChemDraw structure file
Biological activity (% of 1,25-(OH)2D3 effect) : Affinity for pig intestinal receptor and human vitamin D binding protein : 20% and 1%, respectively. Inhibition of proliferation or differentiation induction of human promyeloid leukemia (HL-60), osteosarcoma (MG-63), and breast carcinoma (MCF-7) cells : 12%, 4% and 20%, respectively. Elevation of serum calcium, serum osteocalcin, bone calcium, and duodenal calbindin in rachitic chicks : all < 1%. (Ref. 0240)





By epoxidation of the corresponding olefinic precursor which was constructed from Inhoffen-Lythgoe diol. (Ref. 0240)



34
(22E,24E)-1a,26-dihydroxy-22,23,24,25-tetradehydro-27-norvitamin D3 / (22E,24E)-1a,26-dihydroxy-22,23,24,25-tetradehydro-27-norcholecalciferol
(5Z,7E,22E,24E)-(1S,3R)-27-nor-9,10-seco-5,7,10(19),22,24-cholestapentaene-1,3,26-triol
VVD0036
Sachiko Yamada
(22E,24E)-1a,26-(OH)2-22,23,24,25-tetradehydro-27-nor-D3
C26H38O3 398.578 Download ChemDraw structure file
Biological activity (% of 1,25-(OH)2D3 effect) : Inhibition of proliferation of U937 cells, < 80% ; Induction of differentiation of U 937 cells, < 5%. (Ref. 0288>





From protected (5E)-1a-hydroxy-22-oxo-23,24,25,26,27-pentanorvitamin D3 via side chain introduction by Wittig reaction, reduction, photoisomerization and deprotection. (Ref. 0288)



35
(17E)-1a,25-dihydroxy-17,20-didehydro-21-norvitamin D3 / (17E)-1a,25-dihydroxy-17,20-didehydro-21-norcholecalciferol
(5Z,7E,17E)-(1S,3R)-21-nor-9,10-seco-5,7,10(19),17-cholestatetraene-1,3,25-triol
VVD0037
Sachiko Yamada
(17E)-1a,25-(OH)2-17,20-didehydro-21-nor-D3
C26H40O3 400.594 Download ChemDraw structure file






From 4-hydroxyhydrindanone via introduction of the side chain and A-ring fragments. (Ref. 0315)



36
(17Z)-1a,25-dihydroxy-17,20-didehydro-21-norvitamin D3 / (17Z)-1a,25-dihydroxy-17,20-didehydro-21-norcholecalciferol
(5Z,7E,17Z)-(1S,3R)-21-nor-9,10-seco-5,7,10(19),17-cholestatetraene-1,3,25-triol
VVD0038
Sachiko Yamada
(17Z)-1a,25-(OH)2-17,20-didehydro-21-nor-D3
C26H40O3 400.594 Download ChemDraw structure file






From 4-hydroxyhydrindanone via introduction of the side chain and A-ring fragments. (Ref. 0315)



37
(24R,25S)-25,26-epoxy-1a,24-dihydroxy-27-norvitamin D3 / (24R,25S)-25,26-epoxy-1a,24-dihydroxy-27-norcholecalciferol
(5Z,7E)-(1S,3R,24R,25S)-25,26-epoxy-27-nor-9,10-seco-5,7,10(19)-cholestatriene-1,3,24-triol
VVD0039
Sachiko Yamada
25S,26-epoxy-1a,24R-(OH)2-27-nor-D3
C26H40O4 416.593 Download ChemDraw structure file
Biological activity (% of 1,25-(OH)2D3 effect) : Affinity for pig intestinal receptor and human vitamin D binding protein: 3% and 21%, respectively. Inhibition of proliferation or differentiation induction of human promyeloid leukemia (HL-60) and osteosarcoma (MG-63) cells: both < 1%. Elevation of serum calcium, serum osteocalcin, bone calcium and duodenal calbindin in rachitic chicks: all < 1%. (Ref. 0240)





By Sharpless kinetic epoxidation of the corresponding olefinic precursor. (Ref. 0243)



38
(24S,25R)-25,26-epoxy-1a,24-dihydroxy-27-norvitamin D3 / (24S,25R)-25,26-epoxy-1a,24-dihydroxy-27-norcholecalciferol
(5Z,7E)-(1S,3R,24S,25R)-25,26-epoxy-27-nor-9,10-seco-5,7,10(19)-cholestatriene-1,3,24-triol
VVD0040
Sachiko Yamada
25R,26-epoxy-1a,24S-(OH)2-27-nor-D3
C26H40O4 416.593 Download ChemDraw structure file
Biological activity (% of 1,25-(OH)2D3 effect) : Affinity for pig intestinal receptor and human vitamin D binding protein : 2% and 5%, respectively. Inhibition of proliferation or differentiation induction of human promyeloid leukemia (HL-60) and osteosarcoma (MG-63) cells : both < 1%. Elevation of serum calcium, serum osteocalcin, bone calcium, and duodenal calbindin in rachitic chicks: all < 1%. (Ref. 0240)





By Sharpless kinetic epoxidation of the corresponding olefinic precursor. (Ref. 0243)



39
1a,25-dihydroxy-24-oxo-22-oxavitamin D3 / 1a,25-dihydroxy-24-oxo-22-oxacholecalciferol
(5Z,7E)-(1S,3R)-1,3,25-trihydroxy-22-oxa-9,10-seco-5,7,10(19)-cholestatrien-24-one
VVD0041
Sachiko Yamada
1a,25-(OH)2-24-oxo-22-oxa-D3
C26H40O5 432.593 Download ChemDraw structure file
Antiproliferative activity (HL-60) was the same as that of 22-oxacalcitriol (OCT). The binding affinity for bovine thymus vitamin D receptor was 1/2 of OCT. (Ref. 0213)
lmax (EtOH) (nm) 263, lmin (nm) 227 (Ref. 0213)
1H-NMR (d, CDCl3) 0.53 (3H, s), 1.21 (3H, d, J = 6.3 Hz), 1.40 (6H, s), 4.18-4.27 (1H, m), 4.22 and 4.43 (each 1H, d, J = 16.3 Hz), 4.39-4.48 (1H, m), 5.00 (1H, s), 5.33 (1H, s), 6.03 (1H, d, J = 12.0 Hz), 6.37 (1H, d, J = 12.0 Hz) (Ref. 0213)
m/z 432 (M+), 59 (100%) (Ref. 0213)
Colorless oil. (Ref. 0213)
Preparative TLC developed with AcOEt. (Ref. 0213)

Synthesis from dehydroepiandrostertone via the 5,7-diene by photochemical method. (Ref. 0213)



40
25-hydroxy-3-deoxy-2-oxavitamin D3 / 25-hydroxy-3-deoxy-2-oxacholecalciferol
(5Z,7E)-2-oxa-9,10-seco-5,7,10(19)-cholestatrien-25-ol
VVD0042
Sachiko Yamada
3-deoxy-25-OH-2-oxa-D3
C26H42O2 386.610 Download ChemDraw structure file






From 25,26-dehydro-8-enol triflate upper half and ring A precursor, 2-methyll-3-ethynyl-2,3-dehydro-d-butyrolactone. Coupling of the two precursors followed by catalytic partial hydrogenation and DIBAL reduction afforded 1,3-dihydroxy-2-nor-1,2-seco-vitamin D after spontaneous 1,7-hydrogen shift which by A ring cyclization and oxymercuration-demercuration (25-hydroxy introduction) afforded the title compound. (Ref. 0330)



41
1a,25-dihydroxy-3-deoxy-3-thiavitamin D3 / 1a,25-dihydroxy-3-deoxy-3-thiacholecalciferol
(5Z,7E)-(1R)-9,10-seco-3-thia-5,7,10(19)-cholestatriene-1,25-diol
VVD0043
Sachiko Yamada
3-deoxy-3-thia-1a,25-(OH)2D3
C26H42O2S 418.676 Download ChemDraw structure file
Biological activity (% of 1,25-(OH)2D3 effect): Intestinal calcium absorption and bone calcium mobilization in vitamin D deficient, rachitic chicks : 20% and <10%, respectively. Ability to bind to chick intestinal receptor: 14.5%. (Ref. 0281)
1H-NMR (d) 0.53 (3H, s, 18C-CH3), 0.93 (3H, d, J = 6.3 Hz, 21C-CH3), 1.22 (6H, s, 26- and 27-C-2CH3), 2.75-2.85 (2H, m, 2- and 9b-H), 3.06 (1H, dd, J = 13.4 and 2.3 Hz, 2-H,), 3.12 and 3.33 (2H, AB pattern, J = 12.9 Hz, 2times4-H), 4.36 (1H, m, 1-H), 4.90 (1H, s, 19-H), 5.29 (1H, s, 19-H), 5.93 and 6.43 (2H, AB pattern, J = 11.2 Hz, 6- and 7-H) (Ref. 0281)




Synthesis of the title compound and its 1b-epimer was achieved starting from CD-fragment and enantiomerically pure A-ring fragments, trimethylsilylenynes, which were prepared from 4-methylthiacyclohexane-3,5-dione. (Ref. 0281)



42
1b,25-dihydroxy-3-deoxy-3-thiavitamin D3 / 1b,25-dihydroxy-3-deoxy-3-thiacholecalciferol
(5Z,7E)-(1S)-9,10-seco-3-thia-5,7,10(19)-cholestatriene-1,25-diol
VVD0044
Sachiko Yamada
3-deoxy-3-thia-1b,25-(OH)2D3
C26H42O2S 418.676 Download ChemDraw structure file
Biological activity (% of 1,25-(OH)2D3 effect) : Intestinal calcium absorption and bone calcium mobilization in vitamin D deficient, rachitic chicks: <20% and <10%, respectively. Ability to bind to chick intestinal receptor : 1.23%. (Ref. 0281)
1H-NMR (d) 0.53 (3H, s, 18C-CH3), 0.93 (3H, d, J = 6.0 Hz, 21C-CH3), 1.22 (6H, s, 26-, 27-C-2CH3), 2.65-2.90 (3H, m, 2- and 9b-H), 3.08 (1H, dd, J = 13.2 and 2.1 Hz, 2-H), 3.10 and 3.35 (2H, two d, AB pattern, J = 12.9 Hz, 2times4-H), 4.36 (1H, m, 1-H), 4.91 (1H, br s, 19-H), 5.30 (1H, br s, 19-H), 5.96 and 6.43 (2H, two d, AB pattern, J = 11.2 Hz, 6-, 7-H) (Ref. 0281)




Synthesis of the title compound and its 1a-epimer was achieved starting from CD-fragment and enantiomerically pure A-ring fragments, trimethylsilylenynes, which were prepared from 4-methylthiacyclohexane-3,5-dione. (Ref. 0281)



43
(5Z)-1,25-dihydroxy-3-thiavitamin D3 / (5Z)-1,25-dihydroxy-3-thiacholecalciferol
(5Z,7E)-(1R)-9,10-seco-3-thia-5,7,10(19)-cholestatriene-1,25-diol
VVD0045
Sachiko Yamada
(5Z)-3-thia-1,25-(OH)2D3
C26H42O2S 418.676 Download ChemDraw structure file
Affinity for chicken intestinal recepto : 0.1% of 1,25-(OH)2D3 effect. Inhibitory effect of a series of 3-thiavitamin D derivatives on 25-OHD3 1a-hydroxylase was evaluated. (Ref. 0306)
(100% EtOH) lmax (nm) (emax) 268 (18300) (Ref. 0306)
1H-NMR (d, CDCl3, 300MHz) 0.56 (3H, s, 18C-CH3), 0.94 (3H, d, J = 6.3 Hz, 21C-CH3), 1.22 (6H, s, 26C- and 27C-CH3), 2.75-2.90 (2H, m, 2- and 9b-H), 3.08 (1H, dd, J = 13.2, 2.3 Hz, 2-H), 3.25 and 3.44 (2H, AB pattern, J = 13.5 Hz, 4-H2), 4.39 (1H, m, 1-H), 4.99 (1H, s, 19-H), 5.01 (1H, distorted d, J = 1.8 Hz, 19-H), 5.79 and 6.41 (2H, AB pattern, J = 11.5 Hz, 6- and 7-H) (Ref. 0306)
m/z 418 (34, M+), 400 (7, M+-H2O), 385 (20), 372 (10), 354 (5), 342 (2), 318 (4), 289 (7), 271 (15), 246 (14), 213 (7), 189 (9), 175 (14), 154 (base, A-ring portion due to C7- and C8-cleavage), 135 (68), 121 (12), 108 (66), 95 (31), 81 (22), 69 (13), 59 (16) (Ref. 0306)



From corresponding 5E-vitamin D (1a,25-dihydroxy-3-deoxy-3-thiavitamin D3) by iodine catalyzed isomerization followed by HPLC separation. (Ref. 0306)



44
1a-hydroxy-22-oxavitamin D3 / 1a-hydroxy-22-oxacholecalciferol
(5Z,7E)-(1S,3R)-22-oxa-9,10-seco-5,7,10(19)-cholestatriene-1,3-diol
VVD0046
Sachiko Yamada
1a-OH-22-oxa-D3
C26H42O3 402.610 Download ChemDraw structure file

[a]d-24 -30.2 deg (c = 0.86 in EtOH) (Ref. 0208)
lmax (EtOH) (nm) 262 (Ref. 0208)
1H-NMR (d, CDCl3) 0.53 (3H, s), 0.89 (3H, d, J = 6.7 Hz), 0.90 (3H, d, J = 6.7 Hz), 1.16 (3H, d, J = 6.2 Hz), 2.32 (1H, dd, J = 13.6 and 6.8 Hz), 2.60 (1H, dd, J = 13.6 and 3.4 Hz), 2.84 (1H, dd, J = 12.2 and 3.4 Hz), 3.10-3.30 (2H, m), 3.48-3.62 (1H, m), 4.14-4.28 (1H, m), 4.38-4.50 (1H, m), 4.99 (1H, t, J = 1.6 Hz), 5.32 (1H, t, J = 1.6 Hz), 6.02 (1H, d, J = 11.4 Hz), 6.37 (1H, d, J = 11.4 Hz) (Ref. 0208)
m/z 402 (M+), 71 (100%) (Ref. 0208)
Colorless glass (Ref. 0208)


Synthesis from dehydroepiandrostertone via 5,7-diene compound by photochemical method. (Ref. 0208)



45
25-hydroxy-23-oxavitamin D3 / 25-hydroxy-23-oxacholecalciferol
(5Z,7E)-(3S)-23-oxa-9,10-seco-5,7,10(19)-cholestatriene-3,25-diol
VVD0047
Sachiko Yamada
25-OH-23-oxa-D3
C26H42O3 402.610 Download ChemDraw structure file
Affinity for chick intestinal receptor: 6% of 1,25-(OH)2D3. (Ref. 0359)









46
1a,25-dihydroxy-24-norvitamin D3 / 1a,25-dihydroxy-24-norcholecalciferol
(5Z,7E)-(1S,3R)-24-nor-9,10-seco-5,7,10(19)-cholestatriene-1,3,25-triol
VVD0048
Sachiko Yamada
1a,25-(OH)2-24-nor-D3
C26H42O3 402.610 Download ChemDraw structure file
HL-60 human promyelocytes differentiation: ED50 in nitro blue tetrazolium reduction, phagocytic activity and nonspecific acid esterase activity are 1.5 times 10-7 M, 1.2 times 10-7 M and 1.6 times 10-7 M, respectively, when 1,25-(OH)2D3 shows the respective ED50 values of 1.0 times 10-8 M, 1.0 times 10-8 M and 1.1 times 10-8 M, respectively. (Ref. 0228)
Biological activity (% of 1,25-(OH)2D3effect) : Intestinal calcium absorption in chick, 2.0% ; Bone calcium mobilization in chick, 2.0% ; Competitive binding to the vitamin D receptor in chick intetine, 1.0% ; Inhibition of clonal growth of human leukemia cells (HL-60), ED50 was not reached. (Ref. 0238)









47
1a,25-dihydroxy-19-norprevitamin D3 / 1a,25-dihydroxy-19-norprecholecalciferol
(6Z)-(1S,3R)-19-nor-9,10-seco-5(10),6,8-cholestatriene-1,3,25-triol
VVD0049
Sachiko Yamada
1a,25-(OH)2-19-norpre-D3
C26H42O3 402.610 Download ChemDraw structure file
Biological activity : The affinity of the title compound for the intestinal vitamin D receptor and plasma vitamin D binding protein was 1 and 6% of that of 1,25-(OH)2D3, respectively. The in vitro effects on human promyeloid leukemia (HL-60 cell) differentiation and osteocalcin secretion by human osteosarcoma (MG-63) cells by the title compound were poor (2%). This compound showed no in vivo calcemic effects. (Ref. 0222)





Lower-half of the vitamin, silyl protected 1-ethynyl-1-cyclohexene-3S,5R-diol, was synthesized from shikimic acid in 8 steps in 25% overall yield. Palladium catalyzed coupling of the lower-half with upper-half (25-hydroxy-des-AB-cholest-8-en-8-yl triflate) yielded 6,7-didehydroprevitamin D which by partial hydrogenation followed by deprotection afforded the target vitamin, 1,25-(OH)2-19-norpre-D3. (Ref. 0230)



48
1a,25-dihydroxy-21-norvitamin D3 / 1a,25-dihydroxy-21-norcholecalciferol
(5Z,7E)-(1S,3R)-21-nor-9,10-seco-5,7,10(19)-cholestatriene-1,3,25-triol
VVD0050
Sachiko Yamada
1a,25-(OH)2-21-nor-D3
C26H42O3 402.610 Download ChemDraw structure file
Differentiation inducing activity of HL-60 (ED50):2.9 times 10-8 M (1,25-(OH)2D3: 8.3 times 10-9 M). Binding affinity for chick intestinal receptor: 1/10 of 1a,25-(OH)2D3. Calcemic activity at the dose of 500 mg/kg in normal mice ; 9.68 pm 0.15 (1.25-(OH)2D3 ; 11.04 pm 0.12 at 10mg/kg). (Ref. 0209)
lmax (EtOH) (nm) 262, lmin (nm) 227 (Ref. 0209)
(neat) 3380, 1470, 1450, 1375, 1060 cm-1 (Ref. 0209)
1H-NMR (d) 0.44 (3H, s), 1.21 (6H, s), 1.25 (3H, br s), 4.14-4.28 (1H, br), 4.34-4.47 (1H, br), 5.00 (1H, s), 5.33 (1H, s), 6.01 (1H, d, J = 11.0 Hz), 6.38 (1H, d, J = 11.0 Hz) (Ref. 0209)
m/z 402 (M+), 134 (100%) (Ref. 0209)

Preparative TLC devbeloped twice with CH2Cl2-EtOH (50 : 7) (Ref. 0209)

Synthesis from dehydroepiandrostertone via 5,7-diene compound by photochemical method. (Ref. 0209)



49
1a,25-dihydroxy-3-deoxy-3-thiavitamin D3 3-oxide / 1a,25-dihydroxy-3-deoxy-3-thiacholecalciferol 3-oxide
(5E,7E)-(1R,3R)-1,25-dihydroxy-9,10-seco-3-thia-5,7,10(19)-cholestatriene 3-oxide
VVD0051
Sachiko Yamada
3-deoxy-3-thia-1a,25-(OH)2 3-oxide
C26H42O3S 434.676 Download ChemDraw structure file
Affinity for chicken intestinal receptor : 27.0% of 1,25-(OH)2D3 effect. Inhibitory effect on 25-OHD3 1a-hydroxylase activity was evaluated. (Ref. 0306)
lmax (100% EtOH) (nm) (e) 268 (17500) (Ref. 0306)
1H-NMR (d, CDCl3, 300MHz) 0.53 (3H, s, 18C-CH3), 0.94 (3H, d, J = 6.0 Hz, 21C-CH3), 1.22 (6H, s, 26C- and 27C-CH3), 2.80 (1H, br d, J = 11.7 Hz, 9b-H), 3.00 (1H, dd, J = 12.8, 9.2 Hz, 2-H), 3.20 (1H, d with fine structure, J = 12.8 Hz, 2-H), 3.55 and 3.65 (2H, AB pattern, J = 13.0 Hz, 4-H2), 4.81 (1H, m, 1-H), 5.14 (1H, s, 19-H), 5.49 (1H, s, 19-H), 5.97 and 6.57 (2H, AB pattern, J = 11.1 Hz, 6- and 7-H) (Ref. 0306)
m/z 434 (3, M+), 416 (13, M+-H2O), 399 (7), 381 (5), 367 (9), 350 (11), 323 (6), 305 (3), 287 (5), 239 (8), 225 (5), 213 (7), 197 (7), 185 (9), 171 (10), 159 (15), 145 (22), 133 (21), 119 (30), 107 (28), 95 (40), 81 (42), 69 (58), 59 (base) (Ref. 0306)



From corresponding 3-thiavitamin D (1a,25-dihydroxy-3-deoxy-3-thiavitamin D3) by oxidation with mCPBA followed by separation of epimers at S-3 by HPLC. (Ref. 0306)



50
(5E)-(3S)-1a,25-dihydroxy-3-deoxy-3-thiavitamin D3 3-oxide / (5E)-(3S)-1a,25-dihydroxy-3-deoxy-3-thiacholecalciferol 3-oxide
(5E,7E)-(1R,3S)-1,25-dihydroxy-9,10-seco-3-thia-5,7,10(19)-cholestatrien 3-oxide
VVD0052
Sachiko Yamada
(5E)-3-deoxy-3S-thia-1a,25-(OH)2D3 3-oxide
C26H42O3S 434.676 Download ChemDraw structure file
Affinity for chicken intestinal receptor : 0.8% of 1,25-(OH)2D3 effect. Inhibitory effect on 25-OHD3 1a-hydroxylase activity was evaluated. (Ref. 0306)
lmax (100% EtOH) (nm) (e) 272 (18000) (Ref. 0306)
1H-NMR (d, CDCl3, 300MHz) 0.53 (3H, s, 18C-CH3), 0.93 (3H, d, J = 6.3 Hz, 21C-CH3), 1.21 (6H, s, 26C- and 27C-CH3), 2.76 (1H, dd, J = 14.0, 2.0 Hz, 2-H), 2.85 (1H, br d, J = 13.5 Hz, 9b-H), 3.47 (1H, ddd, J = 14.0, 3.0 Hz, 2-H), 3.60 and 3.80 (2H, AB pattern, J = 13.2 Hz, 4-H2 ; the 3.80 signal was further split, d, J = 2.7 Hz), 4.62 (1H, m, 1-H), 5.08 (1H, d, J = 1.8 Hz, 19-H), 5.37 (1H, d, J = 1.8 Hz, 19-H), 6.05 and 6.72 (2H, AB pattern, J = 11.1 Hz, 6- and 7-H) (Ref. 0306)
m/z 434 (25, M+), 416 (52, M+-H2O), 398 (50), 383 (24), 367 (31), 341 (93), 325 (77), 309 (25), 287 (23), 269 (28), 239 (27), 213 (58), 185 (55), 171 (68), 145 (62), 119 (base), 105 (30), 95 (57), 81 (53), 69 (78), 59 (56) (Ref. 0306)



From corresponding 3-thiavitamin D (1a,25-dihydroxy-3-deoxy-3-thiavitamin D3) by mCPBA oxidation followed by HPLC separation from 3-epimer. (Ref. 0306)



51
(5Z)-1a,25-dihydroxy-3-deoxy-3-thiavitamin D3 3-oxide / (5Z)-1a,25-dihydroxy-3-deoxy-3-thiacholecalciferol 3-oxide
(5Z,7E)-(1R,3R)-1,25-dihydroxy-9,10-seco-3-thia-5,7,10(19)-cholestatriene 3-oxide
VVD0053
Sachiko Yamada
(5Z)-3-deoxy-3-thia-1a,25-(OH)2D3 3-oxide
C26H42O3S 434.676 Download ChemDraw structure file
Affinity for chicken intestinal receptor : 3.7% of 1,25-(OH)2D3 effect. Inhibitory effect on 25-OHD3 1a-hydroxylase activity was evaluated. (Ref. 0306)
lmax (100% EtOH) (nm) (e) 272 (18000) (Ref. 0306)
1H-NMR (d, CDCl3, 300MHz) 0.56 (3H, s, 18C-CH3), 0.94 (3H, d, J = 6.3 Hz, 21C-CH3), 1.22 (6H, s, 26C- and 27C- CH3), 2.85 (1H, br d, J = 12.6 Hz, 9b-H), 3.10 (1H, dd, J = 12.8, 3.0 Hz, 2-H), 3.30 (1H, ddd, J = 12.8, 7.3, 1.3 Hz, 2-H), 3.63 and 4.03 (2H, AB pattern, J = 13.1 Hz, 4-H2), 4.88 (1H, m, 1-H), 5.16 (1H, br s, 19-H), 5.26 (1H, br s, 19-H), 5.86 and 6.78 (2H, AB pattern, J = 11.5 Hz, 6- and 7-H) (Ref. 0306)
m/z 434 (19, M+), 416 (48, M+-H2O), 399 (21), 367 (25), 350 (55), 335 (11), 287 (19), 267 (13), 239 (32), 185 (26), 145 (63), 107 (83), 95 (base), 81 (97), 69 (11), 59 (16) (Ref. 0306)



From corresponding (5E)-vitamin D (1a,25-dihydroxy-3-deoxy-3-thiavitamin D3 3-oxide) by geometrical isomerization catalyzed by iodine. (Ref. 0306)



52
(5Z)-(3S)-1a,25-dihydroxy-3-deoxy-3-thiavitamin D3 3-oxide / (5Z)-(3S)-1a,25-dihydroxy-3-deoxy-3-thiacholecalciferol 3-oxide
(5Z,7E)-(1R,3S)-1,25-dihydroxy-9,10-seco-3-thia-5,7,10(19)-cholestatrien 3-oxide
VVD0054
Sachiko Yamada
(5Z)-3-deoxy-3S-thia-1a,25-(OH)2D3 3-oxide
C26H42O3S 434.676 Download ChemDraw structure file
Affinity for chicken intestinal receptor : 0.9% of 1,25-(OH)2D3 effect. Inhibitory effect on 25-OHD3 1a-hydroxylase activity was evaluated. (Ref. 0306)
lmax (100% EtOH) (nm) (e) 270 (17800) (Ref. 0306)
1H-NMR (d, CDCl3, 300MHz) 0.57 (3H, s, 18C-CH3), 0.94 (3H, d, J = 6.0 Hz, 21C-CH3), 1.22 (6H, s, 26C- and 27C-CH3), 2.77 (1H, dd, J = 13.9, 2.8 Hz, 2-H), 2.85 (1H, br d, J = 12.6 Hz, 9b-H), 3.40 (1H, d, J = 14.0 Hz, 4-H), 3.50 (1H, ddd, J = 13.9, 4.2, 2.6 Hz, 2-H), 4.30 (1H, dd, J = 14.0, 2.3 Hz, 4-H), 4.64 (1H, m, 1-H), 4.80 (1H, d, J = 10.2 Hz ; this has been assigned to the OH), 5.10 (1H, s, 19-H), 5.21 (1H, d, J = 1.2 Hz, 19-H), 5.86 and 6.96 (2H, AB pattern, J = 11.4 Hz, 6- and 7-H) (Ref. 0306)
m/z 434 (5, M+), 416 (11, M+-H2O), 399 (5), 367 (9), 350 (14), 335 (4), 287 (6), 267 (5), 239 (8), 211 (6), 185 (9), 133 (25), 105 (32), 95 (46), 81 (49), 69 (64), 59 (base) (Ref. 0306)



From corresponding 3-thiavitamin D (1a,25-dihydroxy-3-deoxy-3-thiavitamin D3) by mCPBA oxidation followed by iodine catalyzed isomerization. (Ref. 0306)



53
1a,25-dihydroxy-22-thiavitamin D3 / 1a,25-dihydroxy-22-thiacholecalciferol
(5Z,7E)-(1S,3R)-9,10-seco-22-thia-5,7,10(19)-cholestatriene-1,3,25-triol
VVD0055
Sachiko Yamada
22-thia-1a,25-(OH)2D3
C26H42O3S 434.676 Download ChemDraw structure file

lmax (EtOH) (nm) 264, lmin (nm) 227 (Ref. 0215)
(neat) 3380, 2920, 1440, 1370, 1050 cm-1 (Ref. 0215)
1H-NMR (d, CDCl3, 200MHz) 0.58 (3H, s), 1.25 (6H, s), 1.39 (3H, d, J = 6.6 Hz), 2.63 (2H, t, J = 7.8 Hz), 4.17-4.30 (1H, br), 4.35-4.48 (1H, br), 5.00 (1H, s), 5.33 (1H, s), 6.01 (1H, d, J = 11.1 Hz), 6.37 (1H, d, J = 11.1 Hz) (Ref. 0215)

HRMS Calcd 434.2855, Found 434.2829 (Ref. 0215)


Synthesis from dehydroepiandrostertone via the 5,7-diene by photochemical method. (Ref. 0215)



54
1a,25-dihydroxy-22-thia-20-epivitamin D3 / 1a,25-dihydroxy-22-thia-20-epicholecalciferol
(5Z,7E)-(1S,3R,20R)-9,10-seco-22-thia-5,7,10(19)-cholestatriene-1,3,25-triol
VVD0056
Sachiko Yamada
22-thia-1a,25-(OH)2-20-epi-D3
C26H42O3S 434.676 Download ChemDraw structure file

lmax (EtOH) (nm) 264, lmin (nm) 227 (Ref. 0215)
(neat) 3390, 2920, 1450, 1380, 1060 cm-1 (Ref. 0215)
1H-NMR (d, CDCl3, 200MHz) 0.62 (3H, s), 1.25 (6H, s), 1.30 (3H, d, J = 6.6 Hz), 2.61 (2H, t, J = 8.3 Hz), 4.13-4.30 (1H, br), 4.36-4.48 (1H, br), 5.00 (1H, s), 5.33 (1H, s), 6.02 (1H, d, J = 11.1 Hz), 6.37 (1H, d, J = 11.1 Hz) (Ref. 0215)

HRMS Calcd 434.2855, Found 434.2837 (Ref. 0215)


Synthesis from dehydroepiandrostertone via the 5,7-diene by photochemical method. (Ref. 0215)



55
1a,25-dihydroxy-23-thiavitamin D3 / 1a,25-dihydroxy-23-thiacholecalciferol
(5Z,7E)-(1S,3R)-9,10-seco-23-thia-5,7,10(19)-cholestatriene-1,3,25-triol
VVD0057
Sachiko Yamada
23-thia-1a,25-(OH)2D3
C26H42O3S 434.676 Download ChemDraw structure file
Differentiation inducing activity of HL-60 was shown in comparison with 1,25-(OH)2D3. (Ref. 0210)
lmax (EtOH) (nm) 263, lmin (nm) 227 (Ref. 0210)
1H-NMR (d, CDCl3) 0.56 (3H, s), 1.10 (3H, d, J = 6.2 Hz), 1.28 (6H, s), 2.53-2.89 (2H, m), 2.63 (2H, s), 4.09-4.29 (1H, br), 4.36-4.49 (1H, br), 4.99 (1H, s), 5.32 (1H, s), 6.01 (1H, d, J = 11.4 Hz), 6.37 (1H, d, J = 11.4 Hz) (Ref. 0210)
m/z 434 (M+), 134 (100%) (Ref. 0210)

1)flash column chromatography using CH2Cl2-EtOH (5 : 0.3), 2)Preparative TLC developed twice with CH2Cl2-EtOH (10 : 1) (Ref. 0210)

Synthesis from dehydroepiandrostertone via 5,7-diene compound by photochemical method. (Ref. 0210)



56
(24R)-1a,24-dihydroxy-22-oxavitamin D3 / (24R)-1a,24-dihydroxy-22-oxacholecalciferol
(5Z,7E)-(1S,3R,24R)-22-oxa-9,10-seco-5,7,10(19)-cholestatriene-1,3,24-triol
VVD0058
Sachiko Yamada
1a,24R-(OH)2-22-oxa-D3
C26H42O4 418.609 Download ChemDraw structure file
The activity to induce differentiation of human myeloid leukemia cells (HL-60) into macrophases in vitro estimated by superoxide anion generation : ED50 = 9.17 times 10-9 M [ED50 of 1,25-(OH)2D3 : 3.76 times 10-9 M, ED50 of OCT : 1.16 times 10-9 M] the binding affinity for the chick embryonic intestinal 1,25-(OH)2D3 receptor : 0.016, 1,25-(OH)2D3 : 1, OCT : 0.17 (Ref. 0206)
[a]d-24 46.00 deg (c = 0.1 in EtOH) (Ref. 0206)
lmax (EtOH) (nm) 263, lmin (nm) 227 (Ref. 0206)
(neat) 3390, 1470, 1450, 1375, 1055 cm-1 (Ref. 0206)
1H-NMR (d, CDCl3) 0.53 (3H, s), 0.90 (3H, d, J = 6.8 Hz), 0.97 (3H, d, J = 6.8 Hz), 1.18 (3H, d, J = 6.0 Hz), 3.08 (1H, t, J = 8.8 Hz), 3.20-3.32 (1H, m), 3.36-3.48 (1H, m), 3.67 (1H, dd, J = 3.0 and 9.1 Hz), 4.17-4.28 (1H, br), 4.37-4.48 (1H, br), 4.99 (1H, s), 5.33 (1H, s), 6.02 (1H, d, J = 11.4 Hz), 6.37 (1H, d, J = 11.4 Hz) (Ref. 0206)
m/z 418 (M+), 87 (100%) (Ref. 0206)
HRMS Calcd 418.3083, Found 418.3080 (Ref. 0206)


Synthesis from dehydroepiandrostertone via 1a,3b-dihydroxy-20(S)-[2(R)-hydroxy-3-methylbutyloxy]pregna-5,7-diene by photochemical method. (Ref. 0206)



57
(24R)-1a,24-dihydroxy-22-oxa-20-epivitamin D3 / (24R)-1a,24-dihydroxy-22-oxa-20-epicholecalciferol
(5Z,7E)-(1S,3R,20R,24R)-22-oxa-9,10-seco-5,7,10(19)-cholestatriene-1,3,24-triol
VVD0059
Sachiko Yamada
1a,24R-(OH)2-20-epi-22-oxa-D3
C26H42O4 418.609 Download ChemDraw structure file
The activity to induce differentiation of human myeloid leukemia cells (HL-60) into macrophases in vitro estimated by superoxide anion generation : ED50 = 2.40 times 10-8 M [ED50 of 1,25-(OH)2D3 : 3.76 times 10-9 M, ED50 of OCT : 1.16 times 10-9 M] the binding affinity for the chick embryonic intestinal 1,25-(OH)2D3 receptor : 0.16, 1,25-(OH)2D3 : 1, OCT : 0.17 (Ref. 0206)
[a]d-23 -30.68 deg (c = 0.365 in EtOH) (Ref. 0206)
(EtOH) lmax (nm) 263, lmin (nm) 227 (Ref. 0206)
(neat) 3400, 1450, 1370, 1110, 1060 cm-1 (Ref. 0206)
1H-NMR (d, CDCl3) 0.57 (3H, s), 0.91 (3H, d, J = 6.8 Hz), 0.98 (3H, d, J = 6.8 Hz), 1.10 (3H, d, J = 6.2 Hz), 3.23-3.40 (2H, m), 3.40-3.53 (2H, m), 4.16-4.28 (1H, br), 4.37-4.48 (1H, br), 4.99 (1H, s), 5.31 (1H, s), 5.99 (1H, d, J = 11.4 Hz), 6.38 (1H, d, J = 11.4 Hz) (Ref. 0206)
m/z 418 (M+), 87 (100%) (Ref. 0206)
HRMS Calcd 418.3083, Found 418.3080 (Ref. 0206)


Synthesis from dehydroepiandrostertone via 1a,3b-dihydroxy-20(R)-[2(R)-hydroxy-3-methylbutyloxy]pregna-5,7-diene by photochemical method. (Ref. 0206)



58
(24S)-1a,24-dihydroxy-22-oxavitamin D3 / (24S)-1a,24-dihydroxy-22-oxacholecalciferol
(5Z,7E)-(1S,3R,24S)-22-oxa-9,10-seco-5,7,10(19)-cholestatriene-1,3,24-triol
VVD0060
Sachiko Yamada
1a,24S-(OH)2-22-oxa-D3
C26H42O4 418.609 Download ChemDraw structure file
The activity to induce differentiation of human myeloid leukemia cells (HL-60) into macrophases in vitro estimated by superoxide anion generation: ED50 = 1.37 times 10-9 M [ED50 of 1,25-(OH)2D3 : 3.76 times 10-9 M, ED50 of OCT : 1.16 times 10-9 M] the binding affinity for the chick embryonic intestinal 1,25-(OH)2D3 receptor : 0.34, 1,25-(OH)2D3 : 1, OCT : 0.17. (Ref. 0206)
[a]d-24 56.0 deg (c = 0.1 in EtOH) (Ref. 0206)
(EtOH) lmax (nm) 263, lmin (nm) 227 (Ref. 0206)
(neat) 3390, 1470, 1450, 1370, 1050 cm-1 (Ref. 0206)
1H-NMR (d, CDCl3) 0.53 (3H, s), 0.90 (3H, d, J = 6.8 Hz), 0.97 (3H, d, J = 6.6 Hz), 1.17 (3H, d, J = 6.2 Hz), 3.22-3.36 (2H, m), 3.36-3.49 (2H, m), 4.16-4.28 (1H, br), 4.37-4.48 (1H, br), 5.00 (1H, s), 5.34 (1H, s), 6.02 (1H, d, J = 11.4 Hz), 6.37 (1H, d, J = 11.4 Hz) (Ref. 0206)
m/z 418 (M+), 87 (100%) (Ref. 0206)
HRMS Calcd 418.3083, Found 418.3078 (Ref. 0206)


Synthesis from dehydroepiandrostertone via 1a,3b-dihydroxy-20(S)-[2(S)-hydroxy-3-methylbutyloxy]pregna-5,7-diene by photochemical method. (Ref. 0206)



59
(24S)-1a,24-dihydroxy-22-oxa-20-epivitamin D3 / (24S)-1a,24-dihydroxy-22-oxa-20-epicholecalciferol
(5Z,7E)-(1S,3R,20R,24S)-22-oxa-9,10-seco-5,7,10(19)-cholestatriene-1,3,24-triol
VVD0061
Sachiko Yamada
1a,24S-(OH)2-20-epi-22-oxa-D3
C26H42O4 418.609 Download ChemDraw structure file
The activity to induce differentiation of human myeloid leukemia cells (HL-60) into macrophases in vitro estimated by superoxide anion generation : ED50 = 4.68 times 10-8 M [ED50 of 1,25-(OH)2D3 : 3.76 times 10-9 M, ED50 of OCT : 1.16 times 10-9 M] the binding affinity for the chick embryonic intestinal 1,25-(OH)2D3 receptor : 0.003, 1,25-(OH)2D3 : 1, OCT : 0.17 (Ref. 0206)
[a]d-23 -24.24 deg (c = 0.165 in EtOH) (Ref. 0206)
(EtOH) lmax (nm) 263, lmin (nm) 227 (Ref. 0206)
(neat) 3390, 1450, 1370, 1055 cm-1 (Ref. 0206)
1H-NMR (d, CDCl3) 0.57 (3H, s), 0.90 (3H, d, J = 6.8 Hz), 0.97 (3H, d, J = 6.8 Hz), 1.10 (3H, d, J = 6.2 Hz), 3.10 (1H, t, J = 8.6 Hz), 3.24-3.35 (1H, m), 3.35-3.48 (1H, m), 3.61 (1H, dd, J = 3.0 and 9.1 Hz), 4.15-4.27 (1H, br), 4.26-4.34 (1H, br), 4.97 (1H, s), 5.30 (1H, s), 5.97 (1H, d, J = 11.4 Hz), 6.36 (1H, d, J = 11.4 Hz) (Ref. 0206)
m/z 418 (M+), 87 (100%) (Ref. 0206)
HRMS Calcd 418.3083, Found 418.3124 (Ref. 0206)


Synthesis from dehydroepiandrostertone via 1a,3b-dihydroxy-20(R)-[2(S)-hydroxy-3-methylbutyloxy]pregna-5,7-diene by photochemical method. (Ref. 0206)



60
1a,25-dihydroxy-22-oxavitamin D3 / 1a,25-dihydroxy-22-oxacholecalciferol
(5Z,7E)-(1S,3R)-22-oxa-9,10-seco-5,7,10(19)-cholestatriene-1,3,25-triol
VVD0062
Sachiko Yamada
1a,25-(OH)2-22-oxa-D3
C26H42O4 418.609 Download ChemDraw structure file
The activity inducing differentiation of human myeloid leukemia cells (HL-60) into macrophases in vitro estimated by superoxide anion generation : ED50 of OCT : 4.90 times 10-9 M, ED50 of 1,25(OH)2D3 : 1.70 times 10-8 M. the binding affinity for the chick embryonic intestinal 1,25-(OH)2D3 receptor : 12.5%, 1,25-(OH)2D3 : 100%. (Ref. 0203)
(EtOH) lmax (nm) 262, lmin (nm) 227 (Ref. 0203)
(KBr) 3390, 1370, 1145, 1085, 1050 cm-1 (Ref. 0203)
1H-NMR (d, CDCl3) 0.54 (3H, s), 1.18 (3H, d, J = 6.3 Hz), 1.23 (6H, s), 2.31 (1H, dd, J = 13.7, 6.6 Hz), 2.60 (1H, dd, J = 13.7, 3.4 Hz), 2.82 (1H, dd, J = 12.0, 1.7 Hz), 3.25 (1H, quintet, J = 6.3 Hz), 3.47 (1H, dt, J = 9.1, 5.4 Hz), 3.75-3.91 (2H, m), 4.16-4.30 (1H, m), 4.36-4.50 (1H, m), 4.98 (1H, t, J = 1.4 Hz), 5.32 (1H, t, J = 1.4 Hz), 6.02 (1H, d, J = 11.4 Hz), 6.36 (1H, d, J = 11.4 Hz) (Ref. 0208)
m/z 418 (M+), 69 (100%) (Ref. 0208)
colorless glass (Ref. 0208)
1) Flash column chromatography with CH2Cl2/EtOH (12.5 : 1), 2) Flash column chromatography with AcOEt/n-hexane (6 : 1) (Ref. 0203)

Synthesis from dehydroepiandrostertone via 1a,3b-dihydroxy-20(S)-(3-hydroxy-3-methylbutyloxy)pregna-5,7-diene by photochemical method. (Ref. 0203)
Metabolism of the title compound was studied in four cultured cell models representing liver, keratinocyte and osteoblast, and 24-hydroxylated and 26-hydroxylated derivatives as well as the side-chain cleaved molecules, hexanor-1a,20-dihydroxyvitamin D3 and hexanor-20-oxo-1a-hydroxyvitamin D3 were identified. (Ref. 0323)


61
1a,25-dihydroxy-22-oxa-20-epivitamin D3 / 1a,25-dihydroxy-22-oxa-20-epicholecalciferol
(5Z,7E)-(1S,3R,20R)-22-oxa-9,10-seco-5,7,10(19)-cholestatriene-1,3,25-triol
VVD0063
Sachiko Yamada
1a,25-(OH)2-20-epi-22-oxa-D3
C26H42O4 418.609 Download ChemDraw structure file
The activity to induce differentiation of human myeloid leukemia cells (HL-60) into macrophases in vitro estimated by superoxide anion generation : ED50 = 1.46 times 10-9 M [ED50 of 1,25-(OH)2D3 : 3.76 times 10-9 M, ED50 of OCT: 1.16 times 10-9 M] the binding affinity for the chick embryonic intestinal 1,25-(OH)2D3 receptor : 0.08, 1,25-(OH)2D3 : 1, OCT : 0.17 (Ref. 0206)
[a]d-24 -66.0 deg (c = 0.1 in EtOH) (Ref. 0206)
(EtOH) lmax (nm) 263, lmin (nm) 227 (Ref. 0206)
(neat) 3390, 1455, 1370, 1060 cm-1 (Ref. 0206)
1H-NMR (d, CDCl3) 0.55 (3H, s), 1.13 (3H, d, J = 6.0 Hz), 1.23 (6H, s), 3.16-3.32 (1H, m), 3.36-3.58 (1H, m), 3.70-3.90 (1H, m), 4.13-4.27 (1H, m), 4.34-4.48 (1H, br), 4.99 (1H, s), 5.30 (1H, s), 5.99 (1H, d, J = 11.6 Hz), 6.38 (1H, d, J = 11.6 Hz) (Ref. 0206)
m/z 418 (M+), 69 (100%) (Ref. 0206)
HRMS Calcd 418.3083, Found 418.3058 (Ref. 0206)


Synthesis from dehydroepiandrostertone via 1a,3b-dihydroxy-20(R)-(3-hydroxy-3-methylbutyloxy)pregna-5,7-diene by photochemical method. (Ref. 0206)



62
1b,25-dihydroxy-22-oxavitamin D3 / 1b,25-dihydroxy-22-oxacholecalciferol
(5Z,7E)-(1R,3R)-22-oxa-9,10-seco-5,7,10(19)-cholestatriene-1,3,25-triol
VVD0064
Sachiko Yamada
1b,25-(OH)2-22-oxa-D3
C26H42O4 418.609 Download ChemDraw structure file
The antiproliferation activity on HL-60 was 0.003 [1.25-(OH)2D3 : 1]. The binding affinity for both vitamin D receptor and vitamin D binding protein was 0.7% of the effect of a,25-(OH)2D3. (Ref. 0214)
(EtOH) lmax (nm) 263, lmin (nm) 221 (Ref. 0214)
1H-NMR (d, CDCl3) 0.54 (3H, s), 1.19 (3H, d, J = 5.9 Hz), 1.24 (6H, s), 3.21-3.34 (1H, m), 3.43-3.55 (1H, m), 3.79-3.89 (1H, m), 4.05-4.15 (1H, m), 4.31-4.40 (1H, m), 5.00 (1H, s), 5.29 (1H, s), 6.06 (1H, d, J = 10.9 Hz), 6.44 (1H, d, J = 10.9 Hz) (Ref. 0214)
m/z 418 (M+), 69 (100%) (Ref. 0214)
HRMS Calcd 418.3083, Found 418.3112 (Ref. 0214)


Synthesis from OCT by inversion of the 1a-hydroxy group. (Ref. 0214)



63
1a,25-dihydroxy-23-oxavitamin D3 / 1a,25-dihydroxy-23-oxacholecalciferol
(5Z,7E)-(1S,3R)-23-oxa-9,10-seco-5,7,10(19)-cholestatriene-1,3,25-triol
VVD0065
Sachiko Yamada
1a,25-(OH)2-23-oxa-D3
C26H42O4 418.609 Download ChemDraw structure file
Activity of inducing HL-60 cell differentiation was compared with 1,25-(OH)2D3. (Ref. 0210)
lmax (EtOH) (nm) 263, lmin (nm) 227 (Ref. 0210)
1H-NMR (d, CDCl3) 0.57 (3H, s), 1.05 (3H, d, J = 6.2 Hz), 1.21 (6H, s), 3.11-3.47 (4H, m), 4.03-4.27 (1H, br), 4.35-4.47 (1H, br), 4.99 (1H, s), 5.35 (1H, s), 6.00 (1H, d, J = 11.4 Hz), 6.36 (1H, d, J = 11.4 Hz) (Ref. 0210)
m/z 418 (M+), 59 (100%) (Ref. 0210)

1)Flash column chromatography using CH2Cl2-EtOH (5 : 0.3), 2)Preparative TLC developed twice with CH2Cl2-EtOH (10 : 1) (Ref. 0210)

Synthesis from dehydroepiandrostertone via 5,7-diene compound by photochemical method.(Ref. 0210)



64
1a,25-dihydroxy-22-oxa-[2b-3H]vitamin D3 / 1a,25-dihydroxy-22-oxa-[2b-3H]cholecalciferol
(5Z,7E)-(1S,3R)-22-oxa-[2b-3H]-9,10-seco-5,7,10(19)-cholestatriene-1,3,25-triol
VVD0066
Sachiko Yamada
1a,25-(OH)2-22-oxa-[2b-3H]-D3
C26H413H1O4 793.563 Download ChemDraw structure file



15.0 Ci/mmol (Ref. 0218)


Synthesis by photochemical method from the [2b-3H]-5,7-diene. (Ref. 0218/0219)



65
1a,25-dihydroxy-20-oxa-[26,26,26-3H3]vitamin D3 / 1a,25-dihydroxy-20-oxa-[26,26,26-3H3]cholecalciferol
(5Z,7E)-(1S,3R)-22-oxa-[26,26,26-3H3]-9,10-seco-5,7,10(19)-cholestatriene-1,3,25-triol
VVD0067
Sachiko Yamada
1a,25-(OH)2-22-oxa-[26,26,26-3H3]-D3
C26H393H3O4 775.420 Download ChemDraw structure file



86.5 Ci/mmol (Ref. 0218)


Synthesis by photochemical method from the [26,26,26-3H3]-5,7-diene. (Ref. 0218)



66
(20S)-1a,20,25-trihydroxy-24-norvitamin D3/(20S)-1a,20,25-trihydroxy-24-norcholecalciferol
(5Z,7E)-(1S,3R,20S)-24-nor-9,10-seco-5,7,10(19)-cholestatriene-1,3,20,25-tetrol
VVD0068
Sachiko Yamada
1a,20S,25-(OH)3-24-nor-D3
C26H42O4 418.609 Download ChemDraw structure file
Biological activity (% of 1,25-(OH)2D3 effect) : Inhibition of U 937 cell (human histiocytic lymphoma cell line) proliferation : <4% ; Binding for the 1,25-(OH)2D3 receptor from rachitic chicken intestine : <0.1% ; Calcemic activity : not determined. (Ref. 0279)





From (5E)-1a-hydroxy-20-keto-22,23,24,25,26,27-hexanorvitamin D3 derivative by addition of a Grignard reagent followed by photochemical isomerization and deprotection. (Ref. 0279)



67
(24R)-1a,24,25-trihydroxy-22-oxavitamin D3 / (24R)-1a,24,25-trihydroxy-22-oxacholecalciferol
(5Z,7E)-(1S,3R,24R)-22-oxa-9,10-seco-5,7,10(19)-cholestatriene-1,3,24,25-tetrol
VVD0069
Sachiko Yamada
1a,24R,25-(OH)3-22-oxa-D3
C26H42O5 434.609 Download ChemDraw structure file
The antiproliferation activity towards HL-60 was 1/2 of 22-oxacalcitriol (OCT). The binding affinity for bovine thymus vitamin D receptor was 1/3 of OCT. (Ref. 0213)
[a]d-20 44.0 deg (c = 0.29 in EtOH) (Ref. 0212)
(EtOH) lmax (nm) 262, lmin (nm) 227 (Ref. 0212)
1H-NMR (d, CDCl3) 0.53 (3H, s), 1.19 (3H, d, J = 6.1 Hz), 1.22 (3H, s), 1.24 (3H, s), 3.26-3.32 (1H, m),3.37-3.47 (2H, m), 3.73-3.82 (1H, m), 4.16-4.27 (1H, m), 4.38-4.45 (1H, m), 4.99 (1H, s), 5.33 (1H, s), 6.02 (1H, d, J = 11.5 Hz), 6.37 (1H, d, J = 11.5 Hz) (Ref. 0212)
m/z 434 (M+), 134 (100%) (Ref. 0212)
Colorless foam. (Ref. 0213)
HRMS Calcd 434.3032, Found 434.3023 (Ref. 0212)
Preparative TLC developed twice with AcOEt. (Ref. 0213)

Synthesis from dehydroepiandrostertone via the 5,7-diene by photochemical method. (Ref. 0212/0213)



68
(24S)-1a,24,25-trihydroxy-22-oxavitamin D3 / (24S)-1a,24,25-trihydroxy-22-oxacholecalciferol
(5Z,7E)-(1S,3R,24S)-22-oxa-9,10-seco-5,7,10(19)-cholestatriene-1,3,24,25-tetrol
VVD0070
Sachiko Yamada
1a,24S,25-(OH)3-22-oxa-D3
C26H42O5 434.609 Download ChemDraw structure file
The antiproliferation activity towards HL-60 was 1/3 of 22-oxacalcitriol (OCT). The binding affinity for bovine thymus vitamin D receptor was 1/22 of OCT. (Ref. 0213)
[a]d-20 29.0 deg (c = 0.19 in EtOH) (Ref. 0212)
(EtOH) lmax (nm) 263, lmin (nm) 227 (Ref. 0212)
1H-NMR (d, CDCl3) 0.54 (3H, s), 1.19 (3H, d, J = 5.8 Hz), 1.22 (3H, s), 1.25 (3H, s), 3.22-3.29 (1H, m),3.34-3.46 (2H, m), 3.76 (1H, br d, J = 6.3 Hz), 4.14-4.25 (1H, m), 4.37-4.44 (1H, m), 4.99 (1H, s), 5.33 (1H, s), 6.02 (1H, d, J = 11.0 Hz), 6.37 (1H, d, J = 11.0 Hz) (Ref. 0212)
m/z 434 (M+), 134 (100%) (Ref. 0212)
Colorless foam. (Ref. 0213)
HRMS Calcd 434.3032, Found 434.3039 (Ref. 0212)
1)Preparative TLC developed twice with AcOEt. 2)Preparative TLC developed twice with CH2Cl2-EtOH (10 : 1). (Ref. 0213)

Synthesis from dehydroepiandrostertone via the 5,7-diene by photochemical method. (Ref. 0212/0213)



69
(25R)-1a,25,26-trihydroxy-22-oxavitamin D3 / (25R)-1a,25,26-trihydroxy-22-oxacholecalciferol
(5Z,7E)-(1S,3R,25R)-22-oxa-9,10-seco-5,7,10(19)-cholestatriene-1,3,25,26-tetrol
VVD0071
Sachiko Yamada
1a,25R,26-(OH)3-22-oxa-D3
C26H42O5 434.609 Download ChemDraw structure file
The antiproliferation activity towards HL-60 was 1/9 of 22-oxacalcitriol (OCT). The binding affinity for bovine thymus vitamin D receptor was 1/25 of OCT. (Ref. 0213)
[a]d-20 49.35 deg (c = 0.08 in EtOH) (Ref. 0212)
(EtOH) lmax (nm) 263, lmin (nm) 227 (Ref. 0212)
(neat) 3375, 2920, 2865, 1050 cm-1 (Ref. 0212)
1H-NMR (d, CDCl3) 0.53 (3H, s), 1.18 (3H, s), 1.20 (3H, d, J = 7.3 Hz), 3.25-3.57 (4H, m), 3.81-3.93 (1H, m), 4.23 (1H, br s), 4.43 (1H, br s), 4.42 (1H, br s), 4.99 (1H, s), 5.33 (1H, s), 6.02 (1H, d, J = 11.6 Hz), 6.37 (1H, d, J = 11.6 Hz) (Ref. 0212)
m/z 434 (M+), 85 (100%) (Ref. 0212)
Colorless foam. (Ref. 0213)
HRMS Calcd 434.3032, Found 434.3048 (Ref. 0212)
1)Preparative TLC developed twice with AcOEt-EtOH (25 : 1). 2)Preparative TLC developed with CH2Cl2-EtOH (20 : 3). (Ref. 0213)

Synthesis from dehydroepiandrostertone via the 5,7-diene by photochemical method. (Ref. 0212/0213)



70
(25S)-1a,25,26-trihydroxy-22-oxavitamin D3 / (25S)-1a,25,26-trihydroxy-22-oxacholecalciferol
(5Z,7E)-(1S,3R,25S)-22-oxa-9,10-seco-5,7,10(19)-cholestatriene-1,3,25,26-tetrol
VVD0072
Sachiko Yamada
1a,25S,26-(OH)3-22-oxa-D3
C26H42O5 434.609 Download ChemDraw structure file
The antiproliferation activity towards HL-60 was 1/7 of 22-oxacalcitriol (OCT). The binding affinity for bovine thymus vitamin D receptor was 1/30 of OCT. (Ref. 0213)
[a]d-20 65.85 deg (c = 0.09 in EtOH) (Ref. 0212)
(EtOH) lmax (nm) 264, lmin (nm) 227 (Ref. 0212)
(neat) 3385, 2920, 2865, 1050, 730 cm-1 (Ref. 0212)
1H-NMR (d, CDCl3) 0.54 (3H, s), 1.19 (3H, s), 1.19 (3H, d, J = 5.9 Hz), 3.21-3.34 (1H, m), 3.42 (2H, s), 3.44-3.61 (1H, m), 3.69-3.81 (1H, m), 4.22 (1H, br s), 4.43 (1H, br s), 5.00 (1H, s), 5.33 (1H, s), 6.02 (1H, d, J = 11.2 Hz), 6.37 (1H, d, J = 11.2 Hz) (Ref. 0212)
m/z 434 (M+), 85 (100%) (Ref. 0212)
Colorless foam. (Ref. 0213)
HRMS Calcd 434.3032, Found 434.3048 (Ref. 0212)
1)Preparative TLC developed twice with AcOEt-EtOH (25 : 1). 2)Preparative TLC developed with CH2Cl2-EtOH (20 : 3). (Ref. 0213)

Synthesis from dehydroepiandrostertone via the 5,7-diene by photochemical method. (Ref. 0212/0213)



71
25-azavitamin D3 / 25-azacholecalciferol
(5Z,7E)-(3S)-25-aza-9,10-seco-5,7,10(19)-cholestatrien-3-ol
VVD0073
Sachiko Yamada
25-aza-D3
C26H43NO 385.626 Download ChemDraw structure file

(EtOH) lmax (nm) 265 (Ref. 0360)
1H-NMR (d, CDCl3) 6.24 and 6.03 (2 H, AB, J = 11Hz, H-6 and -7), 5.05 (1 H, m, H-19), 4.82 (1 H, m, H-19), 3.95 (1 H, tt, J = 7.4 and 3.7 Hz, H-3), 2.31 (6 H, s, H-26 and 27), 0.93 (3 H, J = 6 Hz, H-21), 0.54 (3 H, s, H-18) (Ref. 0360)
m/z (rel. intensity) 385 (M+, 15), 370 (3), 352 (1), 84 (10), 71 (4), 58 (100) (Ref. 0360)



From C(22) tosyloxysteroid via reaction sith dimethyl acetamide as key step. (Ref. 0369)



72
1a,25-dihydroxy-23-azavitamin D3 / 1a,25-dihydroxy-23-azacholecalciferol
(5Z,7E)-(1S,3R)-23-aza-9,10-seco-5,7,10(19)-cholestatriene-1,3,25-triol
VVD0074
Sachiko Yamada
23-aza-1a,25-(OH)2D3
C26H43NO3 417.625 Download ChemDraw structure file
Differentiation inducing activity of HL-60 was shown in comparison with 1,25-(OH)2D3. (Ref. 0210)
(EtOH) lmax (nm) 263, lmin (nm) 227 (Ref. 0210)
1H-NMR (d, CDCl3) 0.57 (3H, s), 1.02 (3H, d, J = 6.2 Hz), 1.23 (6H, s), 2.51 (2H, s), 4.11-4.28 (1H, br),4.31-4.50 (1H, br), 4.99 (1H, s), 5.32 (1H, s), 6.01 (1H, d, J = 11.4 Hz), 6.37 (1H, d, J = 11.4 Hz) (Ref. 0210)
m/z 417 (M+), 43 (100%) (Ref. 0210)

Preparative TLC developed with CH2Cl2-EtOH (3 : 1). (Ref. 0210)

Synthesis from dehydroepiandrostertone via 5,7-diene compound by photochemical method. (Ref. 0210)



73
1a-hydroxy-24-(dimethylphosphoryl)-25,26,27-trinorvitamin D3 / 1a-hydroxy-24-(dimethylphosphoryl)-25,26,27-trinorcholecalciferol
(5Z,7E)-(1S,3R)-24-(dimethylphosphoryl)-9,10-seco-5,7,10(19)-cholatriene-1,3-diol
VVD0075
Sachiko Yamada
24-(dimethylphosphoryl)-1a-OH-25,26,27-trinor-D3
C26H43O3P 434.592 Download ChemDraw structure file
Biological activity (% of 1,25-(OH)2D3 effect) : Intestinal calcium absorption in chick, 0.3% ; Bone calcium mobilization in chick, 0.15% ; Competitive binding to the vitamin D receptor in chick intestine, 0.35% ; Inhibition of clonal growth of human leukemia cells (HL-60), ED50 was not reached. (Ref. 0238)
[a]D +33.1 deg (c = 0.95 in CH2Cl2) (Ref. 0283)
(EtOH) lmax (nm) (e) 265 (14700), 212 (12700) (Ref. 0283)
(Film) 3380, 2940, 2890, 1650, 1305, 1235, 1060 cm-1 (Ref. 0283)
1H-NMR (d, CD2Cl2, 500MHz) 6.34 (1H, d, J = 11.3 Hz), 6.02 (1H, d, J = 11.3 Hz), 5.29 (1H, m), 4.95 (1H, m), 4.36 (1H, dd, J = 4.3 and 7.9 Hz), 4.15 (1H, m), 2.83 (1H, m), 2.54 (1H, m), 2.26 (1H, dd, J = 6.5 and 13.3 Hz), 2.01-1.46 (16H, m), 1.42 (6H, d, J = 12.5 Hz), 1.36-1.16 (6H, m), 0.95 (3H, d, J = 6.5 Hz), 0.55 (3H, s) (Ref. 0283)
31P-NMR (d, CD2Cl2, 18.8MHz) 43.90 (Ref. 0283)




By Wittig-Horner coupling of upper half of the title compound with lower half phosphine oxide. (Ref. 0283)



74
24-(dimethoxyphosphoryl)-25,26,27-trinorvitamin D3 / 24-(dimethoxyphosphoryl)-25,26,27-trinorcholecalciferol
(5Z,7E)-(3S)-24-(dimethoxyphosphoryl)-9,10-seco-5,7,10(19)-cholatrien-3-ol
VVD0076
Sachiko Yamada
24-(dimethoxyphosphoryl)-25,26,27-trinor-D3
C26H43O4P 450.591 Download ChemDraw structure file

[a]D +27.0 deg (c = 0.73 in CH2Cl2) (Ref. 0283)
(EtOH) lmax (nm) (emax) 264 (14700) (Ref. 0283)
(Film) 3400, 2950, 2890, 1640, 1233, 1060, 1035 cm-1 (Ref. 0283)
1H-NMR (d, d6-acetone, 250MHz) 6.25 (1H, d, J = 11.2 Hz), 6.08 (1H, d, J = 11.2 Hz), 5.03 (1H, m), 4.75 (1H, m), 3.78 (1H, m), 3.64 (6H, d, J = 10.7 Hz), 2.91-1.04 (26H, m), 0.97 (3H, d, J = 6.0 Hz), 0.58 (3H, s) (Ref. 0283)
31P-NMR (d, d6-acetone, 18.8MHz) 35.56 (Ref. 0283)




By Wittig-Horner coupling of upper half of the title compound with lower half phosphine oxide. The upper half was prepared from CD-ring 24-iodide by reaction with trimethylphosphite. (Ref. 0283)



75
1a-hydroxy-24-(dimethoxyphosphoryl)-25,26,27-trinorvitamin D3 / 1a-hydroxy-24-(dimethoxyphosphoryl)-25,26,27-trinorcholecalciferol
(5Z,7E)-(1S,3R)-24-(dimethoxyphosphoryl)-9,10-seco-5,7,10(19)-cholatriene-1,3-diol
VVD0077
Sachiko Yamada
24-(dimethoxyphosphoryl)-1a-OH-25,26,27-trinor-D3
C26H43O5P 466.590 Download ChemDraw structure file
Biological activity (% of 1,25-(OH)2D3 effect) : Intestinal calcium absorption in chick, 0.2% ; Bone calcium mobilization in chick, 0.13% ; Competitive binding to the vitamin D receptor in chick intestine, 6.98% ; Inhibition of clonal growth of human leukemia cells (HL-60), ED50 was not reached. (Ref. 0238)
[a]D +38.3 deg (c = 0.98 in CH2Cl2) (Ref. 0283)
(EtOH) lmax (nm) (e) 264 (18100), 211 (17000) (Ref. 0283)
(Film) 3390, 2944, 2890, 1645, 1235, 1054, 1030 cm-1 (Ref. 0283)
1H-NMR (d, d6-acetone, 250MHz) 6.30 (1H, d, J = 11.1 Hz), 6.10 (1H, d, J = 11.1 Hz), 5.32 (1H, m), 4.87 (1H, m), 3.69 (6H, d, J = 10.7 Hz), 2.51 (1H, m), 2.29 (1H, m), 2.06-1.20 (22H, m), 0.97 (3H, d, J = 6.0 Hz), 0.92-0.90 (1H, m), 0.59 (3H, s) (Ref. 0283)
31P-NMR (d, d6-acetone, 18.8MHz) 35.69 (Ref. 0283)




By Wittig-Horner coupling of upper half of the title compound with lower half phosphine oxide. The upper half was prepared from CD-ring 24-iodide by reaction with trimethylphosphite. (Ref. 0283)



76
1a,25-dihydroxy-19-norvitamin D3 / 1a,25-dihydroxy-19-norcholecalciferol
(7E)-(1R,3R)-19-nor-9,10-seco-5,7-cholestadiene-1,3,25-triol
VVD0078
Sachiko Yamada
1a,25-(OH)2-19-nor-D3
C26H44O3 404.626 Download ChemDraw structure file
The affinity of the title compound for the intestinal vitamin D receptor and plasma vitamin D binding protein was 30% and 20% of that of 1,25-(OH)2D3, respectively. The in vitro effects on human promyeloid leukemia (HL-60 cell) differentiation and osteocalcin secretion by human osteosarcoma (MG-63) cells by the title compound were nearly identical to those of 1,25-(OH)2D3. The in vivo calcemic effects was less than 10% of that of 1,25-(OH)2D3. (Ref. 0222)









77
1,25-dihydroxy-2-nor-1,2-secovitamin D3 / 1,25-dihydroxy-2-nor-1,2-secocholecalciferol
(5Z,7E)-A-nor-(1,2)-(9,10)-diseco-5,7,10(19)-cholestatriene-1,3,25-triol
VVD0079
Sachiko Yamada
1,25-(OH)2-2-nor-1,3-seco-D3
C26H44O3 404.626 Download ChemDraw structure file






From 25,26-dehydro-8-enol triflate CD ring synthon and ring A precursor, 2-methyll-3-ethynyl-2,3-dehydro-d-butyrolactone. Coupling of the two precursors was followed by catalytic partial hydrogenation, oxymercuration-demercuration (25-hydroxy introduction), and DIBAL reduction afforded the title compound after spontaneous 1,7-hydrogen shift. (Ref. 0330)



78
26,26,26,27,27,27-hexadeuterio-1a-fluoro-25-hydroxy-16,17,23,23,24,24-hexadehydrovitamin D3 / 26,26,26,27,27,27-hexadeuterio-1a-fluoro-25-hydroxy-16,17,23,23,24,24-hexadehydrocholecalciferol
(5Z,7E)-(1S,3R)-26,26,26,27,27,27-hexadeuterio-1-fluoro-9,10-seco-5,7,10(19),16-cholestatetraen-23-yne-3,25-diol
VVD0080
Sachiko Yamada
1a-F-25-OH-16,17,23,23,24,24-hexadehydro-[26,26,26,27,27,27-2H]D3
C27H31D6FO2 418.532 Download ChemDraw structure file
Biological activity (% of 1,25-(OH)2D3 effect) : Intestinal calcium absorption in chick, 0.5% ; Bone calcium mobilization in chick, 0.2% ; Competitive binding to the vitamin D receptor in chick intetine, 5.3%, and HL-60 cells, 9.2% ; Inhibition of clonal growth of human leukemia cells (HL-60), 571%. (Ref. 0238)
Biological activity (% of 1,25-(OH)2D3 effect) : Intestinal calcium absorption in chick, 0.2% ; Bone calcium mobilization in chick, 0.02% ; Competitive binding to the vitamin D receptor in chick intetine, 26%, and in human leukemia (HL-60) cells, 55% ; Inhibition of clonal growth of HL-60 cells, 52% ; Differentiation of HL-60 cells, 103%. (Ref. 0239)









79
1a,26,26,26,27,27,27-heptafluoro-25-hydroxy-16,17,23,23,24,24-hexadehydrovitamin D3 / 1a,26,26,26,27,27,27-heptafluoro-25-hydroxy-16,17,23,23,24,24-hexadehydrocholecalciferol
(5Z,7E)-(1S,3R)-1,26,26,26,27,27,27-heptafluoro-9,10-seco-5,7,10(19),16-cholestatetraen-23-yne-3,25-diol
VVD0081
Sachiko Yamada
1a,26,26,26,27,27,27-F7-25-OH-16,17,23,23,24,24-hexadehydro-D3
C27H31F7O2 520.523 Download ChemDraw structure file
Biological activity (% of 1,25-(OH)2D3 effect) : Intestinal calcium absorption in chick, 0.5% ; Bone calcium mobilization in chick, 0.2% ; Competitive binding to the vitamin D receptor in chick intetine, 5.3%, and HL-60 cells, 9.2% ; Inhibition of clonal growth of human leukemia cells (HL-60), 571%. (Ref. 0238)









80
26,26,26,27,27,27-hexadeuterio-1a,25-dihydroxy-16,17,23,23,24,24-hexadehydrovitamin D3 / 26,26,26,27,27,27-hexadeuterio-1a,25-dihydroxy-16,17,23,23,24,24-hexadehydrocholecalciferol
(5Z,7E)-(1S,3R)-26,26,26,27,27,27-hexadeuterio-9,10-seco-5,7,10(19),16-cholestatetraen-23-yne-1,3,25-triol
VVD0082
Sachiko Yamada
[26,26,26,27,27,27-2H]-1a,25-(OH)2-16,17,23,23,24,24-hexadehydro-D3
C27H32D6O3 416.541 Download ChemDraw structure file
Biological activity (% of 1,25-(OH)2D3 effect) : Intestinal calcium absorption in chick, 0.4% ; Bone calcium mobilization in chick, 1.2% ; Competitive binding to the vitamin D receptor in chick intetine, 86%, and in human leukemia (HL-60) cells, 46% ; Inhibition of clonal growth of HL-60 cells, 233% ; Differentiation of HL-60 cells, 300%. (Ref. 0239)









81
26,26,26,27,27,27-hexafluoro-25-hydroxy-16,17,23,23,24,24-hexadehydrovitamin D3 / 26,26,26,27,27,27-hexafluoro-25-hydroxy-16,17,23,23,24,24-hexadehydrocholecalciferol
(5Z,7E)-(3S)-26,26,26,27,27,27-hexafluoro-9,10-seco-5,7,10(19),16-cholestatetraen-23-yne-3,25-diol
VVD0083
Sachiko Yamada
26,26,26,27,27,27-F6-25-OH-16,17,23,23,24,24-hexadehydro-D3
C27H32F6O2 502.532 Download ChemDraw structure file
Biological activity (% of 1,25-(OH)2D3 effect) : Intestinal calcium absorption in chick, 0.13 ; Bone calcium mobilization in chick, 2.0 ; Competitive binding to the vitamin D receptor in chick intetine, 0.58, and HL-60 cells, 2.03 ; Inhibition of clonal growth of human leukemia cells (HL-60), 72. (Ref. 0238)









82
26,26,26,27,27,27-hexafluoro-1a,25-dihydroxy-16,17,23,23,24,24-hexadehydrovitamin D3 / 26,26,26,27,27,27-hexafluoro-1a,25-dihydroxy-16,17,23,23,24,24-hexadehydrocholecalciferol
(5Z,7E)-(1S,3R)-26,26,26,27,27,27-hexafluoro-9,10-seco-5,7,10(19),16-cholestatetraen-23-yne-1,3,25-triol
VVD0084
Sachiko Yamada
26,26,26,27,27,27-F6-1a,25-(OH)2-16,17,23,23,24,24-hexadehydro-D3
C27H32F6O3 518.532 Download ChemDraw structure file
Biological activity (% of 1,25-(OH)2D3 effect) : Intestinal calcium absorption in chick, 6.7% ; Bone calcium mobilization in chick, 10.4% ; Competitive binding to the vitamin D receptor in chick intetine, 45%, and HL-60 cells, 31% ; Inhibition of clonal growth of human leukemia cells (HL-60), 8000%. (Ref. 0238)









83
26,26,26,27,27,27-hexafluoro-25-hydroxy-23,23,24,24-tetradehydrovitamin D3 / 26,26,26,27,27,27-hexafluoro-25-hydroxy-23,23,24,24-tetradehydrocholecalciferol
(5Z,7E)-(3S)-26,26,26,27,27,27-hexafluoro-9,10-seco-5,7,10(19)-cholestatrien-23-yne-1,25-diol
VVD0086
Sachiko Yamada
26,26,26,27,27,27-F6-25-OH-23,23,24,24-tetradehydro-D3
C27H34F6O2 504.548 Download ChemDraw structure file
(% of 1,25-(OH)2D3 effect) Affinity for chick intestinal receptor: 0.18%; Affinity for human vitamin D binding protein: 470%. (Ref. 0359)









84
26,26,26,27,27,27-hexafluoro-1a,25-dihydroxy-23,23,24,24-tetradehydrovitamin D3 / 26,26,26,27,27,27-hexafluoro-1a,25-dihydroxy-23,23,24,24-tetradehydrocholecalciferol
(5Z,7E)-(1S,3R)-26,26,26,27,27,27-hexafluoro-9,10-seco-5,7,10(19)-cholestatrien-23-yne-1,3,25-triol
VVD0087
Sachiko Yamada
26,26,26,27,27,27-F6-1a,25-(OH)2-23,23,24,24-tetradehydro-D3
C27H34F6O3 520.547 Download ChemDraw structure file
Cell differentiation: 10 times as active as 1,25-(OH)2D3 ; hypercalcemic activity: 2 times as active as 1,25-(OH)2D3. (Ref. 0356)









85
(22E)-26,26,26,27,27,27-hexadeuterio-1a,25-dihydroxy-22,23-didehydrovitamin D3 / (22E)-26,26,26,27,27,27-hexadeuterio-1a,25-dihydroxy-22,23-didehydrocholecalciferol
(5Z,7E,22E)-(1S,3R)-26,26,26,27,27,27-hexadeuterio-9,10-seco-5,7,10(19),22-cholestatetraene-1,3,25-triol
VVD0088
Sachiko Yamada
(22E)-1a,25-(OH)2-22,23-didehydro-[26,26,26,27,27,27-2H]D3
C27H36D6O3 420.573 Download ChemDraw structure file










86
24,24,26,26,26,27,27,27-octadeuterio-1a,25-dihydroxyvitamin D3 / 24,24,26,26,26,27,27,27-octadeuterio-1a,25-dihydroxycholecalciferol
(5Z,7E)-(1S,3R)-24,24,26,26,26,27,27,27-octadeuterio-9,10-seco-5,7,10(19)-cholestatriene-1,3,25-triol
VVD0089
Sachiko Yamada
1a,25-(OH)2-[24,24,26,26,26,27,27,27-2H]D3
C27H36D8O3 424.573 Download ChemDraw structure file
Biological activity (% of 1,25-(OH)2D3 effect) : Inhibition of proliferation of human keratinocytes in culture, 100 ; Intestinal calcium absorption in rat, 106 ; Bone calcium mobilization in rat, 147 ; Competitive binding to rat intestinal vitamin D receptor, 100 ; Differentiation of human leukemia cells (HL-60), 100. (Ref. 0237)









87
(22E)-26,26,26,27,27,27-hexafluoro-25-hydroxy-22,23-didehydrovitamin D3 / (22E)-26,26,26,27,27,27-hexafluoro-25-hydroxy-22,23-didehydrocholecalciferol
(5Z,7E,22E)-(3S)-26,26,26,27,27,27-hexafluoro-9,10-seco-5,7,10(19),22-cholestatetraene-3,25-diol
VVD0090
Sachiko Yamada
26,26,26,27,27,27-F6-25-OH-22,23-didehydro-D3
C27H36F6O2 506.564 Download ChemDraw structure file

(EtOH) lmax (nm) 264, lmin (nm) 228 (Ref. 0197)

m/z 506, 473, 271, 253, 136, 118 (Ref. 0197)



The provitamin D constructed from hexafluoro C(5) side chain sulfone and C(22)-steroid aldehyde was converted to the title vitamin D compound by photochemical method. (Ref. 0197)



88
(22E)-26,26,26,27,27,27-hexafluoro-1a,25-dihydroxy-22,23-didehydrovitamin D3 / (22E)-26,26,26,27,27,27-hexafluoro-1a,25-dihydroxy-22,23-didehydrocholecalciferol
(5Z,7E,22E)-(1S,3R)-26,26,26,27,27,27-hexafluoro-9,10-seco-5,7,10(19),22-cholestatetraene-1,3,25-triol
VVD0091
Sachiko Yamada
(22E)-26,26,26,27,27,27-F6-1a,25-(OH)2-22,23-didehydro-D3
C27H36F6O3 522.563 Download ChemDraw structure file
Biological activity (% of 1,25-(OH)2D3 effect) : Inhibition of proliferation of human keratinocytes in culture, 100 ; Intestinal calcium absorption in rat, 221 ; Bone calcium mobilization in rat, 110 ; Competitive binding to rat intestinal vitamin D receptor, 62 ; Differentiation of human leukemia cells (HL-60), 3000. (Ref. 0237)









89
(23E)-26,26,26,27,27,27-hexafluoro-1a,25-dihydroxy-23,24-didehydrovitamin D3 / (23E)-26,26,26,27,27,27-hexafluoro-1a,25-dihydroxy-23,24-didehydrocholecalciferol
(5Z,7E,23E)-(1S,3R)-26,26,26,27,27,27-hexafluoro-9,10-seco-5,7,10(19),23-cholestatetraene-1,3,25-triol
VVD0092
Sachiko Yamada
(23E)-26,26,26,27,27,27-F6-1a,25-(OH)2-23,24-didehydro-D3
C27H36F6O3 522.563 Download ChemDraw structure file
Differentiation of HL-60 cells: 10 times more potent than 1,25-(OH)2D3.(Ref. 0356)









90
26,26,26,27,27,27-hexadeuterio-1a,25-dihydroxyvitamin D3 / 26,26,26,27,27,27-hexadeuterio-1a,25-dihydroxycholecalciferol
(5Z,7E)-(1S,3R)-26,26,26,27,27,27-hexadeuterio-9,10-seco-5,7,10(19)-cholestatriene-1,3,25-triol
VVD0093
Sachiko Yamada
1a,25-(OH)2-[26,26,26,27,27,27-2H]D3
C27H38D6O3 422.589 Download ChemDraw structure file
Biological activity (% of 1,25-(OH)2D3 effect) : Inhibition of proliferation of human keratinocytes in culture, 100 ; Intestinal calcium absorption in rat, 92 ; Bone calcium mobilization in rat, 64 ; competitive binding to rat intestinal vitamin D receptor, 100 ; differentiation of human leukemia cells (HL-60), 100. (Ref. 0237)
Biological activity (% of 1,25-(OH)2D3 effect) : Affinity for rat intestinal receptor : 100 ; Calf intestinal receptor: 100; Intestinal calcium absorption, 92 ; Bone calcium mobilization, 64. (Ref. 0329)
1H-NMR (d, CD2Cl2) 6.33 and 5.98 (2H, AB pattern, d, J = 12.4 Hz, 6- and 7-H), 5.26 (1H, m, 19E-H), 4.93 (1H, br s, 19Z-H), 4.34 (1H, m, 1-H), 4.13 (1H, m, 3-H), 0.90 (3H, d, J = 6.2 Hz, 21C-CH3), 0.51 (3H, s, 18C-CH3) (Ref. 0195)
13C-NMR (d, CD2Cl2) 148.7 (C), 143.5 (C), 133.9 (C), 125.1 (CH), 117.6 (CH), 111.8 (C-19), 71.2 (CH), 70.8, 67.2 (CH), 57.1, 56.8, 46.3, 45.8, 44.8, 43.5, 40.9, 36.9, 36.5, 29.4, 28.0, 24.0, 22.6, 21.2, 19.0, 12.1 (Ref. 0195)




The upper half was synthesized from CD-ring 8,22-diol 22-tosylate via introduction of acetylene unit, reaction with acetone-d6, catalytic hydrogenation, and oxidation. Wittig-Horner coupling of the upper half synthon with ring A phosphine oxide afforded the title compound. (Ref. 0329)
From protected 1a-hydroxy-26,27-dinorvitamin D3 25-carboxylate via reaction with CD3MgI. (Ref. 0195)



91
1a-fluoro-25-hydroxy-16,17,23,23,24,24-hexadehydrovitamin D3 / 1a-fluoro-25-hydroxy-16,17,23,23,24,24-hexadehydrocholecalciferol
(5Z,7E)-(1S,3R)-1-fluoro-9,10-seco-5,7,10(19),16-cholestatetraen-23-yne-3,25-diol
VVD0094
Sachiko Yamada
1a-F-25-OH-16,17,23,23,24,24-hexadehydro-D3
C27H37FO2 412.580 Download ChemDraw structure file
Biological activity (% of 1,25-(OH)2D3 effect) : Intestinal calcium absorption in chick, 0.03 ; Bone calcium mobilization in chick, 0.08 ; Competitive binding to the vitamin D receptor in chick intetine, 24, and in human leukemia (HL-60) cells, 35 ; Inhibition of clonal growth of HL-60 cells, 61 ; Differentiation of HL-60 cells, 417. (Ref. 0239)









92
26,26,26,27,27,27-hexafluoro-1aa-hydroxyvitamin D3 / 26,26,26,27,27,27-hexafluoro-1aa-hydroxycholecalciferol
(5Z,7E)-(1S,3R)-26,26,26,27,27,27-hexafluoro-9,10-seco-5,7,10(19)-cholestatriene-1,3-diol
VVD0095
Sachiko Yamada
26,26,26,27,27,27-F6-1a-OHD3
C27H38F6O2 508.580 Download ChemDraw structure file
Biological activity (% of 1,25-(OH)2D3 effect) : Binding affinity for chick intestinal and HL-60 cell receptor : both 1.4. Inhibition of proliferation and induction of differentiation of HL-60 cells : 100. (Ref. 0247)









93
26,26,26,27,27,27-hexafluoro-25-hydroxyvitamin D3 / 26,26,26,27,27,27-hexafluoro-25-hydroxycholecalciferol
(5Z,7E)-(3S)-26,26,26,27,27,27-hexafluoro-9,10-seco-5,7,10(19)-cholestatriene-3,25-diol
VVD0096
Sachiko Yamada
26,26,26,27,27,27-F6-25-OHD3
C27H38F6O2 508.580 Download ChemDraw structure file
The title compound was equipotent with 25-OHD3 in stimulating intestinal calcium transport, bone calcium mobilization, bone mineralization, epiphyseal plate calcification, and elevation of serum inorganic phosphorus. Bilateral nephrectomy eliminates the response of intestine and bone to this compound suggesting that this compound must be 1a-hydroxylated to be functional. (Ref. 0305)
(EtOH) lmax (nm) (emax) 264 (18000) lmin (nm) (emin) 227.5 (8600) (Ref. 0200)

m/z 508 (M+), 493, 490, 476, 271, 253, 136, 118 (Ref. 0200)



From 24-tosyloxy-5-cholene derivative via reaction of 24-sulfone with trifluoroacetone as key step. (Ref. 0200)



94
6,19-epidioxy-26,26,26,27,27,27-hexafluoro-25-hydroxy-6,19-dihydrovitamin D3 / 6,19-epidioxy-26,26,26,27,27,27-hexafluoro-25-hydroxy-6,19-dihydrocholecalciferol
(7E)-(3S)-6,19-epidioxy-26,26,26,27,27,27-hexafluoro-9,10-seco-5(10),7-cholestadiene-3,25-diol
VVD0097
Sachiko Yamada
6,19-epidioxy-26,26,26,27,27,27-F6-25-OH-6,19-dihydro-D3
C27H38F6O4 540.579 Download ChemDraw structure file
Binding affinity for the vitamin D receptor in HL-60 cells : 1/1500 as active as 1,25-(OH)2D3. Differentiation of HL-60 cells : 1/30 as active as 1,25-(OH)2D3. (Ref. 0339)

m/z 540 (M+), 522, 508, 504, 402, 384, 371, 330, 285 (Ref. 0339)



As a major product by the reaction of 26,26,26,27,27,27-hexafluoro-25-hydroxyvitamin D3 with singlet oxygen generated by dye-sensitized photochemical method. (Ref. 0339)



95
26,26,26,27,27,27-hexafluoro-1a,24-dihydroxyvitamin D3 / 26,26,26,27,27,27-hexafluoro-1a,24-dihydroxycholecalciferol
(5Z,7E)-(1S,3R)-26,26,26,27,27,27-hexafluoro-9,10-seco-5,7,10(19)-cholestatriene-1,3,24-triol
VVD0098
Sachiko Yamada
26,26,26,27,27,27-F6-1a,24-(OH)2D3
C27H38F6O3 524.579 Download ChemDraw structure file
Biological activity (% of 1,25-(OH)2D3 effect) : Binding affinity for chick intestinal and HL-60 cell receptor : 66 and 100, respectively. Inhibition of proliferation and induction of differentiation of HL-60 cells : 1000. (Ref. 0247)









96
26,26,26,27,27,27-hexafluoro-1a,25-dihydroxyvitamin D3 / 26,26,26,27,27,27-hexafluoro-1a,25-dihydroxycholecalciferol
(5Z,7E)-(1S,3R)-26,26,26,27,27,27-hexafluoro-9,10-seco-5,7,10(19)-cholestatriene-1,3,25-triol
VVD0099
Sachiko Yamada
26,26,26,27,27,27-F6-1a,25-(OH)2D3
C27H38F6O3 524.579 Download ChemDraw structure file
Biological activity (% of 1,25-(OH)2D3 effect) : Inhibition of proliferation of human keratinocytes in culture, 100 ; Intestinal calcium absorption in rat, 229 ; Bone calcium mobilization in rat, 137 ; Competitive binding to rat intestinal vitamin D receptor, 82 ; Differentiation of human leukemia cells (HL-60), 2000. (Ref. 0237)
Biological activity (% of 1,25-(OH)2D3 effect) : Binding affinity for chick intestinal and HL-60 cell receptor : 33 and 100, respectively. Inhibition of proliferation and induction of differentiation of HL-60 cells : 1000. (Ref. 0247)
The activity to induce vitamin D 24-hyddroxylase in HL-60 cells : 4 times as potent as 1,25-(OH)2D3. (Ref. 0269)
lmax (nm) 264.5, lmin (nm) 228 (Ref. 0287)

m/z 524 (M+), 506, 488, 473, 462, 383, 287, 269, 251, 152, 134 (Ref. 0287)



From cholenic acid via reaction of 24-sulfone derivative with hexafluoroacetone as key step. (Ref. 0287)
Metabolism of 26,27-F6-1,25-(OH)2D3 in vitamin D-deficient rat was studied and 26,26,26,27,27,27-hexafluoro-1,23S,25-trihydroxyvitamin D3 was idenfified as major metabolite found in intestine (Ref. 0270)
In HL-60 cells pre-treated with 10-9 M 26,27-F6-1,25-(OH)2D3, 26,27-F6-1,25-(OH)2[1b-3H]D3 was mainly metabolized to 26,26,26,27,27,27-hexafluoro-1,23S,25-trihydroxyvitamin D3. (Ref. 0269)


97
(23S)-26,26,26,27,27,27-hexafluoro-1a,23,25-trihydroxyvitamin D3 / (23S)-26,26,26,27,27,27-hexafluoro-1a,23,25-trihydroxycholecalciferol
(5Z,7E)-(1S,3R,23S)-26,26,26,27,27,27-hexafluoro-9,10-seco-5,7,10(19)-cholestatriene-1,3,23,25-tetrol
VVD0100
Sachiko Yamada
26,26,26,27,27,27-F6-1a,23S,25-(OH)3D3
C27H38F6O4 540.579 Download ChemDraw structure file
Binding affinity for chick intestinal receptor: 2-3 times less active than 1,25-(OH)2 D3 ; Intestinal calcium transport: comparable to 1,25-(OH)2 D3.. (Ref. 0270)

TMS ether: spectrum (Ref. 0270)

HPLC: (Ref. 0270)


Major intestinal metabolite produced from 26,27-F6 -1,25-(OH)2 D3 . (Ref. 0270)


98
25-hydroxy-16,17,23,23,24,24-hexadehydrovitamin D3 / 25-hydroxy-16,17,23,23,24,24-hexadehydrocholecalciferol
(5Z,7E)-(3S)-9,10-seco-5,7,10(19),16-cholestatetraen-23-yne-3,25-diol
VVD0101
Sachiko Yamada
25-OH-16,17,23,23,24,24-hexadehydro-D3
C27H38O2 394.589 Download ChemDraw structure file
Biological activity (% of 1,25-(OH)2D3 effect) : Inhibition of proliferation of human keratinocytes in culture, 100 ; Intestinal calcium absorption in rat, 72 ; Bone calcium mobilization in rat, 0 ; Competitive binding to rat intestinal vitamin D receptor, 0.07 ; Differentiation of human leukemia cells (HL-60), 1. (Ref. 0237)









99
(22E)-1a-hydroxy-24-oxo-26,27-cyclo-22,23-didehydrovitamin D3 / (22E)-1a-hydroxy-24-oxo-26,27-cyclo-22,23-didehydrocholecalciferol
(5Z,7E,22E)-(1S,3R)-1,3-dihydroxy-26,27-cyclo-9,10-seco-5,7,10(19),22-cholestatetraen-24-one
VVD0102
Sachiko Yamada
(22E)-1a-OH-24-oxo-22,23-didehydro-26,27-cyclo-D3
C27H38O3 410.589 Download ChemDraw structure file






From protected (5E)-1a-hydroxy-22-oxo-23,24,25,26,27-pentanorvitamin D3 via Wittig-Horner coupling with side chain fragment, followed by photochemical isomerization and deprotection. (Ref. 0289)
Isolated as a metabolite produced from 1a,24S-dihydroxy-26,27-cyclo-22,23-didehydrovitamin D3 (calcipotriol, MC903). (Ref. 0322)


100
24,25-epoxy-1a-hydroxy-22,22,23,23-tetradehydrovitamin D3 / 24,25-epoxy-1a-hydroxy-22,22,23,23-tetradehydrocholecalciferol
(5Z,7E)-(1S,3R)-24,25-epoxy-9,10-seco-5,7,10(19)-cholestatrien-22-yne-1,3-diol
VVD0103
Sachiko Yamada
24,25-epoxy-1a-OH-22,22,23,23-tetradehydro-D3 / 24,25-epoxy-1a-OH-22-yne-D3
C27H38O3 410.589 Download ChemDraw structure file
Biological activity (% of 1,25-(OH)2D3 effect) : Affinity for pig intestinal receptor and human vitamin D binding protein : 2 and 5 respectively. Inhibition of proliferation or differentiation induction of human promyeloid leukemia (HL-60), osteosarcoma (MG-63) and breast carcinoma (MCF-7) cells : 3, 100 and 20, respectively. Elevation of serum calcium, serum osteocalcin, bone calcium and duodenal calbindin in rachitic chicks : all <1. (Ref. 0240)





By epoxidation of the corresponding olefinic precursor which was constructed from Inhoffen-Lythgoe diol. (Ref. 0240)



101
25,26-epoxy-1a-hydroxy-23,23,24,24-tetradehydrovitamin D3 / 25,26-epoxy-1a-hydroxy-23,23,24,24-tetradehydrocholecalciferol
(5Z,7E)-(1S,3R)-25,26-epoxy-9,10-seco-5,7,10(19)-cholestatrien-23-yne-1,3-diol
VVD0104
Sachiko Yamada
25,26-epoxy-1a-OH-23,23,24,24-tetradehydro-D3 / 25,26-epoxy-1a-OH-23-yne-D3
C27H38O3 410.589 Download ChemDraw structure file
Biological activity (% of 1,25-(OH)2D3 effect) : Affinity for pig intestinal receptor and human vitamin D binding protein : 30 and 6 respectively. Inhibition of proliferation or differentiation induction of human promyeloid leukemia (HL-60), osteosarcoma (MG-63) and breast carcinoma (MCF-7) cells : 240, 150 and 127, respectively. Elevation of serum calcium, serum osteocalcin, bone calcium and duodenal calbindin in rachitic chicks : 1, 2, 0.4 and 2 ,respectively. (Ref. 0240)





By epoxidation of the corresponding olefinic precursor which was constructed from Inhoffen-Lythgoe diol. (Ref. 0240)



102
25,26-epoxy-1a-hydroxy-23,23,24,24-tetradehydro-20-epivitamin D3 / 25,26-epoxy-1a-hydroxy-23,23,24,24-tetradehydro-20-epicholecalciferol
(5Z,7E)-(1S,3R,20S)-25,26-epoxy-9,10-seco-5,7,10(19)-cholestatrien-23-yne-1,3-diol
VVD0105
Sachiko Yamada
25,26-epoxy-1a-OH-23,23,24,24-tetradehydro-20-epi-D3 / 25,26-epoxy-1a-OH-23-yne-20-epi-D3
C27H38O3 410.589 Download ChemDraw structure file
Biological activity (% of 1,25-(OH)2D3 effect) : Affinity for pig intestinal receptor and human vitamin D binding protein : 30 and 0, respectively. Inhibition of proliferation or differentiation induction of human promyeloid leukemia (HL-60), osteosarcoma (MG-63), and breast carcinoma (MCF-7) cells : 2000, 3000 and 4000, respectively. Elevation of serum calcium, serum osteocalcin, bone calcium, and duodenal calbindin in rachitic chicks : 3, 1, 1 and 1, respectively. (Ref. 0240)





By epoxidation of the corresponding olefinic precursor which was constructed from Inhoffen-Lythgoe diol. (Ref. 0240)



103
1a,25-dihydroxy-16,17,23,23,24,24-hexadehydrovitamin D3 / 1a,25-dihydroxy-16,17,23,23,24,24-hexadehydrocholecalciferol
(5Z,7E)-(1S,3R)-9,10-seco-5,7,10(19),16-cholestatetraen-23-yne-1,3,25-triol
VVD0106
Sachiko Yamada
1a,25-(OH)2-16,17,23,23,24,24-hexadehydro-D3
C27H38O3 410.589 Download ChemDraw structure file
Biological activity (% of 1,25-(OH)2D3 effect) : Inhibition of proliferation of human keratinocytes in culture, 10000 ; Intestinal calcium absorption in rat, 53 ; Bone calcium mobilization in rat, 0 ; Competitive binding to rat intestinal vitamin D receptor, 51; Differentiation of human leukemia cells (HL-60), 1000. (Ref. 0237)
Biological activity (% of 1,25-(OH)2D3 effect ) : Intestinal calcium absorption in chick, 3.3 ; Bone calcium mobilization in chick, 2 ; Competitive binding to the vitamin D receptor in chick intetine, 75, and HL-60 cells, 79. (Ref. 0238)
Survival of BALB/c mice received myeloid leukemic cells (WEHI 3BD+): Mice treated with the title compound (1.6 mg q.o.d.) had a significantly longer survival, with the last mouse dying of leukemia on day 50. (Ref. 0328)





By Wittig-horner coupling of upper CD-ring plus side chain part and the lower A-ring phophine oxide. The 16-ene CD-side chain part was synthesized from a 1-ethylideneperhydroindan derivative via ene reaction with 4-hydroxy-4-methylpentynal derivative as the key step. (Ref. 0358)



104
1a,25-dihydroxy[26,26,26,27,27,27-3H6]vitamin D3 / 1a,25-dihydroxy[26,26,26,27,27,27-3H6]cholecalciferol / [26,26,26,27,27,27-3H6]calcitriol
(5Z,7E)-(1S,3R)-[26,26,26,27,27,27-3H6]-9,10-seco-5,7,10(19)-cholestatriene-1,3,25-triol
VVD0107
Sachiko Yamada
1a,25-(OH)2-[26,26,26,27,27,27-3H6]D3 / [26,26,26,27,27,27-3H6]calcitriol
C27H38T6O3 428.589 Download ChemDraw structure file

lmax (95% EtOH) (nm) 262 (Ref. 0235)

m/z 428 (M+), 410 (M+-H2O, 9), 392 (M+-2H2O, 10), 287 (M+-side chain, 3), 285 (287-2H, 4), 269 (287-H2O, 5), 267 (285-H2O, 3), 152 (ring A plus carbons 6 and 7, 29), 134 (152-H2O, 100), 71 [(C3H3)2 C-OH]+, 100]; spectrum (Ref. 0235)

HPLC comparisons of 1a,25-(OH)2[26,27-3H]D3, prepared by chemical or enzymatic synthesis, to authentic unlabeled 1a,25-(OH)2D3. The UV peak of unlabeled 1a,25-(OH)2D3 was distinguishable from that of 1a,25-(OH)2[26,27-3H]D3.(Ref. 0235)

From 26,27-dinorvitamin D3 25-carboxylic acid via 1a-hydroxylation through 3,5-cyclovitamin D followed by treatment with [3H]methylmagnesium bromide [80 Ci/mmol) (Ref. 0235)



105
(22E)-(25R)-26,26,26-trideuterio-1a,25-dihydroxy-22,23-didehydrovitamin D3 / (22E)-(25R)-26,26,26-trideuterio-1a,25-dihydroxy-22,23-didehydrocholecalciferol
(5Z,7E,22E)-(1S,3R,25R)-26,26,26-trideuterio-9,10-seco-5,7,10(19),22-cholestatetraene-1,3,25-triol
VVD0108
Sachiko Yamada
(22E)-1a,25R-(OH)2-22,23-didehydro-[26,26,26-2H]D3
C27H39D3O3 417.597 Download ChemDraw structure file
Affinity for chick intestinal receptor: 133% of the effect of 1,25-(OH)2D3. (Ref. 0359)









106
(22E)-(25S)-26,26,26-trideuterio-1a,25-dihydroxy-22,23-didehydrovitamin D3 / (22E)-(25S)-26,26,26-trideuterio-1a,25-dihydroxy-22,23-didehydrocholecalciferol
(5Z,7E,22E)-(1S,3R,25S)-26,26,26-trideuterio-9,10-seco-5,7,10(19),22-cholestatetraene-1,3,25-triol
VVD0109
Sachiko Yamada
(22E)-1a,25S-(OH)2-22,23-didehydro-[26,26,26-2H]D3
C27H39D3O3 417.597 Download ChemDraw structure file
Affinity for chick intestinal receptor: 125% of the effect of 1,25-(OH)2D3. (Ref. 0359)









107
9,9,14,19,19-pentadeuterio-1a,25-dihydroxyvitamin D3 / 9,9,14,19,19-pentadeuterio-1a,25-dihydroxycholecalciferol
(5Z,7E)-(1S,3R)-9,9,14,19,19-pentadeuterio-9,10-seco-5,7,10(19)-cholestatriene-1,3,25-triol
VVD0110
Sachiko Yamada
1a,25-(OH)2-[9,9,14,19,19-2H]D3
C27H39D5O3 421.597 Download ChemDraw structure file
The activities of the title compound in binding to the chick and pig intestinal nuclear 1,25-(OH)2D3 receptors, in inducing differentiation of HL-60 cell, and inhibiting proliferation and inducing the production of osteocalcin in MG-63 cells were approximately same as those of 1,25-(OH)2D3. (Ref. 0226)





Convergent synthesis by combining upper-half fragment (9,14-dideuterio-25-hydroxy-des-AB-cholest-8-en-8-yl triflate) with lower-half fragment (silyl protected 19,19,19-trideuterio-1-ethynyl-2-methyl-1-cyclohexen-3S,5R-diol). The lower-half was synthesized starting from (S)-(+)-carvone and the upper half from Inhoffen-Lythgoe diol obtained by ozonolysis of vitamin D2. (Ref. 0231)



108
9,14,19,19,19-pentadeuterio-1a,25-dihydroxyprevitamin D3 / 9,14,19,19,19-pentadeuterio-1a,25-dihydroxyprecholecalciferol
(6Z)-(1S,3R)-9,14,19,19,19-pentadeuterio-9,10-seco-5(10),6,8-cholestatriene-1,3,25-triol
VVD0111
Sachiko Yamada
1a,25-(OH)2-pre-[9,14,19,19,19-2H]D3
C27H39D5O3 421.597 Download ChemDraw structure file
The title compound was as active as 1,25-(OH)2D3 in two nongenomic systems, transcaltachia as measured in the perfused chick kidney intestine and 45Ca2+ uptake through voltage-gated Ca2+ channels in ROS 17/2.8 cells. This compound was significantly less active both in binding in vitro to the plasma vitamin D-binding protein (7%) and to the chick (10%) and pig (4%) intestinal nuclear 1,25-(OH)2D3 receptors generating genomic biological responses in vivo (induction of plasma levels of osteocalcin, <5%) or in culture cells (inhibition of HL-60 cell differentiation, <5% ; inhibition of MG-63 proliferation, <2% ; and induction of osteocalcin, <2%). (Ref. 0226)





Convergent synthesis by combining upper-half synthon (9,14-dideuterio-25-hydroxy-des-AB-cholest-8-en-8-yl triflate) with lower-half synthon (silyl protected 19,19,19-trideuterio-1-ethynyl-2-methyl-1-cyclohexen-3S,5R-diol). The lower-half was synthesized starting from (S)-(+)-carvone and the upper half synthon from Inhoffen-Lythgoe diol obtained by ozonolysis of vitamin D2. (Ref. 0231)



109
(22E)-(25R)-26,26,26-trifluoro-1a,25-dihydroxy-22,23-didehydrovitamin D3 / (22E)-(25R)-26,26,26-trifluoro-1a,25-dihydroxy-22,23-didehydrocholecalciferol
(5Z,7E,22E)-(1S,3R,25R)-26,26,26-trifluoro-9,10-seco-5,7,10(19),22-cholestatetraene-1,25-diol
VVD0112
Sachiko Yamada
(22E)-26,26,26-F3-1a,25R-(OH)2-22,23-didehydro-D3
C27H39F3O3 468.592 Download ChemDraw structure file
(% of 1,25-(OH)2D3 effect) Affinity for chick intestinal receptor: 57% (Ref. 0359); Induction of differentiation of HL-60 cells: 300% (Ref. 0356)









110
(22E)-(25S)-26,26,26-trifluoro-1a,25-dihydroxy-22,23-didehydrovitamin D3 / (22E)-(25S)-26,26,26-trifluoro-1a,25-dihydroxy-22,23-didehydrocholecalciferol
(5Z,7E,22E)-(1S,3R,25S)-26,26,26-trifluoro-9,10-seco-5,7,10(19),22-cholestatetraene-1,25-diol
VVD0113
Sachiko Yamada
(22E)-26,26,26-F3-1a,25S-(OH)2-22,23-didehydro-D3
C27H39F3O3 468.592 Download ChemDraw structure file
(% of 1,25-(OH)2D3 effect) Affinity for chick intestinal receptor: 40% (Ref. 0359); Induction of differentiation of HL-60 cells: 4000% (Ref. 0356)









111
calicoferol A
(22E)-(8S)-3-hydroxy-9,10-seco-1,3,5(10),22-cholestatetraen-9-one
VVD0114
Sachiko Yamada
calicoferol A
C27H40O2 396.605 Download ChemDraw structure file
Toxic against brine shrimp larvae. (Ref. 0317)




Isolated from a gorgonian of the genus Calicogorgia. (Ref. 0318)




112
25-hydroxy-16,17,23,24-tetradehydrovitamin D3 / 25-hydroxy-16,17,23,24-tetradehydrocholecalciferol
(5Z,7E,23E)-(3S)-9,10-seco-5,7,10(19),16,23-cholestapentaene-3,25-diol
VVD0115
Sachiko Yamada
25-OH-16,17,23,24-tetradehydro-D3
C27H40O2 396.605 Download ChemDraw structure file
Biological activity (% of 1,25-(OH)2D3 effect) : Inhibition of proliferation of human keratinocytes in culture, 100 ; Competitive binding to rat intestinal vitamin D receptor, 0.12 ; Differentiation of human leukemia cells (HL-60), 0.5. (Ref. 0237)









113
(23Z)-25-hydroxy-16,17,23,24-tetradehydrovitamin D3 / (23Z)-25-hydroxy-16,17,23,24-tetradehydrocholecalciferol
(5Z,7E,23Z)-(3S)-9,10-seco-5,7,10(19),16,23-cholestapentaene-3,25-diol
VVD0116
Sachiko Yamada
(23Z)-25-OH-16,17,23,24-tetradehydro-D3
C27H40O2 396.605 Download ChemDraw structure file
Affinity for rat intestinal receptor: 0.8%. (Ref. 0358)





From CD-ring plus side chain fragment and A-ring phosphine oxide by Wittig-Horner coupling. (Ref. 0358)



114
25-hydroxy-23,23,24,24-tetradehydrovitamin D3 / 25-hydroxy-23,23,24,24-tetradehydrocholecalciferol
(5Z,7E)-(3S)-9,10-seco-5,7,10(19)-cholestatrien-23-yne-3,25-diol
VVD0117
Sachiko Yamada
25-OH-23,23,24,24-tetradehydro-D3
C27H40O2 396.605 Download ChemDraw structure file
Biological activity (% of 1,25-(OH)2D3 effect) : Inhibition of proliferation of human keratinocytes in culture, 100 ; Intestinal calcium absorption in rat, 71 ; Bone calcium mobilization in rat, 0 ; Competitive binding to rat intestinal vitamin D receptor, 0.06 ; Differentiation of human leukemia cells (HL-60), 1. (Ref. 0237)









115
1a-hydroxy-24-oxo-26,27-cyclovitamin D3 / 1a-hydroxy-24-oxo-26,27-cyclocholecalciferol
(5Z,7E)-(1S,3R)-1,3-dihydroxy-26,27-cyclo-9,10-seco-5,7,10(19)-cholestatrien-24-one
VVD0118
Sachiko Yamada
1a-OH-24-oxo-26,27-cyclo-D3
C27H40O3 412.605 Download ChemDraw structure file
(% of 1,25-(OH)2 D3effect) Affinity for calf thymus receptor: 0.5%; Transcriptional activity: 12.5%. (Ref. 0322)



HPLC chart. (Ref. 0322)


Produced as a metabolite of 1a,24S-dihydroxy-26,27-cyclo-22,23-didehydrovitamin D3 (Calcipotriol, VVD0121) and further metabolized to 23-hydroxylated compound. (Ref. 0322)


116
(22E)-25-hydroxy-24-oxo-22,23-didehydrovitamin D3 / (22E)-25-hydroxy-24-oxo-22,23-didehydrocholecalciferol
(5Z,7E,22E)-(3S)-3,25-dihydroxy-9,10-seco-5,7,10(19),22-cholestatetraen-24-one
VVD0119
Sachiko Yamada
(22E)-25-OH-24-oxo-22,23-didehydro-D3
C27H40O3 412.605 Download ChemDraw structure file

(EtOH) lmax (nm) 265, lmin (nm) 228 (Ref. 0193)

high resoultion MS: m/z 412.2989 (Ref. 0193)



From Ergosterol via side chain introduction to 5,7-diene protected C(22)-aldehyde. (Ref. 0193)



117
(22E)-(24R)-1a,24-dihydroxy-26,27-cyclo-22,23-didehydrovitamin D3 / (22E)-(24R)-1a,24-dihydroxy-26,27-cyclo-22,23-didehydrocholecalciferol
(5Z,7E,22E)-(1S,3R,24R)-26,27-cyclo-9,10-seco-5,7,10(19),22-cholestatetraene-1,3,24-triol
VVD0120
Sachiko Yamada
(22E)-1a,24R-(OH)2-26,27-cyclo-22,23-didehydro-D3
C27H40O3 412.605 Download ChemDraw structure file

Et2O-hexane :143-145 degC (Ref. 0289)
lmax (nm) (emax) 264 (17000) (Ref. 0289)
1H-NMR (d, CDCl3) 0.15-0.65 (4H, m), 0.56 (3H, s), 0.75-1.10 (1H, m), 1.05 (3H, d, J = 7.0 Hz), 3.47 (1H, m), 4.2 (1H, m), 4.4 (1H, m), 4.99 (1H, m), 5.31 (1H, m), 5.50 (2H, m), 5.99 and 6.36 (each 1H, d, J = 11.0 Hz) (Ref. 0289)
m/z 412 (M+, 5), 394 (8), 379 (1), 376 (5), 287 (5), 285 (6), 283 (7), 269 (10), 267 (5), 265 (4), 251 (10), 152 (27), 134 (100) (Ref. 0289)



From protected (5E)-1a-hydroxy-22-oxo-23,24,25,26,27-pentanorvitamin D3 via Wittig-Horner coupling with side chain fragment, reduction, separation of 24-epimers, photochemical isomerization and deprotection. (Ref. 0289)



118
(22E)-(24S)-1a,24-dihydroxy-26,27-cyclo-22,23-didehydrovitamin D3 / (22E)-(24S)-1a,24-dihydroxy-26,27-cyclo-22,23-didehydrocholecalciferol / Calcipotriol
(5Z,7E,22E)-(1S,3R,24S)-26,27-cyclo-9,10-seco-5,7,10(19),22-cholestatetraene-1,3,24-triol
VVD0121
Sachiko Yamada
(22E)-1a,24S-(OH)2-26,27-cyclo-22,23-didehydro-D3
C27H40O3 412.605 Download ChemDraw structure file
Activity relative to 1,25-(OH)2D3 (defined 100%) : Affinity for the receptor in U937 cells (human histiocytic lymphoma cell line) : 200 ; Antiproliferative effects on U937 cells : 200 ; Induction of differentiation of U937 cells : 100 ; Calciuric effect: <0.5. (Ref. 0309)
This compound named calcipotriol (Leo laboratory code MC903) is the first active vitamin D analog to receive governmental approval to be used as an anti-proliferative agent in the treatment of psoriasis. (Ref. 0327)
(Methyl formate) 166-158 degC (Ref. 0289)
lmax (nm) (e) 264 (17200) (Ref. 0289)
1H-NMR (d, CDCl3) 0.15-0.65 (4H, m), 0.56 (3H, s), 0.75-1.10 (1H, m), 1.05 (3H, d, J = 7.0 Hz), 3.45 (1H, m), 4.2 (1H, m), 4.4 (1H, m), 4.99 (1H, m), 5.31 (1H, m), 5.47 (2H, m), 5.99 (1H, d, J = 11.0 Hz), 6.36 (1H, d, J = 11.0 Hz) (Ref. 0289)
m/z 412 (M+, 6), 394 (8), 379 (2), 376 (5), 287 (5), 285 (7), 283 (8), 269 (11), 267 (6), 265 (4), 251 (12), 152 (26), 134 (100) (Ref. 0289)



From protected (5E)-1a-hydroxy-22-oxo-23,24,25,26,27-pentanorvitamin D3 via Wittig-Horner coupling with side chain fragment, reduction, separation of 24-epimers, photochemical isomerization and deprotection. (Ref. 0289)
The in vitro metabolism of the title compound (calcipotriol) was studied in two keratinocyte cell models. Calcipotriol was initially converted into the 24-ketone and its 22,23-dihydro-derivative. Further metabolites such as two 23-epimeric 23-hydroxylated 22,23-dihydro-24-oxo-derivatives, two 23,24-dihydroxy-derivatives and side chain-cleavage products, tetranor-1,23-(OH)2D3 and calcitroic acid. (Ref. 0322)


119
(22E)-(24R)-1a,24-dihydroxy-26,27-cyclo-22,23-didehydro-20-epivitamin D3 / (22E)-(24R)-1a,24-dihydroxy-26,27-cyclo-22,23-didehydro-20-epicholecalciferol
(5Z,7E,22E)-(1S,3R,20S,24R)-26,27-cyclo-9,10-seco-5,7,10(19),22-cholestatetraene-1,3,24-triol
VVD0122
Sachiko Yamada
(22E)-1a,24R-(OH)2-20-epi-22,23-didehydro-26,27-cyclo-D3 / (22E)-1a,24R-(OH)2-20-epi-22-ene-26,27-cyclo-D3
C27H40O3 412.605 Download ChemDraw structure file
Biological activity (% of 1,25-(OH)2D3 effect) : Inhibition of proliferation of U 937 cells, 130% ; Induction of differentiation of U 937 cells, 100% ; Calciuric effects on normal rats, <1%. (Ref. 0284)





From protected (5E)-22-oxo-23,24,25,26,27-pentanorvitamin D3 via side chain introduction by Wittig-Horner reaction followed by reduction, dye-sensitized photoisomerization and deprotection. (Ref. 0284)



120
(22E)-(24S)-1a,24-dihydroxy-26,27-cyclo-22,23-didehydro-20-epivitamin D3 / (22E)-(24S)-1a,24-dihydroxy-26,27-cyclo-22,23-didehydro-20-epicholecalciferol
(5Z,7E,22E)-(1S,3R,20S,24S)-26,27-cyclo-9,10-seco-5,7,10(19),22-cholestatetraene-1,3,24-triol
VVD0123
Sachiko Yamada
(22E)-1a,24S-(OH)2-20-epi-22,23-didehydro-26,27-cyclo-D3 / (22E)-1a,24S-(OH)2-20-epi-22-ene-26,27-cyclo-D3
C27H40O3 412.605 Download ChemDraw structure file
Biological activity (% of 1,25-(OH)2D3 effect) : Inhibition of proliferation of U 937 cells, 60% ; Induction of differentiation of U 937 cells, 10% ; Calciuric effects on normal rats, <1%. (Ref. 0284)





From protected (5E)-22-oxo-23,24,25,26,27-pentanorvitamin D3 via side chain introduction by Wittig-Horner reaction followed by reduction, dye-sensitized photoisomerization and deprotection. (Ref. 0284)



121
(23E)-1a,25-dihydroxy-16,17,23,24-tetradehydrovitamin D3 / (23E)-1a,25-dihydroxy-16,17,23,24-tetradehydrocholecalciferol
(5Z,7E,23E)-(1S,3R)-9,10-seco-5,7,10(19),16,23-cholestapentaene-1,3,25-triol
VVD0124
Sachiko Yamada
1a,25-(OH)2-16,17,23,24-tetradehydro-D3
C27H40O3 412.605 Download ChemDraw structure file
Biological activity (% of 1,25-(OH)2D3 effect) : Inhibition of proliferation of human keratinocytes in culture, 100 ; Competitive binding to rat intestinal vitamin D receptor, 80 ; Differentiation of human leukemia cells (HL-60), 300. (Ref. 0237)









122
(23Z)-1a,25-dihydroxy-16,17,23,24-tetradehydrovitamin D3 / (23Z)-1a,25-dihydroxy-16,17,23,24-tetradehydrocholecalciferol
(5Z,7E,23Z)-(1S,3R)-9,10-seco-5,7,10(19),16,23-cholestapentaene-1,3,25-triol
VVD0125
Sachiko Yamada
(23Z)-1a,25-(OH)2-16,17,23,24-tetradehydro-D3 / (23Z)-1a,25-(OH)2-16,23-diene-D3
C27H40O3 412.605 Download ChemDraw structure file
(% of 1,25-(OH)2D3 effect) Affinity for rat intestinal receptor: 145%; Affinity for human vitmin D binding protein: 17%; HL-60 cell differentiation: 100. (Ref. 0359)









123
(22R)-1a,25-dihydroxy-22,23,23,24-tetradehydrovitamin D3 / (22R)-1a,25-dihydroxy-22,23,23,24-tetradehydrocholecalciferol
(5Z,7E)-(1S,3R,22R)-9,10-seco-5,7,10(19),22,23-cholestapentaene-1,3,25-triol
VVD0126
Sachiko Yamada
(22R)-1a,25-(OH)2-22,23,23,24-tetradehydro-D3
C27H40O3 412.605 Download ChemDraw structure file
(% of 1,25-(OH)2D3 effect) Affinity for chick intestinal receptor: 52%; Affinity for human vitmin D binding protein: 48%. (Ref. 0359)









124
(22S)-1a,25-dihydroxy-22,23,23,24-tetradehydrovitamin D3 / (22S)-1a,25-dihydroxy-22,23,23,24-tetradehydrocholecalciferol
(5Z,7E)-(1S,3R,22S)-9,10-seco-5,7,10(19),22,23-cholestapentaene-1,3,25-triol
VVD0127
Sachiko Yamada
(22S)-1a,25-(OH)2-22,23,23,24-tetradehydro-D3
C27H40O3 412.605 Download ChemDraw structure file
(% of 1,25-(OH)2D3 effect) Affinity for chick intestinal receptor: 21%; Affinity for human vitmin D binding protein: 25%. (Ref. 0359)









125
1a,25-dihydroxy-23,23,24,24-tetradehydrovitamin D3 / 1a,25-dihydroxy-23,23,24,24-tetradehydrocholecalciferol
(5Z,7E)-(1S,3R)-9,10-seco-5,7,10(19)-cholestatrien-23-yne-1,3,25-triol
VVD0128
Sachiko Yamada
1a,25-(OH)2-23,23,24,24-tetradehydro-D3
C27H40O3 412.605 Download ChemDraw structure file
Biological activity (% of 1,25-(OH)2D3 effect) : Inhibition of proliferation of human keratinocytes in culture, 100 ; Intestinal calcium absorption in rat, 95 ; Bone calcium mobilization in rat, 15 ; Competitive binding to rat intestinal vitamin D receptor, 39 ; Differentiation of human leukemia cells (HL-60), 300. (Ref. 0237)









126
(22E,24E)-1a,26a-dihydroxy-22,23,24,25-tetradehydro-26a-homo-27-norvitamin D3 / (22E,24E)-1a,26a-dihydroxy-22,23,24,25-tetradehydro-26a-homo-27-norcholecalciferol
(5Z,7E,22E,24E)-(1S,3R)-26a-homo-27-nor-9,10-seco-5,7,10(19),22,24-cholestapentaene-1,3,26a-triol
VVD0129
Sachiko Yamada
(22E,24E)-1a,26a-(OH)2-22,23,24,25-tetradehydro-26a-homo-27-nor-D3
C27H40O3 412.605 Download ChemDraw structure file
Biological activity (% of 1,25-(OH)2D3 effect) : Inhibition of proliferation of U937 cells, 300% ; Induction of differentiation of U 937 cells, 200% ; Calciuric activity, 1%. (Ref. 0288)





From protected (5E)-1a-hydroxy-22-oxo-23,24,25,26,27-pentanorvitamin D3 via side chain introduction by Wittig reaction, reduction, photoisomerization and deprotection. (Ref. 0288)



127
(23R,25R)-25-hydroxyvitamin D3 26,23-lactone / (23R,25R)-25-hydroxycholecalciferol 26,23-lactone
(5Z,7E)-(3S,23R,25R)-3,25-dihydroxy-9,10-seco-5,7,10(19)-cholestatrieno-26,23-lactone
VVD0130
Sachiko Yamada
25R-OHD3 26,23R-lactone
C27H40O4 428.604 Download ChemDraw structure file

lmax (nm) 265 (Ref. 0117)
1H-NMR (d, CDCl3, 400MHz) 6.23, 6.02 (2H, AB q, J = 10 Hz, 6-, 7-H), 5.04, 4.81 (2H, m, 19-H), 4.77 (1H, m, 23-H), 3.96 (1H, m, 3a-H), 1.52 (3H, s, 27-H), 1.02 (3H, d, J = 6 Hz, 21-H), 0.57 (3H, s, 18-H) (Ref. 0117)
m/z 428 (M+, 98), 413 (M+-Me, 6), 411 (6), 410 (M+-H2O, 22), 395 (M+-H2O-Me, 100), 369 (28), 253 (54) (Ref. 0117)



Synthesis from C(22) steroid aldehyde via iodolactonization of 22-ene-26-carboxylic acid as a key step. (Ref. 0117/0122)
Stereoselective synthesis of 23-epimers of 25R-OHD3 26,23-lactones from C(22)-steroid aldehyde and chiral side chain synthon prepared from (R)-citramalic acid. (Ref. 0113)



128
(23S,25R)-25-hydroxyvitamin D3 26,23-lactone / (23S,25R)-25-hydroxycholecalciferol 26,23-lactone
(5Z,7E)-(3S,23S,25R)-3,25-dihydroxy-9,10-seco-5,7,10(19)-cholestatrieno-26,23-lactone
VVD0131
Sachiko Yamada
25R-OHD3 26,23S-lactone
C27H40O4 428.604 Download ChemDraw structure file
Dose-response of 25-OHD3-26,23-lactone on intestinal calcium transport and bone calcium mobilization in vitamin D-deficient rats on a low calcium diet.: Table (Ref. 0112)
Effect of prior dosing of 25-OHD3-26,23-lactone on intestinal calcium transport and bone calcium mobilizing activity of 1,25-(OH)2D3 in vitamin D-deficient rats.: Table (Ref. 0112)
Ability of 25-OHD3 and 25-OHD3-26,23 lactone stereoisomers to competitively inhibit binding of 25-OH[3H]D3 to the 4.2s rat plasma vitamin D binding protein and competitively inhibit 1,25-(OH)2[3H]D3 binding to the 3.7s 1,25-(OH)2D3 cytosol receptor: Table (Ref. 0119)
lmax (nm) 264, lmin (nm) 229 (Ref. 0111)
lmax(nm) 265, lmin (nm) 228 (Ref. 0115)
(CCl4) 1784 cm-1 (Ref. 0115)
1H-NMR (d, CDCl3) spectrum (Ref. 0111)
1H-NMR (d, CDCl3) 6.28 (1H, d, J = 11.8 Hz, C-6), 6.03 (1H, d, J = 10.7 Hz, C-7), 5.05 (1H, m, C-19E), 4.82 (1H, m, C-19Z), 4.44 (1H, m, C-23), 3.96 (1H, m, C-3), 1.49 (3H, s, C-27), 1.03 (3H, d, J = 5.2 Hz, C-21), 0.56 (3H, s, C-18) (Ref. 0115)
1H-NMR (d, CDCl3, 400 MHz) 6.22, 6.03 (2H), 5.05 (1H), 4.82 (1H), 4.43 (1H), 3.95 (1H), 1.51 (3H), 1.03 (3H), 0.56 (3H) (Ref. 0117)
m/z 428 (27.6, M+), 410 (4.1, M+-H2O), 395 (12.0, M+-H2O-CH3), 271 (4.5, M+-side chain), 253 (9.3, M+-side chain-H2O), 136 (100, A ring+C6+C7+ : A ring fragment+) 118 (94, A ring fragment+-H2O) spectrum (Ref. 0111)
m/z 428.2919 (calcd, 428.2926) (26%, M+), 410 (2%, M+-H2O), 395 (9%, M+-H2O-CH3). 271 (1%, M+-side chain), 253 (8%, M+-side chain-H2O), 136 [100%, (A ring+C6+C7)+], 118 [83%, (A ring+C6+C7)+-H2O] (Ref. 0115)
m/z 428 (97, M+), 413 (10), 411 (9), 410 (25), 395 (100), 369 (28), 253 (22) (Ref. 0117)
CD : four isomers (23S,25S) [q]230 = 3.04 times 103, (23R,25R) [q]230 = 4.95 times 104, (23S,25R) [q]225 = -8.08 times 102, (23R,25S) [q]225 = -3.7 times 103.; spectra (Ref. 0114)
HPLC : (Ref. 0114)
Isolation and Identification from blood plasma of Chickens given either maintenance leueles or large doses of vitamin D3. (Ref. 0111)
Isolation and identification from vitamin D supplemented rat kidney homogenates incubated with 24,25-(OH)2D3. (Ref. 0118)
Stereoselective synthesis starting with C(22)-steroid aldehyde and chiral C(5)-side chain synthon (Ref. 0113/0123) and determination of the stereochemistry at C(23) and C(25) of natural metabolite.(Ref. 0113)
Synthesis of four diastereomers at C(23) and C(25) of 25-OHD3 26,23-lactone from C(22) steroid and the determination of the stereochemistry of the natural product. (Ref. 0114)
Synthesis of four diastereomers at C(23) and C(25) of 25-OHD3 26,23-lactone from 3b-acetoxy-24-nor-5,7-choladien-23-carboxylic acid ester. (Ref. 0115)
Synthesis of four diastereomers at C(23) and C(25) of 25-OHD3 26,23-lactone from C(22) steroid aldehyde via vinylation and orthoester claisen rearrangement as a key step. The stereochemistries at C(23) and C(25) were determined by X-ray analysis. (Ref. 0116/0117)
All four possible stereoisomers of 25-OHD3 26,23-lactone were synthesized from norcholadienoic acid. (Ref. 0121)
The role of kidney in the production of 25-OHD3 26,23-lactone and 1,25-(OH)2D3 26,23-lactone was demonstrated. (Ref. 0120)


129
(23R,25S)-25-hydroxyvitamin D3 26,23-lactone / (23R,25S)-25-hydroxycholecalciferol 26,23-lactone
(5Z,7E)-(3S,23R,25S)-3,25-dihydroxy-9,10-seco-5,7,10(19)-cholestatrieno-26,23-lactone
VVD0132
Sachiko Yamada
25S-OHD3 26,23R-lactone
C27H40O4 428.604 Download ChemDraw structure file

lmax (nm) 265 (Ref. 0117/0123)
(CHCl3) 1772 cm-1 (Ref. 0123)
1H-NMR (d, CDCl3, 400MHz) 6.22, 6.03 (2H, AB q, J = 10 Hz, 6-, 7-H), 5.04, 4.80 (2H, m, 19-H), 4.45 (1H, m, 23-H), 3.94 (1H, m, 3a-H), 1.51 (3H, s, 27-H), 1.01 (3H, d, J = 6 Hz, 21-H), 0.56 (3H, s, 18-H). (Ref. 0117)
1H-NMR (d, CDCl3) 0.57 (3H, s, 18-H), 1.01 (3H, d, J = 6 Hz, 21-H), 1.50 (3H, s, 27-H), 3.97 (1H, m, 3a-H), 4.45 (1H, m, 23-H), 4.83 (1 H, br s, H-19), 5.06 (1 H, br s, H-19), 6.13 (2 H, ABq, J = 11 Hz, H-6 and 7). (Ref. 0123)
m/z 428 (M+, 98), 413 (M+-Me, 7), 411 (6), 410 (M+-H2O, 21), 395 (M+-H2O-Me, 100), 369 (34), 253 (54) (Ref. 0117)
m/z 428 (M+), 410, 395, 369, 136, 118. (Ref. 0123)



Stereoselective synthesis of 25S-OHD3 26,23-lactone from C(22)-steroid aldehyde and chiral side chain synthon prepared from (S)-citramalic acid. (Ref. 0123)
Synthesis from C(22) steroid aldehyde via iodolactonization of 22-ene-26-carboxylic acid as a key step. (Ref. 0117)



130
(23S,25S)-25-hydroxyvitamin D3 26,23-lactone / (23S,25S)-25-hydroxycholecalciferol 26,23-lactone
(5Z,7E)-(3S,23S,25S)-3,25-dihydroxy-9,10-seco-5,7,10(19)-cholestatrieno-26,23-lactone
VVD0133
Sachiko Yamada
25S-OHD3 26,23S-lactone
C27H40O4 428.604 Download ChemDraw structure file

lmax (nm) 265 (Ref. 0117)
1H-NMR (d, CDCl3, 400MHz) 6.22, 6.02 (2H, AB q, J = 10 Hz, 6-, 7-H), 5.04, 4.80 (2H, m, 19-H), 4.72 (1H, m, 23-H), 3.95 (1H, m, 3a-H), 1.52 (3H, s, 27-H), 1.03 (3H, d, J = 6 Hz, 21-H), 0.57 (3H, s, 18-H) (Ref. 0117)
m/z 428 (M+, 100), 413 (M+-Me, 8), 411 (7), 395 (M+-H2O-Me, 71), 369 (15), 253 (10) (Ref. 0117)



Synthesis from C(22) steroid aldehyde via iodolactonization of 22-ene-26-carboxylic acid as a key step. (Ref. 0117)



131
(22E)-(24R,25R)-25,26-epoxy-1a,24-dihydroxy-22,23-didehydrovitamin D3 / (22E)-(24R,25R)-25,26-epoxy-1a,24-dihydroxy-22,23-didehydrocholecalciferol
(5Z,7E,22E)-(1S,3R,24R,25R)-25,26-epoxy-9,10-seco-5,7,10(19),22-cholestatetraene-1,3,24-triol
VVD0134
Sachiko Yamada
(22E)-25R,26-epoxy-1a,24R-(OH)2-22,23-didehydro-D3 / (22E)-25R,26-epoxy-1a,24R-(OH)2-22-ene-D3
C27H40O4 428.604 Download ChemDraw structure file
Biological activity (% of 1,25-(OH)2D3 effect) : Affinity for pig intestinal receptor and human vitamin D binding protein : 8 and 2 respectively. Inhibition of proliferation or differentiation induction of human promyeloid leukemia (HL-60), osteosarcoma (MG-63) and breast carcinoma (MCF-7) cells : 30, 140 and 22, respectively. Elevation of serum calcium, serum osteocalcin, bone calcium and duodenal calbindin in rachitic chicks : 1, 3, 2 and 1, respectively. (Ref. 0240)





By Sharpless kinetic epoxidation of the corresponding olefinic precursor. (Ref. 0243)



132
(22E)-(24S,25S)-25,26-epoxy-1a,24-dihydroxy-22,23-didehydrovitamin D3 / (22E)-(24S,25S)-25,26-epoxy-1a,24-dihydroxy-22,23-didehydrocholecalciferol
(5Z,7E,22E)-(1S,3R,24S,25S)-25,26-epoxy-9,10-seco-5,7,10(19),22-cholestatetraene-1,3,24-triol
VVD0135
Sachiko Yamada
(22E)-25S,26-epoxy-1a,24S-(OH)2-22,23-didehydro-D3 / (22E)-25S,26-epoxy-1a,24S-(OH)2-22-ene-D3
C27H40O4 428.604 Download ChemDraw structure file
Biological activity (% of 1,25-(OH)2D3 effect) : Affinity for pig intestinal receptor and human vitamin D binding protein : 8 and 3 respectively. Inhibition of proliferation or differentiation induction of human promyeloid leukemia (HL-60), osteosarcoma (MG-63) and breast carcinoma (MCF-7) cells : 15, 100 and 65, respectively. Elevation of serum calcium, serum osteocalcin, bone calcium and duodenal calbindin in rachitic chicks : all 1. (Ref. 0240)





By Sharpless kinetic epoxidation of the corresponding olefinic precursor. (Ref. 0243)



133
(23S,25R)-25-hydroxyvitamin D3 26,23-peroxylactone / (23S,25R)-25-hydroxycholecalciferol 26,23-peroxylactone
(5Z,7E)-(3S,23S,25R)-3,25-dihydroxy-9,10-seco-5,7,10(19)-cholestatrieno-26,23-peroxylactone
VVD0136
Sachiko Yamada
25R-OHD3 26,23S-peroxylactone
C27H40O5 444.604 Download ChemDraw structure file

lmax (nm) 264, lmin (nm) 228; spectrum (Ref. 0135)
1733 cm-1; spectrum(Ref. 0135)

m/z 444 (M+), 412 (M+-O2), 400 (M+-CO2), 372 (M+C3H4O2), 354 (372-H2O), 339 (354-CH3 and 372-OOH), 313 (M+C5H7O4), 271 (M+-side chain), 253 (M+-side chain-H2O), 136 (A ring+C6+C7)+, 118 (A ring+-H2O); spectrum(Ref. 0135)

HPLC: (Ref. 0135)
Isolated and identification : From the serum of rats given large doses of vitamin D3. (Ref. 0135)




134
(23R,25R)-1a,25-dihydroxyvitamin D3 26,23-lactone / (23R,25R)-1a,25-dihydroxycholecalciferol 26,23-lactone
(5Z,7E)-(1S,3R,23R,25R)-1,3,25-trihydroxy-9,10-seco-5,7,10(19)-cholestatrieno-26,23-lactone
VVD0137
Sachiko Yamada
1a,25R-(OH)2D3 26,23R-lactone
C27H40O5 444.604 Download ChemDraw structure file
Ability of the four diastereomers at C-23 and -25 of 1,25-(OH)2D3 26,23-lactone and 1,25-(OH)2D3 to bind to chick intestinal receptor was compared : Affinity relative to 1,25-(OH)2D3 : (23S,25S)-isomer, 8% ; (23R,25R)-isomer, 2% ; (23R,25S)-isomer, 0.2% ; (23S,25R)-isomer, 0.15%. (Ref. 0280)
Time-course response of 1,25-(OH)2D3 26,23-lactone four diastereomers in bone calcium mobilization induced in rats and dose-response of 1,25-(OH)2D3 26,23-lactone diastereomers in intestinal calcium transport and bone calcium mobilization. Figure (Ref. 0282)
1H-NMR (d, CDCl3, 400MHz) 6.38 (1H, d, J = 11.3 Hz, 6-H), 6.02 (1H, d, J = 11.3 Hz, 7-H), 5.33 (1H, m, 19-H), 5.01 (1H, m, 19-H), 4.77 (1H, m, 23-H), 4.43 (1H, m, 1b-H), 4.24 (1H, m, 3a-H), 1.52 (3H, s, 27-H), 1.03 (3H, d, J = 6.7 Hz, 21-H), 0.51 (3H, s, 18-H) (Ref. 0280)




Synthesis of four diastereomers at C-23 and -25 of the title compound from 1a-hydroxyergosterol. The stereochemistries at C-23 and -25 of the four diastereomers were determined by comparing their NMR spectra and HPLC properties with those of the four diastereomers at C-23 and -25 of 25-hydroxyvitamin D3 26,23-lactone. (Ref. 0280)



135
(23S,25R)-1a,25-dihydroxyvitamin D3 26,23-lactone / (23S,25R)-1a,25-dihydroxycholecalciferol 26,23-lactone
(5Z,7E)-(1S,3R,23S,25R)-1,3,25-trihydroxy-9,10-seco-5,7,10(19)-cholestatrieno-26,23-lactone
VVD0138
Sachiko Yamada
1a,25R-(OH)2D3 26,23S-lactone
C27H40O5 444.604 Download ChemDraw structure file
Affinity for the chick intestinal receptor: 1/662 as active as 1,25-(OH)2D3. In vitamin D deficient rats fed a low-calcium diet, this compound has a weak potency to increase intestinal calcium transport but it decrreases the serum calcium level: 500 ng dose decreases the serum calcium level by about 20% at 24 h. (Ref. 0242)
Ability of the four diastereomers at C-23 and -25 of 1,25-(OH)2D3 26,23-lactone and 1,25-(OH)2D3 to bind to chick intestinal receptor was compared: Affinity relative to 1,25-(OH)2D3: (23S,25S)-isomer, 7.9% ; (23R,25R)-isomer, 2.3%; (23R,25S)-isomer, 0.22%; (23S,25R)-isomer, 0.17%. (Ref. 0280)
Time-course response of 1,25-(OH)2D3 26,23-lactone four diastereomers in bone calcium mobilization induced in rats. Dose-response of 1,25-(OH)2D3 26,23-lactone diastereomers in intestinal calcium transport and bone calcium mobilization. (Ref. 0282)
[a]d-25 +21.3 degC (c = 0.47 in Et2O) [Lit. [a]D +24.66 degC (in Et2O)] (Ref. 0078/0280)
(95% EtOH) lmax (nm) 264, lmin (nm) 228 (Ref. 0078/0280)
(KBr) 3416, 2940, 1771, 1212, 1054 cm-1 (Ref. 0078/0280)
1H-NMR (d, CDCl3) 0.55 (3H, s, 18-H), 1.03 (3H, d, J = 5.9 Hz, 21-H), 1.48 (3H, s, 27-H), 4.22 (1H, m, 3-H), 4.44 (2H, m, 1- and 23-H), 5.00 and 5.33 (each 1H, m, 19-H), 6.02 and 6.38 (each 1H, d, J = 11 Hz, 7- and 6-H, respectively) (Ref. 0078/0280)
1H-NMR (d, CD3OD) 0.59 (3H, s, 18-H), 1.05 (3H, d, J = 6.4 Hz, 21-H), 1.44 (3H, s, 27-H), 4.14 (1H, m, 3-H), 4.36 (1H, m, 1-H), 4.49 (1H, m, 23-H), 4.91 and 5.29 (each 1H, m, 19-H), 6.09 and 6.33 (each 1H, d, J = 11 Hz, 7- and 6-H, respectively) (Ref. 0078/0280)
m/z 444 (M+, 6), 426 (13), 408 (14), 269 (7), 251 (16), 134 (100) (Ref. 0078/0280)


In normal beagle dogs, serum concentrations of 1,25R-(OH)2D3 26,23S-lactone, 1,25-(OH)2D3 and 1,24,25-(OH)3D3 were 100, 36, and 6 pg/ml serum. (Ref. 0085)
From 1a-hydroxydehydroepiandrosterone: The side chain was introduced via the reaction of C(22)-aldehyde with chiral C(5)-sulfone having the desired stereochemistry at C(25) of the target compound as key step. The lactone structure was constructed stereoselectively by iodolactonization of 22-ene-25-carboxylic acid. Provitamin D with the required side chain was converted to the title compound by photochemical method. (Ref. 0078)
Synthesis of four diastereomers at C-23 and -25 of the title compound from 1a-hydroxyergosterol and determination of the stereochemistry of the natural metabolite to be (23S, 25R). The stereochemistries at C-23 and -25 of the four diastereomers were determined by comparing their NMR spectra and HPLC properties with those of the four diastereomers at C-23 and -25 of 25-hydroxyvitamin D3 26,23-lactone (Ref. 0280)
The role of kidney in the production of 25-OHD3 26,23-lactone and 1,25-(OH)2D3 26,23-lactone was demonstrated. (Ref. 0120)


136
(23R,25S)-1a,25-dihydroxyvitamin D3 26,23-lactone / (23R,25S)-1a,25-dihydroxycholecalciferol 26,23-lactone
(5Z,7E)-(1S,3R,23R,25S)-1,3,25-trihydroxy-9,10-seco-5,7,10(19)-cholestatrieno-26,23-lactone
VVD0139
Sachiko Yamada
1a,25S-(OH)2D3 26,23R-lactone
C27H40O5 444.604 Download ChemDraw structure file
Ability of the four diastereomers at C-23 and -25 of 1,25-(OH)2D3 26,23-lactone and 1,25-(OH)2D3 to bind to chick intestinal receptor was compared : Affinity relative to 1,25-(OH)2D3 : (23S,25S)-isomer, 8% ; (23R,25R)-isomer, 2% ; (23R,25S)-isomer, 0.2% ; (23S,25R)-isomer, 0.15%. (Ref. 0280)
Time-course response of 1,25-(OH)2D3 26,23-lactone four diastereomers in bone calcium mobilization induced in rats and dose-response of 1,25-(OH)2D3 26,23-lactone diastereomers in intestinal calcium transport and bone calcium mobilization. Figure (Ref. 0282)
1H-NMR (d, CDCl3, 400MHz) 6.37 (1H, d, J = 11.3 Hz, 6-H), 6.02 (1H, d, J = 11.3 Hz, 7-H), 5.34 (1H, m, 19-H), 5.00 (1H, m, 19-H), 4.46 (2H, m, 23- and 1b-H), 4.24 (1H, m, 3a-H), 1.50 (3H, s, 27-H), 1.01 (3H, d, J = 6.4 Hz, 21-H), 0.57 (3H, s, 18-H) (Ref. 0280)




Synthesis of four diastereomers at C-23 and -25 of the title compound from 1a-hydroxyergosterol. The stereochemistries at C-23 and -25 of the four diastereomers were determined by comparing their NMR spectra and HPLC properties with those of the four diastereomers at C-23 and -25 of 25-hydroxyvitamin D3 26,23-lactone. (Ref. 0280)



137
(23S,25S)-1a,25-dihydroxyvitamin D3 26,23-lactone / (23S,25S)-1a,25-dihydroxycholecalciferol 26,23-lactone
(5Z,7E)-(1S,3R,23S,25S)-1,3,25-trihydroxy-9,10-seco-5,7,10(19)-cholestatrieno-26,23-lactone
VVD0140
Sachiko Yamada
1a,25S-(OH)2D3 26,23S-lactone
C27H40O5 444.604 Download ChemDraw structure file
Ability of the four diastereomers at C-23 and -25 of 1,25-(OH)2D3 26,23-lactone and 1,25-(OH)2D3 to bind to chick intestinal receptor was compared: Affinity relative to 1,25-(OH)2D3 : (23S,25S)-isomer, 8% ; (23R,25R)-isomer, 2% ; (23R,25S)-isomer, 0.2% ; (23S,25R)-isomer, 0.15%. (Ref. 0280)
Time-course response of 1,25-(OH)2D3 26,23-lactone four diastereomers in bone calcium mobilization induced in rats and dose-response of 1,25-(OH)2D3 26,23-lactone diastereomers in intestinal calcium transport and bone calcium mobilization. Figure (Ref. 0282)
1H-NMR (d, CDCl3, 400MHz) 6.38 (1H, d, J = 11.3 Hz, 6-H), 6.01 (1H, d, J = 11.3 Hz, 7-H), 5.33 (1H, m, 19-H), 5.00 (1H, m, 19-H), 4.72 (1H, m, 23-H), 4.33 (1H, m, 1b-H), 4.23 (1H, m, 3a-H), 1.51 (3H, s, 27-H), 1.03 (3H, d, J = 6.4 Hz, 21-H), 0.56 (3H, s, 18-H) (Ref. 0280)




Synthesis of four diastereomers at C-23 and -25 of the title compound from 1a-hydroxyergosterol. The stereochemistries at C-23 and -25 of the four diastereomers were determined by comparing their NMR spectra and HPLC properties with those of the four diastereomers at C-23 and -25 of 25-hydroxyvitamin D3 26,23-lactone. (Ref. 0280)



138
(25R)-26,26,26-trideuterio-1a,25-dihydroxyvitamin D3 / (25R)-26,26,26-trideuterio-1a,25-dihydroxycholecalciferol
(5Z,7E)-(1S,3R,25R)-26,26,26-trideuterio-9,10-seco-5,7,10(19)-cholestatriene-1,25-diol
VVD0141
Sachiko Yamada
1a,25R-(OH)2-[26,26,26-2H]D3
C27H41D3O3 419.613 Download ChemDraw structure file
Biological activity (% of 1,25-(OH)2D3 effect) : Affinity for rat intestinal receptor : 83 ; Calf intestinal receptor : 97 ; Intestinal calcium absorption, 136 ; Bone calcium mobilization, 143. (Ref. 0329)





Total convergent synthesis via Wittig-Horner coupling of upper half 8-ketone with A ring phosphine oxide. The upper half was synthesized from CD-ring 23-nitrone via 1,3-dipolar cycloaddition with methyl methacrylate as key step. (Ref. 0329)



139
(25S)-26,26,26-trideuterio-1a,25-dihydroxyvitamin D3 / (25S)-26,26,26-trideuterio-1a,25-dihydroxycholecalciferol
(5Z,7E)-(1S,3R,25S)-26,26,26-trideuterio-9,10-seco-5,7,10(19)-cholestatriene-1,25-diol
VVD0142
Sachiko Yamada
1a,25S-(OH)2-[26,26,26-2H]D3
C27H41D3O3 419.613 Download ChemDraw structure file
Biological activity (% of 1,25-(OH)2D3 effect) : Affinity for rat intestinal receptor : 148 ; Calf intestinal receptor : 161 ; Intestinal calcium absorption, 92 ; Bone calcium mobilization, 149. (Ref. 0329)





Total convergent synthesis via Wittig-Horner coupling of upper half 8-ketone with A ring phosphine oxide. The upper half was synthesized from CD-ring 23-nitrone via 1,3-dipolar cycloaddition with methyl methacrylate as key step. (Ref. 0329)



140
(24R)-24,25-dihydroxy-[6,19,19-2H3]vitamin D3 / (24R)-24,25-dihydroxy-[6,19,19-2H3]cholecalciferol
(5Z,7E)-(3S,24R)-[6,19,19-2H3]-9,10-seco-5,7,10(19)-cholestatriene-3,24,25-triol
VVD0143
Sachiko Yamada
24R,25-(OH)2-[6,19,19-2H3]D3
C27H41D3O3 419.613 Download ChemDraw structure file

(EtOH) lmax (nm) 265 (Ref. 0332)
(KBr) 3450, 2970, 2900, 1640, 1630, 1450, 1380, 1162, 1075, 965 cm-1 (Ref. 0332)
1H-NMR (d, CDCl3) 0.55 (3H, s, 18-H), 0.94 (3H, d, J = 5.0 Hz, 21-H), 1.17 and 1.22 (each 3H, s, 26- and 27-H), 3.31 (1H, m, 24-H), 3.93 (1H, m, 3-H), 6.02 (1H, s, 7-H) (Ref. 0332)




From 24R,25-dihydroxyvitamin D3 via proton-deuterium exchange at 6 and 19-positions of its sulfur dioxide adduct under basic conditions. (Ref. 0332)



141
(5E)-(24R)-24,25-dihydroxy-[6,19,19-2H3]vitamin D3 / (5E)-(24R)-24,25-dihydroxy-[6,19,19-2H3]cholecalciferol
(5E,7E)-(3S,24R)-[6,19,19-2H3]-9,10-seco-5,7,10(19)-cholestatriene-3,24,25-triol
VVD0144
Sachiko Yamada
(5E)-24R,25-(OH)2-[6,19,19-2H3]D3
C27H41D3O3 419.613 Download ChemDraw structure file

(EtOH) lmax (nm) 273 (Ref. 0332)
(KBr) 3650, 3450, 3020, 2950, 1210, 1060 cm-1 (Ref. 0332)
1H-NMR (d, CDCl3) 0.57 (3H, s, 18-H), 0.95 (3H, d, J = 5.0 Hz, 21-H), 1.17 and 1.22 (each 3H, s, 26- and 27-H), 3.32 (1H, m, 24-H), 3.84 (1H, m, 3-H), 5.86 (1H, s, 7-H) (Ref. 0332)
m/z 419 (M+, 83), 401 (30), 274 (67), 256 (68), 160 (68), 139 (70), 121 (100) (Ref. 0332)



From 24R,25-dihydroxyvitamin D3 via proton-deuterium exchange at 6 and 19-positions of its sulfur dioxide adduct under basic conditions. (Ref. 0332)



142
(20R,24R)-20-fluoro-1a,24-dihydroxy-26,27-cyclovitamin D3 / (20R,24R)-20-fluoro-1a,24-dihydroxy-26,27-cyclocholecalciferol
(5Z,7E)-(1S,3R,20R,24R)-20-fluoro-26,27-cyclo-9,10-seco-5,7,10(19)-cholestatriene-1,3,24-triol
VVD0145
Sachiko Yamada
20R-F-1a,24R-(OH)2-26,27-cyclo-D3
C27H41FO3 432.611 Download ChemDraw structure file

(KBr) 3400, 2900 cm-1 (Ref. 0161)
1H-NMR (d, CDCl3, 300MHz) 6.02 and 6.39 (1H each, 2 times d, J = 11 Hz, 6- and 7-H), 5.00 and 5.34 (1H each, 2 times s, 19-H), 4.43 (1H, m, 1-H), 4.22 (1H, m, 3-H), 2.88 (1H, m, 24-H), 1.30 (3H, d, J = 20 Hz, 21-H), 0.90 (1H, m, 25-H), 0.70 (3H, d, J = 3 Hz, 18-H), 0.54 and 0.28 (2H each, 2 times m, 26- and 27-H) (Ref. 0161)
m/z 432 (M+, 9%),414 (10%), 394 (10%), 376 (7%), 358 (3%), 134 (100%) (Ref. 0161)



Synthesis of the four diastereomers at C(20) and C(24) from protected (5E)-1a-hydroxy-22-oxo-23,24,25,26,27-pentanorvitamin D3 via fluorination of its silylenol ether and introduction of the side chain fragment by Wittig type reaction as key steps. (Ref. 0161)



143
(20S,24R)-20-fluoro-1a,24-dihydroxy-26,27-cyclovitamin D3 / (20S,24R)-20-fluoro-1a,24-dihydroxy-26,27-cyclocholecalciferol
(5Z,7E)-(1S,3R,20S,24R)-20-fluoro-26,27-cyclo-9,10-seco-5,7,10(19)-cholestatriene-1,3,24-triol
VVD0146
Sachiko Yamada
20S-F-1a,24R-(OH)2-26,27-cyclo-D3
C27H41FO3 432.611 Download ChemDraw structure file

(KBr) 3400, 2930 cm-1 (Ref. 0161)
1H-NMR (d, CDCl3, 300MHz) 6.02 and 6.39 (1H each, 2 times d, J = 11 Hz, 6- and 7-H), 5.00 and 5.33 (1H each, 2 times s, 19-H), 4.43 (1H, m, 1-H), 4.22 (1H, m, 3-H), 2.85 (1H, m, 24-H), 1.41 (3H, d, J = 21 Hz, 21-H), 0.70 (3H, d, J = 4 Hz, 18-H) (Ref. 0161)
m/z 432 (M+, 7%),414 (10%), 394 (8%), 376 (7%), 152 (34%), 134 (100%) (Ref. 0161)



Synthesis of the four diastereomers at C(20) and C(24) from protected (5E)-1a-hydroxy-22-oxo-23,24,25,26,27-pentanorvitamin D3 via fluorination of its silylenol ether and introduction of the side chain fragment by Wittig type reaction as key steps. (Ref. 0161)



144
(20R,24S)-20-fluoro-1a,24-dihydroxy-26,27-cyclovitamin D3 / (20R,24S)-20-fluoro-1a,24-dihydroxy-26,27-cyclocholecalciferol
(5Z,7E)-(1S,3R,20R,24S)-20-fluoro-26,27-cyclo-9,10-seco-5,7,10(19)-cholestatriene-1,3,24-triol
VVD0147
Sachiko Yamada
20R-F-1a,24S-(OH)2-26,27-cyclo-D3
C27H41FO3 432.611 Download ChemDraw structure file

(KBr) 3400, 2900 cm-1 (Ref. 0161)
1H-NMR (d, CDCl3, 300MHz) 6.02 and 6.39 (1H each, 2 times d, J = 11 Hz, 6- and 7-H), 5.01 and 5.34 (1H each, 2 times s, 19-H), 4.43 (1H, m, 1-H), 4.22 (1H, m, 3-H), 2.85 (1H, m, 24-H), 1.30 (3H, d, J = 20 Hz, 21-H), 0.90 (1H, m, 25-H), 0.70 (3H, d, J = 3 Hz, 18-H), 0.53 and 0.27 (2H each, 2 times m, 26- and 27-H) (Ref. 0161)
m/z 432 (M+, 8%),414 (13%), 394 (14%), 376 (8%), 358 (3%), 134 (100%) (Ref. 0161)



Synthesis of the four diastereomers at C(20) and C(24) from protected (5E)-1a-hydroxy-22-oxo-23,24,25,26,27-pentanorvitamin D3 via fluorination of its silylenol ether and introduction of the side chain fragment by Wittig type reaction as key steps. (Ref. 0161)



145
(20S,24S)-20-fluoro-1a,24-dihydroxy-26,27-cyclovitamin D3 / (20S,24S)-20-fluoro-1a,24-dihydroxy-26,27-cyclocholecalciferol
(5Z,7E)-(1S,3R,20S,24S)-20-fluoro-26,27-cyclo-9,10-seco-5,7,10(19)-cholestatriene-1,3,24-triol
VVD0148
Sachiko Yamada
20S-F-1a,24S-(OH)2-26,27-cyclo-D3
C27H41FO3 432.611 Download ChemDraw structure file

(KBr) 3400, 2920 cm-1 (Ref. 0161)
1H-NMR (d, CDCl3, 300MHz) 6.02 and 6.39 (1H each, 2 times d, J = 11 Hz, 6- and 7-H), 5.00 and 5.33 (1H each, 2 times s, 19-H), 4.43 (1H, m, 1-H), 4.22 (1H, m, 3-H), 2.85 (1H, m, 24-H), 1.41 (3H, d, J = 21 Hz, 21-H), 0.70 (3H, d, J = 4 Hz, 18-H) (Ref. 0161)
m/z 432 (M+, 8%),414 (13%), 394 (12%), 376 (9%), 152 (33%), 134 (100%) (Ref. 0161)



Synthesis of the four diastereomers at C(20) and C(24) from protected (5E)-1a-hydroxy-22-oxo-23,24,25,26,27-pentanorvitamin D3 via fluorination of its silylenol ether and introduction of the side chain fragment by Wittig type reaction as key steps. (Ref. 0161)



146
26,26,26-trifluoro-25-hydroxyvitamin D3 / 26,26,26-trifluoro-25-hydroxycholecalciferol
(5Z,7E)-(3S)-26,26,26-trifluoro-9,10-seco-5,7,10(19)-cholestatriene-3,25-diol
VVD0149
Sachiko Yamada
26,26,26-F3-25-OHD3
C27H41F3O2 454.608 Download ChemDraw structure file

lmax (nm) 265, lmin (nm) 227 (Ref. 0201)

m/z 454 (M+), 493, 436, 421, 271, 253, 136, 118 (Ref. 0201)



From 24-phenylsulfonyl-5-cholen-3-ol via reaction with trifluoroacetate as a key step. (Ref. 0201)



147
(25R)-26,26,26-trifluoro-1a,25-dihydroxyvitamin D3 / (25R)-26,26,26-trifluoro-1a,25-dihydroxycholecalciferol
(5Z,7E)-(1S,3R,25R)-26,26,26-trifluoro-9,10-seco-5,7,10(19)-cholestatriene-1,3,25-triol
VVD0150
Sachiko Yamada
26,26,26-F3-1a,25R-(OH)2D3
C27H41F3O3 470.608 Download ChemDraw structure file
Potency relative to 1,25-(OH)2D3 (defined 1): Differentiation of HL-60 cells: 3; Calcemic activity: 2. (Ref. 0356)









148
(25S)-26,26,26-trifluoro-1a,25-dihydroxyvitamin D3 / (25S)-26,26,26-trifluoro-1a,25-dihydroxycholecalciferol
(5Z,7E)-(1S,3R,25S)-26,26,26-trifluoro-9,10-seco-5,7,10(19)-cholestatriene-1,3,25-triol
VVD0151
Sachiko Yamada
26,26,26-F3-1a,25S-(OH)2D3
C27H41F3O3 470.608 Download ChemDraw structure file
Biological activity (% of 1,25-(OH)2D3 effect) : Inhibition of proliferation of human keratinocytes in culture, 100 ; Intestinal calcium absorption in rat, 197 ; Bone calcium mobilization in rat, 163 ; Competitive binding to rat intestinal vitamin D receptor, 199 ; Differentiation of human leukemia cells (HL-60), 300. (Ref. 0237)









149
4,4-difluorovitamin D3 / 4,4-difluorocholecalciferol
(5E,7E)-(3S)-4,4-difluoro-9,10-seco-5,7,10(19)-cholestatrien-3-ol
VVD0152
Sachiko Yamada
4,4-F2-D3
C27H42F2O 420.619 Download ChemDraw structure file

(95% EtOH) lmax (nm) (emax) 270 (19400) (Ref. 0333)
1H-NMR (d, CDCl3) 0.55 (3H, s, 18-H), 0.86 and 0.87 (each 3H, d, J = 6.6 Hz, 26- and 27-H), 0.92 (3H, d, J = 6.2 Hz, 21-H), 2.19 (1H, m, 1-H), 2.47 (1H, m, 1-H), 3.98 (1H, m, 3-H), 5.00 and 5.23 (each 1H, s, 19-H), 6.09 (1H, d, J = 11.4 Hz, 7-H), 6.94 (1H, d, J = 11.4 Hz, 6-H) (Ref. 0333)
19F-NMR (d, CDCl3) -114.0 (dd, J = 234.6 and 11.5 Hz, 4b-F), -108.0 (d, J = 234.6 Hz, 4a-F) (Ref. 0333)
m/z 420 (M+, 93), 382 (79), 380 (18), 335 (22), 307 (61), 269 (33), 267 (16), 135 (100) (Ref. 0333)



From 4,7-cholestadien-3-one via electrophilic difluorination at C(4) followed by reduction giving 4,4-difluoroprovitamin D3 as a key step. (Ref. 0345)



150
(5Z)-4,4-difluorovitamin D3 / (5Z)-4,4-difluorocholecalciferol
(5Z,7E)-(3S)-4,4-difluoro-9,10-seco-5,7,10(19)-cholestatrien-3-ol
VVD0153
Sachiko Yamada
(5Z)-4,4-F2-D3
C27H42F2O 420.619 Download ChemDraw structure file

(95% EtOH) lmax (nm) (emax) 277 (23000) (Ref. 0333)
1H-NMR (d, CD3OD) 0.60 (3H, s, 18-H), 0.89 (6H, d, J = 6.6 Hz, 26- and 27-H), 0.96 (3H, d, J = 6.1 Hz, 21-H), 2.23 (1H, m, 1-H), 2.52 (1H, m, 1-H), 3.88 (1H, m, 3-H), 4.82 and 5.01 (each 1H, s, 19-H), 6.40 (1H, d, J = 12.0 Hz, 7-H), 6.83 (1H, d, J = 12.0 Hz, 6-H) (Ref. 0333)
19F-NMR (d, CDCl3) -109.0 (d, J = 248.7 Hz), -101.7 (d, J = 248.7 Hz) (Ref. 0333)




From 4,7-cholestadien-3-one via electrophilic difluorination at C(4) followed by reduction giving 4,4-difluoroprovitamin D3 as a key step. (Ref. 0345)



151
1a,25-difluorovitamin D3 / 1a,25-difluorocholecalciferol
(5Z,7E)-(1S,3R)-1,25-difluoro-9,10-seco-5,7,10(19)-cholestatrien-3-ol
VVD0154
Sachiko Yamada
1a,25-F2-D3
C27H42F2O 420.619 Download ChemDraw structure file
The title compound showed no response in intestinal calcium transport and elevation of serum calcium level in vitamin D deficient rats. Antivitamin D properties of the title compound was tested. At a 1000-fold excess administration, this compound failed to block the expression of vitamin D activity. (Stereochemistry at C-1 is ambiguous) (Ref. 0296)
lmax (nm) 265 (Ref. 0296)
1H-NMR (d) 0.53 (3H, s, 18-CH3), 0.93 (3H, d, J = 6.0 Hz, 21-CH3), 1.34 (6H, d, J = 22.0 Hz, 26- and 27-CH3), 3.98 (1H, m, 3-H), 5.02 (1H, d m, J = 52.0 Hz, 1-H), 5.12 [1H, m(sharp), 19(Z)-H], 5.41 [1H, m(sharp), 19(E)-H], 6.03 (1H, d, J = 11.0 Hz, 7-H), 6.44 (1H, d, J = 11.0 Hz, 6-H) (Ref. 0296)
m/z 420 (M+, 20), 400 (70), 382 (35), 135 (100) (Ref. 0296)



From 1a,25-(OH)2D3 3-acetate, by fluorination with diethylaminosulfurtrifluoride followed by deprotection. (Stereochemistry at C-1 is ambiguous) (Ref. 0296)



152
24,24-difluoro-1a-hydroxyvitamin D3 / 24,24-difluoro-1a-hydroxycholecalciferol
(5Z,7E)-(1S,3R)-24,24-difluoro-9,10-seco-5,7,10(19)-cholestatriene-1,3-diol
VVD0155
Sachiko Yamada
24,24-F2-1a-OH-D3
C27H42F2O2 436.618 Download ChemDraw structure file
The analogue showed higher activity than 24,24-difluoro-1a,25-dihydroxyvitamin D3 in intestinal calcium absorption. (Ref. 0251)
[a]D +75.6 deg (c = 0.15 in CHCl3) (Ref. 0251)
(EtOH) lmax (nm) (e) 264 (18100) (Ref. 0251)
(neat) 3422, 1645, 1456 cm-1 (Ref. 0251)
1H-NMR (d, CDCl3, 400MHz) 0.55 (3H, s), 0.94 (3H, d, J = 6.4 Hz), 1.00 (6H, d, J = 7.0 Hz), 4.20-4.25 (1H, m), 4.43 (1H, dd, J = 4.6, 7.6 Hz), 5.00 (1H, s), 5.33 (1H, t, J = 1.7 Hz), 6.02 (1H, d, J = 11.5 Hz), 6.38 (1H, d, J = 11.5 Hz) (Ref. 0251)
m/z 436 (M+), 418 (M+-H2O), 400 (M+-2H2O), 152, 134 (Ref. 0251)

HPLC : Lichrosorb Si-60, 25 times 250 mm ; mobile phase, 8 % isoPrOH-CH2Cl2 (Ref. 0251)

The PTAD adduct of 1a,3b-bis[(tert-butyldimethylsilyl)oxy]-24-norchol-5,7-dien-23-al was modified to give the analogues with fluorine atoms in the side-chain. The radical deoxygenation of the 25-OH was a key feature in the synthesis. (Ref. 0251)



153
4,4-difluoro-1a-hydroxyvitamin D3 / 4,4-difluoro-1a-hydroxycholecalciferol
(5E,7E)-(1S,3S)-4,4-difluoro-9,10-seco-5,7,10(19)-cholestatriene-1,3-diol
VVD0156
Sachiko Yamada
4,4-F2-25-OHD3
C27H42F2O2 436.618 Download ChemDraw structure file

(95% EtOH) lmax (nm) 271 (Ref. 0333)
1H-NMR (d, CDCl3) 0.55 (3H, s, H-18), 0.86 and 0.87 (each 3H, d, J = 6.6 Hz, H-26 and 27), 0.92 (3H, d, J = 6.2 Hz, H-21), 2.08 (2H, m, H-2), 2.90 (1H, m, H-9), 4.26 (1H, m, H-3), 4.49 (1H, t, J = 5.6 Hz, H-1), 5.18 and 5.50 (each 1H, s, H-19), 6.07 (1H, d, J = 11.4 Hz, H-7), 7.06 (1H, d, J = 11.4 Hz, H-6) (Ref. 0333)
19F-NMR (d, CDCl3) -116.3 (d, J = 237.9 Hz, 4b-F), -107.7 (br d, J = 237.9 Hz, 4a-F) (Ref. 0333)
m/z 436 (M+, 54), 418 (6), 398 (9), 380 (6), 351 (25), 323 (58), 305 (12), 285 (6), 259 (11), 135 (100) (Ref. 0333)



From 4,7-cholestadien-3-one via electrophilic difluorination at C(4) followed by reduction giving 4,4-difluoroprovitamin D3 as a key step. (Ref. 0345)



154
(5Z)-4,4-difluoro-1a--hydroxyvitamin D3 / (5Z)-4,4-difluoro-1a--hydroxycholecalciferol
(5Z,7E)-(1S,3S)-4,4-difluoro-9,10-seco-5,7,10(19)-cholestatriene-1,3-diol
VVD0157
Sachiko Yamada
(5Z)-4,4-F2-25-OHD3
C27H42F2O2 436.618 Download ChemDraw structure file






From 4,7-cholestadien-3-one via electrophilic difluorination at C(4) followed by reduction giving 4,4-difluoroprovitamin D3 as a key step. (Ref. 0345)



155
23,23-difluoro-25-hydroxyvitamin D3 / 23,23-difluoro-25-hydroxycholecalciferol
(5Z,7E)-(3S)-23,23-difluoro-9,10-seco-5,7,10(19)-cholestatriene-3,25-diol
VVD0158
Sachiko Yamada
23,23-F2-25-OHD3
C27H42F2O2 436.618 Download ChemDraw structure file
The title compound is 5-10 times less active than 25-OHD3 in stimulating intestinal calcium transport, bone calcium mobilization, increasing serum phosphorus, mineralization of rachitic bone, and binding to the plasma transport protein in rats. (Ref. 0301)
(EtOH) lmax (nm) 265, lmin (nm) 228 (Ref. 0202)
1H-NMR (d, CDCl3) 0.58 (3H, s, 18-H3), 1.07 (3H, d, J = 6.1 Hz, 21-H3), 1.34 (6H, s, 26- and 27-H3), 3.95 (1H, m, 3-H), 4.81 (1H, bs, 19-H), 5.04 (1H, bs, 19-H), 6.03 (1H, d, J = 10.7 Hz, 7-H), 6.23 (1H, J = 10.7 Hz, 6-H) (Ref. 0202)
m/z 436 (M+), 418, 403 (Ref. 0202)



From 6b-methoxy-3a,5-cyclo-23,24-dinor-5a-cholan-22-ol via methyl 23,23-difluoro-cholan-24-oate. as key intermediate. (Ref. 0202)



156
24,24-difluoro-25-hydroxyvitamin D3 / 24,24-difluoro-25-hydroxycholecalciferol
(5Z,7E)-(3S)-24,24-difluoro-9,10-seco-5,7,10(19)-cholestatriene-3,25-diol
VVD0159
Sachiko Yamada
24,24-F2-25-OHD3
C27H42F2O2 436.618 Download ChemDraw structure file

(95% EtOH) lmax (nm) (logemax) 265 (4.24) (Ref. 0303)
1H-NMR (d, CDCl3) 0.56 (3 H, s), 0.95 (3 H, d, J = 6 Hz), 1.32 (6 H, s), 3.95 (1 H, m, W/2 = 20 Hz), 4.85 (1 H, bs), 5.08 (1 H, bs), 6.16 (2 H, AB type q, J = 11 Hz) (Ref. 0303)
m/z 436 (M+), 421, 418, 403, 377, 271, 253, 136, 118 (Ref. 0199)



From lithocholic acid via fluorination of 24-oxo-25-carboxylic acid ester with DAST (diethylaminosulfur trifluoride) as a key step to construct the desired side chain structure. (Ref. 0303)



157
4,4-difluoro-1a,25-dihydroxyvitamin D3 / 4,4-difluoro-1a,25-dihydroxycholecalciferol
(5E,7E)-(1S,3S)-4,4-difluoro-9,10-seco-5,7,10(19)-cholestatriene-1,3,25-triol
VVD0160
Sachiko Yamada
4,4-F2-1a,25-(OH)2D3
C27H42F2O3 452.617 Download ChemDraw structure file

(95% EtOH) lmax (nm) 271 (Ref. 0333)
1H-NMR (d, CDCl3) 0.55 (3H, s, 18-H), 0.94 (3H, d, J = 6.4 Hz, 21-H), 1.22 (6H, s, 26- and 27-H), 2.09 (2H, m, 2-H), 2.90 (1H, m, 9-H), 4.25 (1H, m, 3-H), 4.49 (1H, t, J = 5.6 Hz, 1-H), 5.18 and 5.50 (each 1H, s, 19-H), 6.07 (1H, d, J = 11.5 Hz, 7-H), 7.06 (1H, d, J = 11.5 Hz, 6-H) (Ref. 0333)
19F-NMR (d, CDCl3) -116.3 (d, J = 237.0 Hz, 4b-F), -107.6 (br d, J = 237.0 Hz, 4a-F) (Ref. 0333)
m/z 452 (M+, 17), 434 (34), 419 (12), 414 (10), 396 (10), 351 (13), 323 (56), 305 (18), 303 (11), 285 (12), 135 (100) (Ref. 0333)



From 25-hydroxy-4,7-cholestadien-3-one via electrophilic difluorination at C(4) followed by reduction giving 4,4-difluoro-25-hydroxyprovitamin D3 as a key step. (Ref. 0333)



158
(5Z)-4,4-difluoro-1a,25-dihydroxyvitamin D3 / (5Z)-4,4-difluoro-1a,25-dihydroxycholecalciferol
(5Z,7E)-(1S,3S)-4,4-difluoro-9,10-seco-5,7,10(19)-cholestatriene-1,3,25-triol
VVD0161
Sachiko Yamada
(5Z)-4,4-F2-1a,25-(OH)2D3
C27H42F2O3 452.617 Download ChemDraw structure file






From 25-hydroxy-4,7-cholestadien-3-one via electrophilic difluorination at C(4) followed by reduction giving 4,4-difluoro-25-hydroxyprovitamin D3 as a key step. (Ref. 0333)



159
23,23-difluoro-1a,25-dihydroxyvitamin D3 / 23,23-difluoro-1a,25-dihydroxycholecalciferol
(5Z,7E)-(1S,3R)-23,23-difluoro-9,10-seco-5,7,10(19)-cholestatriene-1,3,25-triol
VVD0162
Sachiko Yamada
23,23-F2-1a,25-(OH)2D3
C27H42F2O3 452.617 Download ChemDraw structure file
Affinity for chick intestinal receptor : 1/7 as active as 1,25-(OH)2D3 ; Intestinal calcium transport, approximately as potent as 1,25-(OH)2D3. (Ref. 0301)

m/z 452 (M+), 434, 416, 287, 269, 251, 152, 134 (Ref. 0301)



From 23,23-difluoro-25-hydroxyvitamin D3 by in vitro incubation with vitamin D-deficient chick kidney homogenates and subsequent purification on three HPLC systems. (Ref. 0301)



160
24,24-difluoro-1a,25-dihydroxyvitamin D3 / 24,24-difluoro-1a,25-dihydroxycholecalciferol
(5Z,7E)-(1S,3R)-24,24-difluoro-9,10-seco-5,7,10(19)-cholestatriene-1,3,25-triol
VVD0163
Sachiko Yamada
24,24-F2-1a,25-(OH)2D3
C27H42F2O3 452.617 Download ChemDraw structure file
Biological activity (% of 1,25-(OH)2D3 effect) : Inhibition of proliferation of human keratinocytes in culture, 100 ; Intestinal calcium absorption in rat, 235 ; Bone calcium mobilization in rat, 58 ; Competitive binding to rat intestinal vitamin D receptor, 229 ; Differentiation of human leukemia cells (HL-60), 1000. (Ref. 0237)
The analogue was about four to five times more active than 1a,25-dihydroxyvitamin D3 to stimulate the chick intestinal calcium uptake. (Ref. 0253)
The analogue, 24,24-F2-1a,25-(OH)2D3 was four to seven times more potent than 1a,25-(OH)2D3 in inducing phagocytosis and C3 rosette formation of HL-60 cells. (Ref. 0254)
The analogue induced macrophage differentiation of leukemic myeloid colony-forming cells, and the potency of the induction by 1a,25-(OH)2D3 and 24,24-F2-1a,25-(OH)2D3 was almost equivalent. (Ref. 0255)
The analogue induced a significantly greater hypercalcemia and hyperphophatemia than did 1a,25-(OH)2D3. (Ref. 0256)
[a]D +10.0 deg (c = 0.25 in EtOH) (Ref. 0258)
lmax (nm) (emax) 265 (18100) (Ref. 0258)
(CHCl3) 3690 cm-1 (Ref. 0258)
1H-NMR (d, CDCl3, 400MHz) 0.55 (3H, s), 0.95 (3H, d, J = 6.4 Hz), 1.30-2.14 (3H, m), 1.31 (6H, s), 2.31 (1H, dd, J = 6.4, 13.1 Hz), 2.60 (1H, dd, J = 3.4, 13 Hz), 2.83 (1H, dd, J = 3.5, 12 Hz), 4.23 (1H, tt, J = 3.2, 6.4 Hz), 4.43 (1H, dd, J = 4.3, 7.3 Hz), 5.33 (1H, t, J = 1.5 Hz), 6.02 (1H, d, J = 11.3 Hz), 6.38 (1H, d, J = 11.3 Hz) (Ref. 0258)
m/z 452 (M+), 434 (M+-H2O), 416 (M+-2H2O) (Ref. 0258)



The analogue was synthesized from 24,24-difluoro-5b-chorestane-3a,25-diol, which was prepared from lithocholic acid in 20 % overall yield. (Ref. 0252)
Synthesis was accomplished from vitamin D2 via vitamin D2-SO2 adducts in 12.5 % overall yield in 11 steps. (Ref. 0257/0258)



161
(6RS)-6,19-epidioxy-24,24-difluoro-25-hydroxy-6,19-dihydrovitamin D3 / (6RS)-6,19-epidioxy-24,24-difluoro-25-hydroxy-6,19-dihydrocholecalciferol
(7E)-(3S, 6RS)-6,19-epidioxy-24,24-difluoro-9,10-seco-5(10),7-cholestadiene-3,25-diol
VVD0164
Sachiko Yamada
6,19-epidioxy-24,24-F2-25-OH-6,19-dihydro-D3
C27H42F2O4 468.617 Download ChemDraw structure file
Binding affinity for the vitamin D receptor in HL-60 cells : 1/1000 as active as 1,25-(OH)2D3. Differentiation of HL-60 cells : 1/45 as active as 1,25-(OH)2D3. (Ref. 0339)

m/z 468 (M+), 450, 330, 312, 299, 285, 258 (Ref. 0339)



As a major product by the reaction of 24,24-difluoro-25-hydroxyvitamin D3 with singlet oxygen generated by dye-sensitized photochemical method. (Ref. 0339)



162
24,25-didehydrovitamin D3 / 24,25-didehydrocholecalciferol
(5Z,7E)-(3S)-9,10-seco-5,7,10(19),24-cholestatetraen-3-ol
VVD0165
Sachiko Yamada
24,25-didehydro-D3 / 24-ene-D3
C27H42O 382.622 Download ChemDraw structure file










163
(22E)-1a-hydroxy-22,23-didehydrovitamin D3 / (22E)-1a-hydroxy-22,23-didehydrocholecalciferol
(5Z,7E,22E)-(1S,3R)-9,10-seco-5,7,10(19),22-cholestatetraene-1,3-diol
VVD0166
Sachiko Yamada
(22E)-1a-OH-22,23-didehydro-D3 / (22E)-1a-OH-22-ene-D3
C27H42O2 398.621 Download ChemDraw structure file
HL-60 human promyelocytes differentiation : ED50 in nitro blue tetrazplium reduction, phagocytic activity, and nonspecific acid esterase activity are 4.7 times 10-7 M, 6.0 times 10-7 M and 4.0 times 10-7 M, respectively, when 1,25-(OH)2D3 shows the respective ED50 values of 1.0 times 10-8 M, 1.0 times 10-8 M and 1.1 times 10-8 M, respectively. (Ref. 0228)





The side chain with 22E-stereochemistry was constructed with high selectivity by coupling of C(22) steroid aldehyde with isopentyl phenyl sulfone followed by reductive desulfonylation as a key step. 1a-Hydroxyl group was introduced by SeO2 oxidation of 3,5-cyclovitamin D after photochemical conversion to (22E)-22,23-didehydrovitamin D3. The 5Z isomer was obtained as a minor product in the cycloreversion of the 1a-hydroxylated cyclovitamin D. (Ref. 0244)



164
(22E)-1b-hydroxy-22,23-didehydrovitamin D3 / (22E)-1b-hydroxy-22,23-didehydrocholecalciferol
(5Z,7E,22E)-(1R,3R)-9,10-seco-5,7,10(19),22-cholestatetraene-1,3-diol
VVD0167
Sachiko Yamada
(22E)-1b-OH-22,23-didehydro-D3 / (22E)-1b-OH-22-ene-D3
C27H42O2 398.621 Download ChemDraw structure file






The side chain with 22E-stereochemistry was constructed with high selectivity by coupling of C(22) steroid aldehyde with isopentyl phenyl sulfone followed by reductive desulfonylation as a key step. The 1b-hydroxylated vitamin was obtained as a minor product in the SeO2 oxidation of 3,5-cyclo derivative of (22E)-22,23-didehydrovitamin D followed by cycloreversion. (Ref. 0244)



165
(22Z)-1a-hydroxy-22,23-didehydrovitamin D3 / (22Z)-1a-hydroxy-22,23-didehydrocholecalciferol
(5Z,7E,22Z)-(1S,3R)-9,10-seco-5,7,10(19),22-cholestatetraene-1,3-diol
VVD0168
Sachiko Yamada
(22Z)-1a-OH-22,23-didehydro-D3 / (22Z)-1a-OH-22-ene-D3
C27H42O2 398.621 Download ChemDraw structure file






The side chain with 22Z-stereochemistry was constructed with high selectivity by coupling of C(22) steroid aldehyde with appropriate Wittig reagent. 1a-Hydroxyl group was introduced by SeO2 oxidation of 3,5-cyclovitamin D derivative after photochemical conversion to (22Z)-22,23-didehydrovitamin D3. The 5Z isomer was obtained as a minor product in the cycloreversion of the 1a-hydroxylated cyclovitamin D. (Ref. 0244)



166
(22Z)-1b-hydroxy-22,23-didehydrovitamin D3 / (22Z)-1b-hydroxy-22,23-didehydrocholecalciferol
(5Z,7E,22Z)-(1R,3R)-9,10-seco-5,7,10(19),22-cholestatetraene-1,3-diol
VVD0169
Sachiko Yamada
(22Z)-1b-OH-22,23-didehydro-D3 / (22Z)-1b-OH-22-ene-D3
C27H42O2 398.621 Download ChemDraw structure file






The side chain with 22Z-stereochemistry was constructed with high selectivity by coupling of C(22) steroid aldehyde with appropriate Wittig reagent. The 1b-hydroxylated vitamin was obtained as a minor product in the SeO2 oxidation of 3,5-cyclo derivative of (22Z)-22,23-didehydrovitamin D followed by cycloreversion. (Ref. 0244)



167
(22Z)-1a-hydroxy-22,23-didehydrovitamin D3 / (22Z)-1a-hydroxy-22,23-didehydrocholecalciferol
(5Z,7E,22E)-(1S,3R)-9,10-seco-5,7,10(19),22-cholestatetraene-1,3-diol
VVD0170
Sachiko Yamada
(22Z)-1a-OH-22,23-didehydro-D3
C27H42O2 398.621 Download ChemDraw structure file
HL-60 human promyelocytes differentiation : ED50 in nitro blue tetrazplium reduction, phagocytic activity, and nonspecific acid esterase activity are all > 10-6 M, when 1,25-(OH)2D3 shows the respective ED50 values of 1.0 times 10-8 M, 1.0 times 10-8 M and 1.1 times 10-8 M, respectively. (Ref. 0228)









168
1a-hydroxy-24,25-didehydrovitamin D3 / 1a-hydroxy-24,25-didehydrocholecalciferol
(5Z,7E)-(1S,3R)-9,10-seco-5,7,10(19),24-cholestatetraene-1,3-diol
VVD0171
Sachiko Yamada
1a-OH-24,25-didehydro-D3 / 1a-OH-24-ene-D3
C27H42O2 398.621 Download ChemDraw structure file










169
1a,25-dihydroxy-9,11-didehydro-3-deoxyvitamin D3 / 1a,25-dihydroxy-9,11-didehydro-3-deoxycholecalciferol
(5Z,7E)-(1S)-9,10-seco-5,7,10(19),9(11)-cholestatetraene-1,25-diol
VVD0172
Sachiko Yamada
3-deoxy-1a,25-(OH)2-9,11-didehydro-D3
C27H42O2 398.621 Download ChemDraw structure file






From de-A,B-cholesta-9(11),25-dien-8-one and A-ring synthon (1-ethynyl-3-hydroxy-2-methyl-1-cyclohexene) via 9,10-seco-5(10),6,7,9(11),25- cholestapentaen-1-ol derivative as the key intermediate. (Ref. 0225)



170
25-hydroxy-16,17-didehydrovitamin D3 / 25-hydroxy-16,17-didehydrocholecalciferol
(5Z,7E)-(3S)-9,10-seco-5,7,10(19),16-cholestatetraene-3,25-diol
VVD0173
Sachiko Yamada
25-OH-16,17-didehydro-D3
C27H42O2 398.621 Download ChemDraw structure file
Biological activity (% of 1,25-(OH)2D3 effect) : Inhibition of proliferation of human keratinocytes in culture, 10 ; Competitive binding to rat intestinal vitamin D receptor, 0.23 ; Differentiation of human leukemia cells (HL-60), 3. (Ref. 0237)









171
23,24-didehydro-25-hydroxyvitamin D3 / 23,24-didehydro-25-hydroxycholecalciferol
(5Z,7E,23E)-(3S)-9,10-seco-5,7,10(19),23-cholestatetraene-3,25-diol
VVD0174
Sachiko Yamada
25-OH-23-dehydro-D3
C27H42O2 398.621 Download ChemDraw structure file


m/z 398 (11, M+), 380 (5, M+-H2O), 271 (2, M+-side chain), 253 (5, 271-H2O), 136 [100, (A ring+C6+C7)+], 118 (74, 136-H2O); spectrum (Ref. 0100)
bis-TMS-derivative : m/z 542 (22, M+), 527 (8, M+-CH3), 452 (18, M+HOSiMe3), 437 (8, 452-CH3), 208 [60, (A ring+C6+C7)+], 131 (56, C3H6OSiMe3+), 118 (100, 208-HOSiMe3); spectrum (Ref. 0100)


Isolated and identified from blood plasma of chicks given large doses of vitamin D3. (Ref. 0100)




172
calicoferol E
(8S)-3-hydroxy-9,10-seco-1,3,5(10)-cholestatrien-9-one
VVD0175
Sachiko Yamada
calicoferol E
C27H42O2 398.621 Download ChemDraw structure file

[a]D +21.6 deg (c = 0.6 in CHCl3) (Ref. 0316)
1H-NMR (d, CDCl3, 400MHz) 0.87 (6H, d, J = 6.5 Hz, 26-, 27-CH3), 0.93 (3H, d, J = 6.5 Hz, 21-CH3), 0.98 (3H, s, 18-CH3), 2.24 (3H, s, 19-CH3), 6.57 (1H, dd, J = 8.1, 2.7 Hz, 2-H), 6.67 (1H, d, J = 2.7 Hz, 4-H), 6.98 (1H, d, J = 8.1 Hz, 1-H) (Ref. 0316)
13C-NMR (d, CDCl3, 100MHz) 11.5, 18.4, 18.5, 22.5, 22.8, 23.8, 25.1, 27.6, 28.0, 29.0, 31.0, 35.6, 35.9, 38.3, 38.5, 39.4, 42.8, 50.4, 55.0, 55.2, 112.5, 115.7, 128.0, 131.0, 142.5, 153.7, 213.4 (Ref. 0316)
m/z 398 (M+), 277, 268, 264, 249, 223 (Ref. 0316)


Source see (Ref. 0319)
By the coupling of upper-half fragment derived from Grundmann



173
1-oxoprevitamin D3 / 1-oxoprecholecalciferol
(6Z)-(3R)-3-hydroxy-9,10-seco-5(10),6,8-cholestatriene-1-one
VVD0176
Sachiko Yamada
1-oxo-pre-D3
C27H42O2 398.621 Download ChemDraw structure file

(EtOH) lmax (nm) (emax) 288 (7100), 237 (6800) (Ref. 0176)
1H-NMR (d, CDCl3, 270MHz) 0.72 (3H, s, 13-Me), 1.80 (3H, s, 10-Me), 4.16 (1H, m, 3-H), 5.47 (1H, narrow m, 9-H), 6.14 and 6.03 (2H, AB q, J = 11.9 Hz, 6- and 7-H) (Ref. 0176)
m/z 398 (M+, 60%), 380 (100%), 365 (10%) (Ref. 0176)



From 1a-hydroxyvitamin D3 by selective (MnO2) oxidation of the allylic 1-hydroxyl group. (Ref. 0176)



174
1a-hydroxy-22-oxovitamin D3 / 1a-hydroxy-22-oxocholecalciferol
(5Z,7E)-(1S,3R)-1,3-dihydroxy-9,10-seco-5,7,10(19)-cholestatrien-22-one
VVD0177
Sachiko Yamada
1a-OH-22-oxo-D3
C27H42O3 414.621 Download ChemDraw structure file










175
24,25-epoxy-1a-hydroxyvitamin D3 / 24,25-epoxy-1a-hydroxycholecalciferol
(5Z,7E)-(1S,3R)-24,25-epoxy-9,10-seco-5,7,10(19)-cholestatriene-1,3-diol
VVD0178
Sachiko Yamada
24,25-epoxy-1a-OHD3
C27H42O3 414.621 Download ChemDraw structure file
Biological activity (% of 1,25-(OH)2D3 effect): Inhibition of proliferation or differentiation induction of human promyeloid leukemia (HL-60), osteosarcoma (MG-63) and breast carcinoma (MCF-7) cells : 6, 40 and 18, respectively. Elevation of serum calcium, serum osteocalcin, bone calcium and duodenal calbindin in rachitic chicks : 1, 11, 2 and 2, respectively. Affinity for pig intestinal receptor and human vitamin D binding protein: 16 and 27, respectively. (Ref. 0240)





By epoxidation of the corresponding olefinic precursor which was constructed from Inhoffen-Lythgoe diol. (Ref. 0240)



176
25,26-epoxy-1a-hydroxyvitamin D3 / 25,26-epoxy-1a-hydroxycholecalciferol
(5Z,7E)-(1S,3R)-25,26-epoxy-9,10-seco-5,7,10(19)-cholestatriene-1,3-diol
VVD0179
Sachiko Yamada
25,26-epoxy-1a-OHD3
C27H42O3 414.621 Download ChemDraw structure file
Biological activity (% of 1,25-(OH)2D3 effect) : Inhibition of proliferation or differentiation induction of human promyeloid leukemia (HL-60), osteosarcoma (MG-63) and breast carcinoma (MCF-7) cells : 37, 18 and 22, respectively. Elevation of serum calcium, serum osteocalcin, bone calcium and duodenal calbindin in rachitic chicks : 14, 25, 9 and 17, respectively. Affinity for pig intestinal receptor and human vitamin D binding protein : 27 and 76, respectively. (Ref. 0240)





By epoxidation of the corresponding olefinic precursor which was constructed from Inhoffen-Lythgoe diol. (Ref. 0240)



177
24,25-epoxy-1a-hydroxy-23,23-dimethyl-26,27-dinorvitamin D3 / 24,25-epoxy-1a-hydroxy-23,23-dimethyl-26,27-dinorcholecalciferol
(5Z,7E)-(1S,3R)-24,25-epoxy-23,23-dimethyl-26,27-dinor-9,10-seco-5,7,10(19)-cholestatriene-1,3-diol
VVD0180
Sachiko Yamada
24,25-epoxy-23,23-dimethyl-1a-OH-26,27-dinor-D3
C27H42O3 414.621 Download ChemDraw structure file
Biological activity (% of 1,25-(OH)2D3 effect) : Inhibition of proliferation or differentiation induction of human promyeloid leukemia (HL-60), osteosarcoma (MG-63) and breast carcinoma (MCF-7) cells : 0, 5 and 0, respectively. Elevation of serum calcium, serum osteocalcin, bone calcium and duodenal calbindin in rachitic chicks : all < 0.1. Affinity for pig intestinal receptor and human vitamin D binding protein : 1 and 0, respectively. (Ref. 0240)





By epoxidation of the corresponding olefinic precursor which was constructed from Inhoffen-Lythgoe diol. (Ref. 0240)



178
25-hydroxy-23-oxovitamin D3 / 25-hydroxy-23-oxocholecalciferol
(5Z,7E)-(3S)-3,25-dihydroxy-9,10-seco-5,7,10(19)-cholestatrien-23-one
VVD0181
Sachiko Yamada
25-OH-23-oxo-D3
C27H42O3 414.621 Download ChemDraw structure file
Affinity for bovine thymus receptor (% of 1,25-(OH)2D3 effect), 2.5 ; Affinity for rat plasma vitamin D binding protein : % of 25-OHD3 effect, 272, % of 1,25-(OH)2D3 effect, 13600. (Ref. 0099>
lmax (nm) 264, lmin (nm) 228 (Ref. 0099)

m/z 414, 356, 323, 136, 118, 58 (Ref. 0099)




Produced as a minor metabolite from 23S,25-(OH)2D3 and a major metabolite from 23R,25-(OH)2D3 when incubated with chick kidney. (Ref. 0099)


179
25-hydroxy-24-oxovitamin D3 / 25-hydroxy-24-oxocholecalciferol
(5Z,7E)-(3S)-3,25-dihydroxy-9,10-seco-5,7,10(19)-cholestatrien-24-one
VVD0182
Sachiko Yamada
25-OH-24-oxo-D3
C27H42O3 414.621 Download ChemDraw structure file
Influences of vitamin D3 metabolites on medullary bone formation; Table (Ref. 0097)
(KBr) spectrum (Ref. 0097)
1H-NMR (d, CDCl3) spectrum (Ref. 0097)
m/z 414 (M+), 271, 253, 136, 118, 59; spectrum (Ref. 0096)


Isolation and identification from Chicken kidney homogenates incubated with 25-OHD3. (Ref. 0096)
Isolation and identification from Rat kidneys perfused with pharmacological concentration of 25-OHD3. (Ref. 0098)
Isolated and identified from blood plasma of chicks given large doses of vitamin D3. (Ref. 0100)
Five step synthesis from 22-phenylsulfonyl-23,24-dinor-5,7-choladien-3b-ol tetrahydropyranyl ether and 1,2-epoxy-3-hydroxy-3-methyl butane. (Ref. 0097)
In vitro, 25-hydroxy-24-oxovitamin D3 is hydroxylated at C(23) to give 23S,25-dihydroxy-24-oxovitamin D3 (Ref. 0102) and then cleaved at 23,24-bond to afford 23-hydroxy-24,25,26,27-tetranorvitamin D3. (Ref. 0105)


180
25-hydroxy-1-oxo-3-epiprevitamin D3 / 25-hydroxy-1-oxo-3-epiprecholecalciferol
(6Z)-(3S)-3,25-dihydroxy-9,10-seco-5(10),6,8-cholestatrien-1-one
VVD0183
Sachiko Yamada
25-OH-1-oxo-3-epipre-D3
C27H42O3 414.621 Download ChemDraw structure file

(95% EtOH) lmax (nm) (emax) 242 (10000), 298 (11200) (Ref. 0182)
1H-NMR (d, CDCl3, 300MHz) 0.71 (3H, 18C-CH3), 0.96 (3H, d, J = sim6.6 Hz, 21C-CH3), 1.21 (6H, s, 26, 27C-2CH3), 1.78 (3H, s, 19C-CH3), 2.4-2.6 (1H, m), 2.70-2.85 (1H, m), 4.16 (1H, m, 3-H), 5.47 (1H, m, 9-H), 6.05 and 6.11 (2H, AB pattern, J = sim11.7 Hz, 6-, 7-H) (Ref. 0182)
(CI, NH3) m/z 415 (M+H, 15), 414 (M+, 7), 396 (M+-H2O, 86), 379 (M+H-2H2O, base), 363 (4), 338 (2), 323 (3), 295 (2), 267 (10), 253 (4), 239 (3), 213 (6), 199 (4), 171 (9), 157 (6), 135 (3), 121 (4), 107 (3), 95 (6), 81 (4), 69 (2) (Ref. 0182)



From 1b,25-dihydroxy-3-epivitamin D3 by Des-Martin oxidation. (Ref. 0182)



181
(6E)-(8S)-8,25-dihydroxy-9,10-seco-4,6,10(19)-cholestatrien-3-one
VVD0184
Sachiko Yamada
8a,25-(OH)2-3-oxo-4,6,10(19)-triene-D3
C27H42O3 414.621 Download ChemDraw structure file

(95 % EtOH) lmax (nm) 295, (log e 4.2) (Ref. 0136)
(KBr) 3210-3600, 2950, 1660, 1565, 1380 cm-1 (Ref. 0136)
1H-NMR (d, CDCl3) spectrum (Ref. 0136)
m/z 414 (M+), 396, 381, 378, 368, 363, 325, 267, 135, 122; spectrum(Ref. 0136)


Isolation and identification in various phagocytic cells [alveolar macrophages, murine myeloid leukemia cells (M1), human promyelocytic leukemia cells (HL-60); human monoblast-like lymphoma cells (U 937) ] (Ref. 0136/0137) and in rat liver microsomes incubated with 25-OHD3.. (Ref. 0138)
Synthesis from 25-OHD3 via regio- and stereoselective 7,8-epoxidation as the key step and the determination of the C(18) stereochemistry of the natural metabolite to be S. (Ref. 0136)



182
(23S)-1a,23-dihydroxy-25,26-didehydrovitamin D3 / (23S)-1a,23-dihydroxy-25,26-didehydrocholecalciferol
(5Z,7E)-(1S,3R,23S)-9,10-seco-5,7,10(19),25-cholestatetraene-1,3,23-triol
VVD0185
Sachiko Yamada
1a,23S-(OH)2-25,26-dehydro-D3
C27H42O3 414.621 Download ChemDraw structure file
Biological activity (% of 1,25-(OH)2D3 effect) : Inhibition of proliferation of human keratinocytes in culture, 100 ; Competitive binding to rat intestinal vitamin D receptor, 0.048. (Ref. 0237)









183
(22E)-(24R)-1a,24-dihydroxy-22,23-didehydrovitamin D3 / (22E)-(24R)-1a,24-dihydroxy-22,23-didehydrocholecalciferol
(5Z,7E,22E)-(1S,3R,24R)-9,10-seco-5,7,10(19),22-cholestatetraene-1,3,24-triol
VVD0186
Sachiko Yamada
(22E)-1a,24R-(OH)2-22,23-didehydro-D3
C27H42O3 414.621 Download ChemDraw structure file
Affinity for chick the intestinal receptor : 1/10 as active as 1,25-(OH)2D3. Activities in increasing intestinal calcium transport, serum calcium and inorganic phosphorus concentration and bone ash were determined in compared with 1,25-(OH)2D3 and its 24S-epimer. This compound is less potent than either its 24S-epimer or 1,25-(OH)2D3 in these activities. (Ref. 0241)
(EtOH) lmax (nm) 265, lmin (nm) 228 (Ref. 0241)
1H-NMR (d, CDCl3, 400.5MHz) 0.57 (3H, s, 18-H3), 0.87 (3H, d, J = 6.7 Hz, 26-H3), 0.92 (3H, d, J = 6.7 Hz, 27-H3), 1.04 (3H, d, J = 6.6 Hz, 21-H3), 2.32 (1H, dd, J = 13.7 and 6.6 Hz), 2.60 (1H, dd, J = 13.4 and 3.4 Hz), 2.83 (1H, dd, J = 12.6 and 4.0 Hz), 4.23 (1H, m, 3-H), 4.43 (1H, m, 1-H), 5.00 (1H, br s, W1/2 = 4.3 Hz, 19-H), 5.33 (1H, br s, W1/2 = 4.3 Hz, 19-H), 5.39 (1H, dd, J = 15.2 and 7.1 Hz, 22-H), 5.51 (1H, dd, J = 15.2 and 8.3 Hz, 23-H), 6.01 (1H, d, J = 11.4 Hz, 7-H), 6.38 (1H, d, J = 11.4 Hz, 6-H) (Ref. 0241)
m/z 414 (M+), 396, 378, 363, 360, 345, 335, 317, 287, 269, 251, 249, 152, 135, 134, 109 (Ref. 0241)



Synthesis was started with dinorcholenic acid acetate and achieved via Barton



184
(22E)-(24S)-1a,24-dihydroxy-22,23-didehydrovitamin D3 / (22E)-(24S)-1a,24-dihydroxy-22,23-didehydrocholecalciferol
(5Z,7E,22E)-(1S,3R,24S)-9,10-seco-5,7,10(19),22-cholestatetraene-1,3,24-triol
VVD0187
Sachiko Yamada
(22E)-1a,24S-(OH)2-22,23-didehydro-D3
C27H42O3 414.621 Download ChemDraw structure file
Affinity for chick the intestinal receptor : nearly as active as 1,25-(OH)2D3. Activities in increasing intestinal calcium transport, serum calcium and inorganic phosphorus concentration and bone ash were determined in compared with 1,25-(OH)2D3 and its 24R-epimer. This compound is less potent than 1,25-(OH)2D3 in these activities but it more potent than its 24R-epimer. (Ref. 0241)
(EtOH) lmax (nm) 265, lmin (nm) 228 (Ref. 0241)
1H-NMR (d, CDCl3, 400.5MHz) 0.57 (3H, s, 18-H3), 0.87 (3H, d, J = 6.7 Hz, 26-H3), 0.92 (3H, d, J = 6.7 Hz, 27-H3), 1.05 (3H, d, J = 6.6 Hz, 21-H3), 2.32 (1H, dd, J = 13.7 and 6.6 Hz), 2.60 (1H, dd, J = 13.4 and 3.4 Hz), 2.83 (1H, dd, J = 12.6 and 4.0 Hz), 4.23 (1H, m, 3-H), 4.43 (1H, m, 1-H), 5.00 (1H, br s, W1/2 = 4.3 Hz, 19-H), 5.33 (1H, br s, W1/2 = 4.3 Hz, 19-H), 5.37 (1H, dd, J = 15.4 and 7.5 Hz, 22-H), 5.46 (1H, dd, J = 15.4 and 8.3 Hz, 23-H), 6.01 (1H, d, J = 11.4 Hz, 7-H), 6.38 (1H, d, J = 11.4 Hz, 6-H) (Ref. 0241)
m/z 414 (M+), 396, 378, 363, 360, 345, 335, 317, 287, 269, 251, 249, 152, 135, 134, 109 (Ref. 0241)



Synthesis was started with dinorcholenic acid acetate and achieved via Barton



185
1a,25-dihydroxy-9,11-didehydrovitamin D3 / 1a,25-dihydroxy-9,11-didehydrocholecalciferol
(5Z,7E)-(1S,3R)-9,10-seco-5,7,9(11),10(19)-cholestatetraene-1,3,25-triol
VVD0188
Sachiko Yamada
1a,25-(OH)2-9,11-didehydro-D3
C27H42O3 414.621 Download ChemDraw structure file






From de-A,B-cholesta-9(11),25-dien-8-one and A-ring synthon (1-ethynyl-3S,5R-dihydroxy-2-methyl-1-cyclohexene derivative), which was obtained in 6 steps from Carvone, via 9,10-seco-5(10),6,7,9(11),25-cholestapentaene-1,3-diol derivative as the key intermediate. (Ref. 0225)



186
1a,25-dihydroxy-16,17-didehydrovitamin D3 / 1a,25-dihydroxy-16,17-didehydrocholecalciferol
(5Z,7E)-(1S,3R)-9,10-seco-5,7,10(19),16-cholestatetraene-1,3,25-triol
VVD0189
Sachiko Yamada
1a,25-(OH)2-16,17-didehydro-D3
C27H42O3 414.621 Download ChemDraw structure file
Biological activity (% of 1,25-(OH)2D3 effect) : Inhibition of proliferation of human keratinocytes in culture, 10 ; Competitive binding to rat intestinal vitamin D receptor, 240 ; Differentiation of human leukemia cells (HL-60), 500. (Ref. 0237)









187
1a,25-dihydroxy-22,23-didehydrovitamin D3 / 1a,25-dihydroxy-22,23-didehydrocholecalciferol
(5Z,7E,22E)-(1S,3R)-9,10-seco-5,7,10(19),22-cholestatetraene-1,3,25-triol
VVD0190
Sachiko Yamada
(22E)-1a,25-(OH)2-22,23-didehydro-D3
C27H42O3 414.621 Download ChemDraw structure file
Biological activity (% of 1,25-(OH)2D3 effect) : Inhibition of proliferation of human keratinocytes in culture, 10 ; Intestinal calcium absorption in rat, 92 ; Bone calcium mobilization in rat, 133 ; Competitive binding to rat intestinal vitamin D receptor, 122 ; Differentiation of human leukemia cells (HL-60), 125. (Ref. 0237)
[a]d-20 +57.2 deg (c = 0.14 in EtOH) (Ref. 0159)
(MeOH) lmax (nm) (emax) 266 (17300) lmin (nm) 228 (Ref. 0159)
1H-NMR (d, CDCl3, 400MHz) 0.57 (3H, s, 18-CH3), 1.05 (3H, d, J = 6.6 Hz, 21-CH3), 1.20 (6H, s, 26- and 27-CH3), 4.23 (1H, m, 3-H), 4.45 (1H, m, 1-H), 5.02 [1H, m (sharp), 19Z-H], 5.35 [1H, m (sharp), 19E-H], 5.42 (2H, m, 22- and 23-H), 6.04 (1H, d, J = 11.3 Hz, 7-H), 6.39 (1H, d, J = 11.3 Hz, 6-H) (Ref. 0159)
m/z 415 (6.8%) (M++1), 397 (100%) (M++1-H2O), 379 (38%) (M++1-2 times H2O), 287 (6.4%) (M+-side chain), 269 (7.2%), 251 (2.0%), 152 (2.4%), 134 (2.0%) (Ref. 0159)







188
(23E)-1a,25-dihydroxy-23,24-didehydrovitamin D3 / (23E)-1a,25-dihydroxy-23,24-didehydrocholecalciferol
(5Z,7E,23E)-(1S,3R)-9,10-seco-5,7,10(19),23-cholestatetraene-1,3,25-triol
VVD0191
Sachiko Yamada
(23E)-1a,25-(OH)2-23,24-didehydro-D3
C27H42O3 414.621 Download ChemDraw structure file










189
1a,25-dihydroxy-6,7-didehydroprevitamin D3 / 1a,25-dihydroxy-6,7-didehydroprecholecalciferol
(1S,3R)-9,10-seco-5(10),8-cholestadien-6-yne-1,3,25-triol
VVD0192
Sachiko Yamada
1a,25-(OH)2-6,7-dehydro-pre-D3
C27H42O3 414.621 Download ChemDraw structure file










190
1b,25-dihydroxy-6,7-didehydro-3-epiprevitamin D3 / 1b,25-dihydroxy-6,7-didehydro-3-epiprecholecalciferol
(1R,3S)-9,10-seco-5(10),8-cholestadien-6-yne-1,3,25-triol
VVD0193
Sachiko Yamada
1b,25-(OH)2-6,7-didehydro-3-epipre-D3
C27H42O3 414.621 Download ChemDraw structure file










191
(17S,20S)-1a,25-dihydroxy-17,20-methano-21-norvitamin D3 / (17S,20S)-1a,25-dihydroxy-17,20-methano-21-norcholecalciferol
(5Z,7E)-(1S,3R,17S,20S)-17,20-methano-21-nor-9,10-seco-5,7,10(19)-cholestatriene-1,3,25-triol
VVD0194
Sachiko Yamada
17S,20S-methano-1a,25-(OH)2-21-nor-D3
C27H42O3 414.621 Download ChemDraw structure file






From 4-hydroxyhydrindanone via introduction of the side chain and A-ring fragment. Stereoselective introduction of 17,20-methano-bridge was achieved by the reaction of 17E(20)-ene CD-fragment with dichlorocarbene followed by reduction with sodium in ethanol. (Ref. 0315)



192
(17S,20R)-1a,25-dihydroxy-17,20-methano-21-norvitamin D3 / (17S,20R)-1a,25-dihydroxy-17,20-methano-21-norcholecalciferol
(5Z,7E)-(1S,3R,17S,20R)-17,20-methano-21-nor-9,10-seco-5,7,10(19)-cholestatriene-1,3,25-triol
VVD0195
Sachiko Yamada
17S,20R-methano-1a,25-(OH)2-21-nor-D3
C27H42O3 414.621 Download ChemDraw structure file






From 4-hydroxyhydrindanone via introduction of the side chain and A-ring fragment. Stereoselective introduction of 17,20-methano-bridge was achieved by the reaction of 17Z(20)-ene CD-fragment with dichlorocarbene followed by reduction with sodium in ethanol. (Ref. 0315)



193
(22E)-(24R)-24,25-dihydroxy-22,23-didehydrovitamin D3 / (22E)-(24R)-24,25-dihydroxy-22,23-didehydrocholecalciferol
(5Z,7E,22E)-(3S,24R)-9,10-seco-5,7,10(19),22-cholestatetraene-3,24,25-triol
VVD0196
Sachiko Yamada
(22E)-24,25-(OH)222,23-didehydro-D3
C27H42O3 414.621 Download ChemDraw structure file

(EtOH) lmax (nm) 265, lmin (nm) 228 (Ref. 0193)
1H-NMR (d, CDCl3) 0.56 (3H, s, 13-Me), 1.05 (3H, d, J = 6 Hz, 20-Me), 1.16 and 1.20 (each 3H, s, 25-Me), 3.83 (1H, d, J = 7 Hz, 24-H), 3.96 (1H, m, 3a-H), 4.83 and 5.06 (each 1H, br s, 19-H2), 5.42 (1H, dd, J = 15.7 Hz, 23-H), 5.60 (1H, dd, J = 15.8 Hz, 22-H), 6.05 and 6.25 (each 1H, d, J = 11 Hz, 6- and 7-H) (Ref. 0193)
m/z 414.3132 (Ref. 0193)







194
(22E)-(24S)-24,25-dihydroxy-22,23-didehydrovitamin D3 / (22E)-(24S)-24,25-dihydroxy-22,23-didehydrocholecalciferol
(5Z,7E,22E)-(3S,24S)-9,10-seco-5,7,10(19),22-cholestatetraene-3,24,25-triol
VVD0197
Sachiko Yamada
(22E)-24S,25-(OH)2-22,23-didehydro-D3
C27H42O3 414.621 Download ChemDraw structure file

(EtOH) lmax (nm) 265, lmin (nm) 228 (Ref. 0193)
1H-NMR (d, CDCl3) 0.56 (3H, s, 13-Me), 1.04 (3H, d, J = 6 Hz, 20-Me), 1.16 and 1.20 (each 3H, s, 25-Me), 3.86 (1H, d, J = 7 Hz, 24-H), 3.96 (1H, m, 3a-H), 4.84 and 5.07 (each 1H, br s, 19-H2), 5.44 (1H, dd, J = 15.7 Hz, 23-H), 5.64 (1H, dd, J = 15.8 Hz, 22-H), 6.04 and 6.26 (each 1H, d, J = 11 Hz, 6- and 7-H) (Ref. 0193)
m/z 414.3125 (Ref. 0193)







195
calicoferol B
(8S,16S)-3,16-dihydroxy-9,10-seco-1,3,5(10)-cholestatrien-9-one
VVD0198
Sachiko Yamada
calicoferol B
C27H42O3 414.621 Download ChemDraw structure file
Toxic against brine shrimp larvae. (Ref. 0317)




Isolated from a gorgonian of the genus Calicogorgia. (Ref. 0318)




196
(24R,25R)-25,26-epoxy-1a,24-dihydroxyvitamin D3 / (24R,25R)-25,26-epoxy-1a,24-dihydroxycholecalciferol
(5Z,7E)-(1S,3R,24R,25R)-25,26-epoxy-9,10-seco-5,7,10(19)-cholestatriene-1,3,24-triol
VVD0199
Sachiko Yamada
25R,26-epoxy-1a,24R-(OH)2D3
C27H42O4 430.620 Download ChemDraw structure file
Biological activity (% of 1,25-(OH)2D3 effect) : Affinity for pig intestinal receptor and human vitamin D binding protein : 20 and 73, respectively. Inhibition of proliferation or differentiation induction of human promyeloid leukemia (HL-60), osteosarcoma (MG-63) and breast carcinoma (MCF-7) cells : 12, 160 and 45, respectively. Elevation of serum calcium, serum osteocalcin, bone calcium and duodenal calbindin in rachitic chicks : 1, 3, 1 and < 1, respectively. (Ref. 0240)





By Sharpless kinetic epoxidation of the corresponding olefinic precursor. (Ref. 0243)



197
(24R,25S)-25,26-epoxy-1a,24-dihydroxyvitamin D3 / (24R,25S)-25,26-epoxy-1a,24-dihydroxycholecalciferol
(5Z,7E)-(1S,3R,24R,25S)-25,26-epoxy-9,10-seco-5,7,10(19)-cholestatriene-1,3,24-triol
VVD0200
Sachiko Yamada
25S,26-epoxy-1a,24R-(OH)2D3
C27H42O4 430.620 Download ChemDraw structure file
Biological activity (% of 1,25-(OH)2D3 effect) : Affinity for pig intestinal receptor and human vitamin D binding protein : 9 and 30, respectively. Inhibition of proliferation or differentiation induction of human promyeloid leukemia (HL-60), osteosarcoma (MG-63) and breast carcinoma (MCF-7) cells : 33, 4 and 34, respectively. Elevation of serum calcium, serum osteocalcin, bone calcium and duodenal calbindin in rachitic chicks : 1, 2, 4 and 1, respectively. (Ref. 0240)





By Sharpless kinetic epoxidation of the corresponding olefinic precursor. (Ref. 0243)



198
(24S,25R)-25,26-epoxy-1a,24-dihydroxyvitamin D3 / (24S,25R)-25,26-epoxy-1a,24-dihydroxycholecalciferol
(5Z,7E)-(1S,3R,24S,25R)-25,26-epoxy-9,10-seco-5,7,10(19)-cholestatriene-1,3,24-triol
VVD0201
Sachiko Yamada
25R,26-epoxy-1a,24S-(OH)2D3
C27H42O4 430.620 Download ChemDraw structure file
Biological activity (% of 1,25-(OH)2D3 effect) : Affinity for pig intestinal receptor and human vitamin D binding protein : 10 and 7, respectively. Inhibition of proliferation or differentiation induction of human promyeloid leukemia (HL-60), osteosarcoma (MG-63) and breast carcinoma (MCF-7) cells : 44, 7 and 20, respectively. Elevation of serum calcium, serum osteocalcin, bone calcium and duodenal calbindin in rachitic chicks : 3, 2, 1 and 2, respectively. (Ref. 0240)





By Sharpless kinetic epoxidation of the corresponding olefinic precursor. (Ref. 0243)



199
(24S,25S)-25,26-epoxy-1a,24-dihydroxyvitamin D3 / (24S,25S)-25,26-epoxy-1a,24-dihydroxycholecalciferol
(5Z,7E)-(1S,3R,24S,25S)-25,26-epoxy-9,10-seco-5,7,10(19)-cholestatriene-1,3,24-triol
VVD0202
Sachiko Yamada
25S,26-epoxy-1a,24S-(OH)2D3
C27H42O4 430.620 Download ChemDraw structure file
Biological activity (% of 1,25-(OH)2D3 effect) : Affinity for pig intestinal receptor and human vitamin D binding protein : 5 and 3, respectively. Inhibition of proliferation or differentiation induction of human promyeloid leukemia (HL-60), osteosarcoma (MG-63) and breast carcinoma (MCF-7) cells : 7, 15 and 20, respectively. Elevation of serum calcium, serum osteocalcin, bone calcium and duodenal calbindin in rachitic chicks : 2, < 1, < 1 and < 1, respectively. (Ref. 0240)





By Sharpless kinetic epoxidation of the corresponding olefinic precursor. (Ref. 0243)



200
1a,25-dihydroxy-18-oxovitamin D3 / 1a,25-dihydroxy-18-oxocholecalciferol
(5Z,7E)-(1S,3R)-1,3,25-trihydroxy-9,10-seco-5,7,10(19)-cholestatrien-18-al
VVD0203
Sachiko Yamada
1a,25-(OH)2-18-oxo-D3
C27H42O4 430.620 Download ChemDraw structure file










201
1a,25-dihydroxy-24-oxovitamin D3 / 1a,25-dihydroxy-24-oxocholecalciferol
(5Z,7E)-(1S,3R)-1,3,25-trihydroxy-9,10-seco-5,7,10(19)-cholestatrien-24-one
VVD0204
Sachiko Yamada
1a,25-(OH)2-24-oxo-D3
C27H42O4 430.620 Download ChemDraw structure file
Competition of 1,25-(OH)2D3 and its derivatives for the 3.7 S cytosolic receptors present in intestine and thymus; Table (Ref. 0068)
lmax (nm) 265, lmin (nm) 228 (Ref. 0067)
1H-NMR (d, CDCl3, 200MHz) 6.39 (d, J = 11.2Hz, 6-H), 6.03 (d, J = 11.2 Hz, 7-H), 5.34 (broad s, 19Z-H), 5.01 (broad s, 19E-H), 4.44 (m, 1b-H), 4.24 (m, 3a-H), 1.40 (s, 26C, 27C-CH3), 0.94 (d, J = 5.86 Hz, 21C-CH3), 0.56 (s, 18C-CH3); spectrum (Ref. 0067)
m/z 430 (5, M+), 412 (38, M+-H2O), 394 (59, M+-2H2O), 376 (10, M+-3H2O), 269 (16, M+-side chain), 251 (42, 269-H2O), 152 [24, (A ring+C6+C7)+], 134 (59, 152-H2O); spectrum (Ref. 0067)
m/z 430 (M+), 412, 394, 287, 269, 251, 152, 134; spectrum (Ref. 0102)


Isolation and identification from homogenates of either chick small intestine mucoca or rat kidney incubated with either 1,25-(OH)2D3 or 1,24,25-(OH)3D3. (Ref. 0067)

1,25-(OH)2-24-oxo-D3 is metabolized to 1-OH-tetranor-D3 23-carboxylic acid (calcitroic acid) (Ref. 0070/0073) via 1,23S,25-(OH)3-24-oxo-D3 (Ref. 0067) and 1,23-(OH)2-tetranor-D3 (Ref. 0069) .


202
(23S)-23,25-dihydroxy-24-oxovitamin D3 / (23S)-23,25-dihydroxy-24-oxocholecalciferol
(5Z,7E)-(3S,23S)-3,23,25-trihydroxy-9,10-seco-5,7,10(19)-cholestatrien-24-one
VVD0205
Sachiko Yamada
23S,25-(OH)2-24-oxo-D3
C27H42O4 430.620 Download ChemDraw structure file

lmax (nm) 265, lmin (nm) 228 (Ref. 0103)
(CHCl3) 3500, 2930, 2860, 1708 cm-1 (Ref. 0103)
1H-NMR (d, CDCl3, 100MHz) 0.57 (3H, s, 18-H), 1.09(3H, d, J = 6 Hz, 21-H), 1.42 and 1.44 (each 3H, s, 26- and 27-H), 3.96 (1H, m, 3-H), 4.66 (1H, m, 23-H), 4.84 (1H, bs, 19E-H), 5.07 (1H, bs, 19Z-H), 6.04 (1H, d, J = 11.5 Hz, 7-H), 6.24 (1H, d, J = 11.5 Hz, 6-H) (Ref. 0103)
m/z 430 (M+), 412, 372, 342, 271, 253, 136, 118; spectrum(Ref. 0102)


Isolation and identification from chicken kidney homogenate incubated with 25-OH-24-oxo D3. (Ref. 0102)
Isolation and identification from rat kidneys perfused with pharmacological concentration of 25-OHD3. (Ref. 0098)
Stereoselective synthesis of (23S)-23,25-dihydroxy-24-oxovitamin D3 from 3b-hydroxy-5,7-cholestadien-24-one, and determination of the configulation at C(23) of the natural metabolite. (Ref. 0103)
In vitro, 23S,25-dihydroxy-24-oxovitamin D3 is cleaved at 23,24-bond to afford 23-hydroxy-24,25,26,27-tetranorvitamin D3. (Ref. 0105)
In vivo, 23S,25-(OH)2-24-oxo-D3 is conjugated at 23-hydroxyl group as b-glucuronide to be excreted to bile. (Ref. 0106)


203
(23S,25R)-25-hydroxyvitamin D3 26,23-lactol / (23S,25R)-25-hydroxycholecalciferol 26,23-lactol
(5Z,7E)-(3S,23S,25R)-3,25-dihydroxy-9,10-seco-5,7,10(19)-cholestatrieno-26,23-lactol
VVD0206
Sachiko Yamada
25R-OHD3 26,23S-lactol
C27H42O4 430.620 Download ChemDraw structure file

lmax (nm) 265, lmin (nm) 228 (Ref. 0124)

m/z 430 (M+), 412 (M+-H2O), 342, 309 (342-H2O-CH3), 136, 118; spectrum (Ref. 0124)


Produced by incubating vitamin D supplemented Chick Kidney homogenate with 23S,25R,26-(OH)3D3. (Ref. 0124)
From 25R-OHD3 26,23S-lactone (Ref. 0113) by reduction with diisobutyl alminium hydride. (Ref. 0125)



204
(22E)-(24R)-1a,24,25-trihydroxy-22,23-didehydrovitamin D3 / (22E)-(24R)-1a,24,25-trihydroxy-22,23-didehydrocholecalciferol
(5Z,7E,22E)-(1S,3R,24R)-9,10-seco-5,7,10(19),22-cholestatetraene-1,3,24,25-tetrol
VVD0207
Sachiko Yamada
(22E)-1a,24R,25-(OH)3-22,23-didehydro-D3
C27H42O4 430.620 Download ChemDraw structure file
Increase of Intestinal Calcium Transport and Serum Calcium Concentration in Response to Either (22E,24R)-1,24-(OH)2-D22-D3, (22E,24S)-1,24-(OH)2-D22-D3 or 1,25-(OH)2D3. :Table (Ref. 0194)
Increase of Serum Inorganic Phosphorus Concentration and Bone Ash in Response to Either (22E,24R)-1,24-(OH)2-D22-D3, (22E,24S)-1,24-(OH)2-D22-D3 or 1,25-(OH)2D3. : Table (Ref. 0194)
(EtOH) lmax (nm) 265, lmin (nm) 228 (Ref. 0194)
1H-NMR (d, CDCl3, 400.5MHz) 0.57 (3H, s, 18-H3), 0.87 (3H, d, J = 6.7 Hz, 26-H3), 0.92 (3H, d, J = 6.7 Hz, 27-H3), 1.05 (3H, d, J = 6.6 Hz, 21-H3), 2.32 (1H, dd, J = 13.7 and 6.6 Hz), 2.60 (1H, dd, J = 13.4 and 3.4 Hz), 2.83 (1H, dd, J = 12.6 and 4.0 Hz), 4.23 (1H, m, 3-H), 4.43 (1H, m, 1-H), 5.00 (1H, br s, W1/2 = 4.3 Hz, 19-H), 5.33 (1H, br s, W1/2 = 4.3 Hz, 19-H), 5.37 (1H, dd, J = 15.4 and 7.5 Hz, 22-H), 5.46 (1H, dd, J = 15.4 and 8.3 Hz, 23-H), 6.01 (1H, d, J = 11.4 Hz, 7-H), 6.38 (1H, d, J = 11.4 Hz, 6-H) (Ref. 0194)
m/z 414 (M+), 396, 378, 363, 360, 345, 335, 317, 287, 269, 251, 249, 152, 135, 134, 109 (Ref. 0194)







205
(22E)-(24S)-1a,24,25-trihydroxy-22,23-didehydrovitamin D3 / (22E)-(24S)-1a,24,25-trihydroxy-22,23-didehydrocholecalciferol
(5Z,7E,22E)-(1S,3R,24S)-9,10-seco-5,7,10(19),22-cholestatetraene-1,3,24,25-tetrol
VVD0208
Sachiko Yamada
(22E)-1a,24S,25-(OH)3-22,23-didehydro-D3
C27H42O4 430.620 Download ChemDraw structure file
Increase of Intestinal Calcium Transport and Serum Calcium Concentration in Response to Either (22E,24R)-1,24-(OH)2-D22-D3, (22E,24S)-1,24-(OH)2-D22-D3 or 1,25-(OH)2D3. : Table(Ref. 0194)
Increase of Serum Inorganic Phosphorus Concentration and Bone Ash in Response to Either (22E,24R)-1,24-(OH)2-D22-D3, (22E,24S)-1,24-(OH)2-D22-D3 or 1,25-(OH)2D3. : Table (Ref. 0194)
(EtOH) lmax (nm) 265, lmin (nm) 228 (Ref. 0194)
1H-NMR (d, CDCl3, 400.5MHz) 0.57 (3H, s, 18-H3), 0.87 (3H, d, J = 6.7 Hz, 26-H3), 0.92 (3H, d, J = 6.7 Hz, 27-H3), 1.04 (3H, d, J = 6.6 Hz, 21-H3), 2.32 (1H, dd, J = 13.7 and 6.6 Hz), 2.60 (1H, dd, J = 13.4 and 3.4 Hz), 2.83 (1H, dd, J = 12.6 and 4.0 Hz), 4.23 (1H, m, 3-H), 4.43 (1H, m, 1-H), 5.00 (1H, br s, W1/2 = 4.3 Hz, 19-H), 5.33 (1H, br s, W1/2 = 4.3 Hz, 19-H), 5.39 (1H, dd, J = 15.2 and 7.1 Hz, 22-H), 5.51 (1H, dd, J = 15.2 and 8.3 Hz, 23-H), 6.01 (1H, d, J = 11.4 Hz, 7-H), 6.38 (1H, d, J = 11.4 Hz, 6-H) (Ref. 0194)
m/z 414 (M+), 396, 378, 363, 360, 345, 335, 317, 287, 269, 251, 249, 152, 135, 134, 109 (Ref. 0194)







206
(22E)-(25R)-1a,25,26-trihydroxy-22,23-didehydrovitamin D3 / (22E)-(25R)-1a,25,26-trihydroxy-22,23-didehydrocholecalciferol
(5Z,7E,22E)-(1S,3R,25R)-9,10-seco-5,7,10(19),22-cholestatetraene-1,3,25,26-tetrol
VVD0209
Sachiko Yamada
(22E)-1a,25R,26-(OH)3-22,23-didehydro-D3
C27H42O4 430.620 Download ChemDraw structure file










207
(22E)-(25S)-1a,25,26-trihydroxy-22,23-didehydrovitamin D3 / (22E)-(25S)-1a,25,26-trihydroxy-22,23-didehydrocholecalciferol
(5Z,7E,22E)-(1S,3R,25S)-9,10-seco-5,7,10(19),22-cholestatetraene-1,3,25,26-tetrol
VVD0210
Sachiko Yamada
(22E)-1a,25S,26-(OH)3-22,23-didehydro-D3
C27H42O4 430.620 Download ChemDraw structure file
Biological activity (% of 1,25-(OH)2D3 effect) : Vitamin D receptor binding (chick intestine), 5.5% ; Inhibition of cell (HL-60) proliferation, 50% ; Induction cell (HL-60) differentiation, 100% ; 45Ca retention in kidney in rats, <10%. (Ref. 0297)





By convergent method in which CD ring synthon and A-ring precursor were combined by Wittig-Horner reaction. The desired side chain structure was constructed stereoselectively by 1,3-dipolar cycloaddition of C-23 nitrone with methyl methacrylate as key step. (Ref. 0297)



208
(23S,25R)-1a,25-dihydroxyvitamin D3 26,23-lactol / (23S,25R)-1a,25-dihydroxycholecalciferol 26,23-lactol
(5Z,7E)-(1S,3R,23S,25R)-1,3,25-trihydroxy-9,10-seco- 5,7,10,(19)-cholestatrieno-26,23-lactol
VVD0211
Sachiko Yamada
1a,25R-(OH)2D3 26,23S-lactol
C27H42O5 446.619 Download ChemDraw structure file
Affinity for the chick intestinal receptor : 1/59 as active as 1,25-(OH)2D3. (Ref. 0242)









209
(23R)-1a,23,25-trihydroxy-24-oxovitamin D3 / (23R)-1a,23,25-trihydroxy-24-oxocholecalciferol
(5Z,7E)-(1S,3R,23R)-1,3,23,25-tetrahydroxy-9-10-seco-5,7,10(19)-cholestatrien-24-one
VVD0212
Sachiko Yamada
1a,23R,25-(OH)3-24-oxo-D3
C27H42O5 446.619 Download ChemDraw structure file
The title compound suppressed PTH secretion significantly (p < 0.01) at 10-12 M and is equipotent with 1,25-(OH)2D3, though the affinity of the former for the receptor in paratyroid cells was 10 times less effective than that of the latter. (Ref. 0271)
Mixture (9:1) of 23R and 23S epimers : (neat) 3391.4, 2925.3, 1711.7, 1375.1, 1043.7 cm-1 (Ref. 0271)
13C-NMR (d, CDCl3, 100MHz) major isomer, 217.03, 147.64, 142.87, 133.02, 124.93, 117.19, 111.80, 77.20, 71.01, 70.84, 66.86, 56.90, 56.39, 46.11, 45.27, 42.87, 40.97, 40.50, 33.12, 29.04, 27.77, 27.72, 27.64, 23.53, 22.27, 18.14, 12.08 (Ref. 0271)




Two C(23) epimers of the title compound were synthesized by palladium catalyzed coupling of the appropriate CD ring fragment with A ring enyne as key step. The A-ring precursor was prepared from quinic acid. The configuration at C(23) of natural metabolite produced in neonatal human keratinocytes was determined to be S by direct comparison with the synthetic two epimers on HPLC. (Ref. 0271)



210
(23S)-1a,23,25-trihydroxy-24-oxovitamin D3 / (23S)-1a,23,25-trihydroxy-24-oxocholecalciferol
(5Z,7E)-(1S,3R,23S)-1,3,23,25-tetrahydroxy-9-10-seco-5,7,10(19)-cholestatrien-24-one
VVD0213
Sachiko Yamada
1a,23S,25-(OH)3-24-oxo-D3
C27H42O5 446.619 Download ChemDraw structure file
The title compound suppressed PTH secretion significantly (p < 0.01) at 10-12 M and is equipotent with 1,25-(OH)2D3, though the affinity of the former for the receptor in paratyroid cells was 10 times less effective than that of the latter. (Ref. 0271)
lmax (nm) 265, lmin (nm) 228 (Ref. 0067)
Mixture (9:1) of 23R and 23S epimers : (neat) 3391.4, 2925.3, 1711.7, 1375.1, 1043.7 cm -1 (Ref. 0271)
1H-NMR (d, CDCl3, 200MHz) 6.39 (d, J = 11.2 Hz, 6-H), 6.02 (d, J = 11.2 Hz, 7-H), 5.34 (broad s, 19Z-H), 5.01 (broad s, 19E-H), 4.44 (m, 1b-H), 4.23 (m, 3a-H), 1.10 (d, J = 6.3 Hz, 21C-CH3), 0.57 (s, 18C-CH3); spectrum (Ref. 0067)
13C-NMR (d, CDCl3, 100MHz) major isomer, 217.03, 147.64, 142.87, 133.02, 124.93, 117.19, 111.80, 77.20, 71.01, 70.84, 66.86, 56.90, 56.39, 46.11, 45.27, 42.87, 40.97, 40.50, 33.12, 29.04, 27.77, 27.72, 27.64, 23.53, 22.27, 18.14, 12.08 (Ref. 0271)
m/z 446 (8, M+), 428 (2.7, M+-H2O), 410 (10, M+-2H2O), 388 (6, M+-C3H6O), 370 (17, 388-H2O), 352 (10, 388-2H2O), 287 (2, M+-side chain), 269 (10, 287-H2O), 251 (10, 287-2H2O), 152 [28, (A ring+C6+C7)+], 134 (100, 152-H2O); spectrum(Ref. 0067)


Isolation and identification from homogenates of either chick small intestine mucoca or rat kidney incubated with either 1,25-(OH)2D3 or 1,24,25-(OH)3D3. (Ref. 0067)
Two C(23) epimers of the title compound were synthesized by palladium catalyzed coupling of the appropriate CD ring fragment with A ring enyne as key step. The A-ring precursor was prepared from quinic acid. The configuration at C(23) of natural metabolite produced in neonatal human keratinocytes was determined to be S by direct comparison with the synthetic two epimers on HPLC. (Ref. 0271)
1,23S,25-(OH)3 -24-oxo-D3 is metabolized to 1-OH-tetranor-D3 23-carboxylic acid (calcitroic acid) (Ref. 0070/0073) via 1,23-(OH)2-tetranor-D3. (Ref. 0069)


211
2a-chloro-1b,25-dihydroxyvitamin D3 / 2a-chloro-1b,25-dihydroxycholecalciferol
(5Z,7E)-(1S,2S,3R)-2-chloro-9,10-seco-5,7,10(19)-cholestatriene-1,3,25-triol
VVD0214
Sachiko Yamada
2a-chloro-1b,25-(OH)2D3
C27H43ClO3 451.081 Download ChemDraw structure file
Affinity for rat intestinal VDR, 10 % of the activity of 25-OHD3 ; gene transcription (VDRE-CAT assay), nearly 10,000 times weaker than 1,25-(OH)2D3. (Ref. 0325)
CH3OH :173-179 degC (Ref. 0325)
(CH3OH) lmax (nm) (emax) 264 (15300) (Ref. 0325)
1H-NMR (d, CDCl3, 400MHz) 0.50 (3H, s, 18-H), 0.91 (3H, d, J = 6.3 Hz, 21-H), 1.19 (6H, s, 26- and 27-H), 2.25 (1H, m, 4b-H), 2.54 (1H, t, J = 9.7 Hz, 4a-H), 2.71 (1H, m, 9b-H), 3.81-3.83 (2H, m, 2b-H and 3a-H), 4.12 (1H, m, 1a-H), 5.11 and 5.56 (2H, 2timest, J = 2 Hz, 19-H), 5.94 and 6.38 (2H, 2timesd, J = 11.3 Hz, 7- and 6-H) (Ref. 0325)




From 1b,2b-epoxy-25-hydroxy-7-dehydrocholesterol via the reaction with hydrogen chloride followed by photochemical transformation. (Ref. 0325)



212
6-fluorovitamin D3 / 6-fluorocholecalciferol
(5E,7E)-(3S)-6-fluoro-9,10-seco-5,7,10(19)-cholestatrien-3-ol
VVD0215
Sachiko Yamada
6-F-D3
C27H43FO 402.628 Download ChemDraw structure file
Ability to compete with tritiated 1,25-(OH)2-D3 for binding to the chick intestinal receptor (RCI) : 0.26% of 1,25-(OH)2D3 effect. The title compound showed no biological action on either intestinal calcium absorption (ICA) or bone calcium mobilization at doses up to 130 nmol but it significantly inhibited vitamin D-mediated ICA. (Ref. 0294)
(Hexane) lmax (nm) (emax) 268 (10300) (Ref. 0295)
1H-NMR (d, CDCl3) 6.00 (1H, br d, J = 6.0 Hz), 5.10 (1H, s), 4.93 (1H, s), 4.02 (1H, m), 0.95 (3H, d, J = 6.4 Hz), 0.87 (6H, d, J = 6.4 Hz), 0.66 (3H, s) (Ref. 0295)
m/z (relative intensity) 402 (parent, 50), 369 (67), 315 (26), 314 (100), 299 (21), 281 (23), 271 (25), 299 (33), 163 (30), 161 (32), 147 (23), 145 (30), 133 (30), 109 (29), 107 (32), 105 (30), 95 (40), 81 (41) (Ref. 0295)



From 6-fluorocholesteryl acetate via conventional photochemical conversion of the corresponding 7-dehydro derivative. (Ref. 0295)



213
(10Z)-19-fluorovitamin D3 / (10Z)-19-fluorocholecalciferol
(5Z,7E,10Z)-(3S)-19-fluoro-9,10-seco-5,7,10(19)-cholestatrien-3-ol
VVD0216
Sachiko Yamada
(10Z)-19-F-D3
C27H43FO 402.628 Download ChemDraw structure file

(95% EtOH) lmax (nm) 263 (Ref. 0333)
1H-NMR (d, CDCl3) 0.55 (3H, s, 18-H), 0.86 and 0.87 (each 3H, d, J = 6.6 Hz, 26- and 27-H), 0.92 (3H, d, J = 6.2 Hz, 21-H), 2.60 (1H, dd, J = 13.2 and 3.5 Hz, 4-H), 2.81 (1H, m, 9-H), 3.95 (1H, tt, J = 7.3 and 3.6 Hz, 3-H), 5.63 (1H, d, J = 11.3 and 5.3 Hz, 7-H), 6.37 (1H, d, J = 11.3 Hz, 6-H), 6.47 (1H, d, J = 85.5 Hz, 19-H) (Ref. 0333)
19F-NMR (d, CDCl3) -127.5 (d, J = 85.5 Hz) (Ref. 0333)




From vitamin D3 via elimination of the exocyclic methylene and introduction of a fluoromethylene group as key steps. (Ref. 0333)



214
(10E)-19-fluorovitamin D3 / (10E)-19-fluorocholecalciferol
(5Z,7E,10E)-(3S)-19-fluoro-9,10-seco-5,7,10(19)-cholestatrien-3-ol
VVD0217
Sachiko Yamada
(10E)-19-F-D3
C27H43FO 402.628 Download ChemDraw structure file

(EtOH) lmax (nm) (emax) 260 (20900) (Ref. 0333)
1H-NMR (d, CDCl3) 0.53 (3H, s, 18-H), 0.86 and 0.87 (each 3H, d, J = 6.6 Hz, 26- and 27-H), 0.92 (3H, d, J = 6.4 Hz, 21-H), 2.56 (2H, m), 2.78 (1H, m), 3.93 (1H, m, 3-H), 5.93 and 6.28 (each 1H, d, J = 11.1 Hz, 6, 7-H), 6.51 (1H, d, J = 87.4 Hz, 19-H) (Ref. 0333)
19F-NMR (d, CDCl3) -132.5 (d, J = 87.4 Hz, 19-F) (Ref. 0333)
m/z 402 (M+, 36), 384 (21), 382 (8), 364 (16), 317 (5), 289 (13), 271 (19), 269 (6), 259 (11), 154 (45), 136 (70), 135 (100) (Ref. 0333)



From vitamin D3 by regioselective electrophilic 19-fluorination of its sulfur dioxide adduct as a key step. (Ref. 0346)



215
(5E,10Z)-19-fluorovitamin D3 / (5E,10Z)-19-fluorocholecalciferol
(5E,7E,10Z)-(3S)-19-fluoro-9,10-seco-5,7,10(19)-cholestatrien-3-ol
VVD0218
Sachiko Yamada
(5E,10Z)-19-F-D3
C27H43FO 402.628 Download ChemDraw structure file

(EtOH) lmax (nm) 270 (Ref. 0333)
1H-NMR (d, CDCl3) 0.56 (3H, s, 18-H), 0.867 and 0.871 (each 3H, d, J = 6.6 Hz, 26- and 27-H), 0.92 (3H, d, J = 6.4 Hz, 21-H), 2.83 (2H, m), 3.86 (1H, m, 3-H), 5.93 and 6.63 (each 1H, d, J = 11.5 Hz, 6, 7-H), 6.51 (1H, d, J = 86.6 Hz, 19-H) (Ref. 0333)
19F-NMR (d, CDCl3) -134.8 (d, J = 86.6 Hz, 19-F) (Ref. 0333)
m/z 402 (M+, 100), 384 (7), 382 (4), 364 (4), 317 (20), 289 (42), 271 (18), 269 (7), 259 (47), 194 (12), 176 (16), 154 (20), 136 (39), 135 (67) (Ref. 0333)



From vitamin D3 by regioselective electrophilic 19-fluorination of its sulfur dioxide adduct as a key step. (Ref. 0346)



216
(5E,10E)-19-fluorovitamin D3 / (5E,10E)-19-fluorocholecalciferol
(5E,7E,10E)-(3S)-19-fluoro-9,10-seco-5,7,10(19)-cholestatrien-3-ol
VVD0219
Sachiko Yamada
(5E,10E)-19-F-D3
C27H43FO 402.628 Download ChemDraw structure file

(EtOH) lmax (nm) 209, 269 (Ref. 0333)
1H-NMR (d, CDCl3) 0.55 (3H, s, 18-H), 0.868 and 0.873 (each 3H, d, J = 6.6 Hz, 26- and 27-H), 0.92 (3H, d, J = 6.7 Hz, 21-H), 2.67 (1H, m), 2.82 (2H, m), 3.88 (1H, m, 3-H), 5.83 and 6.35 (each 1H, d, J = 11.5 Hz, 6, 7-H), 6.69 (1H, d, J = 86.7 Hz, 19-H) (Ref. 0333)
19F-NMR (d, CDCl3) -135.4 (d, J = 86.7 Hz, 19-F) (Ref. 0333)
m/z 402 (M+, 84), 384 (7), 382 (3), 364 (4), 317 (11), 289 (25), 271 (13), 269 (7), 259 (21), 194 (6), 176 (13), 154 (50), 136 (89), 135 (100) (Ref. 0333)



From vitamin D3 by regioselective electrophilic 19-fluorination of its sulfur dioxide adduct as a key step. (Ref. 0346)



217
22-fluorovitamin D3 / 22-fluorocholecalciferol
(5Z,7E)-(3S)-22-fluoro-9,10-seco-5,7,10(19)-cholestatrien-3-ol
VVD0220
Sachiko Yamada
22-F-D3
C27H43FO 402.628 Download ChemDraw structure file
Serosal/Mucosal Ratio after Administration of Sterols or Vehicle. Mean pm SEM (n=Number of Animals). : (Ref. 0162)
Serum Calcium (mg/dL) after Administration of Sterols or Vehicle. Mean pm SEM (n=Number). (Ref. 0162)
Serosal/Mucosal Ratio and Serum Calcium Response Following Administration of Vitamin D3 or 22-Fluorovitamin D3. Mean pm SEM (n=Number). (Ref. 0162)
Calcium Binding Protein Induction by 22-Fluorovitamin D3 in Duodenal Organ Culture. (Ref. 0162)
(EtOH) lmax (nm) 264, lmin (nm) 227 (Ref. 0162)
1H-NMR (d, CDCl3) 3.82 (1H, m, 3a-H), 4.44 (1H, dm, J = 48.2 Hz, 22-H), 4.82 (1H, d, J = 2.24 Hz, 19-H), 5.05 (1H, d, J = 2.24 Hz, 19-H), 6.01 and 6.25 (2H, ABq, J = 11.22 Hz, 6- and 7-H) (Ref. 0162)
m/z 402 (M+, 80.51), 384 (M+-H2O, 8.05), 382 (M+-HF, 8.88), 369 (25.11), 136 (25.51), 118 (53.82) (Ref. 0162)







218
(5Z,10Z)-19-fluoro-1a-hydroxyvitamin-D3 / (5Z,10Z)-19-fluoro-1a-hydroxycholecalciferol
(5Z,7E,10Z)-(1S,3R)-19-fluoro-9,10-seco-5,7,10(19)-cholestatriene-1,3-diol
VVD0221
Sachiko Yamada
(5Z,10Z)-19-F-1a-OHD3
C27H43FO2 418.628 Download ChemDraw structure file

(EtOH) lmax (nm) 262 (Ref. 0333)
1H-NMR (d, CDCl3) 0.53 (3H, s, 18-H), 0.863 and 0.867 (each 3H, d, J = 6.6 Hz, 26- and 27-H), 0.91 (3H, d, J = 6.3 Hz, 21-H), 2.19 (1H, m), 2.32 (1H, m), 2.68 (1H, m), 2.80 (1H, m, 9-H), 4.16 (1H, m, 3-H), 5.09 (1H, br s, 1-H), 5.90 (1H, d, J = 11.1 Hz, 7-H), 6.46 (1H, d, J = 11.1 Hz, 6-H), 6.50 (1H, d, J = 86.0 Hz, 19-H) (Ref. 0333)
19F-NMR (d, CDCl3) -129.8 (d, J = 86.0 Hz) (Ref. 0333)
m/z 418 (M+, 6), 400 (5), 398 (5), 380 (10), 362 (52), 347 (8), 305 (5), 287 (5), 285 (5), 267 (8), 249 (34), 195 (35), 135 (100) (Ref. 0333)







219
(5Z,10E)-19-fluoro-1a-hydroxyvitamin-D3 / (5Z,10E)-19-fluoro-1a-hydroxycholecalciferol
(5Z,7E,10E)-(1S,3R)-19-fluoro-9,10-seco-5,7,10(19)-cholestatriene-1,3-diol
VVD0222
Sachiko Yamada
(5Z,10E)-19-F-1a-OHD3
C27H43FO2 418.628 Download ChemDraw structure file

(EtOH) lmax (nm) 264 (Ref. 0333)
1H-NMR (d, CDCl3) 0.54 (3H, s, 18-H), 0.86 and 0.87 (each 3H, d, J = 6.6 Hz, 26- and 27-H), 0.92 (3H, d, J = 6.3 Hz, 21-H), 2.14 (1H, m), 2.28 (1H, dd, J = 13.0, 8.6 Hz, 4-H), 2.66 (1H, dd, J = 13.0, 3.9 Hz, 4-H), 2.82 (1H, m, 9-H), 4.20 (1H, m, 3-H), 4.44 (1H, dd, J = 9.2, 4.7 Hz, 1-H), 5.62 (1H, dd, J = 11.3, 5.4 Hz, 7-H), 6.52 (1H, d, J = 11.3 Hz, 6-H), 6.70 (1H, d, J = 84.0 Hz, 19-H) (Ref. 0333)
19F-NMR (d, CDCl3) -127.8 (broard s) (Ref. 0333)
m/z 418 (M+, 55), 400 (7), 398 (12), 380 (22), 362 (100), 347 (21), 305 (16), 287 (9), 285 (10), 267 (16), 249 (68), 195 (52), 135 (43) (Ref. 0333)







220
(5E,10Z)-19-fluoro-1a-hydroxyvitamin-D3 / (5E,10Z)-19-fluoro-1a-hydroxycholecalciferol
(5E,7E,10Z)-(1S,3R)-19-fluoro-9,10-seco-5,7,10(19)-cholestatriene-1,3-diol
VVD0223
Sachiko Yamada
(5E,10Z)-19-F-1a-OHD3
C27H43FO2 418.628 Download ChemDraw structure file

(EtOH) lmax (nm) 269 (Ref. 0333)
1H-NMR (d, CDCl3) 0.55 (3H, s, 18-H), 0.868 and 0.872 (each 3H, d, J = 6.5 Hz, 26- and 27-H), 0.93 (3H, d, J = 6.2 Hz, 21-H), 2.31 (1H, m), 2.81 (1H, m, 9-H), 3.15 (1H, m, 4-H), 4.15 (1H, m, 3-H), 5.05 (1H, d, J = 3.2 Hz, 1-H), 5.87 (1H, d, J = 11.4 Hz, 7-H), 6.38 (1H, d, J = 11.4 Hz, 6-H), 6.69 (1H, d, J = 85.6 Hz, 19-H) (Ref. 0333)
19F-NMR (d, CDCl3) -133.2 (d, J = 85.6 Hz) (Ref. 0333)
m/z 418 (M+, 12), 398 (26), 380 (31), 362 (51), 347 (13), 305 (7), 287 (7), 285 (15), 267 (26), 249 (44), 195 (41), 135 (100) (Ref. 0333)







221
(5E,10E)-19-fluoro-1a-hydroxyvitamin-D3 / (5E,10E)-19-fluoro-1a-hydroxycholecalciferol
(5E,7E,10E)-(1S,3R)-19-fluoro-9,10-seco-5,7,10(19)-cholestatriene-1,3-diol
VVD0224
Sachiko Yamada
(5E,10E)-19-F-1a-OHD3
C27H43FO2 418.628 Download ChemDraw structure file

(EtOH) lmax (nm) 272 (Ref. 0333)
1H-NMR (d, CDCl3) 0.57 (3H, s, 18-H), 0.87 and 0.88 (each 3H, d, J = 6.6 Hz, 26- and 27-H), 0.93 (3H, d, J = 6.3 Hz, 21-H), 2.19 (1H, m), 2.32 (1H, m), 2.68 (1H, m), 2.80 (1H, m, 9-H), 3.07 (1H, dd, 4-H), 4.19 (1H, m, 3-H), 4.34 (1H, br s, 1-H), 5.97 (1H, d, J = 11.6 Hz, 7-H), 6.68 (1H, d, J = 11.6 Hz, 6-H), 6.74 (1H, d, J = 83.4 Hz, 19-H) (Ref. 0333)
19F-NMR (d, CDCl3) -132.8 (d, J = 83.4 Hz) (Ref. 0333)
m/z 418 (M+, 100), 398 (61), 380 (23), 362 (54), 347 (14), 305 (30), 287 (19), 285 (36), 267 (30), 249 (53), 195 (40), 135 (88) (Ref. 0333)







222
25-fluoro-1a-hydroxyvitamin D3 / 25-fluoro-1a-hydroxycholecalciferol
(5Z,7E)-(1S,3R)-25-fluoro-9,10-seco-5,7,10(19)-cholestatriene-1,3-diol
VVD0225
Sachiko Yamada
1a-OH-25-F-D3
C27H43FO2 418.628 Download ChemDraw structure file
Binding affinity for chick intestinal cytosol protein : 25-F-1-OHD3 is 315 times less efective than 1,25-(OH)2D3 in competitive protein-binding assay. Intestinal calcium transport and bone mineral mobilization : 25-F-1-OHD3 is about 50 times less active than 1,25-(OH)2D3. Antirachitic potency : 25-F-1-OHD3 is 40 times less potent than 1,25-(OH)2D3. (Ref. 0229)

m/z 418 (M+), 380, 152, 134 (Ref. 0229)







223
(24R)-25-fluoro-24-hydroxyvitamin D3 / (24R)-25-fluoro-24-hydroxycholecalciferol
(5Z,7E)-(3S,24R)-25-fluoro-9,10-seco-5,7,10(19)-cholestatriene-3,24-diol
VVD0226
Sachiko Yamada
24R-OH-25-F-D3
C27H43FO2 418.628 Download ChemDraw structure file










224
1a-fluoro-25-hydrovitamin D3 / 1a-fluoro-25-hydrocholecalciferol
(5Z,7E)-(1S,3R)-3-fluoro-9,10-seco-5,7,10(19)-cholestatriene-3,25-diol
VVD0227
Sachiko Yamada
1a-F-25-OHD3
C27H43FO2 418.628 Download ChemDraw structure file
Biological activity (% of 1,25-(OH)2D3 effect) : Inhibition of proliferation of human keratinocytes in culture, 100. (Ref. 0237)









225
24-fluoro-25-hydroxyvitamin D3 / 24-fluoro-25-hydroxycholecalciferol
(5Z,7E)-(3S)-24-fluoro-9,10-seco-5,7,10(19)-cholestatriene-3,25-diol
VVD0228
Sachiko Yamada
24-F-25-OHD3
C27H43FO2 418.628 Download ChemDraw structure file

(EtOH) lmax (nm) 263, lmin (nm) 228 (Ref. 0199)

m/z 418 (M+), 403, 400, 385, 359, 271, 253, 136, 118 (Ref. 0199)







226
(24R)-25-fluoro-1a,24-dihydroxyvitamin D3 / (24R)-25-fluoro-1a,24-dihydroxycholecalciferol
(5Z,7E)-(1S,3R,24R)-25-fluoro-9,10-seco-5,7,10(19)-cholestatriene-1,3,24-triol
VVD0229
Sachiko Yamada
25-F-1a,24R-(OH)2-D3
C27H43FO3 434.627 Download ChemDraw structure file
Biological activity (% of 1,25-(OH)2D3 effect) : Inhibition of proliferation of human keratinocytes in culture, 100 ; Competitive binding to rat intestinal vitamin D receptor, 0.165. (Ref. 0237)








227
(10Z)-19-fluoro-1a,25-dihydroxyvitamin D3 / (10Z)-19-fluoro-1a,25-dihydroxycholecalciferol
(5Z,7E,10Z)-(1S,3R)-19-fluoro-9,10-seco-5,7,10(19)-cholestatriene-1,3,25-triol
VVD0230
Sachiko Yamada
(10Z)-19-F-1a,25-(OH)2D3
C27H43FO3 434.627 Download ChemDraw structure file

(95% EtOH) lmax (nm) 261 (Ref. 0333)
1H-NMR (d, CDCl3) 0.53 (3H, s, 18-H), 0.93 (3H, d, J = 6.4 Hz, 21-H), 1.21 (6H, s, 26- and 27-H), 2.18 (1H, t, J = 11.6 Hz, 4-H), 2.31 (1H, m, 2-H), 2.67 (1H, dm, J = 11.6 Hz, 4-H), 2.80 (1H, m, 9-H), 4.17 (1H, tt, J = 10.9 and 4.4 Hz, 3-H), 5.08 (1H, t, J = 3.1 Hz, 1-H), 5.90 (1H, d, J = 11.1 Hz, 7-H), 6.46 (1H, d, J = 11.1 Hz, 6-H), 6.50 (1H, d, J = 86.1 Hz, 19-H) (Ref. 0333)
19F-NMR (d, CDCl3) -129.6 (d, J = 86.1 Hz) (Ref. 0333)
13C-NMR (d, CDCl3) 12.3, 19.0, 21.0, 22.5, 23.6, 27.9, 29.4, 29.6, 29.9, 36.3, 36.6, 40.7, 42.0, 44.6, 46.2, 46.3, 56.5, 56.7, 63.1 (d, J = 6.2 Hz), 66.5, 71.4, 116.6, 121.4 (d, J = 4.1 Hz), 126.1, 126.7 (d, J = 6.1 Hz), 144.5, 146.5 (d, J = 267.9 Hz) (Ref. 0333)
m/z 434 (M+, 13), 416 (17), 398 (13), 396 (18), 378 (25), 360 (52), 305 (8), 287 (16), 285 (11), 269 (9), 267 (13), 249 (32), 135 (100) (Ref. 0333)



From (1) vitamin D2, via side chain cleavage, side chain introduction, 1a-hydroxylation, and 19-fluorination of 6,19-sulfur-dioxide adduct of the resulting 1a,25-dihydroxyvitamin D3 derivative as key steps or (2) from (5E)-1a,25-dihydroxyvitamin D3 via elimination of the exocyclic methylene and introduction of a fluoromethylene group as key steps. (Ref. 0345)



228
(10E)-19-fluoro-1a,25-dihydroxyvitamin D3 / (10E)-19-fluoro-1a,25-dihydroxycholecalciferol
(5Z,7E,10E)-(1S,3R)-19-fluoro-9,10-seco-5,7,10(19)-cholestatriene-1,3,25-triol
VVD0231
Sachiko Yamada
(10E)-19-F-1a,25-(OH)2D3
C27H43FO3 434.627 Download ChemDraw structure file

(95% EtOH) lmax (nm) 264 (Ref. 0333)
1H-NMR (d, CDCl3) 0.54 (3H, s, 18-H), 0.93 (3H, d, J = 6.4 Hz, 21-H), 1.21 (6H, s, 26- and 27-H), 2.13 (1H, m, 2-H), 2.27 (1H, dd, J = 13.0 and 8.5 Hz, 4-H), 2.66 (1H, dd, J = 13.0 and 3.8 Hz, 4-H), 2.82 (1H, m, 9-H), 4.20 (1H, tt, J = 8.5 and 3.8 Hz, 3-H), 4.43 (1H, dd, J = 5.5 and 3.8 Hz, 1-H), 5.63 (1H, d, J = 11.3 and 5.4 Hz, 7-H), 6.51 (1H, d, J = 11.3 Hz, 6-H), 6.70 (1H, d, J = 83.8 Hz, 19-H) (Ref. 0333)
19F-NMR (d, CDCl3) -128.0 (br. signal) (Ref. 0333)
13C-NMR (d, CDCl3) 12.2, 19.0, 21.0, 22.4, 23.8, 27.6, 29.36, 29.39, 29.5, 36.3, 36.6, 40.7, 43.2, 44.6, 45.1, 46.1, 56.5, 56.8, 66.8, 67.7 (d, J = 9.5 Hz), 71.4, 117.9 (d, J = 3.0 Hz), 122.0 (d, J = 4.8 Hz), 124.9, 126.7, 143.4 (d, J = 265.2 Hz), 144.4 (Ref. 0333)
m/z 434 (M+, 28), 416 (31), 398 (13), 396 (11), 378 (20), 360 (100), 305 (16), 287 (14), 285 (10), 269 (14), 267 (15), 249 (69), 135 (42) (Ref. 0333)



From (5E)-1a,25-dihydroxyvitamin D3 via elimination of the exocyclic methylene and introduction of a fluoromethylene group as key steps. (Ref. 0345)



229
(5E,10Z)-19-fluoro-1a,25-dihydroxyvitamin D3 / (5E,10Z)-19-fluoro-1a,25-dihydroxycholecalciferol
(5E,7E,10Z)-(1S,3R)-19-fluoro-9,10-seco-5,7,10(19)-cholestatriene-1,3,25-triol
VVD0232
Sachiko Yamada
(5E,10Z)-19-F-1a,25-(OH)2D3
C27H43FO3 434.627 Download ChemDraw structure file

(95% EtOH) lmax (nm) 269 (Ref. 0333)
1H-NMR (d, CDCl3) 0.56 (3H, s, 18-H), 0.95 (3H, d, J = 6.4 Hz, 21-H), 1.22 (6H, s, 26- and 27-H), 2.31 (1H, m), 2.81 (1H, m, 9-H), 3.15 (1H, dm, J = 13.2 Hz, 4-H), 4.16 (1H, tt, J = 11.0 and 4.3 Hz, 3-H), 5.05 (1H, br s, 1-H), 5.87 (1H, d, J = 11.5 Hz, 7-H), 6.38 (1H, d, J = 11.5 Hz, 6-H), 6.69 (1H, d, J = 86.5 Hz, 19-H) (Ref. 0333)
19F-NMR (d, CDCl3) -133.2 (d, J = 86.5 Hz) (Ref. 0333)
13C-NMR (d, CD2Cl2-CD3OD = 2 : 1) 12.3, 19.1, 21.5, 22.8, 24.1, 28.2, 29.0, 29.1, 29.6, 36.8, 37.1, 37.9, 41.1, 42.0, 44.8, 46.5, 57.1, 57.3, 62.5 (d, J = 5.9 Hz), 65.4, 71.3, 116.3, 122.8, 127.6 (d, J = 6.2 Hz), 128.4 (d, J = 6.2 Hz), 144.1 (d, J = 266.1 Hz), 145.6 (Ref. 0333)
m/z 434 (M+, 25), 416 (18), 398 (10), 396 (19), 378 (15), 360 (61), 305 (13), 287 (18), 285 (21), 269 (15), 267 (21), 249 (53), 135 (100) (Ref. 0333)



From (1) vitamin D2, via side chain cleavage, side chain introduction, 1a-hydroxylation, and 19-fluorination of 6,19-sulfur-dioxide adduct of the resulting 1a,25-dihydroxyvitamin D3 derivative as key steps or (2) from (5E)-1a,25-dihydroxyvitamin D3 via elimination of the exocyclic methylene and introduction of a fluoromethylene group as key steps. (Ref. 0345)



230
(5E,10E)-19-fluoro-1a,25-dihydroxyvitamin D3 / (5E,10E)-19-fluoro-1a,25-dihydroxycholecalciferol
(5E,7E,10E)-(1S,3R)-19-fluoro-9,10-seco-5,7,10(19)-cholestatriene-1,3,25-triol
VVD0233
Sachiko Yamada
(5E,10E)-19-F-1a,25-(OH)2D3
C27H43FO3 434.627 Download ChemDraw structure file

(95% EtOH) lmax (nm) 269 (Ref. 0333)
1H-NMR (d, CDCl3) 0.58 (3H, s, 18-H), 0.95 (3H, d, J = 6.4 Hz, 21-H), 1.22 (6H, s, 26- and 27-H), 2.25 (1H, m), 2.68 (1H, m), 2.81 (1H, m, 9-H), 3.07 (1H, dd, J = 13.7 and 3.7 Hz, 4-H), 4.19 (1H, tt, J = 10.0 and 4.4 Hz, 3-H), 4.34 (1H, t, J = 3.6 Hz, 1-H), 5.97 (1H, d, J = 11.5 Hz, 7-H), 6.68 (1H, d, J = 11.5 Hz, 6-H), 6.75 (1H, d, J = 83.4 Hz, 19-H) (Ref. 0333)
19F-NMR (d, CDCl3) -132.6 (d, J = 83.4 Hz) (Ref. 0333)
13C-NMR (d, CD2Cl2-CD3OD = 2 : 1) 12.3, 19.1, 21.5, 22.9, 24.2, 28.2, 29.0, 29.1, 29.6, 36.8, 37.1, 37.2, 41.2, 42.5, 44.9, 46.5, 57.2, 57.3, 65.6, 67.7 (d, J = 9.0 Hz), 71.3, 116.5, 125.7 (d, J = 6.1 Hz), 127.7 (d, J = 5.7 Hz), 145.6, 145.8 (d, J = 264.4 Hz) (Ref. 0333)
m/z 434 (M+, 59), 416 (35), 398 (19), 396 (33), 378 (21), 360 (52), 305 (31), 287 (32), 285 (31), 269 (30), 267 (36), 249 (66), 135 (100) (Ref. 0333)



From (5E)-1a,25-dihydroxyvitamin D3 via elimination of the exocyclic methylene and introduction of a fluoromethylene group as key steps. (Ref. 0345)



231
24R-fluoro-1a,25-dihydroxyvitamin D3 / 24R-fluoro-1a,25-dihydroxycholecalciferol
(5Z,7E)-(1S,3R,24R)-24-fluoro-9,10-seco-5,7,10(19)-cholestatriene-1,3,25-triol
VVD0234
Sachiko Yamada
24R-F-1a,25-(OH)2D3
C27H43FO3 434.627 Download ChemDraw structure file
Biological activity (% of 1,25-(OH)2D3 effect) : Inhibition of proliferation of human keratinocytes in culture, 100 ; Intestinal calcium absorption in rat, 65 ; Bone calcium mobilization in rat, 40 ; Competitive binding to rat intestinal vitamin D receptor, 115 ; Differentiation of human leukemia cells (HL-60), 30. (Ref. 0237)
[a]d-25 +67.9 deg (c = 0.52 in MeOH) (Ref. 0191)
(EtOH) lmax (nm) (emax) 213 (12500), 265 (16385) (Ref. 0191)
(CHCl3) 3420 (OH), 1635 (C=C) cm-1 (Ref. 0191)
1H-NMR (d, CDCl3, 200MHz) 0.56 (3H, s, CH3), 0.95 (3H, d, J = 7 Hz, CHCH3), 1.22 and 1.24 (6H, 2 s, CMe2), 2.33 (1H, m), 2.64 (1H, m), 2.84 (1H, m), 4.21 (1H, d m, J = 48 Hz, CHF), 4.26 (1H, br s, CHO), 4.46 (1H, br s, CHO), 5.01 (1H, s, vinyl CH), 5.33 (1H, s, vinyl CH), 6.03 (1H, d, J = 12 Hz, vinyl CH), 6.39 (1H, d, J = 12 Hz, vinyl CH) (Ref. 0191)
m/z 434 (M+, 13), 416 (11), 398 (3), 375 (2), 287 (7), 152 (36), 134 (100) (Ref. 0191)







232
1a,25-dihydroxy-24-oxo-23-azavitamin D2 / 1a,25-dihydroxy-24-oxo-23-azaergocalciferol
(5Z,7E)-(1S,3R,24R)-23-aza-22-oxo-9,10-seco-5,7,10(19)-ergostatriene-1,3,25-triol
VVD0235
Sachiko Yamada
C27H43NO4 445.635 Download ChemDraw structure file
The analogue showed almost no affinity to the chick cytosol vitamin D receptor. (Ref. 0259)
[a]D +1.5 deg (c = 0.0023 in EtOH) (Ref. 0259)
(EtOH) lmax (nm) (emax) 265 (18300) (Ref. 0259)
(CHCl3) 3441, 1651 cm-1 (Ref. 0259)
1H-NMR (d, CDCl3, 400MHz) 0.56 (3H, s), 1.14 (3H, d, J = 7.0 Hz), 1.20 (3H, s), 1.21 (3H, d, J = 6.3 Hz), 1.23 (3H, s), 3.89 (1H, dq, J = 8.2, 6.3 Hz), 4.23 (1H, m), 4.43 (1H, m), 4.99 (1H, s), 5.32 (1H, t, J = 1.8 Hz), 6.02 (1H, d, J = 11.3 Hz), 6.38 (1H, d, J = 11.5 Hz) (Ref. 0259)
m/z 445 (M+), 427 (M+-H2O), 409 (M+-2H2O) (Ref. 0259)

HPLC : Lichrosorb Si-60, 10 times 250 mm ; mobile phase, isoPrOH-CH2Cl2 (13 : 87). Zorbax-SIL,4.6 times 250 mm times 2 ; mobile phase, hexane-CH2Cl2-MeOH-isoPrOH (60 : 30 : 5 : 5). (Ref. 0259)

Condensation of the steroidal 20-carboxylic acid with the requisite side-chain amine, followed by the usual ring opening reactions, gave the amide analogue. (Ref. 0259)



233
1a-hydroxy-3-deoxyvitamin D3 / 1a-hydroxy-3-deoxycholecalciferol
(5Z,7E)-(1S)-9,10-seco-5,7,10(19)-cholestatrien-1-ol
VVD0236
Sachiko Yamada
3-deoxy-1a-OHD3
C27H44O 384.638 Download ChemDraw structure file
Intestinal Calcium Transport and Bone Calcium Mobilization Activity of Analog 4* (3-deoxy-1a-hydroxyvitamin D3) and 3* (1a-OH-D3). (Ref. 0179)
lmax (nm) 264.5, lmin (nm) 229 (Ref. 0179)

m/z 384 (M+), 366, 271, 253, 136 (Ref. 0179)



From 1a,2a-epoxy-6-ethylenedioxycholestan-3-one: treatment with hydrazine hydrate, catalytic reduction, introduction of 5,7-diene function by conventional method and photochemical followed by thermal isomerization. (Ref. 0179)
From 1a-acetoxycholesterol tosylate: reduction of the tosylate function, introduction of 5,7-diene function and photochemical followed by thermal isomerization. (Ref. 0179)



234
vitamin D3 / cholecalciferol / calciol
(5Z,7E)-(3S)-9,10-seco-5,7,10(19)-cholestatrien-3-ol
VVD0237
Sachiko Yamada
D3
C27H44O 384.638 Download ChemDraw structure file
Activities of vitamin D3 in intestinal calcium transport and bone calcium mobilization were compared with those of 25-OHD3: Tables (Ref. 0014)
84-85 degC (Ref. 0001)
[a]d-25 +51.9 deg (c = 1.6 in CHCl3) (Ref. 0001)
(95% EtOH or Hexane) lmax (nm) (e) 264.5 (18200) (Ref. 0001)
1H-NMR (d, CDCl3, 300MHz) 0.54 (3 H, s, 18-CH3), 0.87 (6 H, d, J = 6.5 Hz, 26-, 27-CH3), 0.92 (3 H, d, J = 6 Hz, 21-CH3), 2.17 (1 H, ddd, 4.5, 8.6 and 13.9 Hz, 1a-H), 2.28 (1 H, dd, J = 7.5 and 13.2 Hz, 4b-H), 2.39 (1 H, ddd, J = 5.0, 7.7 and 13.9 Hz, 1b-H), 2.56 (1 H, dd, J = 3.6 and 13.2 Hz, 4a-H), 2.82 (1 H, d, J = 12 Hz, 9b-H), 3.94 (1 H, dddd, J = 3.6, 3.8, 7.5 and 7.6 Hz, 3a-H), 4.82 (1 H, d, J = 2.5 Hz, 19-H), 5.05 (1 H, dt, J = 2.5 and 1.2 Hz, 19-H), 6.03 (1 H, d, J = 11.2 Hz, 7-H), 6.25 (1 H, d, J = 11.2 Hz, 6-H) (Ref. 0002)
1H-NMR (d, CDCl3, 300MHz) spectrum (Ref. 0004)
13C-NMR (d, CDCl3, 22.6MHz) 32.1 (1), 35.3 (2), 69.2 (3), 46.0 (4), 135.3 (5), 122.5 (6) 117.8 (7), 142.2 (8), 29.1 (9),* 145.3 (10), 22.4 (11), 40.6 (12), 46.0 (13), 56.5 (14),** 23.7 (15), 27.8 (16),* 56.7 (17),** 11.9 (18), 112.5 (19), 36.2 (20), 18.9 (21), 36.2 (22), 24.0 (23), 39.6 (24), 28.1 (25),* 22.7 (26), 22.9 (27); * and **, the assignments may be interchanged. (Ref. 0003)
m/z 384 (M+), 351, 325, 271, 253, 158, 136, 118; spectrum (Ref. 0015)


Upon sunlight irradiation, 7-dehydrocholesterol (provitamin D3) on the skin isomerizes to previtamin D3 which in turn isomerizes to vitamin D3 at skin temperature. (Ref. 0005/0006)
Synthesis from cholesterol acetate via photochemical isomerization of the corresponding 5,7-diene (provitamin D3) followed by thermal isomerization. (Ref. 0007)
By convergent method from des-AB-cholestan-8-one and A-ring precursor using Wittig-Horner coupling. (Ref. 0286)
Vitamin D3 is hydroxylated by vitamin D 25-hydroxylase (CYP27) in the liver (Ref. 0016/0017) to yield 25-OHD3 and then by 1a-hydroxylase (CYP24B1) (Ref. 0030/0031) in the kidney to afford 1,25-(OH)2D3 (Ref. 0026/0027) , the biologically active form of vitamin D3.


235
3-epivitamin D3 / 3-epicholecalciferol
(5Z,7E)-(3R)-9,10-seco-5,7,10(19)-cholestatrien-3-ol
VVD0238
Sachiko Yamada
3-epi-D3
C27H44O 384.638 Download ChemDraw structure file

p-nitrobenzoate : 117-118 degC (Ref. 0165)
[a]D -0.5 deg (c = 0.9 in C6H6) (Ref. 0165)
lmax (nm) (emax) 264 (18000) (Ref. 0165)
1H-NMR (d, CDCl3) 6.2 (1H, J = 11.2 Hz, 6-H), 6.0 (1H, J = 11.2 Hz, 7-H), 5.0 (1H, 19Z-H), 4.8 (1H, 19E-H), 3.9 (1H, J = 4.1 Hz, 3-H), 0.5 (3H, 18-H) (Ref. 0165)
13C-NMR (d, CDCl3, 20MHz) 32.40 (1), 35.60 (2), 69.70 (3), 46.25 (4), 145.05 (5), 122.25 (6), 117.65 (7), 142.15 (8), 29.10 (9), 135.40 (10), 22.35 (11), 40.65 (12), 45.95 (13), 56.45 (14), 23.70 (15), 27.65 (16), 56.80 (17), 12.00 (18), 112.50 (19) (Ref. 0165)




From vitamin D3 by inverting the configuration at C(3). (Ref. 0165)



236
(5E)-vitamin D3 / (5E)-cholecalciferol / (5E)-calciol
(5E,7E)-(3S)-9,10-seco-5,7,10(19)-cholestatrien-3-ol
VVD0239
Sachiko Yamada
(5E)-D3
C27H44O 384.638 Download ChemDraw structure file

1H-NMR (d, CDCl3, 300MHz) 6.52 (1H, d, J = 11.2 Hz, 6-H), 5.84 (1H, d, J = 11.2 Hz, 7-H), 4.95 (1H, br, 19Z-H), 4.65 (1H, br, 19E-H), 3.86 (1H, dddd, J = 8.5, 8.5, 4.1 and 4.1 Hz, 3a-H), 2.84 (1H, br d, J = 13.8 Hz, 4a-H), 2.84 (1H, d, J = 12.0 Hz, 9b-H), 2.44 (1H, ddd, J = 14.0, 5.0 and 5.0 Hz, 1b-H), 2.21 (1H, dd, J = 13.8 and 8.5 Hz, 4b-H), 2.17 (1H, br d, J = 14.0 Hz, 1a-H), 1.94 (1H, 2a-H), 1.58 (1H, 2b-H), 0.92 (3H, d, J = 6.2 Hz, 21-CH3), 0.87 (6H, d, J = 6.7 Hz, 26-, 27-CH3), 0.57 (3H, s, 18-CH3) (Ref. 0164)
13C-NMR (d, CDCl3, 20MHz) 31.20 (1), 34.80 (2), 69.00 (3), 37.25 (4), 149.25 (5), 121.05 (6), 116.0 (7), 145.55 (8), 29.15 (9), 134.95 (10), 22.40 (11), 40.70 (12), 46.00 (13), 56.70 (14), 23.65 (15), 27.70 (16), 56.85 (17), 12.20 (18), 108.15 (19) (Ref. 0165)




From vitamin D3 via its SO2 adduct: Treatment of D3 with liquid SO2 at its refluxing temperature gives D3-SO2 adduct in quantitative yeild which upon heating in refluxing EtOH in the presence of weak base (such as NaHCO3) gives exclusively 5E-D3. (Ref. 0267/0265)



237
(5E)-3-epivitamin D3 / (5E)-3-epicholecalciferol
(5E,7E)-(3R)-9,10-seco-5,7,10(19)-cholestatrien-3-ol
VVD0240
Sachiko Yamada
(5E)-3-epi-D3
C27H44O 384.638 Download ChemDraw structure file

p-nitrobenzoate : 104-105 degC (Ref. 0165)
[a]D -30.0 deg (c = 0.85 in C6H6) (Ref. 0165)
lmax (nm) (emax) 272 (22000) (Ref. 0165)
1H-NMR (d, CDCl3) 6.5 (1H, J = 11.1 Hz, 6-H), 5.8 (1H, J = 11.1 Hz, 7-H), 4.9 (1H, 19Z-H), 4.6 (1H, 19E-H), 3.8 (1H, J = 4.2 Hz, 3-H), 0.5 (3H, 18-H) (Ref. 0165)
13C-NMR (d, CDCl3, 20MHz) 31.15 (1), 34.75 (2), 68.95 (3), 37.10 (4), 149.20 (5), 121.05 (6), 115.9 (7), 144.65 (8), 29.10 (9), 134.80 (10), 22.35 (11), 40.60 (12), 46.00 (13), 56.60 (14), 23.65 (15), 27.70 (16), 56.75 (17), 12.15 (18), 108.2 (19) (Ref. 0165)




From (5E)-vitamin D3 by inverting the configuration at C(3). (Ref. 0165)



238
previtamin D3 / precholecalciferol / (6Z)-tacalciol
(6Z)-(3S)-9,10-seco-5(10),6,8-cholestatrien-3-ol
VVD0241
Sachiko Yamada
pre-D3
C27H44O 384.638 Download ChemDraw structure file

3:5-Dinitrobenzoate : 104.5-105 degC (Ref. 0008)
[a]d-20 +54 deg (in CHCl3) (Ref. 0008)
lmax (nm) (emax) 260 (9250) (Ref. 0008)









239
tachysterol3
(6E)-(3S)-9,10-seco-5(10),6,8-cholestatrien-3-ol
VVD0242
Sachiko Yamada
tachysterol3
C27H44O 384.638 Download ChemDraw structure file










240
isotachysterol3
(6E)-(3S)-9,10-seco-5(10),6,8(14)-cholestatrien-3-ol
VVD0243
Sachiko Yamada
isotachysterol3
C27H44O 384.638 Download ChemDraw structure file

(EtOH) lmax (nm) 288, 277, 301 (Ref. 0011)
Dinitrobenzoate : 1H=NMR (d, CDCl3, 100MHz) 5.37 (1H, m), 6.54 (1H, d, J = 16 Hz), 6.30 (1H, d, J = 16 Hz), 0.91 (3H, s), 1.90 (3H, s), 0.92 (3H, d, J = 6 Hz), 0.89 (6H, d, J = 6 Hz) (Ref. 0011)
m/z 384 (M+) (Ref. 0011)

RF(TLC) [0.2 nm silicagel plate (Kieselgel G Merk), benzen/acetone] 0.71 (Ref. 0011)
Rrel(GC) [1% SE-30 on GasChrom Q (80-100 mesh), retention time relative to cholestane] 1.47/1.62/2.36/2.60 (Ref. 0011)

Obtained as a minor product by overirradiation of 7-dehydrocholesterol in ethanol or methanol. (Ref. 0011)
Better method of producing this compound is to treat vitamin D3 with Lewis acids as described in vitamin D2 series. (Ref. 0268)



241
(5E)-isovitamin D3 / (5E)-isocholecalciferol
(5E,7E)-(3S)-9,10-seco-1(10),5,7-cholestatrien-3-ol
VVD0244
Sachiko Yamada
(5E)-iso-D3
C27H44O 384.638 Download ChemDraw structure file

(EtOH) lmax (nm) 287, 276, 298 (Ref. 0011)
Dinitrobenzoate : 1H-NMR (d, CDCl3, 100MHz) 5.42 (1H, m), 6.54 (1H, d, J = 12 Hz), 5.91 (1H, d, J = 12 Hz), 0.52 (3H, s), 1.96 (3H, s), 0.93 (3H, d, J = 6 Hz), 0.87 (6H, d, J = 6 Hz) (Ref. 0011)
m/z 384 (M+) (Ref. 0011)

RF(TLC) [0.2 nm silicagel plate (Kieselgel G Merk), benzen/acetone] 0.85 (Ref. 0011)
Rrel(GC) [1% SE-30 on GasChrom Q (80-100 mesh), retention time relative to cholestane] 1.39/1.59/2.27 (Ref. 0011)

Obtained as a minor product by overirradiation of 7-dehydrocholesterol in ethanol or methanol. (Ref. 0011)
Better method of producing this compound is to treat vitamin D3 with Lewis acids as described in vitamin D2 series. (Ref. 0268)



242
provitamin D3 /procholecalciferol / 7-dehydrocholesterol
(3S)-5,7-cholestadien-3-ol
VVD0245
Sachiko Yamada
pro-D3
C27H44O 384.638 Download ChemDraw structure file

126 degC (Ref. 0187)
141.5 degC (Alcohol) (Ref. 0188)
[a]d-25 -50.45 to -49.69 deg (in CHCl3) (Ref. 0188)
lmax (nm) (e) 262.5 pm 5 (7400), 271.0 pm 5 (10400), 281.5 pm 5 (10750), 293.0 pm 5 (6150) (Ref. 0187)
13C-NMR (d, CDCl3, 22.6MHz) 38.5 (1), 32.0 (2), 70.5 (3), 40.8 (4), 141.3 (5), 119.8 (6), 116.5 (7), 140.0 (8), 46.5 (9), 37.2 (10), 21.2 (11), 39.2 (12), 43.1 (13), 54.6 (14), 23.1 (15), 28.1 (16), 56.2 (17), 11.9 (18), 16.4 (19), 36.3 (20), 18.9 (21), 36.3 (22), 24.0 (23), 39.6 (24), 28.1 (25), 22.6 (26), 22.8 (27) (Ref. 0003)



Isolation and identification from pig skin. (Ref. 0190)




243
pyrovitamin D3 / pyrocholecalciferol
(3S)-10a-cholesta-5,7-dien-3-ol
VVD0246
Sachiko Yamada
pyro-D3
C27H44O 384.638 Download ChemDraw structure file

lmax (nm) 274, 285, 296 (Ref. 0009)
1H-NMR (d, CCl4, 100MHz) 0.84 (s, 18-H3), 1.07 (s, 19-H3), 3.95 (narrow m, 3a-H), 5.36 (q, J = 6 Hz, 6-, 7-H2) (Ref. 0009)




From vitamin D3 by heating (110-170 degC) in various organic solvent. (Ref. 0009)



244
isopyrovitamin D3 / isopyrocholecalciferol
(3S)-9b-cholesta-5,7-dien-3-ol
VVD0247
Sachiko Yamada
isopyro-D3
C27H44O 384.638 Download ChemDraw structure file

lmax (nm) 274, 284, 295 (Ref. 0009)
1H-NMR (d, CCl4, 100MHz) 0.85 (s, 18-H3), 1.24 (s, 19-H3), 3.40 (broad m, 3a-H), 5.42 (q, J = 6 Hz, 6-, 7-H2) (Ref. 0009)




From vitamin D3 by heating (110-170 degC) in various organic solvent. (Ref. 0009)



245
toxisterol3 A1
(3S,4S,8S)-4,8-cyclo-9,10-seco-5(10),6-cholestadien-3-ol
VVD0248
Sachiko Yamada
toxisterol3 A1
C27H44O 384.638 Download ChemDraw structure file

94.5-96.5 degC (Ref. 0011/0012)
[a]d-22 -100 deg (in CHCl3) (Ref. 0011/0012)
(EtOH) lmax (nm) (emax) 251 (15000) (Ref. 0011/0012)
(KBr) 3340, 3060, 2950, 2870, 1470, 1380, 1120, 1040, 1020, 990, 930, 860, 760, 500 cm-1 (Ref. 0011)
1H-NMR (d, CDCl3, 100MHz) 3.85 (1 H, dt, J = 3.5, 11 Hz), 6.27 (2 H, s), 0.89 (3 H, s), 1.67 (3 H, d, J = 2 Hz), 0.90 (3 H, d, J = 5 Hz), 0.86 (6 H, d, J = 6 Hz) (Ref. 0011)
13C-NMR (d, CDCl3, 100MHz) 35.2 t (1), 33.8 t (2), 69.8 d (3), 54.0 d (4), 122.6 s (5), 129.2 d (6), 140.6 d (7), 54.0 s (8), 31.4 t (9), 135.7 s (10), 20.1 t (11), 40.0 t (12), 43.9 s (13), 55.7 d (14), 22.3 t (15), 27.2 t (16), 57.0 d (17), 140.0 q (18), 18.4 q (19), 35.4 d (20), 18.4 q (21), 35.9 t (22), 23.7 t (23), 39.5 t (24), 27.9 d (25), 22.5 q (26), 22.8 q (27) (Ref. 0011/0012)
m/z 384 (M+) (Ref. 0011)

RF(TLC) (benzene) 0.57 (Ref. 0011)
Rrel(GC) (retention time relative to cholestane) 1.41 (Ref. 0011)

Obtained as one of overirradiation products of 7-dehydrocholesterol. (Ref. 0011)



246
toxisterol3 A2
(3S,4S,8S)-4,8,-cyclo-9,10-seco-5(10),6-cholestadien-3-ol
VVD0249
Sachiko Yamada
toxisterol3 A2
C27H44O 384.638 Download ChemDraw structure file

[a]d-22 +39 deg (in CHCl3) (Ref. 0011)
(EtOH) lmax (nm) (emax) 251 (15000) (Ref. 0011)
(Neat) 3390, 3060, 2960, 2940, 2870, 1460, 1370, 1120, 1030, 1015, 990, 775, 755, 675 cm-1 (Ref. 0011)
1H-NMR (d, CDCl3, 100MHz) 3.81(1H, dt, J = 3.5, 11 Hz), 6.33 (1H, d, J = 6 Hz), 6.06 (1H, d, J = 6 Hz), 0.90 (3H, s), 1.65 (3H, d, J = 2 Hz), 0.94 (3H, d, J = 6 Hz), 0.87 (6H, d, J = 6 Hz) (Ref. 0011)
13C-NMR (d, CDCl3, 100MHz) 31.4 t (1), 34.0 t (2), 69.8 d (3), 59.7 d (4), 120.5 s (5), 128.6 d (6), 140.8 d (7), 53.2 s (8), 35.7 t (9), 138.1 s (10), 19.6 t (11), 40.2 t (12), 45.0 s (13), 48.0 d (14), 24.2 t (15), 29.8 t (16), 54.3 d (17), 18.2 q (18), 25.5 q (19), 36.2 d (20), 19.4 q (21), 36.8 t (22), 23.8 t (23), 39.5 t (24), 28.0 d (25), 22.5 q (26), 22.8 q (27) (Ref. 0011)
m/z 384 (M+), 253 (base) (Ref. 0011)

RF(TLC) [0.2 nm silicagel plate (Kieselgel G Merk), benzene] 0.31 (Ref. 0011)
Rrel(GC) [1% SE-30 on GasChrom Q (80-100mesh), retention time relative to cholestane] 0.98 (Ref. 0011)

Obtained as one of overirradiation products of 7-dehydrocholesterol. (Ref. 0011)



247
toxisterol3 A3
(3S,4R,8R)-4,8-cyclo-9,10-seco-5(10),6-cholestadien-3-ol
VVD0250
Sachiko Yamada
toxisterol3 A3
C27H44O 384.638 Download ChemDraw structure file

[a]d-22 +128 deg (in CHCl3) (Ref. 0011)
(Diethyl ether) lmax (nm) (emax) 251 (15000) (Ref. 0011)
(Neat) 3430, 3050, 3020, 2930, 2860, 1470, 1380, 1370, 1175, 1090, 1070, 1015, 990, 870, 810, 770 cm-1 (Ref. 0011)
1H-NMR (d, CDCl3, 100MHz) 4.61 (1H, m), 6.14 (1H, d, J = 5.5 Hz), 5.35 (1H, d, J = 5.5 Hz), 0.75 (3H, s), 1.76 (3H, d, J = 1.5 Hz), 0.93 (3H, d, J = 6 Hz), 0.88 (6H, d, J = 6 Hz) (Ref. 0011)
m/z 384 (M+) (Ref. 0011)

RF(TLC) [0.2 nm silicagel plate (Kieselgel G Merk), benzene] 0.31 (Ref. 0011)
Rrel(GC) [1% SE-30 on GasChrom Q (80-100 mesh), retention time relative to cholestane] 1.31 (Ref. 0011)

Obtained as one of overirradiation products of 7-dehydrocholesterol. (Ref. 0011)



248
toxisterol3 C1
(5R,6R,9S,10R)-9(10a_right5),10(9a_right6)abeo-7-cholesten-3b-ol
VVD0251
Sachiko Yamada
toxisterol3 C1
C27H44O 384.638 Download ChemDraw structure file

112 degC (Ref. 0011/0012)
[a]d-22 +141 deg (in CHCl3) (Ref. 0011/0012)
(EtOH) lmax (nm) (emax) 227 (6600) (Ref. 0011/0012)
(KBr) 3380, 3060, 2960, 2940, 2880, 1660, 1470, 1380, 1080, 1045, 1030, 1015, 840 cm-1 (Ref. 0011)
1H-NMR (d, CDCl3, 100MHz) 3.56 (1H, m), 5.02 (1H, d, J = 1.8 Hz), 0.57 (3H, s), 0.81 (3H, s), 0.90 (3H, d, J = 6 Hz), 0.86 (6H, d, J = 6 Hz) (Ref. 0011/0012)
13C-NMR (d, CDCl3, 100MHz) 39.7 t (1), 32.8 t (2), 67.9 d (3), 31.5 t (4), 34.0 s (5), 31.1d (6), 117.7 d (7), 148.1 s (8), 50.2 d (9), 24.5 s (10), 22.3 t (11), 40.5 t (12), 45.4 s (13), 51.6 d (14), 25.5 t (15), 28.6 t (16), 55.6 d (17), 12.2 q (18), 15.2 q (19), 36.3d(20), 18.9 q (21), 36.3 t (22), 23.9 t (23), 39.5 t (24), 28.0 d (25), 22.6 q (26), 22.8 q (27) (Ref. 0011)
m/z 384 (M+), 351 (base) (Ref. 0011)

RF(TLC) [0.2 nm silicagel plate (Kieselgel G Merk), benzene/acetate] 0.63 (Ref. 0011)
Rrel(GC) [1% SE-30 on GasChrom Q (80-100 mesh), retention time relative to cholestane] 1.40 (Ref. 0011)

A major overirradiation products of 7-dehydrocholesterol. (Ref. 0011)



249
toxisterol3 C2
(5S,6S,9S,10S)-9(10a_right5),10(9a_right6)abeo-7-cholesten-3b-ol
VVD0252
Sachiko Yamada
toxisterol3 C2
C27H44O 384.638 Download ChemDraw structure file

102-103 degC (Ref. 0011)
[a]d-22 -69 deg (in CHCl3) (Ref. 0011)
(EtOH) lmax (nm) (emax) 229 (5400) (Ref. 0011)
(KBr) 3360, 3040, 2940, 2860, 1650, 1480, 1390, 1070, 1050, 1020, 825 cm-1 (Ref. 0011)
1H-NMR (d, CDCl3, 100MHz) 3.59 (1H, m), 5.15 (1H, d, J = 2 Hz), 0.73 (3H, s), 0.92 (3H, s), 0.90 (3H, d, J = 6 Hz), 0.86 (6H, d, J = 6 Hz) (Ref. 0011)
13C-NMR (d, CDCl3, 100MHz) 38.4 t (1), 33.6 t (2), 68.9 d (3), 31.7 t (4), 37.7 s (5), 30.1 d (6), 119.7 d (7), 148.6 s (8), 46.4 d (9), 28.3 s (10), 19.3 t (11), 40.8 t (12), 42.6 s (13), 48.0 d (14), 24.0 t (15), 29.1 t (16), 57.2 d (17), 15.5 q (18), 18.4 q (19), 36.0 d (20), 18.9 q (21), 36.0 t (22), 24.0 t (23), 39.5 t (24), 28.0 d (25), 22.5 q (26), 22.8 q (27) (Ref. 0011)
m/z 384 (M+), 351 (Ref. 0011)

RF(TLC) [0.2 nm silicagel plate (Kieselgel G Merk), benzen/acetone] 0.60 (Ref. 0011)
Rrel(GC) [1% SE-30 on GasChrom Q (80-100 mesh), retention time relative to cholestane] 0.95/1.52/1.60 (Ref. 0011)

Obtained as one of overirradiation products of 7-dehydrocholesterol. (Ref. 0011)



250
toxisterol3 D1
(5Z)-(3S)-9,10-seco-5,8,10(19)-cholestatrien-3-ol
VVD0253
Sachiko Yamada
toxisterol3 D1
C27H44O 384.638 Download ChemDraw structure file

Dinitrobenzoate : 108.5-109.5 degC (Ref. 0011/0012)
Dinitrobenzoate : [a]d-22 +37 deg (in CHCl3) (Ref. 0011/0012)
(EtOH) lmax (nm) (emax) 217 (shoulder) (7200) (Ref. 0011/0012)
(Neat) 3340, 3075, 2950, 2930, 2860, 1640, 1460, 1370, 1050, 900 cm-1 (Ref. 0011)
1H-NMR (d, CDCl3, 100MHz) 3.92 (1H, m), 5.34 (1H, t, J = 7 Hz), 2.79 (1H, d, J = 7 Hz), 0.67 (3H, s), 4.73 (3H, d, J = 2 Hz), 4.93 (3H, d, J = 2 Hz), 0.93 (3H, d, J = 7 Hz), 0.86 (6H, d, J = 6 Hz) (Ref. 0011/0012)
m/z 384 (M+) (Ref. 0011)

RF(TLC) [0.2 nm silicagel plate (Kieselgel G Merk), benzen/acetone] 0.71 (Ref. 0011)
Rrel(GC) [1% SE-30 on GasChrom Q (80-100 mesh), retention time relative to cholestane] 1.69/2.58 (Ref. 0011)

Obtained as one of overirradiation products of 7-dehydrocholesterol. (Ref. 0011)



251
toxisterol3 E1
(3S,6R,9R)-9(10a_right6)abeo-5(10),7-cholestadien-3-ol
VVD0254
Sachiko Yamada
toxisterol3 E1
C27H44O 384.638 Download ChemDraw structure file

[a]d-22 +155 deg (in CHCl3) (Ref. 0011)
lmax (nm) (emax) (diethyl ether) no absorption maximum at l > 210 (Ref. 0011)
(KBr) 3420, 2960, 2930, 2870, 1660, 1480, 1390, 1380, 1100, 1040, 810 cm-1 (Ref. 0011)
1H-NMR (d, CDCl3, 100MHz) 3.90 (1H, m), 3.76 (1H, m), 5.57 (1H, s), 0.63 (3H, s), 1.58 (3H, s), 0.94 (3H, d, J = 6 Hz), 0.88 (6H, d, J = 6 Hz) (Ref. 0011)
Dinitrobenzoate : m/z 578 (M+), 366 (base) (Ref. 0011)

RF(TLC) [0.2 nm silicagel plate (Kieselgel G Merk), benzene

Obtained as one of overirradiation products of 7-dehydrocholesterol in ether. (Ref. 0011)



252
(3S,6S)-9,10-seco-5(10),6,7-cholestatrien-3-ol
VVD0255
Sachiko Yamada
C27H44O 384.638 Download ChemDraw structure file

lmax (nm) 230 (Ref. 0013)
1950, 1625 cm -1 (Ref. 0013)
1H-NMR (d, CDCl3, 100MHz) 0.73 (3H, s) 3.90 (1H, m), 6.18 (1H, t, J = 4 Hz) (Ref. 0013)




One of minor irradiation (>250 nm) products of vitamin D3 in ethanol. (Ref. 0013)



253
(3S,6R)-9,10-seco-5(10),6,7-cholestatrien-3-ol
VVD0256
Sachiko Yamada
C27H44O 384.638 Download ChemDraw structure file

lmax (nm) 230 (Ref. 0013)
1950, 1625 cm -1 (Ref. 0013)
1H-NMR (d, CDCl3, 100MHz) 0.65 (3H, s), 0.87 (6H, d, J = 7 Hz), 0.91 (3H, d, J = 7 Hz), 1.74 (3H, s), 3.90 (1H, m), 6.14 (1H, t, J = 4 Hz) (Ref. 0013)




One of minor irradiation (>250 nm) products of vitamin D3 in ethanol. (Ref. 0013)



254
(7E)-(3S,6S)-6,19-cyclo-9,10-seco-5(10),7-cholestadien-3-ol
VVD0257
Sachiko Yamada
C27H44O 384.638 Download ChemDraw structure file

No absorption maxima at l > 200 nm (Ref. 0013)
3,5-Dinitrobenzoate of one of C(6) epimers : 1H-NMR (d, CDCl3, 100MHz) 0.54 (3H, s), 0.86 (6H, d, J = 7 Hz), 0.93 (3H, d, J = 7 Hz), 3.71 (1H, m), 4.91 (1H, d, J = 9 Hz), 5.30 (1H, m) (Ref. 0013)




One of minor irradiation (>250 nm) products of vitamin D3 in ethanol. (Ref. 0013)



255
1a-hydroxyvitamin D3 / 1a-hydroxycholecalciferol
(5Z,7E)-(1S,3R)-9,10-seco-5,7,10(19)-cholestatriene-1,3-diol
VVD0258
Sachiko Yamada
1a-OHD3
C27H44O2 400.637 Download ChemDraw structure file
Intestinal calcium transport and bone mineral mobilization response to 1a-OH-D3 and 25-OH-D3 in anephric rats. : Table(Ref. 0168)
Intestinal calcium transport and bone calcium mobilization response of rats to 1a-OH-D3. Results are means of six rats ; S.E., standard error. : Table (Ref. 0172)
HL-60 human promyelocytes differentiation : ED50 in nitro blue tetrazplium reduction, phagocytic activity, and nonspecific acid esterase activity are 9.3 times 10-7 M, 1.0 times 10-6 M and 1.0 times 10-6 M, respectively, when 1,25-(OH)2D3 shows the respective ED50 values of 1.0 times 10-8 M, 1.0 times 10-8 M and 1.1 times 10-8 M, respectively. (Ref. 0228)
Treatment of psoriasis : A case of psoriasis with senile osteoporosis is reported in which skin lesions were cured two and half months after the start of administration of 0.75 mg/day of 1a-OHD3. (Ref. 0248)
134-136 degC (Ref. 0167)
[a]d-25 +28.0 deg (c = 0.6 in Et2O) (Ref. 0167)
(Et2O) lmax (nm) (emax) 264-265 (18000) (Ref. 0167)
(CHCl3) 895m, 912m, 952m, 1040s, 1645m, 3450m, 3600s cm-1 (Ref. 0167)
1H-NMR (d, CDCl3) 3.58 (1H, d, J = 12 Hz, 6- or 7-H), 3.99 (1H, d, J = 12 Hz, 6- or 7-H), 4.66 (1H, m, 19-H), 4.99 (1H, m, 19-H), 5.45-6.05 (2H, m, >CH-O), 9.12 (9H, d, J = 6 Hz, MeCH<), 9.45 (3H, s, 18-H) (Ref. 0167)
m/z 382 (5.2%), 364 (16.2%), 149 (26.0%), 134 (6.1%), 128 (30.4%), 121 (67.5%), 119 (32.0%), 95 (49.4%), 83 (50.5%), 81 (59%), 71 (58.5%), 69 (76.3%), 57 (100%) (Ref. 0167)



From cholesterol. (Ref. 0035)
From 1,4,6-cholestatrien-3-one via its regio- and stereoselective epoxidation followed by deconjugative reduction to yield 1a-hydroxycholesterol as the key step. (Ref. 0166)
Total synthesis from 9a-chloro-des-AB-cholestan-8-one and optically active A-ring synthon having C(6)-C(7) linker part as ethyl group. (Ref. 0167)
From 1,4-cholestadien-3-one via steps of deconjugation followed by reduction, hydroboration, bromination, dehydrobromination, and photochemical and thermal isomerizations. (Ref. 0168)
Synthesis of 1a-hydroxyprovitamin D3 from 1,4,6-cholestatrien-3-one via steps of deconjugation followed by reduction, protection of 5,7-diene, epoxidation, and reduction. (Ref. 0169/0170)
From vitamin D3 via SeO2 oxidation of 3,5-cyclo-vitamin D derivative. (Ref. 0171)



256
1a-hydroxy-3-epivitamin D3 / 1a-hydroxy-3-epicholecalciferol
(5Z,7E)-(1S,3S)-9,10-seco-5,7,10(19)-cholestatriene-1,3-diol
VVD0259
Sachiko Yamada
1a-OH-3-epi-D3
C27H44O2 400.637 Download ChemDraw structure file
Relative Efficacy of 1,3-diol Stereoisomers in Competing with 1,25-(OH)2-[26 ,27-3H]D3 for Binding to The Receptor Protein. (Ref. 0175)
lmax (nm) 263 (Ref. 0175)
1H-NMR (d, CDCl 3) 0.54 (3H, s, 18-H3), 4.05 (1H, m, 3-H), 4.30 (1H, m, 1-H), 5.00 [1H, m, 19(Z)-H], 5.30 [1H, m, 19(E)-H], 6.02 (1H, d, J = 11.4 Hz, 7-H), 6.44 (1H, d, J = 11.4 Hz, 6-H) (Ref. 0175)
m/z 400 (M+, 20), 382 (35), 364 (15), 152 (100), 134 (90) (Ref. 0175)



From 3-epivitamin D3 : SeO2 oxidation of its 3,5-cyclovitamin D derivative gave 1-oxo-derivative as a minor product which by LiAlH4 gave 1a-hydroxylated cyclovitamin D as the major product. 1a-Hydroxy-3-epivitamin D3 was obtained from this compound by cycloreversion followed by hydrolysis. (Ref. 0175)
From 1a-hydroxycholesterol via the steps of the inversion of the configuration at C(3) by Mitsunobu method, bromination, dehydrobromination and photochemical followed by thermal isomerization. (Ref. 0177)



257
(5E)-1a-hydroxyvitamin D3 / (5E)-1a-hydroxycholecalciferol
(5E,7E)-(1S,3R)-9,10-seco-5,7,10(19)-cholestatriene-1,3-diol
VVD0260
Sachiko Yamada
(5E)-1a-OHD3
C27H44O2 400.637 Download ChemDraw structure file
Relative Efficacy of 1,3-diol Stereoisomers in Competing with 1,25-(OH)2-[26 ,27-3H]D3 for Binding to The Receptor Protein. Table (Ref. 0175)
lmax (nm) 273 (Ref. 0175)
1H-NMR (d, CDCl3) 0.57 (3H, s, 18-H3), 4.24 (1H, m, 3-H), 4.50 (1H, m, 1-H), 4.97 [1H, m, 19(Z)-H], 5.12 [1H, m, 19(E)-H], 5.89 (1H, d, J = 11.6 Hz, 7-H), 6.58 (1H, d, J = 11.6 Hz, 6-H) (Ref. 0175)
m/z 400 (M+, 15), 382 (5), 364 (1), 152 (40), 134 (100) (Ref. 0175)



From vitamin D3 via SeO2 oxidation of its 3,5-cyclovitamin D derivative as the key step. Cycloreversion followed by hydrolysis of 1a-hydroxylated cyclovitamin D gave (5Z)- and (5E)-1ahydroxyvitamin D3 in about 2 : 1 ratio. (Ref. 0175)



258
(5E)-1a-hydroxy-3-epivitamin D3 / (5E)-1a-hydroxy-3-epicholecalciferol
(5E,7E)-(1S,3S)-9,10-seco-5,7,10(19)-cholestatriene-1,3-diol
VVD0261
Sachiko Yamada
(5E)-1a-OH-3-epi-D3
C27H44O2 400.637 Download ChemDraw structure file
Relative Efficacy of 1,3-diol Stereoisomers in Competing with 1,25-(OH)2-[26 ,27-3H]D3 for Binding to The Receptor Protein. Table (Ref. 0175)
lmax (nm) 271 (Ref. 0175)
1H-NMR (d, CDCl3) 0.57 (3H, s, 18-H3), 4.13 (1H, m, 3-H), 4.38 (1H, m, 1-H), 4.96 [1H, m, 19(Z)-H], 5.12 [1H, m, 19(E)-H], 5.90 (1H, d, J = 11.4 Hz, 7-H), 6.64 (1H, d, J = 11.4 Hz, 6-H) (Ref. 0175)
m/z 400 (M+, 20), 382 (5), 364 (1), 152 (100), 134 (70) (Ref. 0175)



From 3-epivitamin D3 : SeO2 oxidation of its 3,5-cyclovitamin D derivative gave 1-oxo-derivative as a minor product which by LiAlH4 gave 1a-hydroxylated cyclovitamin D as the major product. Cycloreversion followed by hydrolysis gave (5Z)- and (5E)-isomers of 1a-hydroxy-3-epivitamin D3 in about 2 : 1 ratio. (Ref. 0175)



259
1b-hydroxyvitamin D3 / 1b-hydroxycholecalciferol
(5Z,7E)-(1R,3R)-9,10-seco-5,7,10(19)-cholestatriene-1,3-diol
VVD0262
Sachiko Yamada
1b-OHD3
C27H44O2 400.637 Download ChemDraw structure file
Binding affinity for intestinal vitamin D receptor was 1/1.65 times105 relative to 1,25-(OH)2D3. (Ref. 0176)
(EtOH) lmax (nm) (emax) 263 (17000) (Ref. 0176)
1H-NMR (d, CDCl3, 270MHz) 0.55 (3H, s, 13-Me), 0.87 (6H, d, 25-Me2), 4.11 (1H, narrow m, 3-H), 4.37 (1H, narrow m, 1-H), 5.01 [1H, d, J = 1.9 Hz, 19(Z)-H], 5.29 (1H, d, J = 1.9 Hz, 19(E)-H], 6.46 and 6.06 (2H, AB q, J = 11.7 Hz, 6- and 7-H) (Ref. 0176)
m/z 400 (M+, 18%), 382 (35%), 264 (25%), 152 (100%), 134 (90%) (Ref. 0176)



From 1a-hydroxyvitamin D3 : Selective oxidation of the 1-hydroxyl group yielded 1-oxoprevitamin D3 which by LiAlH4 reduction gave 1b-hydroxyvitamin D3 and its 1a-isomer in 4 : 1 ratio. (Ref. 0176/0178)



260
1b-hydroxy-3-epivitamin D3 / 1b-hydroxy-3-epicholecalciferol
(5Z,7E)-(1R,3S)-9,10-seco-5,7,10(19)-cholestatriene-1,3-diol
VVD0263
Sachiko Yamada
1b-OH-3-epi-D3
C27H44O2 400.637 Download ChemDraw structure file
Relative Efficacy of 1,3-diol Stereoisomers in Competing with 1,25-(OH)2-[26 ,27-3H]D3 for Binding to The Receptor Protein. : Table (Ref. 0175)
lmax (nm) 264 (Ref. 0175)
1H-NMR (d, CDCl3) 0.55 (3H, m, 18-H3), 4.21 (1H, m, 3-H), 4.44 (1H, m, 1-H), 5.01 [1H, m, 19(Z)-H], 5.32 [1H, m, 19(E)-H], 6.00 (1H, d, J = 11.4 Hz, 7-H), 6.39 (1H, d, J = 11.4 Hz, 6-H) (Ref. 0175)
m/z 400 (M+, 25), 382 (20), 364 (10), 152 (55), 134 (100) (Ref. 0175)



From 3-epivitamin D3 via SeO2 oxidation of its 3,5-cyclovitamin D derivative as the key step. (Ref. 0175)



261
(5E)-1b-hydroxyvitamin D3 / (5E)-1b-hydroxycholecalciferol
(5E,7E)-(1R,3R)-9,10-seco-5,7,10(19)-cholestatriene-1,3-diol
VVD0264
Sachiko Yamada
(5E)-1b-OHD3
C27H44O2 400.637 Download ChemDraw structure file
Relative Efficacy of 1,3-diol Stereoisomers in Competing with 1,25-(OH)2-[26 ,27-3H]D3 for Binding to The Receptor Protein. : Table (Ref. 0175)
lmax (nm) 271 (Ref. 0175)
1H-NMR (d, CDCl3) 0.57 (3H, s, 18-H3), 4.11 (1H, m, 3-H), 4.38 (1H, m, 1-H), 4.96 [1H, m, 19(Z)-H], 5.12 [1H, m, 19(E)-H], 5.90 (1H, d, J = 11.4 Hz, 7-H), 6.64 (1H, d, J = 11.4 Hz, 6-H) (Ref. 0175)
m/z 400 (M+, 15), 382 (5), 364 (2), 152 (100), 134 (80) (Ref. 0175)



From 3-epivitamin D3 : SeO2 oxidation of its 3,5-cyclovitamin D derivative gave 1-oxo-derivative as a minor product which by LiAlH4 gave 1b-hydroxylated cyclovitamin D as the major product. Cycloreversion followed by hydrolysis gave (5Z)- and (5E)-isomers of 1b-hydroxy-3-epivitamin D3 in about 2 : 1 ratio. (Ref. 0175)



262
(5E)-1b-hydroxy-3-epivitamin D3 / (5E)-1b-hydroxy-3-epicholecalciferol
(5E,7E)-(1R,3S)-9,10-seco-5,7,10(19)-cholestatriene-1,3-diol
VVD0265
Sachiko Yamada
(5E)-1b-OH-3-epi-D3
C27H44O2 400.637 Download ChemDraw structure file
Relative Efficacy of 1,3-diol Stereoisomers in Competing with 1,25-(OH)2-[26 ,27-3H]D3 for Binding to The Receptor Protein.(Ref. 0175)
lmax (nm) 273 (Ref. 0175)
1H-NMR (d, CDCl3) 0.57 (3H, m, 18-H3), 4.25 (1H, m, 3-H), 4.50 (1H, m, 1-H), 4.97 [1H, m, 19(Z)-H], 5.12 [1H, m, 19(E)-H], 5.88 (1H, d, J = 11.4 Hz, 7-H), 6.58 (1H, d, J = 11.4 Hz, 6-H) (Ref. 0175)
m/z 400 (M+, 10), 382 (6), 364 (1), 152 (35), 134 (100) (Ref. 0175)



From 3-epivitamin D3 via SeO2 oxidation of its 3,5-cyclovitamin D derivative as the key step. (Ref. 0175)



263
2a-hydroxyvitamin D3 / 2a-hydroxycholecalciferol
(5Z,7E)-(2R,3R)-9,10-seco-5,7,10(19)-cholestatriene-2,3-diol
VVD0266
Sachiko Yamada
2a-OHD3
C27H44O2 400.637 Download ChemDraw structure file










264
2b-hydroxyvitamin D3 / 2b-hydroxycholecalciferol
(5Z,7E)-(2S,3R)-9,10-seco-5,7,10(19)-cholestatriene-2,3-diol
VVD0267
Sachiko Yamada
2b-OHD3
C27H44O2 400.637 Download ChemDraw structure file










265
1a,25-dihydroxy-3-deoxyvitamin D3 / 1a,25-dihydroxy-3-deoxycholecalciferol
(5Z,7E)-(1S)-9,10-seco-5,7,10(19)-cholestatriene-1,25-diol
VVD0268
Sachiko Yamada
C27H44O2 400.637 Download ChemDraw structure file
Affinity for chick intestinal receptor : 1/8 as effective as 1,25-(OH)2D3. (Ref. 0310)





From 1a,25-dihydroxycholesterol via reductive deoxygenation of 3-tosyloxy group followed by conventional photochemical transformation. (Ref. 0310)



266
astrogorgiadiol B
(8S,9R)-9,10-seco-1,3,5(10)-cholestatriene-3,9-diol
VVD0269
Sachiko Yamada
astrogorgiadiol B
C27H44O2 400.637 Download ChemDraw structure file
Inhibit cell division in fertilized starfish eggs. (Ref. 0317)
[a]D -4.6 deg (c = 0.2 in CHCl3) (Ref. 0316)
1H-NMR (d, CDCl3, 400MHz) 0.69 (3H, s, 18-CH3), 0.86 (3H, d, J = 6.6 Hz, 26- or 27-CH3), 0.87 (3H, d, J = 6.6 Hz, 26- or 27-CH3), 0.92 (3H, d, J = 6.5 Hz, 21-CH3), 2.22 (3H, s, 19-CH3), 2.42 (1H, ddd, J = 13.5, 10.7, 3.4 Hz, 6-H), 2.69 (1H, ddd, J = 13.5, 11.1, 3.4 Hz, 6'-H), 4.05 (1H, bs, 9-H), 6.57 (1H, dd, J = 8.1, 2.7 Hz, 2-H), 6.65 (1H, d, J = 2.7 Hz, 4-H), 6.97 (1H, d, J = 8.1 Hz, 1-H) (Ref. 0316)
13C-NMR (d, CDCl3, 100MHz) 11.5, 18.4, 18.5, 22.5, 22.8, 23.8, 25.1, 27.6, 28.0, 29.0, 31.0, 35.6, 35.9, 38.3, 38.5, 39.4, 42.8, 50.4, 55.0, 55.2, 112.5, 115.7, 128.0, 131.0, 142.5, 153.7, 213.4 (Ref. 0316)
m/z 400 (M+), 382, 367 (Ref. 0316)


Isolated from a gorgonian of the genus Astrogorgia. (Ref. 0319)
By the coupling of upper-half fragment derived from Grundmann's ketone with lower-half fragment of benzyl iodide derivative. (Ref. 0316)



267
(22S)-22-hydroxyvitamin D3 / (22S)-22-hydroxycholecalciferol
(5Z,7E)-(3S,22S)-9,10-seco-5,7,10(19)-cholestatriene-3,22-diol
VVD0270
Sachiko Yamada
22S-OHD3
C27H44O2 400.637 Download ChemDraw structure file
Displayed no vitamin D agonist activity in the intestine or in bone in vivo and did not block the activity of D3 or 25-OHD3. Affinity for chick intestinal receptor : B-50 (molar concentration sufficient to displace 50% of specifically bound radiolabeled 1,25-(OH)2D3 from the chick intestinal receptor), > 1.19 times 10-4 M (B-50 value for 1,25-(OH)2D3 and 25-OHD3, 2.11 times 10-10 M and 1.4 times 10-7 M, respectively). (Ref. 0311)
(EtOH) lmax (nm) 265, lmin (nm) 227 (Ref. 0311)
1H-NMR (d, CDCl3) 3.67 (1H, m, 22-H), 4.04 (1H, m, 3a-H), 4.82 (1H, d, J = 2.24 Hz, 19-H), 5.06 (1H, d, J = 2.24 Hz, 19-H), 6.03 and 6.28 (each 1H, d, J = 11.2 Hz, 6- and 7-H) (Ref. 0311)
m/z 400 (M+, 43.44), 382 (M+-H2O, 12.56), 367 (M+-H2O-CH3, 42.64), 349 (M+-2H2O-CH3, 11.43), 271 (M+-side chain, 11.77), 254 (M+-side chain-H2O, 22.41), 136 (ring A plus C-6 and C-7, 98.56), 118 (136-H2O, 88.76) (Ref. 0311)



From 23,24-dinor-5-cholenoic acid via the Grignard reaction of the corresponding C-22 aldehyde with side chain fragment as key step. (Ref. 0311)



268
(24R)-24-hydroxyvitamin D3 / (24R)-24-hydroxycholecalciferol
(5Z,7E)-(3S,24R)-9,10-seco-5,7,10(19)-cholestatriene-3,24-diol
VVD0271
Sachiko Yamada
24R-OHD3
C27H44O2 400.637 Download ChemDraw structure file


m/z 400 (M+), 271, 253, 136, 118; spectrum(Ref. 0133)
Bis (trimethylsilyl) ether : m/z 544 (M+), 544, 501, 454, 208, 145, 118; spectrum(Ref. 0133)


Isolation and identification: From the blood plasma of chickens given large doses of vitamin D3. (Ref. 0133)
Synthesis of epimeric mixture at C(24) of 24,25-(OH)2D3 from 3b-acetoxy-27-nor-5-cholesten-25-one. (Ref. 0133)



269
(24S)-24-hydroxyvitamin D3 / (24S)-24-hydroxycholecalciferol
(5Z,7E)-(3S,24S)-9,10-seco-5,7,10(19)-cholestatriene-3,24-diol
VVD0272
Sachiko Yamada
24S-OHD3
C27H44O2 400.637 Download ChemDraw structure file










270
25-hydroxyvitamin D3 / 25-hydroxycholecalciferol / calcidiol
(5Z,7E)-(3S)-9,10-seco-5,7,10(19)-cholestatriene-3,25-diol
VVD0273
Sachiko Yamada
25-OHD3
C27H44O2 400.637 Download ChemDraw structure file
Activities of vitamin D3 in intestinal calcium transport and bone calcium mobilization were compared with those of 25-OHD3: Tables (Ref. 0014)
Antirachitic Activity (IU/mg)(the standard line test assay for vitamin D activity as described in The United States Pharmacopoeia): 25-OHD3 56 pm 6 ; vitamin D3, 40 pm 4. (Ref. 0019)
HL-60 human promyelocytes differentiation: ED50 in nitro blue tetrazplium reduction, phagocytic activity, and nonspecific acid esterase activity are 8.4 times 10-7 M, 8.0 times 10-7 M and 8.0 times 10-7 M, respectively, when 1,25-(OH)2D3 shows the respective ED50 values of 1.0 times 10-8 M, 1.0 times 10-8 M and 1.1 times 10-8 M, respectively. (Ref. 0228)
96-106 degC (Ref. 0262)
95-100 degC (Ref. 0298)
[a]d-25 +88.1 deg (c = 0.5 in EtOH) (Ref. 0262)
(EtOH) lmax (nm) (e) 265 (18000) (Ref. 0014)
lmax (nm) (e) 265 (17700) (Ref. 0298)
(KBr) 3500, 3360, 3080, 3030, 1650, 1635, 1050, 900, 880, 860, 765 cm-1 (Ref. 0298)
1H-NMR (d, CDCl3, 100MHz) 0.54 (3H, s), 0.90 (3H, d, J = 8 Hz), 1.22 (6H, s), 4.80 and 5.00 (each 1H, s), 5.97 and 6.25 (each 1H, d, J = 12 Hz) (Ref. 0014)
1H-NMR (d) 0.54 (3H, s, 18-CH3), 0.93 (3H, d, J = 5 cps, 21-CH3), 1.21 (6H, s, 26- and 27-CH3), 3.90 (1H, bm, 3-CH), 4.81 and 5.04 (2H, 2d, =CH2), 6.02 (1H, d, J = 12 cps, 7-CH), 6.21 (1H, d, J = 12 cps, 6-CH) (Ref. 0298)
m/z 400, 367, 341, 271, 253, 158, 136, 118; spectrum(Ref. 0014/0015)
X-ray crystal structure (Ref. 0274)
HPLC: (Ref. 0023)
Isolation and identification: from plasma of pigs (Ref. 0015/0021) ; from human plasma. (Ref. 0019)
Concentration in human plasma : 10-40 ng/ml (Ref. 0020)
Synthesis from 25-hydroxycholesterol acetate and 3b-acetoxy-27-nor-cholest-5-en-25-one by standard photochemical method via 5,7-cholestadiene-3b,25-diol. (Ref. 0014)
8b,25-Dihydroxy-3,5-cyclovitamin D derivative was synthesized in a convergent method from 25-hydroxylated Grundman's ketone and A-ring precursor and the title compound was prepared from the 3,5-cyclovitamin D by cycloreversion followed by photochemical isomerization. (Ref. 0262)
Biosynthesis: Hydroxylation of D3 by vitamin D 25-hydroxylase (CYP27) in the liver. (Ref. 0016/0017)
Further metabolism : 1a-Hydroxylation in the kidney to give 1a,25-(OH)2D3 under vitamin D deficient conditions. (Ref. 0017/0018/0022)
24-Hydroxylation to give 24R,25-(OH)2D3 in tissues possessing vitamin D receptor under vitamin D supplemented conditions. (Ref. 0017/0018)
26-Hydroxylation to give 25,26-(OH)2D3. (Ref. 0126)


271
25-hydroxy-14-epivitamin D3 / 25-hydroxy-14-epicholecalciferol
(5Z,7E)-(3S)-9,10-seco-5,7,10(19)-cholestatriene-3,25-diol
VVD0274
Sachiko Yamada
14-epi-25-OHD3
C27H44O2 400.637 Download ChemDraw structure file
Biological activity (% of 1,25-(OH)2D3 effect) : Affinity for chick intestinal receptor, 0.08% ; Affinity for human vitamin D binding protein, 3450% ; Intestinal calcium absorption in vitamin D-deficient chicks, < 0.1% ; Bone calcium mobilization in vitamin D-deficient chicks, < 1%. (Ref. 0314)
(95% EtOH) lmax (nm) (e) 264 (18100), lmin (nm) (emin) 230 (11000) (Ref. 0314)
1H-NMR (d, CDCl3, 300MHz) 0.88 (3H, d, J = 6.4 Hz, 21C-CH3), 0.92 (3H, s, 18C-CH3), 1.2 - 2.6 (remaining ring and side chain hydrogens, series of m), 1.22 (6H, s, 26, 27C-CH3), 3.91 (1H, m, 3H), 4.84 (1H, narrow m, 19H), 5.08 (1H, narrow m, 19H), 6.17 (2H, s, 6, 7H-AB pattern) (Ref. 0314)
m/z 400 (13, M+), 382 (17, M+-18), 367 (41), 349 (11), 323 (3), 309 (4), 293 (3), 271 (22), 253 (21), 227 (7), 199 (13), 176 (24), 158 (59), 136 (95, A-ring fragment due to C7,8 cleavage), 118 (base, 152-H2O), 95 (22), 81 (24), 69 (21), 59 (11) (Ref. 0314)



By Wittig-Horner coupling of des-AB 14-epivitamin D 8-ketone with A-ring phosphine oxide. The desired 14-epi-CD ketone was obtained from vitamin D3 by ozonolysis followed by oxidation at C-25 and epimerization at C-14. (Ref. 0314)



272
(6R)-6,19-epidioxy-6,19-dihydrovitamin D3 / (6R)-6,19-epidioxy-6,19-dihydrocholecalciferol
(7E)-(3S,6R)-6,19-epidioxy-9,10-seco-5(10),7-cholestadien-3-ol
VVD0275
Sachiko Yamada
C27H44O3 416.636 Download ChemDraw structure file
Activities in stimulating intestinal calcium transport and in increasing serum calcium and inorganic phosphorus were evaluated compared with vitamin D3. : Insert Table 1 (Ref. 0336)
1H-NMR (d, CDCl3) 0.56 (3H, s, 18-H), 4.07 (1H, m, 3-H), 4.88 (d, J = 10 Hz, 6-H), 5.17 (d, J = 10 Hz, 7-H), 4.36 (br s, 19-H) (Ref. 0335)
13C-NMR (d, CDCl3) 125.7 (s, C-5), 125.7 (s, C-10), 115.6 (d, C-7), 148.1 (s, C-8), 65.9 (d, C-3), 76.9 (d, C-6), 72.2 (t, C-19) (Ref. 0335)
m/z 416 (M+), 398, 285 (Ref. 0335)
CD : 207 nm (e -23.3) (in Hexane) (Ref. 0335)


As a major product by the reaction of vitamin D3 with singlet oxygen generated by dye-sensitized photochemical method. (Ref. 0335)



273
(6S)-6,19-epidioxy-6,19-dihydrovitamin D3 / (6S)-6,19-epidioxy-6,19-dihydrocholecalciferol
(7E)-(3S,6S)-6,19-epidioxy-9,10-seco-5(10),7-cholestadien-3-ol
VVD0276
Sachiko Yamada
C27H44O3 416.636 Download ChemDraw structure file
Activities in stimulating intestinal calcium transport and in increasing serum calcium and inorganic phosphorus were evaluated compared with vitamin D3. : Insert Table 1 (Ref. 0336)
1H-NMR (d, CDCl3) 4.76 (d, J = 9 Hz, 6-H), 5.23 (d, J = 9 Hz, 7-H), 4.17 and 4.60 (each d, J = 16 Hz, 19-H) (Ref. 0335)
13C-NMR (d, CDCl3) 126.8 (s, C-5), 125.7 (s, C-10), 114.5 (d, C-7), 149.2 (s, C-8), 67.2 (d, C-3), 76.8 (d, C-6), 72.0 (t, C-19) (Ref. 0335)
m/z 416 (M+), 398, 285 (Ref. 0335)
CD : 215 nm (e +6.5) (in Hexane) (Ref. 0335)


As a major product by the reaction of vitamin D3 with singlet oxygen generated by dye-sensitized photochemical method. (Ref. 0335)



274
(6R)-vitamin D3 6,19-sulfur dioxide adduct / (6R)-cholecalciferol 6,19-sulfur dioxide adduct
(7E)-(3S,6R)-6,19-epithio-9,10-seco-5(10),7-cholestadien-3-ol S,S-dioxide
VVD0277
Sachiko Yamada
6R-D3 6,19-sulfur dioxide adduct
C27H44O3S 448.702 Download ChemDraw structure file

(CHCl3) 1310, 1148 cm-1 (Ref. 0331)
1H-NMR (d, CDCl3) 0.55 (s, 18-H), 3.30 (br s, 19-H), 4.52 (d, J = 9.0 Hz, 6-H), 4.78 (d, J = 9.0 Hz, 7-H) (Ref. 0331)
13C-NMR (d, CDCl3) 65.90 (d, C-3), 130.63 (s, C-5), 67.29 (d, C-6), 109.84 (d, C-7), 150.84 (s, C-8), 126.62 (s, C-10), 58.00 (t, C-19) (Ref. 0331)
m/z 384 (M+-SO2) (Ref. 0331)



From vitamin D3 by treatment with liquid sulfur dioxide. (Ref. 0331)



275
(6S)-vitamin D3 6,19-sulfur dioxide adduct / (6S)-cholecalciferol 6,19-sulfur dioxide adduct
(7E)-(3S,6S)-6,19-epithio-9,10-seco-5(10),7-cholestadien-3-ol S,S-dioxide
VVD0278
Sachiko Yamada
6S-D3 6,19-sulfur dioxide adduct
C27H44O3S 448.702 Download ChemDraw structure file

(CHCl3) 1308, 1150 cm-1 (Ref. 0331)
1H-NMR (d, CDCl3) 0.70 (s, 18-H), 3.28 (br s, 19-H), 4.49 (d, J = 9.0 Hz, 6-H), 4.78 (d, J = 9.0 Hz, 7-H) (Ref. 0331)
13C-NMR (d, CDCl3) 65.42 (d, C-3), 130.14 (s, C-5), 66.97 (d, C-6), 109.50 (d, C-7), 150.38 (s, C-8), 126.82 (s, C-10), 58.13 (t, C-19) (Ref. 0331)
m/z 384 (M+-SO2) (Ref. 0331)



From vitamin D3 by treatment with liquid sulfur dioxide. (Ref. 0331)



276
(7E)-(3S,6R)-6-hydroperoxy-9,10-seco-4,7,10(19)-cholestatrien-3-ol
VVD0279
Sachiko Yamada
C27H44O3 416.636 Download ChemDraw structure file

(CHCl3) 3350, 2950 cm-1 (Ref. 0335)
1H-NMR (d, CDCl3) 0.52 (s, 18-H), 4.96 (br s, 19-H), 5.13 (br s, 19-H), 5.00 and 5.54 (each d, J = 9 Hz, 6- and 7-H), 6.02 (m, 4-H) (Ref. 0335)
m/z 416.400 (M+), 398.382 (Ref. 0335)



As a minor product by the reaction of vitamin D3 with singlet oxygen generated by dye-sensitized photochemical method. (Ref. 0335)



277
(7E)-(3S,6S)-6-hydroperoxy-9,10-seco-4,7,10(19)-cholestatrien-3-ol
VVD0280
Sachiko Yamada
C27H44O3 416.636 Download ChemDraw structure file

(95% EtOH ) lmax (nm) 232.5 (Ref. 0335)
(CHCl3) 3350, 2950 cm-1 (Ref. 0335)
1H-NMR (d, CDCl3) 0.60 (s, 18-H), 4.96 (br s, 19-H), 5.12 (br s, 19-H), 5.00 and 5.53 (each d, J = 9 Hz, 6- and 7-H), 6.04 (m, 4-H) (Ref. 0335)
m/z 416.400 (M+), 398.382 (Ref. 0335)



As a minor product by the reaction of vitamin D3 with singlet oxygen generated by dye-sensitized photochemical method. (Ref. 0335)



278
1a,18-dihydroxyvitamin D3 / 1a,18-dihydroxycholecalciferol
(5Z,7E)-(1S,3R)-9,10-seco-5,7,10(19)-cholestatriene-1,3,18-triol
VVD0281
Sachiko Yamada
1a,18-(OH)2D3
C27H44O3 416.636 Download ChemDraw structure file










279
22-ethyl-1a,22-dihydroxy-25,26,27-trinorvitamin D3 / 22-ethyl-1a,22-dihydroxy-25,26,27-trinorcholecalciferol
(5Z,7E)-(1S,3R)-22-ethyl-9,10-seco-5,7,10(19)-cholatriene-1,3,22-triol
VVD0282
Sachiko Yamada
1a,22-(OH)2-26,27-dimethyl-23,24-dinor-D3
C27H44O3 416.636 Download ChemDraw structure file
HL-60 human promyelocytes differentiation : ED50 in nitro blue tetrazplium reduction, phagocytic activity, and nonspecific acid esterase activity are all > 10-6 M, when 1,25-(OH)2D3 shows the respective ED50 values of 1.0 times 10-8 M, 1.0 times 10-8 M and 1.1 times 10-8 M, respectively. (Ref. 0228)









280
(24R)-1a,24-dihydroxyvitamin D3 / (24R)-1a,24-dihydroxycholecalciferol
(5Z,7E)-(1S,3R,24R)-9,10-seco-5,7,10(19)-cholestatriene-1,3,24-triol
VVD0283
Sachiko Yamada
1a,24R-(OH)2D3
C27H44O3 416.636 Download ChemDraw structure file
HL-60 human promyelocytes differentiation : ED50 in nitro blue tetrazplium reduction, phagocytic activity, and nonspecific acid esterase activity are 8.0 times 10-9 M, 7.0 times 10-9 M and 1.2 times 10-8 M, respectively, when 1,25-(OH)2D3 shows the respective ED50 values of 1.0 times 10-8 M, 1.0 times 10-8 M and 1.1 times 10-8 M, respectively. (Ref. 0228)
Affinity for the chick intestinal receptor : nearly as active as 1,25-(OH)2D3. (Ref. 0241)
Mixture of 24R and 24S epimers : 84-85 degC (Ref. 0075)
Mixture of 24R and 24S epimers : lmax (nm) (emax) 266 (17000) (Ref. 0075)
Mixture of 24R and 24S epimers : 1H-NMR (d, (CD3)2CO) 0.57 (3H, s, 13-Me), 0.87 (6H, d, J = 7 Hz, 25-Me2), 0.96 (3H, d, J = 5 Hz, 20-Me), 3.19 (1H, m, 24-H), 4.15 (1H, m, 1b-H), 4.36 (1H, m, 3a-H), 4.85 and 5.30 (each 1H, br s, 19-H), 6.05 and 6.26 (each 1H, d, JAB = 11 Hz, 6- and 7-H) (Ref. 0075)
Mixture of 24R and 24S epimers : m/z 416 (M+), 398 (M+-H2O), 380 (M+-2H2O), 269, 251, 134, 105 (Ref. 0075)



A mixture of epimers at C(24) was synthesized from 24-oxocholesterol via steps of Barton's 1a-hydroxylation, introduction of 5,7-diene structure, and photochemical followed by thermal isomerization. (Ref. 0075)



281
(24S)-1a,24-dihydroxyvitamin D3 / (24S)-1a,24-dihydroxycholecalciferol
(5Z,7E)-(1S,3R,24S)-9,10-seco-5,7,10(19)-cholestatriene-1,3,24-triol
VVD0284
Sachiko Yamada
1a,24S-(OH)2D3
C27H44O3 416.636 Download ChemDraw structure file
HL-60 human promyelocytes differentiation : ED50 in nitro blue tetrazplium reduction, phagocytic activity, and nonspecific acid esterase activity are 3.0 times 10-8 M, 2.7 times 10-8 M and 1.7 times 10-8 M, respectively, when 1,25-(OH)2D3 shows the respective ED50 values of 1.0 times 10-8 M, 1.0 times 10-8 M and 1.1 times 10-8 M, respectively. (Ref. 0228)
Affinity for the chick intestinal receptor : 1/10 as active as 1,25-(OH)2D3. (Ref. 0241)
Mixture of 24R and 24S epimers : 84-85 degC (Ref. 0075)
Mixture of 24R and 24S epimers : lmax (nm) (emax) 266 (17000) (Ref. 0075)
Mixture of 24R and 24S epimers : 1H-NMR (d, (CD3)2CO) 0.57 (3H, s, 13-Me), 0.87 (6H, d, J = 7 Hz, 25-Me2), 0.96 (3H, d, J = 5 Hz, 20-Me), 3.19 (1H, m, 24-H), 4.15 (1H, m, 1b-H), 4.36 (1H, m, 3a-H), 4.85 and 5.30 (each 1H, br s, 19-H), 6.05 and 6.26 (each 1H, d, JAB = 11 Hz, 6- and 7-H) (Ref. 0075)
Mixture of 24R and 24S epimers : m/z 416 (M+), 398 (M+-H2O), 380 (M+-2H2O), 269, 251, 134, 105 (Ref. 0075)



A mixture of epimers at C(24) was synthesized from 24-oxocholesterol via steps of Barton's 1a-hydroxylation, introduction of 5,7-diene structure, and photochemical followed by thermal isomerization. (Ref. 0075)



282
1a,25-dihydroxyvitamin D3 / 1a,25-dihydroxycholecalciferol / calcitriol
(5Z,7E)-(1S,3R)-9,10-seco-5,7,10(19)-cholestatriene-1,3,25-triol
VVD0285
Sachiko Yamada
1a,25-(OH)2D3
C27H44O3 416.636 Download ChemDraw structure file
Mechanism of action of 1,25-(OH)2D3: (Ref. 0027/0028)
Clinical use: (Ref. 0058/0059)
Cell differentiation: Table (Ref. 0060)
Relative effects of 1a,25-(OH)2D3 and its A-ring diastereomers on components of the vitamin D endocrine system:Table (Ref. 0183)
Dissociation constant (Kd) for vitamin D receptor (VDR): 8.2 pm10 -11 (Ref. 0235); Kd, Mammalian VDR: 10-11 - 10-10M : (Ref. 0184)<
106-112 degC (Ref. 0024)
[a]D +29 deg (in Et2O) (Ref. 0024)
(Et2O) lmax (nm) (e) 264 (18000), lmin (nm) (e) 228.5 (10100) (Ref. 0024)
1H-NMR (d, CDCl3, 500MHz) 0.54 (3H, s, 18-CH3), 0.94 (3H, d, J = 6.2 Hz, 21-CH3), 1.20 (6H, s, 26-, 27-CH3), 2.32 (1H, dd, J = 13.6 and 6.7 Hz, 4b-H), 2.59 (1H, dd, J = 13.5 and 3.4 Hz, 4a-H), 2.83 (1H, dd, J = 11.8 and 3.7 Hz, 9b-H), 4.23 (1H, tt, J = 6.5 and 3.5 Hz, 3a-H), 4.43 (1H, dd, J = 7.5 and 4.0 Hz, 1b-H), 5.00 (1H, br s, 19-H), 5.33 (1H, br t, J = 1.4 Hz, 19-H), 6.02 (1H, d, J = 11.3 Hz, 7-H), 6.38 (1H, d, J = 11.3 Hz, 6-H) (Ref. 0025)
13C-NMR (d, CD3OD-CFCl3, 67.5MHz) spectrum (Ref. 0025)
m/z 416 (M+), 287, 269, 251, 152, 134 (Ref. 0026)
X-ray crystal structure: (Ref. 0186)

Isolation and identification: from chicken intestine (Ref. 0026/0027); from chick kidney homogenates incubated with 25-OHD3. (Ref. 0028); from plants such as Solanum malacoxylon. (Ref. 0063)
Concentration in human plasma: 20-65 pg/ml (Ref. 0029)

From 25-hydroxycholesterol: Dehydration, epoxidation, and reductive deconjugation of the resulting 1,2-epoxy-4,6-dien-3-one gave the key intermediate, 1a,25-dihydroxycholesterol, which was converted to 1a,25-(OH)2D3 by standard procedures of dehydration to the provitamin D, uv irradiation, and thermal isomerization. (Ref. 0024)
From 6-methoxy-3,5-cyclo-24-homocholanic acid via 1a,3b,25-triacetoxy cholestan-6-one as a key intermediate. (Ref. 0035)
From 25-OHD3 via 3,5-cyclovitamin D derivative by SeO2 oxidation as a key step. (Ref. 0062)
Total chiral synthesis from d-carvone as an A-ring precursor and tetrahydroindan-5-one derivative as a CD-ring precursor. (Ref. 0357)
Biosynthesis: Hydroxylation of 25-OHD3 by 1a-hydroxylase, a cytochrome P450 (CYP24B1) (Ref. 0030/0031) located in the kidney (Ref. 0017/0018/0022) .
Further metabolism (catabolism), 24-Hydroxylation pathway: 24-Hydroxylation by vitamin D-24-hydroxylase (CTP24) (Ref. 0031/0033) to give 1,24R,25-(OH)3D3 (Ref. 0065/0034/0066) which is further oxidized by the same enzyme to 1-OH-tetranor-D3 23-carboxylic acid (calcitroic acid) (Ref. 0070/0073) via 1,25-(OH)2-24-oxo-D3 (Ref. 0068/0067) , 1,23,25-(OH)3D3-24-oxo-D3 (Ref. 0067) and 1,23-(OH)2-tetranor-D3 (Ref. 0069) . 23-Hydroxylation pathway: 1,25-(OH)2D3 is also metabolized to 1,25R-(OH)2D3 26,23S-lactone (Ref. 0077) via 1,23S,25-(OH)3D3 (Ref. 0076) , 1,23,25,26-(OH)4D3 (Ref. 0084) , and 1,25R-(OH)2D3 26,23S-lactol (Ref. 0084). 26-Hydroxylation pathway: Kidney homogenates from vitamin D-supplemented chicks convert 1,25-(OH)2D3 to 1,25.26-(OH)3D3. (Ref. 0087)
Vitamin D receptor (VDR), Avian receptor: (Ref. 0037/0038/0039) ; Human receptor: (Ref. 0040) ; Rat receptor: (Ref. 0041/0042); Mouse receptor : (Ref. 0043) .
VDR knock out mice: (Ref. 0057) .
Dissociation constant (Kd, Mammalian) : 10-11 - 10-10M: (Ref. 0184)
Relationship between vitamin D receptor alleles and born density: (Ref. 0185)
Vitamin D responsive elements (VDRE) sequences
1) Calcium binding protein (CaBP) 9K : GGGTGT CGG AAGCCC (Ref. 0044)
2) Rat osteocalcin : GGGTGA ATG AGGACA (Ref. 0045)
3) Human osteocalcin : GGGTGA ACG GGGGCA (Ref. 0046/0047)
4) Mouse osteopontin : GGTTCA CGA GGTTCA (Ref. 0048)
5) Rat 24-hydroxylase,distal : GGTTCA GCG GGTGCG (Ref. 0049)
6) Human 24-hydroxylase,distal : AGTTCA CCG GGTGTG (Ref. 0050)
7) Rat 24-hydroxylase,proximal : GAGTCA GCG AGGTGA GTG AGGGCG (Ref. 0051)
8) Human 24-hydroxylase,proximal : GAGTCA GCG AGGTGA GCG AGGGCG (Ref. 0050)
9) Human PTH : GGTTCA AAG CAGACA (Ref. 0052)
10) Mouse calbindin D28K : AGGTGA TGA AAGTCA (Ref. 0053)
11) Chicken carbonic anhydrase-II : GGGGGA AAA AGTCCA (Ref. 0054)
12) Human calbindin D9K : TGCCCTTCCTTATGGGGTTCA (Ref. 0055)
13) Mouse calbindin D28K : CTGGGGGATGTGAGGAGAAATGAGTCTGAGC (Ref. 0056)

283
1a,25-dihydroxy-3-epivitamin D3 / 1a,25-dihydroxy-3-epicholecalciferol
(5Z,7E)-(1S,3S)-9,10-seco-5,7,10(19)-cholestatriene-1,3,25-triol
VVD0286
Sachiko Yamada
3-epi-1a,25-(OH)2D3
C27H44O3 416.636 Download ChemDraw structure file
Affinity to chick intestinal vitamin D receptor : 1/4 as active as 1,25-(OH)2D3. (Ref. 0182)
Relative effect of 1a,25-(OH)2D3 and its A-ring diastereomers upon components of the vitamin D endocrine system.: Table (Ref. 0183)
(95% EtOH) lmax (nm) (emax) 264 (16900) (Ref. 0182)
1H-NMR (d, CDCl3, 300MHz) 0.54 (3H, s, 18C-CH3), 0.93 (3H, d, J = sim6.2 Hz, 21C-CH3), 1.21 (6H, s, 26, 27C-2CH3), 2.43 (1H, dd, J = sim13.5, 5.5 Hz, 4b-H), 2.56 (1H, dd, J = sim13.5, 2.9, 4a-H), 2.83 (1H, dd, J = sim11.8, 3.0 Hz, 9b-H), 4.0-4.1 (1H, m, 3-H), 4.25-4.35 (1H, m, 1-H), 5.0 (1H, narrow m, 19-H), 5.29 (1H, narrow m, 19-H), 6.02 and 6.43 (2H, AB pattern, J = sim11.3 Hz, 6-,7-H) (Ref. 0182)
13C-NMR (d, CDCl3, 75.5MHz) 12.0, 18.8, 20.8, 22.2, 23.5, 27.7, 29.1, 29.2, 29.4, 36.1, 36.4, 40.5, 40.7, 44.4, 45.5, 45.9, 56.3, 56.5, 68.2, 71.1, 73.2, 112.9, 117.0, 125.6, 131.6, 143.2, 147.2 (Ref. 0182)
m/z 416 (M+, 19), 398 (M+-H2O, 28), 380 (M+-2H2O, 10), 330 (3), 285 (12), 251 (7), 227 (6), 152 (base, A-ring portion due to C7,8-cleavage), 134 (152-H2O, 73), 107 (26), 95 (26), 81 (27), 55 (30) (Ref. 0182)



From 1b,25-dihydroxy-3-epivitamin D3 by following transformations : oxidation with Des-Martin reagent, reduction (NaBH4), and thermal isomerization. (Ref. 0182)



284
1a,25-dihydroxy-14-epivitamin D3 / 1a,25-dihydroxy-14-epicholecalciferol
(5Z,7E)-(1S,3R,14R)-9,10-seco-5,7,10(19)-cholestatriene-1,3,25-triol
VVD0287
Sachiko Yamada
14-epi-1a,25-(OH)2D3
C27H44O3 416.636 Download ChemDraw structure file
Biological activity (% of 1,25-(OH)2D3 effect) : Affinity for chick intestinal receptor, 15% ; Affinity for human vitamin D binding protein, 12% ; Intestinal calcium absorption in vitamin D-deficient chicks, 3.9% ; Bone calcium mobilization in vitamin D-deficient chicks. (Ref. 0314)
(95% EtOH) lmax (nm) (emax) 266 (17700), lmin (nm) (emin) 230 (10400) (Ref. 0314)
1H-NMR (d, CDCl3, 300MHz) 0.87 (3H, d, J = 6.4 Hz, 21C-CH3), 0.90 (3H, s, 18C-CH3), 1.22 (6H, s, 26,27C-CH3), 1.0-2.3 (remaining ring and side chain hydrogens, series of m), 2.31 (1H, dd, J = 13.2 and 7.2 Hz), 2.46 (1H, br d, J = 14.3 Hz), 2.60 (1H, dd, J = 13.3 and 3.5 Hz), 4.23 (1H, m, 3-H), 4.44 (1H, t, J = 5.4 Hz, 1-H), 5.00 (1H, br s, 19-H), 5.34 (1H, br s, 19-H), 6.14 and 6.33 (2H, d, J = 11.2 Hz, 6-, 7-H-AB pattern) (Ref. 0314)
m/z 416 (11, M+), 398 (31, M+-H2O), 380 (36, M+-2H2O), 365 (9), 347 (5), 329 (3), 310 (2), 285 (11), 269 (9), 251 (16), 227 (8), 197 (14), 174 (17), 152 (34, A-ring fragment due to C7,8-cleavage), 134 (base, 152-H2O), 109 (19), 95 (24), 81 (22), 69 (25), 59 (15) (Ref. 0314)



By Wittig-Horner coupling of des-AB 14-epivitamin D 8-ketone with A-ring phosphine oxide. The desired 14-epi-CD ketone was obtained from vitamin D3 by ozonolysis followed by oxidation at C-25 and epimerization at C-14. (Ref. 0314)



285
1a,25-dihydroxy-14-epiprevitamin D3 / 1a,25-dihydroxy-14-epiprecholecalciferol
(6Z)-(1S,3R,14R)-9,10-seco-5(10),6,8-cholestatriene-1,3,25-triol
VVD0288
Sachiko Yamada
14-epipre-1a,25-(OH)2D3
C27H44O3 416.636 Download ChemDraw structure file










286
1a,25-dihydroxy-20-epivitamin D3 / 1a,25-dihydroxy-20-epicholecalciferol
(5Z,7E)-(1S,3R,20S)-9,10-seco-5,7,10(19)-cholestatriene-1,3,25-triol
VVD0289
Sachiko Yamada
1a,25-(OH)2-20-epi-D3
C27H44O3 416.636 Download ChemDraw structure file
Biological activity (% of 1,25-(OH)2D3 effect) Inhibition of U 937 cell (human histiocytic lymphoma cell line) proliferation : 5000 (IC50 : the title compound, 2.8 times 10-10 M ; 1,25-(OH)2D3, 1.4 times 10-8 M) ; Induction of U 937 cell differentiation : 2666 ; Binding to the 1,25-(OH)2D3 receptor from rachitic chicken intestine : 120 ; Calcemic activity determined by the increase in urinary calcium excretion in rats : 230. Inhibitory effects on murine thymocyte activation : 730800 (IC50 : the title compound, 2.6 times 10-14 M ; 1,25-(OH)2D3, 1.9 times 10-10 M). (Ref. 0278)






In vitro metabolism in human HPK1A-ras. cells was studied. 20-Epi-1,25-(OH)2D3 was found to be metabolized 36 times slowly than the natural hormone, 1,25-(OH)2D3 forming several metabolites which were analogous to metabolites of 1,25-(OH)2D3 formed in the side chain oxidation pathway. (Ref. 0324)


287
1a,25-dihydroxy-24a-homo-22-thiavitamin D3 / 1a,25-dihydroxy-24a-homo-22-thiacholecalciferol
(5Z,7E)-(1S,3R)-24a-homo-9,10-seco-22-thia-5,7,10(19)-cholestatriene-1,3,25-triol
VVD0290
Sachiko Yamada
22-thia-24a-homo-1a,25-(OH)2D3
C27H44O3S 448.702 Download ChemDraw structure file






Synthesis from dehydroepiandrostertone via the 5,7-diene by photochemical method. (Ref. 0215)



288
1a,25-dihydroxy-24a-homo-22-thia-20-epivitamin D3 / 1a,25-dihydroxy-24a-homo-22-thia-20-epicholecalciferol
(5Z,7E)-(1S,3R,20R)-24a-homo-9,10-seco-22-thia-5,7,10(19)-cholestatriene-1,3,25-triol
VVD0291
Sachiko Yamada
20-epi-22-thia-24a-homo-1a,25-(OH)2D3
C27H44O3S 448.702 Download ChemDraw structure file






Synthesis from dehydroepiandrostertone via the 5,7-diene by photochemical method. (Ref. 0215)



289
(5E)-1a,25-dihydroxyvitamin D3 / (5E)-1a,25-dihydroxycholecalciferol
(5E,7E)-(1S,3R)-9,10-seco-5,7,10(19)-cholestatriene-1,3,25-triol
VVD0292
Sachiko Yamada
(5E)-1a,25-(OH)2D3
C27H44O3 416.636 Download ChemDraw structure file
The title compound was approximately 1/16 and 1/64 as active as 1,25-(OH)2D3 in intestinal calcium transport and bone calcium mobilization, respectively. The affinity for intestinal vitamin D receptor was 13% of that of 1,25-(OH)2D3. (Ref. 0221)









290
1b,25-dihydroxyvitamin D3 / 1b,25-dihydroxycholecalciferol
(5Z,7E)-(1R,3R)-9,10-seco-5,7,10(19)-cholestatriene-1,3,25-triol
VVD0293
Sachiko Yamada
1b,25-(OH)2D3
C27H44O3 416.636 Download ChemDraw structure file
Binding affinity for intestinal vitamin D receptor was 1/3000 relative to 1,25-(OH)2D3. (Ref. 0176)
Relative effect of 1a,25-(OH)2D3 and its A-ring diastereomers upon components of the vitamin D endocrine system. (Ref. 0183)
lmax (nm) 263 (Ref. 0176)
1H-NMR (d, CDCl 3) 0.55 and 1.22 (s, 13-Me, 25-Me2), 4.11 (m, 3-H), 4.37 (m, 1-H), 5.01 [d, J = 1.9 Hz, 19(Z)-H], 5.29 (d, J = 1.9 Hz, 19(E)-H], 6.43 and 6.06 (AB q, J = 11.8 Hz, 6- and 7-H) (Ref. 0176)
m/z 416 (M+, 10%), 152 (100%), 134 (95%), 59 (85%) (Ref. 0176)



From 1a,25-dihydroxyvitamin D3 : Selective oxidation of the 1-hydroxyl group yielded 25-hydroxy-1-oxoprevitamin D3 which by LiAlH4 reduction gave 1b,25-dihydroxyvitamin D3 and its 1a-isomer in 3 : 1 ratio. (Ref. 0176)



291
1b,25-dihydroxy-3-epivitamin D3 / 1b,25-dihydroxy-3-epicholecalciferol
(5Z,7E)-(1R,3S)-9,10-seco-5,7,10(19)-cholestatriene-1,3,25-triol
VVD0294
Sachiko Yamada
3-epi-1b,25-(OH)2D3
C27H44O3 416.636 Download ChemDraw structure file
Affinity to chick intestinal vitamin D receptor : 1/500 as active as 1,25-(OH)2D3. (Ref. 0182)
Relative effect of 1a,25-(OH)2D3 and its A-ring diastereomers upon components of the vitamin D endocrine system.: Table (Ref. 0183)
(95% EtOH) lmax (nm) (emax) 264 (17000) (Ref. 0182)
1H-NMR (d, CDCl3, 300MHz) 0.54 (3H, s, 18C-CH3), 0.93 (3H, d, J = sim6.0 Hz, 21C-CH3), 1.21 (6H, s, 26, 27C-2CH3), 2.30 (1H, dd, J = sim13.0, 7.5 Hz, 4b-H), 2.62 (1H, dd, J = sim13.0, 3.7, 4a-H), 2.82 (1H, dd, J = sim11.8, 3.0 Hz, 9b-H), 4.15-4.30 (1H, m, 3-H), 4.40-4.50 (1H, m, 1-H), 5.0 (1H, narrow m, 19-H), 5.32 (1H, narrow m, 19-H), 6.01 and 6.39 (2H, AB pattern, J = sim11.4 Hz, 6-,7-H) (Ref. 0182)
13C-NMR (d, CDCl3, 75.5MHz) 12.0, 18.8, 20.8, 22.3, 23.6, 27.6, 29.1, 29.2, 29.4, 29.7, 36.1, 36.4, 40.5, 42.8, 44.4, 45.5, 45.9, 56.3, 56.5, 66.8, 71.4, 112.6, 117.0, 125.0, 132.7, 143.3, 147.3 (Ref. 0182)
m/z 416 (M+, 21), 398 (M+-H2O, 72), 380 (M+-2H2O, 36), 362 (3), 329 (3), 285 (11), 251 (10), 227 (9), 197 (8), 152 (A-ring portion after C7,8-cleavage, 29), 134 (152-H2O, base) (Ref. 0182)



Ethynylated chiral A-ring synthon derived from (R)-carvone was combined with upper half synthon (CD-ring plus side chain), the triple bond was partially reduced, and the resulting previtamin D was isomerized thermally. (Ref. 0182)



292
18,25-dihydroxyvitamin D3 / 18,25-dihydroxycholecalciferol
(5Z,7E)-(3S)-9,10-seco-5,7,10(19)-cholestatriene-3,18,25-triol
VVD0295
Sachiko Yamada
18,25-(OH)2D3
C27H44O3 416.636 Download ChemDraw structure file






By Wittig-Horner coupling of 18,25-dihydroxylated des-AB vitamin D 8-ketone with A-ring phosphine oxide. Functionalization of C-18 methyl was achieved by treatment of 8-hydroxy-des AB vitamin D with lead tetraacetate yielding the corresponding 8,18-cyclic ether (62% yield). (Ref. 0313)



293
(22R)-22,25-dihydroxyvitamin D3 / (22R)-22,25-dihydroxycholecalciferol
(5Z,7E)-(3S,22R)-9,10-seco-5,7,10(19)-cholestatriene-3,22,25-triol
VVD0296
Sachiko Yamada
22R,25-(OH)2D3
C27H44O3 416.636 Download ChemDraw structure file

(EtOH) lmax (nm) 263, lmin (nm) 228 (Ref. 0163)

m/z 416 (M+), 398 (M+-H2O), 383 (M+-Me-H2O), 365 (M+-Me-H2O), 357 (C24-C25 cleavage), 311 (C22-C23 cleavage-H2O), 300 (C20-C22 cleavage), 269, 267, 253, 251, 118 (Ref. 0163)







294
(22S)-22,25-dihydroxyvitamin D3 / (22S)-22,25-dihydroxycholecalciferol
(5Z,7E)-(3S,22S)-9,10-seco-5,7,10(19)-cholestatriene-3,22,25-triol
VVD0297
Sachiko Yamada
22S,25-(OH)2D3
C27H44O3 416.636 Download ChemDraw structure file

(EtOH) lmax (nm) 263, lmin (nm) 228 (Ref. 0163)

m/z 416 (M+), 398 (M+-H2O), 383 (M+-Me-H2O), 365 (M+-Me-H2O), 357 (C24-C25 cleavage), 311 (C22-C23 cleavage-H2O), 300 (C20-C22 cleavage), 269, 267, 253, 251, 118 (Ref. 0163)







295
(23R)-23,25-dihydroxyvitamin D3 / (23R)-23,25-dihydroxycholecalciferol
(5Z,7E)-(3S,23R)-9,10-seco-5,7,10(19)-cholestatriene-3,23,25-triol
VVD0298
Sachiko Yamada
23R,25-(OH)2D3
C27H44O3 416.636 Download ChemDraw structure file

lmax (nm) 265, lmin (nm) 228 (Ref. 0107)
1H-NMR (d, CDCl3) 6.23 (1H, d, J = 11 Hz, C-6), 6.03 (1H, d, J = 11 Hz, C-7), 5.05 (1H, m, C-19E), 4.81 (1H, m, C-19Z), 4.13 (1H, m, C-23), 3.94 (1H, m, C-3), 1.33 (3H, s, C-26), 1.26 (3H, s, C-27), 1.00 (3H, d, J = 7 Hz, C-21), 0.58 (3H, s, C-18) (Ref. 0107)
m/z 416.3319 (calcd, 416.3290 ) (27, M+), 398 (2.5, M+-H2O), 383 (13, M+-H2O-CH3), 271 (8.5, M+-side chain), 253 (9.7, M+-side chain-H2O), 136 (100, A ring+C6+C7+), 118 (96, 136-H2O); spectrum (Ref. 0107)
Tris(trimethylsilyl) ether; spectrum (Ref. 0107)

HPLC: (Ref. 0107/0108)
Produced by incubating kidney homogenates from vitamin D supplemented chickens with 25-OHD3. (Ref. 0107)
Synthesis of 23x,25-(OH)2D3 from 3b,23x-dihydroxy-27-nor-5,7-cholestadien-25-one by methylation, UV irradiation and thernal isomerization. (Ref. 0107)
Synthesis of two epimers at C(23) of 23,25-(OH)2D3 from cholenic acid ester, determination of the C(23) stereochemistry of a synthetic intermediate by X-ray analysis and determination of the C(23) configuration of the natural metabolite. (Ref. 0108)



296
(23S)-23,25-dihydroxyvitamin D3 / (23S)-23,25-dihydroxycholecalciferol
(5Z,7E)-(3S,23S)-9,10-seco-5,7,10(19)-cholestatriene-3,23,25-triol
VVD0299
Sachiko Yamada
23S,25-(OH)2D3
C27H44O3 416.636 Download ChemDraw structure file

lmax (nm) 265, lmin (nm) 228 (Ref. 0107)
1H-NMR (d, CDCl3) 6.23 (1H, d, J = 10.5 Hz, C-6), 6.03 (1H, d, J = 10.5 Hz, C-7), 5.05 (1H, m, C-19E), 4.82 (1H, m, C-19Z), 4.10 (1H, m, C-23), 3.95 (1H, m, C-3), 1.32 (3H, s, C-26), 1.28 (3H, s, C-27), 0.98 (3H, d, J = 6 Hz, C-21), 0.56 (3H, s, C-18) (Ref. 0107)
m/z 416.3273 (calcd, 416.3290 ) (18, M+), 398 (2, M+-H2O), 383 (10, M+-H2O-CH3), 271 (7, M+-side chain), 253 (8, M+-side chain-H2O), 136 (100, A ring+C6+C7+), 118 (97, A ring+C6+C7+-H2O); spectrum (Ref. 0107)
Tris(trimethylsilyl) ether; spectrum (Ref. 0107)

HPLC: Co-chromatography of the natural metabolite with synthetic two C(23) epimers.(Ref. 0107/0108)
Produced by incubating kidney homogenates from vitamin D supplemented chickens with 25-OHD3. (Ref. 0107)
Synthesis of 23x,25-(OH)2D3 from 3b,23x-dihydroxy-27-nor-5,7-cholestadien-25-one by methylation, UV irradiation and thernal isomerization. (Ref. 0107)
Synthesis of two epimers at C(23) of 23,25-(OH)2D3 from Cholenic acid ester, determination of the C(23) stereochemistry of a synthetic intermediate by X-ray analysis and determination of the C(23) configuration of the natural metabolite. (Ref. 0108)
23S,25-(OH)2D3 was efficiently converted to 25-OHD3 26,23-lactone by incubating with vitamin D-supplemented chickens kidney homogenates. (Ref. 0109)


297
(24R)-24,25-dihydroxyvitamin D3 / (24R)-24,25-dihydroxycholecalciferol
(5Z,7E)-(3S,24R)-9,10-seco-5,7,10(19)-cholestatriene-3,24,25-triol
VVD0300
Sachiko Yamada
24R,25-(OH)2D3
C27H44O3 416.636 Download ChemDraw structure file
The increase in serum calcium concentration and intestinal calcium transport in response to the isomers of 24,25-(OH)2D3.: Table (Ref. 0089)
Serum inorganic phosphorus and epiphyseal plate calcification response to the 24,25-(OH)2D3: Table (Ref. 0089)
HL-60 human promyelocytes differentiation : ED50 in nitro blue tetrazplium reduction, phagocytic activity, and nonspecific acid esterase activity are 1.1 times 10-6 M, 9.5 times 10-7 M and 9.5 times 10-7 M, respectively, when 1,25-(OH)2D3 shows the respective ED50 values of 1.0 times 10-8 M, 1.0 times 10-8 M and 1.1 times 10-8 M, respectively. (Ref. 0228)
lmax (nm) 265 (Ref. 0088/0090)
1H-NMR (d, CDCl3) 0.55 (3H, s), 0.93 (3H, d, J = 4 Hz) , 1.17 (3H, s), 1.22 (3H, s), 3.33 (1H, m), 3.95 (1H, m), 4.85 (1H, bs), 5.07 (1H, bs), 6.08 (1H, d, J = 11 Hz), 6.25 (1H, d, J = 11 Hz) (Ref. 0090)
m/z 416 (M+), 271, 253, 136, 118; spectrum (Ref. 0088)
m/z 416, 136, 118 (Ref. 0090)

HPLC: The stereochemistry at C(24) of the natural 24,25-(OH)2D3 was determined to be R by co-chromatography on HPLC with synthetic (24R)- and (24S)- 24,25-(OH)2D3 in a form of tris-trimethylsilyl ether.(Ref. 0089) .
Isolation and identification: from chicken kidney homogenates incubated with 24-OHD3. (Ref. 0088)
Stereoselective synthesis from dinor-5,7-choladien-3b-ol and a chiral side-chain fragment. (Ref. 0090)
Synthesis of epimeric mixture of 24x,25-(OH)2D3 from 3b-acetoxy-27-nor-5-cholesten-25-one. (Ref. 0091)
The stereochemistry at C(24) of the natural 24,25-(OH)2D3 was determined to be R by Co-chromatography on HPLC with synthetic (24R)- and (24S)-24,25-(OH)2D3. (Ref. 0089)
In vitro, 24R,25-(OH)2D3 is oxidized at C(24) to yield 25-hydroxy-24-oxovitamin D3 (Ref. 0096) , then hydroxylated at C(23) to give 23S,25-dihydroxy-24-oxovitamin D3 (Ref. 0102) , and cleaved at 23,24-bond to afford 23-hydroxy-24,25,26,27-tetranorvitamin D3 (Ref. 0105) . All these metabolic transformations were demonstrated to be catalyzed by vitamin D3 24-hydroxylase (CYP24)(Ref. 0266) . In vivo, 24R,25-(OH)2D3 has long half-life (17 days in dog) and metabolized similarly as found in the in vitro studies up to 23S,25-(OH)2-24-oxo-D3. However in vivo 23S,25-(OH)2-24-oxo-D3 is conjugated as it is produced in a form of 23b-glucuronide and excreted to bile (Ref. 0106) .
Cloning of the enzyme to produce 24R,25-dihydroxyvitamin D3 from 25-hydroxyvitamin D3, vitamin D-24-hydroxylase (Ref. 0031/0033)

298
(24S)-24,25-dihydroxyvitamin D3 / (24S)-24,25-dihydroxycholecalciferol
(5Z,7E)-(3S,24S)-9,10-seco-5,7,10(19)-cholestatriene-3,24,25-triol
VVD0301
Sachiko Yamada
24S,25-(OH)2D3
C27H44O3 416.636 Download ChemDraw structure file
The increase in serum calcium concentration and intestinal calcium transport in response to the isomers of 24,25-(OH)2D3.: Table (Ref. 0089)
Serum inorganic phosphorus and epiphyseal plate calcification response to the 24,25-(OH)2D3: Table (Ref. 0089)



HPLC : The stereochemistry at C(24) was determined by co-chromatography of tris(trimethylsilyl) ethers of the natural and synthetic (24R)- and (24S)-24,25-(OH)2D3. on HPLC (Ref. 0092/0089)
Isolation and identification from kidney homogenates from either vitamin D-supplemented or deficient chickens incubated with 25-OH-24-oxo-D3. (Ref. 0092)
Synthesis of epimeric mixture of 24x,25-(OH)2D3 from 3b-acetoxy-27-nor-5-cholesten-25-one. (Ref. 0091)
Asymmetric synthesis of (24R)- and (24S)-24,25-dihydroxyprovitamin D3 from 5-Cholen-24-oic acid via asymmetric reduction of 4,25-Cholestadien-24-one as a key step.(Ref. 0129)
Incubation of 25-OH-24-oxo-D3 with kidney homogenates from either vitamin D-supplemented or deficient chickens yielded 24S,25-(OH)2 D3 (Ref. 0092)


299
(25R)-25,26-dihydroxyvitamin D3 / (25R)-25,26-dihydroxycholecalciferol
(5Z,7E)-(3S,25R)-9,10-seco-5,7,10(19)-cholestatriene-3,25,26-triol
VVD0302
Sachiko Yamada
25R,26-(OH)2D3
C27H44O3 416.636 Download ChemDraw structure file
Effect of intrajugular administration of 0.25 or 2.5 mg of 25,26-(OH)2D3 on calcium transport and serum calcium of rats on a low calcium diet. : Table I (Ref. 0126)
Stimulation of intestinal calcium transport by a epimeric mixture of synthetic 25,26-(OH)2D3.; Table (Ref. 0128)
Effect of a synthetic mixture of (25S)- and (25R)-25,26-(OH)2D3 on calcium mobilization from bone at dose levels of 0.25 and 2.5 mg: Table (Ref. 0128)
126-128 degC (Ref. 0131/0132)
[a]D +88 deg (c = 0.5 in CH3OH) (Ref. 0131)
lmax (nm) 265, lmin (nm) 228 (Ref. 0126)
lmax (EtOH) (nm) (e) 265 (18000) (Ref. 0129)
lmax (nm) (e) 264 (17700) (Ref. 0132)
1H-NMR (d, CDCl3) 0.54 (3H, s, 13-Me), 0.94 (3H, d, J = 6 Hz, 20-Me), 1.20 (3H, s, 25-Me), 3.43 (1H, d, J = 12 Hz, 26-H), 3.48 (1H, d, J = 12 Hz, 26-H), 3.95 (1H, m, 3a-H), 4.86 (1H, d, J = 3 Hz, 19-H), 5.09 (1H, d, J = 3 Hz, 19-H), 6.03 (1H, d, J = 12 Hz, 6- or 7-H), 6.25 (1H, d, J = 12 Hz, 6- or 7-H) (Ref. 0129)
1H-NMR (d, CDCl3, 270Hz) 0.54 [s, H3C (18)], 0.95 [d, J = 7 Hz, 3H-C (21)], 1.2 [s, H3C-C (25)], ca. 1.0-2.9 (m, CH and CH2), 3.45 [AB-System, J = 12 Hz, dn = 16, 2H-C (26)], 3.95 [m, H-C (3)], 4.86 and 5.09 [AB-System, J = 3 Hz, 2H-C (19)], 6.03 and 6.25 [AB-System, J = 12 Hz, H-C (6), H-C (7)] (Ref. 0132)
m/z 416 (M+), 398, 383, 367, 271, 253, 136, 118; spectrum(Ref. 0126)
CD [ 1:1 complexes of Eu(fod)3, substrate (c 0.0002 M) in CHCl3] 318 nm (e -2.9) (Ref. 0131)
HPLC: (Ref. 0127)
Isolation and identification from the plasma of pigs given large doses of vitamin D3. (Ref. 0126)
25,26-(OH)2D3 obtained either by incubating vitamin D supplemented chick kidney with 25-OHD3 or from rat serum was shown to be a epimeric mixture of (25S)- and (25R)- isomers. (Ref. 0127)
Synthesis of an epimeric mixture of (25S)- and (25R)-25,26-(OH)2D3 from 3-hydroxy-27-nor-5-cholesten-25-one. (Ref. 0128/0130)
Asymmetric synthesis of (25R)- and (25S)-25,26-(OH)2D3 from 5-Cholen-24-oic acid via asymmetric epoxidation of 5,24-Cholestadien-26-ol as a key step and determination of the configuration at C(25) of the natural metabolite. (Ref. 0129)
(25R)- and (25S)-25,26-(OH)2D3 were stereoselectively synthesized from C(21) steroid carboxylic acid ester and chiral C(6) side chain synthons and the stereochemistry at C(25) of the natural human metabolite was determined to be S. (Ref. 0131)
Stereoselective synthesis of (25S)- and (25R)-25,26-(OH)2D3 from stigmasterol-derived C(22) steroid-units and chiral C(5) side chain synthons via Grignard- or Wittig -coupling as key step. (Ref. 0132)



300
(25S)-25,26-dihydroxyvitamin D3 / (25S)-25,26-dihydroxycholecalciferol
(5Z,7E)-(3S,25S)-9,10-seco-5,7,10(19)-cholestatriene-3,25,26-triol
VVD0303
Sachiko Yamada
25S,26-(OH)2D3
C27H44O3 416.636 Download ChemDraw structure file
Effect of intrajugular administration of 0.25 or 2.5 mg of 25,26-(OH)2D3 on calcium transport and serum calcium of rats on a low calcium diet. : Table(Ref. 0126)
Stimulation of intestinal calcium transport by a epimeric mixture of synthetic 25,26-(OH)2D3.; Table (Ref. 0128)
Effect of a synthetic mixture of (25S)- and (25R)-25,26-(OH)2D3 on calcium mobilization from bone at dose levels of 0.25 and 2.5 mg: Table (Ref. 0128)
140-142 degC (Ref. 0131)
139-140 degC (Ref. 0132)
[a]D +91 deg (c = 0.5 in CH3OH) (Ref. 0131)
lmax (nm) 265, lmin (nm) 228 (Ref. 0126)
lmax (EtOH) (nm) (e) 265 (18000) (Ref. 0129)
lmax (nm) (e) 264 (17700) (Ref. 0132)
1H-NMR (d, CDCl3) 0.54 (3H, s, 13-Me), 0.94 (3H, d, J = 6 Hz, 20-Me), 1.20 (3H, s, 25-Me), 3.43 (1H, d, J = 12 Hz, 26-H), 3.48 (1H, d, J = 12 Hz, 26-H), 3.95 (1H, m, 3a-H), 4.86 (1H, d, J = 3 Hz, 19-H), 5.09 (1H, d, J = 3 Hz, 19-H), 6.03 (1H, d, J = 12 Hz, 6- or 7-H), 6.25 (1H, d, J = 12 Hz, 6- or 7-H) (Ref. 0129)
1H-NMR (d, CDCl3, 270Hz) 0.54 [s, H3C (18)], 0.95 [d, J = 7 Hz, 3H-C (21)], 1.2 [s, H3C-C (25)], ca. 1.0-2.9 (m, CH and CH2), 3.45 [AB-System, J = 12 Hz, dn = 16, 2H-C (26)], 3.95 [m, H-C (3)], 4.86 and 5.09 [AB-System, J = 3 Hz, 2H-C (19)], 6.03 and 6.25 [AB-System, J = 12 Hz, H-C (6), H-C (7)] (Ref. 0132)
m/z 416 (M+), 398, 383, 367, 271, 253, 136, 118; spectrum(Ref. 0126)
CD [ 1:1 complexes of Eu(fod)3, substrate (c 0.0002 M) in CHCl3] 318 nm (e -2.3) (Ref. 0131)
HPLC: (Ref. 0127)
Isolation and identification from the plasma of pigs given large doses of vitamin D3. (Ref. 0126)
25,26-(OH)2D3 obtained either by incubating vitamin D supplemented chick kidney with 25-OHD3 or from rat serum was shown to be a epimeric mixture of (25S)- and (25R)- isomers. (Ref. 0127)
Synthesis of an epimeric mixture of (25S)- and (25R)-25,26-(OH)2D3 from 3-hydroxy-27-nor-5-cholesten-25-one. (Ref. 0128/0130)
Asymmetric synthesis of (25R)- and (25S)-25,26-(OH)2D3 from 5-Cholen-24-oic acid via asymmetric epoxidation of 5,24-Cholestadien-26-ol as a key step and determination of the configuration at C(25) of the natural metabolite. (Ref. 0129)
(25R)- and (25S)-25,26-(OH)2D3 were stereoselectively synthesized from C(21) steroid carboxylic acid ester and chiral C(6) side chain synthons and the stereochemistry at C(25) of the natural human metabolite was determined to be S. (Ref. 0131)
Stereoselective synthesis of (25S)- and (25R)-25,26-(OH)2D3 from stigmasterol-derived C(22) steroid-units and chiral C(5) side chain synthons via Grignard- or Wittig -coupling as key step. (Ref. 0132)



301
(6R)-6,19-epidioxy-1a-hydroxy-6,19-dihydrovitamin D3 / (6R)-6,19-epidioxy-1a-hydroxy-6,19-dihydrocholecalciferol
(7E)-(1S,3R,6R)-6,19-epidioxy-9,10-seco-5(10),7-cholestadiene-1,3-diol
VVD0304
Sachiko Yamada
C27H44O4 432.636 Download ChemDraw structure file
Binding affinity for the vitamin D receptor in HL-60 cells : < 1/10000 as active as 1,25-(OH)2D3. Differentiation of HL-60 cells : > 1/1000 as active as 1,25-(OH)2D3. (Ref. 0339)
1H-NMR (d, CDCl3) 0.58 (3H, s, 18-H), 0.89 (6H, d, J = 6 Hz, 26- and 27-H), 0.93 (3H, d, J = 6 Hz, 21-H), 4.24 (1H, m, 3-H), 4.41 (1H, m, 1-H), 4.52 (1H, d, J = 8 Hz, 19-H), 4.82 (1H, d, J = 18 Hz, 19-H), 5.03 (1H, d, J = 9 Hz, 6- or 7-H), 5.19 (1H, d, J = 9 Hz, 7- or 6-H) (Ref. 0339)
m/z 414 (M+-H2O), 301, 283, 167 (Ref. 0339)
CD : 208 nm (e -50.1) (in MeOH) (Ref. 0339)


As a major product by the reaction of 1a-hydroxyvitamin D3 with singlet oxygen generated by dye-sensitized photochemical method. (Ref. 0339)



302
(6S)-6,19-epidioxy-1a-hydroxy-6,19-dihydrovitamin D3 / (6S)-6,19-epidioxy-1a-hydroxy-6,19-dihydrocholecalciferol
(7E)-(1S,3R,6S)-6,19-epidioxy-9,10-seco-5(10),7-cholestadiene-1,3-diol
VVD0305
Sachiko Yamada
C27H44O4 432.636 Download ChemDraw structure file
Binding affinity for the vitamin D receptor in HL-60 cells : < 1/10000 as active as 1,25-(OH)2D3. Differentiation of HL-60 cells : > 1/1000 as active as 1,25-(OH)2D3. (Ref. 0339)
135-136 degC (Ref. 0339)
1H-NMR (d, CDCl3) 0.56 (3H, s, 18-H), 0.86 (6H, d, J = 6 Hz, 26- and 27-H), 0.91 (3H, d, J = 6 Hz, 21-H), 4.12 (1H, m, 3-H), 4.25 (1H, m, 1-H), 4.67 (2H, s, 19-H), 4.74 (1H, d, J = 9 Hz, 6- or 7-H), 5.33 (1H, d, J = 9 Hz, 7- or 6-H) (Ref. 0339)
m/z 414 (M+-H2O), 301, 206, 167 (Ref. 0339)
CD : 212 nm (e +13.4) (in MeOH) (Ref. 0339)


As a major product by the reaction of 1a-hydroxyvitamin D3 with singlet oxygen generated by dye-sensitized photochemical method. (Ref. 0339)



303
(6R)-25-hydroxyvitamin D3 6,19-sulfur dioxide adduct / (6R)-25-hydroxycholecalciferol 6,19-sulfur dioxide adduct
(7E)-(3S,6R)-6,19-epithio-9,10-seco-5(10),7-cholestadiene-3,25-diol S,S-dioxide
VVD0306
Sachiko Yamada
25-OHD3 6R,19-sulfur dioxide adduct
C27H44O4S 464.702 Download ChemDraw structure file






From 25-hydroxyvitamin D3 by treatment with liquid sulfur dioxide. (Ref. 0267/0331)



304
(6S)-25-hydroxyvitamin D3 6,19-sulfur dioxide adduct / (6S)-25-hydroxycholecalciferol 6,19-sulfur dioxide adduct
(7E)-(3S,6S)-6,19-epithio-9,10-seco-5(10),7-cholestadiene-3,25-diol S,S-dioxide
VVD0307
Sachiko Yamada
25-OHD3 6S,19-sulfur dioxide adduct
C27H44O4S 464.702 Download ChemDraw structure file






From 25-hydroxyvitamin D3 by treatment with liquid sulfur dioxide. (Ref. 0267/0331)



305
(6R)-6,19-epidioxy-25-hydroxy-6,19-dihydrovitamin D3 / (6R)-6,19-epidioxy-25-hydroxy-6,19-dihydrocholecalciferol
(7E)-(3S,6R)-6,19-epidioxy-9,10-seco-5(10),7-cholestadiene-3,25-diol
VVD0308
Sachiko Yamada
C27H44O4 432.636 Download ChemDraw structure file
Binding affinity for the vitamin D receptor in HL-60 cells : 1/3000 as active as 1,25-(OH)2D3. Differentiation of HL-60 cells : 1/120 as active as 1,25-(OH)2D3. (Ref. 0339)
137-138 degC (Ref. 0339)
1H-NMR (d, CDCl3) 0.56 (3H, s, 18-H), 0.94 (3H, d, J = 6 Hz, 21-H), 1.22 (6H, s, 26- and 27-H), 4.10 (1H, m, 3-H), 4.36 (1H, d, J = 15 Hz, 19-H), 4.44 (1H, d, J = 15 Hz, 19-H), 4.92 (1H, d, J = 10 Hz, 6-H), 5.20 (1H, d, J = 10 Hz, 7-H) (Ref. 0339)
m/z 432 (M+), 414, 396, 151 (Ref. 0339)
CD : 210 nm (e -39.4) (in MeOH) (Ref. 0339)


As a major product by the reaction of 25-hydroxyvitamin D3 with singlet oxygen generated by dye-sensitized photochemical method. (Ref. 0339)



306
(6S)-6,19-epidioxy-25-hydroxy-6,19-dihydrovitamin D3 / (6S)-6,19-epidioxy-25-hydroxy-6,19-dihydrocholecalciferol
(7E)-(3S,6S)-6,19-epidioxy-9,10-seco-5(10),7-cholestadiene-3,25-diol
VVD0309
Sachiko Yamada
C27H44O4 432.636 Download ChemDraw structure file
Binding affinity for the vitamin D receptor in HL-60 cells : 1/3000 as active as 1,25-(OH)2D3. Differentiation of HL-60 cells : 1/130 as active as 1,25-(OH)2D3. (Ref. 0339)
148-150 degC (Ref. 0339)
1H-NMR (d, CDCl3) 0.56 (3H, s, 18-H), 0.94 (3H, d, J = 6 Hz, 21-H), 1.22 (6H, s, 26- and 27-H), 3.96 (1H, m, 3-H), 4.20 (1H, d, J = 16 Hz, 19-H), 4.60 (1H, d, J = 16 Hz, 19-H), 4.80 (1H, d, J = 9 Hz, 6- or 7-H), 5.28 (1H, d, J = 9 Hz, 7- or 6-H) (Ref. 0339)

CD : 213 nm (e +9.9) (in MeOH) (Ref. 0339)


As a major product by the reaction of 25-hydroxyvitamin D3 with singlet oxygen generated by dye-sensitized photochemical method.(Ref. 0339)



307
1a,25-dihydroxy-24a-homo-22-oxavitamin D3 / 1a,25-dihydroxy-24a-homo-22-oxacholecalciferol
(5Z,7E)-(1S,3R)-24a-homo-22-oxa-9,10-seco-5,7,10(19)-cholestatriene-1,3,25-triol
VVD0310
Sachiko Yamada
22-oxa-24a-homo-1a,25-(OH)2D3
C27H44O4 432.636 Download ChemDraw structure file
The activity inducing differentiation of human myeloid leukemia cells (HL-60) into macrophases in vitro estimated by superoxide anion generation : ED50 = 1.58 times 10-9 M [ED50 of 1,25-(OH)2D3 : 1.70 times 10-8 M, ED50 of OCT : 1.78 times 10-8 M] the binding properties to the chick embryonic intestinal 1,25-(OH)2D3 receptor : 9%, 1,25-(OH)2D3 : 100%, OCT : 12.5%. (Ref. 0203)
(EtOH) lmax (nm) 263, lmin (nm) 227 (Ref. 0203)
1H-NMR (d, CDCl3) 0.53 (3H, s), 1.17 (3H, d, J = 6.1 Hz), 1.22 (6H, s), 3.26 (2H, m), 3.59 (1H, m), 4.23 (1H, m), 4.43 (1H, m), 5.00 (1H, t, J = 1.7 Hz), 5.33 (1H, t, J = 1.7 Hz), 6.02 (1H, d, J = 11.4 Hz), 6.37 (1H, d, J = 11.4 Hz) (Ref. 0203)
m/z 432 (M+), 83 (100%) (Ref. 0203)
Colorless foam. (Ref. 0203)
Flash column chromatography with AcOEt/n-hexane (5;1) (Ref. 0203)

Synthesis from dehydroepiandrostertone via 1a,3b-dihydroxy-20(S)-(4-hydroxy-4-methylpentyloxy)pregna-5,7-diene by photochemical method. (Ref. 0203)



308
1a,25-dihydroxy-24a-homo-22-oxa-20-epivitamin D3 / 1a,25-dihydroxy-24a-homo-22-oxa-20-epicholecalciferol
(5Z,7E)-(1S,3R,20R)-24a-homo-22-oxa-9,10-seco-5,7,10(19)-cholestatrien-1,3,25-triol
VVD0311
Sachiko Yamada
C27H44O4 432.636 Download ChemDraw structure file
Biological activity (% of 1,25-(OH)2D3 effect) Inhibition of U 937 cell (human histiocytic lymphoma cell line) proliferation : 8200 (IC50 : the title compound, 1.7 times 10-10 M ; 1,25-(OH)2D3, 1.4 times 10-8 M) ; Induction of U 937 cell differentiation : 117600 ; Binding to the 1,25-(OH)2D3 receptor from rachitic chicken intestine : 9 ; Calcemic activity determined by the increase in urinary calcium excretion in rats : 270. (Ref. 0278)









309
1a,25-dihydroxy-10,19-methano-23-oxavitamin D3 / 1a,25-dihydroxy-10,19-methano-23-oxacholecalciferol
(5Z,7E)-(1S,3R)-10,19-methano-23-oxa-9,10-seco-5,7-cholestadiene-1,3,25-triol
VVD0312
Sachiko Yamada
10,19-methano-23-oxa-1a,25-(OH)2D3
C27H44O4 432.636 Download ChemDraw structure file






From protected (5E)-1a,22-dihydroxy-23,24,25,26,27-pentanorvitamin D3 via alkylation under phase-transfer conditions, Grignard reaction, photoisomerization, deprotection of the 1-hydroxyl group, Simmons-Smith methylenation and deprotection. (Ref. 0299/0300)



310
1a,2,25-trihydroxyvitamin D3 / 1a,2,25-trihydroxycholecalciferol
(5Z,7E)-(1,2,3R)-9,10-seco-5,7,10(19)-cholestatriene-1,2,3,25-tetrol
VVD0313
Sachiko Yamada
1a,2,25-(OH)3D3
C27H44O4 432.636 Download ChemDraw structure file










311
1a,11a,25-trihydroxyvitamin D3 / 1a,11a,25-trihydroxycholecalciferol
(5Z,7E)-(1S,3R,11S)-9,10-seco-5,7,10(19)-cholestatriene-1,3,11,25-tetrol
VVD0314
Sachiko Yamada
1a,11a,25-(OH)3D3
C27H44O4 432.636 Download ChemDraw structure file










312
1a,11b,25-trihydroxyvitamin D3 / 1a,11b,25-trihydroxycholecalciferol
(5Z,7E)-(1S,3R,11R)-9,10-seco-5,7,10(19)-cholestatriene-1,3,11,25-tetrol
VVD0315
Sachiko Yamada
1a,11b,25-(OH)3D3
C27H44O4 432.636 Download ChemDraw structure file










313
1a,18,25-trihydroxyvitamin D3 / 1a,18,25-trihydroxycholecalciferol
(5Z,7E)-(1S,3R)-9,10-seco-5,7,10(19)-cholestatriene-1,3,18,25-tetrol
VVD0316
Sachiko Yamada
1a,18,25-(OH)3D3
C27H44O4 432.636 Download ChemDraw structure file






By palladium-catalyzed coupling of des-AB 8-triflate with 5(10)-en-6-yne A-ring fragment as key step. Functionalization of C-18 methyl was achieved by treatment of 8-hydroxy-des AB vitamin D with lead tetraacetate yielding the corresponding 8,18-cyclic ether (62% yield). (Ref. 0313)



314
(20S)-1a,20,25-trihydroxyvitamin D3 / (20S)-1a,20,25-trihydroxycholecalciferol
(5Z,7E)-(1S,3R,20S)-9,10-seco-5,7,10(19)-cholestatriene-1,3,20,25-tetrol
VVD0317
Sachiko Yamada
1a,20S,25-(OH)3D3
C27H44O4 432.636 Download ChemDraw structure file
Biological activity (% of 1,25-(OH)2D3 effect) : Inhibition of U 937 cell (human histiocytic lymphoma cell line) proliferation : 50% ; Binding to the 1,25-(OH)2D3 receptor from rachitic chicken intestine : 0.006% ; Calcemic activity determined by the increase in urinary calcium excretion in rats : 0.6%. (Ref. 0279)





From (5E)-1a-hydroxy-20-keto-22,23,24,25,26,27-hexanorvitamin D3 derivative by addition of a Grignard reagent followed by photochemical isomerization and deprotection. (Ref. 0279)



315
(22R)-1a,22,25-trihydroxy-20-epivitamin D3 / (22R)-1a,22,25-trihydroxy-20-epicholecalciferol
(5Z,7E)-(1S,3R,20R,22R)-9,10-seco-5,7,10(19)-cholestatriene-1,3,22,25-tetrol
VVD0318
Sachiko Yamada
20-epi-1a,22R,25-(OH)3D3
C27H44O4 432.636 Download ChemDraw structure file
Relative potency (1,25-(OH)2D3 = 1) : Induction of differentiation of U 937 cells, 10 ; Inhibition of proliferation, 10. (Ref. 0321)





From protected (5E)-1a-hydroxy-22-oxo-23,24,25,26,27-pentanor-20-epivitamin D3 via the reaction with Grignard reagent of side chain fragment giving major (19:1) 22R-hydroxy product as a key step. (Ref. 0321)



316
(23S)-1a,23,25-trihydroxyvitamin D3 / (23S)-1a,23,25-trihydroxycholecalciferol
(5Z,7E)-(1S,3R,23S)-9,10-seco-5,7,10( 19)-cholestatriene-1,3,23,25-tetrol
VVD0319
Sachiko Yamada
1a,23S,25-(OH)3D3
C27H44O4 432.636 Download ChemDraw structure file
Biological activity (% of 1,25-(OH)2D3 effect) : Inhibition of proliferation of human keratinocytes in culture, 100 ; Intestinal calcium absorption in rat, 0 ; Bone calcium mobilization in rat, 0 ; Differentiation of human leukemia cells (HL-60), 14. (Ref. 0237)









317
(24R)-1a,24,25-trihydroxyvitamin D3 / (24R)-1a,24,25-trihydroxycholecalciferol
(5Z,7E)-(1S,3R,24R)-9,10-seco-5,7,10(19)-cholestatriene-1,3, 24,25-tetrol
VVD0320
Sachiko Yamada
1a,24R,25-(OH)3D3
C27H44O4 432.636 Download ChemDraw structure file
Antirachitic activity of 1,24,25-(OH)2D3 and vitamin D3: Table (Ref. 0065)
HL-60 human promyelocytes differentiation : ED50 in nitro blue tetrazplium reduction, phagocytic activity, and nonspecific acid esterase activity are 3.5 times 10-8 M, 3.5 times 10-8 M and 3.5 times 10-8 M, respectively, when 1,25-(OH)2D3 shows the respective ED50 values of 1.0 times 10-8 M, 1.0 times 10-8 M and 1.1 times 10-8 M, respectively. (Ref. 0228)
Biological activity (% of 1,25-(OH)2D3 effect) : Inhibition of proliferation of human keratinocytes in culture, 100 ; Intestinal calcium absorption in rat, 93 ; Bone calcium mobilization in rat, 17 ; Competitive binding to rat intestinal vitamin D receptor, 2 ; Differentiation of human leukemia cells (HL-60), 20. (Ref. 0237)
lmax (nm) 265, lmin (nm) 228 (Ref. 0064)
: 1H-NMR (d, Aceton-d6) 0.58 (3H, s, 18-Me), 1.12 (6H, s, 26- ,27-Me), 3.25 (1H, m, 24C-H), 4.15 (1H, m, 1C-H), 4.39 (1H, m, 3C-H), 5.30 and 4.93 (2H, two s, 19-CH2), and 6.18 ppm (2H, BAq, J = 11 Hz, 6C-, 7C-Hs) (Ref. 0064)
m/z 432 (M+), 414, 396, 287, 269, 251, 134 (Ref. 0064)
m/z 432 (M+), 414, 396, 287, 269, 251, 152, 134; spectrum (Ref. 0065)



From 24x,25-dihydroxycholesterol via 1a-hydroxylation, separation of the 24-epimers, dehydration, UV irradiation and thernal isomerization. (Ref. 0064)
Generated in vivo in rats from 25-OHD3 and in vitro from 24,25-(OH)2D3 by incubating with chicken kidney homogenate. (Ref. 0065)
Production in vivo in vitamin D-deficient rats from either 25-OHD3 or 1,25-(OH)2D3 and determination of the structure including the stereochemistry at C(24). (Ref. 0066)
Produced from 1,25-dihydroxyvitamin D3 by hydroxylation catalyzed by vitamin D3 24-hydroxylase. (Ref. 0031/0033)
1a,24R,25-Trihydroxyvitamin D3 is further oxidized by the same enzyme to 1-OH-tetranor-D3 23-carboxylic acid (calcitroic acid) (Ref. 0070/0073) via 1,25-(OH)2-24-oxo-D3 (Ref. 0068/0067), 1,23,25-(OH)3D3-24-oxo-D3 (Ref. 0067) and 1,23-(OH)2-tetranor-D3 (Ref. 0069) .
Vitamin D responsive elements (VDRE) of rat 24-hydroxylase,distal : GGTTCA GCG GGTGCG (Ref. 0049) ; Human 24-hydroxylase, distal : AGTTCA CCG GGTGTG (Ref. 0050) ; Rat 24-hydroxylase,proximal : GAGTCA GCG AGGTGA GTG AGGGCG (Ref. 0051) ; Human 24-hydroxylase,proximal : GAGTCA GCG AGGTGA GCG AGGGCG (Ref. 0050) .

318
(24S)-1a,24,25-trihydroxyvitamin D3 / (24S)-1a,24,25-trihydroxycholecalciferol
(5Z,7E)-(1S,3R,24S)-9,10-seco-5,7,10(19)-cholestatriene-1,3,24,25-tetrol
VVD0321
Sachiko Yamada
1a,24S,25-(OH)3D3
C27H44O4 432.636 Download ChemDraw structure file










319
(5E)-(25R)-1a,25,26-trihydroxyvitamin D3 / (5E)-(25R)-1a,25,26-trihydroxycholecalciferol
(5E,7E)-(1S,3R,25R)-9,10-seco-5,7,10(19)-cholestatriene-1,3,25,26-tetrol
VVD0322
Sachiko Yamada
(5E)-1a,25R,26-(OH)3D3
C27H44O4 432.636 Download ChemDraw structure file
Affinity for the chick intestinal receptor : 1/8 as active as 1,25-(OH)2D3. (Ref. 0242)









320
(25S)-1a,25,26-trihydroxyvitamin D3 / (25S)-1a,25S,26-trihydroxycholecalciferol
(5Z,7E)-(1S,3R,25S)-9,10-seco-5,7,10(19)-cholestatriene-1,3,25,26-tetrol
VVD0323
Sachiko Yamada
1a,25S,26-(OH)3D3
C27H44O4 432.636 Download ChemDraw structure file
Biological activity (% of 1,25-(OH)2D3 effect) : Vitamin D receptor binding (chick intestine), 9% ; Inhibition of cell (HL-60) proliferation, 50% ; Induction cell (HL-60) differentiation, 100% ; 45Ca retention in kidney in rats, <10%. (Ref. 0297)
163-164 degC (Ref. 0291)
[a]d-25 +58.8 deg (c = 0.5 in MeOH) (Ref. 0291)
(EtOH) lmax (nm) (e) 265 (17080) (Ref. 0291)
(KBr) 3400, 1050 cm-1 (Ref. 0291)
1H-NMR (d, CD3OD, 200MHz) 0.57 (3H, s), 0.96 (3H, d, J = 6.4 Hz), 1.12 (3H, s), 4.87 (1H, br s), 5.28 (1H, br s), 6.08 (1H, d of AB, J = 10.4 Hz), 6.34 (1H, d of AB, J = 10.4 Hz) (Ref. 0291)
m/z 432 (M+, 6), 414 (8), 396 (6), 287 (8), 269 (10), 251 (10), 152 (36), 134 (100) (Ref. 0291)



Stereoselective synthesis of (25S)- and (25R)-1,25,26-(OH)3D3 from C(17) steroid and C(6)-chiral side chain synthons. The stereochemistry at C(25) of metabolite isolated from bovine serum was determined to be S. (Ref. 0086)
Total convergent synthesis via Wittig-Horner coupling of CD ring 8-ketone with A ring phosphine oxide. The upper half was constructed via 1,3-dipolar cycloaddition of C-23 nitrone with methyl methacrylate as key step. (Ref. 0291)
1,25,26-Trihydroxyvitamin D3 was produced from either 1,25-(OH)2D3 incubated with kidney homogenate from vitamin D-supplemented chickens or from 25,26-(OH)2D3 incubated with vitamin D-deficient chicken kidney homogenate. (Ref. 0087)


321
22,24,25-trihydroxyvitamin D3 / 22,24,25-trihydroxycholecalciferol
(5Z,7E)-(3S)-9,10-seco-5,7,10(19)-cholestatriene-3,22,24,25-tetrol
VVD0324
Sachiko Yamada
22,24,25-(OH)3D3
C27H44O4 432.636 Download ChemDraw structure file

(EtOH) lmax (nm) 265, lmin (nm) 228 (Ref. 0193)
Isomer A : 1H-NMR (d, CDCl3) 0.56 (3H, s, 13-Me), 0.97 (3H, d, J = 6 Hz, 20-Me), 1.20 and 1.24 (each 3H, s, 25-Me2), 3.60 (1H, m, 22- or 24-H), 4.00 (2H, m, 22- or 24-H and 3a-H), 4.85 and 5.08 (each 1H, br s, 19-H2), 6.07 and 6.27 (each 1H, d, J = 11 Hz, 6- and 7-H). Isomer B : 1H-NMR (d, CDCl3) 0.54 (3H, s, 13-Me), 0.98 (3H, d, J = 6 Hz, 20-Me), 1.17 and 1.21 (each 3H, s, 25-Me2), 3.73 (3H, m, 3a-, 22- and 24-H), 4.84 and 5.06 (each 1H, br s, 19-H2), 6.05 and 6.25 (each 1H, d, J = 11 Hz, 6- and 7-H) (Ref. 0193)
Isomer A : m/z 432.3217, Isomer B : m/z 432.3235 (Ref. 0193)







322
(23S)-23,24,25-trihydroxyvitamin D3 / (23S)-23,24,25-trihydroxycholecalciferol
(5Z,7E)-(3S,23S)-9,10-seco-5,7,10(19)-cholestatriene-3,23,24,25-tetrol
VVD0325
Sachiko Yamada
23S,24,25-(OH)3D3
C27H44O4 432.636 Download ChemDraw structure file

lmax (nm) 265 (Ref. 0100)

m/z 432 (M+), 399, 271, 253, 136, 118; spectrum(Ref. 0102)


Isolation and identification from Chicken kidney homogenate incubated with 25-OH-24-oxo D3. (Ref. 0102)
Isolated and identified from blood plasma of chicks given large doses of vitamin D3. (Ref. 0100)

Isolated as one of the metabolites produced from 25-hydroxy-24-oxovitamin D3 when the latter vitamin D metabolite was incubated with kidney homogenate from vitamin D supplemented chicks. (Ref. 0102)


323
(23S,25R)-23,25,26-trihydroxyvitamin D3 / (23S,25R)-23,25,26-trihydroxycholecalciferol
(5Z,7E)-(3S,23S,25R)-9,10-seco-5,7,10(19)-cholestatriene-3,23,25,26-tetrol
VVD0326
Sachiko Yamada
23S,25R,26-(OH)3D3
C27H44O4 432.636 Download ChemDraw structure file

lmax (95% EtOH) (nm) 265 (Ref. 0125)
1H-NMR (d, CD3OD) 0.56 (3 H, s, H-18), 1.22 (3 H, s, H-27), 3.57 (2 H, AB q, J = 11 Hz, H-26), 3.8-4.2 (2 H, m, H-3 and H-23), 4.82 (1 H, br s, H-19), 5.04 (1 H, br s, H-19), 6.13 (2 H, AB q, J = 11 Hz, H-6 and -7). (Ref. 0125)



Isolated and identified from chick kidney homogenates incubated with 23S,25-(OH)2D3. (Ref. 0110)
From triazolinedione adduct of (3S,23S,25R)-3,25-dihydroxy-5,7-cholestadiene 26,23-lactone (an intermediate of the synthesis of 25R-OHD3 26,23S-lactone) by reduction with LiAlH4 followed by photochemical and thernal isomerization. (Ref. 0125/0113)
Metabolized to (23S,25R)-25-OHD3 26,23-lactone via (23S,25R)-25-OHD3 26,23-lactol by incubation with vitamin D supplemented chick kidney homogenates. (Ref. 0124)


324
24,25,26-trihydroxyvitamin D3 / 24,25,26-trihydroxycholecalciferol
(5Z,7E)-(3S)-9,10-seco-5,7,10(19)-cholestatriene-3,24,25,26-tetrol
VVD0327
Sachiko Yamada
24,25,26-(OH)3D3
C27H44O4 432.636 Download ChemDraw structure file

lmax (nm) 265 (Ref. 0100)

m/z 432 (12%, M+), 399 (3%, M+-H2O-CH3), 136 [100%, (A ring+C6+C7)+], 118 (74%, 136-H2O); spectrum (Ref. 0100)


Isolated and identified from blood plasma of chicks given large doses of vitamin D3. (Ref. 0100)




325
(24R)-6,19-epidioxy-1a,24-dihydroxy-6,19-dihydrovitamin D3 / (24R)-6,19-epidioxy-1a,24-di hydroxy-6,19-dihydrocholecalciferol
(7E)-(1S,3R,24R)-6,19-epidioxy-9,10-seco-5(10),7-cholestadiene-1,3,24-triol
VVD0328
Sachiko Yamada
C27H44O5 448.635 Download ChemDraw structure file
Less polar epimer : Binding affinity for the vitamin D receptor in HL-60 cells : 1/800 as active as 1,25-(OH)2D3. Differentiation of HL-60 cells : 1/150 as active as 1,25-(OH)2D3. More polar epimer : Binding affinity for the vitamin D receptor in HL-60 cells : 1/800 as active as 1,25-(OH)2D3. Differentiation of HL-60 cells : 1/200 as active as 1,25-(OH)2D3. (Ref. 0339)

Less polar C(6)-epimer : m/z 430 (M+-H2O), 412, 394, 379. More polar C(6)-epimer : m/z 430 (M+-H2O), 412, 394, 379 (Ref. 0339)







326
(6R)-6,19-epidioxy-1a,25-dihydroxy-6,19-dihydrovitamin D3 / (6R)-6,19-epidioxy-1a,25-dihydroxy-6,19-dihydrocholecalciferol
(7E)-(1S,3R)-6,19-epidioxy-9,10-seco-5(10),7-cholestadiene-1,3,25-triol
VVD0329
Sachiko Yamada
C27H44O5 448.635 Download ChemDraw structure file
Less polar epimer : Binding affinity for the vitamin D receptor in HL-60 cells : 1/800 as active as 1,25-(OH)2D3. Differentiation of HL-60 cells : 1/130 as active as 1,25-(OH)2D3. (Ref. 0339)
More polar epimer : Binding affinity for the vitamin D receptor in HL-60 cells : 1/800 as active as 1,25-(OH)2D3. Differentiation of HL-60 cells : 1/200 as active as 1,25-(OH)2D3. (Ref. 0339)

Less polar C(6)-epimer : m/z 430 (M+-H2O), 412, 394, 379. More polar C(6)-epimer : m/z 430 (M+-H2O), 412, 394, 379 (Ref. 0339)







327
(6R)-1a,25-dihydroxyvitamin D3 6,19-sulfur dioxide adduct / (6R)-1a,25-dihydroxycholecalciferol 6,19-sulfur dioxide adduct
(7E)-(1S,3R,6R)-6,19-epithio-9,10-seco-5(10),7-cholestadiene-1,3,25-triol S,S-dioxide
VVD0330
Sachiko Yamada
1a,25-(OH)2D3 6R,19-sulfur dioxide adduct
C27H44O5S 480.701 Download ChemDraw structure file

1-Methoxymethyl-3-t-butyldimethylsilyl-25-triethylsilyl derivative : 1H-NMR (d, CDCl3) 0.05 and 0.07 (each 3H, s, 2 times Si-CH3), 0.561(3H, s, 18-H), 0.564 (6H, q, J = 8.0 Hz, 3 times CH2CH3), 0.88 (9H, s, Si-tBu), 0.95 (9H, t, J = 8.0 Hz, 3 times CH2CH3), 1.19 (6H, s, 26- and 27-H), 3.39 (3H, s, OCH2OCH3), 3.67 and 3.96 (each 1H, m, 19-H), 4.13 (1H, m, 3-H), 4.22 (1H, m, 1-H), 4.60 and 4.73 (each 1H, d, J = 7.0 Hz, OCH2OCH3), 4.62 and 4.80 (each 1H, d, J = 10.1 Hz, 6- and 7-H) (Ref. 0333)
1-Methoxymethyl-3-t-butyldimethylsilyl-25-triethylsilyl derivative : m/z 688 (M+-SO2, 28.6), 626 (30.2), 556 (57.7), 494 (65.7), 379 (12.3), 248 (100), 115 (15.9), 103 (20.2), 75 (29.2) (Ref. 0333)



From 1a,25-dihydroxyvitamin D3 derivative by treatment with liquid sulfur dioxide. (Ref. 0267/0331/0333)



328
(6S)-1a,25-dihydroxyvitamin D3 6,19-sulfur dioxide adduct / (6S)-1a,25-dihydroxycholecalciferol 6,19-sulfur dioxide adduct
(7E)-(1S,3R,6S)-6,19-epithio-9,10-seco-5(10),7-cholestadiene-1,3,25-triol S,S-dioxide
VVD0331
Sachiko Yamada
1a,25-(OH)2D3 6S,19-sulfur dioxide adduct
C27H44O5S 480.701 Download ChemDraw structure file

1-Methoxymethyl-3-t-butyldimethylsilyl-25-triethylsilyl derivative : 1H-NMR (d, CDCl3) 0.06 and 0.07 (each 3H, s, 2 times Si-CH3), 0.56 (6H, q, J = 8.0 Hz, 3 times CH2CH3), 0.65 (3H, s, 18-H), 0.88 (9H, s, Si-tBu), 0.94 (9H, t, J = 8.0 Hz, 3 times CH2CH3), 1.184 and 1.187 (each 3H, s, 26- and 27-H), 3.38 (3H, s, OCH2OCH3), 3.66 and 3.98 (each 1H, m, 19-H), 4.16 (1H, m, 3-H), 4.21 (1H, m, 1-H), 4.59 and 4.72 (each 1H, d, J = 7.1 Hz, OCH2OCH3), 4.65 and 4.72 (each 1H, d, J = 9.5 Hz, 6- and 7-H) (Ref. 0333)
1-Methoxymethyl-3-t-butyldimethylsilyl-25-triethylsilyl derivative : m/z 688 (M+-SO2, 8.4), 626 (16.8), 556 (25.4), 512 (26.7), 494 (49.2), 380 (11.3), 248 (100), 134 (17.2), 103 (18.7), 75 (41.1) (Ref. 0333)



From 1a,25-dihydroxyvitamin D3 derivative by treatment with liquid sulfur dioxide. (Ref. 0267/0331/0333)



329
(6RS,24R)-24,25-dihydroxyvitamin D3 6,19-sulfur dioxide adduct / (6RS,24R)-24,25-dihydroxycholecalciferol 6,19-sulfur dioxide adduct
(7E)-(3S,6RS,24R)-6,19-epithio-9,10-seco-5(10),7-cholestadiene-3,24,25-triol S,S-dioxide
VVD0332
Sachiko Yamada
24R,25-(OH)2D3 6RS,19-sulfur dioxide adduct
C27H44O5S 480.701 Download ChemDraw structure file

(KBr) 3500, 2980, 1310, 1150, 1115 cm-1 (Ref. 0332)
1H-NMR (d, CDCl3) 0.58 and 0.66 (3H, s, 18-H), 0.96 (3H, d, J = 5.0 Hz, 21-H), 1.17 and 1.22 (each 3H, s, 26- and 27-H), 3.33 (1H, m, 24-H), 3.67 (2H, m, 19-H), 4.05 (1H, m, 3-H), 4.70 (2H, m, 6- and 7-H) (Ref. 0332)
m/z 416 (M+-SO2, 70), 398 (55), 380 (28), 271 (56), 253 (76), 176 (50), 159 (71), 147 (71), 118 (72), 105 (100) (Ref. 0332)



From 24R,25-dihydroxyvitamin D3 by treatment with liquid sulfur dioxide. (Ref. 0332)



330
(23S,25R)-1a,23,25,26-tetrahydroxyvitamin D3 / (23S,25R)-1a,23,25,26-tetrahydroxycholecalciferol
(5Z,7E)-(1S,3R,23S,25R)-9,10-seco-5,7,10(19)-cholestatriene-1,3,23,25,26-pentol
VVD0333
Sachiko Yamada
1a,23S,25R,26-(OH)4D3
C27H44O5 448.635 Download ChemDraw structure file
Affinity for the chick intestinal receptor : 1/216 as active as 1,25-(OH)2D3. (Ref. 0242)









331
dihydrotachysterol3 / (5E)-(10S)-10,19-dihydrovitamin D3 / (5E)-(10S)-10,19-dihydrocholecalciferol
(5E,7E)-(3S,10S)-9,10-seco-5,7-cholestatrien-3-ol
VVD0334
Sachiko Yamada
DHT3
C27H46O 386.654 Download ChemDraw structure file

1H-NMR (d, CDCl3, 300MHz) (Ref. 0004)








332
toxisterol3 R1 / 6,19-dihydrovitamin D3 / 6,19-dihydrocholecalciferol
(7E)-(3S)-9,10-seco-5(10),7-cholestadien-3-ol
VVD0335
Sachiko Yamada
6,19-dihydro-D3
C27H46O 386.654 Download ChemDraw structure file

Dinitrobenzoate : [a]d-22 +34 deg (in CHCl3) (Ref. 0011)
lmax (nm) (emax) (diethyl ether) no absorption maximum at l > 210 (Ref. 0011)
(Neat) 3330, 3020, 2940, 2920, 2860, 1660, 1470, 1380, 1370, 1040, 675 cm -1 (Ref. 0011)
1H-NMR (d, CDCl3, 100MHz) 3.93 (1H, m), 2.80 (1H, d, J = 7 Hz), 4.80 (1H, t, J = 7 Hz), 0.55 (3H, s), 1.68 (3H, s), 0.95 (3H, d, J = 6 Hz), 0.88 (6H, d, J = 6 Hz) (Ref. 0011)
m/z 386 (M+) (Ref. 0011)

RF(TLC) [0.2 nm silicagel plate (Kieselgel G Merk), benzene/acetone] 0.80 (Ref. 0011)
Rrel(GC) [1% SE-30 on GasChrom Q (80-100 mesh), retention time relative to cholestane] 1.56 (Ref. 0011)

Obtained as one of overirradiation products of 7-dehydrocholesterol in EtOH or MeOH. (Ref. 0011)



333
1-methyl-1,25-dihydroxy-4-nor-2,3-secovitamin D3 / 1-methyl-1,25-dihydroxy-4-nor-2,3-secocholecalciferol
(5E,7E)-1-methyl-A-nor-(2,3)-(9,10)-diseco-5,7,10(19)-cholestatriene-1,3,25-triol
VVD0336
Sachiko Yamada
C27H46O3 418.652 Download ChemDraw structure file










334
26,26,26,27,27,27-hexadeuterio-1a,25-dihydroxyvitamin D2 / 26,26,26,27,27,27-hexadeuterio-1a,25-dihydroxyergocalciferol
(5Z,7E,22E)-(1S,3R)-26,26,26,27,27,27-hexadeuterio-9,10-seco-5,7,10(19),22-ergostatetraene-1,3,25-triol
VVD0337
Sachiko Yamada
1a,25-(OH)2-[26,26,26,27,27,27-2H]D2
C28H38D6O3 434.600 Download ChemDraw structure file










335
26,26,26,27,27,27-hexadeuterio-1a,25-dihydroxy-24-epivitamin D2 / 26,26,26,27,27,27-hexadeuterio-1a,25-dihydroxy-24-epiergocalciferol
(5Z,7E,22E)-(1S,3R,24R)-26,26,26,27,27,27-hexadeuterio-9,10-seco-5,7,10(19),22-ergostatetraene-1,3,25-triol
VVD0338
Sachiko Yamada
1a,25-(OH)2-24-epi-[26,26,26,27,27,27-2H]D2
C28H38D6O3 434.600 Download ChemDraw structure file










336
26,26,26,27,27,27-hexafluoro-25-hydroxyvitamin D2 / 26,26,26,27,27,27-hexafluoro-25-hydroxyergocalciferol
(5E,7E,22E)-(3S)-26,26,26,27,27,27-hexafluoro-9,10-seco-5,7,10(19),22-ergostatetraene-3,25-diol
VVD0339
Sachiko Yamada
26,27-F6-25-OHD2
C28H38F6O2 520.591 Download ChemDraw structure file
HL-60 human promyelocytes differentiation : ED50 in nitro blue tetrazplium reduction, phagocytic activity, and nonspecific acid esterase activity are 1.3 times 10-7 M, 1.2 times 10-7 M and 1.3 times 10-7 M, respectively, when 1,25-(OH)2D3 shows the respective ED50 values of 1.0 times 10-8 M, 1.0 times 10-8 M and 1.1 times 10-8 M, respectively. (Ref. 0228)









337
26,26,26,27,27,27-hexafluoro-25-hydroxyvitamin D2 / 26,26,26,27,27,27-hexafluoro-25-hydroxyergocalciferol
(5Z,7E,22E)-(3S)-26,26,26,27,27,27-hexafluoro-9,10-seco-5,7,10(19),22-ergostatetraene-3,25-diol
VVD0340
Sachiko Yamada
C28H38F6O2 520.591 Download ChemDraw structure file




HPLC of two 24-epimers. (Ref. 0197)

Two 24-epimers were synthesized starting from C(22) steroid aldehyde having 5,7-diene structure. and side chain fragment with phenylsulfonyl group. (Ref. 0197)



338
1a-hydroxy-22-(3-hydroxyphenyl)-23,24,25,26,27-pentanorvitamin D3 / 1a-hydroxy-22-(3-hydroxyphenyl)-23,24,25,26,27-pentanorcholecalciferol
(5Z,7E)-(1S,3R)-22-(3-hydroxyphenyl)-23,24-dinor-9,10-seco-5,7,10(19)-cholatriene-1,3-diol
VVD0341
Sachiko Yamada
1a-OH-22-(3-hydroxyphenyl)-23,24,25,26,27-pentanor-D3
C28H38O3 422.600 Download ChemDraw structure file
(% of 1,25-(OH)2D3 effect) Intestinal calcium absorption: 0.28; bone calcium mobilization: 1.0; affinity for chick intestinal receptor, HL-60 cell receptor and serum vitamin D binding protein: 28, 26 and 980, respectively; Inhibition of 1a-hydroxylase activity: 97; differentiation of HL-60 cells: 60. (Ref. 0364)





By coupling of enol trifltes of modified CD steroid fragment with the vitamin D A-ring enyne. (Ref. 0364)



339
1a-hydroxy-22-(4-hydroxyphenyl)-23,24,25,26,27-pentanorvitamin D3 / 1a-hydroxy-22-(4-hydroxyphenyl)-23,24,25,26,27-pentanorcholecalciferol
(5Z,7E)-(1S,3R)-22-(4-hydroxyphenyl)-23,24-dinor-9,10-seco-5,7,10(19)-cholatriene-1,3-diol
VVD0342
Sachiko Yamada
1a-OH-22-(4-hydroxyphenyl)-23,24,25,26,27-pentanor-D3
C28H38O3 422.600 Download ChemDraw structure file
(% of 1,25-(OH)2D3 effect) Intestinal calcium absorption: 0.04; bone calcium mobilization: 0.08; affinity for chick intestinal receptor, HL-60 cell receptor and serum vitamin D binding protein: 5, 8 and 1980, respectively; Inhibition of 1a-hydroxylase activity: 104; differentiation of HL-60 cells: 15. (Ref. 0364)





By coupling of enol trifltes of modified CD steroid fragment with the vitamin D A-ring enyne. (Ref. 0364)



340
(22E,24E,26E)-1a,26b-dihydroxy-22,23,24,25,26,26a-hexadehydro-26a,26b-dihomo-27-norvitamin D3 / (22E,24E,26E)-1a,26b-dihydroxy-22,23,24,25,26,26a-hexadehydro-26a,26b-dihomo-27-norcholecalciferol
(5Z,7E,22E,24E,26E)-(1S,3R)-26a,26b-dihomo-27-nor-9,10-seco-5,7,10(19),22,24,26(26a)-cholestahexaene-1,3,26b-triol
VVD0343
Sachiko Yamada
(22E,24E,26E)-22,23,24,25,26,26a-hexadehydro-26a,26b-dihomo-27-nor-1a,26b-(OH)2D3
C28H40O3 424.615 Download ChemDraw structure file
Biological activity (% of 1,25-(OH)2D3 effect) : Inhibition of proliferation of U937 cells, < 80% ; Induction of differentiation of U 937 cells, 100%. (Ref. 0285)





From protected (5E)-1a-hydroxy-22-oxo-23,24,25,26,27-pentanorvitamin D3 via side chain introduction, photoisomerization and deprotection. (Ref. 0285)



341
(24RS)-28,28,28-trifluoro-25-hydroxyvitamin D2 / (24RS)-28,28,28-trifluoro-25-hydroxyergocalciferol
(5Z,7E,22E)-(3S,24RS)-28,28,28-trifluoro-9,10-seco-5,7,10(19),22-ergostatetraene-3,25-diol
VVD0344
Sachiko Yamada
C28H41F3O2 466.619 Download ChemDraw structure file

(EtOH) lmax (nm) 265, lmin (nm) 228 (Ref. 0197)

m/z 466, 433, 271, 253, 136, 118, 591 (Ref. 0197)



From C(22) steroid aldehyde having 5,7-diene structure. and side chain fragment with phenylsulfonyl group. The side chain fragment was prepared from 3,3,3-trifluoro-1-phenylsulfonyl-1-propene (Ref. 0197)



342
calicoferol D
(22E)-(8S)-3-hydroxy-22-methyl-9,10-seco-1,3,5(10),22-cholestatetraen-9-one
VVD0345
Sachiko Yamada
calicoferol D
C28H42O2 410.632 Download ChemDraw structure file
Exhibits potent activity against Herpes simplex viruses I and II and polio virus. (Ref. 0317)




Isolated from a gorgonian of the genus Muricella. (Ref. 0320)




343
(22E,24E)-1a,25-dihydroxy-22,23,24,24a-tetradehydro-24a-homovitamin D3 / (22E,24E)-1a,25-dihydroxy-22,23,24,24a-tetradehydro-24a-homocholecalciferol
(5Z,7E,22E,24E)-(1S,3R)-24a-homo-9,10-seco-5,7,10(19),22,24-cholestapentaene-1,25-diol
VVD0346
Sachiko Yamada
C28H42O3 426.631 Download ChemDraw structure file
Biological activity (% of 1,25-(OH)2D3 effect) : Inhibition of proliferation of U937 cells, 140% ; Induction of differentiation of U 937 cells, 600% ; Calciuric activity, 70%. (Ref. 0288)





From protected (5E)-1a-hydroxy-22-oxo-23,24,25,26,27-pentanorvitamin D3 via side chain introduction by Wittig reaction followed by Grignard reaction, photoisomerization and deprotection. (Ref. 0288)



344
(22S)-1a,22,25-trihydroxy-23,24-tetradehydro-24a-homo-20-epivitamin D3 / (22S)-1a,22,25-trihydroxy-23,24-tetradehydro-24a-homo-20-epicholecalciferol
(5Z,7E)-(1S,3R,20R,22S)-24a-homo-9,10-seco-5,7,10(19)-cholestatrien-23-yne-1,3,22,25-tetrol
VVD0347
Sachiko Yamada
23,24-tetradehydro-24a-homo-20-epi-1a,22S,25-(OH)3D3
C28H42O4 442.631 Download ChemDraw structure file
Relative potency (1,25-(OH)2D3 = 1) : Induction of differentiation of U 937 cells, 10; Inhibition of proliferation, 17 ; VDR (rachitic chicken intestinal receptor) binding affinity, 0.007. (Ref. 0321)





From protected (5E)-1a-hydroxy-22-oxo-23,24,25,26,27-pentanor-20-epivitamin D3 via the reaction with lithiated acetylene side chain fragment giving major (19:1) 22S-hydroxy product as a key step. (Ref. 0321)



345
(24R)-24-fluoro-1a,25-dihydroxyvitamin D2 / (24R)-24-fluoro-1a,25-dihydroxyergocalciferol
(5Z,7E,22E)-(1S,3R,24R)-24-fluoro-9,10-seco-5,7,10(19),22-ergostatetraene-1,3,25-triol
VVD0348
Sachiko Yamada
24-F-1a,25-(OH)2D2
C28H43FO3 446.638 Download ChemDraw structure file
Chick intestinal VDR binding : 100. HL-60 cell antiproliferative activity : 100. HL-60 cell differentiation (phagocytosis) : 100. HL-60 cell differentiation (NBT reduction) : 100. DBP binding : 50. (The results for 1a,25-dihydroxyvitamin D3 are normalized to 100.) The analogue was as active as 1a,25-dihydroxyvitamin D3 and 1a,25-dihydroxyvitamin D2 in both in vivo and in vitro bone calcium mobilization test. The analogue was also shown to stimulate intestinal calcium transport as much as 1a,25-dihydroxyvitamin D3 and 1a,25-dihydroxyvitamin D2. (Ref. 0250)
[a]D +0.4 deg (c = 0.01 in EtOH) (Ref. 0249)
(EtOH) lmax (nm) (emax) 264 (18800) (Ref. 0249)
(CHCl3) 3420, 1576, 1541, 1047 cm-1 (Ref. 0249)
1H-NMR (d, CDCl3, 400 MHz) 0.57 (3H, s), 1.06 (3H, d, J = 6.4 Hz), 1.23 (3H, s), 1.26 (3H, s), 1.43 (3H, d, J = 22.8 Hz), 2.32 (1H, dd, J = 6.4, 13.8 Hz), 2.60 (1H, dd, J = 3.2, 13.8 Hz), 2.83 (1H, dd, J = 3.9, 12.1 Hz), 4.19-4.26 (1H, m), 4.42-4.46 (1H, m), 5.00 (1H, s), 5.32 (1H, t, J = 1.5 Hz), 5.55 (1H, dd, J = 7.2, 15.3 Hz ), 5.60 (1H, t, J = 15.3 Hz), 6.02 (1H, d, J = 11.1 Hz), 6.38 (1H, d, J = 11.1 Hz) (Ref. 0249)
m/z 426 (M+-HF), 408 (M+-HF-H2O), 390 (M+-HF-2H2O), 372 (M+-HF-3H2O) (Ref. 0249)

HPLC : Lichrosorb RP-18, 10 times 250 mm ; mobile phase, H2O-MeCN (55 : 45) ; 4 ml/min ; tR = 17.6 min (Ref. 0249)

Starting with 1a,3b-bis[(tert-butyldimethylsilyl)oxy]-24-norchol-5,7-dien-23-al, a mixture of 24-Fluoro-1a,25-dihydroxyvitamin D2 and its 24-Epimer was obteined in 3 % overall yield. (Ref. 0249)



346
(24S)-24-fluoro-1a,25-dihydroxyvitamin D2 / (24S)-24-fluoro-1a,25-dihydroxyergocalciferol
(5Z,7E,22E)-(1S,3R,24S)-24-fluoro-9,10-seco-5,7,10(19),22-ergostatetraene-1,3,25-triol
VVD0349
Sachiko Yamada
24-epi-24-F-1a,25-(OH)2D2
C28H43FO3 446.638 Download ChemDraw structure file
Chick intestinal VDR binding : 10. HL-60 cell antiproliferative activity : 100. HL-60 cell differentiation (phagocytosis) : 100. HL-60 cell differentiation (NBT reduction) : 100. DBP binding : 10. (The results for 1a,25-dihydroxyvitamin D3 are normalized to 100.) The analogue showed weak response in both in vivo and in vitro bone calcium mobilization test. The analogue had weak activity to stimulate intestinal calcium transport. (Ref. 0250)
[a]D +1.6 deg (c = 0.03 in EtOH) (Ref. 0249)
(EtOH) lmax (nm) (emax) 264 (18900) (Ref. 0249)
(CHCl3) 3420, 1576, 1541, 1047 cm-1 (Ref. 0249)
1H-NMR (d, CDCl3, 400MHz) 0.57 (3H, s), 1.05 (3H, d, J = 6.7 Hz), 1.23 (3H, s), 1.26 (3H, s), 1.43 (3H, d, J = 22.8 Hz), 2.32 (1H, dd, J = 6.4, 13.9 Hz), 2.60 (1H, dd, J = 3.1, 13.9 Hz), 2.83 (1H, dd, J = 3.8, 12.1 Hz), 4.19-4.26 (1H, m), 4.42-4.45 (1H, m), 5.00 (1H, s), 5.32 (1H, t, J = 1.6 Hz), 5.54 (1H, t, J = 16.0 Hz ), 5.61 (1H, dd, J = 8.3, 16.0 Hz), 6.01 (1H, d, J = 11.3 Hz), 6.38 (1H, d, J = 11.3 Hz) (Ref. 0249)
m/z 426 (M+-HF), 408 (M+-HF-H2O), 390 (M+-HF-2H2O), 372 (M+-HF-3H2O) (Ref. 0249)

HPLC : Lichrosorb RP-18, 10 times 250 mm ; mobile phase, H2O-MeCN (55 : 45) ; 4 ml/min ; tR = 18.2 min (Ref. 0249)

Starting with 1a,3b-bis[(tert-butyldimethylsilyl)oxy]-24-norchol-5,7-dien-23-al, a mixture of 24-Fluoro-1a,25-dihydroxyvitamin D2 and its 24-Epimer was obteined in 3 % overall yield. (Ref. 0249)



347
24,24-difluoro-1a,25-dihydroxy-24a-homovitamin D3 / 24,24-difluoro-1a,25-dihydroxy-24a-homocholecalciferol
(5Z,7E)-(1S,3R)-24,24-difluoro-24a-homo-9,10-seco-5,7,10(19)-cholestatrien-1,3,25-triol
VVD0350
Sachiko Yamada
24,24-difluoro-24-homo-1a,25-(OH)2D3
C28H44F2O3 466.644 Download ChemDraw structure file
Binding affinity for chick intestinal receptor : 28% of that of 1,25-(OH)2D3 ; Binding affinity for rat serum vitamin D binding protein : 15% of that of 1,25-(OH)2D3. Potency of the title compound in 45Ca release from neonatal mouse parietal bones in culture : significantly higher than that of 1,25-(OH)2D3. Potency in the formation of osteoclast-like cells : 100 times of that of 1,25-(OH)2D3. Potency in bone calcium mobilization in vitamin D deficient rats : significantly lower than that of 1,25-(OH)2D3. Potency in intestinal Ca transport response in situ : similar to 1,25-(OH)2D3. (Ref. 0246)
lmax (nm) 265, lmin (nm) 228 (Ref. 0245)

m/z 466 (M+), 448, 430, 415, 407, 287, 269, 251, 134, 43 (Ref. 0245)



The desired provitamin D was synthesized from 1a-hydroxy-5-cholen-24-ol derivative by introducing the desired side chain and a double bond to the 7-position. The provitamin D was converted to the title compound by photochemical method. (Ref. 0245)



348
vitamin D2 / ergocalciferol / ercalciol
(5Z,7E,22E)-(3S)-9,10-seco-5,7,10(19),22-ergostatetraen-3-ol
VVD0351
Sachiko Yamada
D2
C28H44O 396.648 Download ChemDraw structure file
Effect of vitamins D2 and D3 on serum calcium and phosphorus and on bone ash in rachitic chicks was evaluated. Dose-response curves based on the 3 parameters indicated a flatter response to vitamin D2 than vitamin D3. When based on CD50 (curative dose giving a response midway between animals on rachitogenic and standard chick diets), the vitamin D3 to D2 efficacy ratio was estimated at about 8:1 to 11:1. (Ref. 0273)
115-116 degC (Ref. 0139)
[a]D +48.2 deg (in CHCl3), +85 degC (in benzene) (Ref. 0139)
lmax (nm) (emax) 265 (18300) (Ref. 0139)
887 cm-1 (Ref. 0139)
1H-NMR (d, CCl4, 100MHz) 0.57 (3 H, s, 18-CH3), 2.24 (1 H, dd, J = 13 and 7.4 Hz, 4-H), 2.51 (1 H, dd, J = 13 and 3.7 Hz, 4-H), 2.80 (1 H, dd, J = 10.5 and 2.5 Hz, 14-H), 3.82 (1 H, tt, J = 7.4 and 3.7 Hz, 3-H), 4.73 (1 H, d, J = 2.4 Hz, 19-H), 4.97 (1 H, dt, J = 2.4 and 1.0 Hz, 19-H), 5.17 (2 H, m, 22- and 23-H), 5.94 (1 H, dd, J = 11.3 and 0.8 Hz, 7-H), 6.14 (1 H, d, J = 11.3 Hz, 6-H) (Ref. 0140)
13C-NMR (d, CCl4, 22.6MHz) 32.0 (1), 35.3 (2), 69.2 (3), 46.2 (4), 135.4 (5), 122.4 (6), 117.8 (7), 142.2 (8), 29.1 (9),* 145.3 (10), 22.4 (11), 40.4 (12), 46.0 (13), 56.5 (14), 23.7 (15), 27.8 (16),* 56.5 (17), 12.3 (18), 112.5 (19), 40.4 (20), 19.7 (21), 132.0 (22), 135.7 (23), 42.8 (24), 33.2 (25), 20.0 (26), 21.1 (27), 17.7 (28) (Ref. 0003) * The assignments may be interchanged.




From ergosterol by photochemical followed by thermal isomerization. (Ref. 0272/0290)
By convergent method using Wittig-Horner coupling of the A-ring fragment with Windaus-Grundmann ketone. (Ref. 0286)
Metabolism of vitamin D2 is similar to that of vitamin D3 : Vitamin D2 is first metabolized to 25-hydroxyvitamin D2 (Ref. 0263) and then to 1a,25-dihydroxyvitamin D2. (Ref. 0146)
25-Hydroxyvitamin D2 is metabolized to 24R,25-dihydroxyvitamin D2 in normocalcemic and normophosphatemic animals receiving adequate intakes of vitamin D. (Ref. 0150/0264)


349
(5E)-vitamin D2 / 5,6-trans-vitamin D2 / (5E)-ergocalciferol / (5E)-ercalciol
(5E,7E,22E)-(3S)-9,10-seco-5,7,10(19),22-ergostatetraen-3-ol
VVD0352
Sachiko Yamada
(5E)-D2 / 5,6-trans-D2
C28H44O 396.648 Download ChemDraw structure file

99-101 degC (Ref. 0139)
[a]D +223 deg (in benzene) (Ref. 0139)
E1% 1cm (ether) 273 mn, 580 (Ref. 0141)
lmax (nm) (emax) 272-273 (2400) (Ref. 0139)
887 cm-1 (Ref. 0139)





Treatment of vitamin D2 in petroleum ether with I2. (Ref. 0141)



350
previtamin D2 / preergocalciferol
(6Z,24E)-(3S)-9,10-seco-5(10),6,8,22-ergostatetraen-3-ol
VVD0353
Sachiko Yamada
pre-D2
C28H44O 396.648 Download ChemDraw structure file

101-102 degC (Ref. 0139)
[a]D +30 deg (in benzene) (Ref. 0139)
lmax (nm) (emax) 262 (9000) (Ref. 0139)





From ergosterol by ultraviolet light irradiation. (Ref. 0361)



351
tachysterol2
(6E,22E)-(3S)-9,10-seco-5(10),6,8,22-ergostatetraen-3-ol
VVD0354
Sachiko Yamada
tachysterol2
C28H44O 396.648 Download ChemDraw structure file

4-Methyl-3, 5-dinitro-benzoate : 154-155 degC (Ref. 0139)
[a]D -70 deg (Ref. 0139)
lmax (nm) (emax) 281 (24600) (Ref. 0139)
957 cm-1 (Ref. 0139)





From ergosterol by ultraviolet light irradiation. (Ref. 0361)



352
isotachysterol2
(6E,22E)-(3S)-9,10-seco-5(10),6,8(14),22-ergostatetraen-3-ol
VVD0355
Sachiko Yamada
isotachysterol2
C28H44O 396.648 Download ChemDraw structure file

4-methyl-3,5-dinitro-benzoate : 126-127.5 degC (Ref. 0142)
125-126 degC (Ref. 0362)
[a]D -71 deg (in CHCl3) (Ref. 0139)
4-methyl-3,5-dinitro-benzoate : [a]D +55.6 deg (Ref. 0142)
lmax (nm) (e) 280 (31300), 290 (40800), 302 (30650); spectrum. (Ref. 0142)
955 cm-1 (Ref. 0139)
(KBr) 3360, 1640, 1590, 1040, 972, 955 cm-1 (Ref. 0362)





Treatment of vitamin D2 in benzene with BF3-Et2O. (Ref. 0142)



353
(5Z)-isovitamin D2 / 5,6-cis-isovitamin D2 / (5Z)-isoergocalciferol / 5,6-cis-isoergocalciferol
(5Z,7E,22E)-(3S)-9,10-seco-1(10),5,7,22-ergostatetraen-3-ol
VVD0356
Sachiko Yamada
(5Z)-iso-D2
C28H44O 396.648 Download ChemDraw structure file

lmax (isopropanol) nm (log e): 276 sh (4.51), 286.5 (4.58), 298 sh (4.42); spectrum. (Ref. 0362)
(KBr) 3380, 1635, 1582, 1045, 968, 825, 794, cm-1; spectrum. (Ref. 0362)
1H-NMR (d, CDCl3) 0.57 (3 H, s), 0.83 (6 H, d, J = 5.5 Hz), 0.93 (3 H, d, J = 6 Hz), 1.02 (3 H, d, J = 6 Hz), 1.75 (1 H, br s), 2.07 (3 H, m), 4.03 (1 H, m), 5.10 (2 H, n), 5.45 (1 H, m), 6.20 (2 H, s); spectrum. (Ref. 0362)

CD [c = 0.0134 (310-230 nm), isooctane] [q] (nm): 0deg (310), -9800deg (275), 0deg (230); spectrum. (Ref. 0362)


From vitamin D2 by treatment with CaHPO4. (Ref. 0362)



354
(5E)-isovitamin D2 / (5E)-isoergocalciferol
(5E,7E,22E)-(3S)-9,10-seco-1(10),5,7,22-ergostatetraen 3-ol
VVD0357
Sachiko Yamada
(5E)-iso-D2
C28H44O 396.648 Download ChemDraw structure file

108-110 degC (Ref. 0139)
[a]D +108 deg (in CHCl3) (Ref. 0139)
lmax (nm) (e) 278 (33600), 288 (41800), 300 (30500) (Ref. 0142)
spectrum (Ref. 0362)
(KBr) 3290, 1637, 1587, 1040, 970, 835, 792 cm-1; spectrum. (Ref. 0362)
1H-NMR (d, CDCl3) 0.55 (3 H, s), 0.82 (6 H, d, J = 5.5 Hz), 0.93 (3 H, d, J = 6 Hz), 1.02 (3 H, d, J = 6 Hz), 1.87 (3 H, br s), 3.93 (1




Pyrolytic dehydration of (5E)-10-hydroxy-10, 19-dihydrovitamin D2. (Ref. 0142)
By treatment of vitamin D2 with BF3-etherate in benzene. (Ref. 0362)



355
provitamin D2 / ergosterol / proergocalciferol
(22E)-(3S)-5,7,22-ergostatrien-3-ol
VVD0358
Sachiko Yamada
pro-D2
C28H44O 396.648 Download ChemDraw structure file

168 (Nearly anhydrous), 175 (Semihydrous), 183 (Very hydrous) degC (Ref. 0189)
[a]d-20 -132 deg (in CHCl3) (Ref. 0189)
lmax (nm) (emax) 262.0 pm 5 (6750), 271.0 pm 5 (9700), 281.0 pm 5 (10050), 293.0 pm 10 (5800) (Ref. 0187)




Isolation from yeast. (Ref. 0233)




356
lumisterol2
(22E)-(3S)-9b,10a-ergosta-5,7,22-trien-3-ol
VVD0359
Sachiko Yamada
lumisterol2
C28H44O 396.648 Download ChemDraw structure file

118-119 degC (Ref. 0008)
[a]d-20 +186 deg (in 2% Aceton) (Ref. 0008)
lmax (nm) (e) 272 (9450) (Ref. 0008)





From ergosterol by ultraviolet light irradiation. (Ref. 0361)



357
pyrovitamin D2 / pyroergocalciferol
(22E)-(3S)-10a-ergosta-5,7,22-trien-3-ol
VVD0360
Sachiko Yamada
pyro-D2
C28H44O 396.648 Download ChemDraw structure file

93-94 degC (Ref. 0008)
[a]d-20 +495 deg (in 0.25% EtOH) (Ref. 0008)
lmax (nm) (e) 274 (10250) (Ref. 0008)





By heating vitamin D2 at 180 degC (Ref. 0008).



358
isopyrovitamin D2 / isopyroergocalciferol
(22E)-(3S)-9b-ergosta-5,7,22-trien-3-ol
VVD0361
Sachiko Yamada
isopyro-D2
C28H44O 396.648 Download ChemDraw structure file

112-116 degC (Ref. 0008)
[a]d-20 +320 deg (in 0.5% CHCl3) (Ref. 0008)
lmax (nm) (emax) 274 (10350) (Ref. 0008)





By heating vitamin D2 at 180 degC (Ref. 0008).



359
photopyrovitamin D2 / photopyroergocalciferol
(3S,5R,8R)-5,8-cyclo-10a-ergost-6-en-3-ol
VVD0362
Sachiko Yamada
photopyro-D2
C28H44O 396.648 Download ChemDraw structure file

104-105 degC (Ref. 0010)
[a]d-22 +52 deg (in CHCl3) (Ref. 0010)
970, 750 cm-1 (Ref. 0010)





By ultraviolet light irradiation of pyrovitamin D2. (Ref. 0010)



360
photoisopyrovitamin D2 / photoisopyroergocalciferol
(3S,5S,8S)-5,8-cyclo-9b-ergost-6-en-3-ol
VVD0363
Sachiko Yamada
photoisopyro-D2
C28H44O 396.648 Download ChemDraw structure file

81-82 degC (Ref. 0010)
[a]d-22 -11.5 deg (in CHCl3) (Ref. 0010)
970, 748 cm-1(Ref. 0010)





By ultraviolet light irradiation of isopyrovitamin D2. (Ref. 0010)



361
suprasterol2 I
(22E)-(3S,6R,7R,8S)-(6,8)-(7,19)-dicyclo-9,10-seco-5(10),22-ergostadien-3-ol
VVD0364
Sachiko Yamada
suprasterol2 I
C28H44O 396.648 Download ChemDraw structure file

Dinitrobenzoate : 146-147 degC (Ref. 0143)
[a]d-22 -53.2 deg (CHCl3) (Ref. 0143)
lmax (nm) 210 (Ref. 0143)
(CCl4) 3625 (3-OH), 1030 (3C-OH), 968 (22, 23CH=CH) cm-1 (Ref. 0143)
1H-NMR (d, CDCl3, 60MHz) 0.78 (s, 18-CH3), 0.83 (d, J = 6.1 Hz, 26- and 27-CH3), 0.92 (d, J = 5.5 Hz, 21- or 28-CH3), 1.03 (d, J = 6.1Hz, 21- or 28-CH3), 3.96 (1H, m, 3-CH), 5.22 (2H, m, 22- , 23-CH=CH) (Ref. 0143)
m/z 396 (M+), 378 (M+-H2O), 271 (M+-side chain), 253 (M+-side chain-H2O), 136, 118 (Ref. 0143)



Irradiation of vitamin D2 in EtOH by high pressure mercury lamp. (Ref. 0143)



362
suprasterol2 II
(22E)-(3S,6R,7R,8S)-(6,8)-(7,19)-dicyclo-9,10-seco-5(10),22-ergostadien-3-ol
VVD0365
Sachiko Yamada
suprasterol2 II
C28H44O 396.648 Download ChemDraw structure file

110 degC (Ref. 0143)
[a]d-22 +47.8 deg (in CHCl3) (Ref. 0143)
lmax (nm) 210 (Ref. 0143)
(CCl4) 3650 (3-OH), 1030 (3C-OH), 968 (22, 23CH=CH) cm-1 (Ref. 0143)
1H-NMR (d, CDCl3, 60MHz) 0.78 (s, 18-CH3), 0.83 (d, J = 5.5 Hz, 26- and 27-CH3), 0.92 (d, J = 4.5 Hz, 21- or 28-CH3), 1.02 (d, J = 6.3 Hz, 21- or 28-CH3), 1.52 (1H, s, 3-OH), 4.03 (1H, m 3-CH), 5.22 (2H, m , 22-, 23-CH=CH) (Ref. 0143)
m/z 396 (M+), 378 (M+-H2O), 271 (M+-side chain), 253 (M+-side chain-H2O), 136 , 118 (Ref. 0143)
X-ray analysis : 4-ido-5nitrobenzoate derivative (Ref. 0144)


Irradiation of vitamin D2 in EtOH by high pressure mercury lamp. (Ref. 0143)



363
1a-hydroxyvitamin D2 / 1a-hydroxyergocalciferol
(5Z,7E,22E)-(1S,3R)-9,10-seco-5,7,10(19),22-ergostatetraene-1,3-diol
VVD0366
Sachiko Yamada
1a-OHD2
C28H44O2 412.648 Download ChemDraw structure file
Intestinal calcium transport and bone mineral mobilization. (Ref. 0173)
HL-60 human promyelocytes differentiation : ED50 in nitro blue tetrazplium reduction, phagocytic activity and nonspecific acid esterase activity are 5.8 times 10-7 M, 5.8 times 10-7 M and 6.0 times 10-7 M, respectively, when 1,25-(OH)2D3 shows the respective ED50 values of 1.0 times 10-8 M, 1.0 times 10-8 M and 1.1 times 10-8 M, respectively. (Ref. 0228)
(EtOH) lmax (nm) 265, lmin (nm) 228 (Ref. 0174)
1H-NMR (d, CDCl3, 90MHz) 6.40 and 6.00 (2H, AB quartet, J = 12 Hz, 6-, 7-C), 5.32, 5.00 (2H, narrow multiplets, 19-C), 5.20 (2H, m, 22-, 23-C), 4.40 (1H, m, 1-C), 4.20 (1H, m, 3-C), 0.55 (3H, s, 18-C) (Ref. 0174)
m/z 412 (M+, 24), 394 (19), 376 (10), 287 (12), 269 (15), 251 (14), 152 (35), 135 (71), 134 (100) (Ref. 0174)



From ergosterol via epoxidation of 1,4,6-trien-3-one derivative followed by reductive deconjugation as the key step. (Ref. 0173)



364
24-hydroxyvitamin D2 / 24-hydroxyergocalciferol
(5Z,7E,22E)-(3S)-9,10-seco-5,7,10(19),22-ergostatetraene-3,24-diol
VVD0367
Sachiko Yamada
24S-OHD2
C28H44O2 412.648 Download ChemDraw structure file


m/z 412 (M+), 379, 369, 271, 253, 136, 118 (spectrum); bisTMS ether m/z 556 (M+), 513, 423, 333, 253, 208. (Ref. 0264)

HPLC in compared with 25-OHD2: (Ref. 0264)
Isolation and identification from blood of rats: (Ref. 0264)




365
25-hydroxyvitamin D2 / 25-hydroxyergocalciferol
(5Z,7E,22E)-(3S)-9,10-seco-5,7,10(19),22-ergostatetraene-3,25-diol
VVD0368
Sachiko Yamada
25-OHD2
C28H44O2 412.648 Download ChemDraw structure file
HL-60 human promyelocytes differentiation : ED50 in nitro blue tetrazplium reduction, phagocytic activity, and nonspecific acid esterase activity are 3.8 times 10-7 M, 4.6 times 10-7 M and 3.4 times 10-7 M, respectively, when 1,25-(OH)2D3 shows the respective ED50 values of 1.0 times 10-8 M, 1.0 times 10-8 M and 1.1 times 10-8 M, respectively. (Ref. 0228)
[a]d-25 +56.8 deg (c = 0.2 in EtOH) (Ref. 0232)
lmax (nm) (e) 265 (17950) (Ref. 0232)
3401 (OH), 1645, 1631 (C=C), 971 cm-1 (trans C=C) (Ref. 0232)
1H-NMR (d, CDCl3) 0.56 (3 H, s), 0.99 (3 H, d, J = 7.5 Hz), 1.03 (3 H, d, J = 6.5 Hz), 1.13 (3 H, s), 1.16 (3 H, s), 3.95 (1 H, m), 4.81 (1 H, d, J = 2 Hz), 5.03 (1 H, s), 5.33 (2 H, m), 6.01 (1 H, d, J = 11 Hz), 6.23 (1 H, d, J = 11 Hz) (Ref. 0363) .
1H-NMR (d, CDCl3) 0.57 (s, 18-H), 1.00 (d, J = 7 Hz, 28-H), 1.04 (d, J = 7 Hz, 21-H), 1.15 and 1.17 (2 s, 26- and 27-H), 3.95 (m, 1H, 3a-H), 4.82 and 5.05 (2 narrow m, 2 times 1H, 19(Z)- and 19(E)-H), 5.23-5.43 (m, 2H, 22- and 23-H), 6.05 and 6.22 (2 d, J = 11 Hz, 2 times 1H, 7- and 6-H) (Ref. 0232)
m/z (relative intensity) 412 (M+, 63), 394 (M+-H2O, 10), 379 (M+-H2O-Me, 23), 271 (M+-side chain, 37), 253 (M+-side chain-H2O, 43), 136 (100), 118 (86), 59 (99) (Ref. 0232/0363)



Stereoselective synthesis from C(22) steroid aldehyde with 5,7-diene function and chiral side chain fragment which was synthesized enatiospecifically from prenol by Sharpless oxidation as key step. (Ref. 0363) Synthesis of epimeric isomers at C(24) from C(22) steroid aldehyde involving separation of the epimers by HPLC. (Ref. 0232)



366
(22E)-(25R)-25-hydroxy-26-methyl-22,23-didehydrovitamin D3 / (22E)-(25R)-25-hydroxy-26-methyl-22,23-didehydrocholecalciferol
(5Z,7E,22E)-(3S,25R)-26-methyl-9,10-seco-5,7,10(19),22-cholestatetraene-3,25-diol
VVD0369
Sachiko Yamada
(22E)-26-methyl-22,23-didehydro-25R-OHD3
C28H44O2 412.648 Download ChemDraw structure file

(EtOH) lmax (nm) 264, lmin (nm) 228 (Ref. 0307)
1H-NMR (d, CDCl3, 500MHz) 0.67 (3H, s, 18-H), 0.90 (3H, t, J = 7.0 Hz, 26-CH3), 1.03 (3H, d, J = 6.0 Hz, 21-H), 1.13 (3H, s, 27-H), 3.55 (1H, m, 3-H), 4.81 and 5.05 (2H, each br s, 19-H), 5.38 (2H, m, 22- and 23-H), 6.03 (1H, d, J = 11.5 Hz, 7-H), 6.24 (1H, d, J = 11.5 Hz, 6-H) (Ref. 0307)
m/z 412 (M+), 394 (M+-H2O), 379, 340, 271, 253, 211, 136 (base peak), 118, 73 (Ref. 0307)



From 25-hydroxy-5,22-cholestadien-26-oic acid derivative via methylation of 25,26-epoxide as key step. Separation of 25-epimers was achieved via a chiral amide derivative of the starting 26-carboxylic acid. (Ref. 0307)



367
(22E)-(25S)-25-hydroxy-26-methyl-22,23-didehydrovitamin D3 / (22E)-(25S)-25-hydroxy-26-methyl-22,23-didehydrocholecalciferol
(5Z,7E,22E)-(3S,25S)-26-methyl-9,10-seco-5,7,10(19),22-cholestatetraene-3,25-diol
VVD0370
Sachiko Yamada
(22E)-26-methyl-22,23-didehydro-25S-OHD3
C28H44O2 412.648 Download ChemDraw structure file

(EtOH) lmax (nm) 264, lmin (nm) 228 (Ref. 0307)
1H-NMR (d, CDCl3, 500MHz) 0.67 (3H, s, 18-H), 0.90 (3H, t, J = 7.0 Hz, 26-CH3), 1.03 (3H, d, J = 6.0 Hz, 21-H), 1.13 (3H, s, 27-H), 3.55 (1H, m, 3-H), 4.81 and 5.05 (2H, each br s, 19-H), 5.39 (2H, m, 22- and 23-H), 6.03 (1H, d, J = 11.5 Hz, 7-H), 6.24 (1H, d, J = 11.5 Hz, 6-H) (Ref. 0307)
m/z 412 (M+), 394 (M+-H2O), 379, 340, 271, 253, 211, 136 (base peak), 118, 73 (Ref. 0307)



From 25-hydroxy-5,22-cholestadien-26-oic acid derivative via methylation of 25,26-epoxide as key step. Separation of 25-epimers was achieved via a chiral amide derivative of the starting 26-carboxylic acid. (Ref. 0307)



368
25-hydroxy-24-methyl-23,24-didehydrovitamin D3 / 25-hydroxy-24-methyl-23,24-didehydrocholecalciferol
(5Z,7E,23E)-(3S)-9,10-seco-5,7,10(19),23-ergostatetraene-3,25-diol
VVD0371
Sachiko Yamada
24-methyl-23,24-didehyero-25-OHD3
C28H44O2 412.648 Download ChemDraw structure file
HL-60 human promyelocytes differentiation : ED50 in nitro blue tetrazplium reduction, phagocytic activity, and nonspecific acid esterase activity are 7.5 times 10-7 M, 8.0 times 10-7 M and 8.6 times 10-7 M, respectively, when 1,25-(OH)2D3 shows the respective ED50 values of 1.0 times 10-8 M, 1.0 times 10-8 M and 1.1 times 10-8 M, respectively. (Ref. 0228)









369
24-epi-25-hydroxyvitamin D2 / 24-epi-25-hydroxyergocalciferol
(5Z,7E,22E)-(3S,24R)-9,10-seco-5,7,10(19),22-ergostatetraene-3,25-diol
VVD0372
Sachiko Yamada
24-epi-25-OHD2
C28H44O2 412.648 Download ChemDraw structure file
HL-60 human promyelocytes differentiation : ED50 in nitro blue tetrazplium reduction, phagocytic activity, and nonspecific acid esterase activity are 3.0 times 10-7 M, 2.8 times 10-7 M and 2.8 times 10-7 M, respectively, when 1,25-(OH)2D3 shows the respective ED50 values of 1.0 times 10-8 M, 1.0 times 10-8 M and 1.1 times 10-8 M, respectively. (Ref. 0228)
[a]d-25 +50.7 deg (c = 0.2 in EtOH) (Ref. 0232)
lmax (nm) (emax) 265 (17300) (Ref. 0232)
(KBr) 3401 (OH), 1643, 1630 (C=C), 971 cm-1 (trans C=C) (Ref. 0232)
1H-NMR (d, CDCl3) 0.57 (s, 18-H), 0.99 (d, J = 7 Hz, 28-H), 1.03 (d, J = 7 Hz, 21-H), 1.14 and 1.16 (2 s, 26- and 27-H), 3.94 (m, 1H, 3a-H), 4.82 and 5.03 (2 narrow m, 2 times 1H, 19(Z)- and 19(E)-H), 5.20-5.40 (m, 2H, 22- and 23-H), 6.04 and 6.22 (2 d, J = 11 Hz, 2 times 1H, 7- and 6-H) (Ref. 0232)
m/z (relative intensity) 412 (M+, 62), 394 (M+-H2O, 12), 379 (M+-H2O-Me, 31), 271 (M+-side chain, 44), 253 (M+-side chain-H2O, 55), 136 (100), 118 (67), 59 (38) (Ref. 0232)







370
(22E)-1a,25-dihydroxy-26-methyl-22,23-didehydrovitamin D3 / (22E)-1a,25-dihydroxy-26-methyl-22,23-didehydrocholecalciferol
(5Z,7E,22E)-(1S,3R)-26-methyl-9,10-seco-5,7,10(19),22-cholestatetraene-1,3,25-triol
VVD0373
Sachiko Yamada
(22E)-26-methyl-22-ene-1a,25-(OH)2D3
C28H44O3 428.647 Download ChemDraw structure file
Affinity for chick intestinal receptor : equal to that of 1,25-(OH)2D3. Bone calcium mobilization in hypocalcemic rat : equal to that of 1,25-(OH)2D3. (Ref. 0234)
lmax (nm) 265 lmin (nm) 228 (Ref. 0234)
1H-NMR (d, CDCl3, 400MHz) 0.56 (3H, s, 18-H3), 0.91 (3H, t, J =7.6 Hz, -CH2CH3), 1.04 (3H, d, J = 6.8 Hz, 21-H3), 1.13 (3H, s, 27-H3), 4.23 (1H, m, W1/2 = 18.4 Hz, 3a-H), 4.43 (1H, m, W1/2 = 16.9 Hz, 1b-H), 5.00 (1H, br s, W1/2 = 3.2 Hz, 19-H), 5.32 (1H, br s, W1/2 = 3.2 Hz, 19-H), 5.37 (2H, m, 22- and 23-H), 6.02 (1H, d, J = 11.5 Hz, 7-H), 6.38 (1H, d, J = 11.5 Hz, 6-H) (Ref. 0234)
m/z 428 (M+), 410, 392, 356, 338, 320, 287, 269, 251, 152, 134, 73 (Ref. 0234)



Chemical method : The title vitamin D was synthesized from 1a-hydroxylated C(23) steroid precursor via introduction of the desired side chain and the double bond at C(7), and final photochemical and thermal isomerizations. Biological conversion : In vitro incubation of 24-epi-25-hydroxyvitamin D2 with chicken kidney homogenate. (Ref. 0234)



371
1a,25-dihydroxy-20-epivitamin D2 / 1a,25-dihydroxy-20-epiergocalciferol
(5Z,7E,22E)-(1S,3R,20S)-9,10-seco-5,7,10(19),22-ergostatetraene-1,3,25-triol
VVD0374
Sachiko Yamada
20-epi-1a,25-(OH)2D2
C28H44O3 428.647 Download ChemDraw structure file
Biological activity (% of 1,25-(OH)2D3 effect) : Inhibition of proliferation of U 937 cells, 4000% ; Induction of differentiation of U 937 cells, 200% ; Calciuric effects on normal rats, 80%. (Ref. 0284)





From protected (5E)-22-oxo-23,24,25,26,27-pentanorvitamin D3 via side chain introduction by reaction with side chain fragment with terminal phenylsulfonyl group, reductive desulfonylation, separation of 22E/Z-isomers, dye-sensitized photoisomerization and deprotection. (Ref. 0284)



372
(22Z)-1a,25-dihydroxy-20-epivitamin D2 / (22Z)-1a,25-dihydroxy-20-epiergocalciferol
(5Z,7E,22Z)-(1S,3R,20S)-9,10-seco-5,7,10(19),22-ergostatetraene-1,3,25-triol
VVD0375
Sachiko Yamada
(22Z)-20-epi-1a,25-(OH)2D2
C28H44O3 428.647 Download ChemDraw structure file
Biological activity (% of 1,25-(OH)2D3 effect) : Inhibition of proliferation of U 937 cells, 300% ; Induction of differentiation of U 937 cells, 100%. (Ref. 0284)





From protected (5E)-22-oxo-23,24,25,26,27-pentanorvitamin D3 via side chain introduction by reaction with side chain fragment with terminal phenylsulfonyl group, reductive desulfonylation, separation of 22E/Z-isomers, dye-sensitized photoisomerization and deprotection. (Ref. 0284)



373
(6R)-vitamin D2 6,19-sulfur dioxide adduct / (6R)-ergocalciferol 6,19-sulfur dioxide adduct
(7E)-(3S,6R)-6,19-epithio-9,10-seco-5(10),7,22-ergostatrien-3-ol S,S-dioxide
VVD0376
Sachiko Yamada
D2 6R,19-sulfur dioxide adduct
C28H44O3S 460.713 Download ChemDraw structure file

(KBr) 1300, 1140 cm-1 (Ref. 0267)
1H-NMR (d, C6D6) 4.55 and 4.95 (d, J = 9.0 Hz, 6- and 7-C), 3.75 (m, 3-C), 0.48 (s, 18-CH3) (Ref. 0267)
m/z 397 [(M++1)-SO2], 379 [(M++1)-SO2-H2O] (Ref. 0267)
CD (95% EtOH) 208 nm (e -26.2) (Ref. 0267)


From vitamin D2 by treatment with liquid sulfur dioxide. (Ref. 0267)



374
(6S)-vitamin D2 6,19-sulfur dioxide adduct / (6S)-ergocalciferol 6,19-sulfur dioxide adduct
(7E)-(3S,6S)-6,19-epithio-9,10-seco-5(10),7,22-ergostatrien-3-ol S,S-dioxide
VVD0377
Sachiko Yamada
D2 6S,19-sulfur dioxide adduct
C28H44O3S 460.713 Download ChemDraw structure file

(KBr) 1300, 1140 cm-1 (Ref. 0267)
1H-NMR (d, C6D6) 4.48 and 4.90 (d, J = 9.0 Hz, 6- and 7-C), 3.75 (m, 3-C), 0.75 (s, 18-CH3) (Ref. 0267)
m/z 397 [(M++1)-SO2], 379 [(M++1)-SO2-H2O] (Ref. 0267)
CD (95% EtOH) 203 nm (e +11.5) (Ref. 0267)


From vitamin D2 by treatment with liquid sulfur dioxide. (Ref. 0267)



375
(6R)-6,19-epidioxy-6,19-dihydrovitamin D2 / (6R)-6,19-epidioxy-6,19-dihydroergocalciferol
(7E,22E)-(3S,6R)-6,19-epidioxy-9,10-seco-5(10),7,22-ergostatrien-3-ol
VVD0378
Sachiko Yamada
C28H44O3 428.647 Download ChemDraw structure file

Benzoate : 132-133 degC (Ref. 0335)
Benzoate : [a]d-30 +77.5 deg (c = 0.69 in CHCl3) (Ref. 0335)
Benzoate : (95% EtOH ) lmax (nm) (logemax) 227 (4.19) (Ref. 0335/0338)
Benzoate : (KBr) 2960, 1710, 1275, 710 cm-1 (Ref. 0335/0338)
Benzoate : 1H-NMR (d, CDCl3) 0.59 (3H, s, 18-H), 0.82, 0.84, 0.92 and 1.02 (each 3H, d, J = 7 Hz, 21-, 26-, 27- and 28-H), 4.3 (1H, d, J = 15 Hz, 19-H), 4.56 (1H, d, J = 15 Hz, 19-H), 4.88 (1H, d, J = 10 Hz, 6- or 7-H), 5.18 (2H, m, 22- and 23-H), 5.32 (1H, d, J = 10 Hz, 7- or 6-H), 5.4 (1H, m, 3-H), 7.3-7.6 (3H, m, Ar-H), 8.01 (2H, dd, J = 8.2 Hz, Ar-H) (Ref. 0335/0338)
13C-NMR (d, CDCl3) 125.9 (s, C-5), 125.4 (s, C-10), 114.9 (d, C-7), 148.9 (s, C-8), 69.0 (d, C-3), 76.7 (d, C-6), 72.1 (t, C-19) (Ref. 0335/0338)
m/z 532 (M+), 514, 392, 267 (Ref. 0335/0338)
CD : 210 nm (e -17.7) (in Hexane) (Ref. 0335/0338)


As a major product by the reaction of vitamin D2 with singlet oxygen generated by dye-sensitized photochemical method. (Ref. 0335/0337)



376
(6S)-6,19-epidioxy-6,19-dihydrovitamin D2 / (6S)-6,19-epidioxy-6,19-dihydroergocalciferol
(7E,22E)-(3S,6S)-6,19-epidioxy-9,10-seco-5(10),7,22-ergostatrien-3-ol
VVD0379
Sachiko Yamada
C28H44O3 428.647 Download ChemDraw structure file

Benzoate : 126-127 degC (Ref. 0335)
Benzoate : [a]d-30 -6.1 deg (c = 0.54 in CHCl3) (Ref. 0335)
Benzoate : (95% EtOH ) lmax (nm) (logemax) 209 (4.30), 229 (4.18), 274 (3.09), 281 (3.04) (Ref. 0337)
(KBr) 2960, 1720, 1275, 710 cm-1 (Ref. 0335)
1H-NMR (d, CDCl3, 100MHz) 0.59 (3H, s), 0.83 (3H, d, J = 7 Hz), 0.84 (3H, d, J = 7 Hz), 0.92 (3H, d, J = 7 Hz), 1.03 (3H, d, J = 7Hz), 4.21 (1H, d, J = 16 Hz), 4.63 (1H, d, J = 16 Hz), 4.78 (1H, d, J = 10 Hz), 5.18 (2H, m), 5.30 (1H, d, J = 10 Hz), 5.25 (1H, m), 7.3-7.6 (3H, m), 8.01 (2H, dd, J = 8 and 2 Hz) (Ref. 0337)
13C-NMR (d, CDCl3) 114.3, 125.9, 126.4, 128.2, 129.5, 130.4, 132.0, 132.8, 135.4, 149.6, 165.9 (Ref. 0337)
m/z 532 (M+), 514, 392, 267 (Ref. 0335)
CD : 211 nm (e +11.3) (in Hexane), (Benzoate) 206 nm (e +7.7), 219 nm (e +5.8) (in Hexane) (Ref. 0338)


As a major product by the reaction of vitamin D2 with singlet oxygen generated by dye-sensitized photochemical method. (Ref. 0335/0337)



377
(7E,22E)-(3S,6R)-6-hydroperoxy-9,10-seco-4,7,10(19),22-ergostatetraen-3-ol
VVD0380
Sachiko Yamada
C28H44O3 428.647 Download ChemDraw structure file

(95% EtOH ) lmax (nm) 235 (Ref. 0335)
(CHCl3) 3350, 2950 cm-1 (Ref. 0335)
1H-NMR (d, CDCl3) 0.52 (s, 18-H), 4.97 (br s, 19-H), 5.0-5.4 (22- and 23-H), 5.54 (d, J = 8 Hz, 7-H), 6.04 (m, 4-H) (Ref. 0335)
m/z 428.412 (M+), 410.394 (Ref. 0335)



As a minor product by the reaction of vitamin D2 with singlet oxygen generated by dye-sensitized photochemical method. (Ref. 0335)



378
(7E,22E)-(3S,6S)-6-hydroperoxy-9,10-seco-4,7,10(19),22-ergostatetraen-3-ol
VVD0381
Sachiko Yamada
C28H44O3 428.647 Download ChemDraw structure file

(95% EtOH ) lmax (nm) 234 (Ref. 0335)
(CHCl3) 3350, 2950 cm-1 (Ref. 0335)
1H-NMR (d, CDCl3) 0.61 (s, 18-H), 4.95 (br s, 19-H), 4.9-5.3 (22- and 23-H), 5.50 (d, J = 8 Hz, 7-H), 6.04 (m, 4-H) (Ref. 0335)
m/z 428.412 (M+), 410.394 (Ref. 0335)



As a minor product by the reaction of vitamin D2 with singlet oxygen generated by dye-sensitized photochemical method. (Ref. 0335)



379
1a,,25-dihydroxyvitamin D2 / 1a,,25-dihydroxyergocalciferol
(5Z,7E,22E)-(1S,3R)-9,10-seco-5,7,10(19),22-ergostatetraene-1,3,25-triol
VVD0382
Sachiko Yamada
1a,25-(OH)2D2
C28H44O3 428.647 Download ChemDraw structure file
Antirachitic Activity of 1,25-(OH)2D2 in the Rat. Table (Ref. 0146)
Biological Activity of 312 pmol of 1,25-(OH)2D2 in the Chick Duodenal Assay System. Table (Ref. 0147)
Biological Activity of 625 and 1250 pmol of 1,25-(OH)2D2 in the Chick Duodenal Assay System. Table (Ref. 0147)
HL-60 human promyelocytes differentiation: ED50 in nitro blue tetrazplium reduction, phagocytic activity, and nonspecific acid esterase activity are 2.0 times 10-8 M, 2.0 times 10-8 M and 2.6 times 10-8 M, respectively, when 1,25-(OH)2D3 shows the respective ED50 values of 1.0 times 10-8 M, 1.0 times 10-8 M and 1.1 times 10-8 M, respectively. (Ref. 0228)
lmax (nm) 265, lmin (nm) 228 (Ref. 0146)
(EtOH) lmax (nm) 265.5, lmin (nm) 227.5 (Ref. 0148)
1H-NMR (d, CDCl3) 0.56 (3H, s, 18-H3), 1.01 (3H, d, J = 6.5 Hz, 28-H3), 1.04 (3H, d,J = 6.5 Hz, 21-H3),1.14 and 1.18 (6H, each s, 26- and 27-H3), 4.24 (1H, m, 3-H), 4.43 (1H, m, 1-H), 5.01 (1H, narrow m, 19-H), 5.34 (3H, broad m, 19-H, 22- and 23-H), 6.02 (1H, d, J = 11 Hz, 7-H), 6.39 (1H, d, J = 11 Hz, 6-H) (Ref. 0148)
m/z 428 (M+), 410, 370, 352, 287, 269, 251, 152, 134; spectrum (Ref. 0146)
TMS-ether : m/z 644 (M+), 554, 296, 206, 131; spectrum (Ref. 0146)
m/z 428 (M+, 6), 410 (4), 352 (4), 287 (6), 269 (10), 251 (10), 152 (42), 134 (100), 59 (99) (Ref. 0148)

Chromatography: Sephadex LH-20 column (1 times 150 cm packed and eluted with methanol) (Ref. 0146)
Isolation and identification from rachitic chick kidney mitochondria incubated with 25-OHD2. (Ref. 0146)
Synthesis of 1,25-(OH)2D2 and its 24-epimer from 24x-25-OHD2 via SeO2 oxidation of its 3,5-cyclovitamin D derivative. (Ref. 0148)



380
1a,25-dihydroxy-24-epivitamin D2 / 1a,25-dihydroxy-24-epiergocalciferol
(5Z,7E,22E)-(1S,3R,24R)-9,10-seco-5,7,10(19),22-ergostatetraene-1,3,25-triol
VVD0383
Sachiko Yamada
24-epi-1a,25-(OH)2D2
C28H44O3 428.647 Download ChemDraw structure file

(EtOH) lmax (nm) 265.5, lmin (nm) 227.5 (Ref. 0148)
(EtOH) lmax (nm) 264, lmin (nm) 229, A264/A229 = 1.57 (Ref. 0192)
(Film) 3411, 1643, 1630, 971 cm-1 (Ref. 0192)
1H-NMR (d, CDCl3, 270 or 400MHz) 0.54 (3H, s, 18-CH3), 0.97 (3H, d, J = 6.9 Hz, 28-CH3), 1.01 (3H, d, J = 6.6 Hz, 21-CH3), 1.10 and 1.15 (3H and 3H, each s, 26- and 27-CH3), 4.21 (1H, m, 3-H), 4.41 (1H, m, 1-H), 4.97 (1H, br s, 19Z-H), 5.29 (2H, m, 22- and 23-H), 5.31 (1H, br s, 19E-H), 5.99 (1H, d, J = 11.2 Hz, 7-H), 6.35 (1H, d, J = 11.2 Hz, 6-H) (Ref. 0192)
m/z 428 (M+, 13), 410 (9), 352 (7), 287 (11), 269 (15), 251 (13), 152 (52), 134 (100), 59 (97) (Ref. 0148)
m/z 428 (3), 410 (9), 392 (10), 374 (3), 352 (8), 287 (2), 269 (6), 251 (6), 155 (11), 152 (10), 135 (28), 134 (33), 59 (100) (Ref. 0192)



Synthesis of 1,25-(OH)2D2 and its 24-epimer from 24x-25-OHD2 via SeO2 oxidation of its 3,5-cyclovitamin D derivative. (Ref. 0148)



381
5(E)-1a,25-dihydroxyvitamin D2 / 5(E)-1a,25-dihydroxyergocalciferol
(5E,7E,22E)-(1S,3R)-9,10-seco-5,7,10(19),22-ergostatetraene-1,3,25-triol
VVD0384
Sachiko Yamada
5(E)-1a,25-(OH)2D2
C28H44O3 428.647 Download ChemDraw structure file

(EtOH) lmax (nm) 273.5, lmin (nm) 230 (Ref. 0148)

m/z 428 (M+, 8), 410 (3), 287 (3), 269 (7), 251 (7), 152 (34), 134 (100), 59 (78) (Ref. 0148)



Synthesis of 5(E)-1,25-(OH)2D2 and its 24-epimer from 24x-25-OHD2 via SeO2 oxidation of its 3,5-cyclovitamin D derivative. (Ref. 0148)



382
5(E)-1a,25-dihydroxy-24-epivitamin D2 / 5(E)-1a,25-dihydroxy-24-epiergocalciferol
(5E,7E,22E)-(1S,3R,24R)-9,10-seco-5,7,10(19),22-ergostatetraene-1,3,25-triol
VVD0385
Sachiko Yamada
5(E)-24-epi-1a,25-(OH)2D2
C28H44O3 428.647 Download ChemDraw structure file

(EtOH) lmax (nm) 273.5, lmin (nm) 230 (Ref. 0148)

m/z 428 (M+, 10), 410 (4), 352 (4), 287 (5), 269 (9), 251 (8), 152 (37), 134 (100), 59 (82) (Ref. 0148)



Synthesis of 5(E)-1,25-(OH)2D2 and its 24-epimer from 24x-25-OHD2 via SeO2 oxidation of its 3,5-cyclovitamin D derivative. (Ref. 0148)



383
1b,25-dihydroxyvitamin D2 / 1b,25-dihydroxyergocalciferol
(5Z,7E,22E)-(1R,3R)-9,10-seco-5,7,10(19),22-ergostatetraene-1,3,25-triol
VVD0386
Sachiko Yamada
1b,25-(OH)2D2
C28H44O3 428.647 Download ChemDraw structure file

(EtOH) lmax (nm) 263.5, lmin (nm) 227 (Ref. 0149)

m/z 428 (M+, 9), 410 (27), 392 (12), 352 (8), 334 (7), 269 (12), 251 (15), 152 (48), 135 (68), 134 (53), 59 (100) (Ref. 0149)



Synthesis of 1b,25-(OH)2D2 and its 24-epimer from 24x-25-OHD2 via SeO2 oxidation of its 3,5-cyclovitamin D derivative. (Ref. 0148)



384
1b,25-dihydroxy-24-epivitamin D2 / 1b,25-dihydroxy-24-epiergocalciferol
(5Z,7E,22E)-(1R,3R,24R)-9,10-seco-5,7,10(19),22-ergostatetraene-1,3,25-triol
VVD0387
Sachiko Yamada
24-epi-1b,25-(OH)2D2
C28H44O3 428.647 Download ChemDraw structure file

(EtOH) lmax (nm) 263.5, lmin (nm) 227 (Ref. 0148)

m/z 428 (M+, 10), 410 (29), 392 (13), 352 (9), 334 (7), 269 (13), 251 (16), 152 (58), 135 (76), 134 (59), 59 (100) (Ref. 0148)



Synthesis of 1b,25-(OH)2D2 and its 24-epimer from 24x-25-OHD2 via SeO2 oxidation of its 3,5-cyclovitamin D derivative. (Ref. 0148)



385
5(E)-1b,25-dihydroxyvitamin D2 / 1b,25-dihydroxyergocalciferol
(5E,7E,22E)-(1R,3R)-9,10-seco-5,7,10(19),22-ergostatetraene-1,3,25-triol
VVD0388
Sachiko Yamada
5(E)-1b,25-(OH)2D2
C28H44O3 428.647 Download ChemDraw structure file

(EtOH) lmax (nm) 270, lmin (nm) 229.5 (Ref. 0148)

m/z 428 (M+, 11), 410 (5), 351 (4), 287 (4), 269 (12), 251 (11), 152 (67), 135 (100), 134 (75), 59 (72) (Ref. 0148)



Synthesis of 5(E)-1b,25-(OH)2D2 and its 24-epimer from 24x-25-OHD2 via SeO2 oxidation of its 3,5-cyclovitamin D derivative. (Ref. 0148)



386
5(E)-1b,25-dihydroxy-24-epivitamin D2 / 5(E)-1b,25-dihydroxy-24-epiergocalciferol
(5E,7E,22E)-(1R,3R,24R)-9,10-seco-5,7,10(19),22-ergostatetraene-1,3,25-triol
VVD0389
Sachiko Yamada
5(E)-24-epi-1b,25-(OH)2D2
C28H44O3 428.647 Download ChemDraw structure file

(EtOH) lmax (nm) 270, lmin (nm) 229.5 (Ref. 0148)

m/z 428 (M+, 11), 410 (4), 351 (4), 287 (4), 269 (13), 251 (12), 152 (64), 135 (100), 134 (70), 59 (63) (Ref. 0148)



Synthesis of 5(E)-1b,25-(OH)2D2 and its 24-epimer from 24x-25-OHD2 via SeO2 oxidation of its 3,5-cyclovitamin D derivative. (Ref. 0148)



387
1a,25-dihydroxy-18-methylidenevitamin D3 / 1a,25-dihydroxy-18-methylidenecholecalciferol
(5Z,7E)-(1S,3R)-18-methylidene-9,10-seco-5,7,10(19)-cholestatriene-1,3,25-triol
VVD0390
Sachiko Yamada
C28H44O3 428.647 Download ChemDraw structure file
(% of 1,25-(OH)2D3 effect) Affinity for calf thymus receptor and vitamin D binding protein: 25 and 100 ,respectively; differentiation of HL-60 cells: 50; intestinal calcium transport activity evaluated using Caco-2 intestinal cancer cell line: much less than 1,25-(OH)2D3. (Ref. 0365)





From Inhoffen-Lythgoe diol (CD-ring plus 20-22 side chain) and A-ring enyne via palladium-catalyzed coupling. Modification of the methyl at C(18) was achieved by photo-irradiation in the presence of Pb(OAC)4 and iodine as a key step. (Ref. 0365)



388
(22E)-1a,25-dihydroxy-22,23-didehydro-24a-homovitamin D3 / (22E)-1a,25-dihydroxy-22,23-didehydro-24a-homocholecalciferol
(5Z,7E,22E)-(1S,3R)-24a-homo-9,10-seco-5,7,10(19),22-cholestatetraene-1,3,25-triol
VVD0391
Sachiko Yamada
(22E)-1a,25-(OH)2-22-ene-24-homo-D3
C28H44O3 428.647 Download ChemDraw structure file

(EtOH) lmax (nm) 265, lmin (nm) 228 (Ref. 0196)
1H-NMR (d, CDCl3, 360MHz) 0.55 (3H, s, 18-H3), 1.02 (3H, d, J = 6.6 Hz, 21-H3), 1.22 (6H, s, 26- and 27-H3), 2.32 (1H, dd, J = 13.2 and 6.7 Hz), 2.60 (1H, dd, J = 13.0 and 3.0 Hz), 2.83 (1H, dd, J = 12.0 and 3.0 Hz), 4.23 (1H, m, W1/2 = 18.4 Hz, 3a-H), 4.43 (1H, m, W1/2 = 16.9 Hz, 1b-H), 5.00 (1H, br s, W1/2 = 3.2 Hz, 19-H), 5.30 (1H, dd, J = 15.0 and 7.1 Hz, 23- or 22-H), 5.33 (1H, br s, W1/2 = 3.2 Hz, 19-H), 5.37 (1H, dd, J = 15.0 and 5.8 Hz, 22- or 23-H), 6.01 (1H, d, J = 11.0 Hz, 7-H), 6.32 (1H, d, J = 11.0 Hz, 6-H) (Ref. 0196)
m/z 428 (M+ 3.9), 410 (82), 392 (100), 374 (20), 287 (4.8), 269 (21), 251 (38), 152 (10), 134 (30), 123 (54), 59 (4.2). (Ref. 0196)







389
(22E)-(25R)-1a,25-dihydroxy-26-methyl-22,23-didehydrovitamin D3 / (22E)-(25R)-1a,25-dihydroxy-26-methyl-22,23-didehydrocholecalciferol
(5Z,7E,22E)-(1S,3R,25R)-26-methyl-9,10-seco-5,7,10(19),22-cholestatetraene-1,3,25-triol
VVD0392
Sachiko Yamada
(22E)-1a,25(R)-(OH)2-26-methyl-22,23-didehydro-D3
C28H44O3 428.647 Download ChemDraw structure file
Biological activity (% of 1,25-(OH)2D3 effect) : Affinity for chick intestinal vitamin D receptor, 170% ; Intestinal calcium transport, 360% ; Bone calcium mobilization, 220%. (Ref. 0307)
Induction of differentiation (NBT reduction) of HL-60 cells in compared with the effect of 1,25-(OH)2D3 (value in parentheses) : 26.2% (18.1%) at 10-9 M and 72.3% (56.4%) at 10-8 M. (Ref. 0308)





From chemically synthesized (22E)-(25R)-25-hydroxy-26-methyl-22,23-didehydrovitamin D3 by enzymatic 1-a-hydroxylation using vitamin D-deficient chick kidney homogenates. (Ref. 0307)
(22E)-1a,25-dihydroxy-26-methyl-22,23-didehydrovitamin D3 with unknown C-25 configuration has been isolated from chick kidney homogenates incubated with 25-hydroxy-24-epivitamin D2. (Ref. 0234)


390
(22E)-(25S)-1a,25-dihydroxy-26-methyl-22,23-didehydrovitamin D3 / (22E)-(25S)-1a,25-dihydroxy-26-methyl-22,23-didehydrocholecalciferol
(5Z,7E,22E)-(1S,3R,25S)-26-methyl-9,10-seco-5,7,10(19),22-cholestatetraene-1,3,25-triol
VVD0393
Sachiko Yamada
22-ene-26-methyl-1a,25S-(OH)2D3
C28H44O3 428.647 Download ChemDraw structure file
Biological activity (% of 1,25-(OH)2D3 effect) : Affinity for chick intestinal vitamin D receptor, 150% ; Intestinal calcium transport, 210% ; Bone calcium mobilization, 160%. (Ref. 0307)
Induction of differentiation (NBT reduction) of HL-60 cells in compared with the effect of 1,25-(OH)2D3 (value in parentheses) : 37.6% (18.1%) at 10-9 M and 76.5% (56.4%) at 10-8 M. (Ref. 0308)





From chemically synthesized (22E)-(25S)-25-hydroxy-26-methyl-22,23-didehydrovitamin D3 by enzymatic 1-a-hydroxylation using vitamin D-deficient chick kidney homogenates. (Ref. 0307)
(22E)-1a,25-dihydroxy-26-methyl-22,23-didehydrovitamin D3 with unknown C-25 configuration has been isolated from chick kidney homogenates incubated with 25-hydroxy-24-epivitamin D2. (Ref. 0234)


391
(22E)-1a,25-dihydroxy-26-methyl-22,23-didehydrovitamin D3 / (22E)-1a,25-dihydroxy-26-methyl-22,23-didehydrocholecalciferol
(5Z,7E,22E)-(1S,3R)-26-methyl-9,10-seco-5,7,10(19),22-cholestatetraene-1,3,25-triol
VVD0394
Sachiko Yamada
C28H44O3 428.647 Download ChemDraw structure file
Affinity to chick intestinal receptor was equal to that of 1,25-(OH)2D2. (Ref. 0234)
(EtOH) lmax (nm) 265, lmin (nm) 228 (Ref. 0196)
1H-NMR (d, CDCl3, 400MHz) 0.56 (3H, s, 18-H3), 0.91 (3H, t, J = 7.6 Hz, -CH2CH3), 1.04 (3H, d, J = 6.8 Hz, 21-H3), 1.13 (3H, s, 27-H3), 4.23 (1H, m, W1/2 = 18.4 Hz, 3a-H), 4.43 (1H, m, W1/2 = 16.9 Hz, 1b-H), 5.00 (1H, br s, W1/2 = 3.2 Hz, 19-H), 5.32 (1H, br s, W1/2 = 3.2 Hz, 19-H), 5.37 (2H, m, 22- and 23-H), 6.02 (1H, d, J = 11.5 Hz, 7-H), 6.38 (1H, d, J = 11.5 Hz, 6-H) (Ref. 0196)
m/z 428 (M+ 15), 410 (25), 392 (20), 374 (1.0), 338 (6.8), 320 (4.4), 287 (9.0), 269 (15), 251 (14), 141 (8.6), 134 (99), 123 (8.2), 73 (100) (Ref. 0196)


Produced from 24-epi-25-hydroxyvitamin D2 by in vitro incubation with chicken kidney homogenate. (Ref. 0234)




392
(24R)-24,25-dihydroxyvitamin D2 / (24R)-24,25-dihydroxyergocalciferol
(5Z,7E,22E)-(3S,24R)-9,10-seco-5,7,10(19),22-ergostatetraene-3,24,25-triol
VVD0395
Sachiko Yamada
24R,25-(OH)2D2
C28H44O3 428.647 Download ChemDraw structure file

lmax (nm) 265, lmin (nm) 228 (Ref. 0149)
(EtOH) lmax (nm) 265, lmin (nm) 228 (Ref. 0193)
1H-NMR (d, CDCl3) 4.84 and 5.08 (each 1H, br s, 19-H2), 5.64 (2H, m, 22- and 23-H) (Ref. 0193)
m/z 428 (M+), 395, 370, 337, 271, 253, 136, 118 (Ref. 0149)
m/z 428 (M+), 395, 370, 337, 271, 253, 136, 118,59 (Ref. 0150)
m/z 428.3271 (Ref. 0193)

HPLC : Zorbax-SIL column, 5.5% / 94.5% : isopropyl alcohol / hexane, 2ml/min (Ref. 0150)

Asymmetric synthesis of (24R)- and (24S)-24,25-(OH)2D2 from C(22) steroid aldehyde via reduction of 3b,25-dihydroxy-5,22-cholestadien-24-one as a key step, the stereochemistry at C(24) being determined by X-ray analysis. The configuration of 24,25-(OH)2D2 produced by kidney was determined to be R using these synthetic compounds. (Ref. 0151)
Asymmetric synthesis of (24R)- and (24S)-24,25-(OH)2D2 from C(22) steroid aldehyde via triazoline adduct of 3b-acetoxy-25-hydroxy-5,7,22-cholestadien-24-one. (Ref. 0152)
24,25-Dihydroxyvitamin D2 was biologically generated from synthetic 25-hydroxyvitamin D2 using an isolated perfused rat kidney incubated under normocalcemic and normophosphatemic conditions. (Ref. 0150)


393
24,25-dihydroxy-24-epivitamin D2 / 24,25-dihydroxy-24-epiergocalciferol
(5Z,7E,22E)-(3S,24S)-24-methyl-9,10-seco-5,7,10(19),22-cholestatetraene-3,24,25-triol
VVD0396
Sachiko Yamada
24-epi-24,25-(OH)2D2
C28H44O3 428.647 Download ChemDraw structure file

(EtOH) lmax (nm) 265, lmin (nm) 228 (Ref. 0193)
1H-NMR (d, CDCl3) 0.50 (3H, s, 13-Me), 0.98 (3H, d, J = 6 Hz, 20-Me), 1.14, 1.16 and 1.20 (each 3H, s, 24-Me and 25-Me2), 3.88 (1H, m, 3a-H), 4.76 and 4.99 (each 1H, br s, 19-H2), 5.50 (2H, m, 22- and 23-H), 5.97 and 6.20 (each 1H, d, J = 11 Hz, 6- and 7-H) (Ref. 0193)
m/z 428.3307 (Ref. 0193)







394
(24R)-24,26-dihydroxyvitamin D2 / (24R)-24,26-dihydroxyergocalciferol
(5Z,7E,22E)-(3S,24R)-9,10-seco-5,7,10(19),22-ergostatetraene-3,24,26-triol
VVD0397
Sachiko Yamada
24R,26-(OH)2D2
C28H44O3 428.647 Download ChemDraw structure file
Ability of Vitamin D Metabolites to Displace [3H]-25-OHD3 from the Rat Plasma Vitamin D Binding Protein. (Ref. 0157)
Biological Evaluation of 24,26-(OH)2D2. Using the Rat Bioassay. (Ref. 0157)

m/z 428 (M+), 410, 395, 380, 271, 253, 136, 118 (Ref. 0157)

HPLC : Zorbax-SIL column, methanol-acetinitrile-methylene chloride (1:20:180) (Ref. 0157)





395
1a,25-dihydroxy-26,27-dimethyl-20,21-didehydro-23-oxavitamin D3 / 1a,25-dihydroxy-26,27-dimethyl-20,21-didehydro-23-oxacholecalciferol
(5Z,7E)-(1S,3R)-26,27-dimethyl-23-oxa-9,10-seco-5,7,10(19),20-cholestatetraene-1,3,25-triol
VVD0398
Sachiko Yamada
20-ene-23-oxa-26,27-dimethyl-1a,25-(OH)2D3
C28H44O4 444.647 Download ChemDraw structure file
Biological activity : Affinity for pig intestinal nuclear receptor, 33% of 1,25-(OH)2D3 effect ; Affinity for human vitamin D binding protein, < 0.02% of 25-OHD3 effect ; Differentiation of HL-60 cells, 33% of 1,25-(OH)2D3 effect ; Calciuric effect, 20% of 1,25-(OH)2D3 effect. (Ref. 0299)









396
(24R)-1a,24,25-trihydroxyvitamin D2 / (24R)-1a,24,25-trihydroxyergocalciferol
(5Z,7E,22E)-(1S,3R,24R)-9,10-seco-5,7,10(19),22-ergostatetraene-1,3,24,25-tetrol
VVD0399
Sachiko Yamada
1a,24R,25-(OH)3D2
C28H44O4 444.647 Download ChemDraw structure file

lmax (nm) 265, lmin (nm) 228 (Ref. 0155)
1H-NMR (d, CDCl3, 300MHz) : (Ref. 0156)
m/z 444 (M+), 426, 408, 390, 368, 350, 287, 269, 251, 152, 134, 59 (Ref. 0155)
m/z 444 (M+),426, 408, 390, 368, 350, 285, 269, 251, 155, 134, 59 (Ref. 0156)

HPLC : Zorbax-SIL column (25 cm times 4.6 mm), methyolene chloric-2-propanol (98 : 2), 2mL/min (Ref. 0155)
HPLC : Zorbax-SIL column , isopropanol-methylen chloride (7 : 93) (Ref. 0156)





397
(25S)-1a,25,26-trihydroxyvitamin D2 / (25S)-1a,25,26-trihydroxyergocalciferol
(5Z,7E,22E)-(1S,3R,25S)-9,10-seco-5,7,10(19),22-ergostatetraene-1,3,25,26-tetrol
VVD0400
Sachiko Yamada
1a,25S,26-(OH)3D2
C28H44O4 444.647 Download ChemDraw structure file




HPLC: (Ref. 0156)





398
1a,25,28-trihydroxyvitamin D2 / 1a,25,28-trihydroxyergocalciferol
(5Z,7E,22E)-(1S,3R)-9,10-seco-5,7,10(19),22-ergostatetraene-1,3,25,28-tetrol
VVD0401
Sachiko Yamada
1a,25,28-(OH)3D2
C28H44O4 444.647 Download ChemDraw structure file




HPLC: (Ref. 0156)





399
(24R)-1a,24,25,26-tetrahydroxyvitamin D2 / (24R)-1a,24,25,26-tetrahydroxyergocalciferol
(5Z,7E,22E)-(1S,3R,24R,25)-9,10-seco-5,7,10(19),22-ergostatetraene-1,3,24,25,26-pentol
VVD0402
Sachiko Yamada
1a,24R,25,26-(OH)4D2
C28H44O5 460.646 Download ChemDraw structure file

lmax (nm) 265, lmin (nm) 228 (Ref. 0155)

m/z 460 (M+), 442, 424, 406, 384, 368, 366, 350, 348, 287, 269, 251, 152, 134, 75 (Ref. 0155)

HPLC : Zorbax-SIL column (25 cm times 4.6 mm), methyolene chloric-2-propanol (98 : 2), 2mL/min (Ref. 0155)





400
1a,24,25,28-tetrahydroxyvitamin D2 / 1a,24,25,28-tetrahydroxyergocalciferol
(5Z,7E,22E)-(1S,3R)-9,10-seco-5,7,10(19),22-ergostatetraene-1,3,24,25,28-pentol
VVD0403
Sachiko Yamada
1a,24S,25,28-(OH)4D2
C28H44O5 460.646 Download ChemDraw structure file

lmax (nm) 265, lmin (nm) 228 (Ref. 0155)

m/z 460 (M+), 442, 424, 406, 384, 366, 351, 348, 333, 287, 269, 251, 152, 134 (Ref. 0155)

HPLC : Zorbax-SIL column (25 cm times 4.6 mm), methyolene chloric-2-propanol (98 : 2), 2mL/min (Ref. 0155)





401
11a-(chloromethyl)-1a,25-dihydroxyvitamin D3 / 11a-(chloromethyl)-1a,25-dihydroxycholecalciferol
(5Z,7E)-(1S,3R,11S)-11-(chloromethyl)-9,10-seco-5,7,10(19)-cholestatriene-1,3,25-triol
VVD0404
Sachiko Yamada
11a-(chloromethyl)-1a,25-(OH)2D3
C28H45ClO3 465.108 Download ChemDraw structure file






By Horner coupling of 11-substituted CD-ring ketone with the A-ring phosphine oxide. (Ref. 0366)



402
(24R)-25-fluoro-1a,24-dihydroxy-24-methylvitamin D3 / (24R)-25-fluoro-1a,24-dihydroxy-24-methylcholecalciferol
(5Z,7E)-(1S,3R,24R)-25-fluoro-24-methyl-9,10-seco-5,7,10(19)-cholestatrien-1,3,24-triol
VVD0405
Sachiko Yamada
C28H45FO3 448.654 Download ChemDraw structure file










403
11a-(fluoromethyl)-1a,25-dihydroxyvitamin D3 / 11a-(fluoromethyl)-1a,25-dihydroxycholecalciferol
(5Z,7E)-(1S,3R,11S)-11-(fluoromethyl)-9,10-seco-5,7,10(19)-cholestatriene-1,3,25-triol
VVD0406
Sachiko Yamada
11a-(fluoromethyl)-1a,25-(OH)2D3
C28H45FO3 448.654 Download ChemDraw structure file
Biological activity of C-ring analogs of 1a,25-(OH)2D3 : (Ref. 0224)





Convergent synthesis by Horner coupling of 25-hydroxylated CD-ring ketone, which was constructed from Inhoffen-Lythgoe diol (vitamin D2 ozonolysis product), with A-ring phosphine oxide. The substituent at C(11) was introduced by conjugate addition of vinylcopper reagent to 9(11)-en-8-one of the CD-ring fragment followed by appropriate modification of the vinyl group. (Ref. 0224)



404
1a-hydroxy-25-methoxyvitamin D3 / 1a-hydroxy-25-methoxycholecalciferol
(5Z,7E)-(1S,3R)-25-methoxy-9,10-seco-5,7,10(19)-cholestatriene-1,3-diol
VVD0407
Sachiko Yamada
1a-OH-25-methoxy-D3
C28H45O3 429.655 Download ChemDraw structure file
HL-60 human promyelocytes differentiation : ED50 in nitro blue tetrazplium reduction, phagocytic activity, and nonspecific acid esterase activity are 6.5 times 10-8 M, 6.5 times 10-8 M and 6.5 times 10-8 M, respectively, when 1,25-(OH)2D3 shows the respective ED50 values of 1.0 times 10-8 M, 1.0 times 10-8 M and 1.1 times 10-8 M, respectively. (Ref. 0228)









405
6-methylvitamin D3 / 6-methylcholecalciferol
(5Z,7E)-(3S)-6-methyl-9,10-seco-5,7,10(19)-cholestatrien-3-ol
VVD0408
Sachiko Yamada
6-methyl-D3
C28H46O 398.664 Download ChemDraw structure file

(Hexane) lmax (nm) 240 (sh) (Ref. 0265)
1H-NMR (d, CD3COCD3) 0.59 (3H, s, 18-H), 1.79 (3H, s, 6-Me), 4.64 (1H, bs, 19-H), 4.85 (1H, bs, 19-H), 5.59 (1H, bs, 7-H) (Ref. 0265)
m/z 398 (M+), 365, 150, 132 (Ref. 0265)



From vitamin D3 via methylation of its sulfur dioxide adduct using NaH as a base. (Ref. 0265)



406
(5E)-6-methylvitamin D3 / (5E)-6-methylcholecalciferol
(5E,7E)-(3S)-6-methyl 9,10-seco-5,7,10(19)-cholestatrien-3-ol
VVD0409
Sachiko Yamada
(5E)-6-methyl-D3
C28H46O 398.664 Download ChemDraw structure file

(95% EtOH) lmax (nm) 240 (Ref. 0265)
1H-NMR (d, CDCl3) 0.61 (3H, s, 18-H), 1.81 (3H, s, 6-Me), 3.85 (1H, m, 3-H), 4.74 (1H, bs, 19-H), 5.03 (1H, bs, 19-H), 5.44 (1H, bs, 7-H) (Ref. 0265)
m/z 398 (M+), 150, 132 (Ref. 0265)



From vitamin D3 via methylation of its sulfur dioxide adduct using NaH as a base. (Ref. 0265)



407
6-methylprevitamin D3 / 6-methylprecholecalciferol
(6E)-(3S)-6-methyl-9,10-seco-5(10),6,8-cholestatrien-3-ol
VVD0410
Sachiko Yamada
6-methylpre-D3
C28H46O 398.664 Download ChemDraw structure file

(95% EtOH) lmax (nm) 248 (Ref. 0265)
1H-NMR (d, CDCl3) 0.68 (3H, s, 18-H), 1.76 (3H, s, 6-Me), 1.54 (3H, s, 19-H), 3.90 (1H, m, 3-H), 5.50 (2H, m, 7- and 9-H) (Ref. 0265)
m/z 398 (M+), 365, 285 (Ref. 0265)



From vitamin D3 via methylation of its sulfur dioxide adduct using NaH as a base. (Ref. 0265)



408
(10E)-19-methylvitamin D3 / (10E)-19-methylcholecalciferol
(5Z,7E,10E)-(3S)-19-methyl-9,10-seco-5,7,10(19)-cholestatrien-3-ol
VVD0411
Sachiko Yamada
(10E)-19-methyl-D3
C28H46O 398.664 Download ChemDraw structure file

(95% EtOH) lmax (nm) 268 (Ref. 0265)
1H-NMR (d, CDCl3) 0.54 (3H, s, 18-H), 1.72 (3H, d, J = 7.0 Hz, 19-Me), 3.95 (1H, m, 3-H), 5.37 (1H, q, J = 7.0 Hz, 19-H), 5.93 (1H, d, J = 11.0 Hz, 7-H), 6.16 (1H, d, J = 11.0 Hz, 6-H) (Ref. 0265)
m/z 398 (M+), 150, 132 (Ref. 0265)



From vitamin D3 via methylation of its sulfur dioxide adduct using a bulky base. (Ref. 0265)



409
(5E,10E)-19-methylvitamin D3 / (5E,10E)-19-methylcholecalciferol
(5E,7E,10E)-(3S)-19-methyl-9,10-seco-5,7,10(19)-cholestatrien-3-ol
VVD0412
Sachiko Yamada
(5E,10E)-19-methyl-D3
C28H46O 398.664 Download ChemDraw structure file

(95% EtOH) lmax (nm) 264 (Ref. 0265)
1H-NMR (d, CDCl3) 0.58 (3H, s, 18-H), 1.70(3H, d, J = 7.0 Hz, 19-Me), 3.88 (1H, m, 3-H), 5.36 (1H, q, J = 7.0 Hz, 19-H), 5.95 (1H, d, J = 11.0 Hz, 7-H), 6.28 (1H, d, J = 11.0 Hz, 6-H) (Ref. 0265)
m/z 398 (M+), 150, 132 (Ref. 0265)



From vitamin D3 via methylation of its sulfur dioxide adduct using a bulky base. (Ref. 0265)



410
dihydrotachysterol2 / (5E)-(10S)-10,19-dihydrovitamin D2 / (5E)-(10S)-10,19-dihydroergocalciferol
(5E,7E,22E)-(3S,10S)-9,10-seco-5,7,22-ergostatrien-3-ol
VVD0413
Sachiko Yamada
dihydrotachysterol2 / (5E)-10S,19-dihydro-D2
C28H46O 398.664 Download ChemDraw structure file

125-127 degC (Ref. 0145)
[a]d-22 +97.5 deg (in CHCl3) (Ref. 0145)
lmax (nm) (E1%1cm) 242 (870), 251 (1010), 261 (650) (Ref. 0145)
1H-NMR (d, CDCl3) 6.1 (1H, J = 11.1 Hz, 6-H), 5.9 (1H, J = 11.1 Hz, 7-H), 3.6 (1H, J = 4.8 Hz, 3-H), 0.5 (3H, 18-H) (Ref. 0165)
13C-NMR (d, CDCl3, 20MHz) 33.20 (1), 34.95 (2), 70.90 (3), 38.30 (4), 139.75 (5), 117.05 (6), 115.75 (7), 142.15 (8), 29.00 (9), 37.80 (10), 22.40 (11), 40.55 (12), 45.70 (13), 56.60 (14), 23.60 (15), 27.80 (16), 56.60 (17), 12.40 (18), 17.85 (19) (Ref. 0165)








411
3-epidihydrotachysterol2 / (5E)-(10S)-10,19-dihydro-3-epivitamin D2 / (5E)-(10S)-10,19-dihydro-3-epiergocalciferol
(5E,7E,22E)-(3R,10S)-9,10-seco-5,7,22-ergostatrien-3-ol
VVD0414
Sachiko Yamada
3-epidihydrotachysterol2
C28H46O 398.664 Download ChemDraw structure file

p-nitrobenzoate : 100-101 degC (Ref. 0165)
p-nitrobenzoate : [a]D -141deg (c = 1.0 in CHCl3) (Ref. 0165)
lmax (nm) (emax) 242, 251 and 261 (34500, 40000 and 26000) (Ref. 0165)
1H-NMR (d, CDCl3) 6.2 (1H, J = 11.2 Hz, 6-H), 5.8 (1H, J = 11.2 Hz, 7-H), 3.8 (1H, J = 3.7 Hz, 3-H), 0.5 (3H, 18-H) (Ref. 0165)
13C-NMR (d, CDCl3, 20MHz) 31.30 (1), 32.05 (2), 69.65 (3), 35.65 (4), 139.30 (5), 119.15 (6), 115.60 (7), 142.20 (8), 28.95 (9), 38.40 (10), 22.35 (11), 40.45 (12), 45.65 (13), 56.55 (14), 23.50 (15), 27.80 (16), 56.55 (17), 12.40 (18), 18.70 (19) (Ref. 0165)




From dihydrotachysterol by inverting the configuration at C(3). (Ref. 0165)



412
vitamin D4 / 22,23-dihydroergocalciferol
(5Z,7E)-(3S)-9,10-seco-5,7,10(19)-ergostatrien-3-ol
VVD0415
Sachiko Yamada
D4
C28H46O 398.664 Download ChemDraw structure file
Antirachitic activity: 75% of the effect of vitamin D3. (Ref. 0368)









413
provitamin D4
(3S)-5,7-ergostadien-3-ol
VVD0416
Sachiko Yamada
pro-D4
C28H46O 398.664 Download ChemDraw structure file










414
vitamin D7 / 24R-methylvitamin D3
(5Z,7E)-(3S,24R)-24-methyl-9,10-seco-5,7,10(19)-cholestatrien-3-ol
VVD0417
Sachiko Yamada
D7
C28H46O 398.664 Download ChemDraw structure file
Antirachitic activity: 10% of the effect of vitamin D3. (Ref. 0369)









415
provitamin D7
(3S,24R)-24-methyl-5,7-cholestadien-3-ol
VVD0418
Sachiko Yamada
pro-D7
C28H46O 398.664 Download ChemDraw structure file










416
1a-hydroxy-3a-methyl-3-deoxyvitamin D3 / 1a-hydroxy-3a-methyl-3-deoxycholecalciferol
(5Z,7E)-(1S,3S)-3-methyl-9,10-seco-5,7,10(19)-cholestatrien
VVD0419
Sachiko Yamada
3-deoxy-3a-methyl-1a-OHD3
C28H46O 398.664 Download ChemDraw structure file

lmax (nm) 262, lmin (nm) 227 (Ref. 0180)
1H-NMR (d, CDCl3, 300MHz) 628 and 6.06 (AB q, J = sim11.5 Hz, 6-, 7-H), 5.36 (dd, J = sim2.5, 2.5 Hz, 19-H), 4.98 (dd, J = sim2.5, 2.5 Hz, 19E-H), 4.08 (d with fine splittings, J = sim11.5 Hz, 1b-H), 2.82 (d, J = sim13 Hz, 9b-H), 2.28 (1H, d, J = sim12.5 Hz), 2.13 (1H, d, J = sim11.5 Hz), 0.97 (d, J = simHz, 3C-CH3), 0.93 (d, J = sim6 Hz, 21C-CH3), 0.87 (d, J = sim7 Hz, 26, 27C-2CH3), 0.55 (s, 18C-CH3) (Ref. 0180)
(80 eV) m/e (rel intensity ; at m/e > 130, > 7%, and at m/e < 130, > 10%) 398 (M+, 7), 380 (M+-H2O, 8), 190 (8), 175 (7), 173 (11), 172 (7), 171 (8), 161 (8), 159 (11), 157 (12), 151 (26), 150 (base, A-ring portion by C7,8 cleavage), 149 (37), 147 (12), 145 (12), 143 (7), 138 (14), 135 (22), 133 (18), 133 (11), 131 (10), 119 (12), 109 (10), 107 (13), 105 (15), 95 (13), 93 (11), 91 (14) (Ref. 0180)



From 1a-hydroxycholesterol 3-tosylate via the following steps: selective 3a-methylation with Me2CuLi, oxidation of the 1-hydroxyl group, bromination, dehydrobromination, reduction and photochemical followed by thermal isomerization. (Ref. 0180)



417
1a,25-dihydroxy-3a-methyl-3-deoxyvitamin D3 /1a,25-dihydroxy-3a-methyl-3-deoxycholecalciferol
(5Z,7E)-(1S,3S)-3-methyl-9,10-seco-5,7,10(19)-cholestatriene-1,25-diol
VVD0420
Sachiko Yamada
3-deoxy-3a-methyl-1a,25-(OH)2D3
C28H46O2 414.664 Download ChemDraw structure file

lmax (nm) 262, lmin (nm) 227 (Ref. 0180)

(70 eV) m/e (rel intensity ; ge7% for m/e 130-200 and ge45% for m/e < 130) 414 (M+, 0.7), 396 (M+-H2O, 0.8), 378 (M+-2H2O, 0.4) 190 (8), 189 (10), 187 (7), 175 (12), 172 (13), 172 (8), 171 (8), 169 (8), 161 (16), 159 (16), 157 (11), 155 (11), 151 (35), 150 (100, A-ring portion by C7,8 cleavage), 149 (35), 148 (8), 147 (17), 145 (20), 143 (9), 141 (11), 138 (14), 137 (11), 135 (25), 134 (14), 133 (45), 132 (8), 131 (22), 95 (59), 91 (45), 81 (74), 69 (49), 67 (48), 59 (C3H7O, 58) (Ref. 0180)



From 1a,25-dihydroxycholesterol 3-tosylate via the following steps: selective 3a-methylation with Me2CuLi, oxidation of the 1-hydroxyl group, bromination, dehydrobromination, reduction and photochemical followed by thermal isomerization. (Ref. 0180)



418
(6R)-6-methylvitamin D3 6,19-sulfur dioxide adduct / (6R)-6-methylcholecalciferol 6,19-sulfur dioxide adduct
(7E)-(3S,6R)-6-methyl-6,19-epithio-9,10-seco-5(10),7-cholestadien-3-ol S,S-dioxide
VVD0421
Sachiko Yamada
6R-methyl-D3 6,19-sulfur dioxide adduct
C28H46O3S 462.729 Download ChemDraw structure file

3-Tetrahydropyranyl ether : (CHCl3) 1305, 1120 cm-1 (Ref. 0265)
3-Tetrahydropyranyl ether : 1H-NMR (d, C6D6) 0.82 (3H, s, 18-H), 1.47 (3H, s, 6-Me), 3.13 (2H, bs, 19-H), 4.75 (1H, bs, 7-H) (Ref. 0265)
3-Tetrahydropyranyl ether : m/z 482 (M+-SO2) (Ref. 0265)
CD (95% EtOH) 208 nm (e -34.0) (Ref. 0265)


From vitamin D3 SO2 adduct by treatment with methyl iodide in the presence of NaH as a 1:1 mixture of C(6) epimers. (Ref. 0265)



419
(6S)-6-methylvitamin D3 6,19-sulfur dioxide adduct / (6S)-6-methylcholecalciferol 6,19-sulfur dioxide adduct
(7E)-(3S,6S)-6-methyl-6,19-epithio-9,10-seco-5(10),7-cholestadien-3-ol S,S-dioxide
VVD0422
Sachiko Yamada
6S-methyl-D3 6,19-sulfur dioxide adduct
C28H46O3S 462.729 Download ChemDraw structure file

3-Tetrahydropyranyl ether : (CHCl3) 1305, 1120 cm-1 (Ref. 0265)
3-Tetrahydropyranyl ether : 1H-NMR (d, C6D6) 0.73 (3H, s, 18-H), 1.53 (3H, s, 6-Me), 3.10 (2H, bs, 19-H), 4.82 (1H, bs, 7-H) (Ref. 0265)
3-Tetrahydropyranyl ether : m/z 482 (M+-SO2) (Ref. 0265)
CD (95% EtOH) 212 nm (e +17.3) (Ref. 0265)


From vitamin D3 SO2 adduct by treatment with methyl iodide in the presence of NaH as a 1:1 mixture of C(6) epimers. (Ref. 0265)



420
25-methyl-1a,26-dihydroxyvitamin D3 / 25-methyl-1a,26-dihydroxycholecalciferol
(5Z,7E)-(1S,3R)-25-methyl-9,10-seco-5,7,10(19)-cholestatriene-1,3,26-triol
VVD0423
Sachiko Yamada
1a-OH-25-hydroxymethyl-D3
C28H46O3 430.663 Download ChemDraw structure file










421
(1R)-25-hydroxy-1-(hydroxymethyl)vitamin D3 / (1R)-25-hydroxy-1-(hydroxymethyl)cholecalciferol
(5Z,7E)-(1R,3R)-1-(hydroxymethyl)-9,10-seco-5,7,10,(19)-cholestatriene-3,25-diol
VVD0424
Sachiko Yamada
25-OH-1R-(hydroxymethyl)D3
C28H46O3 430.663 Download ChemDraw structure file
The title compound was less than 0.1% as effective as 1,25-(OH)2D3 for binding to the 1,25-(OH)2D3 receptor. However this compound and 1,25-(OH)2D3 were equipotent at inhibiting growth of PE cells (murine keratinocyte cell line) and inhibiting the effect of TPA (12-O-tetradecanoylphorbol-13-acetate) on the activity of ornithinedecarboxylase (ODC). (Ref. 0223)
[a]d-23 +24 deg (c = 0.74 in CH2Cl2) (Ref. 0223)
(MeOH) lmax (nm) 265 (Ref. 0223)
1H-NMR (d, CDCl3) 6.31 (1H, d, J = 11.3 Hz), 5.94 (1H, d, J = 11.3 Hz), 5.15 (1H, dd, J = 2.1 and 1.0 Hz), 4.99 (1H, d, J = 2.0 Hz), 4.03-3.97 (1H, m), 3.63-3.55 (2H, m), 2.83-2.78 (1H, m), 2.65-2.57 (1H, m), 2.30-2.24 (1H, m), 0.93 (3H, d, J = 9.8 Hz), 0.50 (3H, s) (Ref. 0223)
13C-NMR (d, CDCl3) 145.4, 143.3, 134.1, 123.7, 117.0, 113.9, 71.1, 67.2, 64.4, 56.5, 56.3, 46.3, 45.9, 44.5, 44.4, 40.5, 37.5, 36.4, 36.1, 29.4, 29.2, 29.1, 27.7, 23.6, 22.3, 20.8, 18.8, 11.9 (Ref. 0223)
m/z (M+) calcd for C28H46O3 430.3447, found 430.3453 (Ref. 0223)



The title compound was synthesized in a convergent manner by combining enatiomerically pure 25-hydroxylated C,D-ring ketone with highly enantiomerically enriched A-ring phosphine oxide, which was prepared starting from thermal [2+4] cycloaddition of 3-bromo-2-pyrone and acrolein. (Ref. 0223)



422
(1S)-25-hydroxy-1-(hydroxymethyl)vitamin D3 / (1S)-25-hydroxy-1-(hydroxymethyl)cholecalciferol
(5Z,7E)-(1S,3S)-1-(hydroxymethyl)-9,10-seco-5,7,10(19)-cholestatriene-3,25-diol
VVD0425
Sachiko Yamada
25-OH-1S-(hydroxymethyl)D3
C28H46O3 430.663 Download ChemDraw structure file
The title compound was less than 0.1% as effective as 1,25-(OH)2D3 for binding to the 1,25-(OH)2D3 receptor. However this compound and 1,25-(OH)2D3 were equipotent at inhibiting growth of PE cells (murine keratinocyte cell line) and inhibiting the effect of TPA (12-O-tetradecanoylphorbol-13-acetate) on the activity of ornithinedecarboxylase (ODC). (Ref. 0223)
[a]d-23 -64 deg (c = 0.09 in CH2Cl2) (Ref. 0223)
(MeOH) lmax (nm) 264 (Ref. 0223)
1H-NMR (d, CDCl3) 6.32 (1H, d, J = 11.2 Hz), 5.95 (1H, d, J = 11.2 Hz), 5.18 (1H, d, J = 2.0 Hz), 5.02 (1H, d, J = 2.0 Hz), 0.93 (3H, d, J = 6.4 Hz), 0.54 (3H, s) (Ref. 0223)
13C-NMR (d, CD3OD) 147.7, 142.6, 136.7, 124.0, 119.0, 114.1, 71.5, 67.4, 64.7, 58.0, 57.6, 47.4, 47.0, 46.5, 45.3, 41.9, 37.8, 37.6, 37.5, 30.0, 29.3, 29.1, 28.7, 24.7, 23.3, 22.0, 19.4, 12.3 (Ref. 0223)
m/z (M+) calcd for C28H46O3 430.3447, found 430.3449 (Ref. 0223)



The title compound was synthesized in a convergent manner by combining enatiomerically pure 25-hydroxylated C,D-ring ketone with highly enantiomerically enriched A-ring chiron, which was prepared starting from thermal [2+4] cycloaddition of 3-bromo-2-pyrone and acrolein. (Ref. 0223)



423
(22R)-25-hydroxy-22-methoxyvitamin D3 / (22R)-25-hydroxy-22-methoxycholecalciferol
(5Z,7E)-(3S,22R)-22-methoxy-9,10-seco-5,7,10(19)-cholestatriene-3,25-diol
VVD0426
Sachiko Yamada
22R-methoxy-25-OHD3
C28H46O3 430.663 Download ChemDraw structure file

(EtOH) lmax (nm) 267, lmin (nm) 228 (Ref. 0163)

m/z 430 (M+), 412 (M+-H2O), 398 (M+-MeOH), 397 (M+-H2O-Me), 383 (M+-Me-MeOH), 380 (M+-H2O-MeOH), 379 (M+-2H2O-Me), 365 (M+-H2O-MeOH-Me), 362 (M+-2H2O-MeOH), 347 (M+-2H2O-MeOH-Me), 343 (C22-C23 cleavage), 325 (343-H2O), 293 (343-H2O-MeOH), 271, 269, 253, 251, 136 (C7-C8 cleavage), 118 (Ref. 0163)







424
(22S)-25-hydroxy-22-methoxyvitamin D3 / (22S)-25-hydroxy-22-methoxycholecalciferol
(5Z,7E)-(3S,22S)-22-methoxy-9,10-seco-5,7,10(19)-cholestatriene-3,25-diol
VVD0427
Sachiko Yamada
22S-methoxy-25-OHD3
C28H46O3 430.663 Download ChemDraw structure file

(EtOH) lmax (nm) 267, lmin (nm) 228 (Ref. 0163)

m/z 430 (M+), 412 (M+-H2O), 398 (M+-MeOH), 397 (M+-H2O-Me), 383 (M+-Me-MeOH), 380 (M+-H2O-MeOH), 379 (M+-2H2O-Me), 365 (M+-H2O-MeOH-Me), 362 (M+-2H2O-MeOH), 347 (M+-2H2O-MeOH-Me), 343 (C22-C23 cleavage), 325 (343-H2O), 293 (343-H2O-MeOH), 271, 269, 253, 251, 136 (C7-C8 cleavage), 118 (Ref. 0163)







425
25-hydroxy-3,3-dimethyl-3-deoxy-A-homo-2,4-dioxavitamin D3 / 25-hydroxy-3,3-dimethyl-3-deoxy-A-homo-2,4-dioxacholecalciferol
(5Z,7E)-3,3-dimethyl-A-homo-2,4-dioxa-9,10-seco-5,7,10(19)-cholestatrien-25-ol
VVD0428
Sachiko Yamada
C28H46O3 430.663 Download ChemDraw structure file
Affinity for chick intestinal receptor: 4% of the effect of 1,25-(OH)2D3. (Ref. 0359)









426
1a,25-dihydroxy-1b-methylvitamin D3 / 1a,25-dihydroxy-1b-methylcholecalciferol
(5Z,7E)-(1S,3R)-1-methyl-9,10-seco-5,7,10(19)-cholestatriene-1,3,25-triol
VVD0429
Sachiko Yamada
1b-methyl-1a,25-(OH)2D3
C28H46O3 430.663 Download ChemDraw structure file
Binding affinity for calf thymus vitamin D receptor : 1/150 relative to 1,25-(OH)2D3. (Ref. 0181)
(95% EtOH) lmax (nm) 264.6, 252 (sh) (Ref. 0181)
(Neat) 3366, 2937, 2870, 1467, 1377, 1148, 1086, 1037, 912, 895 cm-1 (Ref. 0181)
1H-NMR (d, CDCl3) 0.53 (3H, s), 0.93 (3H, d, J = 6.4 Hz), 1.21 (6H, s), 1.46 (3H, s), 4.15 (1H, tt, J = 9.2 and 4.3 Hz), 4.95 and 5.32 (each 1H, d, J = 1.5 Hz), 5.93 and 6.41 (each 1H, d, J = 11.3 Hz) (Ref. 0181)
m/z 430 (M+, 3), 412 (23), 394 (28), 379 (10), 376 (12), 361 (8), 265 (18), 169 (49), 166 (41), 155 (100), 151 (92) (Ref. 0181)



From bisnorchola-5,7-diene-1a,3b,22-triol N-phenyltriazolinedione (PTAD) adduct: selective oxidation of the 1a-hydroxyl group, methylation, removal of PTAD group and introduction of the side chain gave 1a,25-dihydroxy-1b-methylprovitamin D3. UV irradiation of the provitamin D gave the corresponding previtamin D as a minor product which was converted to the target compound by thermal isomerization. (Ref. 0181)
From 1a,25-dihydroxyvitamin D3: Oxidation of the 1-hydroxyl group, methylation (MeLi) of the 1-ketone and thermal isomerization gave 1a,25-dihydroxy-1b-methylvitamin D3 and its 1-epimer (1b,25-dihydroxy-1a-methylvitamin D3) in 66:25 ratio. (Ref. 0181)



427
1b,25-dihydroxy-1a-methylvitamin D3 / 1b,25-dihydroxy-1a-methylcholecalciferol
(5Z,7E)-(1R,3R)-1-methyl-9,10-seco-5,7,10(19)-cholestatriene-1,3,25-triol
VVD0430
Sachiko Yamada
1a-methyl-1b,25-(OH)2D3
C28H46O3 430.663 Download ChemDraw structure file
Binding affinity for calf thymus vitamin D receptor : < 1/1000 relative to 1,25-(OH)2D3. (Ref. 0181)
(95% EtOH) lmax (nm) 262 (Ref. 0181)
(Neat) 3371, 2927, 2852, 1557, 1467, 1378, 1129, 1104, 936, 912 cm-1 (Ref. 0181)
1H-NMR (d, CDCl3) 0.54 (3H, s), 0.94 (3H, d, J = 6.4 Hz), 1.22 (6H, s), 1.39 (3H, s), 4.08 (1H, m), 4.95 and 5.32 (each 1H, d, J = 1.5 Hz), 5.98 and 6.41 (each 1H, d, J = 11.0 Hz) (Ref. 0181)
m/z 430 (M+, 3), 412 (32), 394 (20), 379 (10), 265 (12), 166 (59), 155 (54), 151 (100) (Ref. 0181)



From 1a,25-dihydroxyvitamin D3: Oxidation of the 1-hydroxyl group, methylation (MeLi) of the 1-ketone and thermal isomerization gave 1b,25-dihydroxy-1a-methylvitamin D3 and its 1-epimer (1a,25-dihydroxy-1b-methylvitamin D3) in 25:66 ratio. (Ref. 0181)



428
1a,25-dihydroxy-8(14)a-homovitamin D3 / 1a,25-dihydroxy-8(14)a-homocholecalciferol
(5Z,7E)-(1S,3R)-8(14)a-homo-9,10-seco-5,7,10(19)-cholestatriene-1,3,25-triol
VVD0431
Sachiko Yamada
C28H46O3 430.663 Download ChemDraw structure file
The title compound was bound to the pig intestinal receptor with an affinity slightly less than 1,25-(OH)2D3, showed the same potency in inducing HL-60 cell differentiation and inhibition of keratinocyte proliferation as 1,25-(OH)2D3, and was found to be approximately 10-fold less potent in inducing hypercalcemia and hypercalciuria after a single injection in normal rats. (Ref. 0220)





Convergent synthesis by Horner coupling of 25-hydroxylated C-homo-CD-ring ketone with A-ring phosphine oxide. C-homo-CD-ring ketone was derived from 25-hydroxylated Grundmann's ketone via ring enlargement by Tiffeneau-Demyanov reaction as key step. (Ref. 0220)



429
2b-methyl-1a,25-dihydroxyvitamin D3 / 2b-methyl-1a,25-dihydroxycholecalciferol
(5Z,7E)-(1S,2R,3R)-2-methyl-9,10-seco-5,7,10(19)-cholestatriene-1,3,25-triol
VVD0432
Sachiko Yamada
2b-methyl-1a,25-(OH)2D3
C28H46O3 430.663 Download ChemDraw structure file
Bovine thymus VDR binding : 13. Bone calcium mobilization : 2. HL-60 cell differentiation : 10. DBP binding : 79. (The results for 1a,25-dihydroxyvitamin D3 are normalized to 100.) (Ref. 0260)





The analogue was synthesized by employing the convergent method of Trost et al. using Pd catalyst. (Ref. 0260)



430
2a-methyl-3-epi-1a,25-dihydroxyvitamin D3 / 2a-methyl-3-epi-1a,25-dihydroxycholecalciferol
(5Z,7E)-(1S,2S,3S)-2-methyl-9,10-seco-5,7,10(19)-cholestatriene-1,3,25-triol
VVD0433
Sachiko Yamada
2a-methyl-3-epi-1a,25-(OH)2D3
C28H46O3 430.663 Download ChemDraw structure file
Bovine thymus VDR binding : 4. HL-60 cell differentiation : 13. DBP binding : 45. (The results for 1a,25-dihydroxyvitamin D3 are normalized to 100.) (Ref. 0260)





The analogue was synthesized by employing the convergent method of Trost et al. using Pd catalyst. (Ref. 0260)



431
2b-methyl-3-epi-1a,25-dihydroxyvitamin D3 / 2b-methyl-3-epi-1a,25-dihydroxycholecalciferol
(5Z,7E)-(1S,2R,3S)-2-methyl-9,10-seco-5,7,10(19)-cholestatriene-1,3,25-triol
VVD0434
Sachiko Yamada
2b-methyl-3-epi-1a,25-(OH)2D3
C28H46O3 430.663 Download ChemDraw structure file
Bovine thymus VDR binding : 0.3. HL-60 cell differentiation : 1.5. DBP binding : 21. (The results for 1a,25-dihydroxyvitamin D3 are normalized to 100.) (Ref. 0260)





The analogue was synthesized by employing the convergent method of Trost et al. using Pd catalyst. (Ref. 0260)



432
2a-methyl-1b,25-dihydroxyvitamin D3 / 2a-methyl-1b,25-dihydroxycholecalciferol
(5Z,7E)-(1R,2S,3R)-2-methyl-9,10-seco-5,7,10(19)-cholestatriene-1,3,25-triol
VVD0435
Sachiko Yamada
2a-methyl-1b,25-(OH)2D3
C28H46O3 430.663 Download ChemDraw structure file
Bovine thymus VDR binding : < 0.1. HL-60 cell differentiation : 1.0. DBP binding : 200. (The results for 1a,25-dihydroxyvitamin D3 are normalized to 100.) (Ref. 0260)





The analogue was synthesized by employing the convergent method of Trost et al. using Pd catalyst. (Ref. 0260)



433
2b-methyl-1b,25-dihydroxyvitamin D3 / 2b-methyl-1b,25-dihydroxycholecalciferol
(5Z,7E)-(1R,2R,3R)-2-methyl-9,10-seco-5,7,10(19)-cholestatriene-1,3,25-triol
VVD0436
Sachiko Yamada
2b-methyl-1b,25-(OH)2D3
C28H46O3 430.663 Download ChemDraw structure file
Bovine thymus VDR binding : < 0.1. HL-60 cell differentiation : 1.5. DBP binding : 1000. (The results for 1a,25-dihydroxyvitamin D3 are normalized to 100.) (Ref. 0260)





The analogue was synthesized by employing the convergent method of Trost et al. using Pd catalyst. (Ref. 0260)



434
2a-methyl-3-epi-1b,25-dihydroxyvitamin D3 / 2a-methyl-3-epi-1b,25-dihydroxycholecalciferol
(5Z,7E)-(1R,2S,3S)-2-methyl-9,10-seco-5,7,10(19)-cholestatriene-1,3,25-triol
VVD0437
Sachiko Yamada
2a-methyl-3-epi-1b,25-(OH)2D3
C28H46O3 430.663 Download ChemDraw structure file
Bovine thymus VDR binding : < 0.1. HL-60 cell differentiation : 0.5. DBP binding : 1200. (The results for 1a,25-dihydroxyvitamin D3 are normalized to 100.) (Ref. 0260)





The analogue was synthesized by employing the convergent method of Trost et al. using Pd catalyst. (Ref. 0260)



435
2b-methyl-3-epi-1b,25-dihydroxyvitamin D3 / 2b-methyl-3-epi-1b,25-dihydroxycholecalciferol
(5Z,7E)-(1R,2R,3S)-2-methyl-9,10-seco-5,7,10(19)-cholestatriene-1,3,25-triol
VVD0438
Sachiko Yamada
2b-methyl-3-epi-1b,25-(OH)2D3
C28H46O3 430.663 Download ChemDraw structure file
Bovine thymus VDR binding : 0.8. HL-60 cell differentiation : 3.0. DBP binding :1300. (The results for 1a,25-dihydroxyvitamin D3 are normalized to 100.) (Ref. 0260)





The analogue was synthesized by employing the convergent method of Trost et al. using Pd catalyst. (Ref. 0260)



436
2a-methyl-20-epi-1a,25-dihydroxyvitamin D3 / 2a-methyl-20-epi-1a,25-dihydroxycholecalciferol
(5Z,7E)-(1S,2S,3R,20S)-2-methyl-9,10-seco-5,7,10(19)-cholestatriene-1,3,25-triol
VVD0439
Sachiko Yamada
2a-methyl-20-epi-1a,25-(OH)2D3.........................................
C28H46O3 430.663 Download ChemDraw structure file
Bovine thymus VDR binding : 1200. Bone calcium mobilization : 655. HL-60 cell differentiation : 59000. DBP binding : < 0.3 (The results for 1a,25-dihydroxyvitamin D3 are normalized to 100.) (Ref. 0261)
(EtOH) lmax (nm) 266 (Ref. 0261)
1H-NMR (d, CDCl3-D2O, 400MHz) 0.53 (3H, s), 0.85 (3H, d, J = 6.7 Hz), 1.08 (3H, d, J = 6.8 Hz), 1.21 (6H, s), 2.23 (1H, dd, J = 7.9, 13.4 Hz), 2.67 (1H, dd, J = 4.0, 13.2 Hz), 2.83 (1H, dd, J= 4,0, 12.5 Hz), 3.83 (1H, ddd, J = 7.9, 4.4, 4.0 Hz), 4.29 (1H, d, J = 3.3 Hz), 5.01 (1H, m), 5.28 (1H, m), 6.01 (1H, d, J = 11.3 Hz), 6.39 (1H, d, J = 11.3 Hz) (Ref. 0261)
m/z 430 (M+), 412 (M+-H2O), 394 (M+-2H2O) (Ref. 0261)



The analogue was synthesized by employing the convergent method of Trost et al. using Pd catalyst. (Ref. 0261)



437
2b-methyl-20-epi-1a,25-dihydroxyvitamin D3 / 2b-methyl-20-epi-1a,25-dihydroxycholecalciferol
(5Z,7E)-(1S,2R,3R,20S)-2-methyl-9,10-seco-5,7,10(19)-cholestatriene-1,3,25-triol
VVD0440
Sachiko Yamada
2b-methyl-20-epi-1a,25-(OH)2D3
C28H46O3 430.663 Download ChemDraw structure file
Bovine thymus VDR binding : 160. Bone calcium mobilization : 115. HL-60 cell differentiation : 2600. DBP binding : < 0.3. (The results for 1a,25-dihydroxyvitamin D3 are normalized to 100.) (Ref. 0261)





The analogue was synthesized by employing the convergent method of Trost et al. using Pd catalyst. (Ref. 0261)



438
2a-methyl-3-epi-20-epi-1a,25-dihydroxyvitamin D3 / 2a-methyl-3-epi-20-epi-1a,25-dihydroxycholecalciferol
(5Z,7E)-(1S,2S,3S,20S)-2-methyl-9,10-seco-5,7,10(19)-cholestatriene-1,3,25-triol
VVD0441
Sachiko Yamada
2a-methyl-3-epi-20-epi-1a,25-(OH)2D3
C28H46O3 430.663 Download ChemDraw structure file
Bovine thymus VDR binding : 17. Bone calcium mobilization : 144. HL-60 cell differentiation : 730. DBP binding : < 0.3. (The results for 1a,25-dihydroxyvitamin D3 are normalized to 100.) (Ref. 0261)





The analogue was synthesized by employing the convergent method of Trost et al. using Pd catalyst. (Ref. 0261)



439
2b-methyl-3-epi-20-epi-1a,25-dihydroxyvitamin D3 / 2b-methyl-3-epi-20-epi-1a,25-dihydroxycholecalciferol
(5Z,7E)-(1S,2R,3S,20S)-2-methyl-9,10-seco-5,7,10(19)-cholestatriene-1,3,25-triol
VVD0442
Sachiko Yamada
2b-methyl-3-epi-20-epi-1a,25-(OH)2D3
C28H46O3 430.663 Download ChemDraw structure file
Bovine thymus VDR binding : < 0.1. HL-60 cell differentiation : 6. DBP binding : < 0.3. (The results for 1a,25-dihydroxyvitamin D3 are normalized to 100.) (Ref. 0261)





The analogue was synthesized by employing the convergent method of Trost et al. using Pd catalyst. (Ref. 0261)



440
2a-methyl-20-epi-1b,25-dihydroxyvitamin D3 / 2a-methyl-20-epi-1b,25-dihydroxycholecalciferol
(5Z,7E)-(1R,2S,3R,20S)-2-methyl-9,10-seco-5,7,10(19)-cholestatriene-1,3,25-triol
VVD0443
Sachiko Yamada
2a-methyl-20-epi-1b,25-(OH)2D3
C28H46O3 430.663 Download ChemDraw structure file
Bovine thymus VDR binding : < 0.1. HL-60 cell differentiation : 3. DBP binding : < 0.3. (The results for 1a,25-dihydroxyvitamin D3 are normalized to 100.) (Ref. 0261)





The analogue was synthesized by employing the convergent method of Trost et al. using Pd catalyst. (Ref. 0261)



441
2b-methyl-20-epi-1b,25-dihydroxyvitamin D3 / 2b-methyl-20-epi-1b,25-dihydroxycholecalciferol
(5Z,7E)-(1R,2R,3R,20S)-2-methyl-9,10-seco-5,7,10(19)-cholestatriene-1,3,25-triol
VVD0444
Sachiko Yamada
2b-methyl-20-epi-1b,25-(OH)2D3
C28H46O3 430.663 Download ChemDraw structure file
Bovine thymus VDR binding : < 0.1. HL-60 cell differentiation : 1. DBP binding : < 0.3. (The results for 1a,25-dihydroxyvitamin D3 are normalized to 100.) (Ref. 0261)





The analogue was synthesized by employing the convergent method of Trost et al. using Pd catalyst. (Ref. 0261)



442
2a-methyl-3-epi-20-epi-1b,25-dihydroxyvitamin D3 / 2a-methyl-3-epi-20-epi-1b,25-dihydroxycholecalciferol
(5Z,7E)-(1R,2S,3S,20S)-2-methyl-9,10-seco-5,7,10(19)-cholestatriene-1,3,25-triol
VVD0445
Sachiko Yamada
2a-methyl-3-epi-20-epi-1b,25-(OH)2D3
C28H46O3 430.663 Download ChemDraw structure file
Bovine thymus VDR binding : < 0.1. HL-60 cell differentiation : 1. DBP binding : < 0.3. (The results for 1a,25-dihydroxyvitamin D3 are normalized to 100.) (Ref. 0261)





The analogue was synthesized by employing the convergent method of Trost et al. using Pd catalyst. (Ref. 0261)



443
2b-methyl-3-epi-20-epi-1b,25-dihydroxyvitamin D3 / 2b-methyl-3-epi-20-epi-1b,25-dihydroxycholecalciferol
(5Z,7E)-(1R,2R,3S,20S)-2-methyl-9,10-seco-5,7,10(19)-cholestatriene-1,3,25-triol
VVD0446
Sachiko Yamada
2b-methyl-3-epi-20-epi-1b,25-(OH)2D3
C28H46O3 430.663 Download ChemDraw structure file
Bovine thymus VDR binding : 7. Bone calcium mobilization : 19. HL-60 cell differentiation : 190. DBP binding : < 0.3. (The results for 1a,25-dihydroxyvitamin D3 are normalized to 100.) (Ref. 0261)





The analogue was synthesized by employing the convergent method of Trost et al. using Pd catalyst. (Ref. 0261)



444
1a,25-dihydroxy-11a-methylvitamin D3 / 1a,25-dihydroxy-11a-methylcholecalciferol
(5Z,7E)-(1S,3R,11S)-11-methyl-9,10-seco-5,7,10(19)-cholestatriene-1,3,25-triol
VVD0447
Sachiko Yamada
11a-methyl-1a,25-(OH)2D3
C28H46O3 430.663 Download ChemDraw structure file
(% of 1a,25-(OH)2D3 effect) Affinity for rat duodenum receptor, UMR 106 cell receptor and human vitamin D binding protein: 230, 80 and 340, respectively; Differentiation of HL-60 cells: 113; Inhibition of the proliferation of peripheral blood mononuclear cells (PBMC): 90; Bone resorption: 100 (3 day), 100 (6 day); Biological activity in rachitic chick: serum calcium, 40; bone calcium, 46; serum osteocalcin, 50; calbindin D-28K, 60. <0224>>





Convergent synthesis by Horner coupling of 25-hydroxylated CD-ring ketone, which was constructed from Inhoffen-Lythgoe diol (vitamin D2 ozonolysis product), with A-ring phosphine oxide. The substituent at C(11) was introduced by conjugate addition of organocopper reagent to 9(11)-en-8-one of the CD-ring fragment. (Ref. 0224)



445
1a,25-dihydroxy-11b-methylvitamin D3 / 1a,25-dihydroxy-11b-methylcholecalciferol
(5Z,7E)-(1S,3R,11R)-11-methyl-9,10-seco-5,7,10(19)-cholestatriene-1,3,25-triol
VVD0448
Sachiko Yamada
11b-methyl-1a,25-(OH)2D3
C28H46O3 430.663 Download ChemDraw structure file
(% of 1a,25-(OH)2D3 effect) Affinity for rat duodenum receptor and human vitamin D binding protein: 37 and 86, respectively; Differentiation of HL-60 cells: 19; Inhibition of the proliferation of peripheral blood mononuclear cells (PBMC): 1.4; Bone resorption: <1 (3 day), 1 (6 day); Biological activity in rachitic chick: serum calcium, 2; bone calcium, 5; serum osteocalcin, 5; calbindin D-28K, 3. <0224>>





Convergent synthesis by Horner coupling of 25-hydroxylated CD-ring ketone, which was constructed from Inhoffen-Lythgoe diol (vitamin D2 ozonolysis product), with A-ring phosphine oxide. The substituent at C(11) was introduced by conjugate addition of organocopper reagent to 9(11)-en-8-one of the CD-ring fragment and inversion of the configuration at C(11) by introducing 9(11)-double bond followed by catalytic hydrogenation. (Ref. 0224)



446
1a,25-dihydroxy-18-methylvitamin D3 / 1a,25-dihydroxy-18-methylcholecalciferol
(5Z,7E)-(1S,3R)-18-methyl-9,10-seco-5,7,10(19)-cholestatriene-1,3,25-triol
VVD0449
Sachiko Yamada
18-methyl-1a,25-(OH)2D3
C28H46O3 430.663 Download ChemDraw structure file
(% of 1,25-(OH)2D3 effect) Affinity for calf thymus receptor and vitamin D binding protein: 100 and 100 ,respectively; differentiation of HL-60 cells: 50; intestinal calcium transport activity evaluated using Caco-2 intestinal cancer cell line: similarly potent as 1,25-(OH)2D3. (Ref. 0365)





From Inhoffen-Lythgoe diol (CD-ring plus 20-22 side chain) and A-ring enyne via palladium-catalyzed coupling. Modification of the methyl at C(18) was achieved via photo-irradiation in the presence of Pb(OAC)4 and iodine as a key step. (Ref. 0365)



447
1a,25-dihydroxy-24a-homovitamin D3 / 1a,25-dihydroxy-24a-homocholecalciferol
(5Z,7E)-(1S,3R)-24a-homo-9,10-seco-5,7,10(19)-cholestatriene-1,3,25-triol
VVD0450
Sachiko Yamada
1a,25-(OH)2-24a-homo-D3
C28H46O3 430.663 Download ChemDraw structure file
HL-60 human promyelocytes differentiation : ED50 in nitro blue tetrazplium reduction, phagocytic activity, and nonspecific acid esterase activity are 1.2 times 10-9 M, 1.6 times 10-9 M and 1.3 times 10-9 M, respectively, when 1,25-(OH)2D3 shows the respective ED50 values of 1.0 times 10-8 M, 1.0 times 10-8 M and 1.1 times 10-8 M, respectively. (Ref. 0228)
(EtOH) lmax (nm) 265, lmin (nm) 228 (Ref. 0196)

m/z 430 (M+ 5.5), 412 (51), 394 (100), 376 (18), 287 (3.8), 269 (9.4), 251 (21), 152 (9), 134 (28), 59 (7.1) (Ref. 0196)



From hydroxy protected (5E)-23,24,25,26,27-pentanorvitamin D3 22-bis(methylseleno)acetal via displacement of one methylseleno group by side chain fragment, reduction of the other methylseleno group via 6,19-SO2 adduct, desulfonylation, dye-sensitized photoisomerization and deprotection. From hydroxy protected (5E)-22-tosyloxy-23,24,25,26,27-pentanorvitamin D3 via cuprate catalyzed Grignard reaction, photoisomerization and deprotection. (Ref. 0285)



448
(24R)-1a,25-dihydroxy-24-methylvitamin D3 /(24R)-1a,25-dihydroxy-24-methylcholecalciferol
(5Z,7E)-(1S,3R,24R)-24-methyl-9,10-seco-5,7,10(19)-cholestatriene-1,3,25-triol
VVD0451
Sachiko Yamada
24R-methyl-1a,25-(OH)2D3
C28H46O3 430.663 Download ChemDraw structure file










449
1a,25-dihydroxy-24a-homo-20-epivitamin D3 / 1a,25-dihydroxy-24a-homo-20-epicholecalciferol
(5Z,7E)-(1S,3R,20S)-24a-homo-9,10-seco-5,7,10(19)-cholestatrien-1,3,25-triol
VVD0452
Sachiko Yamada
C28H46O3 430.663 Download ChemDraw structure file
Biological activity (% of 1,25-(OH)2D3 effect) Inhibition of U 937 cell (human histiocytic lymphoma cell line) proliferation : 31800 (IC50 : the title compound, 4.4 times 10-11 M ; 1,25-(OH)2D3, 1.4 times 10-8 M) ; Induction of U 937 cell differentiation : 20000 ; Binding to the 1,25-(OH)2D3 receptor from rachitic chicken intestine : 110 ; Calcemic activity determined by the increase in urinary calcium excretion in rats : 500. Inhibitory effects on murine thymocyte activation : 38000 (IC50 : the title compound, 5.0 times 10-13 M ; 1,25-(OH)2D3, 1.9 times 10-10 M). (Ref. 0278)





From protected (5E)-1a-hydroxy-22-p-toluenesulfonyloxy-23,24,25,26,27-pentanorvitamin D3 via introduction of the side chain by the reaction with Grignard reagent in the presence of copper catalyst, photoisomerization and deprotection. (Ref. 0284)



450
1a,25-dihydroxy-24a,24b-didihomo-22-thia-20-epivitamin D3 / 1a,25-dihydroxy-24a,24b-didihomo-22-thia-20-epicholecalciferol
(5Z,7E)-(1S,3R,20R)-24a,24b-dihomo-9,10-seco-22-thia-5,7,10(19)-cholestatriene-1,3,25-triol
VVD0453
Sachiko Yamada
20-epi-22-thia-24a,24b-dihomo-1a,25-(OH)2D3
C28H46O3S 462.729 Download ChemDraw structure file






Synthesis from dehydroepiandrostertone via the 5,7-diene by photochemical method. (Ref. 0215)



451
1a,25-dihydroxy-24a,24b-dihomo-22-thiavitamin D3 / 1a,25-dihydroxy-24a,24b-dihomo-22-thiacholecalciferol
(5Z,7E)-(1S,3R)-24a,24b-dihomo-9,10-seco-22-thia-5,7,10(19)-cholestatriene-1,3,25-triol
VVD0454
Sachiko Yamada
22-thia-24a,24b-dihomo-1a,25-(OH)2D3
C28H46O3S 462.729 Download ChemDraw structure file






Synthesis from dehydroepiandrostertone via the 5,7-diene by photochemical method. (Ref. 0215)



452
1a,25-dihydroxy-26-methylvitamin D3 / 1a,25-dihydroxy-26-methylcholecalciferol
(5Z,7E)-(1S,3R)-26-methyl-9,10-seco-5,7,10(19)-cholestatriene-1,3,25-triol
VVD0455
Sachiko Yamada
26-methyl-1a,25-(OH)2D3
C28H46O3 430.663 Download ChemDraw structure file
HL-60 human promyelocytes differentiation : ED50 in nitro blue tetrazplium reduction, phagocytic activity, and nonspecific acid esterase activity are 1.2 times 10-9 M, 1.6 times 10-9 M and 1.3 times 10-9 M, respectively, when 1,25-(OH)2D3 shows the respective ED50 values of 1.0 times 10-8 M, 1.0 times 10-8 M and 1.1 times 10-8 M, respectively. (Ref. 0228)









453
1a,25-dihydroxy-26-methylvitamin D3 / 1a,25-dihydroxy-26-methylcholecalciferol
(5Z,7E)-(1S,3R)-26-methyl-9,10-seco-5,7,10(19)-cholestatriene-1,3,25-triol(5Z,7E)-(1S,3R)-26-methyl-9,10-seco-5,7,10(19)-cholestatriene-1,3,25-triol
VVD0456
Sachiko Yamada
26-methyl-1a,25-(OH)2D3
C28H46O3 430.663 Download ChemDraw structure file

(EtOH) lmax (nm) 265, lmin (nm) 228 (Ref. 0196)

m/z 430 (M+ 2.9), 412 (9.7), 394 (8.8), 379 (2.3), 376 (0.9), 287 (2.0), 269 (4.1), 251 (5.9), 152 (30), 134 (100), 116 (17), 73 (89), 55 (69) (Ref. 0196)







454
1a,25-dihydroxy-26,27-dimethyl-22-thiavitamin D3 / 1a,25-dihydroxy-26,27-dimethyl-22-thiacholecalciferol
(5Z,7E)-(1S,3R)-26,27-dimethyl-9,10-seco-22-thia-5,7,10(19)-cholestatriene-1,3,25-triol
VVD0457
Sachiko Yamada
1a,25-(OH)2-26,27-dimethyl-22-thia-D3
C28H46O3S 462.729 Download ChemDraw structure file






Synthesis from dehydroepiandrostertone via the 5,7-diene by photochemical method. (Ref. 0215)



455
1a,25-dihydroxy-26,27-dimethyl-22-thia-20-epivitamin D3 / 1a,25-dihydroxy-26,27-dimethyl-22-thia-20-epicholecalciferol
(5Z,7E)-(1S,3R,20R)-26,27-dimethyl-9,10-seco-22-thia-5,7,10(19)-cholestatriene-1,3,25-triol
VVD0458
Sachiko Yamada
1a,25-(OH)2-20-epi-26,27-dimethyl-22-thia-D3
C28H46O3S 462.729 Download ChemDraw structure file






Synthesis from dehydroepiandrostertone via the 5,7-diene by photochemical method. (Ref. 0215)



456
(24R)-1a,24-dihydroxy-26,27-dimethyl-22-oxavitamin D3 / (24R)-1a,24-dihydroxy-26,27-dimethyl-22-oxacholecalciferol
(5Z,7E)-(1S,3R,24R)-26,27-dimethyl-22-oxa-9,10-seco-5,7,10(19)-cholestatriene-1,3,24-triol
VVD0459
Sachiko Yamada
1a,24R-(OH)2-26,27-dimethyl-22-oxa-D3
C28H46O4 446.662 Download ChemDraw structure file
The activity to induce differentiation of human myeloid leukemia cells (HL-60) into macrophases in vitro estimated by superoxide anion generation was shown in comparison with 1,25-(OH)2D3. (Ref. 0205)
[a]d-24 43.47 deg (c = 0.115 in EtOH) (Ref. 0205)
(EtOH) lmax (nm) 263, lmin (nm) 227 (Ref. 0205)
1H-NMR (d) 0.54 (3H, s), 0.89 (6H, t, J = 6.8 Hz), 1.19 (3H, d, J = 6.2 Hz), 3.16 (1H, t, J = 9.6 Hz) 3.30 (1H, br t, J = 6.4 Hz), 3.61-3.76 (2H, m), 4.16-4.28 (1H, br), 4.37-4.48 (1H, br), 4.99 (1H, s), 5.33 (1H, s), 6.02 (1H, d, J = 11.4 Hz), 6.37 (1H, d, J = 11.4 Hz) (Ref. 0205)
m/z 446 (M+), 97 (100%) (Ref. 0205)
HRMS Calcd 446.3396, Found 446.3394 (Ref. 0205)


Synthesis from dehydroepiandrostertone via 1a,3b-dihydroxy-20(S)-[2(R)-hydroxy-3-methylbutyloxy]pregna-5,7-diene by photochemical method. (Ref. 0205)



457
(24S)-1a,24-dihydroxy-26,27-dimethyl-22-oxavitamin D3 / (24S)-1a,24-dihydroxy-26,27-dimethyl-22-oxacholecalciferol
(5Z,7E)-(1S,3R,24S)-26,27-dimethyl-22-oxa-9,10-seco-5,7,10(19)-cholestatriene-1,3,24-triol
VVD0460
Sachiko Yamada
1a,24S-(OH)2-22-oxa-26,27-dimethyl-D3
C28H46O4 446.662 Download ChemDraw structure file
The activity to induce differentiation of human myeloid leukemia cells (HL-60) into macrophases in vitro estimated by superoxide anion generation was shown in comparison with 1,25-(OH)2D3. (Ref. 0205)
[a]D 38.99 deg (c = 0.159 in EtOH) (Ref. 0205)
(EtOH) lmax (nm) 263, lmin (nm) 227 (Ref. 0205)
1H-NMR (d) 0.53 (3H, s), 0.89 (6H, t, J = 6.8 Hz), 1.17 (3H, d, J = 6.2 Hz), 3.21-3.36 (2H, m), 3.46 (1H, t, J = 8.6 Hz), 3.60-3.72 (1H, br), 4.15-4.27 (1H, br), 4.36-4.46 (1H, br), 4.99 (1H, s), 5.33 (1H, s), 6.03 (1H, d, J = 11.6 Hz), 6.37 (1H, d, J = 11.6 Hz) (Ref. 0205)
m/z 446 (M+), 97 (100%) (Ref. 0205)
HRMS Calcd 446.3396, Found 446.3394 (Ref. 0205)


Synthesis from dehydroepiandrostertone via 1a,3b-dihydroxy-20(S)-[2(S)-hydroxy-3-methylbutyloxy]pregna-5,7-diene by photochemical method. (Ref. 0205)



458
1a,25-dihydroxy-11a-methoxyvitamin D3 / 1a,25-dihydroxy-11a-methoxycholecalciferol
(5Z,7E)-(1S,3R,11S)-11-methoxy-9,10-seco-5,7,10(19)-cholestatriene-1,3,25-triol
VVD0461
Sachiko Yamada
1a,25-(OH)2-11a-methoxy-D3
C28H46O4 446.662 Download ChemDraw structure file










459
1a,25-dihydroxy-11a-(hydroxymethyl)vitamin D3 / 1a,25-dihydroxy-11a-(hydroxymethyl)cholecalciferol
(5Z,7E)-(1S,3R,11S)-11-(hydroxymethyl)-9,10-seco-5,7,10(19)-cholestatriene-1,3,25-triol
VVD0462
Sachiko Yamada
C28H46O4 446.662 Download ChemDraw structure file
Biological activity of C-ring analogs of 1a,25-(OH)2D3 (Ref. 0224)





Convergent synthesis by Horner coupling of 25-hydroxylated CD-ring ketone, which was constructed from Inhoffen-Lythgoe diol (vitamin D2 ozonolysis product), with A-ring phosphine oxide. The substituent at C(11) was introduced by conjugate addition of vinylcopper reagent to 9(11)-en-8-one of the CD-ring fragment followed by appropriate modification of the vinyl group. (Ref. 0224)



460
1a,25-dihydroxy-11b-methoxyvitamin D3 / 1a,25-dihydroxy-11b-methoxycholecalciferol
(5Z,7E)-(1S,3R,11R)-11-methoxy-9,10-seco-5,7,10(19)-cholestatriene-1,3,25-triol
VVD0463
Sachiko Yamada
1a,25-(OH)2-11b-methoxy-D3
C28H46O4 446.662 Download ChemDraw structure file










461
(20S)-1a,25-dihydroxy-20-methoxyvitamin D3 / (20S)-1a,25-dihydroxy-20-methoxycholecalciferol
(5Z,7E)-(1S,3R,20S)-20-methoxy-9,10-seco-5,7,10(19)-cholestatriene-1,3,25-triol
VVD0464
Sachiko Yamada
20S-methoxy-1a,25-(OH)2D3
C28H46O4 446.662 Download ChemDraw structure file
Biological activity (% of 1,25-(OH)2D3 effect) : Inhibition of U 937 cell (human histiocytic lymphoma cell line) proliferation : 900% ; Binding to the 1,25-(OH)2D3 receptor from rachitic chicken intestine : 2% ; Calcemic activity determined by the increase in urinary calcium excretion in rats : 8%. (Ref. 0279)





From (5E)-1a-hydroxy-20-keto-22,23,24,25,26,27-hexanorvitamin D3 derivative by addition of a Grignard reagent followed by methylation, photochemical isomerization and deprotection. (Ref. 0279)



462
1a,25-dihydroxy-24a,24b-dihomo-22-oxavitamin D3 / 1a,25-dihydroxy-24a,24b-dihomo-22-oxacholecalciferol
(5Z,7E)-(1S,3R)-24a,24b-dihomo-22-oxa-9,10-seco-5,7,10(19)-cholestatriene-1,3,25-triol
VVD0465
Sachiko Yamada
22-oxa-24a,24b-dihomo-1a,25-(OH)2D3
C28H46O4 446.662 Download ChemDraw structure file
The activity inducing differentiation of human myeloid leukemia cells (HL-60) into macrophases in vitro estimated by superoxide anion generation : ED50 = 8.61 times 10-9 M [ED50 of 1,25-(OH)2D3 : 1.70 times 10-8 M, ED50 of OCT : 1.78 times 10-8 M]. (Ref. 0203)
(EtOH) lmax (nm) 263, lmin (nm) 227 (Ref. 0203)
1H-NMR (d, CDCl3) 0.53 (3H, s), 1.16 (3H, d, J = 6.1 Hz), 1.21 (6H, s), 3.17-3.25 (2H, m), 3.51- 3.58 (1H, m), 4.23 (1H, m), 4.41 (1H, m), 5.00 (1H, br t), 5.33 (1H, br t), 6.03 (1H, d, J = 10.9 Hz), 6.38 (1H, d, J = 10.9 Hz) (Ref. 0203)
m/z 446 (M+), 96 (100%) (Ref. 0203)
Colorless foam. (Ref. 0203)
1)Flash column chromatography with CH2Cl2/EtOH (9 : 1), 2)Preparative TLC developed twice with AcOEt. (Ref. 0203)

Synthesis from dehydroepiandrostertone via 1a,3b-dihydroxy-20(S)-(5-hydroxy-5-methylhexyloxy)pregna-5,7-diene by photochemical method. (Ref. 0203)



463
1a,25-dihydroxy-24a,24b-dihomo-22-oxa-20-epivitamin D3 / 1a,25-dihydroxy-24a,24b-dihomo-22-oxa-20-epicholecalciferol
(5Z,7E)-(1S,3R,20R)-24a,24b-dihomo-22-oxa-9,10-seco-5,7,10(19) -cholestatrien-1,3,25-triol
VVD0466
Sachiko Yamada
C28H46O4 446.662 Download ChemDraw structure file
Biological activity (% of 1,25-(OH)2D3 effect) Inhibition of U 937 cell (human histiocytic lymphoma cell line) proliferation : 33300 (IC50 : the title compound, 4.2 times 10-11 M ; 1,25-(OH)2D3, 1.4 times 10-8 M) ; Induction of U 937 cell differentiation : 40000 ; Binding to the 1,25-(OH)2D3 receptor from rachitic chicken intestine : 35 ; Calcemic activity determined by the increase in urinary calcium excretion in rats : 140. (Ref. 0278)









464
1a,25-dihydroxy-26,27-dimethyl-22-oxavitamin D3 / 1a,25-dihydroxy-26,27-dimethyl-22-oxacholecalciferol
(5Z,7E)-(1S,3R)-26,27-dimethyl-22-oxa-9,10-seco-5,7,10(19)-cholestatriene-1,3,25-triol
VVD0467
Sachiko Yamada
1a,25-(OH)2-22-oxa-26,27-dimethyl-D3
C28H46O4 446.662 Download ChemDraw structure file
The activity inducing differentiation of human myeloid leukemia cells (HL-60) into macrophases in vitro estimated by superoxide anion generation : ED50 = 1.48 times 10-9 M, ED50 of 1,25-(OH)2D3 : 1.70 times 10-8 M, ED50 of OCT : 1.78 times 10-8 M. the binding properties to the chick embryonic intestinal 1,25-(OH)2D3 receptor : 50%, 1,25-(OH)2D3 : 100%, OCT : 12.5%. (Ref. 0203)
(EtOH) lmax (nm) 263, lmin (nm) 227 (Ref. 0203)
1H-NMR (d, CDCl3) 0.53 (3H, s), 0.86 (6H, t, J = 8.0 Hz), 1.18 (3H, d, J = 7.9 Hz), 3.25 (1H, br t, J = 7.4 Hz), 3.38-3.51 (1H, m), 3.72-3.88 (1H, m), 4.14-4.28 (1H, br), 4.36-4.48 (1H, br), 4.98 (1H, s), 5.31 (1H, s), 6.01 (1H, d, J = 11.4 Hz), 6.35 (1H, d, J = 11.4 Hz) (Ref. 0203)
m/z 446 (M+), 97 (100%) (Ref. 0203)
colorless foam (Ref. 0203)
Flash column chromatography with CH2Cl2/EtOH (12.5 : 1) (Ref. 0203)

Synthesis from dehydroepiandrostertone via 1a,3b-dihydroxy-20(S)-(3-ethyl-3-hydroxypentyloxy)pregna-5,7-diene by photochemical method. (Ref. 0203)



465
1a,25-dihydroxy-24a,24b-dihomo-23-oxavitamin D3 / 1a,25-dihydroxy-24a,24b-dihomo-23-oxacholecalciferol
(5Z,7E)-(1S,3R)-24a,24b-dihomo-23-oxa-9,10-seco-5,7,10(19)-cholestatriene-1,3,25-triol
VVD0468
Sachiko Yamada
23-oxa-24a,24b-dihomo-1a,25-(OH)2D3
C28H46O4 446.662 Download ChemDraw structure file
Biological activity : Affinity for pig intestinal nuclear receptor, 50% of 1,25-(OH)2D3 effect ; Affinity for human vitamin D binding protein, < 0.02% of 25-OHD3 effect ; Differentiation of HL-60 cells, 100% of 1,25-(OH)2D3 effect ; Calciuric effect, 1% of 1,25-(OH)2D3 effect. (Ref. 0299)





From protected (5E)-1a,22-dihydroxy-23,24,25,26,27-pentanorvitamin D3 via alkylation under phase-transfer conditions, Grignard reaction, photoisomerization, and deprotection. (Ref. 0299/0300/0153)



466
1a,25-dihydroxy-24a,24b-dihomo-23-oxa-20-epivitamin D3 / 1a,25-dihydroxy-24a,24b-dihomo-23-oxa-20-epicholecalciferol
(5Z,7E)-(1S,3R,20R)-24a,24b-dihomo-23-oxa-9,10-seco-5,7,10(19)-cholestatriene-1,3,25-triol
VVD0469
Sachiko Yamada
20-epi-23-oxa-24a,24b-dihomo-1a,25-(OH)2D3
C28H46O4 446.662 Download ChemDraw structure file
Biological activity (% of 1,25-(OH)2D3 effect) : Inhibition of cell (U 937) proliferation, 100000% ; Induction of cell (U 937) differentiation, 200000%; Inhibition of T-cell (murine MLR) activation, 8000% ; Vitamin D receptor (chick intestine) binding, 60% ; Calciuric effect (urinary calcium excretion in rats), 60%. (Ref. 0292)
(EtOH) lmax (nm) (emax) 264 (17400) (Ref. 0292)
1H-NMR (d, CDCl3, SiMe4, 300MHz) 0.56 (3H, s, 18-H3), 0.95 (3H, d, J = 6.6 Hz, 21-H3), 1.23 (6H, s, 26- and 27-H3), 2.31 (1H, dd, J = 7 and 13 Hz, 4b-H), 2.52 (1H, bs, exchanges with D2O, 25-OH), 2.59 (1H, bd, J = 13 Hz, 4a-H), 2.83 (1H, bd, J = 12 Hz, 9b-H), 3.20 (1H, dd, J = 7.5 and 9 Hz, 22-H), 3.42 (2H, m, 24-H2), 3.51 (1H, dd, J = 4 and 9 Hz, 22-H), 4.23 (1H, m, 3-H), 4.43 (1H, m, 1-H), 5.00 (1H, br s, 19E-H), 5.33 (1H, br s, 19Z-H), 6.02 and 6.38 (each 1H, J = 11.3 Hz, 7- and 6-H) (Ref. 0292)




From protected (5E)-1a-hydroxy-22-oxo-23,24,25,26,27-pentanorvitamin D3 via C-20 epimerization, reduction, coupling with side chain bromide, photoisomerization and deprotection. (Ref. 0292)



467
1a,25-dihydroxy-26,27-dimethyl-23-oxavitamin D3 / 1a,25-dihydroxy-26,27-dimethyl-23-oxacholecalciferol
(5Z,7E)-(1S,3R)-26,27-dimethyl-23-oxa-9,10-seco-5,7,10(19)-cholestatriene-1,3,25-triol
VVD0470
Sachiko Yamada
23-oxa-26,27-dimethyl-1a,25-(OH)2D3
C28H46O4 446.662 Download ChemDraw structure file
Biological activity : Affinity for pig intestinal nuclear receptor, 50% of 1,25-(OH)2D3 effect ; Affinity for human vitamin D binding protein, < 0.02% of 25-OHD3 effect ; Differentiation of HL-60 cells, 143% of 1,25-(OH)2D3 effect ; Calciuric effect, < 20% of 1,25-(OH)2D3 effect. (Ref. 0299)





From protected (5E)-1a,22-dihydroxy-23,24,25,26,27-pentanorvitamin D3 via alkylation under phase-transfer conditions, Grignard reaction, photoisomerization, and deprotection. (Ref. 0299/0300/0153)



468
(20S)-1a,20,25-trihydroxy-24a-homovitamin D3 / (20S)-1a,20,25-trihydroxy-24a-homocholecalciferol
(5Z,7E)-(1S,3R,20S)-24a-homo-9,10-seco-5,7,10(19)-cholestatriene-1,3,20,25-tetrol
VVD0471
Sachiko Yamada
24a-homo-1a,20S,25-(OH)3D3
C28H46O4 446.662 Download ChemDraw structure file
Biological activity (% of 1,25-(OH)2D3 effect) : Inhibition of U 937 cell (human histiocytic lymphoma cell line) proliferation : 70% ; Binding to the 1,25-(OH)2D3 receptor from rachitic chicken intestine : 0.04% ; Calcemic activity : not determined. (Ref. 0279)





From (5E)-1a-hydroxy-20-keto-22,23,24,25,26,27-hexanorvitamin D3 derivative by addition of a Grignard reagent followed by photochemical isomerization and deprotection. (Ref. 0279)



469
(23R)-1a,23,25-trihydroxyvitamin D3 / (23R)-1a,23,25-trihydroxycholecalciferol
(5Z,7E)-(1S,3R,23R)-9,10-seco-5,7,10(19)-cholestatriene-1,3,23,25-tetrol
VVD0472
Sachiko Yamada
1a,23R,25-(OH)3D3
C28H46O4 446.662 Download ChemDraw structure file
Biological activity (% of 1,25-(OH)2D3 effect) : Inhibition of proliferation of human keratinocytes in culture, 100 ; Intestinal calcium absorption in rat, 6 ; Bone calcium mobilization in rat, 0 ; Competitive binding to rat intestinal vitamin D receptor, 1 ; Differentiation of human leukemia cells (HL-60), 50. (Ref. 0237)









470
(23R)-1a,23,25-trihydroxy-23-methylvitamin D3 / (23R)-1a,23,25-trihydroxy-23-methylcholecalciferol
(5Z,7E)-(1S,3R,23R)-23-methyl-9,10-seco-5,7,10(19)-cholestatrien-1,3,23,25-tetrol
VVD0473
Sachiko Yamada
1a,23R,25-(OH)3-23-methyl-D3
C28H46O4 446.662 Download ChemDraw structure file










471
1a-hydroxy-22-(3-methylphenyl)-23,24,25,26,27-pentanorvitamin D3 / 1a-hydroxy-22-(3-methylphenyl)-23,24,25,26,27-pentanorcholecalciferol
(5Z,7E)-(1S,3R)-22-(3-methylphenyl)-23,24-dinor-9,10-seco-5,7,10(19)-cholatriene-1,3-diol
VVD0474
Sachiko Yamada
C29H40O2 420.627 Download ChemDraw structure file
(% of 1,25-(OH)2D3 effect) Intestinal calcium absorption: 0.3; bone calcium mobilization: 0.06; affinity for chick intestinal receptor and HL-60 cell receptor 1.4 and 3.5, respectively; Inhibition of 1a-hydroxylase activity: 96; differentiation of HL-60 cells: 15. (Ref. 0364)









472
(17Z)-1a,25-dihydroxy-26,27-dimethyl-17,20,22,22,23,23-hexadehydrovitamin D3 / (17Z)-1a,25-dihydroxy-26,27-dimethyl-17,20,22,22,23,23-hexadehydrocholecalciferol
(5Z,7E,17Z)-(1S,3R)-26,27-dimethyl-9,10-seco-5,7,10(19),17(20)-cholestatetraen-22-yne-1,3,25-triol
VVD0475
Sachiko Yamada
17(20)Z-ene-22-yne-26,27-dimethyl-1a,25-(OH)2D3
C29H42O3 438.642 Download ChemDraw structure file
Biological activity (% of 1,25-(OH)2D3 effect) : Inhibition of proliferation of U937 cells, 3200% ; Affinity for chicken intestinal vitamin D receptor, 7%. (Ref. 0293)





From hydroxy protected (5E)-1a-hydroxy-20-oxo-22,23,24,25,26,27-hexanorvitamin D3 via reaction with appropriate lithium acetylide, treatment with acid, separation of regio- and stereoisomers, dye-sensitized photoisomerization and deprotection. (Ref. 0293)



473
1a,25-dihydroxy-26,27-dimethyl-20,21,22,22,23,23-hexadehydrovitamin D3 / 1a,25-dihydroxy-26,27-dimethyl-20,21,22,22,23,23-hexadehydrocholecalciferol
(5Z,7E)-(1S,3R)-26,27-dimethyl-9,10-seco-5,7,10(19),20-cholestatetraen-22-yne-1,3,25-triol
VVD0476
Sachiko Yamada
20-ene-22-yne-26,27-dimethyl-1a,25-(OH)2D3
C29H42O3 438.642 Download ChemDraw structure file
Biological activity (% of 1,25-(OH)2D3 effect) : Inhibition of proliferation of U937 cells, 140% ; Affinity for chicken intestinal vitamin D receptor, 87%. (Ref. 0293)





From hydroxy protected (5E)-1a-hydroxy-20-oxo-22,23,24,25,26,27-hexanorvitamin D3 via reaction with appropriate lithium acetylide, treatment with acid, separation of regio- and stereoisomers, dye-sensitized photoisomerization and deprotection. (Ref. 0293)



474
24a,24b-epoxy-23-tetradehydro-24a,24b-dihomo-1a,25-dihydroxyvitamin D3 / 24a,24b-epoxy-23-tetradehydro-24a,24b-dihomo-1a,25-dihydroxycholecalciferol
(5Z,7E)-(1S,3R)-24a,24b-dihomo-24a,24b-epoxy-9,10-seco-5,7,10(19)-cholestatriene-23-yne-1,3,25-triol
VVD0477
Sachiko Yamada
24a,24b-epoxy-23-yne-24a,24b-dihomo-1a,25-(OH)2D3
C29H42O4 454.641 Download ChemDraw structure file
Biological activity (% of 1,25-(OH)2D3 effect) : Affinity for pig intestinal receptor and human vitamin D binding protein : 3 and, respectively. Inhibition of proliferation or differentiation induction of human promyeloid leukemia (HL-60) and osteosarcoma (MG-63) cells : 4 and 1, respectively. (Ref. 0240)





By epoxidation of the corresponding olefinic precursor which was constructed from Inhoffen-Lythgoe diol. (Ref. 0240)



475
11a-ethynyl-1a,25-dihydroxyvitamin D3 / 11a-ethynyl-1a,25-dihydroxycholecalciferol
(5Z,7E)-(1S,3R,11S)-11-ethynyl-9,10-seco-5,7,10(19)-cholestatriene-1,3,25-triol
VVD0478
Sachiko Yamada
11a-ethynyl-1a,25-(OH)2D3
C29H44O3 440.658 Download ChemDraw structure file










476
(22E,24E)-1a,25-dihydroxy-22,23,24,24a-tetradehydro-24a,24b-dihomovitamin D3 / (22E,24E)-1a,25-dihydroxy-22,23,24,24a-tetradehydro-24a,24b-dihomocholecalciferol
(5Z,7E,22E,24E)-(1S,3R)-24a,24b-dihomo-9,10-seco-5,7,10(19),22,24-cholestapentaene-1,3,25-triol
VVD0479
Sachiko Yamada
(22E,24E)-22,23,24,24a-tetradehydro-24a,24b-dihomo-1a,25-(OH)2D3
C29H44O3 440.658 Download ChemDraw structure file
Biological activity (% of 1,25-(OH)2D3 effect) : Inhibition of proliferation of U937 cells, 500% ; Induction of differentiation of U 937 cells, 600% ; Calciuric activity, 30%. (Ref. 0285)





From protected (5E)-1a-hydroxy-22-oxo-23,24,25,26,27-pentanorvitamin D3 via side chain introduction, photoisomerization and deprotection. (Ref. 0285)



477
1a,25-dihydroxy-26,27-dimethyl-22,22,23,23-tetradehydrovitamin D3 / 1a,25-dihydroxy-26,27-dimethyl-22,22,23,23-tetradehydro-cholecalciferol
(5Z,7E)-(1S,3R)-26,27-dimethyl-9,10-seco-5,7,10(19)-cholestatrien-22-yne-1,3,25-triol
VVD0480
Sachiko Yamada
22-yne-26,27-dimethyl-1a,25-(OH)2D3
C29H44O3 440.658 Download ChemDraw structure file
Biological activity (% of 1,25-(OH)2D3 effect) : Inhibition of proliferation of U937 cells, 350% ; Affinity for chicken intestinal vitamin D receptor, 89%. (Ref. 0293)





From hydroxy protected (5E)-1a-hydroxy-22,22,23,23-tetradehydro-24,25,26,27-tetranorvitamin D3, which was derived from corresponding 22-aldehyde, via side chain introduction, dye-sensitized photoisomerization and deprotection. (Ref. 0293)



478
1a,25-dihydroxy-26,27-dimethyl-22,22,23,23-tetradehydro-20-epivitamin D3 / 1a,25-dihydroxy-26,27-dimethyl-22,22,23,23-tetradehydro-20-epicholecalciferol
(5Z,7E)-(1S,3R,20R)-26,27-dimethyl-9,10-seco-5,7,10(19)-cholestatrien-22-yne-1,3,25-triol
VVD0481
Sachiko Yamada
20-epi-22-yne-26,27-dimethyl-1a,25-(OH)2D3
C29H44O3 440.658 Download ChemDraw structure file
Biological activity (% of 1,25-(OH)2D3 effect) : Inhibition of proliferation of U937 cells, 390% ; Affinity for chicken intestinal vitamin D receptor, 27%. (Ref. 0293)





From hydroxy protected (5E)-1a-hydroxy-22,22,23,23-tetradehydro-24,25,26,27-tetranor-20-epivitamin D3, which was derived from corresponding 22-aldehyde, via side chain introduction, dye-sensitized photoisomerization and deprotection. (Ref. 0293)



479
(22S)-1a,22,25-trihydroxy-26,27-dimethyl-23,23,24,24-tetradehydrovitamin D3 / (22S)-1a,22,25-trihydroxy-26,27-dimethyl-23,23,24,24-tetradehydrocholecalciferol
(5Z,7E)-(1S,3R,22S)-26,27-dimethyl-9,10-seco-5,7,10(19)-cholestatrien-23-yne-1,3,22,25-tetrol
VVD0482
Sachiko Yamada
23-yne-26,27-dimethyl-1a,22S,25-(OH)3D3
C29H44O4 456.657 Download ChemDraw structure file










480
(22R)-1a,22,25-trihydroxy-23,24-tetradehydro-24a,24b-dihomo-20-epivitamin D3 / (22R)-1a,22,25-trihydroxy-23,24-tetradehydro-24a,24b-dihomo-20-epicholecalciferol
(5Z,7E)-(1S,3R,20R,22R)-24a,24b-dihomo-9,10-seco-5,7,10(19)-cholestatrien-23-yne-1,3,22,25-tetrol
VVD0483
Sachiko Yamada
23,24-tetradehydro-24a,24b-dihomo-20-epi-1a,22R,25-(OH)3D3
C29H44O4 456.657 Download ChemDraw structure file
Relative potency (1,25-(OH)2D3 = 1) : Induction of differentiation of U 937 cells, 0.02 ; Inhibition of proliferation, < 0.05 ; VDR (rachitic chicken intestinal receptor) binding affinity, < 0.005. (Ref. 0321)





From protected (5E)-1a-hydroxy-22-oxo-23,24,25,26,27-pentanor-20-epivitamin D3 via the reaction with lithiated acetylene side chain fragment giving minor (1:19) 22R-hydroxy product. (Ref. 0321)



481
(22S)-1a,22,25-trihydroxy-23,24-tetradehydro-24a,24b-dihomo-20-epivitamin D3 / (22S)-1a,22,25-trihydroxy-23,24-tetradehydro-24a,24b-dihomo-20-epicholecalciferol
(5Z,7E)-(1S,3R,20R,22S)-24a,24b-dihomo-9,10-seco-5,7,10(19)-cholestatrien-23-yne-1,3,22,25-tetrol
VVD0484
Sachiko Yamada
23,24-tetradehydro-24a,24b-dihomo-20-epi-1a,22S,25-(OH)3D3
C29H44O4 456.657 Download ChemDraw structure file
Relative potency (1,25-(OH)2D3 = 1) : Induction of differentiation of U 937 cells, 10 ; Inhibition of proliferation, 12 ; VDR (rachitic chicken intestinal receptor) binding affinity, 0.005 ; Calciuric effect in normal rats, 0.3. (Ref. 0321)





From protected (5E)-1a-hydroxy-22-oxo-23,24,25,26,27-pentanor-20-epivitamin D3 via the reaction with lithiated acetylene side chain fragment giving major (19:1) 22S-hydroxy product as a key step. (Ref. 0321)



482
(22R)-1a,22,25-trihydroxy-26,27-dimethyl-23,24-tetradehydro-20-epivitamin D3 / (22R)-1a,22,25-trihydroxy-26,27-dimethyl-23,24-tetradehydro-20-epicholecalciferol
(5Z,7E)-(1S,3R,20R,22R)-26,27-dimethyl-9,10-seco-5,7,10(19)-cholestatrien-23-yne-1,3,22,25-tetrol
VVD0485
Sachiko Yamada
26,27-dimethyl-23,24-tetradehydro-20-epi-1a,22R,25-(OH)3D3
C29H44O4 456.657 Download ChemDraw structure file
Relative potency (1,25-(OH)2D3 = 1) : Induction of differentiation of U 937 cells, 1; Inhibition of proliferation, 1.1 ; VDR (rachitic chicken intestinal receptor) binding affinity, < 0.003. (Ref. 0321)





From protected (5E)-1a-hydroxy-22-oxo-23,24,25,26,27-pentanor-20-epivitamin D3 via the reaction with lithiated acetylene side chain fragment giving minor (1:19) 22R-hydroxy product. (Ref. 0321)



483
(22S)-1a,22,25-trihydroxy-26,27-dimethyl-23,24-tetradehydro-20-epivitamin D3 / (22S)-1a,22,25-trihydroxy-26,27-dimethyl-23,24-tetradehydro-20-epicholecalciferol
(5Z,7E)-(1S,3R,20R,22S)-26,27-dimethyl-9,10-seco-5,7,10(19)-cholestatrien-23-yne-1,3,22,25-tetrol
VVD0486
Sachiko Yamada
26,27-dimethyl-23,24-tetradehydro-20-epi-1a,22S,25-(OH)3D3
C29H44O4 456.657 Download ChemDraw structure file
Relative potency (1,25-(OH)2D3 = 1) : Induction of differentiation of U 937 cells, 100 ; Inhibition of proliferation, 190 ; VDR (rachitic chicken intestinal receptor) binding affinity, 0.19 ; Calciuric effect in normal rats, 8.2. (Ref. 0321)





From protected (5E)-1a-hydroxy-22-oxo-23,24,25,26,27-pentanor-20-epivitamin D3 via the reaction with lithiated acetylene side chain fragment giving major (19:1) 22S-hydroxy product as a key step. (Ref. 0321)



484
24,24-difluoro-1a,25-dihydroxy-26,27-dimethylvitamin D3 / 24,24-difluoro-1a,25-dihydroxy-26,27-dimethylcholecalciferol
(5Z,7E)-(1S,3R)-24,24-difluoro-26,27-dimethyl-9,10-seco-5,7,10(19)-cholestatrien-1,3,25-triol
VVD0487
Sachiko Yamada
24,24-difluoro-26,27-dimethyl-1a,25-(OH)2D3
C29H46F2O3 480.671 Download ChemDraw structure file
Binding affinity for chick intestinal receptor : 53% of that of 1,25-(OH)2D3. Binding affinity for vitamin D binding protein in rat serum : 4% of that of 1,25-(OH)2D3. Potency of the title compound in 45Ca release from neonatal mouse parietal bones in culture: higher than that of 1,25-(OH)2D3. Potency in the formation of osteoclast-like cells : 100 times of that of 1,25-(OH)2D3. Potency in bone calcium mobilization in vitamin D deficient rats : slightly lower than that of 1,25-(OH)2D3. Potency in intestinal Ca transport response in situ : similar to 1,25-(OH)2D3. (Ref. 0246)









485
vitamin D6
(5Z,7E,22E)-(3S,24R)-24-ethyl-9,10-seco-5,7,10(19),22-cholestatetraen-3-ol
VVD0488
Sachiko Yamada
D6
C29H46O 410.675 Download ChemDraw structure file
Antirachitic activity: <1% of the effect of vitamin D3. (Ref. 0370)









486
provitamin D6
(22E)-(3S,24R)-24-ethyl-5,7,22-cholestatrien-3-ol
VVD0489
Sachiko Yamada
pro-D6
C29H46O 410.675 Download ChemDraw structure file










487
1a-hydroxy-24-methylvitamin D2 / 1a-hydroxy-24-methylergocalciferol
(5Z,7E)-(1S,3R)-24-methyl-9,10-seco-5,7,10(19),22-ergostatetraene-1,3-diol
VVD0490
Sachiko Yamada
22-methyl-1a-OHD2
C29H46O2 426.674 Download ChemDraw structure file
Increases in Serum Calcium and Inorganic Phosphorus Concentration and Decrease in Alkaline Phosphatase Activity in Response to 1a-OH-24,24-Me2-D22-D3, 1a,25-(OH)2-24,24-Me2-D22-D3 and 1a-OH-D3. (Ref. 0160)
lmax (nm) 265 lmin (nm) 228 (Ref. 0160)
1H-NMR (d, CDCl3, 400MHz) 0.56 (3H, s, 18-H3), 0.81 (6H, d, J = 6.8 Hz, 26-, 27-H3), 0.89 (6H, s, 24-CH3), 1.01 (3H, d, J = 6.6 Hz, 21-H3), 4.23 (1H, m, W1/2 = 18.4 Hz, 3a-H), 4.43 (1H, m, W1/2 = 16.9 Hz, 1b-H), 5.00 (1H, br s, W1/2 = 3.2 Hz, 19-H), 5.10 (1H, dd, J = 15.9, 8.6 Hz, 22-H), 5.27 (1H, d, J = 15.9 Hz, 23-H), 5.32 (1H, br s, W1/2 = 3.2 Hz, 19-H), 6.02 (1H, d, J = 11.5 Hz, 7-H), 6.38 (1H, d, J = 11.5 Hz, 6-H) (Ref. 0160)
m/z 426 (M+), 408 (M+-18), 390 (M+-2 times 18), 383 (M+-43, C24-C25 cleavage), 365 (383-18), 347 (383-2 times 18), 287 (M+-139, C17-C20 cleavage), 269 (287-18), 251 (287-2 times 18), 152 (C7-C8 cleavage), 134 (152-18, base peak), 116 (152-2 times 18) (Ref. 0160)







488
18-acetoxy-vitamin D3 / 18-acetoxy-cholecalciferol
(5Z,7E)-(3S)-18-acetoxy-9,10-seco-5,7,10(19)-cholestatrien-3-ol
VVD0491
Sachiko Yamada
18-acetoxy-D3
C29H46O3 442.674 Download ChemDraw structure file
Intestinal calcium absorption (ICA) and bone calcium mobilization (BCM) evaluated in vivo in comparison to 1,25-(OH)2D3 (100%) in the vitamin D deficient chick system (ref. 17) : ICA, < 0.03% ; BCM, < 0.2%. Affinity to the chick intestinal receptor relative to 1,25-(OH)2D3 (100%) : < 0.001%. (Ref. 0236)





Convergent synthesis from upper part (CD ring ketone with side chain) and lower part (A-ring plus seco-B-ring part) phosphine oxide by Horner-Wittig coupling. Upper part with 18-acetoxy modification was derived from Grundmann



489
1a,25-dihydroxy-11a-vinylvitamin D3 / 1a,25-dihydroxy-11a-vinylcholecalciferol
(5Z,7E)-(1S,3R,11S)-11-vinyl-9,10-seco-5,7,10(19)-cholestatriene-1,3,25-triol
VVD0492
Sachiko Yamada
11a-vinyl-1a,25-(OH)2D3
C29H46O3 442.674 Download ChemDraw structure file
Biological activity of C-ring analogs of 1a,25-(OH)2D3 (Ref. 0224)





Convergent synthesis by Horner coupling of 25-hydroxylated CD-ring ketone, which was constructed from Inhoffen-Lythgoe diol (vitamin D2 ozonolysis product), with A-ring phosphine oxide. The substituent at C(11) was introduced by conjugate addition of organocopper reagent to 9(11)-en-8-one of the CD-ring fragment. (Ref. 0224)



490
(22E)-1a,25-dihydroxy-26,27-dimethyl-22,23-didehydrovitamin D3 / (22E)-1a,25-dihydroxy-26,27-dimethyl-22,23-didehydrocholecalciferol
(5Z,7E,22E)-(1S,3R)-26,27-dimethyl-9,10-seco-5,7,10(19),22-cholestatetraene-1,3,25-triol
VVD0493
Sachiko Yamada
(22E)-22-ene-26,27-dimethyl-1a,25-(OH)2D3
C29H46O3 442.674 Download ChemDraw structure file










491
1a,25-dihydroxy-24-methylvitamin D2 / 1a,25-dihydroxy-24-methylergocalciferol
(5Z,7E,22E)-(1S,3R)-24-methyl-9,10-seco-5,7,10(19),22-ergostatetraene-1,3,25-triol
VVD0494
Sachiko Yamada
24-methyl-1a,25-(OH)2D2
C29H46O3 442.674 Download ChemDraw structure file
Increases in Serum Calcium and Inorganic Phosphorus Concentration and Decrease in Alkaline Phosphatase Activity in Response to 1a-OH-24,24-Me2-D22-D3, 1a,25-(OH)2-24,24-Me2-D22-D3 and 1a-OH-D3. (Ref. 0160)
lmax (nm) 265 lmin (nm) 228 (Ref. 0160)
1H-NMR (d, CDCl3, 400MHz) 0.56 (3H, s, 18-H3), 1.02 (3H, s, 24-CH3), 1.03 (3H, s, 24-CH3), 1.16 (6H, s, 26-, 27-H3), 4.23 (1H, m, 3-H), 4.43 (1H, m, 1-H), 5.00 (1H, br s, 19-H), 5.28 (1H, dd, J = 15.9, 8.6 Hz, 22-H), 5.32 (1H, br s, 19-H), 5.69 (1H, d, J = 15.9 Hz, 23-H), 6.02 (1H, d, J = 11.5 Hz, 7-H), 6.38 (1H, d, J = 11.5 Hz, 6-H) (Ref. 0160)
m/z 424 (M+-18), 406 (M+-2 times 18), 383 (M+-59, C24-C25 cleavage), 365 (383-18), 347 (383-2 times 18), 287 (M+-155, C17-C20 cleavage), 269 (287-18), 251 (287-2 times 18), 155 (side chain), 152 (C7-C8 cleavage), 134 (152-18, base peak), 116 (152-2 times 18), 96 (155-59), 59 (C24-C25 cleavage) (Ref. 0160)







492
1a,25-dihydroxy-22,23-didehydro-24a,24b-dihomovitamin D3 /1a,25-dihydroxy-22,23-didehydro-24a,24b-dihomocholecalciferol
(5Z,7E,22E)-(1S,3R)-24a,24b-dihomo-9,10-seco-5,7,10(19),22-cholestatetraene-1,3,25-triol
VVD0495
Sachiko Yamada
22-dehydro-24-dihomo-1a,25-(OH)2D3
C29H46O3 442.674 Download ChemDraw structure file
The title compound is approximately 10 times more active than 1,25-(OH)2D3 in differentiating HL-60 cells, whereas it is approximately 1000 times less active in mobilizing skeletal calcium than is 1,25-(OH)2D3. (Ref. 0158)
(EtOH) lmax (nm) 264, lmin (nm) 228 (Ref. 0158)
1H-NMR (d, CDCl3) 0.55 (3H, s, 18-CH3), 1.0 (3H, d, J = 6.6 Hz, 21-CH3), 1.23 (6H, s, 26, 27-CH3), 4.23 (1H, m, 3-H), 4.43 (1H, m, 1-H), 5.00 (1H, br s, 1.9Z-H), 5.32 (1H, br s, 19E-H), 5.29 (2H, m, 22- and 23-H), 6.01 (1H, d, J = 11.3 Hz, 7-H), 6.36 (1H, d, J = 11.2 Hz) (Ref. 0158)
m/z 442 (M+, 15), 424 (23), 406 (33), 391 (7), 287 (11), 285 (10), 269 (27), 251 (23), 152 (33), 134 (100), 116 (6), 59 (20) (Ref. 0158)



From 1a-hydroxylated pentanorvitamin D 22-calboxaldehyde and C(7) side chain fragment with terminal phenylsulfonyl group. (Ref. 0158)



493
1a,25-dihydroxy-26,27-ethanovitamin D3 / 1a,25-dihydroxy-26,27-ethanocholecalciferol
(5Z,7E)-(1S,3R)-26,27-ethano-9,10-seco-5,7,10(19)-cholestatriene-1,3,25-triol
VVD0496
Sachiko Yamada
26,27-ethano-1a,25-(OH)2D3
C29H46O3 442.674 Download ChemDraw structure file

(10% 2-propanol in hexane) lmax (nm) 264, lmin (nm) 228, A264/A228 = 1.71 (Ref. 0192)
(Film) 3360, 2930, 1605, 1442, 1378, 1291, 1145, 1105, 1080, 1062 cm-1 (Ref. 0192)
1H-NMR (d, CD3OD, 270 or 400MHz) 0.48 (3H, s, 18-CH3), 0.87 (3H, d, J = 6.4 Hz, 21-CH3), 4.03 (1H, m, 3-H), 4.25 (1H, m, 1-H), 4.80 (1H, br s, 19Z-H), 5.19 (1H, br s, 19E-H), 5.98 (1H, d, J = 11.2 Hz, 7-H), 6.23 (1H, d, J = 11.1 Hz, 6-H) (Ref. 0192)
m/z 442 (M+, 5), 424 (43), 406 (38), 388 (7), 373 (7), 298 (6), 285 (12), 269 (20), 251 (24), 134 (100), 85 (28) (Ref. 0192)







494
18-acetoxy-1a-hydroxyvitamin D3 / 18-acetoxy-1a-hydroxycholecalciferol
(5Z,7E)-(1S,3R)-18-acetoxy-9,10-seco-5,7,10(19)-cholestatriene-1,3-diol
VVD0497
Sachiko Yamada
18-acetoxy-1a-OHD3
C29H46O4 458.673 Download ChemDraw structure file
Intestinal calcium absorption (ICA) and bone calcium mobilization (BCM) evaluated in vivo in comparison to 1,25-(OH)2D3 (100%) in the vitamin D deficient chick system (ref. 17) : ICA, < 0.05% ; BCM, < 0.3%. Affinity to the chick intestinal receptor relative to 1,25-(OH)2D3 (100%) : 0.017 pm 0.010%. (Ref. 0236)





Convergent synthesis from upper part (CD ring ketone with side chain) and lower part (A-ring plus seco-B-ring part) phosphine oxide by Horner-Wittig coupling. Upper part with 18-acetoxy modification was derived from Grundmann



495
18-acetoxy-25-hydroxyvitamin D3 / 18-acetoxy-25-hydroxycholecalciferol
(5Z,7E)-(3S)-18-acetoxy-9,10-seco-5,7,10(19)-cholestatriene-3,25-diol
VVD0498
Sachiko Yamada
18-acetoxy-25-OHD3
C29H46O4 458.673 Download ChemDraw structure file
Intestinal calcium absorption (ICA) and bone calcium mobilization (BCM) evaluated in vivo in comparison to 1,25-(OH)2D3 (100%) in the vitamin D deficient chick system (ref. 17) : ICA, < 0.05% ; BCM, < 0.3%. Affinity to the chick intestinal receptor relative to 1,25-(OH)2D3 (100%) : < 0.01%. (Ref. 0236)





Convergent synthesis from upper part (CD ring ketone with side chain) and lower part (A-ring plus seco-B-ring part) phosphine oxide by Horner-Wittig coupling. Upper part with 18-acetoxy and 25-hydroxy modifications was derived from Grundmann



496
1a,25-dihydroxy-11a-[(1R)-oxiranyl]vitamin D3 / 1a,25-dihydroxy-11a-[(1R)-oxiranyl]cholecalciferol
(5Z,7E)-(1S,3R,11S)-11-[(1R)-oxiranyl]-9,10-seco-5,7,10(19)-cholestatriene-1,3,25-triol
VVD0499
Sachiko Yamada
C29H46O4 458.673 Download ChemDraw structure file
(% of 1,25-(OH)2D3 effect) Affinity for rat intestinal receptor and human vitamin D binding protein: 2 and 80, respectively; Differentiation of HL-60 cells: <1. (Ref. 0359)









497
1a,25-dihydroxy-11a-[(1S)-oxiranyl]vitamin D3 / 1a,25-dihydroxy-11a-[(1S)-oxiranyl]cholecalciferol
(5Z,7E)-(1S,3R,11S)-11-[(1S)-oxiranyl]-9,10-seco-5,7,10(19)-cholestatriene-1,3,25-triol
VVD0500
Sachiko Yamada
C29H46O4 458.673 Download ChemDraw structure file
(% of 1,25-(OH)2D3 effect) Affinity for rat intestinal receptor and human vitamin D binding protein: 1 and 62, respectively; Differentiation of HL-60 cells: <1. (Ref. 0359)









498
1a,25-dihydroxy-26,27-dimethyl-20,21-methano-23-oxavitamin D3 / 1a,25-dihydroxy-26,27-dimethyl-20,21-methano-23-oxacholecalciferol
(5Z,7E)-(1S,3R)-26,27-dimethyl-20,21-methano-23-oxa-9,10-seco-5,7,10(19)-cholestatriene-1,3,25-triol
VVD0501
Sachiko Yamada
20,21-methano-23-oxa-26,27-dimethyl-1a,25-(OH)2D3
C29H46O4 458.673 Download ChemDraw structure file
Biological activity : Affinity for pig intestinal nuclear receptor, 50% of 1,25-(OH)2D3 effect ; Affinity for human vitamin D binding protein, < 0.02% of 25-OHD3 effect ; Differentiation of HL-60 cells, 20% of 1,25-(OH)2D3 effect ; Calciuric effect, 100% of 1,25-(OH)2D3 effect. (Ref. 0299)









499
18-acetoxy-1a,25-dihydroxyvitamin D3 / 18-acetoxy-1a,25-dihydroxycholecalciferol
(5Z,7E)-(1S,3R)-18-acetoxy-9,10-seco-5,7,10(19)-cholestatriene-1,3,25-triol
VVD0502
Sachiko Yamada
18-acetoxy-1a,25-(OH)2D3
C29H46O5 474.673 Download ChemDraw structure file
Intestinal calcium absorption (ICA) and bone calcium mobilization (BCM) evaluated in vivo in comparison to 1,25-(OH)2D3 (100%) in the vitamin D deficient chick system (ref. 17) : ICA, < 0.15% ; BCM, < 1.0%. Affinity to the chick intestinal receptor relative to 1,25-(OH)2D3 (100%) : 0.036 pm 0.021%. (Ref. 0236)





Convergent synthesis from upper part (CD ring ketone with side chain) and lower part (A-ring plus seco-B-ring part) phosphine oxide by Horner-Wittig coupling. Upper part with 18-acetoxy and 25-hydroxy modifications was derived from Grundmann's alcohol via light-induced lead tetraacetate oxidation and ruthenium tetraoxide oxidation as key steps. (Ref. 0236)



500
vitamin D5
(5Z,7E)-(3S,24S)-24-ethyl-9,10-seco-5,7,10(19)-cholestatrien-3-ol
VVD0503
Sachiko Yamada
D5
C29H48O 412.691 Download ChemDraw structure file
Antirachitic activity: <2% of the effect of vitamin D3. (Ref. 0371)









501
provitamin D5
(3S,24S)-24-ethyl-5,7-cholestadien-3-ol
VVD0504
Sachiko Yamada
pro-D5
C29H48O 412.691 Download ChemDraw structure file










502
1a-hydroxy-26,27-dimethylvitamin D3 / 1a-hydroxy-26,27-dimethylcholecalciferol
(5Z,7E)-(1S,3R)-26,27-dimethyl-9,10-seco-5,7,10(19)-cholestatriene-1,3-diol
VVD0505
Sachiko Yamada
26,27-dimethyl-1a-OHD3
C29H48O2 428.690 Download ChemDraw structure file
Binding affinity of the title compound for serum vitamin D binding protein (DBP) relative to 25-OHD3 was < 0.01%. Binding affinity for the receptor of HL-60 cells was 0.1% of that of 1,25-(OH)2D3. (Ref. 0275)
lmax (nm) 265, lmin (nm) 228 (Ref. 0277)
1H-NMR (d, CDCl3) 0.54 (3H, s, 18-H3), 0.83 (6H, t, J = 7.0 Hz, 26- and 27-CH3), 0.92 (3H, d, J = 6.1 Hz, 21-H3), 4.24 (1H, m, 3-H), 4.36 (1H, m, 1-H), 5.01 (1H, br s, 19Z-H), 5.33 (1H, br s, 19E-H), 6.03 (1H, d, J = 11.0 Hz, 7-H), 6.39 (1H, d, J = 11.0 Hz, 6-H) (Ref. 0277)
m/z 428 (M+), 410, 392, 287, 269, 251, 152, 134 (Ref. 0277)



From 3b-hydroxycholenic acid via steps of 1a-hydroxylation, side chain construction, introduction of 5,7-diene structure and conventional photochemical conversion. (Ref. 0277)



503
25-hydroxy-26,27-dimethylvitamin D3 / 25-hydroxy-26,27-dimethylcholecalciferol
(5Z,7E)-(3S)-26,27-dimethyl-9,10-seco-5,7,10(19)-cholestatriene-3,25-diol
VVD0506
Sachiko Yamada
26,27-dimethyl-25-OHD3
C29H48O2 428.690 Download ChemDraw structure file
Binding affinity of the title compound for serum vitamin D binding protein (DBP) relative to 25-OHD3 was 66.7%. Binding affinity for the receptor of HL-60 cells was 0.9% of that of 1,25-(OH)2D3. (Ref. 0275)
lmax (nm) 265, lmin (nm) 228 (Ref. 0277)
(EtOH) lmax (nm) 264, lmin (nm) 228 (Ref. 0312)
1H-NMR (d, CDCl3) 0.54 (3H, s, 18-H3), 0.858 and 0.860 (6H, each t, J = 7.6 Hz, 26- and 27-CH3), 0.97 (3H, d, J = 6.6 Hz, 21-H3), 1.47 (q, J = 7.6 Hz, 26- and 27--H2), 3.95 (1H, m, 3-H), 4.82 (1H, br s, 19E-H), 5.05 (1H, br s, 19Z-H), 6.03 (1H, d, J = 11.0 Hz, 7-H), 6.24 (1H, d, J = 11.0 Hz, 6-H) (Ref. 0277)
1H-NMR (d, CDCl3) 0.54 (3H, s, 18-CH3), 3.94 (1H, m, 3a-H), 4.82 (1H, m, 19-H), 5.04 (1H, m, 19-H), 6.00 (1H, d, J = 11.22 Hz, 7-H), 6.25 (1H, d, J = 11.22 Hz, 6-H) (Ref. 0312)
m/z 428 (M+),410, 395, 271, 253, 136, 118, 87 (Ref. 0277)
m/z 428 (M+, 4.24), 410 (M+-H2O, 27.12), 392 (M+-2H2O, 22.03), 377 (392-CH3, 3.39), 271 (M+-side chain, 5.93), 253 (M+-side chain-H2O, 32.20), 136 (ring A plus C6 and C7, 91.53), 118 (136-H2O, 79.66), 87 (C5H11O, 12.71) (Ref. 0312)



From 3b-hydroxycholenic acid via steps of side chain construction, introduction of 5,7-diene structure and conventional photochemical conversion. (Ref. 0277)
From 4-cholenoic acid by a conventional method including transformation to the corresponding provitamin D followed by photochemical conversion. (Ref. 0312)



504
(6S)-6,19-ethano-25-hydroxy-6,19-dihydrovitamin D3 / (6S)-6,19-ethano-25-hydroxy-6,19-dihydrocholecalciferol
(7E)-(3S,6S)-6,19-ethano-9,10-seco-5(10),7-cholestadiene-3,25-diol
VVD0507
Sachiko Yamada
C29H48O2 428.690 Download ChemDraw structure file
Binding affinity for the vitamin D receptor in HL-60 cells : < 1/10000 as active as 1,25-(OH)2D3. Differentiation of HL-60 cells : < 1/1000 as active as 1,25-(OH)2D3. (Ref. 0339)
1H-NMR (d, CDCl3) 0.54 (3H, s, 18-H), 0.97 (3H, d, J = 5 Hz, 21-H), 1.22 (6H, s, 26- and 27-H), 3.92 (1H, m, 3-H), 4.80 (1H, d, J = 10 Hz, 7-H) (Ref. 0339)
m/z 428 (M+-H2O), 410, 164, 146 (Ref. 0339)
CD : 205 nm (e +33.1) (in Hexane) (Ref. 0339)


From (5E)-25-hydroxyvitamin D3 via reaction with vinyl phenyl sulfone followed by desulfonylation. (Ref. 0339)



505
(6R)-6,19-ethano-25-hydroxy-6,19-dihydrovitamin D3 / (6R)-6,19-ethano-25-hydroxy-6,19-dihydrocholecalciferol
(7E)-(3S,6R)-6,19-ethano-9,10-seco-5(10),7-cholestadiene-3,25-diol
VVD0508
Sachiko Yamada
C29H48O2 428.690 Download ChemDraw structure file
Binding affinity for the vitamin D receptor in HL-60 cells : < 1/10000 as active as 1,25-(OH)2D3. Differentiation of HL-60 cells : < 1/1000 as active as 1,25-(OH)2D3. (Ref. 0339)
1H-NMR (d, CDCl3) 0.56 (3H, s, 18-H), 0.97 (3H, d, J = 5 Hz, 21-H), 1.22 (6H, s, 26- and 27-H), 3.96(1H, m, 3-H), 4.82 (1H, d, J = 10 Hz, 7-H) (Ref. 0339)
m/z 428 (M+-H2O), 410, 164, 146 (Ref. 0339)
CD : 209 nm (e -123.8) (in Hexane) (Ref. 0339)


From (5E)-25-hydroxyvitamin D3 via reaction with vinyl phenyl sulfone followed by desulfonylation. (Ref. 0339)



506
11a-ethyl-1a,25-dihydroxyvitamin D3 / 11a-ethyl-1a,25-dihydroxycholecalciferol
(5Z,7E)-(1S,3R,11S)-11-ethyl-9,10-seco-5,7,10(19)-cholestatriene-1,3,25-triol
VVD0509
Sachiko Yamada
11a-ethyl-1a,25-(OH)2D3
C29H48O3 444.690 Download ChemDraw structure file
Biological activity of C-ring analogs of 1a,25-(OH)2D3 :(Ref. 0224)





Convergent synthesis by Horner coupling of 25-hydroxylated CD-ring ketone, which was constructed from Inhoffen-Lythgoe diol (vitamin D2 ozonolysis product), with A-ring phosphine oxide. The substituent at C(11) was introduced by conjugate addition of organocopper reagent to 9(11)-en-8-one of the CD-ring fragment. (Ref. 0224)



507
1a,25-dihydroxy-26,27-dimethylvitamin D3 / 1a,25-dihydroxy-26,27-dimethylcholecalciferol
(5Z,7E)-(1S,3R)-26,27-dimethyl-9,10-seco-5,7,10(19)-cholestatriene-1,3,25-triol
VVD0510
Sachiko Yamada
26,27-dimethyl-1a,25-(OH)2D3
C29H48O3 444.690 Download ChemDraw structure file
Binding affinity of the title compound for serum vitamin D binding protein (DBP) relative to 25-OHD3 and 1,25-(OH)2D3 was 0.1% and 10%, respectively. Binding affinity for receptor of HL-60 cells relative to 1,25-(OH)2D3 was 116.7%. The ability of the title compound to induce HL-60 cell differentiation (assayed by NBT reduction) was approximately four times of that of 1,25-(OH)2D3 under serum-supplemented culture conditions, whereas the same compound was as equally active as 1,25-(OH)2D3 under serum-free culture conditions. (Ref. 0275)
Bone Ca mobilization response to the title compound compared with 1,25-(OH)2D3. (Ref. 0276)
Dose response of various 26,27-dialkyl-1,25-(OH)2D3 in bone Ca mobilization. (Ref. 0276)
The title comopund was slighly less active than 1,25-(OH)2D3 in increasing serum calcium in vitamin D-deficient rats. (Ref. 0272)
(EtOH) lmax (nm) 265, lmin (nm) 228 (Ref. 0198)
lmax (nm) 265, lmin (nm) 228 (Ref. 0277)
(EtOH) lmax (nm) 264, lmin (nm) 227 (Ref. 0312)
1H-NMR (d, CDCl3) 0.55 (3H, s, 18-H3), 0.86 (6H, t, J = 7.0 Hz, 26- and 27-CH3), 0.93 (3H, d, J = 6.0 Hz, 21-H3), 1.45 (4H, q, J = 7.0 Hz, 26- and 27-CH2), 4.22 (1H, m, 3-H), 4.43 (1H, m, 1-H), 5.01 (1H, br s, 19Z-H), 5.33 (1H, br s, 19E-H), 6.03 (1H, d, J = 11.0 Hz, 7-H), 6.38 (1H, d, J = 11.0 Hz, 6-H) (Ref. 0277)
1H-NMR (d, CDCl3) 0.56 (3H, s, 18-CH3), 4.23 (1H, m, 3-H), 4.42 (1H, m, 1-H), 4.98 (1H, m, 19-H), 5.32 (1H, m, 19-H), 5.98 (1H, d, J = 11.22 Hz, 7-H), 6.37 (1H, d, J = 11.22 Hz, 6-H) (Ref. 0312)
FD-MS m/z 444 (M+), EI-MS m/z 426 (M+-18), 408 (M+-36, base peak), 390 (M+-54), 269 [287 (side chain cleavage)-18], 251 (287-36), 152 (C7-C8 cleavage), 134 (152-18), 116 (152-36) (Ref. 0198)
m/z 444 (M+), 408, 390, 375, 269, 251, 157, 152, 134, 116, 87 (Ref. 0277)
m/z 444 (M+, 3.45), 426 (M+-H2O, 32.76), 408 (M+-2H2O, 79.31), 390 (M+-3H2O, 89.66), 379 (17.24), 287 (M+-side chain, 5.17), 269 (M+-side chain-H2O, 8.28), 251 (M+-side chain-2H2O, 48.28), 152 (ring A plus C-6 and C-7, 25.86), 134 (152-H2O, 70.69), 116 (134-H2O, 13.79), 105 (100), 87 (C5H11O, 40.52) (Ref. 0312)



From 3b-hydroxycholenic acid via steps of 1a-hydroxylation, side chain construction, introduction of 5,7-diene structure and conventional photochemical conversion. (Ref. 0277)
From 25-hydroxy-26,27-dimethylvitamin D3 by 1a-hydroxylation via 3,5-cyclovitamin D. (Ref. 0312)



508
1a,25-dihydroxy-24a,24b-dihomovitamin D3 / 1a,25-dihydroxy-24a,24b-dihomocholecalciferol
(5Z,7E)-(1S,3R)-24a,24b-dihomo-9,10-seco-5,7,10(19)-cholestatriene-1,3,25-triol
VVD0511
Sachiko Yamada
C29H48O3 444.690 Download ChemDraw structure file
The title compound was approximately 10 times more active than 1,25-(OH)2D3 in differentiating HL-60 cells but it was approximately 1000 times less active than the natural hormone in mobilizing skeletal calcium. (Ref. 0158)
(10% 2-propanol in hexane) lmax (nm) 264, lmin (nm) 228, A264/A228 = 1.91 (Ref. 0192)
(Film) 3360, 2927, 1602, 1447, 1376, 1297, 1146, 1106, 1086, 1064 cm-1 (Ref. 0192)
1H-NMR (d, CDCl3, 270 or 400 MHz) 0.52 (3H, s, 18-CH3), 0.90 (3H, d, J = 6.4 Hz, 21-CH3), 1.19 (6H, s, 26- and 27-CH3), 4.22 (1H, ms, 3-H), 4.42 (1H, m, 1-H), 4.99 (1H, br s, 19Z-H), 5.31 (1H, br s, 19E-H), 6.00 (1H, d, J = 11.1 Hz, 7-H), 6.36 (1H, d, J = 11.2 Hz, 6-H) (Ref. 0192)
m/z 444 (M+, 1.4), 426 (41), 393 (10), 251 (26), 209 (17), 197 (20), 157 (29), 155 (37), 134 (58), 105 (54), 59 (100) (Ref. 0192)



From hydroxy protected (5E)-23,24,25,26,27-pentanorvitamin D3 22-bis(methylseleno)acetal via displacement of one methylseleno group by side chain fragment, reduction of the other methylseleno group via 6,19-SO2 adduct, desulfonylation, dye-sensitized photoisomerization and deprotection. From hydroxy protected (5E)-22-tosyloxy-23,24,25,26,27-pentanorvitamin D3 via cuprate catalyzed Grignard reaction, photoisomerization and deprotection. (Ref. 0285)



509
1a,25-dihydroxy-24a,24b-dihomo-20-epivitamin D3 / 1a,25-dihydroxy-24a,24b-dihomo-20-epicholecalciferol
(5Z,7E)-(1S,3R,20S)-24a,24b-dihomo-9,10-seco-5,7,10(19)-cholestatriene-1,3,25-triol
VVD0512
Sachiko Yamada
24a,24b-dihomo-20-epi-1a,25-(OH)2D3
C29H48O3 444.690 Download ChemDraw structure file
Biological activity (% of 1,25-(OH)2D3 effect) : Inhibition of proliferation of U 937 cells, 5000% ; Induction of differentiation of U 937 cells, 10000% ; Calciuric effects on normal rats, 40%. (Ref. 0284)





From protected (5E)-1a-hydroxy-22-p-toluenesulfonyloxy-23,24,25,26,27-pentanorvitamin D3 via introduction of the side chain by the reaction with Grignard reagent in the presence of copper catalyst, dye-sensitized photoisomerization and deprotection. (Ref. 0284)



510
1a,25-dihydroxy-24a-homo-26,27-dimethyl-22-thiavitamin D3 / 1a,25-dihydroxy-24a-homo-26,27-dimethyl-22-thiacholecalciferol
(5Z,7E)-(1S,3R)-26,27-dimethyl-24a-homo-9,10-seco-22-thia-5,7,10(19)-cholestatriene-1,3,25-triol
VVD0513
Sachiko Yamada
22-thia-24a-homo-26,27-dimethyl-1a,25-(OH)2D3
C29H48O3S 476.756 Download ChemDraw structure file






Synthesis from dehydroepiandrostertone via the 5,7-diene by photochemical method. (Ref. 0215)



511
1a,25-dihydroxy-26,27-dimethyl-24a-homo-22-thia-20-epivitamin D3 / 1a,25-dihydroxy-26,27-dimethyl-24a-homo-22-thia-20-epicholecalciferol
(5Z,7E)-(1S,3R,20R)-26,27-dimethyl-24a-homo-9,10-seco-22-thia-5,7,10(19)-cholestatriene-1,3,25-triol
VVD0514
Sachiko Yamada
20-epi-22-thia-24a-homo-26,27-dimethyl-1a,25-(OH)2D3
C29H48O3S 476.756 Download ChemDraw structure file






Synthesis from dehydroepiandrostertone via the 5,7-diene by photochemical method. (Ref. 0215)



512
1a,25-dihydroxy-24a,24b,24c-trihomo-22-thiavitamin D3 / 1a,25-dihydroxy-24a,24b,24c-trihomo-22-thiacholecalciferol
(5Z,7E)-(1S,3R)-24a,24b,24c-trihomo-9,10-seco-22-thia-5,7,10(19)-cholestatriene-1,3,25-triol
VVD0515
Sachiko Yamada
22-thia-24a,24b,24c-trihomo-1a,25-(OH)2D3
C29H48O3S 476.756 Download ChemDraw structure file






Synthesis from dehydroepiandrostertone via the 5,7-diene by photochemical method. (Ref. 0215)



513
1a,25-dihydroxy-24a,24b,24c-trihomo-22-thia-20-epivitamin D3 / 1a,25-dihydroxy-24a,24b,24c-trihomo-22-thia-20-epicholecalciferol
(5Z,7E)-(1S,3R,20R)-24a,24b,24c-trihomo-9,10-seco-22-thia-5,7,10(19)-cholestatriene-1,3,25-triol
VVD0516
Sachiko Yamada
20-epi-22-thia-24a,24b,24c-trihomo-1a,25-(OH)2D3
C29H48O3S 476.756 Download ChemDraw structure file






Synthesis from dehydroepiandrostertone via the 5,7-diene by photochemical method. (Ref. 0215)



514
1a-hydroxy-2b-(2-hydroxyethoxy)vitamin D3 / 1a-hydroxy-2b-(2-hydroxyethoxy)cholecalciferol
(5Z,7E)-(1R,2R,3R)-2-(2-hydroxyethoxy)-9,10-seco-5,7,10(19)-cholestatriene-1,3-diol
VVD0517
Sachiko Yamada
2b-(2-hydroxyethoxy)-1a-OHD3
C29H48O4 460.689 Download ChemDraw structure file
Plasma calcium levels in rats fed with a low calcium/vitamin D deficient diet after administration (6.25mg/kg times 5). (Ref. 0216)
(EtOH) lmax (nm) 262.5 (Ref. 0216)
1H-NMR (d, CDCl3) 0.55 (3H, s), 0.86 (6H, d, J = 6.6 Hz), 0.92 (3H, d, J = 5.8 Hz), 3.62-3.92 (5H, br), 4.18-4.39 (2H, m), 5.09 (1H, s), 5.49 (1H, s), 6.04 (1H, d, J = 10.5 Hz), 6.37 (1H, d, J = 10.5 Hz) (Ref. 0216)
m/z 460 (M+), 442, 398, 380, 150 (100%) (Ref. 0216)
HRMS Calcd 460.3553, Found 460.3560 (Ref. 0216)


Synthesis by photochemical method of the 5,7-diene. (Ref. 0216)



515
(20S)-1a,25-dihydroxy-20-methoxy-24a-homovitamin D3 / (20S)-1a,25-dihydroxy-20-methoxy-24a-homocholecalciferol
(5Z,7E)-(1S,3R,20S)-20-methoxy-24a-homo-9,10-seco-5,7,10(19)-cholestatriene-1,3,25-triol
VVD0518
Sachiko Yamada
20S-methoxy-24a-homo-1a,25-(OH)2D3
C29H48O4 460.689 Download ChemDraw structure file
Biological activity (% of 1,25-(OH)2D3 effect) : Inhibition of U 937 cell (human histiocytic lymphoma cell line) proliferation : 10000% ; Binding to the 1,25-(OH)2D3 receptor from rachitic chicken intestine : < 0.5% ; Calcemic activity determined by the increase in urinary calcium excretion in rats : 3%. (Ref. 0279)





From (5E)-1a-hydroxy-20-keto-22,23,24,25,26,27-hexanorvitamin D3 derivative by addition of a Grignard reagent followed by methylation, photochemical isomerization and deprotection. (Ref. 0279)



516
1a,25-dihydroxy-24a,24b,24c-trihomo-22-oxavitamin D3 /
(5Z,7E)-(1S,3R)-24a,24b,24c-trihomo-22-oxa-9,10-seco-5,7,10(19)-cholestatriene-1,3,25-triol
VVD0519
Sachiko Yamada
22-oxa-24a,24b,24c-trihomo-1a,25-(OH)2D3
C29H48O4 460.689 Download ChemDraw structure file
The activity inducing differentiation of human myeloid leukemia cells (HL-60) into macrophases in vitro estimated by superoxide anion generation : [ED50 of 1,25-(OH)2D3 : 1.70 times 10-8M, ED50 of OCT : 1.78 times 10-8 M]. (Ref. 0203)
(EtOH) lmax (nm) 262, lmin (nm) 227 (Ref. 0203)
1H-NMR (d, CDCl3) 0.53 (3H, s), 1.15 (3H, d, J = 6.2 Hz), 1.21 (6H, s), 3.12-3.28 (2H, m), 3.47-3.60 (1H, m), 4.16-4.28 (1H, br), 4.36-4.46 (1H, br), 5.00 (1H, s), 5.33 (1H, s), 6.02 (1H, d, J = 11.4 Hz), 6.38 (1H, d, J = 11.4Hz) (Ref. 0203)
m/z 460 (M+), 68 (100%) (Ref. 0203)
Colorless foam. (Ref. 0203)
1)Flash column chromatography with CH2Cl2/EtOH (10 : 1), 2)Preparative TLC developed three times with CH2Cl2/EtOH (8 : 1). (Ref. 0203)

Synthesis from dehydroepiandrostertone via 1a,3b-dihydroxy-20(S)-(6-hydroxy-6-methylheptyloxy)pregna-5,7-diene by photochemical method. (Ref. 0203)



517
1a,25-dihydroxy-26,27-dimethyl-24a-homo-22-oxavitamin D3 / 1a,25-dihydroxy-26,27-dimethyl-24a-homo-22-oxacholecalciferol
(5Z,7E)-(1S,3R)-26,27-dimethyl-24a-homo-22-oxa-9,10-seco-5,7,10(19)-cholestatrien-1,3,25-triol
VVD0520
Sachiko Yamada
22-oxa-24,26,27-trihomo-1a,25-(OH)2D3
C29H48O4 460.689 Download ChemDraw structure file
Biological activity (% of 1,25-(OH)2D3 effect) Inhibition of U 937 cell (human histiocytic lymphoma cell line) proliferation : 10000 (IC50 : the title compound, 1.4 times 10-10 M ; 1,25-(OH)2D3, 1.4 times 10-8 M) ; Induction of U 937 cell differentiation : 2000 ; Binding to the 1,25-(OH)2D3 receptor from rachitic chicken intestine : 32 ; Calcemic activity determined by the increase in urinary calcium excretion in rats : 30. Inhibitory effects on murine thymocyte activation : 900 (IC50 : the title compound, 2.1 times 10-11 M ; 1,25-(OH)2D3, 1.9 times 10-10 M). (Ref. 0278)









518
1a,25-dihydroxy-20,26,27-trimethyl-23-oxavitamin D3 / 1a,25-dihydroxy-20,26,27-trimethyl-23-oxacholecalciferol
(5Z,7E)-(1S,3R)-20,26,27-trimethyl-23-oxa-9,10-seco-5,7,10(19)-cholestatriene-1,3,25-triol
VVD0521
Sachiko Yamada
23-oxa-20,26,27-trimethyl-1a,25-(OH)2D3
C29H48O4 460.689 Download ChemDraw structure file
Biological activity : Affinity for pig intestinal nuclear receptor, 50% of 1,25-(OH)2D3 effect ; Affinity for human vitamin D binding protein, < 0.02% of 25-OHD3 effect ; Differentiation of HL-60 cells, 50% of 1,25-(OH)2D3 effect ; Calciuric effect, 20% of 1,25-(OH)2D3 effect. (Ref. 0299)









519
1a,25-dihydroxy-26,27-dimethyl-24a-homo-22-oxa-20-epivitamin D3 / 1a,25-dihydroxy-26,27-dimethyl-24a-homo-22-oxa-20-epicholecalciferol
(5Z,7E)-(1S,3R,20R)-26,27-dimethyl-24a-homo-22-oxa-9,10-seco-5,7,10(19)-cholestatriene-1,3,25-triol
VVD0522
Sachiko Yamada
C29H48O4 460.689 Download ChemDraw structure file
Biological activity (% of 1,25-(OH)2D3 effect)Inhibition of U 937 cell (human histiocytic lymphoma cell line) proliferation :1400000 (IC50 : the title compound, 1.0 times 10-12 M ; 1,25-(OH)2D3, 1.4 times 10-8 M) ; Induction of U 937 cell differentiation : 20000000 ; Binding to the 1,25-(OH)2D3 receptor from rachitic chicken intestine : 120 ; Calcemic activity determined by the increase in urinary calcium excretion in rats : 130. Inhibitory effects on murine thymocyte activation : 63333300 (IC50 : the title compound, 3.0 times 10-16 M ; 1,25-(OH)2D3, 1.9 times 10-10 M). (Ref. 0278)









520
1a,25-dihydroxy-11a-(2-hydroxyethyl)vitamin D3 / 1a,25-dihydroxy-11a-(2-hydroxyethyl)cholecalciferol
(5Z,7E)-(1S,3R,11S)-11-(2-hydroxyethyl)-9,10-seco-5,7,10(19)-cholestatriene-1,3,25-triol
VVD0523
Sachiko Yamada
C29H48O4 460.689 Download ChemDraw structure file
(% of 1a,25-(OH)2D3 effect) Affinity for rat duodenum receptor and human vitamin D binding protein: <0.1 and 115, respectively; Differentiation of HL-60 cells: 7; Inhibition of the proliferation of peripheral blood mononuclear cells (PBMC): <1; Bone resorption: <1 (3 day), <1 (6 day); Biological activity in rachitic chick: serum calcium, <1; bone calcium, <1; serum osteocalcin, <1; calbindin D-28K, <1. <0224>>





Convergent synthesis by Horner coupling of 25-hydroxylated CD-ring ketone, which was constructed from Inhoffen-Lythgoe diol (vitamin D2 ozonolysis product), with A-ring phosphine oxide. The substituent at C(11) was introduced by conjugate addition of organocopper reagent to 9(11)-en-8-one of the CD-ring fragment. (Ref. 0224)



521
1a,25-dihydroxy-11b-(2-hydroxyethyl)vitamin D3 / 1a,25-dihydroxy-11b-(2-hydroxyethyl)cholecalciferol
(5Z,7E)-(1S,3R,11R)-11-(2-hydroxyethyl)-9,10-seco-5,7,10(19)-cholestatriene-1,3,25-triol
VVD0524
Sachiko Yamada
C29H48O4 460.689 Download ChemDraw structure file
(% of 1a,25-(OH)2D3 effect) Affinity for rat duodenum receptor and human vitamin D binding protein: 0.2 and 40, respectively; Differentiation of HL-60 cells: 5; Inhibition of the proliferation of peripheral blood mononuclear cells (PBMC): <1; Biological activity in rachitic chick: serum calcium, <1; bone calcium, <1; serum osteocalcin, <1; calbindin D-28K, <1. <0224>>





Convergent synthesis by Horner coupling of 25-hydroxylated CD-ring ketone, which was constructed from Inhoffen-Lythgoe diol (vitamin D2 ozonolysis product), with A-ring phosphine oxide. The substituent at C(11) was introduced by conjugate addition of vinylcopper reagent to 9(11)-en-8-one of the CD-ring fragment, appropriate modification of the vinyl group, and inversion of the configuration at C(11) by introducing 9(11)-double bond followed by catalytic hydrogenation. (Ref. 0224)



522
(22R)-1a,22,25-trihydroxy-24a,24b-dihomo-20-epivitamin D3 / (22R)-1a,22,25-trihydroxy-24a,24b-dihomo-20-epicholecalciferol
(5Z,7E)-(1S,3R,20R,22R)-24a,24b-dihomo-9,10-seco-5,7,10(19)-cholestatriene-1,3,22,25-tetrol
VVD0525
Sachiko Yamada
24a,24b-dihomo-20-epi-1a,22R,25-(OH)3D3
C29H48O4 460.689 Download ChemDraw structure file
Relative potency (1,25-(OH)2D3 = 1) : Induction of differentiation of U 937 cells, 20 ; Inhibition of proliferation, 21 ; VDR (rachitic chicken intestinal receptor) binding affinity, 0.001 ; Calciuric effect in normal rats, 0.1. (Ref. 0321)





From protected (5E)-1a-hydroxy-22-oxo-23,24,25,26,27-pentanor-20-epivitamin D3 via the reaction with Grignard reagent of side chain fragment giving major (19:1) 22R-hydroxy product as a key step. (Ref. 0321)



523
(20S)-1a,20,25-trihydroxy-24a,24b-dihomovitamin D3 / (20S)-1a,20,25-trihydroxy-24a,24b-dihomocholecalciferol
(5Z,7E)-(1S,3R,20S)-24a,24b-dihomo-9,10-seco-5,7,10(19)-cholestatriene-1,3,20,25-tetrol
VVD0526
Sachiko Yamada
24a,24b-dihomo-1a,20S,25-(OH)3D3
C29H48O4 460.689 Download ChemDraw structure file
Biological activity (% of 1,25-(OH)2D3 effect) : Inhibition of U 937 cell (human histiocytic lymphoma cell line) proliferation : < 10%. (Ref. 0279)





From (5E)-1a-hydroxy-20-keto-22,23,24,25,26,27-hexanorvitamin D3 derivative by addition of a Grignard reagent followed by photochemical isomerization and deprotection. (Ref. 0279)



524
(20S)-14a,20,25-trihydroxy-26,27-dimethylvitamin D3 / (20S)-1a,20,25-trihydroxy-26,27-dimethylcholecalciferol
(5Z,7E)-(1S,3R,20S)-26,27-dimethyl-9,10-seco-5,7,10(19)-cholestatriene-1,3,20,25-tetrol
VVD0527
Sachiko Yamada
26,27-dimethyl-1a,20S,25-(OH)3D3
C29H48O4 460.689 Download ChemDraw structure file
Biological activity (% of 1,25-(OH)2D3 effect) : Inhibition of U 937 cell (human histiocytic lymphoma cell line) proliferation : 10000% ; Binding to the 1,25-(OH)2D3 receptor from rachitic chicken intestine : 20% ; Calcemic activity determined by the increase in urinary calcium excretion in rats : 6%. (Ref. 0279)





From (5E)-1a-hydroxy-20-keto-22,23,24,25,26,27-hexanorvitamin D3 derivative by addition of a Grignard reagent followed by photochemical isomerization and deprotection. (Ref. 0279)



525
(22R)-1a,22,25-trihydroxy-26,27-dimethyl-20-epivitamin D3 /
(5Z,7E)-(1S,3R,20R,22R)-26,27-dimethyl-9,10-seco-5,7,10(19)-cholestatriene-1,3,22,25-tetrol
VVD0528
Sachiko Yamada
26,27-dimethyl-20-epi-1a,22R,25-(OH)3D3
C29H48O4 460.689 Download ChemDraw structure file
Relative potency (1,25-(OH)2D3 = 1) : Induction of differentiation of U 937 cells, 100 ; Inhibition of proliferation, 240 ; VDR (rachitic chicken intestinal receptor) binding affinity, 0.06 ; Calciuric effect in normal rats, 7.1. (Ref. 0321)





From protected (5E)-1a-hydroxy-22-oxo-23,24,25,26,27-pentanor-20-epivitamin D3 via the reaction with a Grignard reagent of side chain fragment giving major (19:1) 22R-hydroxy product as a key step. (Ref. 0321)



526
(22S)-1a,22,25-trihydroxy-26,27-dimethylvitamin D3 / (22S)-1a,22,25-trihydroxy-26,27-dimethylcholecalciferol
(5Z,7E)-(1S,3R,22S)-26,27-dimethyl-9,10-seco-5,7,10(19)-cholestatriene-1,3,22,25-tetrol
VVD0529
Sachiko Yamada
26,27-dimethyl-1a,22S,25-(OH)3D3
C29H48O4 460.689 Download ChemDraw structure file










527
1a,25-dihydroxy-2b-(2-hydroxyethoxy)vitamin D3 / 1a,25-dihydroxy-2b-(2-hydroxyethoxy)cholecalciferol
(5Z,7E)-(1R,2R,3R)-2-(2-hydroxyethoxy)-9,10-seco-5,7,10(19)-cholestatriene-1,3,25-triol
VVD0530
Sachiko Yamada
2b-(2-hydroxyethoxy)-1a,25-(OH)2D3
C29H48O5 476.688 Download ChemDraw structure file
Spinal bone mineral density in pre-osteoporosis model rats and binding affinity to calf thymus vitamin D receptor . (Ref. 0217)
(EtOH) lmax (nm) 264, lmin (nm) 226 (Ref. 0217)
(neat) 3400 (br), 2940, 2880, 1380, 1090, 760 cm-1 (Ref. 0217)
1H-NMR (d, CDCl3) 0.55 (3H, s), 0.94 (3H, d, J = 6.3 Hz), 1.22 (6H, s), 3.48-4.22 (7H, m), 5.09 (1H, s), 5.46 (1H, s), 6.03 (1H, d, J = 11.2 Hz), 6.37 (1H, d, J = 10.5 Hz) (Ref. 0217)
m/z 476 (M+), 59 (100%) (Ref. 0217)
HRMS Calcd 433.3318 (M-C2H3O+), Found 433.3318 (Ref. 0217)


Synthesis by photochemical method of the 5,7-diene. (Ref. 0217)



528
toxisterol3 B1/ (5E)-(10R)-10-ethoxy-10,19-dihydrovitamin D3 / (5E)-(10R)-10-ethoxy-10,19-dihydrocholecalciferol
(5E,7E)-(3S,10R)-10-ethoxy-9,10-seco-5,7-cholestadien-3-ol
VVD0531
Sachiko Yamada
(5E)-10R-ethoxy-10,19-dihydro-D3
C29H50O2 430.706 Download ChemDraw structure file

Acetate: [a]d-22 +27 deg (in CHCl3) (Ref. 0011/0012)
(EtOH) lmax (nm) (emax) 251 (33000), 245 (shoulder), 260 (shoulder) (Ref. 0011/0012)
(Neat) 3370, 2960, 2940, 2880, 1660, 1610, 1470, 1380, 1370, 1160, 1070, 1050, 950 cm-1 (Ref. 0011)
1H-NMR (d, CDCl3, 100MHz) 3.70 (1H, m), 6.23 (2H, s), 0.56 (3H, s), 1.47 (3H, s), 0.94 (3H, d, J = 6 Hz), 0.87 (6H, d, J = 6 Hz) (Ref. 0011/0012)
Acetate : m/z 472 (M+), 412, 366, 253 (Ref. 0011)

RF(TLC) [0.2 nm silicagel plate (Kieselgel G Merk), benzene/acetone] 0.42 (Ref. 0011)
Rrel(GC) [1% SE-30 on GasChrom Q (80-100 mesh), retention time relative to cholestane] 1.19/1.80/2.34 (Ref. 0011)

Obtained as one of overirradiation products of 7-dehydrocholesterol in ethanol. (Ref. 0011)



529
toxisterol3 B2 / (5E)-(10S)-10-ethoxy-10,19-dihydrovitamin D3 / (5E)-(10S)-10-ethoxy-10,19-dihydrocholecalciferol
(5E,7E)-(3S,10S)-10-ethoxy-9,10-seco-5,7-cholestadien-3-ol
VVD0532
Sachiko Yamada
(5E)-10S-ethoxy-10,19-dihydro-D3
C29H50O2 430.706 Download ChemDraw structure file

Acetate : [a]d-22 -24 deg (in CHCl3) (Ref. 0011/0012)
(EtOH) lmax (nm) (emax) 251 (29000), 244, 260 (Ref. 0011/0012)
(Neat) 3370, 2960, 2940, 2880, 1660, 1620, 1470, 1380, 1370, 1160, 1125, 1070, 1040, 1000, 950, 850, 740 cm-1 (Ref. 0011)
1H-NMR (d, CDCl3, 100MHz) 3.50 (1H, m), 6.27 (1H, d, J = 11 Hz), 5.86 (1H, d, J = 11 Hz), 0.57 (3H, s), 1.30 (3H, s), 0.93 (3H, d, J = 6 Hz), 0.87 (6H, d, J = 6 Hz) (Ref. 0011/0012)
Acetate : m/z 472 (M+), 412, 366, 253 (Ref. 0011)

RF(TLC) [0.2 nm silicagel plate (Kieselgel G Merk), benzene/acetone] 0.46 (Ref. 0011)
Rrel(GC) [1% SE-30 on GasChrom Q (80-100 mesh), retention time relative to cholestane] 2.37 (Ref. 0011)

Obtained as one of over irradiation products of 7-dehydrocholesterol in ethanol. (Ref. 0011)



530
toxisterol3 B3 / (10R)-10-ethoxy-10,19-dihydrovitamin D3 / (10R)-10-ethoxy-10,19-dihydrocholecalciferol
(5Z,7E)-(3S,10R)-10-ethoxy-9,10-seco-5,7-cholestadien-3-ol
VVD0533
Sachiko Yamada
10R-ethoxy-10,19-dihydro-D3
C29H50O2 430.706 Download ChemDraw structure file

Acetate : [a]d-22 +19 deg (in CHCl3) (Ref. 0011)
(EtOH) lmax (nm) (emax) 250 (17000), 246 (shoulder), 259 (shoulder) (Ref. 0011)
Acetate : (Neat) 2940, 2920, 2860, 1740, 1650, 1610, 1470, 1380, 1370, 1240, 1030, 760 cm-1 (Ref. 0011)
1H-NMR (d, CDCl3, 100MHz) 3.96 (1H, m), 6.24 (2H, s), 0.57 (3H, s), 1.50 (3H, s), 0.93 (3H, d, J = 6 Hz), 0.87 (6H, d, J = 6 Hz) (Ref. 0011)
Acetate : m/z 472 (M+), 412, 366, 253 (Ref. 0011)

RF(TLC) [0.2 nm silicagel plate (Kieselgel G Merk), benzene/acetone] 0.52 (Ref. 0011)
Rrel(GC) [1% SE-30 on GasChrom Q (80-100 mesh), retention time relative to cholestane] 1.39/1.96/2.26 (Ref. 0011)

Obtained as one of overirradiation products of 7-dehydrocholesterol in ethanol. (Ref. 0011)



531
(17E)-1a,25-dihydroxy-26,27-dimethyl-17,20,22,22,23,23-hexadehydro-24a-homovitamin D3 / (17E)-1a,25-dihydroxy-26,27-dimethyl-17,20,22,22,23,23-hexadehydro-24a-homocholecalciferol
(5Z,7E,17E)-(1S,3R)-26,27-dimethyl-24a-homo-9,10-seco-5,7,10(19),17(20)-cholestatetraen-22-yne-1,3,25-triol
VVD0534
Sachiko Yamada
17(20)E-ene-22-yne-24-homo-26,27-dimethyl-1a,25-(OH)2D3
C30H44O3 452.669 Download ChemDraw structure file
Biological activity (% of 1,25-(OH)2D3 effect) : Inhibition of proliferation of U937 cells, 250% ; Affinity for chicken intestinal vitamin D receptor, 0.1%. (Ref. 0293)





From hydroxy protected (5E)-1a-hydroxy-20-oxo-22,23,24,25,26,27-hexanorvitamin D3 via reaction with appropriate lithium acetylide, treatment with acid, separation of regio- and stereoisomers, dye-sensitized photoisomerization and deprotection. (Ref. 0293)



532
(17Z)-1a,25-dihydroxy-26,27-dimethyl-17,20,22,22,23,23-hexadehydro-24a-homovitamin D3 / (17Z)-1a,25-dihydroxy-26,27-dimethyl-17,20,22,22,23,23-hexadehydro-24a-homocholecalciferol
(5Z,7E,17Z)-(1S,3R)-26,27-dimethyl-24a-homo-9,10-seco-5,7,10(19),17(20)-cholestatetraen-22-yne-1,3,25-triol
VVD0535
Sachiko Yamada
17(20)Z-ene-22-yne-24-homo-26,27-dimethyl-1a,25-(OH)2D3
C30H44O3 452.669 Download ChemDraw structure file
Biological activity (% of 1,25-(OH)2D3 effect) : Inhibition of proliferation of U937 cells, 71000% ; Affinity for chicken intestinal vitamin D receptor, 17% ; Calciuric activity, 71%. (Ref. 0293)





From hydroxy protected (5E)-1a-hydroxy-20-oxo-22,23,24,25,26,27-hexanorvitamin D3 via reaction with appropriate lithium acetylide, treatment with acid, separation of regio- and stereoisomers, dye-sensitized photoisomerization and deprotection. (Ref. 0293)



533
1a,25-dihydroxy-26,27-dimethyl-20,21,22,22,23,23-hexadehydro-24a-homovitamin D3 / 1a,25-dihydroxy-26,27-dimethyl-20,21,22,22,23,23-hexadehydro-24a-homocholecalciferol
(5Z,7E)-(1S,3R)-26,27-dimethyl-24a-homo-9,10-seco-5,7,10(19),20-cholestatetraen-22-yne-1,3,25-triol
VVD0536
Sachiko Yamada
20-ene-22-yne-24-homo-26,27-dimethyl-1a,25-(OH)2D3
C30H44O3 452.669 Download ChemDraw structure file
Biological activity (% of 1,25-(OH)2D3 effect) : Inhibition of proliferation of U937 cells, 120% ; Affinity for chicken intestinal vitamin D receptor, 3%. (Ref. 0293)





From hydroxy protected (5E)-1a-hydroxy-20-oxo-22,23,24,25,26,27-hexanorvitamin D3 via reaction with appropriate lithium acetylide, treatment with acid, separation of regio- and stereoisomers, dye-sensitized photoisomerization and deprotection. (Ref. 0293)



534
(22E,24E,24bE)-1a,25-dihydroxy-22,23,24,24a,24b,24c-hexadehydro-24a,24b,24c-trihomovitamin D3 / (22E,24E,24bE)-1a,25-dihydroxy-22,23,24,24a,24b,24c-hexadehydro-24a,24b,24c-trihomocholecalciferol
(5Z,7E,22E,24E,24bE)-(1S,3R)-24a,24b,24c-trihomo-9,10-seco-5,7,10(19),22,24,24b-cholestahexaene-1,3,25-triol
VVD0537
Sachiko Yamada
(22E,24E,24bE)-22,23,24,24a,24b,24c-hexadehydro-24a,24b,24c-trihomo-1a,25-(OH)2D3
C30H44O3 452.669 Download ChemDraw structure file
Biological activity (% of 1,25-(OH)2D3 effect) : Inhibition of proliferation of U937 cells, < 80% ; Induction of differentiation of U 937 cells, < 5%. (Ref. 0285)





From protected (5E)-1a-hydroxy-22-oxo-23,24,25,26,27-pentanorvitamin D3 via side chain introduction, photoisomerization and deprotection. (Ref. 0285)



535
1a,25-dihydroxy-11-(3-hydroxy-1-propynyl)-9,11-didehydrovitamin D3 / 1a,25-dihydroxy-11-(3-hydroxy-1-propynyl)-9,11-didehydrocholecalciferol
(5Z,7E)-(1S,3R)-11-(3-hydroxy-1-propynyl)-9,10-seco-5,7,9(11),10(19)-cholestatetraene-1,3,25-triol
VVD0538
Sachiko Yamada
C30H44O4 468.668 Download ChemDraw structure file










536
(22E,24E)-1a,25-dihydroxy-26,27-dimethyl-22,23,24,24a-tetradehydro-24a-homovitamin D3 / (22E,24E)-1a,25-dihydroxy-26,27-dimethyl-22,23,24,24a-tetradehydro-24a-homocholecalciferol
(5Z,7E,22E,24E)-(1S,3R)-26,27-dimethyl-24a-homo-9,10-seco-5,7,10(19),22,24-cholestapentaene-1,3,25-triol
VVD0539
Sachiko Yamada
C30H46O3 454.684 Download ChemDraw structure file
Biological activity (% of 1,25-(OH)2D3 effect) : Inhibition of proliferation of U937 cells, 6800% ; Induction of differentiation of U 937 cells, 6700% ; Calciuric activity, 40%. (Ref. 0288)
Inhibition of proliferation of breast cancer cell MCF-7:10 times more potent than 1,25-(OH)2D3 ; This compound inhibited the growth of NMU (N-methylnitrosourea) induced rat mammary tumors in vivo in a dose-dependent manner. (Ref. 0302)





From protected (5E)-1a-hydroxy-22-oxo-23,24,25,26,27-pentanorvitamin D3 via side chain introduction by Wittig reaction followed by Grignard reaction, photoisomerization and deprotection. (Ref. 0288)
In vitro metabolism of the title compound (Leo laboratory code EB1089) was studied in a human keratinocyte cell model HPK1A-ras. Four metabolites were formed, all of which possessed the same UV chromophore as the substrate, indicating the retention of the side-chain conjugated double bond system. Two metabolites which are present in sufficient quantities were identified as 26-hydroxy EB1089 (major product) and 26a-hydroxy EB1089 (minor product). (Ref. 0326)


537
1a,25-dihydroxy-26,27-dimethyl-22,22,23,23-tetradehydro-24a-homovitamin D3 / 1a,25-dihydroxy-26,27-dimethyl-22,22,23,23-tetradehydro-24a-homocholecalciferol
(5Z,7E)-(1S,3R)-26,27-dimethyl-24a-homo-9,10-seco-5,7,10(19)-cholestatrien-22-yne-1,3,25-triol
VVD0540
Sachiko Yamada
22-yne-24-homo-26,27-dimethyl-1a,25-(OH)2D3
C30H46O3 454.684 Download ChemDraw structure file
Biological activity (% of 1,25-(OH)2D3 effect) : Inhibition of proliferation of U937 cells, 180%. (Ref. 0293)





From hydroxy protected (5E)-1a-hydroxy-22,22,23,23-tetradehydro-24,25,26,27-tetranorvitamin D3, which was derived from corresponding 22-aldehyde, via side chain introduction, dye-sensitized photoisomerization and deprotection. (Ref. 0293)



538
1a,25-dihydroxy-26,27-dimethyl-22,22,23,23-tetradehydro-24a-homo-20-epivitamin D3 / 1a,25-dihydroxy-26,27-dimethyl-22,22,23,23-tetradehydro-24a-homo-20-epicholecalciferol
(5Z,7E)-(1S,3R,20R)-26,27-dimethyl-24a-homo-9,10-seco-5,7,10(19)-cholestatrien-22-yne-1,3,25-triol
VVD0541
Sachiko Yamada
20-epi-22-yne-24-homo-26,27-dimethyl-1a,25-(OH)2D3
C30H46O3 454.684 Download ChemDraw structure file
Biological activity (% of 1,25-(OH)2D3 effect) : Inhibition of proliferation of U937 cells, 28000% ; Affinity for chicken intestinal vitamin D receptor, 44%. (Ref. 0293)





From hydroxy protected (5E)-1a-hydroxy-22,22,23,23-tetradehydro-24,25,26,27-tetranor-20-epivitamin D3, which was derived from corresponding 22-aldehyde, via side chain introduction, dye-sensitized photoisomerization and deprotection. (Ref. 0293)



539
(22R)-1a,25-dihydroxy-22-methoxy-26,27-dimethyl-23,23,24,24-tetradehydrovitamin D3 / (22R)-1a,25-dihydroxy-22-methoxy-26,27-dimethyl-23,23,24,24-tetradehydrocholecalciferol
(5Z,7E)-(1S,3R,22R)-22-methoxy-26,27-dimethyl-9,10-seco-5,7,10(19)-cholestatrien-23-yne-1,3,25-triol
VVD0542
Sachiko Yamada
C30H46O4 470.684 Download ChemDraw structure file










540
(22S)-1a,25-dihydroxy-22-methoxy-26,27-dimethyl-23,24-tetradehydro-20-epivitamin D3 / (22S)-1a,25-dihydroxy-22-methoxy-26,27-dimethyl-23,24-tetradehydro-20-epicholecalciferol
(5Z,7E)-(1S,3R,20R,22S)-26,27-dimethyl-22-methoxy-9,10-seco-5,7,10(19)-cholestatrien-23-yne-1,3,25-triol
VVD0543
Sachiko Yamada
22S-methoxy-26,27-dimethyl-23,24-tetradehydro-20-epi-1a,25-(OH)2D3
C30H46O4 470.684 Download ChemDraw structure file
Relative potency (1,25-(OH)2D3 = 1) : Induction of differentiation of U 937 cells, 1000 ; Inhibition of proliferation, 1250 ; VDR (rachitic chicken intestinal receptor) binding affinity, 0.38 ; Calciuric effect in normal rats, 12. (Ref. 0321)





From protected (5E)-1a-hydroxy-22-oxo-23,24,25,26,27-pentanor-20-epivitamin D3 via the reaction with lithiated acetylene side chain fragment giving major (19:1) 22S-hydroxy product as a key step. (Ref. 0321)



541
(22R)-1a,22,25-trihydroxy-26,27-dimethyl-23,24-tetradehydro-24a-homo-20-epivitamin D3 / (22R)-1a,22,25-trihydroxy-26,27-dimethyl-23,24-tetradehydro-24a-homo-20-epicholecalciferol
(5Z,7E)-(1S,3R,20R,22R)-26,27-dimethyl-24a-homo-9,10-seco-5,7,10(19)-cholestatrien-23-yne-1,3,22,25-tetrol
VVD0544
Sachiko Yamada
26,27-dimethyl-23,24-tetradehydro-24a-homo-20-epi-1a,22R,25-(OH)3D3
C30H46O4 470.684 Download ChemDraw structure file
Relative potency (1,25-(OH)2D3 = 1) : Induction of differentiation of U 937 cells, 0.1 ; Inhibition of proliferation, 0.2 ; VDR (rachitic chicken intestinal receptor) binding affinity, 0.005. (Ref. 0321)





From protected (5E)-1a-hydroxy-22-oxo-23,24,25,26,27-pentanor-20-epivitamin D3 via the reaction with lithiated acetylene side chain fragment giving minor (1:19) 22R-hydroxy product. (Ref. 0321)



542
(22S)-1a,22,25-trihydroxy-26,27-dimethyl-23,23,24,24-tetradehydro-24a-homovitamin D3 / (22S)-1a,22,25-trihydroxy-26,27-dimethyl-23,23,24,24-tetradehydro-24a-homocholecalciferol
(5Z,7E)-(1S,3R,22S)-26,27-dimethyl-24a-homo-9,10-seco-5,7,10(19)-cholestatrien-23-yne-1,3,22,25-tetrol
VVD0545
Sachiko Yamada
23-yne-24-homo-26,27-dimethyl-1a,22S,25-(OH)3D3
C30H46O4 470.684 Download ChemDraw structure file










543
(22S)-1a,22,25-trihydroxy-26,27-dimethyl-23,24-tetradehydro-24a-homo-20-epivitamin D3 / (22S)-1a,22,25-trihydroxy-26,27-dimethyl-23,24-tetradehydro-24a-homo-20-epicholecalciferol
(5Z,7E)-(1S,3R,20R,22S)-26,27-dimethyl-24a-homo-9,10-seco-5,7,10(19)-cholestatrien-23-yne-1,3,22,25-tetrol
VVD0546
Sachiko Yamada
26,27-dimethyl-23,24-tetradehydro-24a-homo-20-epi-1a,22S,25-(OH)3D3
C30H46O4 470.684 Download ChemDraw structure file
Relative potency (1,25-(OH)2D3 = 1) : Induction of differentiation of U 937 cells, 200 ; Inhibition of proliferation, 280 ; VDR (rachitic chicken intestinal receptor) binding affinity, 0.06 ; Calciuric effect in normal rats, 1.9. (Ref. 0321)





From protected (5E)-1a-hydroxy-22-oxo-23,24,25,26,27-pentanor-20-epivitamin D3 via the reaction with lithiated acetylene side chain fragment giving major (19:1) 22S-hydroxy product as a key step. (Ref. 0321)



544
24,24-difluoro-1a,25-dihydroxy-26,27-dimethyl-24a-homovitamin D3 / 24,24-difluoro-1a,25-dihydroxy-26,27-dimethyl-24a-homocholecalciferol
(5Z,7E)-(1S,3R)-24,24-difluoro-26,27-dimethyl-24a-homo-9,10-seco-5,7,10(19)-cholestatriene-1,3,25-triol
VVD0547
Sachiko Yamada
24,24-difluoro-24-homo-26,27-dimethyl-1a,25-(OH)2D3
C30H48F2O3 494.697 Download ChemDraw structure file










545
1a,25-dihydroxy-22,23-didehydro-24a,24b,24c-trihomovitamin D3 /1a,25-dihydroxy-22,23-didehydro-24a,24b,24c-trihomocholecalciferol
(5Z,7E,22E)-(1S,3R)-24a,24b,24c-trihomo-9,10-seco-5,7,10(19),22-cholestatetraene-1,3,25-triol
VVD0548
Sachiko Yamada
22-dehydro-24-trihomo-1a,25-(OH)2D3
C30H48O3 456.700 Download ChemDraw structure file
The title compound is half as active as 1,25-(OH)2D3 in differentiating HL-60 cells but it has no activity in mobilizing bone calcium. (Ref. 0158)
(EtOH) lmax (nm) 264, lmin (nm) 228 (Ref. 0158)
1H-NMR (d, CDCl3) 0.56 (3H, s, 18-CH3), 1.00 (3H, d, J = 6.6 Hz, 21-CH3), 1.23 (6H, s, 26, 27-CH3), 4.23 (1H, m, 3-H), 4.43 (1H, m, 1-H), 5.00 (1H, br s, 19Z-H), 5.32 (1H, br s, 19E-H), 5.29 (2H, m, 22-and 23-H), 6.01 (1H, d, J = 11.3 Hz, 7-H) (Ref. 0158)
m/z 456 (M+, 11), 438 (50), 420 (30), 402 (8), 287 (10), 269 (23), 251 (23), 152 (35), 134 (100) (Ref. 0158)



From 1a-hydroxylated pentanorvitamin D 22-calboxaldehyde and C(8) side chain fragment with terminal phenylsulfonyl group. (Ref. 0158)



546
(22E)-1a,25-dihydroxy-26,27-dimethyl-22,23-didehydro-24a-homovitamin D3 / (22E)-1a,25-dihydroxy-26,27-dimethyl-22,23-didehydro-24a-homocholecalciferol
(5Z,7E,22E)-(1S,3R)-26,27-dimethyl-24a-homo-9,10-seco-5,7,10(19),22-cholestatetraene-1,3,25-triol
VVD0549
Sachiko Yamada
C30H48O3 456.700 Download ChemDraw structure file










547
(22E)-1a,25-dihydroxy-26,27-dimethyl-22,23-didehydro-24a-homo-20-epivitamin D3 / (22E)-1a,25-dihydroxy-26,27-dimethyl-22,23-didehydro-24a-homo-20-epicholecalciferol
(5Z,7E,22E)-(1S,3R,20S)-26,27-dimethyl-24a-homo-9,10-seco-5,7,10(19),22-cholestatetraene-1,3,25-triol
VVD0550
Sachiko Yamada
(22E)-20-epi-22-ene-24-homo-26,27-dimethyl-1a,25-(OH)2D3
C30H48O3 456.700 Download ChemDraw structure file
Biological activity (% of 1,25-(OH)2D3 effect) : Inhibition of proliferation of U 937 cells, 15000% ; Induction of differentiation of U 937 cells, 100000% ; Calciuric effects on normal rats, 120%. (Ref. 0284)





From protected (5E)-1a-hydroxy-22-oxo-23,24,25,26,27-pentanorvitamin D3 via side chain introduction by reaction with side chain fragment with terminal phenylsulfonyl group, reductive desulfonylation, separation of 22E/Z-isomers, dye-sensitized photoisomerization and deprotection. (Ref. 0284)



548
(22Z)-1a,25-dihydroxy-26,27-dimethyl-22,23-didehydro-24a-homo-20-epivitamin D3 / (22Z)-1a,25-dihydroxy-26,27-dimethyl-22,23-didehydro-24a-homo-20-epicholecalciferol
(5Z,7E,22Z)-(1S,3R,20S)-26,27-dimethyl-24a-homo-9,10-seco-5,7,10(19),22-cholestatetraene-1,3,25-triol
VVD0551
Sachiko Yamada
(22Z)-26,27-dimethyl-22,23-didehydro-24a-homo-20-epi-1a,25-(OH)2D3
C30H48O3 456.700 Download ChemDraw structure file
Biological activity (% of 1,25-(OH)2D3 effect) : Inhibition of proliferation of U 937 cells, 340000% ; Induction of differentiation of U 937 cells, 1000000% ; calciuric effects on normal rats, 330%. (Ref. 0284)





From protected (5E)-22-oxo-23,24,25,26,27-pentanorvitamin D3 via side chain introduction by reaction with side chain fragment with terminal phenylsulfonyl group, reductive desulfonylation, separation of 22E/Z-isomers, dye-sensitized photoisomerization and deprotection. (Ref. 0284)



549
26,27-diethyl-1a,25-dihydroxy-20,21-didehydro-23-oxavitamin D3 / 26,27-diethyl-1a,25-dihydroxy-20,21-didehydro-23-oxacholecalciferol
(5Z,7E)-(1S,3R)-26,27-diethyl-23-oxa-9,10-seco-5,7,10(19),20-cholestatetraene-1,3,25-triol
VVD0552
Sachiko Yamada
20-ene-23-oxa-26,27-diethyl-1a,25-(OH)2D3
C30H48O4 472.700 Download ChemDraw structure file
Biological activity : Affinity for pig intestinal nuclear receptor, 25% of 1,25-(OH)2D3 effect ; Affinity for human vitamin D binding protein, < 0.02% of 25-OHD3 effect ; Differentiation of HL-60 cells, 25% of 1,25-(OH)2D3 effect ; Calciuric effect, 1% of 1,25-(OH)2D3 effect. (Ref. 0299)









550
1a,25-dihydroxy-24a,24b,24c-trihomovitamin D3 / 1a,25-dihydroxy-24a,24b,24c-trihomocholecalciferol
(5Z,7E)-(1S,3R)-24a,24b,24c-trihomo-9,10-seco-5,7,10(19)-cholestatrien-1,3,25-triol
VVD0553
Sachiko Yamada
24a,24b,24c-trihomo-1a,25-(OH)2D3
C30H50O3 458.716 Download ChemDraw structure file
Biological activity (% of 1,25-(OH)2D3 effect) : Inhibition of proliferation of U937 cells, 20% ; Induction of differentiation of U 937 cells, 40% ; Calciuric activity, 2%. (Ref. 0285)





From hydroxy protected (5E)-23,24,25,26,27-pentanorvitamin D3 22-bis(methylseleno)acetal via displacement of one methylseleno group by side chain fragment, reduction of the other methylseleno group via 6,19-SO2 adduct, desulfonylation, dye-sensitized photoisomerization and deprotection. (Ref. 0285)



551
1a,25-dihydroxy-26,27-dimethyl-24a-homovitamin D3 / 1a,25-dihydroxy-26,27-dimethyl-24a-homocholecalciferol
(5Z,7E)-(1S,3R)-26,27-dimethyl-24a-homo-9,10-seco-5,7,10(19)-cholestatrien-1,3,25-triol
VVD0554
Sachiko Yamada
1a,25-(OH)2-24,26,27-trihomo-D3
C30H50O3 458.716 Download ChemDraw structure file
Biological activity (% of 1,25-(OH)2D3 effect) Inhibition of U 937 cell (human histiocytic lymphoma cell line) proliferation : 800 (IC50 : the title compound, 1.7 times 10-9 M ; 1,25-(OH)2D3, 1.4 times 10-8 M) ; Induction of U 937 cell differentiation : 500 ; Binding to the 1,25-(OH)2D3 receptor from rachitic chicken intestine : 18 ; Calcemic activity determined by the increase in urinary calcium excretion in rats : 20. Inhibitory effects on murine thymocyte activation : 1900 (IC50 : the title compound, 1.0 times 10-11 M ; 1,25-(OH)2D3, 1.9 times 10-10 M). (Ref. 0278)





From hydroxy protected (5E)-23,24,25,26,27-pentanorvitamin D3 22-bis(methylseleno)acetal via displacement of one methylseleno group by side chain fragment, reduction of the other methylseleno group via 6,19-SO2 adduct, desulfonylation, dye-sensitized photoisomerization and deprotection. From hydroxy protected (5E)-22-tosyloxy-23,24,25,26,27-pentanorvitamin D3 via cuprate catalyzed Grignard reaction, photoisomerization and deprotection. (Ref. 0285)



552
1a,25-dihydroxy-26,27-dimethyl-24a-homo-20-epivitamin D3 / 1a,25-dihydroxy-26,27-dimethyl-24a-homo-20-epicholecalciferol
(5Z,7E)-(1S,3R,20S)-26,27-dimethyl-24a-homo-9,10-seco-5,7,10(19)-cholestatriene-1,3,25-triol
VVD0555
Sachiko Yamada
C30H50O3 458.716 Download ChemDraw structure file
Biological activity (% of 1,25-(OH)2D3 effect) Inhibition of U 937 cell (human histiocytic lymphoma cell line) proliferation :17000 (IC50 : the title compound, 8.2 times 10-11 M ; 1,25-(OH)2D3, 1.4 times 10-8 M) ; Induction of U 937 cell differentiation : 20000 ; Binding to the 1,25-(OH)2D3 receptor from rachitic chicken intestine : 100 ; Calcemic activity determined by the increase in urinary calcium excretion in rats : 120. Inhibitory effects on murine thymocyte activation : 2835800 (IC50 : the title compound,6.7 times 10-15 M ; 1,25-(OH)2D3, 1.9 times 10-10 M). (Ref. 0278)





From protected (5E)-1a-hydroxy-22-p-toluenesulfonyloxy-23,24,25,26,27-pentanorvitamin D3 via introduction of the side chain by the reaction with Grignard reagent in the presence of copper catalyst., photoisomerization and deprotection. (Ref. 0284)



553
26,27-diethyl-1a,25-dihydroxy-22-thiavitamin D3 / 26,27-diethyl-1a,25-dihydroxy-22-thiacholecalciferol
(5Z,7E)-(1S,3R)-26,27-diethyl-9,10-seco-22-thia-5,7,10(19)-cholestatriene-1,3,25-triol
VVD0556
Sachiko Yamada
1a,25-(OH)2-26,27-diethyl-22-thia-D3
C30H50O3S 490.782 Download ChemDraw structure file






Synthesis from dehydroepiandrostertone via the 5,7-diene by photochemical method. (Ref. 0215)



554
26,27-diethyl-1a,25-dihydroxy-22-thia-20-epivitamin D3 / 26,27-diethyl-1a,25-dihydroxy-22-thia-20-epicholecalciferol
(5Z,7E)-(1S,3R,20R)-26,27-diethyl-9,10-seco-22-thia-5,7,10(19)-cholestatriene-1,3,25-triol
VVD0557
Sachiko Yamada
1a,25-(OH)2-20-epi-26,27-diethyl-22-thia-D3
C30H50O3S 490.782 Download ChemDraw structure file






Synthesis from dehydroepiandrostertone via the 5,7-diene by photochemical method. (Ref. 0215)



555
1a-hydroxy-2b-(3-hydroxypropoxy)vitamin D3 / 1a-hydroxy-2b-(3-hydroxypropoxy)cholecalciferol
(5Z,7E)-(1R,2R,3R)-2-(3-hydroxypropoxy)-9,10-seco-5,7,10(19)-cholestatriene-1,3-diol
VVD0558
Sachiko Yamada
2b-(3-hydroxypropoxy)-1a-OHD3
C30H50O4 474.716 Download ChemDraw structure file
Plasma calcium levels in rats fed with a low calcium/vitamin D deficient diet after administration (6.25mg/kg times 5). (Ref. 0216)
(EtOH) lmax (nm) 263 (Ref. 0216)
1H-NMR (d, CDCl3) 0.54 (3H, s), 0.86 (6H, d, J = 6.6 Hz), 0.91 (3H, d, J = 6.1 Hz), 3.58-4.00 (5H, br), 4.10-4.36 (2H, m), 5.08 (1H, s), 5.49 (1H, s), 6.04 (1H, d, J = 10.5 Hz), 6.36 (1H, d, J = 10.5 Hz) (Ref. 0216)
m/z 474 (M+), 456, 398, 380, 150 (100%) (Ref. 0216)
HRMS Calcd 474.3709, Found 474.3693 (Ref. 0216)


Synthesis by photochemical method of the 5,7-diene. (Ref. 0216)



556
1a,25-dihydroxy-2b-(3-hydroxypropyl)vitamin D3 / 1a,25-dihydroxy-2b-(3-hydroxypropyl)cholecalciferol
(5Z,7E)-(1S,2R,3R)-2-(3-hydroxypropyl)-9,10-seco-5,7,10(19)-cholestatriene-1,3,25-triol
VVD0559
Sachiko Yamada
2b-(3-hydroxypropyl)-1a,25-(OH)2D3
C30H50O4 474.716 Download ChemDraw structure file
Spinal bone mineral density in pre-osteoporosis model rats and binding affinity to calf thymus vitamin D receptor. (Ref. 0217)
(EtOH) lmax (nm) 264, lmin (nm) 228 (Ref. 0217)
(neat) 3367 (br), 2942, 2871, 1376, 1214, 1056, 755 cm-1 (Ref. 0217)
1H-NMR (d, CDCl3) 0.55 (3H, s), 0.94 (3H, d, J = 6.1 Hz), 1.22 (6H, s), 3.70 (2H, t, J = 6.3 Hz), 4.02-4.10 (1H, m), 4.17 (1H, br s), 5.03 (1H, s), 5.38 (1H, s), 6.03 (1H, d, J = 11.7 Hz), 6.35 (1H, d, J = 11.7 Hz) (Ref. 0217)
m/z 474 (M+), 59 (100%) (Ref. 0217)
HRMS Calcd 474.3709, Found 474.3702 (Ref. 0217)


Synthesis by photochemical method of the 5,7-diene. (Ref. 0217)



557
26,27-diethyl-1a,25-dihydroxy-22-oxavitamin D3 / 26,27-diethyl-1a,25-dihydroxy-22-oxacholecalciferol
(5Z,7E)-(1S,3R)-26,27-diethyl-22-oxa-9,10-seco-5,7,10(19)-cholestatriene-1,3,25-triol
VVD0560
Sachiko Yamada
22-oxa-26,27-diethyl-1a,25-(OH)2D3
C30H50O4 474.716 Download ChemDraw structure file
The activity inducing differentiation of human myeloid leukemia cells (HL-60) into macrophases in vitro estimated by superoxide anion generation : ED50 = 1.78 times 10-8 M [ED50 of 1,25-(OH)2D3 : 1.70 times 10-8 M, ED50 of OCT : 1.78 times10-8 M]. (Ref. 0203)
(EtOH) lmax (nm) 263, lmin (nm) 227 (Ref. 0203)
1H-NMR (d, CDCl3) 0.53 (3H, s), 0.88 (6H, t, J = 6.8 Hz), 1.18 (3H, d, J = 6.1 Hz), 3.17-3.28 (1H, m), 3.37-3.48 (1H, m), 4.23 (1H, m), 4.44 (1H, m), 4.99 (1H, br t), 6.02 (1H, d, J = 10.9 Hz), 6.37 (1H, d, J = 10.9 Hz). (Ref. 0203)
m/z 456 (M+-H2O), 54 (100%) (Ref. 0203)
colorless foam (Ref. 0203)
1)Preparative TLC developed with CH2Cl2/EtOH (12 : 1), 2)Preparative TLC developed with CH2Cl2/EtOH (20 : 1), 3)Preparative TLC developed with AcOEt/n-hexane (3 : 1). (Ref. 0203)

Synthesis from dehydroepiandrostertone via 1a,3b-dihydroxy-20(S)-(3-hydroxy-3-propylhexyloxy)pregna-5,7-diene by photochemical method. (Ref. 0203)



558
26,27-diethyl-1a,25-dihydroxy-23-oxavitamin D3 / 26,27-diethyl-1a,25-dihydroxy-23-oxacholecalciferol
(5Z,7E)-(1S,3R)-26,27-diethyl-23-oxa-9,10-seco-5,7,10(19)-cholestatriene-1,3,25-triol
VVD0561
Sachiko Yamada
23-oxa-26,27-diethyl-1a,25-(OH)2D3
C30H50O4 474.716 Download ChemDraw structure file
Biological activity : Affinity for pig intestinal nuclear receptor, 13% of 1,25-(OH)2D3 effect ; Affinity for human vitamin D binding protein, < 0.02% of 25-OHD3 effect ; Differentiation of HL-60 cells, 25% of 1,25-(OH)2D3 effect ; Calciuric effect, 1% of 1,25-(OH)2D3 effect. (Ref. 0299)





From protected (5E)-1a,22-dihydroxy-23,24,25,26,27-pentanorvitamin D3 via alkylation under phase-transfer conditions, Grignard reaction, photoisomerization, and deprotection. (Ref. 0299/0300/0153)



559
(20S)-1a,25-dihydroxy-20-methoxy-26,27-dimethylvitamin D3 / (20S)-1a,25-dihydroxy-20-methoxy-26,27-dimethylcholecalciferol
(5Z,7E)-(1S,3R,20S)-20-methoxy-26,27-dimethyl-9,10-seco-5,7,10(19)-cholestatriene-1,3,25-triol
VVD0562
Sachiko Yamada
20S-methoxy-26,27-dimethyl-1a,25-(OH)2D3
C30H50O4 474.716 Download ChemDraw structure file
Biological activity (% of 1,25-(OH)2D3 effect) : Inhibition of U 937 cell (human histiocytic lymphoma cell line) proliferation : 800000% ; Binding to the 1,25-(OH)2D3 receptor from rachitic chicken intestine : 50% ; Calcemic activity determined by the increase in urinary calcium excretion in rats : 32%. (Ref. 0279)





From (5E)-1a-hydroxy-20-keto-22,23,24,25,26,27-hexanorvitamin D3 derivative by addition of a Grignard reagent followed by methylation, photochemical isomerization and deprotection. (Ref. 0279)



560
1a,25-dihydroxy-26,27-dimethyl-24a,24b-dihomo-22-oxa-20-epivitamin D3 / 1a,25-dihydroxy-26,27-dimethyl-24a,24b-dihomo-22-oxa-20-epicholecalciferol
(5Z,7E)-(1S,3R,20R)-26,27-dimethyl-24a,24b-dihomo-22-oxa-9,10-seco-5,7,10(19)-cholestatrien-1,3,25-triol
VVD0563
Sachiko Yamada
C30H50O4 474.716 Download ChemDraw structure file
Biological activity (% of 1,25-(OH)2D3 effect) Inhibition of U 937 cell (human histiocytic lymphoma cell line) proliferation : 28000 (IC50 : the title compound, 5.0 times 10-11 M ; 1,25-(OH)2D3, 1.4 times 10-8 M) ; Induction of U 937 cell differentiation : 40000 ; Binding to the 1,25-(OH)2D3 receptor from rachitic chicken intestine : 61; Calcemic activity determined by the increase in urinary calcium excretion in rats : 80. (Ref. 0278)









561
(22R)-1a,22,25-trihydroxy-26,27-dimethyl-24a-homo-20-epivitamin D3 / (22R)-1a,22,25-trihydroxy-26,27-dimethyl-24a-homo-20-epicholecalciferol
(5Z,7E)-(1S,3R,20R,22R)-26,27-dimethyl-24a-homo-9,10-seco-5,7,10(19)-cholestatriene-1,3,22,25-tetrol
VVD0564
Sachiko Yamada
26,27-dimethyl-24a-homo-20-epi-1a,22R,25-(OH)3D3
C30H50O4 474.716 Download ChemDraw structure file
Relative potency (1,25-(OH)2D3 = 1) : Induction of differentiation of U 937 cells, 20 ; Inhibition of proliferation, 28 ; VDR (rachitic chicken intestinal receptor) binding affinity, 0.02 ; Calciuric effect in normal rats, 0.8. (Ref. 0321)





From protected (5E)-1a-hydroxy-22-oxo-23,24,25,26,27-pentanor-20-epivitamin D3 via the reaction with a Grignard reagent of side chain fragment giving major (19:1) 22R-hydroxy product as a key step. (Ref. 0321)



562
(20S)-1a,20,25-trihydroxy-26,27-dimethyl-24a-homovitamin D3 / (20S)-1a,20,25-trihydroxy-26,27-dimethyl-24a-homocholecalciferol
(5Z,7E)-(1S,3R,20S)-26,27-dimethyl-24a-homo-9,10-seco-5,7,10(19)-cholestatriene-1,3,20,25-tetrol
VVD0565
Sachiko Yamada
26,27-dimethyl-24a-homo-1a,20S,25-(OH)3D3
C30H50O4 474.716 Download ChemDraw structure file
Biological activity (% of 1,25-(OH)2D3 effect) : Inhibition of U 937 cell (human histiocytic lymphoma cell line) proliferation : 900% ; Binding to the 1,25-(OH)2D3 receptor from rachitic chicken intestine : 0.6% ; Calcemic activity determined by the increase in urinary calcium excretion in rats : < 0.5%. (Ref. 0279)





From (5E)-1a-hydroxy-20-keto-22,23,24,25,26,27-hexanorvitamin D3 derivative by addition of a Grignard reagent followed by photochemical isomerization and deprotection. (Ref. 0279)



563
(22S)-1a,22,25-trihydroxy-26,27-dimethyl-24a-homovitamin D3 / (22S)-1a,22,25-trihydroxy-26,27-dimethyl-24a-homocholecalciferol
(5Z,7E)-(1S,3R,22S)-26,27-dimethyl-24a-homo-9,10-seco-5,7,10(19)-cholestatriene-1,3,22,25-tetrol
VVD0566
Sachiko Yamada
24-homo-26,27-dimethyl-1a,22S,25-(OH)3D3
C30H50O4 474.716 Download ChemDraw structure file










564
1a,25-dihydroxy-2b-(3-hydroxypropoxy)vitamin D3 / 1a,25-dihydroxy-2b-(3-hydroxypropoxy)cholecalciferol
(5Z,7E)-(1R,2R,3R)-2-(3-hydroxypropoxy)-9,10-seco-5,7,10(19)-cholestatriene-1,3,25-triol
VVD0567
Sachiko Yamada
1a,25-(OH)2-2b-(3-hydroxypropoxy)D3
C30H50O5 490.715 Download ChemDraw structure file
Binding potency to vitamin D binding protein of ED-71 was 2.7 times compared to 1a,25-(OH)2D3. Binding potency to vitamin D receptor was 1/8 compared to 1a,25-(OH)2D3. ED-71 improved bone mineral density and mechanical bone strength in the pre-osteoporosis model rats made by ovariectomy more effectively than 1a,25-(OH)2D3. (Ref. 0227)
(EtOH) lmax (nm) 263 (Ref. 0216)
(nujol) 3360, 1100, 1060, 910 cm-1 (Ref. 0216)
1H-NMR (d, CDCl3) 0.55 (3H, s), 0.91 (3H, d, J = 6.1 Hz), 1.21 (6H, s), 3.60-4.02 (5H, br), 4.12-4.36 (2H, m), 5.08 (1H, s), 5.49 (1H, s), 6.04 (1H, d, J = 10.5 Hz), 6.36 (1H, d, J = 10.5 Hz) (Ref. 0216)
m/z 490 (M+), 472, 454, 396, 59 (100%) (Ref. 0216)
Colorless foam. (Ref. 0216)
HRMS Calcd 490.3658, Found 490.3678 (Ref. 0216)
Preparative TLC developed twice with CH2Cl2-EtOH (20 : 3) (Ref. 0216)

Synthesis by photochemical method of the 5,7-diene. (Ref. 0217)



565
1b,25-dihydroxy-2b-(3-hydroxypropoxy)vitamin D3 / 1b,25-dihydroxy-2b-(3-hydroxypropoxy)cholecalciferol
(5Z,7E)-(1S,2R,3R)-2-(3-hydroxypropoxy)-9,10-seco-5,7,10(19)-cholestatriene-1,3,25-triol
VVD0568
Sachiko Yamada
2b-(3-hydroxypropoxy)-1b,25-(OH)2D3
C30H50O5 490.715 Download ChemDraw structure file
The binding affinity for vitamin D receptor and vitamin D binding protein was 0.003 and 6.7 [1a,25-(OH)2D3 : 1]. (Ref. 0214)
(EtOH) lmax (nm) 264, lmin (nm) 227 (Ref. 0214)
1H-NMR (d, CDCl3) 0.54 (3H, s), 0.94 (3H, d, J = 6.5 Hz), 1.22 (6H, s), 3.58-3.64 (1H, m), 3.84 (2H, t, J = 5.4 Hz), 3.91 (2H, t, J = 5.4 Hz), 4.01-4.10 (1H, m), 4.28-4.33 (1H, br s), 5.08 (1H, s), 5.38 (1H, s), 6.03 (1H, d, J = 12.0 Hz), 6.43 (1H, d, J = 12.0 Hz) (Ref. 0214)
m/z 490 (M+), 60 (100%) (Ref. 0214)
HRMS Calcd 490.3658, Found 490.3706 (Ref. 0214)


Synthesis from pro-ED-71 by inversion of 1a-hydroxy group and photochemical method. (Ref. 0214)



566
1a-hydroxy-22-[3-(1-hydroxy-1-methylethyl)phenyl]-23,24,25,26,27-pentanorvitamin D3 / 1a-hydroxy-22-[3-(1-hydroxy-1-methylethyl)phenyl]-23,24,25,26,27-pentanorcholecalciferol
(5Z,7E)-(1S,3R)-22-[3-(1-hydroxy-1-methylethyl)phenyl]-23,24-dinor-9,10-seco-5,7,10(19)-cholatriene-1,3-diol
VVD0569
Sachiko Yamada
C31H44O3 464.679 Download ChemDraw structure file
(% of 1,25-(OH)2D3 effect) Intestinal calcium absorption: 13; bone calcium mobilization: 7.7; affinity for chick intestinal receptor, HL-60 cell receptor and serum vitamin D binding protein: 62, 32and 25, respectively; Inhibition of 1a-hydroxylase activity: 99; differentiation of HL-60 cells: 80. (Ref. 0364)





By coupling of enol trifltes of modified CD steroid fragment with the vitamin D A-ring enyne. (Ref. 0364)



567
(17Z)-1a,25-dihydroxy-26,27-dimethyl-17,20,22,22,23,23-hexadehydro-24a,24b-dihomovitamin D3 / (17Z)-1a,25-dihydroxy-26,27-dimethyl-17,20,22,22,23,23-hexadehydro-24a,24b-dihomocholecalciferol
(5Z,7E,17Z)-(1S,3R)-26,27-dimethyl-24a,24b-dihomo-9,10-seco-5,7,10(19),17(20)-cholestatetraen-22-yne-1,3,25-triol
VVD0570
Sachiko Yamada
17(20)Z-ene-22-yne-24-dihomo-26,27-dimethyl-1a,25-(OH)2D3
C31H46O3 466.695 Download ChemDraw structure file
Biological activity (% of 1,25-(OH)2D3 effect) : Inhibition of proliferation of U937 cells, 29000% ; Affinity for chicken intestinal vitamin D receptor, 2% ; Calciuric activity, 25%. (Ref. 0293)





From hydroxy protected (5E)-1a-hydroxy-20-oxo-22,23,24,25,26,27-hexanorvitamin D3 via reaction with appropriate lithium acetylide, treatment with acid, separation of regio- and stereoisomers, dye-sensitized photoisomerization and deprotection. (Ref. 0293)



568
1a,25-dihydroxy-(26,26)-(27,27)-diethanovitamin D3 / 1a,25-dihydroxy-(26,26)-(27,27)-diethanocholecalciferol
(5Z,7E)-(1S,3R)-(26,26)-(27,27)-diethano-9,10-seco-5,7,10(19)-cholestatriene-1,3,25-triol
VVD0571
Sachiko Yamada
C31H48O3 468.711 Download ChemDraw structure file

1H-NMR (d, CD2Cl2) 6.44 and 5.99 (2H, AB pattern, d, J = 11 Hz, 6- and 7-H), 5.27 (1H, br d, J = 3.5 Hz, 19E-H), 4.95 (1H, br d,J = 3.5 Hz, 19Z-H), 4.35 (1H, m, 1-H), 4.15 (1H, m, 3-H), 0.92 (3H, d, J = 6.2 Hz, 21C-CH3), 0.81 (2H, m, 26- and 27-H), 0.53 (3H, s, 18C-CH3), 0.34 (8H, m, 4-cyclopropylic CH2) (Ref. 0195)
13C-NMR (d, CD2Cl2) 148.6 (C), 143.5 (C), 133.9 (C), 125.1 (CH), 117.6 (CH), 111.8 (C-19), 71.2 (CH), 71.0 (CH), 67.2, 57.2, 56.8, 45.8 (C-25), 43.5 (CH2), 43.4 (CH2), 41.0 (CH2), 37.1 (CH2), 36.6, 29.4 (CH2), 28.0 (CH2), 24.0 (CH2), 22.6 (CH2), 20.8 (CH2), 19.0 (CH), 12.1, 0.8 (CH2), -0.5 (CH2) (Ref. 0195)








569
(22E,24E)-1a,25-dihydroxy-26,27-dimethyl-22,23,24,24a-tetradehydro-24a,24b-dihomovitamin D3 / (22E,24E)-1a,25-dihydroxy-26,27-dimethyl-22,23,24,24a-tetradehydro-24a,24b-dihomocholecalciferol
(5Z,7E,22E,24E)-(1S,3R)-26,27-dimethyl-24a,24b-dihomo-9,10-seco-5,7,10(19),22,24-cholestapentaene-1,3,25-triol
VVD0572
Sachiko Yamada
(22E,24E)-26,27-dimethyl-22,23,24,24a-tetradehydro-24a,24b-dihomo-1a,25-(OH)2D3
C31H48O3 468.711 Download ChemDraw structure file
Biological activity (% of 1,25-(OH)2D3 effect) : Inhibition of proliferation of U937 cells, 700% ; Induction of differentiation of U 937 cells, 200% ; Calciuric activity, 20%. (Ref. 0285)





From protected (5E)-1a-hydroxy-22-oxo-23,24,25,26,27-pentanorvitamin D3 via side chain introduction, photoisomerization and deprotection. (Ref. 0285)



570
1a,25-dihydroxy-26,27-dimethyl-22,22,23,23-tetradehydro-24a,24b-dihomovitamin D3 / 1a,25-dihydroxy-26,27-dimethyl-22,22,23,23-tetradehydro-24a,24b-dihomocholecalciferol
(5Z,7E)-(1S,3R)-26,27-dimethyl-24a,24b-dihomo-9,10-seco-5,7,10(19)-cholestatrien-22-yne-1,3,25-triol
VVD0573
Sachiko Yamada
22-yne-24-dihomo-26,27-dimethyl-1a,25-(OH)2D3
C31H48O3 468.711 Download ChemDraw structure file
Biological activity (% of 1,25-(OH)2D3 effect) : Inhibition of proliferation of U937 cells, 10% ; Affinity for chicken intestinal vitamin D receptor, 2%. (Ref. 0293)





From hydroxy protected (5E)-1a-hydroxy-22,22,23,23-tetradehydro-24,25,26,27-tetranorvitamin D3, which was derived from corresponding 22-aldehyde, via side chain introduction, dye-sensitized photoisomerization and deprotection. (Ref. 0293)



571
1a,25-dihydroxy-26,27-dimethyl-22,22,23,23-tetradehydro-24a,24b-dihomo-20-epivitamin D3 / 1a,25-dihydroxy-26,27-dimethyl-22,22,23,23-tetradehydro-24a,24b-dihomo-20-epicholecalciferol
(5Z,7E)-(1S,3R,20R)-26,27-dimethyl-24a,24b-dihomo-9,10-seco-5,7,10(19)-cholestatrien-22-yne-1,3,25-triol
VVD0574
Sachiko Yamada
20-epi-22-yne-24-dihomo-26,27-dimethyl-1a,25-(OH)2D3
C31H48O3 468.711 Download ChemDraw structure file
Biological activity (% of 1,25-(OH)2D3 effect) : Inhibition of proliferation of U937 cells, 49000% ; Affinity for chicken intestinal vitamin D receptor, 7% ; Calciuric activity, 63%. (Ref. 0293)





From hydroxy protected (5E)-1a-hydroxy-22,22,23,23-tetradehydro-24,25,26,27-tetranor-20-epivitamin D3, which was derived from corresponding 22-aldehyde, via side chain introduction, dye-sensitized photoisomerization and deprotection. (Ref. 0293)



572
(22R)-1a,25-dihydroxy-22-methoxy-26,27-dimethyl-23,23,24,24-tetradehydro-24a-homovitamin D3 / (22R)-1a,25-dihydroxy-22-methoxy-26,27-dimethyl-23,23,24,24-tetradehydro-24a-homocholecalciferol
(5Z,7E)-(1S,3R,22R)-22-methoxy-26,27-dimethyl-24a-homo-9,10-seco-5,7,10(19)-cholestatrien-23-yne-1,3,25-triol
VVD0575
Sachiko Yamada
22R-methoxy-23-yne-24-homo-26,27-dimethyl-1a,25-(OH)2D3
C31H48O4 484.710 Download ChemDraw structure file










573
(22S)-1a,25-dihydroxy-22-methoxy-26,27-dimethyl-23,24-tetradehydro-24a-homo-20-epivitamin D3 / (22S)-1a,25-dihydroxy-22-methoxy-26,27-dimethyl-23,24-tetradehydro-24a-homo-20-epicholecalciferol
(5Z,7E)-(1S,3R,20R,22S)-26,27-dimethyl-22-methoxy-24a-homo-9,10-seco-5,7,10(19)-cholestatrien-23-yne-1,3,25-triol
VVD0576
Sachiko Yamada
22S-methoxy-26,27-dimethyl-23,24-tetradehydro-24a-homo-20-epi-1a,25-(OH)2D3
C31H48O4 484.710 Download ChemDraw structure file
Relative potency (1,25-(OH)2D3 = 1) : Induction of differentiation of U 937 cells, 200 ; Inhibition of proliferation, 620 ; VDR (rachitic chicken intestinal receptor) binding affinity, 0.14 ; Calciuric effect in normal rats, 1.1. (Ref. 0321)





From protected (5E)-1a-hydroxy-22-oxo-23,24,25,26,27-pentanor-20-epivitamin D3 via the reaction with lithiated acetylene side chain fragment giving major (19:1) 22S-hydroxy product as a key step. (Ref. 0321)



574
(22S)-1a,25-dihydroxy-22-ethoxy-26,27-dimethyl-23,24-tetradehydro-20-epivitamin D3 / (22S)-1a,25-dihydroxy-22-ethoxy-26,27-dimethyl-23,24-tetradehydro-20-epicholecalciferol
(5Z,7E)-(1S,3R,20R,22S)-26,27-dimethyl-22-ethoxy-9,10-seco-5,7,10(19)-cholestatrien-23-yne-1,3,25-triol
VVD0577
Sachiko Yamada
22S-ethoxy-26,27-dimethyl-23,24-tetradehydro-20-epi-1a,25-(OH)2D3
C31H48O4 484.710 Download ChemDraw structure file
Relative potency (1,25-(OH)2D3 = 1) : Induction of differentiation of U 937 cells, 1000 ; Inhibition of proliferation, 790 ; VDR (rachitic chicken intestinal receptor) binding affinity, 0.19 ; Calciuric effect in normal rats, 1. (Ref. 0321)





From protected (5E)-1a-hydroxy-22-oxo-23,24,25,26,27-pentanor-20-epivitamin D3 via the reaction with lithiated acetylene side chain fragment giving major (19:1) 22S-hydroxy product as a key step. (Ref. 0321)



575
(22R)-1a,22,25-trihydroxy-26,27-dimethyl-23,23,24,24-tetradehydro-24a,24b-dihomovitamin D3 / (22R)-1a,22,25-trihydroxy-26,27-dimethyl-23,23,24,24-tetradehydro-24a,24b-dihomocholecalciferol
(5Z,7E)-(1S,3R,22R)-26,27-dimethyl-24a,24b-dihomo-9,10-seco-5,7,10(19)-cholestatrien-23-yne-1,3,22,25-tetrol
VVD0578
Sachiko Yamada
23-yne-24-dihomo-26,27-dimethyl-1a,22R,25-(OH)3D3
C31H48O4 484.710 Download ChemDraw structure file










576
(22S)-1a,22,25-trihydroxy-26,27-dimethyl-23,23,24,24-tetradehydro-24a,24b-dihomovitamin D3 / (22S)-1a,22,25-trihydroxy-26,27-dimethyl-23,23,24,24-tetradehydro-24a,24b-dihomocholecalciferol
(5Z,7E)-(1S,3R,22S)-26,27-dimethyl-24a,24b-dihomo-9,10-seco-5,7,10(19)-cholestatrien-23-yne-1,3,22,25-tetrol
VVD0579
Sachiko Yamada
23-yne-24-dihomo-26,27-dimethyl-1a,22S,25-(OH)3D3
C31H48O4 484.710 Download ChemDraw structure file










577
(22S)-1a,22,25-trihydroxy-26,27-dimethyl-23,24-tetradehydro-24a,24b-dihomo-20-epivitamin D3 / (22S)-1a,22,25-trihydroxy-26,27-dimethyl-23,24-tetradehydro-24a,24b-dihomo-20-epicholecalciferol
(5Z,7E)-(1S,3R,20R,22S)-26,27-dimethyl-24a,24b-dihomo-9,10-seco-5,7,10(19)-cholestatrien-23-yne-1,3,22,25-tetrol
VVD0580
Sachiko Yamada
23,24-tetradehydro-24a,24b-dihomo-20-epi-1a,22R,25-(OH)3D3
C31H48O4 484.710 Download ChemDraw structure file
Relative potency (1,25-(OH)2D3 = 1) : Induction of differentiation of U 937 cells, 100 ; Inhibition of proliferation, 12 ; VDR (rachitic chicken intestinal receptor) binding affinity, 0.005. (Ref. 0321)





From protected (5E)-1a-hydroxy-22-oxo-23,24,25,26,27-pentanor-20-epivitamin D3 via the reaction with lithiated acetylene side chain fragment giving major (19:1) 22S-hydroxy product as a key step. (Ref. 0321)



578
(22R)-1a,22,25-trihydroxy-26,27-dimethyl-23,24-tetradehydro-24a,24b-dihomo-20-epivitamin D3 / (22R)-1a,22,25-trihydroxy-26,27-dimethyl-23,24-tetradehydro-24a,24b-dihomo-20-epicholecalciferol
(5Z,7E)-(1S,3R,20R,22R)-26,27-dimethyl-24a,24b-dihomo-9,10-seco-5,7,10(19)-cholestatrien-23-yne-1,3,22,25-tetrol
VVD0581
Sachiko Yamada
26,27-dimethyl-23,24-tetradehydro-24a,24b-dihomo-20-epi-1a,22R,25-(OH)3D3
C31H48O4 484.710 Download ChemDraw structure file
Relative potency (1,25-(OH)2D3 = 1) : Induction of differentiation of U 937 cells, 0.5 ; Inhibition of proliferation, < 0.1 ; VDR (rachitic chicken intestinal receptor) binding affinity, <0.005. (Ref. 0321)





From protected (5E)-1a-hydroxy-22-oxo-23,24,25,26,27-pentanor-20-epivitamin D3 via the reaction with lithiated acetylene side chain fragment giving minor (1:19) 22R-hydroxy product. (Ref. 0321)



579
1a,25-dihydroxy-22-oxavitamin D3 3-hemiglutarate/ 1a,25-dihydroxy-22-oxacholecalciferol 3-hemiglutarate
(5Z,7E)-(1S,3R)-22-oxa-9,10-seco-5,7,10(19)-cholestatriene-1,3,25-triol 3-hemiglutarate
VVD0582
Sachiko Yamada
22-oxa-1a,25-(OH)2D3-3-hemiglutarate
C31H48O7 532.709 Download ChemDraw structure file
Haptenic derivative of OCT to produce a specific anti-OCT antibody. (Ref. 0204)
(EtOH) lmax (nm) 263, lmin (nm) 227 (Ref. 0204)
1H-NMR (d, CDCl3, 200MHz) 0.53 (3H, s, 18-H), 1.19 (3H, d, J = 6.1Hz, 21-H), 1.23 (6H, s, 26- and 27-H), 2.33-2.42 (4H, m, 2 times CH2CO), 3.18-3.31, 3.42-3.53 (each 1H, m, 23-H), 3.84 (1H, m, 20-H), 4.39 (1H, m, 1-H), 4.98 (1H, br s, 19-H), 5.17 (1H, m, 3-H), 5.33 (1H, br s, 19-H), 5.98 (1H, d, J = 11.0 Hz, 7-H), 6.29 (1H, d, J = 11.0 Hz, 6-H) (Ref. 0204)
m/z 532 (M+) (Ref. 0204)

Flash column chromatography with CH2Cl2/EtOH (12 : 1). (Ref. 0204)

Synthesis from (5Z,7E)-(1S,3R)-1,25-dihydroxy-22-oxa-9,10-secocholesta-5,7,10(19)-trien-3-yl (2,2'2'-trichloroethylglutarate) by deprotection. (Ref. 0204)



580
(10E)-19-(3-carboxylpropyl)vitamin D3 / (10E)-19-(3-carboxylpropyl)cholecalciferol
(5Z,7E,10E)-(3S)-19-(3-carboxylpropyl)-9,10-seco-5,7,10(19)-cholestatrien-3-ol
VVD0583
Sachiko Yamada
(10E)-19-(3-carboxylpropyl)-D3
C31H50O3 470.727 Download ChemDraw structure file

(95% EtOH) lmax (nm) 264 (Ref. 0331)
(CHCl3) 1705 cm-1 (Ref. 0331)
1H-NMR (d, CDCl3) 0.55 (s, 18-H), 5.35 (t, J = 7.0 Hz, 19-H), 6.23 (d, J = 12.0 Hz, 6-H), 5.95 (d, J = 12.0 Hz, 7-H), 3.96 (m, 3-H) (Ref. 0331)
13C-NMR (d, CDCl3) 45.85 (t, C-4), 141.65 (s, C-5), 121.99 (d, C-6), 117.60 (d, C-7), 141.70 (s, C-8), 128.15 (s, C-10), 121.90 (d, C-19) (Ref. 0331)
m/z 470 (M+), 152, 222 (Ref. 0331)



From vitamin D3 via electrophilic substitution of its sulfur dioxide adduct. (Ref. 0331)



581
(5E,10E)-19-(3-carboxylpropyl)vitamin D3 / (5E,10E)-19-(3-carboxylpropyl)cholecalciferol
(5E,7E,10E)-(3S)-19-(3-carboxylpropyl)-9,10-seco-5,7,10(19)-cholestatrien-3-ol
VVD0584
Sachiko Yamada
(5E,10E)-19-(3-carboxylpropyl)-D3
C31H50O3 470.727 Download ChemDraw structure file

(95% EtOH) lmax (nm) 264 (Ref. 0331)
(CHCl3) 1705 cm-1 (Ref. 0331)
1H-NMR (d, CDCl3) 0.57 (s, 18-H), 5.20 (t, J = 7.0 Hz, 19-H), 6.23 (d, J = 12.0 Hz, 6-H), 5.89 (d, J = 12.0 Hz, 7-H), 3.88 (m, 3-H) (Ref. 0331)
13C-NMR (d, CDCl3) 37.95 (t, C-4), 143.25 (s, C-5), 123.20 (d, C-6), 114.90 (d, C-7), 140.59 (s, C-8), 131.40 (s, C-10), 122.98 (d, C-19) (Ref. 0331)
m/z 470 (M+), 452 (M+-H2O), 222 [A ring + C(6) + C(7) + C(19)] (Ref. 0331)



From vitamin D3 via electrophilic substitution of its sulfur dioxide adduct. (Ref. 0331)



582
26,27-diethyl-1a,25-dihydroxy-20,21-methano-23-oxavitamin D3 / 26,27-diethyl-1a,25-dihydroxy-20,21-methano-23-oxacholecalciferol
(5Z,7E)-(1S,3R)-26,27-diethyl-20,21-methano-23-oxa-9,10-seco-5,7,10(19)-cholestatriene-1,3,25-triol
VVD0585
Sachiko Yamada
20,21-methano-23-oxa-26,27-diethyl-1a,25-(OH)2D3
C31H50O4 486.726 Download ChemDraw structure file
Biological activity : Affinity for pig intestinal nuclear receptor, 50% of 1,25-(OH)2D3 effect ; Affinity for human vitamin D binding protein, < 0.02% of 25-OHD3 effect ; Differentiation of HL-60 cells, 12.5% of 1,25-(OH)2D3 effect ; Calciuric effect, 0.3% of 1,25-(OH)2D3 effect. (Ref. 0299)









583
1b-butyl-1a,25-dihydroxyvitamin D3 / 1b-butyl-1a,25-dihydroxycholecalciferol
(5Z,7E)-(1S,3R)-1-butyl-9,10-seco-5,7,10(19)-cholestatriene-1,3,25-triol
VVD0586
Sachiko Yamada
1b-butyl-1a,25-(OH)2D3
C31H52O3 472.743 Download ChemDraw structure file
Binding affinity for calf thymus vitamin D receptor : < 1/1000 relative to 1,25-(OH)2D3. (Ref. 0181)
(95% EtOH) lmax (nm) 262, 252 (sh) (Ref. 0181)
(Neat) 3386, 2950, 2871, 1467, 1377, 1215, 1147, 1028, 911 cm-1 (Ref. 0181)
1H-NMR (d, CDCl3) 0.54 (3H, s), 0.90 (3H, t, J = 7.3 Hz), 0.93 (3H, d, J = 6.2 Hz), 1.21 (6H, s), 4.17 (1H, m), 4.99 and 5.30 (each 1H, d, J = 1.2 Hz), 5.96 and 6.36 (each 1H, d, J = 11.6 Hz) (Ref. 0181)
m/z 472 (M+, 2), 454 (18), 436 (10), 415 (12), 397 (9), 379 (8), 361 (5), 307 (5), 197 (18), 155 (60), 151 (100) (Ref. 0181)



From 1a,25-dihydroxyvitamin D3: Oxidation of the 1-hydroxyl group, treatment with BuLi and thermal isomerization gave 1a,25-dihydroxy-1b-butylvitamin D3 and its 1-epimer (1b,25-dihydroxy-1a-butylvitamin D3) in 92:58 ratio. (Ref. 0181)



584
1a-butyl-1b,25-dihydroxyvitamin D3 / 1a-butyl-1b,25-dihydroxycholecalciferol
(5Z,7E)-(1R,3R)-1-butyl-9,10-seco-5,7,10(19)-cholestatriene-1,3,25-triol
VVD0587
Sachiko Yamada
1a-butyl-1b,25-(OH)2D3
C31H52O3 472.743 Download ChemDraw structure file
Binding affinity for calf thymus vitamin D receptor : < 1/1000 relative to 1,25-(OH)2D3. (Ref. 0181)
(95% EtOH) lmax (nm) 263 (Ref. 0181)
(Neat) 3380, 2948, 2869, 1595, 1464, 1377, 1128, 1049, 911 cm-1 (Ref. 0181)
1H-NMR (d, CDCl3) 0.51 (3H, s), 0.88 (3H, t, J = 7.3 Hz), 0.93 (3H, d, J = 6.8 Hz), 1.22 (6H, s), 3.93 (1H, tt, J = 9.1 and 4.3 Hz), 4.99 and 5.32 (each 1H, d, J = 1.5 Hz), 5.97 and 6.34 (each 1H, d, J = 11.0 Hz) (Ref. 0181)
m/z 472 (M+, 1), 454 (13), 436 (5), 415 (9), 397 (5), 379 (4), 361 (2), 307 (4), 155 (22), 151 (100) (Ref. 0181)



From 1a,25-dihydroxyvitamin D3: Oxidation of the 1-hydroxyl group, treatment with BuLi and thermal isomerization gave 1b,25-dihydroxy-1a-butylvitamin D3 and its 1-epimer (1a,25-dihydroxy-1b-butylvitamin D3) in 58:92 ratio. (Ref. 0181)



585
26,27-diethyl-1a,25-dihydroxyvitamin D3 / 26,27-diethyl-1a,25-dihydroxycholecalciferol
(5Z,7E)-(1S,3R)-26,27-diethyl-9,10-seco-5,7,10(19)-cholestatriene-1,3,25-triol
VVD0588
Sachiko Yamada
26,27-diethyl-1a,25-(OH)2D3
C31H52O3 472.743 Download ChemDraw structure file
The title compound was at least 10 fold as active as 1,25-(OH)2D3 in inhibiting proliferation of HL-60 cells : IC50 value was 2 nM for the title compound and 25 nM for 1,25-(OH)2D3. (Ref. 0245)
Binding affinity of the title compound for serum vitamin D binding protein (DBP) and for the receptor of HL-60 cells was < 1% and 21%, respectively, of those of 1,25-(OH)2D3. The ability of the title compound to induce HL-60 cell differentiation (assayed by NBT reduction) was approximately equal to that of 1,25-(OH)2D3 under serum-supplemented culture conditions, whereas the same compound was less active than 1,25-(OH)2D3 under serum-free culture conditions. (Ref. 0275)
Dose response of various 26,27-dialkyl-1,25-(OH)2D3 in bone Ca mobilization. (Ref. 0276)
lmax (nm) 265, lmin (nm) 228 (Ref. 0245)
lmax (nm) 264.5, lmin (nm) 228 (Ref. 0277)
1H-NMR (d, CDCl3) 0.54 (3H, s, 18-H3), 0.88 (6H, t, J = 6.7 Hz, 26- and 27-CH2CH3), 0.93 (3H, d, J = 5.7 Hz, 21-H3), 4.23 (1H, m, 3-H), 4.43 (1H, m, 1-H), 5.01 (1H, br s, 19Z-H), 5.33 (1H, br s, 19E-H), 6.02 (1H, d, J = 11.0 Hz, 7-H), 6.38 (1H, d, J = 11.0 Hz, 6-H) (Ref. 0277)
m/z 472 (M+), 454, 436, 410, 393, 269, 251, 152, 134 (Ref. 0245)
m/z 472 (M+), 454, 436, 410, 393, 269, 251, 152, 134, 115 (Ref. 0277)



The desired provitamin D was synthesized from cholenic acid by introducing 1a-hydroxyl group, the desired side chain and a double bond to the 7-position. The provitamin D was converted to the title compound by photochemical method. (Ref. 0245)



586
1a,25-dihydroxy-26,27-dimethyl-24a,24b-dihomovitamin D3 / 1a,25-dihydroxy-26,27-dimethyl-24a,24b-dihomocholecalciferol
(5Z,7E)-(1S,3R)-26,27-dimethyl-24a,24b-dihomo-9,10-seco-5,7,10(19)-cholestatrien-1,3,25-triol
VVD0589
Sachiko Yamada
26,27-dimethyl-24a,24b-dihomo-1a,25-(OH)22D3
C31H52O3 472.743 Download ChemDraw structure file
Biological activity (% of 1,25-(OH)2D3 effect) : Inhibition of proliferation of U937 cells, 40% ; Induction of differentiation of U 937 cells, 10% ; Calciuric activity, 2%. (Ref. 0285)





From hydroxy protected (5E)-23,24,25,26,27-pentanorvitamin D3 22-bis(methylseleno)acetal via displacement of one methylseleno group by side chain fragment, reduction of the other methylseleno group via 6,19-SO2 adduct, desulfonylation, dye-sensitized photoisomerization and deprotection. (Ref. 0285)



587
1a-hydroxy-2b-(4-hydroxybutoxy)vitamin D3 / 1a-hydroxy-2b-(4-hydroxybutoxy)cholecalciferol
(5Z,7E)-(1R,2R,3R)-2-(4-hydroxybutoxy)-9,10-seco-5,7,10(19)-cholestatriene-1,3-diol
VVD0590
Sachiko Yamada
2b-(4-hydroxybutoxy)-1a-OHD3
C31H52O4 488.742 Download ChemDraw structure file
Plasma calcium levels in rats fed with a low calcium/vitamin D deficient diet after administration (6.25mg/kg times 5). (Ref. 0216)
(EtOH) lmax (nm) 263.5 (Ref. 0216)
1H-NMR (d, CDCl3) 0.54 (3H, s), 0.86 (6H, d, J = 6.6 Hz), 0.91 (3H, d, J = 6.1 Hz), 3.36-3.88 (5H, br), 4.12-4.36 (2H, m), 5.08 (1H, s), 5.50 (1H, s), 6.04 (1H, d, J = 11.4 Hz), 6.36 (1H, d, J = 11.4 Hz) (Ref. 0216)
m/z 488 (M+), 470, 452, 398, 380, 150 (100%) (Ref. 0216)
HRMS Calcd 488.3866, Found 488.3866 (Ref. 0216)


Synthesis by photochemical method of the 5,7-diene. (Ref. 0216)



588
1a,25-dihydroxy-2b-(4-hydroxybutyl)vitamin D3 / 1a,25-dihydroxy-2b-(4-hydroxybutyl)cholecalciferol
(5Z,7E)-(1S,2R,3R)-2-(4-hydroxybutyl)-9,10-seco-5,7,10(19)-cholestatriene-1,3,25-triol
VVD0591
Sachiko Yamada
2b-(4-hydroxybutyl)-1a,25-(OH)2D3
C31H52O4 488.742 Download ChemDraw structure file
Spinal bone mineral density in pre-osteoporosis model rats and binding affinity to calf thymus vitamin D receptor. (Ref. 0217)
(EtOH) lmax (nm) 264, lmin (nm) 229 (Ref. 0217)
(neat) 3850 (br), 2945, 2875 cm-1 (Ref. 0217)
1H-NMR (d, CDCl3) 0.55 (3H, s), 0.94 (3H, d, J = 5.9 Hz), 1.22 (6H, s), 3.68 (2H, t, J = 6.1 Hz), 4.01-4.12 (1H, m), 4.16 (1H, br s), 5.02 (1H, s), 5.37 (1H, s), 6.03 (1H, d, J = 11.3 Hz), 6.34 (1H, d, J = 11.3 Hz) (Ref. 0217)
m/z 488 (M+), 133 (100%) (Ref. 0217)
HRMS Calcd 488.3865, Found 488.3896 (Ref. 0217)


Synthesis by photochemical method of the 5,7-diene. (Ref. 0217)



589
(20S)-1a,25-dihydroxy-20-methoxy-26,27-dimethyl-24a-homovitamin D3 / (20S)-1a,25-dihydroxy-20-methoxy-26,27-dimethyl-24a-homocholecalciferol
(5Z,7E)-(1S,3R,20S)-20-methoxy-26,27-dimethyl-24a-homo-9,10-seco-5,7,10(19)-cholestatriene-1,3,25-triol
VVD0592
Sachiko Yamada
20S-methoxy-26,27-dimethyl-24a-homo-1a,25(OH)2D3
C31H52O4 488.742 Download ChemDraw structure file
Biological activity (% of 1,25-(OH)2D3 effect) : Inhibition of U 937 cell (human histiocytic lymphoma cell line) proliferation : 30000% ; Binding to the 1,25-(OH)2D3 receptor from rachitic chicken intestine : 1% ; Calcemic activity determined by the increase in urinary calcium excretion in rats : 6%. (Ref. 0279)





From (5E)-1a-hydroxy-20-keto-22,23,24,25,26,27-hexanorvitamin D3 derivative by addition of a Grignard reagent followed by methylation, photochemical isomerization and deprotection. (Ref. 0279)



590
26,27-diethyl-1a,25-dihydroxy-24a-homo-22-oxa-20-epivitamin D3 / 26,27-diethyl-1a,25-dihydroxy-24a-homo-22-oxa-20-epicholecalciferol
(5Z,7E)-(1S,3R,20R)-26,27-diethyl-24a-homo-22-oxa-9,10-seco-5,7,10(19)-cholestatriene-1,3,25-triol
VVD0593
Sachiko Yamada
20-epi-22-oxa-24-homo-26,27-diethyl-1a,25-(OH)2D3
C31H52O4 488.742 Download ChemDraw structure file










591
(22S)-1a,22,25-trihydroxy-26,27-dimethyl-24a,24b-dihomovitamin D3 / (22S)-1a,22,25-trihydroxy-26,27-dimethyl-24a,24b-dihomocholecalciferol
(5Z,7E)-(1S,3R,22S)-26,27-dimethyl-24a,24b-dihomo-9,10-seco-5,7,10(19)-cholestatriene-1,3,22,25-tetrol
VVD0594
Sachiko Yamada
24-dihomo-26,27-dimethyl-1a,22S,25-(OH)3D3
C31H52O4 488.742 Download ChemDraw structure file










592
(20S)-1a,25-dihydroxy-20-ethoxy-26,27-dimethylvitamin D3 / (20S)-1a,25-dihydroxy-20-ethoxy-26,27-dimethylcholecalciferol
(5Z,7E)-(1S,3R,20S)-20-ethoxy-26,27-dimethyl-9,10-seco-5,7,10(19)-cholestatriene-1,3,25-triol
VVD0595
Sachiko Yamada
20S-ethoxy-26,27-dimethyl-1a,25-(OH)2D3
C31H52O4 488.742 Download ChemDraw structure file
Biological activity (% of 1,25-(OH)2D3 effect) : Inhibition of U 937 cell (human histiocytic lymphoma cell line) proliferation : 500000% ; Binding to the 1,25-(OH)2D3 receptor from rachitic chicken intestine : 7% ; Calcemic activity determined by the increase in urinary calcium excretion in rats : 14%. (Ref. 0279)





From (5E)-1a-hydroxy-20-keto-22,23,24,25,26,27-hexanorvitamin D3 derivative by addition of a Grignard reagent followed by ethylation, photochemical isomerization and deprotection. (Ref. 0279)



593
(20S)-1a,20,25-trihydroxy-26,27-diethylvitamin D3 / (20S)-1a,20,25-trihydroxy-26,27-diethylcholecalciferol
(5Z,7E)-(1S,3R,20S)-26,27-diethyl-9,10-seco-5,7,10(19)-cholestatriene-1,3,20,25-tetrol
VVD0596
Sachiko Yamada
26,27-diethyl-1a,20S,25-(OH)3D3
C31H52O4 488.742 Download ChemDraw structure file
Biological activity (% of 1,25-(OH)2D3 effect) : Inhibition of U 937 cell (human histiocytic lymphoma cell line) proliferation : < 10% ; Binding to the 1,25-(OH)2D3 receptor from rachitic chicken intestine : 0.5% ; Calcemic activity : not determined. (Ref. 0279)





From (5E)-1a-hydroxy-20-keto-22,23,24,25,26,27-hexanorvitamin D3 derivative by addition of a Grignard reagent followed by photochemical isomerization and deprotection. (Ref. 0279)



594
(22R)-1a,22,25-trihydroxy-26,27-dimethyl-24a,24b-dihomo-20-epivitamin D3 / (22R)-1a,22,25-trihydroxy-26,27-dimethyl-24a,24b-dihomo-20-epicholecalciferol
(5Z,7E)-(1S,3R,20R,22R)-26,27-dimethyl-24a,24b-dihomo-9,10-seco-5,7,10(19)-cholestatriene-1,3,22,25-tetrol
VVD0597
Sachiko Yamada
26,27-dimethyl-24a,24b-dihomo-20-epi-1a,22R,25-(OH)3D3
C31H52O4 488.742 Download ChemDraw structure file
Relative potency (1,25-(OH)2D3 = 1) : Induction of differentiation of U 937 cells, 100 ; Inhibition of proliferation, 210 ; VDR (rachitic chicken intestinal receptor) binding affinity, < 0.005. (Ref. 0321)





From protected (5E)-1a-hydroxy-22-oxo-23,24,25,26,27-pentanor-20-epivitamin D3 via the reaction with Grignard reagent of side chain fragment giving major (19:1) 22R-hydroxy product as a key step. (Ref. 0321)



595
1a,25-dihydroxy-2b-(4-hydroxybutoxy)vitamin D3 / 1a,25-dihydroxy-2b-(4-hydroxybutoxy)cholecalciferol
(5Z,7E)-(1R,2R,3R)-2-(4-hydroxybutoxy)-9,10-seco-5,7,10(19)-cholestatriene-1,3,25-triol
VVD0598
Sachiko Yamada
2b-(4-hydroxybutoxy)-1a,25-(OH)2D3
C31H52O5 504.742 Download ChemDraw structure file
Spinal bone mineral density in pre-osteoporosis model rats and binding affinity to calf thymus vitamin D receptor. (Ref. 0217)
(EtOH) lmax (nm) 264, lmin (nm) 226 (Ref. 0217)
1H-NMR (d, CDCl3) 0.55 (3H, s), 0.94 (3H, d, J = 5.9 Hz), 1.21 (6H, s), 3.15-3.20 (1H, m), 3.45-4.38 (6H, m), 5.08 (1H, s), 5.48 (1H, s), 6.05 (1H, d, J = 11.6 Hz), 6.36 (1H, d, J = 11.6 Hz) (Ref. 0217)
m/z 504 (M+), 59 (100%) (Ref. 0217)
HRMS Calcd 504.3815, Found 504.3780 (Ref. 0217)


Synthesis by photochemical method of the 5,7-diene. (Ref. 0217)



596
1a,25-dihydroxy-2b-butoxyvitamin D3 / 1a,25-dihydroxy-2b-butoxycholecalciferol
(5Z,7E)-(1R,2R,3R)-2-butoxy-9,10-seco-5,7,10(19)-cholestatriene-1,3,25-triol
VVD0599
Sachiko Yamada
2b-butoxy-1a,25-(OH)2D3
C31H54O4 490.758 Download ChemDraw structure file
Spinal bone mineral density in pre-osteoporosis model rats and binding affinity to calf thymus vitamin D receptor. (Ref. 0217)
(EtOH) lmax (nm) 264, lmin (nm) 228 (Ref. 0217)
(neat) 3390 (br), 2962, 2929, 2871, 1683, 1376, 1261, 1097, 1031, 802 cm-1 (Ref. 0217)
1H-NMR (d, CDCl3) 0.55 (3H, s), 0.91-0.99 (6H, m), 1.22 (6H, s), 3.22 (1H, dd, J = 9.1 and3.7 Hz), 3.47-3.58 (1H, m), 3.65-3.77 (1H, m), 4.23 (1H, br s), 4.29 (1H, d, J = 6.6 Hz), 5.08 (1H, s), 5.90 (1H, s), 6.08 (1H, d, J = 12.2 Hz), 6.34 (1H, d, J = 12.2 Hz) (Ref. 0217)
m/z 488 (M+), 59 (100%) (Ref. 0217)
HRMS Calcd 488.3866, Found 488.3869 (Ref. 0217)


Synthesis by photochemical method of the 5,7-diene. (Ref. 0217)



597
1a-hydroxy-23-[3-(1-hydroxy-1-methylethyl)phenyl]-22,22,23,23-tetradehydro-24,25,26,27-tetranorvitamin D3 / 1a-hydroxy-23-[3-(1-hydroxy-1-methylethyl)phenyl]-22,22,23,23-tetradehydro-24,25,26,27-tetranorcholecalciferol
(5Z,7E)-(1S,3R)-23-[3-(1-hydroxy-1-methylethyl)phenyl]-24-nor-9,10-seco-5,7,10(19)-cholatrien-22-yne-1,3-diol
VVD0600
Sachiko Yamada
C32H42O3 474.674 Download ChemDraw structure file










598
11-(3-acetoxy-1-propynyl)-1a,25-dihydroxy-9,11-didehydrovitamin D3 / 11-(3-acetoxy-1-propynyl)-1a,25-dihydroxy-9,11-didehydrocholecalciferol
(5Z,7E)-(1S,3R)-11-(3-acetoxy-1-propynyl)-9,10-seco-5,7,9(11),10(19)-cholestatetraene-1,3,25-triol
VVD0601
Sachiko Yamada
C32H46O5 510.705 Download ChemDraw structure file










599
(22E,24E,24bE)-1a,25-dihydroxy-26,27-dimethyl-22,23,24,24a,24b,24c-hexadehydro-24a,24b,24c-trihomovitamin D3 / (22E,24E,24bE)-1a,25-dihydroxy-26,27-dimethyl-22,23,24,24a,24b,24c-hexadehydro-24a,24b,24c-trihomocholecalciferol
(5Z,7E,22E,24E,24bE)-(1S,3R)-26,27-dimethyl-24a,24b,24c-trihomo-9,10-seco-5,7,10(19),22,24,24b-cholestahexaene-1,3,25-triol
VVD0602
Sachiko Yamada
(22E,24E,24bE)-26,27-dimethyl-22,23,24,24a,24b,24c-hexadehydro-24a,24b,24c-trihomo-1a,25-(OH)2D3
C32H48O3 480.722 Download ChemDraw structure file
Biological activity (% of 1,25-(OH)2D3 effect) : Inhibition of proliferation of U937 cells, < 80% ; Induction of differentiation of U 937 cells, < 5%. (Ref. 0285)





From protected (5E)-1a-hydroxy-22-oxo-23,24,25,26,27-pentanorvitamin D3 via side chain introduction, photoisomerization and deprotection. (Ref. 0285)



600
(22E,24E)-1a,25-dihydroxy-26,27-diethyl-22,23,24,24a-tetradehydro-24a-homovitamin D3 / (22E,24E)-1a,25-dihydroxy-26,27-diethyl-22,23,24,24a-tetradehydro-24a-homocholecalciferol
(5Z,7E,22E,24E)-(1S,3R)-26,27-diethyl-24a-homo-9,10-seco-5,7,10(19),22,24-cholestapentaene-1,3,25-triol
VVD0603
Sachiko Yamada
(22E,24E)-26,27-diethyl-22,23,24,24a-tetradehydro24a-homo-1a,25-(OH)2D3
C32H50O3 482.738 Download ChemDraw structure file
Biological activity (% of 1,25-(OH)2D3 effect) : Inhibition of proliferation of U937 cells, < 70% ; Induction of differentiation of U 937 cells, < 10%. (Ref. 0285)





From protected (5E)-1a-hydroxy-22-oxo-23,24,25,26,27-pentanorvitamin D3 via side chain introduction by Wittig reaction followed by Grignard reaction, photoisomerization and deprotection. (Ref. 0285)



601
1a,25-dihydroxy-26,27-dimethyl-22,22,23,23-tetradehydro-24a,24b,24c-trihomo-20-epivitamin D3 / 1a,25-dihydroxy-26,27-dimethyl-22,22,23,23-tetradehydro-24a,24b,24c-trihomo-20-epicholecalciferol
(5Z,7E)-(1S,3R,20R)-26,27-dimethyl-24a,24b,24c-trihomo-9,10-seco-5,7,10(19)-cholestatrien-22-yne-1,3,25-triol
VVD0604
Sachiko Yamada
20-epi-22-yne-24-trihomo-26,27-dimethyl-1a,25-(OH)2D3
C32H50O3 482.738 Download ChemDraw structure file
Biological activity (% of 1,25-(OH)2D3 effect) : Inhibition of proliferation of U937 cells, 2500% ; Affinity for chicken intestinal vitamin D receptor, 76%. (Ref. 0293)





From hydroxy protected (5E)-1a-hydroxy-22,22,23,23-tetradehydro-24,25,26,27-tetranor-20-epivitamin D3, which was derived from corresponding 22-aldehyde, via side chain introduction, dye-sensitized photoisomerization and deprotection. (Ref. 0293)



602
(22S)-1a,25-dihydroxy-22-ethoxy-26,27-dimethyl-23,24-tetradehydro-24a-homo-20-epivitamin D3 / (22S)-1a,25-dihydroxy-22-ethoxy-26,27-dimethyl-23,24-tetradehydro-24a-homo-20-epicholecalciferol
(5Z,7E)-(1S,3R,20R,22S)-26,27-dimethyl-22-ethoxy-24a-homo-9,10-seco-5,7,10(19)-cholestatrien-23-yne-1,3,25-triol
VVD0605
Sachiko Yamada
22S-ethoxy-26,27-dimethyl-23,24-tetradehydro-24a-homo-20-epi-1a,25-(OH)2D3
C32H50O4 498.737 Download ChemDraw structure file
Relative potency (1,25-(OH)2D3 = 1) : Induction of differentiation of U 937 cells, > 500 ; Inhibition of proliferation, 840 ; VDR (rachitic chicken intestinal receptor) binding affinity, 0.002 ; Calciuric effect in normal rats, 0.2. (Ref. 0321)





From protected (5E)-1a-hydroxy-22-oxo-23,24,25,26,27-pentanor-20-epivitamin D3 via the reaction with lithiated acetylene side chain fragment giving major (19:1) 22S-hydroxy product as a key step. (Ref. 0321)



603
(22R)-1a,22,25-trihydroxy-26,27-dimethyl-23,24-tetradehydro-24a,24b,24c-trihomo-20-epivitamin D3 / (22R)-1a,22,25-trihydroxy-26,27-dimethyl-23,24-tetradehydro-24a,24b,24c-trihomo-20-epicholecalciferol
(5Z,7E)-(1S,3R,20R,22R)-26,27-dimethyl-24a,24b,24c-trihomo-9,10-seco-5,7,10(19)-cholestatrien-23-yne-1,3,22,25-tetrol
VVD0606
Sachiko Yamada
23,24-tetradehydro-24a,24b,24c-trihomo-20-epi-1a,22R,25-(OH)3D3
C32H50O4 498.737 Download ChemDraw structure file
Relative potency (1,25-(OH)2D3 = 1) : Induction of differentiation of U 937 cells, < 0.01; Inhibition of proliferation, 0.07; VDR (rachitic chicken intestinal receptor) binding affinity, < 0.003. (Ref. 0321)





From protected (5E)-1a-hydroxy-22-oxo-23,24,25,26,27-pentanor-20-epivitamin D3 via the reaction with lithiated acetylene side chain fragment giving minor (1:19) 22R-hydroxy product. (Ref. 0321)



604
(22R)-1a,22,25-trihydroxy-26,27-dimethyl-23,23,24,24-tetradehydro-24a,24b,24c-trihomovitamin D3 / (22R)-1a,22,25-trihydroxy-26,27-dimethyl-23,23,24,24-tetradehydro-24a,24b,24c-trihomocholecalciferol
(5Z,7E)-(1S,3R,22R)-26,27-dimethyl-24a,24b,24c-trihomo-9,10-seco-5,7,10(19)-cholestatrien-23-yne-1,3,22,25-tetrol
VVD0607
Sachiko Yamada
23-yne-24-trihomo-26,27-dimethyl-1a,22R,25-(OH)3D3
C32H50O4 498.737 Download ChemDraw structure file










605
(22S)-1a,22,25-trihydroxy-26,27-dimethyl-23,24-tetradehydro-24a,24b,24c-trihomo-20-epivitamin D3 / (22S)-1a,22,25-trihydroxy-26,27-dimethyl-23,24-tetradehydro-24a,24b,24c-trihomo-20-epicholecalciferol
(5Z,7E)-(1S,3R,20R,22S)-26,27-dimethyl-24a,24b,24c-trihomo-9,10-seco-5,7,10(19)-cholestatrien-23-yne-1,3,22,25-tetrol
VVD0608
Sachiko Yamada
23,24-tetradehydro-24a,24b,24c-trihomo-20-epi-1a,22S,25-(OH)3D3
C32H50O4 498.737 Download ChemDraw structure file
Relative potency (1,25-(OH)2D3 = 1) : Induction of differentiation of U 937 cells, 1 ; Inhibition of proliferation, 0.2 ; VDR (rachitic chicken intestinal receptor) binding affinity, < 0.003. (Ref. 0321)





From protected (5E)-1a-hydroxy-22-oxo-23,24,25,26,27-pentanor-20-epivitamin D3 via the reaction with lithiated acetylene side chain fragment giving major (19:1) 22S-hydroxy product as a key step. (Ref. 0321)



606
(22S)-1a,22,25-trihydroxy-26,27-dimethyl-23,23,24,24-tetradehydro-24a,24b,24c-trihomovitamin D3 / (22S)-1a,22,25-trihydroxy-26,27-dimethyl-23,23,24,24-tetradehydro-24a,24b,24c-trihomocholecalciferol
(5Z,7E)-(1S,3R,22S)-26,27-dimethyl-24a,24b,24c-trihomo-9,10-seco-5,7,10(19)-cholestatrien-23-yne-1,3,22,25-tetrol
VVD0609
Sachiko Yamada
23-yne-24-trihomo-26,27-dimethyl-1a,22S,25-(OH)3D3
C32H50O4 498.737 Download ChemDraw structure file










607
1a,25-dihydroxy-2b-pentylvitamin D3 / 1a,25-dihydroxy-2b-pentylcholecalciferol
(5Z,7E)-(1S,2R,3R)-2-pentyl-9,10-seco-5,7,10(19)-cholestatriene-1,3,25-triol
VVD0610
Sachiko Yamada
2b-pentyl-1a,25-(OH)2D3
C32H54O3 486.769 Download ChemDraw structure file
Spinal bone mineral density in pre-osteoporosis model rats and binding affinity to calf thymus vitamin D receptor. (Ref. 0217)
(EtOH) lmax (nm) 264, lmin (nm) 228 (Ref. 0217)
(neat) 3400 (br), 2945, 2871, 1468, 1377, 1068, 910, 758 cm-1 (Ref. 0217)
1H-NMR (d, CDCl3) 0.55 (3H, s), 0.89 (3H, t, J = 6.8 Hz), 0.94 (3H, d, J = 6.3 Hz), 1.22 (6H, s), 5.02 (1H, s), 5.38 (1H, s), 6.04 (1H, d, J = 11.2 Hz), 6.34 (1H, d, J = 11.2 Hz) (Ref. 0217)
m/z 486 (M+), 133 (100%) (Ref. 0217)
HRMS Calcd 486.4071, Found 486.4071 (Ref. 0217)


Synthesis by photochemical method of the 5,7-diene. (Ref. 0217)



608
1a,25-dihydroxy-26,27-diethyl-24a-homovitamin D3 / 1a,25-dihydroxy-26,27-diethyl-24a-homocholecalciferol
(5Z,7E)-(1S,3R)-26,27-diethyl-24a-homo-9,10-seco-5,7,10(19)-cholestatriene-1,3,25-triol
VVD0611
Sachiko Yamada
26,27-diethyl-24a-homo-1a,25-(OH)2D3
C32H54O3 486.769 Download ChemDraw structure file
Biological activity (% of 1,25-(OH)2D3 effect) : Inhibition of proliferation of U937 cells, 90% ; Induction of differentiation of U 937 cells, 50%. (Ref. 0285)





From hydroxy protected (5E)-22-tosyloxy-23,24,25,26,27-pentanorvitamin D3 via cuprate catalyzed Grignard reaction, photoisomerization and deprotection. (Ref. 0285)



609
1a-hydroxy-2b-(5-hydroxypentoxy)vitamin D3 / 1a-hydroxy-2b-(5-hydroxypentoxy)cholecalciferol
(5Z,7E)-(1R,2R,3R)-2-(5-hydroxypentoxy)-9,10-seco-5,7,10(19)-cholestatriene-1,3-diol
VVD0612
Sachiko Yamada
2b-(5-hydroxypentoxy)-1a-OHD3
C32H54O4 502.769 Download ChemDraw structure file
Plasma calcium levels in rats fed with a low calcium/vitamin D deficient diet after administration (6.25mg/kg times 5). (Ref. 0216)
(EtOH) lmax (nm) 263.5 (Ref. 0216)
1H-NMR (d, CDCl3) 0.55 (3H, s), 0.86 (6H, d, J = 6.6 Hz), 0.91 (3H, d, J = 5.8 Hz), 3.34-3.82 (5H, br), 4.10-4.36 (2H, m), 5.08 (1H, s), 5.50 (1H, s), 6.04 (1H, d, J = 10.8 Hz), 6.36 (1H, d, J = 10.8 Hz) (Ref. 0216)
m/z 502 (M+), 484, 466, 380 (100%) (Ref. 0216)
HRMS Calcd 502.4022, Found 502.4010 (Ref. 0216)


Synthesis by photochemical method of the 5,7-diene. (Ref. 0216)



610
1a,25-dihydroxy-2b-(5-hydroxypentyl)vitamin D3 / 1a,25-dihydroxy-2b-(5-hydroxypentyl)cholecalciferol
(5Z,7E)-(1S,2R,3R)-2-(5-hydroxypentyl)-9,10-seco-5,7,10(19)-cholestatriene-1,3,25-triol
VVD0613
Sachiko Yamada
2b-(5-hydroxypentyl)-1a,25-(OH)2D3
C32H54O4 502.769 Download ChemDraw structure file
Spinal bone mineral density in pre-osteoporosis model rats and binding affinity to calf thymus vitamin D receptor. (Ref. 0217)
(EtOH) lmax (nm) 264, lmin (nm) 228 (Ref. 0217)
(neat) 3349 (br), 2962, 2929, 2873, 1261, 1079, 1052, 802 cm-1 (Ref. 0217)
1H-NMR (d, CDCl3) 0.55 (3H, s), 0.94 (3H, d, J = 5.9 Hz), 1.22 (6H, s), 3.63 (2H, t, J = 6.4 Hz), 4.00-4.09 (1H, m), 4.10-4.18 (1H, m), 5.02 (1H, s), 5.37 (1H, s), 6.03 (1H, d, J = 11.6 Hz), 6.35 (1H, d, J = 11.6 Hz) (Ref. 0217)
m/z 502 (M+), 59 (100%) (Ref. 0217)
HRMS Calcd 502.4022, Found 502.4070 (Ref. 0217)


Synthesis by photochemical method of the 5,7-diene. (Ref. 0217)



611
(20S)-1a,25-dihydroxy-20-methoxy-26,27-diethylvitamin D3 / (20S)-1a,25-dihydroxy-20-methoxy-26,27-diethylcholecalciferol
(5Z,7E)-(1S,3R,20S)-20-methoxy-26,27-diethyl-9,10-seco-5,7,10(19)-cholestatriene-1,3,25-triol
VVD0614
Sachiko Yamada
20S-methoxy-26,27-diethyl-1a,25-(OH)2D3
C32H54O4 502.769 Download ChemDraw structure file
Biological activity (% of 1,25-(OH)2D3 effect) : Inhibition of U 937 cell (human histiocytic lymphoma cell line) proliferation : 10% ; Binding to the 1,25-(OH)2D3 receptor from rachitic chicken intestine : 0.9% ; Calcemic activity : not determined. (Ref. 0279)





From (5E)-1a-hydroxy-20-keto-22,23,24,25,26,27-hexanorvitamin D3 derivative by addition of a Grignard reagent followed by methylation, photochemical isomerization and deprotection. (Ref. 0279)



612
(20S)-1a,25-dihydroxy-20-ethoxy-26,27-dimethyl-24a-homovitamin D3 / (20S)-1a,25-dihydroxy-20-ethoxy-26,27-dimethyl-24a-homocholecalciferol
(5Z,7E)-(1S,3R,20S)-20-ethoxy-26,27-dimethyl-24a-homo-9,10-seco-5,7,10(19)-cholestatriene-1,3,25-triol
VVD0615
Sachiko Yamada
20S-ethoxy-26,27-dimethyl-24a-homo-1a,25-(OH)2D3
C32H54O4 502.769 Download ChemDraw structure file
Biological activity (% of 1,25-(OH)2D3 effect) : Inhibition of U 937 cell (human histiocytic lymphoma cell line) proliferation : 30000% ; Binding to the 1,25-(OH)2D3 receptor from rachitic chicken intestine : 1% ; Calcemic activity : not determined. (Ref. 0279)





From (5E)-1a-hydroxy-20-keto-22,23,24,25,26,27-hexanorvitamin D3 derivative by addition of a Grignard reagent followed by ethylation, photochemical isomerization and deprotection. (Ref. 0279)



613
26,27-diethyl-1a,25-dihydroxy-24a,24b-dihomo-23-oxa-20-epivitamin D3 / 26,27-diethyl-1a,25-dihydroxy-24a,24b-dihomo-23-oxa-20-epicholecalciferol
(5Z,7E)-(1S,3R,20R)-26,27-diethyl-24a,24b-dihomo-23-oxa-9,10-seco-5,7,10(19)-cholestatriene-1,3,25-triol
VVD0616
Sachiko Yamada
20-epi-20-oxa-24-dihomo-26,27-diethyl-1a,25-(OH)2D3
C32H54O4 502.769 Download ChemDraw structure file










614
1a,25-dihydroxy-2b-(5-hydroxypentoxy)vitamin D3 / 1a,25-dihydroxy-2b-(5-hydroxypentoxy)cholecalciferol
(5Z,7E)-(1R,2R,3R)-2-(5-hydroxypentoxy)-9,10-seco-5,7,10(19)-cholestatriene-1,3,25-triol
VVD0617
Sachiko Yamada
2b-(5-hydroxypentoxy)-1a,25-(OH)2D3
C32H54O5 518.768 Download ChemDraw structure file
Spinal bone mineral density in pre-osteoporosis model rats and binding affinity to calf thymus vitamin D receptor. (Ref. 0217)
(EtOH) lmax (nm) 264, lmin (nm) 228 (Ref. 0217)
(neat) 3400 (br), 2930, 2886, 1090, 910, 740 cm-1 (Ref. 0217)
1H-NMR (d, CDCl3) 0.55 (3H, s), 0.94 (3H, d, J = 6.6 Hz), 1.22 (6H, s), 3.45-4.40 (7H, m), 5.08 (1H, s), 5.50 (1H, s), 6.04 (1H, d, J = 10.5 Hz), 6.36 (1H, d, J = 10.5 Hz) (Ref. 0217)
m/z 518 (M+), 69 (100%) (Ref. 0217)
Colorless foam (Ref. 0217)
HRMS Calcd 518.3917, Found 518.4014 (Ref. 0217)
Preparative TLC developed with CH2Cl2-EtOH (10:1). (Ref. 0217)

Synthesis by photochemical method of the 5,7-diene. (Ref. 0217)



615
1a,25-dihydroxy-11a-phenylvitamin D3 / 1a,25-dihydroxy-11a-phenylcholecalciferol
(5Z,7E)-(1S,3R,11S)-11-phenyl-9,10-seco-5,7,10(19)-cholestatriene-1,3,25-triol
VVD0618
Sachiko Yamada
11a-phenyl-1a,25-(OH)2D3
C33H48O3 492.732 Download ChemDraw structure file
Biological activity of C-ring analogs of 1a,25-(OH)2D3 : Table(Ref. 0224)





Convergent synthesis by Horner coupling of 25-hydroxylated CD-ring ketone, which was constructed from Inhoffen-Lythgoe diol (vitamin D2 ozonolysis product), with A-ring phosphine oxide. The substituent at C(11) was introduced by conjugate addition of organocopper reagent to 9(11)-en-8-one of the CD-ring fragment. (Ref. 0224)



616
1a,25-dihydroxy-11b-phenylvitamin D3 / 1a,25-dihydroxy-11b-phenylcholecalciferol
(5Z,7E)-(1S,3R,11R)-11-phenyl-9,10-seco-5,7,10(19)-cholestatriene-1,3,25-triol
VVD0619
Sachiko Yamada
11b-phenyl-1a,25-(OH)2D3
C33H48O3 492.732 Download ChemDraw structure file
Biological activity of C-ring analogs of 1a,25-(OH)2D3 : Table (Ref. 0224)





Convergent synthesis by Horner coupling of 25-hydroxylated CD-ring ketone, which was constructed from Inhoffen-Lythgoe diol (vitamin D2 ozonolysis product), with A-ring phosphine oxide. The substituent at C(11) was introduced by conjugate addition of organocopper reagent to 9(11)-en-8-one of the CD-ring fragment and inversion of the configuration at C(11) by introducing 9(11)-double bond followed by catalytic hydrogenation. (Ref. 0224)



617
VVD0620
Sachiko Yamada
3-(2',2',2'-trichloroethyl)-glutarate (OCT
C33H49O7Cl3 664.096 Download ChemDraw structure file
Intermediate for OCT-3-hemiglutarate. (Ref. 0204)
(EtOH) lmax (nm) 260, lmin (nm) 228 (Ref. 0204)
1H-NMR (d, CDCl3, 200MHz) 0.53 (3H, s, 18-H), 1.19 (3H, d, J = 6.1 Hz, 21-H), 1.23 (6H, s, 26 and 27-H), 2.35-2.43, 2.48-2.56 (each 2H, m, CH2CO), 3.18-3.32, 3.42-3.53 (each 1H, m, 23-H), 4.75 (2H, s CH2CCl3), 5.00 (1H, br s, 19-H), 5.20 (1H, m, 3-H), 5.36 (1H, br s, 19-H), 6.02 (1H, d, J = 12.0 Hz, 7-H), 6.30 (1H, d, J = 12.0 Hz, 6-H) (Ref. 0204)

Yellow oily substance. (Ref. 0204)
Flash column chromatography with n-hexane/AcOEt (11 : 9). (Ref. 0204)

Synthesis from dehydroepiandrostertone via 1,25-dihydroxy-22-oxacholesta-5,7-dien-3b-yl (2,2'2'-trichloroethylglutarate) by photochemical method. (Ref. 0204)



618
(23S)-23,25-dihydroxy-24-oxovitamin D3 23-(b-glucuronide) / (23S)-23,25-dihydroxy-24-oxocholecalciferol 23-(b-glucuronide)
(5Z,7E)-(3S,23S)-9,10-seco-5,7,10(19)-cholestatriene-3,23,25-triol 23-(b-glucuronide)
VVD0621
Sachiko Yamada
23S,25-(OH)2-24-oxo-D3 23-(b-glucuronide)
C33H50O10 606.744 Download ChemDraw structure file

lmax (nm) 265 (Ref. 0106)

Me-ester : m/z 621 (M+), 431, 413, 253, 191, 173, 136; spectrum (Ref. 0106)
Me-ester pentakis(trimethylsilyl) ether : m/z 980 (M+), 573, 407, 317, 131 (Ref. 0106)


Isolation and identification from bile of dogs given 24R,25-(OH)2D3. (Ref. 0106)




619
1a,25-dihydroxy-26,27-dipropylvitamin D3 / 1a,25-dihydroxy-26,27-dipropylcholecalciferol
(5Z,7E)-(1S,3R)-26,27-dipropyl-9,10-seco-5,7,10(19)-cholestatriene-1,3,25-triol
VVD0622
Sachiko Yamada
26,27-dipropyl-1a,25-(OH)2D3
C33H56O3 500.796 Download ChemDraw structure file
Binding affinity of the title compound for serum vitamin D binding protein (DBP) and for the receptor of HL-60 cells was < 1% and 3.4%, respectively, of those of 1,25-(OH)2D3. The title compound did not induce HL-60 cell differentiation under either serum-supplemented or serum-free conditions at a concentration of 48 nM. (Ref. 0275)









620
1a,25-dihydroxy-26,26, 26,27,27,27-hexamethylvitamin D3 / 1a,25-dihydroxy-26,26,26,27,27,27-hexamethylcholecalciferol
(5Z,7E)-(1S,3R)-26,26, 26,27,27,27-hexamethyl-9,10-seco-5,7,10(19)-cholestatriene-1,3,25-triol
VVD0623
Sachiko Yamada
26,27-hexamethyl-1a,25-(OH)2D3
C33H56O3 500.796 Download ChemDraw structure file

1H-NMR (d, CD2Cl2) 6.38 and 6.01 (2H, AB pattern, d, J = 11 Hz, 6- and 7-H), 5.33 (1H, m, 19E-H), 5.00 (1H, m, 19Z-H), 4.43 (1H, m, 1-H), 4.23 (1H, m, 3-H), 1.00 (18H, s, two t-Bu), 0.93 (3H, d, J = 6.2 Hz, 21C-CH3), 0.54 (3H, s, 18C-CH3) (Ref. 0195)
13C-NMR (d, CD2Cl2) 148.7 (C), 143.4 (C), 134.0 (C), 125.0 (CH), 117.6 (CH), 111.8 (C-19), 80.0 (C-25), 71.1 (CH), 67.1(CH), 60.6, 56.9, 56.8, 46.3 (CH2),45.8, 43.4 (CH2), 42.8, 40.9 (CH2), 37.0 (CH2), 36.5, 34.2 (CH2), 29.4 (CH2), 28.8, 28.0 (CH2), 24.0 (CH2), 23.3 (CH2), 22.7 (CH2), 19.2, 12.1 (Ref. 0195)








621
26,27-diethyl-1a,25-dihydroxy-24a,24b-dihomovitamin D3 / 26,27-diethyl-1a,25-dihydroxy-24a,24b-dihomocholecalciferol
(5Z,7E)-(1S,3R)-26,27-diethyl-24a,24b-dihomo-9,10-seco-5,7,10(19)-cholestatriene-1,3,25-triol
VVD0624
Sachiko Yamada
24-dihomo-26,27-diethyl-1a,25-(OH)2D3
C33H56O3 500.796 Download ChemDraw structure file
Biological activity (% of 1,25-(OH)2D3 effect) : Inhibition of proliferation of U937 cells, < 10% ; Induction of differentiation of U 937 cells, 1%. (Ref. 0285)





From hydroxy protected (5E)-23,24,25,26,27-pentanorvitamin D3 22-bis(methylseleno)acetal via displacement of one methylseleno group by side chain fragment, reduction of the other methylseleno group via 6,19-SO2 adduct, desulfonylation, dye-sensitized photoisomerization and deprotection. (Ref. 0285)



622
1a,25-dihydroxy-2b-(6-hydroxyhexyl)vitamin D3 / 1a,25-dihydroxy-2b-(6-hydroxyhexyl)cholecalciferol
(5Z,7E)-(1S,2R,3R)-2-(6-hydroxyhexyl)-9,10-seco-5,7,10(19)-cholestatriene-1,3,25-triol
VVD0625
Sachiko Yamada
2b-(6-hydroxyhexyl)-1a,25-(OH)2D3
C33H56O4 516.795 Download ChemDraw structure file
Spinal bone mineral density in pre-osteoporosis model rats and binding affinity to calf thymus vitamin D receptor. (Ref. 0217)
(EtOH) lmax (nm) 262, lmin (nm) 228 (Ref. 0217)
(neat) 3410 (br), 2970, 2865 cm-1 (Ref. 0217)
1H-NMR (d, CDCl3) 0.55 (3H, s), 0.94 (3H, d, J = 6.1 Hz), 1.22 (6H, s), 3.64 (2H, t, J = 6.6 Hz), 3.99-4.09 (1H, m), 4.15 (1H, br s), 5.02 (1H, s), 5.37 (1H, s), 6.03 (1H, d, J = 10.7 Hz), 6.34 (1H, d, J = 10.7 Hz) (Ref. 0217)
m/z 516 (M+), 59 (100%) (Ref. 0217)
HRMS Calcd 516.4178, Found 516.4152 (Ref. 0217)


Synthesis by photochemical method of the 5,7-diene. (Ref. 0217)



623
1a,25-dihydroxy-11-(4-hydroxymethylphenyl)-9,11-didehydrovitamin D3 / 1a,25-dihydroxy-11-(4-hydroxymethylphenyl)-9,11-didehydrocholecalciferol
(5Z,7E)-(1S,3R)-11-(4-hydroxymethylphenyl)-9,10-seco-5,7,9(11),10(19)-cholestatetraene-1,3,25-triol
VVD0626
Sachiko Yamada
C34H48O4 520.743 Download ChemDraw structure file










624
25-hydroxyvitamin D2 25-(b-glucuronide) / 25 hydroxyergocalciferol 25-(b-glucuronide)
(5Z,7E,22E)-(3S)-9,10-seco-5,7,10(19),22-ergostatetraene-3,25-diol 25-(b-glucuronide)
VVD0627
Sachiko Yamada
25-OHD2 25-(b-glucuronide)
C34H52O8 588.772 Download ChemDraw structure file


TMS-Me-ester : m/z 890 (M+), 466, 407, 317, 275, 217, 204; spectrum (Ref. 0154)
Acetyl-Me-ester : m/z 770 (M+), 710, 650; spectrum (Ref. 0154)







625
(6R)-vitamin D3 6,19-(4-phenyl-1,2,4-triazoline-3,5-dione) adduct / (6R)-cholecalciferol 6,19-(4-phenyl-1,2,4-triazoline-3,5-dione) adduct
(7E)-(3S,6R)-9,10-seco-5,7,10(19)-cholestatrien-3-ol 6,19-(4-phenyl-1,2,4-triazoline-3,5-dione) adduct
VVD0628
Sachiko Yamada
C35H49N3O3 559.782 Download ChemDraw structure file

[a]d-23 -173 deg (c = 0.81 in CHCl3) (Ref. 0341)
[a]d-27 -187 deg (c = 1.0 in CHCl3) (Ref. 0340/0342)
(CHCl3) 3620, 3480 (br), 1760, 1705, 1420, 1134, 1040 cm-1 (Ref. 0340/0342)
1H-NMR (d, CDCl3, 100MHz) 0.54 (3H, s, C-18), 0.87 (6H, d, J = 6.4 Hz, C-26, -27), 0.90 (3H, d, C-21), 2.82 (1H, d, J = 14 Hz, C-14), 3.82 und 4.16 (2H, AB-System, J = 16 Hz, C-19), 3.94 (1H, breites m, C-3), 4.76 (1H, C-6) und 5.01 (1H, C-7) zusammen AB-System (J = 10 Hz), 7.48 (5H, s, Aromat) (Ref. 0341)
13C-NMR (d, CDCl3) 152.92, 151.58, 146.91, 131.41, 128.98, 127.85, 125.44, 125.30, 122.32, 114.57, 66.07, 56.56, 55.64, 54.09, 53.96, 46.45, 45.51, 40.17, 39.49, 36.11, 35.18, 31.69, 30.49, 29.55, 29.26, 27.97, 27.52, 25.35, 23.90, 23.86, 22.80, 22.55, 22.15, 18.85, 12.08 (Ref. 0341)
m/z (70eV, 100degC) 559 (M+, 18), 298 (100) (Ref. 0341)



From vitamin D3, as a minor product, by reaction with 4-phenyl-1,2,4-triazoline-3,5-dione. (Ref. 0340/0341/0342)



626
(6S)-vitamin D3 6,19-(4-phenyl-1,2,4-triazoline-3,5-dione) adduct / (6S)-cholecalciferol 6,19-(4-phenyl-1,2,4-triazoline-3,5-dione) adduct
(7E)-(3S,6S)-9,10-seco-5,7,10(19)-cholestatrien-3-ol 6,19-(4-phenyl-1,2,4-triazoline-3,5-dionne) adduct
VVD0629
Sachiko Yamada
C35H49N3O3 559.782 Download ChemDraw structure file

[a]d-23 +191 deg (c = 1.105 in CHCl3) (Ref. 0341)
[a]d-27 +196 deg (c = 1.4 in CHCl3) (Ref. 0340/0342)
(CHCl3) 3600, 3450 (br), 1760, 1705, 1420, 853, 690, 649 cm-1 (Ref. 0340/0342)
1H-NMR (d, CDCl3, 100MHz) 0.52 (3H, s, C-18), 0.88 (6H, d, J = 6.5 Hz, C-26, -27), 0.92 (3H, d, J = 5.2 Hz, C-21), 2.85 (1H, d, J = 6.5 Hz, C-14), 3.86 und 4.18 (2H, AB-System, J = 16 Hz, C-14), 4.04 (1H, breites m, C-3), 4.77 (1H, C-6) und 4.98 (1H, C-7) zusammen AB-System (J = 10 Hz), 7.46 (5H, s, Aromat) (Ref. 0341)
13C-NMR (d, CDCl3) 152.58, 151.69, 146.84, 131.30, 128.91, 127.831, 125.40, 125.32, 122.02, 114.37, 65.72, 55.82, 54.61, 46.32, 45.49, 40.32, 39.47, 36.07, 35.32, 29.91, 29.81, 27.97, 27.50, 24.25, 23.85, 23.76, 22.76, 22.52, 22.22, 18.80, 11.55 (Ref. 0341)
m/z (70eV, 100degC) 559 (M+, 20), 298 (100) (Ref. 0341)



From vitamin D3, as a major product, by reaction with 4-phenyl-1,2,4-triazoline-3,5-dione. (Ref. 0340/0341/0342)



627
11a-(4-dimethylaminophenyl)-1a,25-dihydroxyvitamin D3 / 11a-(4-dimethylaminophenyl)-1a,25-dihydroxycholecalciferol
(5Z,7E)-(1S,3R,11S)-11-(4-dimethylaminophenyl)-9,10-seco-5,7,10(19)-cholestatriene-1,3,25-triol
VVD0630
Sachiko Yamada
C35H53NO3 535.800 Download ChemDraw structure file










628
11-(4-acetoxymethylphenyl)-1a,25-dihydroxy-9,11-didehydrovitamin D3 / 11-(4-acetoxymethylphenyl)-1a,25-dihydroxy-9,11-didehydrocholecalciferol
(5Z,7E)-(1S,3R)-11-(4-acetoxymethylphenyl)-9,10-seco-5,7,9(11),10(19)-cholestatetraene-1,3,25-triol
VVD0631
Sachiko Yamada
C36H50O5 562.779 Download ChemDraw structure file










629
2a-methyl-1a,25-dihydroxyvitamin D3 / 2a-methyl-1a,25-dihydroxycholecalciferol
(5Z,7E)-(1S,2S,3R)-2-methyl-9,10-seco-5,7,10(19)-cholestatriene-1,3,25-triol
VVD0632
Sachiko Yamada
2a-methyl-1a,25-(OH)2D3
C28H46O3 430.663 Download ChemDraw structure file
Bovine thymus VDR binding : 400. Bone calcium mobilization : 400. HL-60 cell differentiation : 200. DBP binding : 68. (The results for 1a,25-dihydroxyvitamin D3 are normalized to 100.) (Ref. 0260)
(EtOH) lmax (nm) 265 (Ref. 0260)
1H-NMR (d, CDCl3/TMS, 400MHz) 0.54 (3H, s), 0.94 (3 H, d, J = 6.4 Hz), 1.08 (3H, d, J = 7.2 Hz), 1.21 (6H, s), 1.92 (1H, dd q, J = 3.3, 7.7, 7.2 Hz), 2.23 (1H, dd, J = 7.7, 13.4 Hz), 2.67 (1H, dd, J = 4.0, 13.2 Hz), 2.82 (1H, dd, J = 4,0, 12.5 Hz), 3.80-3.88 (1H, m), 4.28-4.32 (1H, m), 5.01 (1H, d, J = 1.8 Hz), 5.28 (1H, dd, J = 1.1, 1.8 Hz), 6.01 (1H, d, J = 11.4 Hz), 6.39 (1H, d, J = 11.4 Hz) (Ref. 0260)
m/z 430 (M+), 412 (M+-H2O), 394 (M+-2H2O), 376 (M+-3H2O), 361 (M+-3H2O-Me) (Ref. 0260)



The analogue was synthesized by employing the convergent method of Trost et al. using Pd catalyst. (Ref. 0260)



630
(6R)-vitamin D3 6,19-[4-{2-(6,7-dimethoxy-4-methyl-3-oxo-3,4-dihydroquinoxalinyl)ethyl}-1,2,4-triazoline-3,5-dione] adduct / (6R)-cholecalciferol 6,19-[4-{2-(6,7-dimethoxy-4-methyl-3-oxo-3,4-dihydroquinoxalinyl)ethyl}-1,2,4-triazoline-3,5-dione] adduct
(7E)-(3S,6R)-9,10-seco-5,7,10(19)-cholestatrien-3-ol 6,19-[4-{2-(6,7-dimethoxy-4-methyl-3-oxo-3,4-dihydroquinoxalinyl)ethyl}-1,2,4-triazoline-3,5-dione] adduct
VVD0633
Sachiko Yamada
C40H53N5O4 667.880 Download ChemDraw structure file

1H-NMR (d, CDCl3) 0.51 (18-Me), 2.37 (d, J = 16.1 Hz, 4a-H), 4.67 (d, J = 9.9 Hz, 6-H), 3.22 (t, J = 6.8 Hz, -CH2-C=N) (Ref. 0343)

CD : 207 nm (e -140), 247 nm (e +10) (in MeOH) (Ref. 0343)


From vitamin D3 by reaction with 4-{2-(6,7-dimethoxy-4-methyl-3-oxo-3,4-dihydroquinoxalinyl)ethyl}-1,2,4-triazoline-3,5-dione (DMEQ-TAD) in CH2Cl2 at room temperature to yield the DMEQ-TAD adduct as a 2:1 mixture of 6S- and 6R-epimers. (Ref. 0343)



631
(6S)-vitamin D3 6,19-[4-{2-(6,7-dimethoxy-4-methyl-3-oxo-3,4-dihydroquinoxalinyl)ethyl}-1,2,4-triazoline-3,5-dione] adduct / (6S)-cholecalciferol 6,19-[4-{2-(6,7-dimethoxy-4-methyl-3-oxo-3,4-dihydroquinoxalinyl)ethyl}-1,2,4-triazoline-3,5-dione] adduct
(7E)-(3S,6S)-9,10-seco-5,7,10(19)-cholestatrien-3-ol
VVD0634
Sachiko Yamada
C40H53N5O4 667.880 Download ChemDraw structure file

1H-NMR (d, CDCl3) 0.52 (18-Me), 4.69 (d, J = 9.2 Hz, 6-H), 3.20 (m, -CH2-C=N) (Ref. 0343)

CD : 206 nm (e +46), 223 nm (e -11) (in MeOH) (Ref. 0343)


From vitamin D3 by reaction with 4-{2-(6,7-dimethoxy-4-methyl-3-oxo-3,4-dihydroquinoxalinyl)ethyl}-1,2,4-triazoline-3,5-dione (DMEQ-TAD) in CH2Cl2 at room temperature to yield the DMEQ-TAD adduct as a 2:1 mixture of 6S- and 6R-epimers. (Ref. 0343)



632
(6RS)-1a-hydroxyvitamin D3 6,19-[4-{2-(6,7-dimethoxy-4-methyl-3-oxo-3,4-dihydroquinoxalinyl)ethyl}-1,2,4-triazoline-3,5-dione] adduct / (6RS)-1a-hydroxycholecalciferol 6,19-[4-{2-(6,7-dimethoxy-4-methyl-3-oxo-3,4-dihydroquinoxalinyl)ethyl}-1,2,4-triazoline-3,5-dione] adduct
(7E)-(1S,3R,6RS)-9,10-seco-5,7,10(19)-cholestatriene-1,3-diol 6,19-[4-{2-(6,7-dimethoxy-4-methyl-3-oxo-3,4-dihydroquinoxalinyl)ethyl}-1,2,4-triazoline-3,5-dione] adduct
VVD0635
Sachiko Yamada
C40H53N5O5 683.880 Download ChemDraw structure file

6S-epimer : 1H-NMR (d, CDCl3) 0.50 (18-Me), 2.22 (d, J = 14.5 Hz, 4a-H), 4.66 (d, J = 9.6 Hz, 6-H), 3.20 (m, -CH2-C=N). 6R-epimer : 1H-NMR (d, CDCl3) 0.49 (18-Me), 2.46 (d, J = 12.9 Hz, 4a-H), 4.70 (d, J = 9.6 Hz, 6-H), 3.25 (t, J = 6.6 Hz, -CH2-C=N) (Ref. 0343)

CD : 6S-epimer : 206 nm (e +38), 227 nm (e -9) (in MeOH). 6R-epimer : 207 nm (e -74), 243 nm (e +4) (in MeOH) (Ref. 0343)


From 1a-hydroxyvitamin D3 by reaction with 4-{2-(6,7-dimethoxy-4-methyl-3-oxo-3,4-dihydroquinoxalinyl)ethyl}-1,2,4-triazoline-3,5-dione (DMEQ-TAD) in CH2Cl2 at room temperature to yield the DMEQ-TAD adduct as a 1:1 mixture of 6S- and 6R-epimers. (Ref. 0343)



633
(6RS)-25-hydroxyvitamin D3 6,19-[4-{2-(6,7-dimethoxy-4-methyl-3-oxo-3,4-dihydroquinoxalinyl)ethyl}-1,2,4-triazoline-3,5-dione] adduct / (6RS)-25-hydroxycholecalciferol 6,19-[4-{2-(6,7-dimethoxy-4-methyl-3-oxo-3,4-dihydroquinoxalinyl)ethyl}-1,2,4-triazoline-3,5-dione] adduct
(7E)-(3S,6RS)-9,10-seco-5,7,10(19)-cholestatriene-3,25-diol 6,19-[4-{2-(6,7-dimethoxy-4-methyl-3-oxo-3,4-dihydroquinoxalinyl)ethyl}-1,2,4-triazoline-3,5-dione] adduct
VVD0636
Sachiko Yamada
C40H53N5O5 683.880 Download ChemDraw structure file

6S-epimer : 1H-NMR (d, CDCl3) 0.53 (18-Me), 4.70 (d, J = 9.9 Hz, 6-H), 3.20 (m, -CH2-C=N). 6R-epimer : 1H-NMR (d, CDCl3) 0.51 (18-Me), 2.37 (d, J = 16.5 Hz, 4a-H), 4.67 (d, J = 10.2 Hz, 6-H), 3.22 (t, J = 6.68 Hz, -CH2-C=N) (Ref. 0343)
a mixture of C(6)-epimers : 1H-NMR (d, CDCl3) 0.52 and 0.51 [3H (2:1), s], 1.20 and 1.21 [6H (2:1), s], 3.69 (3H, s), 3.94 (3H, s), 4.01 (3H, s), 4.69 (1H, d, J = 9.6 Hz), 6.68 (1H, s), 7.23 (1H, s) (Ref. 0344)
Fluorescence spectrum: a mixture of C(6)-epimers : (EtOH) lex 370 nm, lem 440 nm (Ref. 0344)

CD : 6S-epimer : 206 nm (e +46), 224 nm (e -10) (in MeOH). 6R-epimer : 206 nm (e -82), 245 nm (e +6) (in MeOH) (Ref. 0343)


From 25-hydroxyvitamin D3 by reaction with 4-{2-(6,7-dimethoxy-4-methyl-3-oxo-3,4-dihydroquinoxalinyl)ethyl}-1,2,4-triazoline-3,5-dione (DMEQ-TAD) in CH2Cl2 at room temperature to yield the DMEQ-TAD adduct as a 2:1 mixture of 6S- and 6R-epimers. (Ref. 0343/0344)



634
(6RS)-1a,25-dihydroxyvitamin D3 6,19-[4-{2-(6,7-dimethoxy-4-methyl-3-oxo-3,4-dihydroquinoxalinyl)ethyl}-1,2,4-triazoline-3,5-dione] adduct / (6RS)-1a,25-dihydroxycholecalciferol 6,19-[4-{2-(6,7-dimethoxy-4-methyl-3-oxo-3,4-dihydroquinoxalinyl)ethyl}-1,2,4-triazoline-3,5-dione] adduct
(7E)-(1S,3R,6RS)-9,10-seco-5,7,10(19)-cholestatriene-1,3,25-triol 6,19-[4-{2-(6,7-dimethoxy-4-methyl-3-oxo-3,4-dihydroquinoxalinyl)ethyl}-1,2,4-triazoline-3,5-dione] adduct
VVD0637
Sachiko Yamada
C40H53N5O6 699.879 Download ChemDraw structure file

6S-epimer : 1H-NMR (d, CDCl3) 0.52 (18-Me), 2.25 (d, J = 16.4 Hz, 4a-H), 4.67 (d, J = 9.6 Hz, 6-H), 3.20 (m, -CH2-C=N). 6R-epimer : 1H-NMR (d, CDCl3) 0.51 (18-Me), 2.47 (d, J = 14.5 Hz, 4a-H), 4.71 (d, J = 9.6 Hz, 6-H), 3.22 (t, J = 6.6 Hz, -CH2-C=N) (Ref. 0343)
a mixture of C(6)-epimers : 1H-NMR (d, CDCl3) 0.50 and 0.51 [3H (5:4), s], 1.21 and 1.20 [6H (5:4), s], 3.69 (3H, s), 3.94 (3H, s), 4.01 (3H, s), 4.30 (1H, m), 4.70 (1H, d, J = 9.9 Hz), 4.93 (1H, d, J = 9.9 Hz), 6.68 (1H, s), 7.23 (1H, s) (Ref. 0344)

CD : 6S-epimer : 206 nm (e +44), 225 nm (e -10) (in MeOH). 6R-epimer : 205 nm (e -80), 243 nm (e +4) (in MeOH) (Ref. 0343)


From 1a,25-dihydroxyvitamin D3 by reaction with 4-{2-(6,7-dimethoxy-4-methyl-3-oxo-3,4-dihydroquinoxalinyl)ethyl}-1,2,4-triazoline-3,5-dione (DMEQ-TAD) in CH2Cl2 at room temperature to yield the DMEQ-TAD adduct as a 1:1 mixture of 6S- and 6R-epimers. (Ref. 0343/0344)



635
(6RS,24R)-24,25-dihydroxyvitamin D3 6,19-[4-{2-(6,7-dimethoxy-4-methyl-3-oxo-3,4-dihydroquinoxalinyl)ethyl}-1,2,4-triazoline-3,5-dione] adduct / (6RS,24R)-24,25-dihydroxycholecalciferol 6,19-[4-{2-(6,7-dimethoxy-4-methyl-3-oxo-3,4-dihydroquinoxalinyl)ethyl}-1,2,4-triazoline-3,5-dione] adduct
(7E)-(3S,6RS,24R)-9,10-seco-5,7,10(19)-cholestatriene-3,24,25-triol 6,19-[4-{2-(6,7-dimethoxy-4-methyl-3-oxo-3,4-dihydroquinoxalinyl)ethyl}-1,2,4-triazoline-3,5-dione] adduct
VVD0638
Sachiko Yamada
C40H53N5O6 699.879 Download ChemDraw structure file

6S-epimer : 1H-NMR (d, CDCl3) 0.54 (18-Me), 4.70 (d, J = 9.9 Hz, 6-H), 3.20 (m, -CH2-C=N). 6R-epimer : 1H-NMR (d, CDCl3) 0.52 (18-Me), 2.38 (d, J = 16.5 Hz, 4a-H), 4.67 (d, J = 9.9 Hz, 6-H), 3.22 (t, J = 6.3 Hz, -CH2-C=N) (Ref. 0343)
a mixture of C(6)-epimers : 1H-NMR (d, CDCl3) 0.540 and 0.52 [3H (2:1), s], 1.16 (3H, s), 1.21 (3H, s), 3.70 (3H, s), 3.94 (3H, s), 4.01 (3H, s), 4.69 (1H, d, J = 9.6 Hz), 4.88 (1H, d, J = 9.6 Hz), 6.68 (1H, s), 7.23 (1H, s) (Ref. 0344)

CD : 6S-epimer : 206 nm (e +48), 223 nm (e -12) (in MeOH). 6R-epimer : 205 nm (e -58), 245 nm (e +4) (in MeOH) (Ref. 0343)


From 24R,25-dihydroxyvitamin D3 by reaction with 4-{2-(6,7-dimethoxy-4-methyl-3-oxo-3,4-dihydroquinoxalinyl)ethyl}-1,2,4-triazoline-3,5-dione (DMEQ-TAD) in CH2Cl2 at room temperature to yield the DMEQ-TAD adduct as a 2:1 mixture of 6S- and 6R-epimers. (Ref. 0343/0344)



636
1a,25-dihydroxy-25,25-diphenyl-26,27-dinorvitamin D3 / 1a,25-dihydroxy-25,25-diphenyl-26,27-dinorcholecalciferol
(5Z,7E)-(1S,3R)-25,25-diphenyl-26,27-dinor-9,10-seco-5,7,10(19)-cholestatriene-1,3,25-triol
VVD0639
Sachiko Yamada
25-Ph2-26,27-dinor-1a,25-(OH)2D3
C47H48O3 660.882 Download ChemDraw structure file

1H-NMR (d, CD2Cl2) 7.40 (4H, d, J = 8 Hz, o-4H-Ph), 7.31 (4H, t, J = 7 Hz, m-4H-Ph), 7.18 (2H, t, J = 7 Hz, p-H-Ph), 6.34 and 5.99 (2H, AB pattern, J = 11.5 Hz, 6- and 7-H), 5.28 (1H, br s, 19E-H), 4.94 (1H, br s, 19Z-H), 4.35 (1H, m, 1-H), 4.15 (1H, m, 3-H), 0.83 (3H, d, J = 6.5 Hz, 21C-CH3), 0.50 (3H, s, 18C-CH3) (Ref. 0195)
13C-NMR (d, CD2Cl2) 148.6 (C), 148.0 (C), 143.4 (C), 133.9 (C), 128.5 (CH), 127.1 (CH),126.4 (CH), 125.0 (CH),117.6 (CH), 111.8 (C-19), 78.5 (C), 71.2 (CH), 67.2(CH), 57.1, 56.7, 46.2, 45.7 (CH2), 43.4 (CH2), 42.7 (CH2), 40.9 (CH2), 36.6 (CH2), 36.4, 29.4 (CH2), 28.0 (CH2), 24.0 (CH2), 22.6 (CH2), 20.7 (CH2), 18.9, 12.1 (Ref. 0195)








637
1a,25-dihydroxy-26,27-dimethyl-22,23-didehydro-24a,24b-dihomo-19-norvitamin D3 / 1a,25-dihydroxy-26,27-dimethyl-22,23-didehydro-24a,24b-dihomo-19-norcholecalciferol
(7E,22E)-(1R,3R)-26,27-dimethyl-24a,24b-dihomo-19-nor-9,10-seco-5,7,22-cholestatriene-1,3,25-triol
VVD0644
Sachiko Yamada
C31H54O3 474.759 Download ChemDraw structure file

(EtOH)lmax (nm) 243, 251.5, 261 (Ref. 0348)
1H-NMR(d,CDCl3,400 or 600MHz) 0.56(3H, s, 18-CH3), 0.98(3H, d, J = 6.6 Hz, 21-CH3), 4.03(1H, m, 3a-H), 4.09(1H, m, 1b-H), 5.29(2H, m, 22- and 23-H), 5.83(1H, d, J = 11.3 Hz, 7-H), 6.29(1H, d, J = 11.3 Hz, 6-H) (Ref. 0348)
m/z 458(M+,25), 440(16), 422(3), 275(44), 257(23), 239(33), 211(20), 147(35), 135(65), 133(78), 95(70), 81(100) (Ref. 0348)



CD-ring plus C(20)-C(22) part was combined with A-ring phosphine oxide by Wittig type reaction, and then the side chain synthon was attached to it. (Ref. 0348)



638
1a,25-dihydroxy-26,26,26,27,27,27-hexafluoro-16,17,23,23,24,24-hexadehydro-19-norvitamin D3 / 1a,25-dihydroxy-26,26,26,27,27,27-hexafluoro-16,17,23,23,24,24-hexadehydro-19-norcholecalciferol
(7E)-(1R,3R)-26,26,26,27,27,27-hexafluoro-19-nor-9,10-seco-5,7,16-cholestatrien-23-yne-1,3,25-triol
VVD0645
Sachiko Yamada
C26H32F6O3 506.521 Download ChemDraw structure file
The title compound caused a dose dependent growth inhibition of MCF-7 and MDAMB-468 human breast cancer cells at concentrations ranging between 1-100 nM. (Ref. 0352)









639
1a,25-dihydroxy-19-norvitamin D2 / 1a,25-dihydroxy-19-norergocalciferol
(7E,22E)-(1R,3R)-19-nor-9,10-seco-5,7,22-ergostatriene-1,3,25-triol
VVD0646
Sachiko Yamada
C27H44O3 416.636 Download ChemDraw structure file
Binding to porcine intestinal vitamin D receptor: 3.5-fold less potent than 1,25-(OH)2D3 (IC50, 4.8 nM); Intestinal calcium transport and mobilization of calcium from bone in vitamin D-deficient rats: less than 1/10 as potent as 1,25-(OH)2D3; Effect on rat model of renal osteodystrophy: significantly reduced PTH at doses of 8 to 25 ng without affecting serum ionized Ca. (Ref. 0349)









640
1a,25-dihydroxy-19-nor-22-oxavitamin D3 / 1a,25-dihydroxy-19-nor-22-oxacholecalciferol
(7E)-(1R,3R)-19-nor-22-oxa-9,10-seco-5,7-cholestadiene-1,3,25-triol
VVD0647
Sachiko Yamada
C25H42O4 406.599 Download ChemDraw structure file
Affinity for VDR: 1/33 less potent than 1,25-(OH)2D3; Transactivation of a rat 25-hydroxyvitamin D3 24-hydroxylase (CYP24) gene: twice as active as 1,25-(OH)2D3. (Ref. 0350)





22-Oxa homologue of Grundmann ketone was combined with A-ring phosphine oxide, which was synthesized by a combination of regioselective propiolate-ene reaction, catalytic epoxidation and catalytic enantioselective carbonyl-ene cyclization. (Ref. 0350)



641
1a,2a,25-trihydroxy-19-norvitamin D3 / 1a,2a,25-trihydroxy-19-norcholecalciferolcholecalciferol
(7E)-(1R,2S,3R)-19-nor-9,10-seco-5,7-cholestadiene-1,2,3,25-tetrol
VVD0648
Sachiko Yamada
C26H44O4 420.625 Download ChemDraw structure file
Had weak calcemic (intestinal calcium transport and bone calcium-mobilization) actvity but potent cell differentiating activities (HL-60 cell) similar to that of 1,25-(OH)2D3. (Ref. 0353)
(EtOH)lmax (nm) 243, 251.5, 261 (Ref. 0353)
1H-NMR(d,CDCl3) 0.55(3H, s, 18-H3), 0.94(3H, d, J = 6.5 Hz, 21-H3), 1.22(6H, s, 26- and 27-H3), 2.62(1H, dd, J = 13.0, 4.2 Hz), 2.79(1H, br d, J = 12.9 Hz), 2.90(1H, dd, J = 14.3, 4.2 Hz), 3.25(1H, br m), 3.53(1H, dd, J = 8.4, 2.6 Hz), 3.79(1H, br m), 4.10 (1H, m), 5.81 and 6.38(1H and 1H, each d, J = 11.0 Hz, 6- and 7-H) (Ref. 0353)
m/z 420 (M+,100), 402(56), 387(18), 291(58), 245(53), 95(78), 59(90) (Ref. 0353)



By combining A-ring synthon obtained from (-)-quinic acid with 25-hydroxylated Grundmann type ketone. (Ref. 0353)



642
1a,2b,25-trihydroxy-19-norvitamin D3 / 1a,2b,25-trihydroxy-19-norcholecalciferol
(7E)-(1R,2R,3R)-19-nor-9,10-seco-5,7-cholestadiene-1,2,3,25-tetrol
VVD0649
Sachiko Yamada
C26H44O4 420.625 Download ChemDraw structure file
Has potent intestinal calcium transport activity equal to that of 1,25-(OH)2D3 but no ability to mobilize calcium from bone. Cell (HL-60) differentiating activity is about 1/10 of that of 1,25-(OH)2D3 (Ref. 0353)
(EtOH)lmax (nm) 243, 251.5, 261 (Ref. 0353)
1H-NMR(d,CDCl3) 0.55(3H, s, 18-H3), 0.94(3H, d, J = 6.8 Hz, 21-H3), 1.22(6H, s, 26- and 27-H3), 2.79(1H, br d, J = 13.0 Hz), 3.08(1H,dd, J = 13.2, 4.6 Hz), 3.36(2H, br m), 3.49(1H, m), 3.68(1H, br m), 4.08(1H, m), 5.84 and 6.29(1H and 1H, each d, J = 11.3 Hz, 6- and 7-H) (Ref. 0353)
m/z 420 (M+,99), 402(59), 387(50), 291(44), 245(49), 95(94), 59(100) (Ref. 0353)



By combining A-ring synthon obtained from (-)-quinic acid with 25-hydroxylated Grundmann type ketone. (Ref. 0353)



643
1a,25-dihydroxy-2a-(3-hydroxypropoxy)-19-norvitamin D3 / 1a,25-dihydroxy-2a-(3-hydroxypropoxy)-19-norcholecalciferol
(7E)-(1R,2S,3R)-2-(3-hydroxypropoxy)-19-nor-9,10-seco-5,7-cholestadiene-1,3,25-triol
VVD0650
Sachiko Yamada
C29H50O5 478.704 Download ChemDraw structure file
Has low calcemic activity but high cell differentiating activity nearly as potent as 1,25-(OH)2D3. (Ref. 0353>
(EtOH)lmax (nm) 243, 251.5, 261 (Ref. 0353)
1H-NMR(d,CDCl3) 0.55(3H, s, 18-H3), 0.93(3H, d, J = 6.8 Hz, 21-H3), 1.22(6H, s, 26- and 27-H3), 3.3-4.2(at least 7H, complex m), 5.83 and 6.34(1H and 1H, each d, J = 11.2 Hz, 6- and 7-H) (Ref. 0353)
m/z 478 (M+,5), 460(6), 442(2), 402(4), 384(3), 245(15), 184(20), 142(100), 95(50), 59(38) (Ref. 0353)



By combining A-ring synthon obtained from (-)-quinic acid with 25-hydroxylated Grundmann type ketone. (Ref. 0353)



644
1a,25-dihydroxy-2b-(3-hydroxypropoxy)-19-norvitamin D3 / 1a,25-dihydroxy-2b-(3-hydroxypropoxy)-19-norcholecalciferol
(7E)-(1R,2R,3R)-2-(3-hydroxypropoxy)-19-nor-9,10-seco-5,7-cholestadiene-1,3,25-triol
VVD0651
Sachiko Yamada
C29H50O5 478.704 Download ChemDraw structure file
Has low in vivo calcemic activity. (Ref. 0353)
(EtOH)lmax (nm) 243, 251.5, 261 (Ref. 0353)
1H-NMR(d,CDCl3) 0.54(3H, s, 18-H3), 0.94(3H, d, J = 6.5 Hz, 21-H3), 1.22(6H, s, 26- and 27-H3), 2.79(1H, br d, J = 12 Hz, 9b-H), 3.0-4.3(at least 7H, complex m), 5.84 and 6.29(1H and 1H, each d, J = 11.2 Hz, 6- and 7-H) (Ref. 0353)
m/z 478 (M+,6), 460(12), 442(7), 420(15), 402(11), 366(9), 348(8), 245(34), 181(9), 95(80), 69(100), 59(68) (Ref. 0353)



By combining A-ring synthon obtained from (-)-quinic acid with 25-hydroxylated Grundmann type ketone. (Ref. 0353)



645
2a-(benzyloxy)-1a,25-dihydroxy-19-norvitamin D3 / 2a-(benzyloxy)-1a,25-dihydroxy-19-norcholecalciferol
(7E)-(1R,2S,3R)-2-(benzyloxy)-19-nor-9,10-seco-5,7-cholestadiene-1,3,25-triol
VVD0652
Sachiko Yamada
C33H50O4 510.748 Download ChemDraw structure file
Has potent intestinal calcium transport activity nearly equal to that of 1,25-(OH)2D3 but poor ability to mobilize calcium from bone. Cell (HL-60) differentiating activity is about 1/10 of that of 1,25-(OH)2D3 (Ref. 0353)
(EtOH)lmax (nm) 243, 251.5, 261 (Ref. 0353)
1H-NMR(d,CDCl3) 0.55(3H, s, 18-H3), 0.93(3H, d, J = 6.7 Hz, 21-H3), 1.22(6H, s, 26- and 27-H3), 2.79(2H, m), 3.45(1H, dd, J = 7.3, 3.0 Hz, 2b-H), 3.97(1H, m, 3a-H), 4.11(1H, m, 1b-H) 4.65 and 4.72(1H and 1H, each d, J = 11.8 Hz, O-CH2), 5.83 and 6.33(1H and 1H, each d, J = 11.2 Hz, 6- and 7-H), 7.2-7.4(5H, br m, Ar-H) (Ref. 0353)
m/z 510 (M+,11), 492(8), 474(2), 401(8), 91(100) (Ref. 0353)



By combining A-ring synthon obtained from (-)-quinic acid with 25-hydroxylated Grundmann type ketone. (Ref. 0353)



646
1a,25-dihydroxy-2-methylene-19-norvitamin D3 / 1a,25-dihydroxy-2-methylene-19-norcholecalciferol
(7E)-(1R,3R)-2-methylene-19-nor-9,10-seco-5,7-cholestadiene-1,3,25-triol
VVD0653
Sachiko Yamada
C27H44O3 416.636 Download ChemDraw structure file
Affinity for the porcine intestinal vitamin D receptor: ED50 1.2 times 10-10 M (1/1.5 less active than 1,25-(OH)2D3); HL-60 cell differentiation: ED50 4.2 times 10-9 M (equally active as 1,25-(OH)2D3); Intestinal calcium transport: no activity; Bone calcium mobilization: more than twice as active as 1,25-(OH)2D3. (Ref. 0355)
(EtOH)lmax (nm) 243.5, 252, 262.5 (Ref. 0355)
1H-NMR(d,CDCl3) 0.552(3H, s, 18-H3), 0.941(3H, d, J = 6.4 Hz, 21-H3), 1.222(6H, s, 26- and 27-H3), 2.01(2H, m), 2.29(1H, dd, J = 13.3, 8.4 Hz, 10a-H), 2.33(1H, dd, J = 13.4, 6.0 Hz, 4b-H), 2.58(1H, dd, J = 13.4, 3.9 Hz, 4a-H), 2.82(1H, br d, J = 12 Hz, 9b), 2.86(1H, dd, J = 13.3, 4.6 Hz, 10bH), 4.49(2H, m, 1b- and 3a-H), 5.10 and 5.11(1H and 1H, each s, =CH2), 5.89 and 6.37(1H and 1H, each d, J = 11.3 Hz, 7- and 6-H) (Ref. 0355)
m/z 416 (M+,83), 398(25), 384(31), 380(14), 351(20), 313(100) (Ref. 0355)



A-ring synthon obtained from (-)-quinic acid was combined with Grundmann type 8-ketone by Wittig type reaction. (Ref. 0355)



647
1a,25-dihydroxy-2a-methyl-19-norvitamin D3 / 1a,25-dihydroxy-2a-methyl-19-norcholecalciferol
(7E)-(1R,2S,3R)-2-methyl-19-nor-9,10-seco-5,7-cholestadiene-1,3,25-triol
VVD0654
Sachiko Yamada
C27H46O3 418.652 Download ChemDraw structure file
Affinity for the porcine intestinal vitamin D receptor: ED50 4.2 times 10-10 M (1/4.6 less active than 1,25-(OH)2D3); HL-60 cell differentiation: ED50 8.0 times 10-11 M (50 times as active as 1,25-(OH)2D3); Intestinal calcium transport: slightly less active than 1,25-(OH)2D3; Bone calcium mobilization: slightly less active than 1,25-(OH)2D3. (Ref. 0355)





A-ring synthon obtained from (-)-quinic acid was combined with Grundmann type 8-ketone by Wittig type reaction. (Ref. 0355)



648
1a,25-dihydroxy-2b-methyl-19-norvitamin D3 / 1a,25-dihydroxy-2b-methyl-19-norcholecalciferol
(7E)-(1R,2R,3R)-2-methyl-19-nor-9,10-seco-5,7-cholestadiene-1,3,25-triol
VVD0655
Sachiko Yamada
C27H46O3 418.652 Download ChemDraw structure file
Affinity for the porcine intestinal vitamin D receptor: ED50 3.5 times 10-9 M (1/39 less active than 1,25-(OH)2D3); HL-60 cell differentiation: ED50 8.0 times 10-9 M (1/2 less active than 1,25-(OH)2D3); Intestinal calcium transport: no activity; Bone calcium mobilization: no activity. (Ref. 0355)





A-ring synthon obtained from (-)-quinic acid was combined with Grundmann type 8-ketone by Wittig type reaction. (Ref. 0355)



649
1a,25-dihydroxy-2a-hydroxymethyl-19-norvitamin D3 / 1a,25-dihydroxy-2a-hydroxymethyl-19-norcholecalciferolcholecalciferol
(7E)-(1R,2S,3R)-2-hydroxymethyl-19-nor-9,10-seco-5,7-cholestadiene-1,3,25-triol
VVD0656
Sachiko Yamada
C27H46O4 434.652 Download ChemDraw structure file
Affinity for the porcine intestinal vitamin D receptor: ED50 8.0 times 10-10 M (1/13 less active than 1,25-(OH)2D3); HL-60 cell differentiation: ED50 2.0 times 10-8 M (1/5 as active as 1,25-(OH)2D3). (Ref. 0355)





A-ring synthon obtained from (-)-quinic acid was combined with Grundmann type 8-ketone by Wittig type reaction. (Ref. 0355)



650
1a,25-dihydroxy-2b-hydroxymethyl-19-norvitamin D3 / 1a,25-dihydroxy-2b-hydroxymethyl-19-norcholecalciferol
(7E)-(1R,2R,3R)-2-hydroxymethyl-19-nor-9,10-seco-5,7-cholestadiene-1,3,25-triol
VVD0657
Sachiko Yamada
C27H46O4 434.652 Download ChemDraw structure file
Affinity for the porcine intestinal vitamin D receptor: ED50 7.0 times 10-9 M (1/117 less active than 1,25-(OH)2D3); HL-60 cell differentiation: ED50 1.0 times 10-7 M (1/25 less active than 1,25-(OH)2D3). (Ref. 0355)





A-ring synthon obtained from (-)-quinic acid was combined with Grundmann type 8-ketone by Wittig type reaction. (Ref. 0355)



651
1a,25-dihydroxy-2-methylene-19-nor-20-epivitamin D3 / 1a,25-dihydroxy-2-methylene-19-nor-20-epicholecalciferol
(7E)-(1R,3R,20S)-2-methylene-19-nor-9,10-seco-5,7-cholestadiene-1,3,25-triol
VVD0658
Sachiko Yamada
C27H44O3 416.636 Download ChemDraw structure file
Affinity for the porcine intestinal vitamin D receptor: ED50 1.0 times 10-10 M (1/1.3 less active than 1,25-(OH)2D3); HL-60 cell differentiation: ED50 1.5 times 10-10 M (25 times as active as 1,25-(OH)2D3); Intestinal calcium transport: no activity; Bone calcium mobilization: more than twice as active as 1,25-(OH)2D3. (Ref. 0355)
(EtOH)lmax (nm) 243.5, 252, 262.5 (Ref. 0355)
1H-NMR(d,CDCl3) 0.551(3H, s, 18-H3), 0.858(3H, d, J = 6.6 Hz, 21-H3), 1.215(6H, s, 26- and 27-H3), 1.95-2.04(2H, m), 2.30(1H, dd, J = 13.3, 8.4 Hz, 10a-H), 2.33(1H, dd, 13.4, 6.3 Hz, 4b-H), 2.58(1H, dd, J = 13.4, 3.7 Hz, 4a-H), 2.83(1H, br d, J = 13.7 Hz, 9b), 2.85(1H, dd, J = 13.3, 4.5 Hz, 10bH), 4.49(2H, m, 1b- and 3a-H), 5.09 and 5.11(1H and 1H, each s, =CH2), 5.89 and 6.36(1H and 1H, each d, J = 11.3 Hz, 7- and 6-H) (Ref. 0355)
m/z 416 (M+,100), 398(26), 380(13), 366(21), 313(31) (Ref. 0355)



A-ring synthon obtained from (-)-quinic acid was combined with Grundmann type 8-ketone by Wittig type reaction. (Ref. 0355)



652
1a,25-dihydroxy-2a-methyl-19-nor-20-epivitamin D3 / 1a,25-dihydroxy-2a-methyl-19-nor-20-epicholecalciferol
(7E)-(1R,2S,3R,20S)-2-methyl-19-nor-9,10-seco-5,7-cholestadiene-1,3,25-triol
VVD0659
Sachiko Yamada
C27H46O3 418.652 Download ChemDraw structure file
Affinity for the porcine intestinal vitamin D receptor: ED50 4.0 times 10-10 M (1/4.4 less active than 1,25-(OH)2D3); HL-60 cell differentiation: ED50 7.0 times 10-11 M (50 times as active as 1,25-(OH)2D3); Intestinal calcium transport: more than twice as active as 1,25-(OH)2D3; Bone calcium mobilization: more than twice as active as 1,25-(OH)2D3. (Ref. 0355)





A-ring synthon obtained from (-)-quinic acid was combined with Grundmann type 8-ketone by Wittig type reaction. (Ref. 0355)



653
1a,25-dihydroxy-2b-methyl-19-nor-20-epivitamin D3 / 1a,25-dihydroxy-2b-methyl-19-nor-20-epicholecalciferol
(7E)-(1R,2R,3R,20S)-2-methyl-19-nor-9,10-seco-5,7-cholestadiene-1,3,25-triol
VVD0660
Sachiko Yamada
C27H46O3 418.652 Download ChemDraw structure file
Affinity for the porcine intestinal vitamin D receptor: ED50 5.0 times 10-10 M (1/5.5 less active than 1,25-(OH)2D3); HL-60 cell differentiation: ED50 7.0 times 10-10 M (6 times as active as 1,25-(OH)2D3); Intestinal calcium transport: no activity; Bone calcium mobilization: no activity. (Ref. 0355)





A-ring synthon obtained from (-)-quinic acid was combined with Grundmann type 8-ketone by Wittig type reaction. (Ref. 0355)



654
1a,25-dihydroxy-2a-hydroxymethyl-19-nor-20-epivitamin D3 / 1a,25-dihydroxy-2a-hydroxymethyl-19-nor-20-epicholecalciferol
(7E)-(1R,2S,3R,20S)-2-hydroxymethyl-19-nor-9,10-seco-5,7-cholestadiene-1,3,25-triol
VVD0661
Sachiko Yamada
C27H46O4 434.652 Download ChemDraw structure file
Affinity for the porcine intestinal vitamin D receptor: ED50 8.0 times 10-11 M (1/1.3 less active than 1,25-(OH)2D3); HL-60 cell differentiation: ED50 2.0 times 10-9 M (twice as active as 1,25-(OH)2D3); Intestinal calcium transport: some activity; Bone calcium mobilization: no activity. (Ref. 0355)





A-ring synthon obtained from (-)-quinic acid was combined with Grundmann type 8-ketone by Wittig type reaction. (Ref. 0355)



655
1a,25-dihydroxy-2b-hydroxymethyl-19-nor-20-epivitamin D3 / 1a,25-dihydroxy-2b-hydroxymethyl-19-nor-20-epicholecalciferol
(7E)-(1R,2R,3R,20S)-2-hydroxymethyl-19-nor-9,10-seco-5,7-cholestadiene-1,3,25-triol
VVD0662
Sachiko Yamada
C27H46O4 434.652 Download ChemDraw structure file










656
1a,25-dihydroxy-3-deoxy-19-norvitamin D3 / 1a,25-dihydroxy-3-deoxy-19-norcholecalciferol
(7E)-(1S)-19-nor-9,10-seco-5,7-cholestadiene-1,25-diol
VVD0663
Sachiko Yamada
C26H44O2 388.626 Download ChemDraw structure file
Affinity for the porcine intestinal vitamin D receptor: ED50 5.0 times 10-10 M (1/8.3 less active than 1,25-(OH)2D3); HL-60 cell differentiation: ED50 4.5 times 10-9 M (nearly as active as 1,25-(OH)2D3); Intestinal calcium transport: no activity; Bone calcium mobilization: no activity. (Ref. 0355) (Relative potency to 1,25-(OH)2D3 when its potency is defined 1) Affinity for calf thymus vitamin D receptor: 0.0007; Affinity for vitamin D binding protein: 3.2; HL-60 cell anfiproliferation: 0.3; HL-60 cell differentiation: 0.3; Transcriptional activity (rat 25-OHD3 24-hydroxylase promoter): 0.32. (Ref. 0354)





A-ring synthon obtained from (-)-quinic acid was combined with Grundmann type 8-ketone by Wittig type reaction. (Ref. 0355)



657
1b,25-dihydroxy-3-deoxy-19-norvitamin D3 / 1b,25-dihydroxy-3-deoxy-19-norcholecalciferol
(7E)-(1R)-19-nor-9,10-seco-5,7-cholestadiene-1,25-diol
VVD0664
Sachiko Yamada
C26H44O2 388.626 Download ChemDraw structure file
(Relative potency to 1,25-(OH)2D3 when its potency is defined 1) Affinity for calf thymus vitamin D receptor: <0.0006; Affinity for vitamin D binding protein: 23.5; HL-60 cell anfiproliferation: 0.5; HL-60 cell differentiation: 0.1; Transcriptional activity (rat 25-OHD3 24-hydroxylase promoter): 0.1. (Ref. 0354)









658
25-dihydroxy-19-nor-3-epivitamin D3 / 25-dihydroxy-19-nor-3-epicholecalciferol
(7E)-(3R)-19-nor-9,10-seco-5,7-cholestadiene-3,25-diol
VVD0665
Sachiko Yamada
C26H44O2 388.626 Download ChemDraw structure file
(Relative potency to 1,25-(OH)2D3 when its potency is defined 1) Affinity for calf thymus vitamin D receptor: 0.0006; Affinity for vitamin D binding protein: 5.7; HL-60 cell anfiproliferation: 0.4; HL-60 cell differentiation: 0.3; Transcriptional activity (rat 25-OHD3 24-hydroxylase promoter): 0.18. (Ref. 0354)









659
25-dihydroxy-19-norvitamin D3 / 25-dihydroxy-19-norcholecalciferol
(7E)-(3S)-19-nor-9,10-seco-5,7-cholestadiene-3,25-diol
VVD0666
Sachiko Yamada
C26H44O2 388.626 Download ChemDraw structure file
(Relative potency to 1,25-(OH)2D3 when its potency is defined 1) Affinity for calf thymus vitamin D receptor: 0.003; Affinity for vitamin D binding protein: 0.1; HL-60 cell anfiproliferation: 0.8; HL-60 cell differentiation: 0.6; Transcriptional activity (rat 25-OHD3 24-hydroxylase promoter): 0.78. (Ref. 0354)









660
1a,25-dihydroxy-3-deoxy-19-nor-22-oxavitamin D3 / 1a,25-dihydroxy-3-deoxy-19-nor-22-oxacholecalciferol
(7E)-(1S)-19-nor-22-oxa-9,10-seco-5,7-cholestadiene-1,25-diol
VVD0667
Sachiko Yamada
C25H42O3 390.599 Download ChemDraw structure file
(Relative potency to 1,25-(OH)2D3 when its potency is defined 1) Affinity for calf thymus vitamin D receptor: 0.004; Affinity for vitamin D binding protein: NR (no response); HL-60 cell anfiproliferation: 0.8; HL-60 cell differentiation: 0.5; Transcriptional activity (rat 25-OHD3 24-hydroxylase promoter): 1.32. (Ref. 0354)









661
1b,25-dihydroxy-3-deoxy-19-nor-22-oxavitamin D3 / 1b,25-dihydroxy-3-deoxy-19-nor-22-oxacholecalciferol
(7E)-(1R)-19-nor-22-oxa-9,10-seco-5,7-cholestadiene-1,25-diol
VVD0668
Sachiko Yamada
C25H42O3 390.599 Download ChemDraw structure file
(Relative potency to 1,25-(OH)2D3 when its potency is defined 1) Affinity for calf thymus vitamin D receptor: NR (no response); Affinity for vitamin D binding protein: 0.5; HL-60 cell anfiproliferation: 0.2; HL-60 cell differentiation: 0.2; Transcriptional activity (rat 25-OHD3 24-hydroxylase promoter): 0.12. (Ref. 0354)









662
25-dihydroxy-19-nor-22-oxa-3-epivitamin D3 / 25-dihydroxy-19-nor-22-oxa-3-epicholecalciferol
(7E)-(3R)-19-nor-22-oxa-9,10-seco-5,7-cholestadiene-3,25-diol
VVD0669
Sachiko Yamada
C25H42O3 390.599 Download ChemDraw structure file
(Relative potency to 1,25-(OH)2D3 when its potency is defined 1) Affinity for calf thymus vitamin D receptor: 0.001; Affinity for vitamin D binding protein: NR (no response); HL-60 cell anfiproliferation: 0.2; HL-60 cell differentiation: 0.2; Transcriptional activity (rat 25-OHD3 24-hydroxylase promoter): 0.74. (Ref. 0354)









663
25-dihydroxy-19-nor-22-oxavitamin D3 / 25-dihydroxy-19-nor-22-oxacholecalciferol
(7E)-(3S)-19-nor-22-oxa-9,10-seco-5,7-cholestadiene-3,25-diol
VVD0670
Sachiko Yamada
C25H42O3 390.599 Download ChemDraw structure file
(Relative potency to 1,25-(OH)2D3 when its potency is defined 1) Affinity for calf thymus vitamin D receptor: NR (no response); Affinity for vitamin D binding protein: NR; HL-60 cell anfiproliferation: 0.5; HL-60 cell differentiation: 0; Transcriptional activity (rat 25-OHD3 24-hydroxylase promoter): 0.12. (Ref. 0354)









664
24a,25-dihydroxy-1a-hydroxymethyl-26,27-dimethyl-24a-homo-22-oxavitamin D3 / 24a,25-dihydroxy-1a-hydroxymethyl-26,27-dimethyl-24a-homo-22-oxacholecalciferol
(5Z,7E)-(1S,3S,24aS)-1-hydroxymethyl-26,27-dimethyl-24a-homo-22-oxa-9,10-seco-5,7,10(19)-cholestatriene-3,24a,25-triol
VVD0671
Sachiko Yamada
C30H50O5 490.715 Download ChemDraw structure file










665
24a,25-dihydroxy-1b-hydroxymethyl-26,27-dimethyl-24a-homo-22-oxa-3-epivitamin D3 / 24a,25-dihydroxy-1b-hydroxymethyl-26,27-dimethyl-24a-homo-22-oxa-3-epicholecalciferol
(5Z,7E)-(1R,3R,24aS)-1-hydroxymethyl-26,27-dimethyl-24a-homo-22-oxa-9,10-seco-5,7,10(19)-cholestatriene-3,24a,25-triol
VVD0672
Sachiko Yamada
C30H50O5 490.715 Download ChemDraw structure file










666
1a-(2-fluoroethyl)-25-hydroxy-26,27-dimethyl-24a-homo-22-oxavitamin D3 / 1a-(2-fluoroethyl)-25-hydroxy-26,27-dimethyl-24a-homo-22-oxacholecalciferol
(5Z,7E)-(1R,3S)-1-(2-fluoroethyl)-26,27-dimethyl-24a-homo-22-oxa-9,10-seco-5,7,10(19)-cholestatriene-3,25-diol
VVD0673
Sachiko Yamada
C31H51FO3 490.733 Download ChemDraw structure file










667
1b-(2-fluoroethyl)-25-hydroxy-26,27-dimethyl-24a-homo-22-oxa-3-epivitamin D3 / 1b-(2-fluoroethyl)-25-hydroxy-26,27-dimethyl-24a-homo-22-oxa-3-epicholecalciferol
(5Z,7E)-(1S,3R)-1-(2-fluoroethyl)-26,27-dimethyl-24a-homo-22-oxa-9,10-seco-5,7,10(19)-cholestatriene-3,25-diol
VVD0674
Sachiko Yamada
C31H51FO3 490.733 Download ChemDraw structure file










668
25-hydroxy-1a-hydroxymethyl-26,27-dimethyl-24a-homo-22,23,24,24a-tetradehydrovitamin D3 / 25-hydroxy-1a-hydroxymethyl-26,27-dimethyl-24a-homo-22,23,24,24a-tetradehydrocholecalciferol
(5Z,7E,22E,24E)-(1S,3S)-1-hydroxymethyl-26,27-dimethyl-24a-homo-9,10-seco-5,7,10(19),22,24-cholestapentaene-3,25-diol
VVD0675
Sachiko Yamada
C31H48O3 468.711 Download ChemDraw structure file










669
25-hydroxy-1b-hydroxymethyl-26,27-dimethyl-24a-homo-22,23,24,24a-tetradehydro-3-epivitamin D3 / 25-hydroxy-1b-hydroxymethyl-26,27-dimethyl-24a-homo-22,23,24,24a-tetradehydro-3-epicholecalciferol
(5Z,7E,22E,24E)-(1R,3R)-1-hydroxymethyl-26,27-dimethyl-24a-homo-9,10-seco-5,7,10(19),22,24-cholestapentaene-3,25-diol
VVD0676
Sachiko Yamada
C31H48O3 468.711 Download ChemDraw structure file










670
25-hydroxy-1a-hydroxymethyl-23,23,24,24-tetradehydrovitamin D3 / 25-hydroxy-1a-hydroxymethyl-23,23,24,24-tetradehydrocholecalciferol
(5Z,7E)-(1S,3S)-1-hydroxymethyl-9,10-seco-5,7,10(19)-cholestatrien-23-yne-3,25-diol
VVD0677
Sachiko Yamada
C28H40O3 424.615 Download ChemDraw structure file










671
25-hydroxy-1b-hydroxymethyl-23,23,24,24-tetradehydro-3-epivitamin D3 / 25-hydroxy-1b-hydroxymethyl-23,23,24,24-tetradehydro-3-epicholecalciferol
(5Z,7E)-(1R,3R)-1-hydroxymethyl-9,10-seco-5,7,10(19)-cholestatrien-23-yne-3,25-diol
VVD0678
Sachiko Yamada
C28H40O3 424.615 Download ChemDraw structure file










672
25-hydroxy-1a-hydroxymethyl-16,17-didehydrovitamin D3 / 25-hydroxy-1a-hydroxymethyl-16,17-didehydrocholecalciferol
(5Z,7E)-(1S,3S)-1-hydroxymethyl-9,10-seco-5,7,10(19),16-cholestatetraene-3,25-diol
VVD0679
Sachiko Yamada
C28H44O3 428.647 Download ChemDraw structure file










673
25-hydroxy-1b-hydroxymethyl-16,17-didehydro-3-epivitamin D3 / 25-hydroxy-1b-hydroxymethyl-16,17-didehydro-3-epicholecalciferol
(5Z,7E)-(1R,3R)-1-hydroxymethyl-9,10-seco-5,7,10(19),16-cholestatetraene-3,25-diol
VVD0680
Sachiko Yamada
C28H44O3 428.647 Download ChemDraw structure file










674
25-hydroxy-1a-hydroxymethyl-26,27-dimethyl-16,17-didehydrovitamin D3 / 25-hydroxy-1a-hydroxymethyl-26,27-dimethyl-16,17-didehydrocholecalciferol
(5Z,7E)-(1S,3S)-1-hydroxymethyl-26,27-dimethyl-9,10-seco-5,7,10(19),16-cholestatetraene-3,25-diol
VVD0681
Sachiko Yamada
C30H48O3 456.700 Download ChemDraw structure file










675
25-hydroxy-1b-hydroxymethyl-26,27-dimethyl-16,17-didehydro-3-epivitamin D3 / 25-hydroxy-1b-hydroxymethyl-26,27-dimethyl-16,17-didehydro-3-epicholecalciferol
(5Z,7E)-(1R,3R)-1-hydroxymethyl-26,27-dimethyl-9,10-seco-5,7,10(19),16-cholestatetraene-3,25-diol
VVD0682
Sachiko Yamada
C30H48O3 456.700 Download ChemDraw structure file










676
(20S)-1a,25-dihydroxy-20-phenyl-16,17-didehydro-21-norvitamin D3 / (20S)-1a,25-dihydroxy-20-phenyl-16,17-didehydro-21-norcholecalciferol
(5Z,7E)-(1S,3R,20S)-20-phenyl-21-nor-9,10-seco-5,7,10(19),16-cholestatetraene-1,3,25-triol
VVD0683
Sachiko Yamada
C32H44O3 476.690 Download ChemDraw structure file










677
(20S)-20-cyclopropyl-1a,25-dihydroxy-16,17-didehydro-21-norvitamin D3 / (20S)-20-cyclopropyl-1a,25-dihydroxy-16,17-didehydro-21-norcholecalciferol
(5Z,7E,)-(1S,3R,20S)-20-cyclopropyl-21-nor-9,10-seco-5,7,10(19),16-cholestatetraene-1,3,25-triol
VVD0684
Sachiko Yamada
C29H44O3 440.658 Download ChemDraw structure file










678
(20S)-20-butyl-1a,25-dihydroxy-16,17-didehydro-21-norvitamin D3 / (20S)-20-butyl-1a,25-dihydroxy-16,17-didehydro-21-norcholecalciferol
(5Z,7E,)-(1S,3R,20S)-20-butyl-21-nor-9,10-seco-5,7,10(19),16-cholestatetraene-1,3,25-triol
VVD0685
Sachiko Yamada
C30H48O3 456.700 Download ChemDraw structure file










679
(20R)-1a,25-dihydroxy-20-phenyl-16,17-didehydro-21-norvitamin D3 / (20R)-1a,25-dihydroxy-20-phenyl-16,17-didehydro-21-norcholecalciferol
(5Z,7E)-(1S,3R,20R)-20-phenyl-21-nor-9,10-seco-5,7,10(19),16-cholestatetraene-1,3,25-triol
VVD0686
Sachiko Yamada
C32H44O3 476.690 Download ChemDraw structure file










680
(24S)-1a,24-dihydroxyvitamin D2 / (24S)-1a,24-dihydroxyergocalciferol
(5Z,7E,22E)-(1S,3R,24S)-9,10-seco-5,7,10(19),22-ergostatetraene-1,3,24-triol
VVD0687
Sachiko Yamada
C28H44O3 428.647 Download ChemDraw structure file










681
1a-hydroxy-18-(4-hydroxy-4-methylpentyloxy)-23,24,25,26,27-pentanorvitamin D3 / 1a-hydroxy-18-(4-hydroxy-4-methylpentyloxy)-23,24,25,26,27-pentanorcholecalciferol
(5Z,7E)-(1S,3R)-18-(4-hydroxy-4-methylpentyloxy)-23,24-dinor-9,10-seco-5,7,10(19)-cholatriene-1,3-diol
VVD0688
Sachiko Yamada
C28H46O4 446.662 Download ChemDraw structure file










682
1a-hydroxy-18-(4-hydroxy-4-ethylhexyloxy)-23,24,25,26,27-pentanorvitamin D3 / 1a-hydroxy-18-(4-hydroxy-4-ethylhexyloxy)-23,24,25,26,27-pentanorcholecalciferol
(5Z,7E)-(1S,3R)-18-(4-hydroxy-4-ethylhexyloxy)-23,24-dinor-9,10-seco-5,7,10(19)-cholatriene-1,3-diol
VVD0689
Sachiko Yamada
C30H50O4 474.716 Download ChemDraw structure file










683
1a-hydroxy-18-(5-hydroxy-5-methylhexyloxy)-23,24,25,26,27-pentanorvitamin D3 / 1a-hydroxy-18-(5-hydroxy-5-methylhexyloxy)-23,24,25,26,27-pentanorcholecalciferol
(5Z,7E)-(1S,3R)-18-(5-hydroxy-5-methylhexyloxy)-23,24-dinor-9,10-seco-5,7,10(19)-cholatriene-1,3-diol
VVD0690
Sachiko Yamada
C29H48O4 460.689 Download ChemDraw structure file










684
1a-hydroxy-18-[m-(1-hydroxy-1-methylethyl)-benzyloxy]-23,24,25,26,27-pentanorvitamin D3 / 1a-hydroxy-18-[m-(1-hydroxy-1-methylethyl)-benzyloxy]-23,24,25,26,27-pentanorcholecalciferol
(5Z,7E)-(1S,3R)-18-[m-(1-hydroxy-1-methylethyl)-benzyloxy]-23,24-dinor-9,10-seco-5,7,10(19)-cholatriene-1,3-diol
VVD0691
Sachiko Yamada
C32H46O4 494.705 Download ChemDraw structure file










685
1a-hydroxy-18-[m-(1-hydroxy-1-ethylpropyl)-benzyloxy]-23,24,25,26,27-pentanorvitamin D3 / 1a-hydroxy-18-[m-(1-hydroxy-1-ethylpropyl)-benzyloxy]-23,24,25,26,27-pentanorcholecalciferol
(5Z,7E)-(1S,3R)-18-[m-(1-hydroxy-1-ethylpropyl)-benzyloxy]-23,24-dinor-9,10-seco-5,7,10(19)-cholatriene-1,3-diol
VVD0692
Sachiko Yamada
C34H50O4 522.758 Download ChemDraw structure file










686
1a-hydroxy-18-(4-hydroxy-4-methyl-2-pentynyloxy)-23,24,25,26,27-pentanorvitamin D3 / 1a-hydroxy-18-(4-hydroxy-4-methyl-2-pentynyloxy)-23,24,25,26,27-pentanorcholecalciferol
(5Z,7E)-(1S,3R)-18-(4-hydroxy-4-methyl-2-pentynyloxy)-23,24-dinor-9,10-seco-5,7,10(19)-cholatriene-1,3-diol
VVD0693
Sachiko Yamada
C28H42O4 442.631 Download ChemDraw structure file










687
1a-hydroxy-18-(4-hydroxy-4-ethyl-2-hexynyloxy)-23,24,25,26,27-pentanorvitamin D3 / 1a-hydroxy-18-(4-hydroxy-4-ethyl-2-hexynyloxy)-23,24,25,26,27-pentanorcholecalciferol
(5Z,7E)-(1S,3R)-18-(4-hydroxy-4-ethyl-2-hexynyloxy)-23,24-dinor-9,10-seco-5,7,10(19)-cholatriene-1,3-diol
VVD0694
Sachiko Yamada
C30H46O4 470.684 Download ChemDraw structure file










688
1a-hydroxy-18-(5-hydroxy-5-methyl-2-hexynyloxy)-23,24,25,26,27-pentanorvitamin D3 / 1a-hydroxy-18-(5-hydroxy-5-methyl-2-hexynyloxy)-23,24,25,26,27-pentanorcholecalciferol
(5Z,7E)-(1S,3R)-18-(5-hydroxy-5-methyl-2-hexynyloxy)-23,24-dinor-9,10-seco-5,7,10(19)-cholatriene-1,3-diol
VVD0695
Sachiko Yamada
C29H44O4 456.657 Download ChemDraw structure file










689
1a-hydroxy-18-(5-hydroxy-5-methyl-3-hexynyloxy)-23,24,25,26,27-pentanorvitamin D3 / 1a-hydroxy-18-(5-hydroxy-5-methyl-3-hexynyloxy)-23,24,25,26,27-pentanorcholecalciferol
(5Z,7E)-(1S,3R)-18-(5-hydroxy-5-methyl-3-hexynyloxy)-23,24-dinor-9,10-seco-5,7,10(19)-cholatriene-1,3-diol
VVD0696
Sachiko Yamada
C29H44O4 456.657 Download ChemDraw structure file










690
(24E)-1a,25-dihydroxy-24,24a-didehydro-24a,24b-dihomovitamin D3 /(24E)-1a,25-dihydroxy-24,24a-didehydro-24a,24b-dihomocholecalciferol
(5Z,7E,24E)-(1S,3R)-24a,24b-dihomo-9,10-seco-5,7,10(19),24-cholestatetraene-1,3,25-triol
VVD0697
Sachiko Yamada
C29H46O3 442.674 Download ChemDraw structure file










691
(24aE)-1a,25-dihydroxy-24a,24b-didehydro-24a,24b-dihomovitamin D3 /(24aE)-1a,25-dihydroxy-24a,24b-didehydro-24a,24b-dihomocholecalciferol
(5Z,7E,24aE)-(1S,3R)-24a,24b-dihomo-9,10-seco-5,7,10(19),24a-cholestatetraene-1,3,25-triol
VVD0698
Sachiko Yamada
C29H46O3 442.674 Download ChemDraw structure file










692
(24S)-1a,24-dihydroxyvitamin D2 / (24S)-1a,24-dihydroxyergocalciferol
(5Z,7E,22E)-(1S,3R,24S)-9,10-seco-5,7,10(19),22-ergostatetraene-1,3,24-triol
VVD0699
Sachiko Yamada
C28H44O3 428.647 Download ChemDraw structure file










693
(10S)-1a,19,25-trihydroxy-10,19-dihydrovitamin D3 / (10S)-1a,19,25-trihydroxy-10,19-dihydrocholecalciferol
(5Z,7E)-(1S,3R,10S)-9,10-seco-5,7-cholestadiene-1,3,19,25-tetrol
VVD0700
Sachiko Yamada
C27H46O4 434.652 Download ChemDraw structure file

(EtOH)lmax (nm) 243, 251.5, 261 (Ref. 0355)
1H-NMR(d,CDCl3) 0.544(3H, s, 18-H3), 0.943(3H, d, J = 6.5 Hz, 21-H3), 1.219(6H, s, 26- and 27-H3), 2.14(1H, br d, J = 14 Hz, 4b-H), 2.47(1H, br d, J = 14 Hz, 4a-H), 2.80(2H, br d, J = 12.7 Hz, 9b-H), 3.52(1H, m, W/2 = 17 Hz, 10b-H), 3.64(1H, dd, J = 10.4, 5.4 Hz, one of 19-H2), 4.18(2H, br m, 3aH and one of 19-H2), 4.29(1H, -dt, J = 12.2, 4.3 Hz, 1b-H), 5.96 and 6.33(1H and 1H, each d, J = 11.2 Hz, 7- and 6-H), 5.89 and 6.37(1H and 1H, each d, J = 11.3 Hz, 7- and 6-H) (Ref. 0355)
m/z 434 (M+,36), 416(38), 398(21), 383(9), 305(14), 287(18), 245(33), 81(100) (Ref. 0355)



Hydroboration of 1,25-(OH)2D3 followed by oxidation gave a mixture of epimers at C(10). The C(10) epimers were separated by flash column chromatography. (Ref. 0355)



694
(10R)-1a,19,25-trihydroxy-10,19-dihydrovitamin D3 / (10R)-1a,19,25-trihydroxy-10,19-dihydrocholecalciferol
(5Z,7E)-(1S,3R,10R)-9,10-seco-5,7-cholestadiene-1,3,19,25-tetrol
VVD0701
Sachiko Yamada
C27H46O4 434.652 Download ChemDraw structure file

(EtOH)lmax (nm) 243, 251, 261 (Ref. 0355)
1H-NMR(d,CDCl3) 0.543(3H, s, 18-H3), 0.940(3H, d, J = 6.4 Hz, 21-H3), 1.215(6H, s, 26- and 27-H3), 2.23(1H,-t, J = 12 Hz, 4b-H), 2.51(1H, dd, J = 12.6, 4.1 Hz, 4a-H), 2.81(1H, br d, J = 13 Hz, 9b-H), 3.13(1H, m, W/2 = 18 Hz, 10a-H), 3.68(2H, m, 19-H2), 4.04(1H, m, W/2 = 26 Hz, 3aH ), 4.20(1H, m, W/2 = 11 Hz, 1b-H), 5.86 and 6.52(1H and 1H, each d, J = 11.2 Hz, 7- and 6-H) (Ref. 0355)
m/z 434 (M+,35), 416(29), 398(14), 383(7), 305(17), 287(16), 245(37), 81(100) (Ref. 0355)



Hydroboration of 1,25-(OH)2D3 followed by oxidation gave a mixture of epimers at C(10). The C(10) epimers were separated by flash column chromatography. (Ref. 0355)



695
(23S)-1a-hydroxy-25,27-didehydrovitamin D3 26,23-lactone
(5Z,7E)-(1S,3R,23S)-1,3-dihydroxy-9,10-seco-5,7,10(19),25(27)-cholestatetraeno-26,23-lactone
VVD0702
Sachiko Yamada
C27H38O4 426.588 Download ChemDraw structure file
Activity relative to 1,25-(OH)2D3 (defined 1): Affinity for chick intestinal receptor, 1/9.8; Affinity for bovine serum vitamin D binding protein, 1/10.7; HL-60 cell differentiation, no effect; Antagonistic activity, yes. (Ref. 0373)





Convergent synthesis from CD-ring plus side chain fragment and enyne A-ring precursor via palladium catalyzed coupling of the upper and the lower half fragments as a key step. (Ref. 0373)



696
(23R)-1a-hydroxy-25,27-didehydrovitamin D3 26,23-lactone
(5Z,7E)-(1S,3R,23R)-1,3-dihydroxy-9,10-seco-5,7,10(19),25(27)-cholestatetraeno-26,23-lactone
VVD0703
Sachiko Yamada
Download ChemDraw structure file
Activity relative to 1,25-(OH)2D3 (defined 1): Affinity for chick intestinal receptor, 1/3.8; Affinity for bovine serum vitamin D binding protein, 1/39.4; HL-60 cell differentiation, no effect; Antagonistic activity, yes. (Ref. 0373)





Convergent synthesis from CD-ring plus side chain fragment and enyne A-ring precursor via palladium catalyzed coupling of the upper and the lower half fragments as a key step. (Ref. 0373)



697
2b-chloro-1a,25-dihydroxyvitamin D3
(5Z,7E)-(1R,2R,3R)-2-chloro-9,10-seco-5,7,10(19)-cholestatriene-1,3,25-triol
VVD0704
Sachiko Yamada
C27H43ClO3 451.081 Download ChemDraw structure file
(% of 1,25-(OH)2D3 effect) Affinity for chicken intestine vitamin D receptor: 100; Affinity for sheep serum vitamin D binding protein: 140; Inhibition of proliferation of C3H10T(BMP-4) cells: 0.9 (FCS-free), 11 (10% FCS); CAT assay (osteocalcin): 130; Inhibition of adipogenesis: 8. (Ref. 0374)





From C(22) steroid precursor via photochemical method. The C(2) substituent was introduced by nucleophilic opening of 1a,2a-epoxide. (Ref. 0374)



698
2b-fluoro-1a,25-dihydroxyvitamin D3
(5Z,7E)-(1R,2R,3R)-2-fluoro-9,10-seco-5,7,10(19)-cholestatriene-1,3,25-triol
VVD0705
Sachiko Yamada
C27H43FO3 434.627 Download ChemDraw structure file
(% of 1,25-(OH)2D3 effect) Affinity for chicken intestine vitamin D receptor: 667; Affinity for sheep serum vitamin D binding protein: 160; Inhibition of proliferation of C3H10T(BMP-4) cells: 133 (FCS-free), 900 (10% FCS); CAT assay (osteocalcin): 130; Inhibition of adipogenesis: 500. (Ref. 0374)





From C(22) steroid precursor via photochemical method. The C(2) substituent was introduced by nucleophilic opening of 1a,2a-epoxide. (Ref. 0374)



699
2b-methoxy-1a,25-dihydroxyvitamin D3
(5Z,7E)-(1R,2R,3R)-2-methoxy-9,10-seco-5,7,10(19)-cholestatriene-1,3,25-triol
VVD0706
Sachiko Yamada
C28H46O4 446.662 Download ChemDraw structure file
(% of 1,25-(OH)2D3 effect) Affinity for chicken intestine vitamin D receptor: 9; Affinity for sheep serum vitamin D binding protein: 3500; Inhibition of proliferation of C3H10T(BMP-4) cells: 11 (FCS-free), 1.5 (10% FCS); CAT assay (osteocalcin): 70; Inhibition of adipogenesis: 0.08. (Ref. 0374)





From C(22) steroid precursor via photochemical method. The C(2) substituent was introduced by nucleophilic opening of 1a,2a-epoxide. (Ref. 0374)




Reference
[0001]
AUTHOR:Huber, W.; Ewing, G. W.; Kriger, J.
TITLE:The Absorption Spectra of the Vitamins and Provitamins D.
JOURNAL:J. Amer. Chem. Soc.
VOL:67 PAGE : 609-617 (1945)

[0002]
AUTHOR:Wing, R. M., Okamura, W. H., Rego, A., Pirio, M. R., and Norman, A. W.
TITLE:Studies on vitamin D and its analogs. VIII. Solution conformations of vitamin D3 and 1 alpha, 25-dihydroxyvitamin D3 by high-resolution proton magnetic resonance spectroscopy PubMed ID:170323
JOURNAL:J Am Chem Soc.
VOL:97 PAGE : 4980-4985 (1975)

[0003]
AUTHOR:Tsukida, K., Akutsu, K., and Saiki, K.
TITLE:Carbon-13 nuclear magnetic resonance spectra of vitamins D and related compounds PubMed ID:178846
JOURNAL:J Nutr Sci Vitaminol (Tokyo).
VOL:21 PAGE : 411-420 (1975)

[0004]
AUTHOR:Wing, R. M., Okamura, W. H., Pirio, M. R., Sine, S. M., and Norman, A. W.
TITLE:Vitamin D in solution: conformations of vitamin D3, 1alpha,25-dihydroxyvitamin D3, and dihydrotachysterol3 PubMed ID:4377759
JOURNAL:Science.
VOL:186 PAGE : 939-941 (1974)

[0005]
AUTHOR:Holick, M. F., Richtand, N. M., McNeill, S. C., Holick, S. A., Frommer, J. E., Henley, J. W., and Potts, J. T., Jr.
TITLE:Isolation and identification of previtamin D3 from the skin of rats exposed to ultraviolet irradiation PubMed ID:218609
JOURNAL:Biochemistry.
VOL:18 PAGE : 1003-1008 (1979)

[0006]
AUTHOR:Holick, M. F., MacLaughlin, J. A., Clark, M. B., Holick, S. A., Potts, J. T., Jr., Anderson, R. R., Blank, I. H., Parrish, J. A., and Elias, P.
TITLE:Photosynthesis of previtamin D3 in human skin and the physiologic consequences PubMed ID:6251551
JOURNAL:Science.
VOL:210 PAGE : 203-205 (1980)

[0007]
AUTHOR:Windaus, A.; Lettre, H.; Schenck, F.
TITLE:Uder das 7-Dehydro-cholesterin.
JOURNAL:Ann.
VOL:520 PAGE : 98-106 (1935)

[0008]
AUTHOR:Shaw, W. H. C.; Jefferies, J. P.; Holt, T. E.
TITLE:The Determination of Vitamin D and Related Compounds : Part I. Introduction and Preparation of Compounds in the Irradiation Series.
JOURNAL:Analyst
VOL:82 PAGE : 2-7 (1957)

[0009]
AUTHOR:Pelc, B., and Marshall, D. H.
TITLE:Thermal transformation of cholecalciferol between 100--170 degrees C PubMed ID:208197
JOURNAL:Steroids.
VOL:31 PAGE : 23-29 (1978)

[0010]
AUTHOR:Dauben, W. G.; Fonken, G. J.
TITLE:The Structure of Photoisopyrocalciferol and Photopyrocalciferol.
JOURNAL:J. Amer. Chem. Soc.
VOL:81 PAGE : 4060-4068 (1959)

[0011]
AUTHOR:Boomsma, F.; Jacobs, H. J. C.; Havinga, E.; van der Gen, A.
TITLE:The 'overirradiation products' of previtamin D and tachysterol : toxisterols.
JOURNAL:J. R. Neth. Chem. Soc.
VOL:96 PAGE : 104-111 (1977)

[0012]
AUTHOR:Boomsma, F.; Jacobs, H. J. C.; Havinga, E.; van der Gen, A.
TITLE:Studies on Vitamin D and Related Compounds XXIV New Irradiation Products of Previtamin D3 : Toxisterols.
JOURNAL:Tetrahedron Lett.
VOL:7 PAGE : 427-430 (1975)

[0013]
AUTHOR:Bakker, S. A.; Lugtenburg, J.; Havinga, E.
TITLE:Studies on Vitamin D and Related Compounds XXII.
JOURNAL:RECUEIL
VOL:91 PAGE : 1459-1464 (1972)

[0014]
AUTHOR:Blunt, J. W., and DeLuca, H. F.
TITLE:The synthesis of 25-hydroxycholecalciferol. A biologically active metabolite of vitamin D3 PubMed ID:4307413
JOURNAL:Biochemistry.
VOL:8 PAGE : 671-675 (1969)

[0015]
AUTHOR:Blunt, J. W., DeLuca, H. F., and Schnoes, H. K.
TITLE:25-hydroxycholecalciferol. A biologically active metabolite of vitamin D3 PubMed ID:4300699
JOURNAL:Biochemistry.
VOL:7 PAGE : 3317-3322 (1968)

[0016]
AUTHOR:Masumoto, O., Ohyama, Y., and Okuda, K.
TITLE:Purification and characterization of vitamin D 25-hydroxylase from rat liver mitochondria PubMed ID:2844763
JOURNAL:J Biol Chem.
VOL:263 PAGE : 14256-14260 (1988)

[0017]
AUTHOR:DeLuca, H. F., and Schnoes, H. K.
TITLE:Metabolism and mechanism of action of vitamin D PubMed ID:183601
JOURNAL:Annu Rev Biochem.
VOL:45 PAGE : 631-666 (1976)

[0018]
AUTHOR:DeLuca, H. F., and Schnoes, H. K.
TITLE:Vitamin D: recent advances PubMed ID:6311080
JOURNAL:Annu Rev Biochem.
VOL:52 PAGE : 411-439 (1983)

[0019]
AUTHOR:Holick, M. F., DeLuca, H. F., and Avioli, L. V.
TITLE:Isolation and identification of 25-hydroxycholecalciferol from human plasma PubMed ID:4332591
JOURNAL:Arch Intern Med.
VOL:129 PAGE : 56-61 (1972)

[0020]
AUTHOR:Wang, X.; Shimizu, M.; Numano, F.; Asaoka, H.; Yamada, S.
TITLE:Multiple Fluorometric Assay of Three Major Vitamin D3 Metabolites (25-Hydroxyvitamin D3, 24,25-Dihydroxyvitamin D3 and 1,25-Dihydroxyvitamin D3) in Plasma and Its Application to Clinical Studies.
JOURNAL:Anal. Sci.
VOL:13 PAGE : 255-262 (1997)

[0021]
AUTHOR:Blunt, J. W.; DeLuca, H. F.; Schnoes, H. K.
TITLE:25-Hydroxycholecalciferol : A Biologically Active Metabolite of Cholecalciferol.
JOURNAL:Chem. Comm.
VOL: PAGE : 801- (1968)

[0022]
AUTHOR:Fraser, D. R., and Kodicek, E.
TITLE:Unique biosynthesis by kidney of a biological active vitamin D metabolite PubMed ID:4319631
JOURNAL:Nature.
VOL:228 PAGE : 764-766 (1970)

[0023]
AUTHOR:Shimizu, M.; Iwasaki, Y.; Ishida, H.; Yamada, S.
TITLE:Determination of 25-hydroxyvitamin D3 in human plasma using a non-radioactive tetranorvitamin D analogue as an internal standard. PubMed ID:8590938
JOURNAL:J. Chromatogr. B.
VOL:672 PAGE : 63-71 (1995)

[0024]
AUTHOR:Barton, D. H. R.; Hesse, R. H.; Pechet, M. M.; Rizzardo, E.
TITLE:Convenient Synthesis of Crystalline 1a,25-Dihydroxyvitamin D3.
JOURNAL:J. Chem. Soc. Chem. Comm.
VOL: PAGE : 203-204 (1974)

[0025]
AUTHOR:Eguchi, T.; Ikekawa, N.
TITLE:Conformational Analysis of 1a,25-Dihydroxyvitamin D3 by Nuclear Magnetic Resonance.
JOURNAL:Bioorg. Chem.
VOL:18 PAGE : 19-29 (1990)

[0026]
AUTHOR:Holick, M. F., Schnoes, H. K., DeLuca, H. F., Suda, T., and Cousins, R. J.
TITLE:Isolation and identification of 1,25-dihydroxycholecalciferol. A metabolite of vitamin D active in intestine PubMed ID:4326883
JOURNAL:Biochemistry.
VOL:10 PAGE : 2799-2804 (1971)

[0027]
AUTHOR:Holick, M. F., Schnoes, H. K., and DeLuca, H. F.
TITLE:Identification of 1,25-dihydroxycholecalciferol, a form of vitamin D3 metabolically active in the intestine PubMed ID:4323790
JOURNAL:Proc Natl Acad Sci U S A.
VOL:68 PAGE : 803-804 (1971)

[0028]
AUTHOR:Lawson, D. E., Fraser, D. R., Kodicek, E., Morris, H. R., and Williams, D. H.
TITLE:Identification of 1,25-dihydroxycholecalciferol, a new kidney hormone controlling calcium metabolism PubMed ID:4323313
JOURNAL:Nature.
VOL:230 PAGE : 228-230 (1971)

[0029]
AUTHOR:Shimizu, M., Wang, X., and Yamada, S.
TITLE:Fluorimetric assay of 1 alpha,25-dihydroxyvitamin D3 in human plasma PubMed ID:9106025
JOURNAL:J Chromatogr B Biomed Sci Appl.
VOL:690 PAGE : 15-23 (1997)

[0030]
AUTHOR:Takeyama, K., Kitanaka, S., Sato, T., Kobori, M., Yanagisawa, J., and Kato, S.
TITLE:25-Hydroxyvitamin D3 1alpha-hydroxylase and vitamin D synthesis PubMed ID:9295274
JOURNAL:Science.
VOL:277 PAGE : 1827-1830 (1997)

[0031]
AUTHOR:Shinki, T., Shimada, H., Wakino, S., Anazawa, H., Hayashi, M., Saruta, T., DeLuca, H. F., and Suda, T.
TITLE:Cloning and expression of rat 25-hydroxyvitamin D3-1alpha-hydroxylase cDNA PubMed ID:9371776
JOURNAL:Proc Natl Acad Sci U S A.
VOL:94 PAGE : 12920-12925 (1997)

[0032]
AUTHOR:Ohyama, Y., Noshiro, M., and Okuda, K.
TITLE:Cloning and expression of cDNA encoding 25-hydroxyvitamin D3 24-hydroxylase PubMed ID:1991512
JOURNAL:FEBS Lett.
VOL:278 PAGE : 195-198 (1991)

[0033]
AUTHOR:Chen, K. S., Prahl, J. M., and DeLuca, H. F.
TITLE:Isolation and expression of human 1,25-dihydroxyvitamin D3 24-hydroxylase cDNA PubMed ID:8506296
JOURNAL:Proc Natl Acad Sci U S A.
VOL:90 PAGE : 4543-4547 (1993)

[0034]
AUTHOR:Kleiner-Bossaller, A.; DeLuca, H. F.
TITLE:Formation of 1,24,25-Trihydroxyvitamin D3 from 1,25-Dihydroxyvitamin D3.
JOURNAL:Biochim. Biophys. Acta
VOL:338 PAGE : 489-495 (1974)

[0035]
AUTHOR:Semmler, E. J.; Holick, M. F.; Schnoes, H. K.; DeLuca, H. F.
TITLE:The Synthesis of 1a,25-Dihydroxycholecalciferol : A Metabolically Active from of Vitamin D3.
JOURNAL:Tetrahedron Lett.
VOL:40 PAGE : 4147-4150 (1972)

[0036]
AUTHOR:Onisko, B. L., Esvelt, R. P., Schnoes, H. K., and DeLuca, H. F.
TITLE:Metabolites of 1 alpha, 25-dihydroxyvitamin D3 in rat bile PubMed ID:6996717
JOURNAL:Biochemistry.
VOL:19 PAGE : 4124-4130 (1980)

[0037]
AUTHOR:McDonnell, D. P., Mangelsdorf, D. J., Pike, J. W., Haussler, M. R., and O'Malley, B. W.
TITLE:Molecular cloning of complementary DNA encoding the avian receptor for vitamin D PubMed ID:3029866
JOURNAL:Science.
VOL:235 PAGE : 1214-1217 (1987)

[0038]
AUTHOR:Pike, J. W., Sleator, N. M., and Haussler, M. R.
TITLE:Chicken intestinal receptor for 1,25-dihydroxyvitamin D3. Immunologic characterization and homogeneous isolation of a 60,000-dalton protein PubMed ID:3027085
JOURNAL:J Biol Chem.
VOL:262 PAGE : 1305-1311 (1987)

[0039]
AUTHOR:Elaroussi, M. A., Prahl, J. M., and DeLuca, H. F.
TITLE:The avian vitamin D receptors: primary structures and their origins PubMed ID:7972109
JOURNAL:Proc Natl Acad Sci U S A.
VOL:91 PAGE : 11596-11600 (1994)

[0040]
AUTHOR:Baker, A. R., McDonnell, D. P., Hughes, M., Crisp, T. M., Mangelsdorf, D. J., Haussler, M. R., Pike, J. W., Shine, J., and O'Malley, B. W.
TITLE:Cloning and expression of full-length cDNA encoding human vitamin D receptor PubMed ID:2835767
JOURNAL:Proc Natl Acad Sci U S A.
VOL:85 PAGE : 3294-3298 (1988)

[0041]
AUTHOR:Burmester, J. K., Maeda, N., and DeLuca, H. F.
TITLE:Isolation and expression of rat 1,25-dihydroxyvitamin D3 receptor cDNA PubMed ID:2829212
JOURNAL:Proc Natl Acad Sci U S A.
VOL:85 PAGE : 1005-1009 (1988)

[0042]
AUTHOR:Burmester, J. K., Wiese, R. J., Maeda, N., and DeLuca, H. F.
TITLE:Structure and regulation of the rat 1,25-dihydroxyvitamin D3 receptor PubMed ID:2849110
JOURNAL:Proc Natl Acad Sci U S A.
VOL:85 PAGE : 9499-9502 (1988)

[0043]
AUTHOR:Kamei, Y., Kawada, T., Fukuwatari, T., Ono, T., Kato, S., and Sugimoto, E.
TITLE:Cloning and sequencing of the gene encoding the mouse vitamin D receptor PubMed ID:7835717
JOURNAL:Gene.
VOL:152 PAGE : 281-282 (1995)

[0044]
AUTHOR:Darwish, H. M.; DeLuca, H. F.
TITLE:Identification of a 1,25-dihydroxyvitamin D3-response element in the 5'-flanking region of the rat calbindin D-9k gene. PubMed ID:1309950
JOURNAL:Proc. Natl. Acad. Sci. U.S.A.
VOL:89 PAGE : 603-607 (1992)

[0045]
AUTHOR:Demay, M. B., Gerardi, J. M., DeLuca, H. F., and Kronenberg, H. M.
TITLE:DNA sequences in the rat osteocalcin gene that bind the 1,25-dihydroxyvitamin D3 receptor and confer responsiveness to 1,25-dihydroxyvitamin D3 PubMed ID:2153298
JOURNAL:Proc Natl Acad Sci U S A.
VOL:87 PAGE : 369-373 (1990)

[0046]
AUTHOR:Morrison, N. A., Shine, J., Fragonas, J. C., Verkest, V., McMenemy, M. L., and Eisman, J. A.
TITLE:1,25-dihydroxyvitamin D-responsive element and glucocorticoid repression in the osteocalcin gene PubMed ID:2588000
JOURNAL:Science.
VOL:246 PAGE : 1158-1161 (1989)

[0047]
AUTHOR:Ozono, K., Liao, J., Kerner, S. A., Scott, R. A., and Pike, J. W.
TITLE:The vitamin D-responsive element in the human osteocalcin gene. Association with a nuclear proto-oncogene enhancer PubMed ID:2174889
JOURNAL:J Biol Chem.
VOL:265 PAGE : 21881-21888 (1990)

[0048]
AUTHOR:Noda, M., Vogel, R. L., Craig, A. M., Prahl, J., DeLuca, H. F., and Denhardt, D. T.
TITLE:Identification of a DNA sequence responsible for binding of the 1,25-dihydroxyvitamin D3 receptor and 1,25-dihydroxyvitamin D3 enhancement of mouse secreted phosphoprotein 1 (SPP-1 or osteopontin) gene expression PubMed ID:2175918
JOURNAL:Proc Natl Acad Sci U S A.
VOL:87 PAGE : 9995-9999 (1990)

[0049]
AUTHOR:Zierold, C., Darwish, H. M., and DeLuca, H. F.
TITLE:Identification of a vitamin D-response element in the rat calcidiol (25-hydroxyvitamin D3) 24-hydroxylase gene PubMed ID:8302863
JOURNAL:Proc Natl Acad Sci U S A.
VOL:91 PAGE : 900-902 (1994)

[0050]
AUTHOR:Chen, K. S., and DeLuca, H. F.
TITLE:Cloning of the human 1 alpha,25-dihydroxyvitamin D-3 24-hydroxylase gene promoter and identification of two vitamin D-responsive elements PubMed ID:7632726
JOURNAL:Biochim Biophys Acta.
VOL:1263 PAGE : 1-9 (1995)

[0051]
AUTHOR:Ohyama, Y., Ozono, K., Uchida, M., Shinki, T., Kato, S., Suda, T., Yamamoto, O., Noshiro, M., and Kato, Y.
TITLE:Identification of a vitamin D-responsive element in the 5'-flanking region of the rat 25-hydroxyvitamin D3 24-hydroxylase gene PubMed ID:8144641
JOURNAL:J Biol Chem.
VOL:269 PAGE : 10545-10550 (1994)

[0052]
AUTHOR:Demay, M. B.; Kiernan, M. S.; DeLuca, H. F.; Kronenberg, H. M.
TITLE:Sequences in the human parathyroid hormone gene that bind the 1,25-dihydroxyvitamin D3 receptor and mediate transcriptional repression in response to 1,25-dihydroxyvitamin D3.
JOURNAL:Proc. Natl. Acad. Sci. U.S.A.
VOL:89 PAGE : 8097-8101 (1992)

[0053]
AUTHOR:Takeda, T., Arakawa, M., and Kuwano, R.
TITLE:Organization and expression of the mouse spot35/calbindin-D28k gene: identification of the vitamin D-responsive promoter region PubMed ID:7980557
JOURNAL:Biochem Biophys Res Commun.
VOL:204 PAGE : 889-897 (1994)

[0054]
AUTHOR:Quelo, I., Kahlen, J. P., Rascle, A., Jurdic, P., and Carlberg, C.
TITLE:Identification and characterization of a vitamin D3 response element of chicken carbonic anhydrase-II PubMed ID:7811384
JOURNAL:DNA Cell Biol.
VOL:13 PAGE : 1181-1187 (1994)

[0055]
AUTHOR:Schrader, M., Nayeri, S., Kahlen, J. P., Muller, K. M., and Carlberg, C.
TITLE:Natural vitamin D3 response elements formed by inverted palindromes: polarity-directed ligand sensitivity of vitamin D3 receptor-retinoid X receptor heterodimer-mediated transactivation PubMed ID:7862109
JOURNAL:Mol Cell Biol.
VOL:15 PAGE : 1154-1161 (1995)

[0056]
AUTHOR:Gill, R. K., and Christakos, S.
TITLE:Identification of sequence elements in mouse calbindin-D28k gene that confer 1,25-dihydroxyvitamin D3- and butyrate-inducible responses PubMed ID:8464915
JOURNAL:Proc Natl Acad Sci U S A.
VOL:90 PAGE : 2984-2988 (1993)

[0057]
AUTHOR:Yoshizawa, T., Handa, Y., Uematsu, Y., Takeda, S., Sekine, K., Yoshihara, Y., Kawakami, T., Arioka, K., Sato, H., Uchiyama, Y., et al.
TITLE:Mice lacking the vitamin D receptor exhibit impaired bone formation, uterine hypoplasia and growth retardation after weaning PubMed ID:9241280
JOURNAL:Nat Genet.
VOL:16 PAGE : 391-396 (1997)

[0058]
AUTHOR:DeLuca, H. F.
TITLE:The vitamin D story: a collaborative effort of basic science and clinical medicine PubMed ID:3280376
JOURNAL:Faseb J.
VOL:2 PAGE : 224-236 (1988)

[0059]
AUTHOR:Reichel, H., Koeffler, H. P., and Norman, A. W.
TITLE:The role of the vitamin D endocrine system in health and disease PubMed ID:2648151
JOURNAL:N Engl J Med.
VOL:320 PAGE : 980-991 (1989)

[0060]
AUTHOR:Abe, E., Miyaura, C., Sakagami, H., Takeda, M., Konno, K., Yamazaki, T., Yoshiki, S., and Suda, T.
TITLE:Differentiation of mouse myeloid leukemia cells induced by 1 alpha,25-dihydroxyvitamin D3 PubMed ID:6946446
JOURNAL:Proc Natl Acad Sci U S A.
VOL:78 PAGE : 4990-4994 (1981)

[0061]
AUTHOR:Miyaura, C., Abe, E., Kuribayashi, T., Tanaka, H., Konno, K., Nishii, Y., and Suda, T.
TITLE:1 alpha,25-Dihydroxyvitamin D3 induces differentiation of human myeloid leukemia cells PubMed ID:6946774
JOURNAL:Biochem Biophys Res Commun.
VOL:102 PAGE : 937-943 (1981)

[0062]
AUTHOR:Parren, H. E.; DeLuca, H. F.; Schnoes, H. K.
TITLE:Direct C(1) Hydroxylation of Vitamin D3 and Related Compounds.
JOURNAL:J. Org. Chem.
VOL:45 PAGE : 3253-3258 (1980)

[0063]
AUTHOR:Corradino, R. A., and Wasserman, R. H.
TITLE:1,25-Dihydroxycholecalciferol-like activity of Solanum malacoxylon extract on calcium transport PubMed ID:4437623
JOURNAL:Nature.
VOL:252 PAGE : 716-718 (1974)

[0064]
AUTHOR:Ikekawa,N.; Morisaki, M.; Koizumi, N.; Kato, Y.; Takeshita, T.
TITLE:Synthesis of Active Forms of Vitamin D. VIII. Synthesis of [24R]-and [24S]-1a,24,25-Trihydroxyvitamin D3.
JOURNAL:Chem. Pharm. Bull.
VOL:23 PAGE : 695-697 (1975)

[0065]
AUTHOR:Holick, M. F., Kleiner-Bossaller, A., Schnoes, H. K., Kasten, P. M., Boyle, I. T., and DeLuca, H. F.
TITLE:1,24,25-Trihydroxyvitamin D3. A metabolite of vitamin D3 effective on intestine PubMed ID:4355503
JOURNAL:J Biol Chem.
VOL:248 PAGE : 6691-6696 (1973)

[0066]
AUTHOR:Tanaka, Y., Castillo, L., and DeLuca, H. F.
TITLE:The 24-hydroxylation of 1,25-dihydroxyvitamin D3 PubMed ID:838723
JOURNAL:J Biol Chem.
VOL:252 PAGE : 1421-1424 (1977)

[0067]
AUTHOR:Mayer, E., Bishop, J. E., Chandraratna, R. A., Okamura, W. H., Kruse, J. R., Popjak, G., Ohnuma, N., and Norman, A. W.
TITLE:Isolation and identification of 1,25-dihydroxy-24-oxo-vitamin D3 and 1,23,25-trihydroxy-24-oxo-vitamin D3. New metabolites of vitamin D3 produced by a C-24 oxidation pathway of metabolism for 1,25-dihydroxyvitamin D3 present in intestine and kidney PubMed ID:6315697
JOURNAL:J Biol Chem.
VOL:258 PAGE : 13458-13465 (1983)

[0068]
AUTHOR:Napoli, J. L., Pramanik, B. C., Royal, P. M., Reinhardt, T. A., and Horst, R. L.
TITLE:Intestinal synthesis of 24-keto-1,25-dihydroxyvitamin D3. A metabolite formed in vivo with high affinity for the vitamin D cytosolic receptor PubMed ID:6307992
JOURNAL:J Biol Chem.
VOL:258 PAGE : 9100-9107 (1983)

[0069]
AUTHOR:Reddy, G. S., Tserng, K. Y., Thomas, B. R., Dayal, R., and Norman, A. W.
TITLE:Isolation and identification of 1,23-dihydroxy-24,25,26,27-tetranorvitamin D3, a new metabolite of 1,25-dihydroxyvitamin D3 produced in rat kidney PubMed ID:3828305
JOURNAL:Biochemistry.
VOL:26 PAGE : 324-331 (1987)

[0070]
AUTHOR:Esvelt, R. P., Schnoes, H. K., and DeLuca, H. F.
TITLE:Isolation and characterization of 1 alpha-hydroxy-23-carboxytetranorvitamin D: a major metabolite of 1,25-dihydroxyvitamin D3 PubMed ID:486408
JOURNAL:Biochemistry.
VOL:18 PAGE : 3977-3983 (1979)

[0071]
AUTHOR:Esvelt, R. P.; Fivizzani, M. A.; Parren, H. E.; Schnoes, H. K.; DeLuca, H. F.
TITLE:Synthesis of Calcitroic Acid, a Metabolite of 1a, 25-Dihydroxycholecalciferol.
JOURNAL:J. Org. Chem.
VOL:46 PAGE : 456-458 (1981)

[0072]
AUTHOR:Esvelt, R. P., and De Luca, H. F.
TITLE:Calcitroic acid: biological activity and tissue distribution studies PubMed ID:6261697
JOURNAL:Arch Biochem Biophys.
VOL:206 PAGE : 403-413 (1981)

[0073]
AUTHOR:Reddy, G. S., and Tserng, K. Y.
TITLE:Calcitroic acid, end product of renal metabolism of 1,25-dihydroxyvitamin D3 through C-24 oxidation pathway PubMed ID:2719932
JOURNAL:Biochemistry.
VOL:28 PAGE : 1763-1769 (1989)

[0074]
AUTHOR:DeCosta, B. R.; Makk, N.; Midgley, J. M.; Modi, N. T.; Watt, R. A.; Whalley, W. B.
TITLE:Unsaturated Steroids. Part 12. Synthesis of 1a, 3b-Dihydroxy-24-nor-9,10-secochola-5,7,10(19) trien-23-oic (Calcitroic) Acid and of the Cholic-and 25-Homocholic Acid Analogues.
JOURNAL:J. Chem. Soc. Perkin Trans I
VOL: PAGE : 1331-1336 (1985)

[0075]
AUTHOR:Morisaki, M.; Koizumi, N.; Ikekawa, N.; Takeshita, T.; Ishimoto, S.
TITLE:Synthesis of Active Forms of Vitamin D. Part IX. Synthesis of 1a,24-Dihydroxycholecalciferol.
JOURNAL:J. Chem. Soc. Perkin I
VOL: PAGE : 1421-1424 (1975)

[0076]
AUTHOR:Napoli, J. L., and Horst, R. L.
TITLE:(23S)-1,23,25-Trihydroxycholecalciferol, an intestinal metabolite of 1,25-dihydroxycholecalciferol PubMed ID:6688522
JOURNAL:Biochem J.
VOL:214 PAGE : 261-264 (1983)

[0077]
AUTHOR:Ohnuma, N., Bannai, K., Yamaguchi, H., Hashimoto, Y., and Norman, A. W.
TITLE:Isolation of a new metabolite of vitamin D produced in vivo, 1 alpha,25-dihydroxyvitamin D3-26,23-lactone PubMed ID:6252850
JOURNAL:Arch Biochem Biophys.
VOL:204 PAGE : 387-391 (1980)

[0078]
AUTHOR:Yamamoto, K.; Shimizu, M.; Yamada, S.; Iwata, S.; Hoshino, O.
TITLE:Facile Stereoselective Synthesis of (23S,25R)-1a,25-Dihydroxyvitamin D3 26,23-Lactone, a Major Metabolite of 1a,25-Dihydroxyvitamin D3.
JOURNAL:J. Org. Chem.
VOL:57 PAGE : 33-39 (1992)

[0079]
AUTHOR:Wovkulich, P. M.; Baggiolini, E. G.; Hennessy, B. M.; Uskokovic, M. R.; Mayer, E.; Norman, A. W.
TITLE:Total Synthesis of 1a,25(R)-Dihydroxy Vitamin D3 26,23(S)-Lactone (Calcitriol Lactone), a Natural Metabolite of Vitamin D3.
JOURNAL:J. Org. Chem.
VOL:48 PAGE : 4433-4436 (1983)

[0080]
AUTHOR:Johnson, W. S.; Chan, M. F.
TITLE:A Highly Stereoselective Route to Calcitriol Lactone.
JOURNAL:J. Org. Chem.
VOL:50 PAGE : 2598-2600 (1985)

[0081]
AUTHOR:Hatakeyama, S.; Sugawara, M.; Kawamura, M.; Takano, S.
TITLE:A Practical Convergent Route to (23S,25R)-1a,25-Dihydroxyvitamin D3 26,23-Lactone.
JOURNAL:J. Chem. Soc. Chem. Comm.
VOL: PAGE : 1229-1230 (1992)

[0082]
AUTHOR:Conrow, R. E.
TITLE:A Convergent Route to Calcitriol Lactone via Reductive Cleavage of an Enantiopure Glycidyl Ether.
JOURNAL:Tetrahedron Lett.
VOL:34 PAGE : 5553-5554 (1993)

[0083]
AUTHOR:Ishizuka, S., Kurihara, N., Hakeda, S., Maeda, N., Ikeda, K., Kumegawa, M., and Norman, A. W.
TITLE:1 alpha,25-Dihydroxyvitamin D3[1 alpha,25-(OH)2D3]-26,23-lactone inhibits 1,25-(OH)2D3-mediated fusion of mouse bone marrow mononuclear cells PubMed ID:3396507
JOURNAL:Endocrinology.
VOL:123 PAGE : 781-786 (1988)

[0084]
AUTHOR:Ishizuka, S., and Norman, A. W.
TITLE:Metabolic pathways from 1 alpha,25-dihydroxyvitamin D3 to 1 alpha,25-dihydroxyvitamin D3-26,23-lactone. Stereo-retained and stereo-selective lactonization PubMed ID:3034884
JOURNAL:J Biol Chem.
VOL:262 PAGE : 7165-7170 (1987)

[0085]
AUTHOR:Ishizuka, S.; Ohba, T.; Norman, A. W.; (1988) Vitamin D Molecular, Cellular and Clinical Endocrinology. Proceeding of the Vitamin D Rancho Mirage, California, USA April. 1a,25(OH)2D3-26,23-Lactone is a Major Metabolite of 1a,25(OH)2D3 Under Physiological Conditions. (Norman, A. W.; Schaefer, K.; Grigoleit, H. G.; v.
TITLE:
JOURNAL:
VOL: PAGE : - ()

[0086]
AUTHOR:Partrige, J. J.; Shiuey, S-J.; Chadha, N. K.; Baggiolini, E. G.; Hennessy, B. M.; Uskokovic, M. R.; Napoli, J. L.; Reinhardt, T. A.; Horst, R. L.
TITLE:(25S)-1a,25,26-Trihydroxycholecalciferol, a New Vitamin D3 Metabolite : Synthesis and Absolute Stereochemistry at C(25).
JOURNAL:Helvetica Chimica Acta
VOL:64 PAGE : 2138-2141 (1981)

[0087]
AUTHOR:Tanaka, Y., Schnoes, H. K., Smith, C. M., and DeLuca, H. F.
TITLE:1,25,26-trihydroxyvitamin D3: isolation, identification, and biological activity PubMed ID:6895295
JOURNAL:Arch Biochem Biophys.
VOL:210 PAGE : 104-109 (1981)

[0088]
AUTHOR:Holick, M. F., Schnoes, H. K., DeLuca, H. F., Gray, R. W., Boyle, I. T., and Suda, T.
TITLE:Isolation and identification of 24,25-dihydroxycholecalciferol, a metabolite of vitamin D made in the kidney PubMed ID:4342902
JOURNAL:Biochemistry.
VOL:11 PAGE : 4251-4255 (1972)

[0089]
AUTHOR:Tanaka, Y., DeLuca, H. F., Ikekawa, N., Morisaki, M., and Koizumi, N.
TITLE:Determination of stereochemical configuration of the 24-hydroxyl group of 24,25-dihydroxyvitamin D3 and its biological importance PubMed ID:1190783
JOURNAL:Arch Biochem Biophys.
VOL:170 PAGE : 620-626 (1975)

[0090]
AUTHOR:Takayama, H.; Ohmori, M.; Yamada, S.
TITLE:Facile, Stereoselective Synthesis of (24R)-24,25-Dihydroxyvitamin D3 Using D-Glyceric Acid as A Chiral Synthon.
JOURNAL:Tetrahedron Lett.
VOL:21 PAGE : 5027-5028 (1980)

[0091]
AUTHOR:Lam, H. Y., Schnoes, H. K., DeLuca, H. F., and Chen, T. C.
TITLE:24,25-Dihydroxyvitamin D3. Synthesis and biological activity PubMed ID:4761971
JOURNAL:Biochemistry.
VOL:12 PAGE : 4851-4855 (1973)

[0092]
AUTHOR:Yamada, S., Ino, E., Takayama, H., Horiuchi, N., Shinki, T., Suda, T., Jones, G., and DeLuca, H. F.
TITLE:Differences in the side-chain metabolism of vitamin D3 between chickens and rats PubMed ID:2999764
JOURNAL:Proc Natl Acad Sci U S A.
VOL:82 PAGE : 7485-7489 (1985)

[0093]
AUTHOR:Boyle, I. T., Omdahl, J. L., Gray, R. W., and DeLuca, H. F.
TITLE:The biological activity and metabolism of 24,25-dihydroxyvitamin D 3 PubMed ID:4711602
JOURNAL:J Biol Chem.
VOL:248 PAGE : 4174-4180 (1973)

[0094]
AUTHOR:Holick, M. F., Baxter, L. A., Schraufrogel, P. K., Tavela, T. E., and DeLuca, H. F.
TITLE:Metabolism and biologica PubMed ID:1245479
JOURNAL:J Biol Chem.
VOL:251 PAGE : 397-402 (1976)

[0095]
AUTHOR:Seki, M.; Koizumi, N.; Morisaki, M.; Ikekawa, N.
TITLE:Synthesis of Active Forms of Vitamin D : Synthesis of (24R)- and (24S)-24,25-Dihydroxyvitamin D3.
JOURNAL:Tetrahedron Lett.
VOL:1 PAGE : 15-18 (1975)

[0096]
AUTHOR:Takasaki, Y., Suda, T., Yamada, S., Takayama, H., and Nishii, Y.
TITLE:Isolation, identification, and biological activity of 25-hydroxy-24-oxovitamin D3: a new metabolite of vitamin D3 generated by in vitro incubations with kidney homogenates PubMed ID:7225351
JOURNAL:Biochemistry.
VOL:20 PAGE : 1681-1686 (1981)

[0097]
AUTHOR:Takasaki, Y., Suda, T., Yamada, S., Ohmori, M., Takayama, H., and Nishii, Y.
TITLE:Chemical synthesis, biological activity, and metabolism of 25-hydroxy-24-oxovitamin D3 PubMed ID:7061507
JOURNAL:J Biol Chem.
VOL:257 PAGE : 3732-3738 (1982)

[0098]
AUTHOR:Jones, G., Kung, M., and Kano, K.
TITLE:The isolation and identification of two new metabolites of 25-hydroxyvitamin D3 produced in the kidney PubMed ID:6630213
JOURNAL:J Biol Chem.
VOL:258 PAGE : 12920-12928 (1983)

[0099]
AUTHOR:Horst, R. L., Reinhardt, T. A., Pramanik, B. C., and Napoli, J. L.
TITLE:23-Keto-25-hydroxyvitamin D3: a vitamin D3 metabolite with high affinity for the 1,25-dihydroxyvitamin D specific cytosol receptor PubMed ID:6297543
JOURNAL:Biochemistry.
VOL:22 PAGE : 245-250 (1983)

[0100]
AUTHOR:Wichmann, J. K., Schnoes, H. K., and DeLuca, H. F.
TITLE:23,24,25-Trihydroxyvitamin D3, 24,25,26-trihydroxyvitamin D3, 24-keto-25-hydroxyvitamin D3, and 23-dehydro-25-hydroxyvitamin D3: new in vivo metabolites of vitamin D3 PubMed ID:6275880
JOURNAL:Biochemistry.
VOL:20 PAGE : 7385-7391 (1981)

[0101]
AUTHOR:Takasaki, Y., Horiuchi, N., Takahashi, N., Abe, E., Shinki, T., Suda, T., Yamada, S., Takayama, H., Horikawa, H., Masumura, T., et al.
TITLE:Isolation and identificaton of 25-hydroxy-24-oxocholecalciferol: a metabolite of 25-hydroxycholecalciferol PubMed ID:7417247
JOURNAL:Biochem Biophys Res Commun.
VOL:95 PAGE : 177-181 (1980)

[0102]
AUTHOR:Yamada, S., Ohmori, M., Takayama, H., Takasaki, Y., and Suda, T.
TITLE:Isolation and identification of 1 alpha- and 23-hydroxylated metabolites of 25-hydroxy-24-oxovitamin D3 from in vitro incubates of chick kidney homogenates PubMed ID:6848514
JOURNAL:J Biol Chem.
VOL:258 PAGE : 457-463 (1983)

[0103]
AUTHOR:Yamada, S.; Yamamoto, K.; Ino, E.; Sakaida, K.; Takayama, H.; Shinki, T.; Suda, T.; Iitaka, Y.; Itai, A.
TITLE:Synthesis and Determination of the Stereochemistry of 23,25-Dihydroxy-24-oxovitamin D3, a Major Metabolite of 24(R),25-Dihydroxyvitamin D3.
JOURNAL:Biochemistry
VOL:28 PAGE : 4551-4556 (1989)

[0104]
AUTHOR:Mayer, E., Reddy, G. S., Chandraratna, R. A., Okamura, W. H., Kruse, J. R., Popjak, G., Bishop, J. E., and Norman, A. W.
TITLE:23,25-Dihydroxy-24-oxovitamin D3: a metabolite of vitamin D3 made in the kidney PubMed ID:6849888
JOURNAL:Biochemistry.
VOL:22 PAGE : 1798-1805 (1983)

[0105]
AUTHOR:Jones, G., Kano, K., Yamada, S., Furusawa, T., Takayama, H., and Suda, T.
TITLE:Identification of 24,25,26,27-tetranor-23-hydroxyvitamin D3 as a product of the renal metabolism of 24,25-dihydroxyvitamin D3 PubMed ID:6332645
JOURNAL:Biochemistry.
VOL:23 PAGE : 3749-3754 (1984)

[0106]
AUTHOR:Shimoyamada, A., Tomiyama, S., Shimizu, M., Yamamoto, K., Kunii, S., and Yamada, S.
TITLE:In vivo metabolism of 24R,25-dihydroxyvitamin D3: structure of its major bile metabolite PubMed ID:9219897
JOURNAL:Biochim Biophys Acta.
VOL:1346 PAGE : 147-157 (1997)

[0107]
AUTHOR:Tanaka, Y., Wichmann, J. K., Schnoes, H. K., and DeLuca, H. F.
TITLE:Isolation and identification of 23,25-dihydroxyvitamin D3, an in vivo metabolite of vitamin D3 PubMed ID:6268149
JOURNAL:Biochemistry.
VOL:20 PAGE : 3875-3879 (1981)

[0108]
AUTHOR:Ikewada, N.; Eguchi, T.; Hirano, Y.; Tanaka, Y.; DeLuca, H. F.; Itai, A.; Iitaka, Y.
TITLE:Synthesis and Determination of the Configuration of 23,25-Dihydroxyvitamin D3 ; a New Metabolite of Vitamin D3 ; X-Ray Crystal Structure of a 3,23,25-Triol Precursor.
JOURNAL:J. Chem. Soc. Chem. Comm.
VOL: PAGE : 1157-1159 (1981)

[0109]
AUTHOR:Tanaka, Y., DeLuca, H. F., Schnoes, H. K., Ikekawa, N., and Eguchi, T.
TITLE:23,25-Dihydroxyvitamin D3: a natural precursor in the biosynthesis of 25-hydroxyvitamin D3-26,23-lactone PubMed ID:6975475
JOURNAL:Proc Natl Acad Sci U S A.
VOL:78 PAGE : 4805-4808 (1981)

[0110]
AUTHOR:Napoli, J. L., and Horst, R. L.
TITLE:23, 25, 26-trihydroxycholecalciferol. A 25-hydroxycholecalciferol-26,23-lactone precursor PubMed ID:7126191
JOURNAL:Biochem J.
VOL:206 PAGE : 173-176 (1982)

[0111]
AUTHOR:Wichmann, J. K., DeLuca, H. F., Schnoes, H. K., Horst, R. L., Shepard, R. M., and Jorgensen, N. A.
TITLE:25-Hydroxyvitamin D3 26,23-lactone: a new in vivo metabolite of vitamin D PubMed ID:228698
JOURNAL:Biochemistry.
VOL:18 PAGE : 4775-4780 (1979)

[0112]
AUTHOR:Ishizuka, S., Ishimoto, S., and Norman, A. W.
TITLE:Biological activity assessment of 25-hydroxyvitamin D3-26,23-lactone in the rat PubMed ID:6896189
JOURNAL:FEBS Lett.
VOL:139 PAGE : 267-270 (1982)

[0113]
AUTHOR:Yamada, S.; Nakayama, K.; Takayama, H.
TITLE:Stereoselective Synthesis and Structure Proof of a Metabolite of Vitamin D3, (23S,25R)-25-Hydroxyvitamin D3 26,23-Lactone (Calcidiol Lactone).
JOURNAL:Chem. Pharm. Bull.
VOL:29 PAGE : 2393-2396 (1981)

[0114]
AUTHOR:Eguchi, T.; Takatsuto, S.; Ishiguro, M.; Ikekawa, N.; Tanaka, Y.; DeLuca, H. F.
TITLE:Synthesis and determination of configuration of natural 25-hydroxyvitamin D3 26,23-lactone.
JOURNAL:Proc. Natl. Acad. Sci. U.S.A.
VOL:78 PAGE : 6579-6583 (1981)

[0115]
AUTHOR:Wichmann, J. K.; Porn, H. E.; Fivizzani, M. A.; Schnoes, H. K.; DeLuca, H. F.
TITLE:Synthesis of 25-Hydroxyvitamin D3-26,23-Lactone.
JOURNAL:Tetrahedron Lett.
VOL:21 PAGE : 4667-4670 (1980)

[0116]
AUTHOR:Morris, D. S.; Williams, D. H.; Norris, A. F.
TITLE:Structure and Synthesis of 25-Hydroxycholecalciferol-26,23-lactone, a Metabolite of Vitamin D3.
JOURNAL:J. Chem. Soc. Chem. Comm.
VOL:122 PAGE : 424-425 (1981)

[0117]
AUTHOR:Morris, D. S.; Williams, D. H.; Norris, A. F.
TITLE:Structure and Synthesis of 25-Hydroxycholecalciferol-26,23-lactone, a Metabolite of Vitamin D.
JOURNAL:J. Org. Chem.
VOL:46 PAGE : 3422-3428 (1981)

[0118]
AUTHOR:DeLuca, H. F.; Schnoes, H. K.; (1979) Vitamin D, Basic Research and its Clinical Application. Recent Developments in The Metabolism of Vitamin D., pp445-458, Walter de Gruyter & Co., Berlin New York
TITLE:
JOURNAL:
VOL: PAGE : - ()

[0119]
AUTHOR:Horst, R. L., Reinhardt, T. A., and Williams, D. H.
TITLE:Stereochemistry of naturally-occurring 25-hydroxyvitamin D3-26,23 lactone as determined by radioligand binding analysis and high-performance liquid chromatography PubMed ID:6293494
JOURNAL:Biochem Biophys Res Commun.
VOL:108 PAGE : 541-546 (1982)

[0120]
AUTHOR:Tanaka, Y., Wichmann, J. K., Paaren, H. E., Schnoes, H. K., and DeLuca, H. F.
TITLE:Role of kidney tissue in the production of 25-hydroxyvitamin D3-26,23-lactone and 1 alpha, 25-dihydroxyvitamin D3-26,23-lactone PubMed ID:6935655
JOURNAL:Proc Natl Acad Sci U S A.
VOL:77 PAGE : 6411-6414 (1980)

[0121]
AUTHOR:Wichmann, J. K.; Paaren, H. E.; Fivizzani, M. A.; Schnoes, H. K.; DeLuca, H. F.
TITLE:Synthesis of 25-Hydroxyvitamin D3-26,23-Lactone.
JOURNAL:Tetrshedron Lett.
VOL:21 PAGE : 4667-4670 (1980)

[0122]
AUTHOR:Nishizawa, M.; Yamagishi, T.; Nonaka, G.; Nishioka, I.
TITLE:Synthesis of (23R)-Calcidiol Lactone (25-Hydroxyvitamin D3 26,23-Lactone).
JOURNAL:Chem. Pham. Bull.
VOL:28 PAGE : 2852-2854 (1980)

[0123]
AUTHOR:Yamada, S.; Nakayama, K.; Takayama, H.
TITLE:Stereoselective Synthesis of (25S)-25-Hydroxyvitamin D3 26,23-Lactone.
JOURNAL:Tetrahedron Lett.
VOL:22 PAGE : 2591-2594 (1981)

[0124]
AUTHOR:Yamada, S., Nakayama, K., Takayama, H., Shinki, T., Takasaki, Y., and Suda, T.
TITLE:Isolation, identification, and metabolism of (23S,25R)-25-hydroxyvitamin D3 26,23-lactol. A biosynthetic precursor of (23S,25R)-25-hydroxyvitamin D3 26,23-lactone PubMed ID:6693401
JOURNAL:J Biol Chem.
VOL:259 PAGE : 884-889 (1984)

[0125]
AUTHOR:Yamada, S.; Nakayama, K.; Takayama, H.
TITLE:Stereoselective Synthesis of (23S,25R)-23,25,26-Trihydroxyvitamin D3 26,23-Lactol, Presumed Vitamin D3 Metabolites.
JOURNAL:J. Org. Chem.
VOL:47 PAGE : 4770-4772 (1982)

[0126]
AUTHOR:DeLuca, H. F., Suda, T., Schnoes, H. K., Tanaka, Y., and Holick, M. F.
TITLE:25,26-dihydroxycholecalciferol, a metabolite of vitamin D3 with intestinal calcium transport activity PubMed ID:4319987
JOURNAL:Biochemistry.
VOL:9 PAGE : 4776-4780 (1970)

[0127]
AUTHOR:Ikekawa, N., Koizumi, N., Ohshima, E., Ishizuka, S., Takeshita, T., Tanaka, Y., and DeLuca, H. F.
TITLE:Natural 25,26-dihydroxyvitamin D3 is an epimeric mixture PubMed ID:6577424
JOURNAL:Proc Natl Acad Sci U S A.
VOL:80 PAGE : 5286-5288 (1983)

[0128]
AUTHOR:Lam, H. Y., Schnoes, H. K., and DeLuca, H. F.
TITLE:Synthesis and biological activity of 25xi,26-dihydroxycholecalciferol PubMed ID:1118866
JOURNAL:Steroids.
VOL:25 PAGE : 247-256 (1975)

[0129]
AUTHOR:Koizumi, N.; Iahiguro, M.; Yasuda, M.; Ikekawa, N.
TITLE:Stereoselective Introduction of Hydroxy Groups into the Cholesterol Side Chain. Preparation of (24R)- and (24S)-24,25-Dihydroxy- and (25R)- and (25S)-25,26-Dihydroxyvitamin D3 by Asymmetric Synthesis.
JOURNAL:J. Chem. Soc. Perkin Trans I
VOL: PAGE : 1401-1410 (1983)

[0130]
AUTHOR:Redel, J., Bell, P. A., Bazely, N., Calando, Y., Delbarre, F., and Kodicek, E.
TITLE:The synthesis and biological activity of 25,26-dihydroxy-cholecalciferol, a polar metabolite of vitamin D3 PubMed ID:4371613
JOURNAL:Steroids.
VOL:24 PAGE : 463-476 (1974)

[0131]
AUTHOR:Partrige, J. J.; Shiuey, S-J.; Chadha, N. K.; Baggiolini, E. G.; Blount, J. F.; Uskokovic, M. R.
TITLE:Synthesis and Structure Proof of a Vitamin D3 Metabolite, 25(S),26-Dihydroxycholecalciferol.
JOURNAL:J. Am. Chem. Soc.
VOL:103 PAGE : 1253-1255 (1981)

[0132]
AUTHOR:Barner, R.; Hubscher, J.; Daly, J. J.; Schonholzer, P.
TITLE:Zur Konfiguration des Vitamin D3-Metaboliten 25,26-Dihydroxycholecalciferol : Synthese von (25S,26)-und (25R,26)-Dihydroxycholecalciferol.
JOURNAL:Helvetica Chimica Acta
VOL:64 PAGE : 915-938 (1981)

[0133]
AUTHOR:Wichmann, J., Schnoes, H. K., and DeLuca, H. F.
TITLE:Isolation of identification of 24(R)-hydroxyvitamin D3 from chicks give large doses of vitamin D3 PubMed ID:6263312
JOURNAL:Biochemistry.
VOL:20 PAGE : 2350-2353 (1981)

[0134]
AUTHOR:Tanaka, Y., DeLuca, H. F., Akaiwa, A., Morisaki, M., and Ikekawa, N.
TITLE:Synthesis of 24S and 24R-hydroxy-[24-3H]vitamin D3 and their metabolism in rachitic rats PubMed ID:1015836
JOURNAL:Arch Biochem Biophys.
VOL:177 PAGE : 615-621 (1976)

[0135]
AUTHOR:Ishizuka, S., Ishimoto, S., and Norman, A. W.
TITLE:Isolation and identification of 25-hydroxyvitamin D3-26,23-peroxylactone. A novel in vivo metabolite of vitamin D3 PubMed ID:6294074
JOURNAL:J Biol Chem.
VOL:257 PAGE : 14708-14713 (1982)

[0136]
AUTHOR:Yamada, S., Yamamoto, K., Takayama, H., Hayashi, T., Miyaura, C., Tanaka, H., Abe, E., and Suda, T.
TITLE:Isolation, identification, and chemical synthesis of 8 alpha,25-dihydroxy-9,10-seco-4,6,10(19)-cholestatrien-3-one. A new metabolite of 25-hydroxyvitamin D3 produced by mouse myeloid leukemia cells (M1) PubMed ID:3477540
JOURNAL:J Biol Chem.
VOL:262 PAGE : 12939-12944 (1987)

[0137]
AUTHOR:Hayashi, T., Yamada, S., Miyaura, C., Tanaka, H., Yamamoto, K., Abe, E., Takayama, H., and Suda, T.
TITLE:Phagocytic cells metabolize 25-hydroxyvitamin D3 to 10-oxo-19-nor-25-hydroxyvitamin D3 and a new metabolite, 8 alpha,25-dihydroxy-9,10-seco-4,6,10(19)-cholestatrien-3-one PubMed ID:3595867
JOURNAL:FEBS Lett.
VOL:218 PAGE : 200-204 (1987)

[0138]
AUTHOR:Thierry-Palmer, M., Richardson, K. A., Schnoes, H. K., Yamada, S., and Free, A. L.
TITLE:Identification of 8 alpha,25-dihydroxy-9,10-seco-4,6,10(19)-cholestatrien-3-one as a product of metabolism of 25-hydroxycholecalciferol by liver microsomes PubMed ID:2310195
JOURNAL:Arch Biochem Biophys.
VOL:277 PAGE : 277-282 (1990)

[0139]
AUTHOR:Inhoffen, H. H.; Quinkert, G.; Hess, H. J.; Erdnann, H. M.
TITLE:Studien in der Vitamin D-Reihe XVI.
JOURNAL:Chem. Ber.
VOL:89 PAGE : 2273-2284 (1956)

[0140]
AUTHOR:La Mar, G. N., and Budd, D. L.
TITLE:Elucidation of the solution conformation of the A ring in vitamin D using proton coupling constants and a shift reagent PubMed ID:4547774
JOURNAL:J Am Chem Soc.
VOL:96 PAGE : 7317-7324 (1974)

[0141]
AUTHOR:Verloop, A.; Koevoet, A. L.; Havinga, E.
TITLE:Studies on Vitamin D and Related Compound III.
JOURNAL:RECUEIL
VOL:74 PAGE : 1125-1130 (1955)

[0142]
AUTHOR:Inhoffen, H. H.; Bruckner, K.; Grundel, R.
TITLE:Studien in der Vitamin D-Reihe : Umlagerung des Vitamin D2 zu einem iso-Tachysterin und Partialsynthese eines iso-Vitamin D2.
JOURNAL:Chem. Ber.
VOL:87 PAGE : 1-13 (1954)

[0143]
AUTHOR:Kobayashi, T., Yoshimoto, S., and Yasumura, M.
TITLE:An improved procedure for the isolation of suprasterol2 I and II from a photochemical reaction mixture of ergocalciferol (vitamin D2) PubMed ID:303285
JOURNAL:J Nutr Sci Vitaminol (Tokyo).
VOL:23 PAGE : 291-298 (1977)

[0144]
AUTHOR:Saundersn, C. P.; Hodgkin, D. C.
TITLE:The Crystal Structure of Suprasterol II.
JOURNAL:Tetrahedron Lett.
VOL:16 PAGE : 573-578 (1961)

[0145]
AUTHOR:Werder, F. V. Z.
TITLE:Uber Dihydro-tachysterin.
JOURNAL:Physiol.
VOL:260 PAGE : 119-134 (1939)

[0146]
AUTHOR:Jones, G., Schnoes, H. K., and DeLuca, H. F.
TITLE:Isolation and identification of 1,25-dihydroxyvitamin D2 PubMed ID:1078978
JOURNAL:Biochemistry.
VOL:14 PAGE : 1250-1256 (1975)

[0147]
AUTHOR:Jones, G., Baxter, L. A., DeLuca, H. F., and Schnoes, H. K.
TITLE:Biological activity of 1,25-dihydroxyvitamin D2 in the chick PubMed ID:1252421
JOURNAL:Biochemistry.
VOL:15 PAGE : 713-716 (1976)

[0148]
AUTHOR:Sicinski, R. R.; Tanaka, Y.; Schnoes, H. K.; DeLuca, H. F.
TITLE:Synthesis of 1a,25-Dihydroxyvitamin D2, Its 24 Epimer and Related Isomers, and Their Binding Affinity for the 1,25-Dihydroxyvitamin D3 Receptor.
JOURNAL:Bioorg. Chem.
VOL:13 PAGE : 158-169 (1985)

[0149]
AUTHOR:Jones, G.; Schnoes, H. K.; Levan, L.; DeLuca, H. F.
TITLE:Isolation and Identification of 24-Hydroxyvitamin D2 and 24,25-Dihydroxyvitamin D2. PubMed ID:6970013
JOURNAL:Arch Biochem. Biophys.
VOL:202 PAGE : 450-457 (1980)

[0150]
AUTHOR:Jones, G., Rosenthal, A., Segev, D., Mazur, Y., Frolow, F., Halfon, Y., Rabinovich, D., and Shakked, Z.
TITLE:Isolation and identification of 24,25-dihydroxyvitamin D2 using the perfused rat kidney PubMed ID:311655
JOURNAL:Biochemistry.
VOL:18 PAGE : 1094-1011 (1979)

[0151]
AUTHOR:Jones, G.; Rosenthal, A.; Segev, D.; Mazur, Y.; Frolow, F.; Halfon, Y.; Rabinovich, D.; Shakked, Z.
TITLE:24(R),25-Dihydroxyvitamin D2 Synthesis, Determination of Absolute Configuration by X-Ray Analysis and Identification as a Kidney Metabolite of Vitamin D2.
JOURNAL:Tetrahedron Lett.
VOL:2 PAGE : 177-180 (1979)

[0152]
AUTHOR:Katsumi, K.; Okano, T.; Kobayashi, T.; Miyata, O.; Naito, T.; Ninomiya, I.
TITLE:Synthesis of Diastereomeric 24,25-Dihydroxyvitamin D2 and Separation of Its (24R)-and (24S)-Isomers.
JOURNAL:Chem. Pharm. Bull.
VOL:32 PAGE : 3744-3746 (1984)

[0153]
AUTHOR:Schering AG, Int. Pat. Appl. No. WO 94/00428
TITLE:
JOURNAL:
VOL: PAGE : - ()

[0154]
AUTHOR:LeVan, L. W., Schnoes, H. K., and DeLuca, H. F.
TITLE:Isolation and identification of 25-hydroxyvitamin D2 25-glucuronide: a biliary metabolite of vitamin D2 in the chick PubMed ID:6970592
JOURNAL:Biochemistry.
VOL:20 PAGE : 222-226 (1981)

[0155]
AUTHOR:Reddy, G. S., and Tserng, K. Y.
TITLE:Isolation and identification of 1,24,25-trihydroxyvitamin D2, 1,24,25,28-tetrahydroxyvitamin D2, and 1,24,25,26-tetrahydroxyvitamin D2: new metabolites of 1,25-dihydroxyvitamin D2 produced in rat kidney PubMed ID:3490274
JOURNAL:Biochemistry.
VOL:25 PAGE : 5328-5336 (1986)

[0156]
AUTHOR:Horst, R. L., Reinhardt, T. A., Ramberg, C. F., Koszewski, N. J., and Napoli, J. L.
TITLE:24-Hydroxylation of 1,25-dihydroxyergocalciferol. An unambiguous deactivation process PubMed ID:3013880
JOURNAL:J Biol Chem.
VOL:261 PAGE : 9250-9256 (1986)

[0157]
AUTHOR:Koszewski, N. J., Reinhardt, T. A., Napoli, J. L., Beitz, D. C., and Horst, R. L.
TITLE:24,26-Dihydroxyvitamin D2: a unique physiological metabolite of vitamin D2 PubMed ID:3263145
JOURNAL:Biochemistry.
VOL:27 PAGE : 5785-5790 (1988)

[0158]
AUTHOR:Perlman, K., Kutner, A., Prahl, J., Smith, C., Inaba, M., Schnoes, H. K., and DeLuca, H. F.
TITLE:24-homologated 1,25-dihydroxyvitamin D3 compounds: separation of calcium and cell differentiation activities PubMed ID:2322540
JOURNAL:Biochemistry.
VOL:29 PAGE : 190-196 (1990)

[0159]
AUTHOR:Moriarty, R. M.; Kim, J.; Penmasta, R.
TITLE:A Convenient Synthesis of 1a,25-Dihydroxy-28-norvitamin D2.
JOURNAL:Tetrahedron Lett.
VOL:33 PAGE : 3741-3744 (1992)

[0160]
AUTHOR:Sai, H., Takatsuto, S., and Ikekawa, N.
TITLE:Synthesis and biological activity of 1 alpha-hydroxy-24,24-dimethyl-22E-dehydrovitamin D3 and 1 alpha, 25-dihydroxy-24,24-dimethyl-22E-dehydrovitamin D3 PubMed ID:3006936
JOURNAL:Chem Pharm Bull (Tokyo).
VOL:33 PAGE : 4815-4820 (1985)

[0161]
AUTHOR:Schwarz, K.; Neef, G.; Kirsch, G.; Muller-Fahrnow, A.; Steinmeyer, A.
TITLE:Synthesis of 20-Fluorovitamin D Analogues.
JOURNAL:Tetrahedron
VOL:51 PAGE : 9543-9550 (1995)

[0162]
AUTHOR:Gill, H. S., Londowski, J. M., Corradino, R. A., and Kumar, R.
TITLE:The synthesis and biological activity of 22-fluorovitamin D3: a new vitamin D analog PubMed ID:2821660
JOURNAL:Steroids.
VOL:48 PAGE : 93-108 (1986)

[0163]
AUTHOR:Hirano, Y., Ikekawa, N., Tanaka, Y., and DeLuca, H. F.
TITLE:Synthesis of (22R)- and (22S)-22,25-Dihydroxyvitamin D3 and determination of their biological activity PubMed ID:7318035
JOURNAL:Chem Pharm Bull (Tokyo).
VOL:29 PAGE : 2254-2260 (1981)

[0164]
AUTHOR:Okamura, W. H., Hammond, M. L., Rego, A., Norman, A. W., and Wing, R. M.
TITLE:Studies on vitamin D (calciferol) and its analogues. 12. Structural and synthetic studies of 5,6-trans-vitamin D3 and the stereoisomers of 10,19-dihydrovitamin D3 including dihydrotachysterol3 PubMed ID:195026
JOURNAL:J Org Chem.
VOL:42 PAGE : 2284-2291 (1977)

[0165]
AUTHOR:Berman, E., Luz, Z., Mazur, Y., and Sheves, M.
TITLE:Conformational analysis of vitamin D and analogues. 13C and 1H nuclear magnetic resonance study PubMed ID:198519
JOURNAL:J Org Chem.
VOL:42 PAGE : 3325-3330 (1977)

[0166]
AUTHOR:Barton, D. H., Hesse, R. H., Pechet, M. M., and Rizzardo, E.
TITLE:A convenient synthesis of 1 -hydroxy-vitamin D 3 PubMed ID:4348493
JOURNAL:J Am Chem Soc.
VOL:95 PAGE : 2748-2749 (1973)

[0167]
AUTHOR:Harrison, R. G., Lythgoe, B., and Wright, P. W.
TITLE:Calciferol and its relatives. (part)XVIII. Total synthesis of 1alpha-hydroxy vitamin D3 PubMed ID:4376813
JOURNAL:J Chem Soc [Perkin 1].
VOL: PAGE : 2654-2657 (1974)

[0168]
AUTHOR:Kaneko, C., Yamada, S., Sugimoto, A., Eguchi, Y., and Ishikawa, M.
TITLE:Synthesis and biological activity of 1alpha-hydroxyvitamin D3 PubMed ID:4813304
JOURNAL:Steroids.
VOL:23 PAGE : 75-92 (1974)

[0169]
AUTHOR:Kaneko, C.; Sugimoto, A.; Eguchi, Y.; Yamada, S.; Ishikawa, M.
TITLE:A New Synthetic Method of 1a-Hydroxy-7-dehydrocholecalciferol.
JOURNAL:Tetrahedron
VOL:30 PAGE : 2701-2705 (1974)

[0170]
AUTHOR:Guest, D.; W.; Williams, D. H.
TITLE:A Modified Synthesis of 1a-Hydroxyvitamin D3.
JOURNAL:J. Chem. Soc. Perkin I
VOL: PAGE : 1695-1697 (1979)

[0171]
AUTHOR:Paaren, H. E., Hamer, D. E., Schnoes, H. K., and DeLuca, H. F.
TITLE:Direct C-1 hydroxylation of vitamin D compounds: convenient preparation of 1alpha-hydroxyvitamin D3, 1alpha, 25-dihydroxyvitamin D3, and 1alpha-hydroxyvitamin D2 PubMed ID:209448
JOURNAL:Proc Natl Acad Sci U S A.
VOL:75 PAGE : 2080-2081 (1978)

[0172]
AUTHOR:Holick, M. F., Semmler, E. J., Schnoes, H. K., and DeLuca, H. F.
TITLE:1 -Hydroxy derivative of vitamin D 3: a highly potent analog of 1,25-dihydroxyvitamin D 3 PubMed ID:4348463
JOURNAL:Science.
VOL:180 PAGE : 190-191 (1973)

[0173]
AUTHOR:Lam, H. Y., Schnoes, H. K., and DeLuca, H. F.
TITLE:1alpha-Hydroxyvitamin D2: a potent synthetic analog of vitamin D2 PubMed ID:4549739
JOURNAL:Science.
VOL:186 PAGE : 1038-1040 (1974)

[0174]
AUTHOR:Lam, H. Y., Schnoes, H. K., and DeLuca, H. F.
TITLE:Synthesis of 1alpha-hydroxyergocalciferol PubMed ID:306145
JOURNAL:Steroids.
VOL:30 PAGE : 671-677 (1977)

[0175]
AUTHOR:Parren, H. E.; Mellon, W. S.; Schnoes, H. K.; DeLuca, H. F.
TITLE:Ring A-Stereoisomers of 1-Hydroxyvitamin D3 and Their Relative Binding Affinities for the Intestinal 1a,25-Dihydroxyvitamin D3 Receptor Protein.
JOURNAL:Bioorg. Chem.
VOL:13 PAGE : 62-75 (1985)

[0176]
AUTHOR:Parren, H. E.; Schnoes, H. K.; DeLuca, H. F.
TITLE:Synthesis of 1b-Hydroxyvitamin D3 and 1b,25-Dihydroxyvitamin D3.
JOURNAL:J. Chem. Soc. Chem. Comm.
VOL: PAGE : 890-892 (1977)

[0177]
AUTHOR:Okamura, W. H.; Pirio, M. R.
TITLE:Studies on Vitamin D (Calciferol) and Its Analogs. IX. 1$alpha-Hydroxy-3-epivitamin D3 : Its Synthesis and Conformational Analysis.
JOURNAL:Tetrahedron Lett.
VOL:49 PAGE : 4317-4320 (1975)

[0178]
AUTHOR:Sheves, M., Friedman, N., and Mazur, Y.
TITLE:Conformational equilibria in vitamin D. Synthesis of 1beta-hydroxyvitamin D3 PubMed ID:915580
JOURNAL:J Org Chem.
VOL:42 PAGE : 3597-3599 (1977)

[0179]
AUTHOR:Lam, H. Y., Onisko, B. L., Schnoes, H. K., and DeLuca, H. F.
TITLE:Synthesis and biological activity of 3-deoxy-1alpha-hydroxyvitamin D3 PubMed ID:4370422
JOURNAL:Biochem Biophys Res Commun.
VOL:59 PAGE : 845-849 (1974)

[0180]
AUTHOR:Okamura, W. H., Mitra, M. N., Pirio, M. R., Mourino, A., Carey, S. C., and Norman, A. W.
TITLE:Studies on vitamin D (calciferol) and its analogues. 13. 3-Deoxy-3alpha-methyl-1alpha-hydroxyvitamin D3, 3-deoxy-3alpha-methyl-1alpha,25-dihydroxyvitamin D3, and 1alpha-hydroxy-3-epivitamin D3. Analogues with conformationally biased a rings PubMed ID:632961
JOURNAL:J Org Chem.
VOL:43 PAGE : 574-580 (1978)

[0181]
AUTHOR:Ishida, H.; Shimizu, M.; Yamamoto, K.; Iwasaki, Y.; Yamada, S.; Yamaguchi, K.
TITLE:Synthesis of 1-Alkyl-1,25-dihydroxyvitamin D3.
JOURNAL:J. Org. Chem.
VOL:60 PAGE : 1828-1833 (1995)

[0182]
AUTHOR:Muralidharan, K. R.; de Lera, A. R.; Isaeff, S. D.; Norman, A. W.; Okamura, W. H.
TITLE:Studies on the A-Ring Diastereomers of 1a,25-Dihydroxyvitamin D3.
JOURNAL:J. Org. Chem.
VOL:58 PAGE : 1895-1899 (1993)

[0183]
AUTHOR:Norman, A. W., Bouillon, R., Farach-Carson, M. C., Bishop, J. E., Zhou, L. X., Nemere, I., Zhao, J., Muralidharan, K. R., and Okamura, W. H.
TITLE:Demonstration that 1 beta,25-dihydroxyvitamin D3 is an antagonist of the nongenomic but not genomic biological responses and biological profile of the three A-ring diastereomers of 1 alpha,25-dihydroxyvitamin D3 PubMed ID:8397195
JOURNAL:J Biol Chem.
VOL:268 PAGE : 20022-20030 (1993)

[0184]
AUTHOR:Haussler, M. R.
TITLE:Vitamin D receptors: nature and function PubMed ID:3015172
JOURNAL:Annu Rev Nutr.
VOL:6 PAGE : 527-562 (1986)

[0185]
AUTHOR:Morrison, N. A., Qi, J. C., Tokita, A., Kelly, P. J., Crofts, L., Nguyen, T. V., Sambrook, P. N., and Eisman, J. A.
TITLE:Prediction of bone density from vitamin D receptor alleles PubMed ID:8161378
JOURNAL:Nature.
VOL:367 PAGE : 284-287 (1994)

[0186]
AUTHOR:Suwinska, K.; Kutner, A.
TITLE:Crystal and Molecular Structure of 1,25-Dihydroxycholecalciferol.
JOURNAL:Acta Cryst.
VOL:52 PAGE : 550-554 (1996)

[0187]
AUTHOR:Hogness, T. R.; Sidwell, A. E. Jr.; Zscheile, F. P. Jr.
TITLE:The Absorption Spectra of Compounds Related to The Sterols.
JOURNAL:J. Biol. Chem.
VOL:120 PAGE : 239-257 (1937)

[0188]
AUTHOR:Koch, E. M.; Koch, F. C.
TITLE:Provitamin D Potency of Some Sterol Derivatives.
JOURNAL:J. Biol. Chem.
VOL:116 PAGE : 757-769 (1936)

[0189]
AUTHOR:Bills, C. E.; Honeywell, E. M.
TITLE:Antiricketic Substances. VIII. Studies on Highly Purified Ergosterol and Its esters.
JOURNAL:J. Biol. Chem.
VOL:80 PAGE : 15-23 (1928)

[0190]
AUTHOR:Windaus, A.; Bock, F.
TITLE:Uber das Provitamin aus dem Sterin der Schweineschwarte.
JOURNAL:Z. Physiol. Chem.
VOL:245 PAGE : 168-170 (1937)

[0191]
AUTHOR:Shiuey, S. J.; Partridge, J. J.; Uskokovic, M. R.
TITLE:Triply Convergent Synthesis of 1a,25-Dihydroxy-24(R)-fluorocholecalciferol.
JOURNAL:J. Org. Chem.
VOL:53 PAGE : 1040-1046 (1988)

[0192]
AUTHOR:Kutner, A.; Perlman, K. L.; Lago, A.; Sicinski, R. R.; Schnoes, H. K.; DeLuca, H. F.
TITLE:Novel Convergent Synthesis of Side-Chain-Modified Analogues of 1a,25-Dihydroxycholecalciferol and 1a,25-Dihydroxyergocalciferol.
JOURNAL:J. Org. Chem.
VOL:53 PAGE : 3450-3457 (1988)

[0193]
AUTHOR:Katsumi, K., Okano, T., Ono, Y., Maegaki, E., Nishimura, K., Baba, M., Kobayashi, T., Miyata, O., Naito, T., and Ninomiya, I.
TITLE:Syntheses of 24,25-dihydroxyvitamin D2, 24,25-dihydroxy-22-dehydrovitamin D3, 25-hydroxy-24-oxo-22-dehydrovitamin D3 and 22,24,25-trihydroxyvitamin D3 PubMed ID:3496978
JOURNAL:Chem Pharm Bull (Tokyo).
VOL:35 PAGE : 970-979 (1987)

[0194]
AUTHOR:Sai, H.; Takatsuto, S.; Ikekawa, N.; Tanaka, Y.; Smith, C.; DeLuca, H. F.
TITLE:Synthesis and Biological Activity of (22E,24R)- and (22E,24S)-1a,24-Dihydroxy-22-dehydrovitamin D3. PubMed ID:6529792
JOURNAL:Chem. Pharm. Bull.
VOL:32 PAGE : 3866-3872 (1984)

[0195]
AUTHOR:Sestelo, J. P.; Mascarenas, J. L.; Castedo, L.; Mourino, A.
TITLE:Ultrasonically Induced Conjugate Addition of Iodides to Electron-Deficient Olefins and Its Application to the Synthesis of Side-Chain Analogs of the Hormone 1a,25-Dihydroxyvitamin D3.
JOURNAL:J. Org. Chem.
VOL:58 PAGE : 118-123 (1993)

[0196]
AUTHOR:Sai, H., Takatsuto, S., Ikekawa, N., Tanaka, Y., and DeLuca, H. F.
TITLE:Synthesis of some side-chain homologues of 1 alpha,25-dihydroxyvitamin D3 and investigation of their biological activities PubMed ID:3829179
JOURNAL:Chem Pharm Bull (Tokyo).
VOL:34 PAGE : 4508-4515 (1986)

[0197]
AUTHOR:Taguchi, T.; Namba, R.; Nakazawa, M.; Nakajima, M.; Nakama, Y.; Kobayashi, Y.; Hara, N.; Ikekawa, N.
TITLE:Preparation of Fluorine-Modified 25-Hydroxyvitamin D2 : 28,28,28-Trifluoro-, 26,26,26,27,27,27-Hexafluoro- and 28-Nor-26,26,26,27,27,27-Hexafluoro-25-Hydroxyvitamin D2.
JOURNAL:Tetrahedron Lett.
VOL:29 PAGE : 227-230 (1988)

[0198]
AUTHOR:Sai, H., Takatsuto, S., Hara, N., and Ikekawa, N.
TITLE:Synthesis of 1 alpha,25-dihydroxy-26,27-dimethylvitamin D3, a highly active analogue of 1 alpha,25-dihydroxyvitamin D3 PubMed ID:3839441
JOURNAL:Chem Pharm Bull (Tokyo).
VOL:33 PAGE : 878-881 (1985)

[0199]
AUTHOR:Kobayashi, Y.; Taguchi, T.; Terada, T.; Oshida, J.; Morisaki, M.; Ikekawa, N.
TITLE:Studies on Organic Fluorine Compounds. Part 37. Studies on Steroids. Part 78. Synthesis of 24,24-Difluoro- and 24x-Fluoro-25-hydroxyvitamin D3.
JOURNAL:J. Chem. Soc. Perkin I
VOL: PAGE : 85-91 (1982)

[0200]
AUTHOR:Kobayashi, Y.; Taguchi, T.; Kanuma, N.; Ikekawa, N.; Oshida, J.
TITLE:Synthesis of 26,26,26,27,27,27-Hexafluoro-25-hydroxyvitamin D3.
JOURNAL:J. Chem. Soc. Chem. Comm.
VOL: PAGE : 459-460 (1980)

[0201]
AUTHOR:Kobayashi, Y.; Taguchi, T.; Kanuma, N.; Ikekawa, N.; Oshida, J.
TITLE:Synthesis of 26,26,26-Trifluoro-25-Hydroxy and 27-Nor-26,26,26-Trifluoro-25-Hydroxyvitamin D3.
JOURNAL:Tetrahedron Lett.
VOL:22 PAGE : 4309-4312 (1981)

[0202]
AUTHOR:Taguchi, T.; Mitsuhashi, S.; Yamanouchi, A.; Kobayashi, Y.; Sai, H.; Ikekawa, N.
TITLE:Synthesis of 23,23-Difluoro-25-Hydroxyvitamin D3.
JOURNAL:Tetrahedron Lett.
VOL:25 PAGE : 4933-4936 (1984)

[0203]
AUTHOR:Kubodera, N., Watanabe, H., Kawanishi, T., and Matsumoto, M.
TITLE:Synthetic studies of vitamin D analogues. XI. Synthesis and differentiation-inducing activity of 1 alpha,25-dihydroxy-22-oxavitamin D3 analogues PubMed ID:1327561
JOURNAL:Chem Pharm Bull (Tokyo).
VOL:40 PAGE : 1494-1499 (1992)

[0204]
AUTHOR:Kobayashi, N., Asano, T., Kitahori, J., Shimada, K., Kubodera, N., and Watanabe, H.
TITLE:Production and specificity of anti-22-oxacalcitriol antisera PubMed ID:1394671
JOURNAL:Chem Pharm Bull (Tokyo).
VOL:40 PAGE : 1520-1522 (1992)

[0205]
AUTHOR:Kubodera, N.; Watanabe, H.; Miyamoto, K.; Matsumoto, M.
TITLE:Synthesis and Differentiation-Inducing Activity of 1a,24-Dihydroxy-22-oxavitamin D3 Analogues.
JOURNAL:Bioorg. Med. Chem. Lett.
VOL:3 PAGE : 1869-1872 (1993)

[0206]
AUTHOR:Kubodera, N., Watanabe, H., Miyamoto, K., Matsumoto, M., Matsuoka, S., and Kawanishi, T.
TITLE:Synthetic studies of vitamin D analogues. XVII. Synthesis and differentiation-inducing activity of 1 alpha,24-dihydroxy-22-oxavitamin D3 analogues and their 20(R)-epimers PubMed ID:8221979
JOURNAL:Chem Pharm Bull (Tokyo).
VOL:41 PAGE : 1659-1663 (1993)

[0207]
AUTHOR:Kubodera, N.; Miyamoto, K.; Ochi, K.; Matsunaga, I.
TITLE:Synthetic Studies of Vitamin D Analogues. VII. Synthesis of 20-oxa-21-norvitamin D3 analogues.
JOURNAL:Chem. Pharm. Bull.
VOL:34 PAGE : 2286-2289 (1986)

[0208]
AUTHOR:Murayama, E., Miyamoto, K., Kubodera, N., Mori, T., and Matsunaga, I.
TITLE:Synthetic studies of vitamin D3 analogues. VIII. Synthesis of 22-oxavitamin D3 analogues PubMed ID:3829173
JOURNAL:Chem Pharm Bull (Tokyo).
VOL:34 PAGE : 4410-4413 (1986)

[0209]
AUTHOR:Kubodera, N., Miyamoto, K., Matsumoto, M., Kawanishi, T., Ohkawa, H., and Mori, T.
TITLE:Synthetic studies of vitamin D analogues. X. Synthesis and biological activities of 1 alpha,25-dihydroxy-21-norvitamin D3 PubMed ID:1319286
JOURNAL:Chem Pharm Bull (Tokyo).
VOL:40 PAGE : 648-651 (1992)

[0210]
AUTHOR:Kubodera, N., Miyamoto, K., Akiyama, M., Matsumoto, M., and Mori, T.
TITLE:Synthetic studies of vitamin D analogues. IX. Synthesis and differentiation-inducing activity of 1 alpha,25-dihydroxy-23-oxa-, thia-, and azavitamin D3 PubMed ID:1814615
JOURNAL:Chem Pharm Bull (Tokyo).
VOL:39 PAGE : 3221-3224 (1991)

[0211]
AUTHOR:Murayama, E.; Miyamoto, K.; Ochi, K.; Kubodera, N.
TITLE:Synthesis and Immunoregulating Activity of Vitamin D Analogues Bearing Pregnane Side Chain.
JOURNAL:Bioorg. Med. Chem. Lett.
VOL:2 PAGE : 1289-1292 (1992)

[0212]
AUTHOR:Kubodera, N.; Watanabe, H.; Hatakeyama, S.; Tazumi, K.; Takano S.
TITLE:Synthesis of Postulated Metabolites of 1a,25-Dihydroxy-22-oxavitamin D3.
JOURNAL:Bioorg. Med. Chem. Lett.
VOL:4 PAGE : 753-756 (1994)

[0213]
AUTHOR:Watanabe, H., Hatakeyama, S., Tazumi, K., Takano, S., Masuda, S., Okano, T., Kobayashi, T., and Kubodera, N.
TITLE:Synthetic studies of vitamin D analogs. XXII. Synthesis and antiproliferation activity of putative metabolites of 1 alpha, 25-dihydroxy-22-oxavitamin D3 PubMed ID:8996858
JOURNAL:Chem Pharm Bull (Tokyo).
VOL:44 PAGE : 2280-2286 (1996)

[0214]
AUTHOR:Ono, Y.; Watanabe, H.; Kawase, A.; Kubodera, N.; Okano, T.; Tsugawa, N.; Kobayashi, T.; Hatakeyama, S.
TITLE:Synthesis and Biological Character of 1b-Hydroxylated Vitamin D3 Analogues.
JOURNAL:Bioorg. Med. Chem. Lett.
VOL:4 PAGE : 1523-1526 (1994)

[0215]
AUTHOR:Kawase, A.; Hirata, M.; Endo, K.; Kubodera, N.
TITLE:Synthesis of 1a,25-Dihydroxy-22-thiavitamin D3 and Related Analogs.
JOURNAL:Bioorg. Med. Chem. Lett.
VOL:5 PAGE : 279-282 (1995)

[0216]
AUTHOR:Miyamoto, K., Murayama, E., Ochi, K., Watanabe, H., and Kubodera, N.
TITLE:Synthetic studies of vitamin D analogues. XIV. Synthesis and calcium regulating activity of vitamin D3 analogues bearing a hydroxyalkoxy group at the 2 beta-position PubMed ID:8396500
JOURNAL:Chem Pharm Bull (Tokyo).
VOL:41 PAGE : 1111-1113 (1993)

[0217]
AUTHOR:Ono, Y., Watanabe, H., Shiraishi, A., Takeda, S., Higuchi, Y., Sato, K., Tsugawa, N., Okano, T., Kobayashi, T., and Kubodera, N.
TITLE:Synthetic studies of vitamin D analogs. XXIV. Synthesis of active vitamin D3 analogs substituted at the 2 beta-position and their preventive effects on bone mineral loss in ovariectomized rats PubMed ID:9353890
JOURNAL:Chem Pharm Bull (Tokyo).
VOL:45 PAGE : 1626-1630 (1997)

[0218]
AUTHOR:Watanabe, H.; Akiyama, M.; Kawanishi, T.; Kubodera, N.
TITLE:Synthesis of tritiated 1a,25-dihydroxy-22-oxavitamin D3.
JOURNAL:J. Labelled Compd. Radiopharm.
VOL:36 PAGE : 645-654 (1994)

[0219]
AUTHOR:Watanabe, H., Kawanishi, T., Miyamoto, K., Kubodera, N., Sasahara, K., and Ochi, K.
TITLE:Novel procedure for the preparation of 1 alpha,3 beta-dihydroxy-2 beta-tritiated steroidal compounds PubMed ID:1455462
JOURNAL:Steroids.
VOL:57 PAGE : 444-446 (1992)

[0220]
AUTHOR:Steinmeyer, A., Neef, G., Kirsch, G., Schwarz, K., Rach, P., Haberey, M., and Thieroff-Ekerdt, R.
TITLE:Synthesis and biological activities of 8(14)a-homocalcitriol PubMed ID:1333655
JOURNAL:Steroids.
VOL:57 PAGE : 447-452 (1992)

[0221]
AUTHOR:Wecksler, W. R., and Norman, A. W.
TITLE:Studies on the mode of action of calciferol XXV. 1 alpha,25-dihydroxy-5,6-trans-vitamin D3, the 5E-isomer of 1 alpha,25-dihydroxyvitamin D3 PubMed ID:6246662
JOURNAL:Steroids.
VOL:35 PAGE : 419-425 (1980)

[0222]
AUTHOR:Bouillon, R., Sarandeses, L. A., Allewaert, K., Zhao, J., Mascarenas, J. L., Mourino, A., Vrielynck, S., de Clercq, P., and Vandewalle, M.
TITLE:Biologic activity of dihydroxylated 19-nor-(pre)vitamin D3 PubMed ID:8213251
JOURNAL:J Bone Miner Res.
VOL:8 PAGE : 1009-1015 (1993)

[0223]
AUTHOR:Posner, G. H., Nelson, T. D., Guyton, K. Z., and Kensler, T. W.
TITLE:New vitamin D3 derivatives with unexpected antiproliferative activity: 1-(hydroxymethyl)-25-hydroxyvitamin D3 homologs PubMed ID:1324319
JOURNAL:J Med Chem.
VOL:35 PAGE : 3280-3287 (1992)

[0224]
AUTHOR:Bouillon, R., Allewaert, K., van Leeuwen, J. P., Tan, B. K., Xiang, D. Z., De Clercq, P., Vandewalle, M., Pols, H. A., Bos, M. P., Van Baelen, H., et al.
TITLE:Structure function analysis of vitamin D analogs with C-ring modifications PubMed ID:1310680
JOURNAL:J Biol Chem.
VOL:267 PAGE : 3044-3051 (1992)

[0225]
AUTHOR:Okamura, W. H.; Aurrecoechea, J. M.; Gibbs, R. A.; Norman, A. W.
TITLE:Synthesis and Biological Activity of 9,11-Dehydrovitamin D3 Analogues : Stereoselective Preparation of 6b-Vitamin D Vinylallenes and a Concise Enynol Synthesis for Preparing the A-Ring.
JOURNAL:J. Org. Chem.
VOL:54 PAGE : 4072-4083 (1989)

[0226]
AUTHOR:Norman, A. W., Okamura, W. H., Farach-Carson, M. C., Allewaert, K., Branisteanu, D., Nemere, I., Muralidharan, K. R., and Bouillon, R.
TITLE:Structure-function studies of 1,25-dihydroxyvitamin D3 and the vitamin D endocrine system. 1,25-dihydroxy-pentadeuterio-previtamin D3 (as a 6-s-cis analog) stimulates nongenomic but not genomic biological responses PubMed ID:8390978
JOURNAL:J Biol Chem.
VOL:268 PAGE : 13811-13819 (1993)

[0227]
AUTHOR:Kobayashi, T.; Okano, T.; Tsugawa, N.; Murano, M.; Masuda, S.; Takeuchi, A.; Sato, K.; Nishii, Y.
TITLE:2b-(3-Hydroxypropoxy)-1a,25-dihydroxyvitamin D3 (ED-71), Preventive and Therapeutic Effects on Bone Mineral Loss in Ovbariectomized Rats.
JOURNAL:Bioorg. Med. Chem. Lett.
VOL:3 PAGE : 1815-1819 (1993)

[0228]
AUTHOR:Ostrem, V. K., Lau, W. F., Lee, S. H., Perlman, K., Prahl, J., Schnoes, H. K., and DeLuca, H. F.
TITLE:Induction of monocytic differentiation of HL-60 cells by 1,25-dihydroxyvitamin D analogs PubMed ID:3477545
JOURNAL:J Biol Chem.
VOL:262 PAGE : 14164-14171 (1987)

[0229]
AUTHOR:Napoli, J. L., Fivizzani, M. A., Schnoes, H. K., and DeLuca, H. F.
TITLE:1 alpha-hydroxy-25-fluorovitamin D3: a potent analogue of 1 alpha,25-dihydroxyvitamin D3 PubMed ID:678516
JOURNAL:Biochemistry.
VOL:17 PAGE : 2387-2392 (1978)

[0230]
AUTHOR:Sarandeses, L. A.; Mascarenas, J. L.; Castedo, L.; Mourino, A.
TITLE:Synthesis of 1a,25-Dihydroxy-19-norprevitamin D3.
JOURNAL:Tetrahedron Lett.
VOL:33 PAGE : 5445-5448 (1992)

[0231]
AUTHOR:Curtin, M. L.; Okamura, W. H.
TITLE:1a,25-Dihydroxyprevitamin D3 : Synthesis of the 9,14,19,19,19-Pentadeuterio Derivative and a Kinetic Study of Its [1,7]-Sigmatropic Shift to 1a,25-Dihydroxyvitamin D3.
JOURNAL:J. Amer. Chem. Soc.
VOL:113 PAGE : 6958-6966 (1991)

[0232]
AUTHOR:Morzycki, J. W.; Schnoes, H. K.; DeLuca, H. F.
TITLE:Synthesis of 25-Hydroxyvitamin D2 and Its 24-Epimer.
JOURNAL:J. Org. Chem.
VOL:49 PAGE : 2148-2151 (1984)

[0233]
AUTHOR:U.S.Pat., 3,006,932., (1961), Green. et al.
TITLE:
JOURNAL:
VOL: PAGE : - ()

[0234]
AUTHOR:Tanaka, Y., Sicinski, R. R., DeLuca, H. F., Sai, H., and Ikekawa, N.
TITLE:Unique rearrangement of ergocalciferol side chain in vitro: production of a biologically highly active homologue of 1,25-dihydroxyvitamin D3 PubMed ID:3022793
JOURNAL:Biochemistry.
VOL:25 PAGE : 5512-5518 (1986)

[0235]
AUTHOR:Napoli, J. L., Mellon, W. S., Fivizzani, M. A., Schnoes, H. K., and DeLuca, H. F.
TITLE:Direct chemical synthesis of 1 alpha,25-dihydroxy[26,27-3H]vitamin D3 with high specific activity: its use in receptor studies PubMed ID:6892993
JOURNAL:Biochemistry.
VOL:19 PAGE : 2515-2521 (1980)

[0236]
AUTHOR:Maynard, D. F.; Norman, A. W.; Okamura, W. H.
TITLE:18-Substituted Derivative of Vitamin D : 18-Acetoxy-1a,25-dihydroxyvitamin D3 and Related Analogues.
JOURNAL:J. Org. Chem.
VOL:57 PAGE : 3214-3217 (1992)

[0237]
AUTHOR:Chen, T. C.; Persons, K.; Uskokovic, M. R.; Horst, R. L.; Holick, M. F.
TITLE:An Evaluation of 1,25-Dihydroxyvitamin D3 and analogues on the proliferation and differentiation of cultured human keratinocytes, calcium metabolism and the differentiation of human HL-60 cells.
JOURNAL:J. Nutr. Biochem.
VOL:4 PAGE : 49-57 (1993)

[0238]
AUTHOR:Zhou, J. Y., Norman, A. W., Akashi, M., Chen, D. L., Uskokovic, M. R., Aurrecoechea, J. M., Dauben, W. G., Okamura, W. H., and Koeffler, H. P.
TITLE:Development of a novel 1,25(OH)2-vitamin D3 analog with potent ability to induce HL-60 cell differentiation without modulating calcium metabolism PubMed ID:1648977
JOURNAL:Blood.
VOL:78 PAGE : 75-82 (1991)

[0239]
AUTHOR:Norman, A. W., Zhou, J. Y., Henry, H. L., Uskokovic, M. R., and Koeffler, H. P.
TITLE:Structure-function studies on analogues of 1 alpha,25-dihydroxyvitamin D3: differential effects on leukemic cell growth, differentiation, and intestinal calcium absorption PubMed ID:2208153
JOURNAL:Cancer Res.
VOL:50 PAGE : 6857-6864 (1990)

[0240]
AUTHOR:Allewaert, K., Zhao, X. Y., Zhao, J., Glibert, F., Branisteanu, D., De Clercq, P., Vandewalle, M., and Bouillon, R.
TITLE:Biological evaluation of epoxy analogs of 1 alpha,25-dihydroxyvitamin D3 PubMed ID:8539786
JOURNAL:Steroids.
VOL:60 PAGE : 324-332 (1995)

[0241]
AUTHOR:Sai, H.; Takatsuto, S.; Ikekawa, N.; Tanaka, Y.; Smith, C.; DeLuca, H. F.
TITLE:Synthesis and Biological Activity of (22E, 24R)- and (22E,24S)-1a,24-Dihydroxy-22-dehydrovitamin D3. PubMed ID:6529792
JOURNAL:Chem. Pharm. Bull.
VOL:32 PAGE : 3866-3872 (1984)

[0242]
AUTHOR:Ishizuka, S., Sumitani, K., Hiura, K., Kawata, T., Okawa, M., Hakeda, Y., and Kumegawa, M.
TITLE:Biological activity assessment of 1 alpha,25-dihydroxyvitamin D3-26,23-lactone and its intermediate metabolites in vivo and in vitro PubMed ID:2373050
JOURNAL:Endocrinology.
VOL:127 PAGE : 695-701 (1990)

[0243]
AUTHOR:Zhao, X-y.; De Clercq, P.; Vandewalle, M.; Allewaert, K.; Van Baelen, H.; Bouillon, R.
TITLE:Synthesis and Biological Evaluation of some 25,26-epoxy-1a,24-dihydroxyvitamin D3 Analogues.
JOURNAL:Bioorg. Med. Chem. Lett.
VOL:3 PAGE : 1863-1867 (1993)

[0244]
AUTHOR:Sicinski, R. R.; DeLuca, H. F.; Schnoes, H. K.; Tanaka, Y.; Smith, C. M.
TITLE:D22-Unsaturated Analogs of Vitamin D3 and Their C(1)-Hydroxylated Derivatives.
JOURNAL:Bioorg. Chem.
VOL:15 PAGE : 152-166 (1987)

[0245]
AUTHOR:Ikekawa, N., Eguchi, T., Hara, N., Takatsuto, S., Honda, A., Mori, Y., and Otomo, S.
TITLE:26,27-Diethyl-1 alpha,25-dihydroxyvitamin D3 and 24,24-difluoro-24-homo-1 alpha,25-dihydroxyvitamin D3: highly potent inducer for differentiation of human leukemia cells HL-60 PubMed ID:3435961
JOURNAL:Chem Pharm Bull (Tokyo).
VOL:35 PAGE : 4362-4365 (1987)

[0246]
AUTHOR:Harada, M., Miyahara, T., Miyata, M., Komiyama, H., Sugure, A., Ikemoto, Y., Kondo, S., Takamura, T., Higuchi, S., Otomo, S., et al.
TITLE:Calcium regulating activity of 24a-homo-24,24-difluoro-1 alpha,25-dihydroxyvitamin D3 and 26,27-dimethyl-24,24-difluoro-1 alpha,25-dihydroxyvitamin D3 PubMed ID:8287319
JOURNAL:Calcif Tissue Int.
VOL:53 PAGE : 318-323 (1993)

[0247]
AUTHOR:Inaba, M., Okuno, S., Nishizawa, Y., Yukioka, K., Otani, S., Matsui-Yuasa, I., Morisawa, S., DeLuca, H. F., and Morii, H.
TITLE:Biological activity of fluorinated vitamin D analogs at C-26 and C-27 on human promyelocytic leukemia cells, HL-60 PubMed ID:2823715
JOURNAL:Arch Biochem Biophys.
VOL:258 PAGE : 421-425 (1987)

[0248]
AUTHOR:Morimoto, S., and Kumahara, Y.
TITLE:A patient with psoriasis cured by 1 alpha-hydroxyvitamin D3 PubMed ID:4069059
JOURNAL:Med J Osaka Univ.
VOL:35 PAGE : 51-54 (1985)

[0249]
AUTHOR:Hayashi, T.; Ojima, K.; Konno, K.; Manaka, A.; Yamaguchi, K.; Yamada, S.; Takayama, H.
TITLE:A New Synthesis of 24-Fluoro-1a,25-dihydroxyvitamin D2 and its 24-Epimer, and Determination of the C-24 Configuration.
JOURNAL:Chem. Pharm. Bull.
VOL:40 PAGE : 2932-2936 (1992)

[0250]
AUTHOR:Imae, Y., Manaka, A., Yoshida, N., Ishimi, Y., Shinki, T., Abe, E., Suda, T., Konno, K., Takayama, H., and Yamada, S.
TITLE:Biological activities of 24-fluoro-1 alpha,25-dihydroxyvitamin D-2 and its 24-epimer PubMed ID:8049243
JOURNAL:Biochim Biophys Acta.
VOL:1213 PAGE : 302-308 (1994)

[0251]
AUTHOR:Kondo, F.; Maki, S.; Konno, K.; Takayama, H.
TITLE:The First Synthesis of 24,24-Difluoro-1a-hydroxyvitamin D3 by Means of Radical Deoxygenation of Alcohols.
JOURNAL:Chem. Pharm. Bull.
VOL:44 PAGE : 62-66 (1996)

[0252]
AUTHOR:Yamada, S.; Ohmori, M.; Takayama, H.
TITLE:Synthesis of 24,24-Difluoro-1a,25-dihydroxyvitamin D3.
JOURNAL:Chem. Pharm. Bull.
VOL:27 PAGE : 3196-3198 (1979)

[0253]
AUTHOR:Kabakoff, B. D., Kendrick, N. C., Faber, D., Deluca, H. F., Yamada, S., and Takayama, H.
TITLE:Determination of biological activity of 24,24-difluoro-1,25-dihydroxyvitamin D3 in the chick using a new method for assessing intestinal calcium uptake PubMed ID:6896415
JOURNAL:Arch Biochem Biophys.
VOL:215 PAGE : 582-588 (1982)

[0254]
AUTHOR:Shiina, Y., Abe, E., Miyaura, C., Tanaka, H., Yamada, S., Ohmori, M., Nakayama, K., Takayama, H., Matsunaga, I., Nishii, Y., et al.
TITLE:Biological activity of 24,24-difluoro-1 alpha, 25-dihydroxyvitamin D3 and 1 alpha, 25-dihydroxyvitamin D3-26,23-lactone in inducing differentiation of human myeloid leukemia cells PubMed ID:6572492
JOURNAL:Arch Biochem Biophys.
VOL:220 PAGE : 90-94 (1983)

[0255]
AUTHOR:Koeffler, H. P., Amatruda, T., Ikekawa, N., Kobayashi, Y., and DeLuca, H. F.
TITLE:Induction of macrophage differentiation of human normal and leukemic myeloid stem cells by 1,25-dihydroxyvitamin D3 and its fluorinated analogues PubMed ID:6594194
JOURNAL:Cancer Res.
VOL:44 PAGE : 5624-5628 (1984)

[0256]
AUTHOR:Goff, J. P., Horst, R. L., Littledike, E. T., Boris, A., and Uskokovic, M. R.
TITLE:Bone resorption, renal function and mineral status in cows treated with 1,25-dihydroxycholecalciferol and its 24-fluoro analogues PubMed ID:3761006
JOURNAL:J Nutr.
VOL:116 PAGE : 1500-1510 (1986)

[0257]
AUTHOR:Ando, K.; Kondo, F.; Koike, F.; Takayama, H.
TITLE:An Improved Synthesis of 24,24-Difluoro-1a,25-dihydroxyvitamin D3 from Vitamin D2.
JOURNAL:Chem. Pharm. Bull.
VOL:40 PAGE : 1662-1664 (1992)

[0258]
AUTHOR:Ando, K.; Koike, F.; Kondo, F.; Takayama, H.
TITLE:An Improved Synthesis of 24,24-Difluoro-1a,25-dihydroxyvitamin D3 from Readily Available Vitamin D2.
JOURNAL:Chem. Pharm. Bull.
VOL:43 PAGE : 189-192 (1995)

[0259]
AUTHOR:Konno, K., Ojima, K., Hayashi, T., Tanabe, M., and Takayama, H.
TITLE:Synthesis and biological activity of a 1 alpha,25-dihydroxyvitamin D2 analog bearing an amide group in the side-chain PubMed ID:9023979
JOURNAL:Chem Pharm Bull (Tokyo).
VOL:45 PAGE : 185-188 (1997)

[0260]
AUTHOR:Konno, K.; Maki, S.; Fujishima, T.; Liu, Z. P.; Miura, D.; Chokki, M.; Takayama, H.
TITLE:A Novel and Practical Route to A-ring Enyne Synthon for 1a,25-Dihydroxyvitamin D3 Analogs : Synthesis of A-ring Diastereomers of 1a,25-Dihydroxyvitamin D3 and 2-Methyl-1,25-Dihydroxyvitamin D3.
JOURNAL:Bioorg. Med. Chem. Lett.
VOL:8 PAGE : 151-156 (1998)

[0261]
AUTHOR:Fujishima, T.; Liu, Z.; Miura, D.; Chokki, M.; Ishizuka, S.; Konno, K.; Takayama, H.
TITLE:Synthesis and Biological Activity of 2-Methyl-20-epi Analogues of 1a,25-Dihydroxyvitamin D3.
JOURNAL:Bioorg. Med. Chem. Lett.
VOL:8 PAGE : 2145-2148 (1998)

[0262]
AUTHOR:Kabat, M. M.; Kiegiel, J.; Cohen, N.; Toth, K.; Wovkulich, P. M.; Uskokovic, M. R.
TITLE:Convergent Synthesis of Vitamin D3 Metabolites. Control of the Stereoselectivity in Samarium-Induced Cyclopropanations of Cyclopentenes.
JOURNAL:J. Org. Chem.
VOL:61 PAGE : 118-124 (1996)

[0263]
AUTHOR:Suda, T., DeLuca, H. F., Schnoes, H. K., and Blunt, J. W.
TITLE:The isolation and identification of 25-hydroxyergocalciferol PubMed ID:5307049
JOURNAL:Biochemistry.
VOL:8 PAGE : 3515-3520 (1969)

[0264]
AUTHOR:Jones, G.; Schnoes, H. K.; Levan, L.; DeLuca, H. F.
TITLE:Isolation and Identification of 24-Hydroxyvitamin D2 and 24,25-Dihydroxyvitamin D2. PubMed ID:6970013
JOURNAL:Arch. Biochem. Biophys.
VOL:202 PAGE : 450-457 (1980)

[0265]
AUTHOR:Yamada, S.; Suzuki, T.; Takayama, H.
TITLE:Novel Regioselective C-6 and C-19 Alkylation of Vitamin D3 via Its Sulfur-Dioxide Adducts.
JOURNAL:Tetrahedron Lett.
VOL:22 PAGE : 3085-3088 (1981)

[0266]
AUTHOR:Beckman, M. J., Tadikonda, P., Werner, E., Prahl, J., Yamada, S., and DeLuca, H. F.
TITLE:Human 25-hydroxyvitamin D3-24-hydroxylase, a multicatalytic enzyme PubMed ID:8679605
JOURNAL:Biochemistry.
VOL:35 PAGE : 8465-8472 (1996)

[0267]
AUTHOR:Yamada, S.; Takayama, H.
TITLE:Studies on The Adducts of Sulfur Dioxide with Vitamin D.
JOURNAL:Chem. Lett.
VOL: PAGE : 583-586 (1979)

[0268]
AUTHOR:Takahashi, T.; Yamamoto, R.
TITLE:1969, Studies on the Stability of Vitamin D2 Powder Preparations. III. Structure of a New Isomer of Vitamin D2. PubMed ID:5307139
JOURNAL:Yakugaku Zasshi
VOL:89 PAGE : 919-924 (1969)

[0269]
AUTHOR:
TITLE:
JOURNAL:
VOL: PAGE : - ()

[0270]
AUTHOR:Nagata, A.; Hamma, N.; Katsumata, T.; Sato, R.; Komuro, S.; Iba, K.; Yoshitake, A.; Kiriyama, T.; Okamoto, S.; Nagataki, S.; (1988) Vitamin D Molecular, Cellular and Clinical Endocrinology. Proceeding of the Vitamin D Rancho Mirage, California, USA April. Mechanism of Action of 26,27-Hexafluoro-1,25-(OH)2D3. (Norman, A. W.; Schaefer, K.; Grigoleit, H. G.; v. Herrath, D.; eds), pp141-142, Walter de Gruyter Berlin New York
TITLE:
JOURNAL:
VOL: PAGE : - ()

[0271]
AUTHOR:Lee, N. E., Reddy, G. S., Brown, A. J., and Williard, P. G.
TITLE:Synthesis, stereochemistry, and biological activity of 1alpha,23,25-trihydroxy-24-oxovitamin D3, a major natural metabolite of 1alpha,25-dihydroxyvitamin D3 PubMed ID:9235987
JOURNAL:Biochemistry.
VOL:36 PAGE : 9429-9437 (1997)

[0272]
AUTHOR:Windaus, von A.; Linsert, O.; Luttringhaus, A.; Weidlich, G.
TITLE:Uber das krystallisierte Vitamin D2.
JOURNAL:Ann.
VOL:492 PAGE : 226-241 (1932)

[0273]
AUTHOR:Chen, P. S., Jr., and Bosmann, H. B.
TITLE:Effect Of Vitamins D2 And D3 On Serum Calcium And Phosphorus In Rachitic Chicks PubMed ID:14171311
JOURNAL:J Nutr.
VOL:83 PAGE : 133-139 (1964)

[0274]
AUTHOR:Trinh-Toan.; Ryan, R. C.; Simon, G. L.; Calabrese, J. C.; Dahl, L. F.; DeLuca, H. F.
TITLE:Crystal Structure of 25-Hydroxy-vitamin D3 Monohydrate : A Stereochemical Analysis of Vitamin D Molecules.
JOURNAL:J. Chem. Soc. Perkin Trans II
VOL: PAGE : 393-401 (1977)

[0275]
AUTHOR:Honda, A., Mori, Y., Otomo, S., Ishizuka, S., and Ikekawa, N.
TITLE:Effects of novel 26,27-dialkyl analogs of 1 alpha,25-dihydroxyvitamin D3 on differentiation-inducing activity of human promyelocytic leukemia (HL-60) cells in serum-supplemented or serum-free culture PubMed ID:1645892
JOURNAL:Steroids.
VOL:56 PAGE : 142-147 (1991)

[0276]
AUTHOR:Miyahara, T., Harada, M., Miyata, M., Sugure, A., Ikemoto, Y., Takamura, T., Higuchi, S., Otomo, S., Kozuka, H., and Ikekawa, N.
TITLE:Calcium regulating activity of 26,27-dialkyl analogs of 1 alpha,25-dihydroxyvitamin D3 PubMed ID:1330237
JOURNAL:Calcif Tissue Int.
VOL:51 PAGE : 218-222 (1992)

[0277]
AUTHOR:Eguchi, T., Sai, H., Takatsuto, S., Hara, N., and Ikekawa, N.
TITLE:Synthesis of 26,27-dialkyl analogues of 1 alpha,25-dihydroxyvitamin D3 PubMed ID:3240463
JOURNAL:Chem Pharm Bull (Tokyo).
VOL:36 PAGE : 2303-2311 (1988)

[0278]
AUTHOR:Binderup, L., Latini, S., Binderup, E., Bretting, C., Calverley, M., and Hansen, K.
TITLE:20-epi-vitamin D3 analogues: a novel class of potent regulators of cell growth and immune responses PubMed ID:1656990
JOURNAL:Biochem Pharmacol.
VOL:42 PAGE : 1569-1575 (1991)

[0279]
AUTHOR:Hansen, K.; Hansen, C. M.; (1994) Vitamin D A Pluripotent Steroid Hormone : Structural Studies, Molecular Endocrinology and Clinical Applications. Proceedings of the Ninth Workshop on Vitamin D Orlando, Florida (USA) May 28-June 2. Synthesis and Biological Activity of 20-Hydroxylated Vitamin D Analogues. (Norman, A. W.; Bouillon, R.; Thomasset, M.; eds), pp95-96, Walter de Gruyter Berlin New York
TITLE:
JOURNAL:
VOL: PAGE : - ()

[0280]
AUTHOR:Ishizuka, S., Oshida, J., Tsuruta, H., and Norman, A. W.
TITLE:The stereochemical configuration of the natural 1 alpha,25-dihydroxyvitamin D3-26,23-lactone PubMed ID:2996437
JOURNAL:Arch Biochem Biophys.
VOL:242 PAGE : 82-89 (1985)

[0281]
AUTHOR:Lee, A. S.; Norman, A. W.; Okamura, W. H.
TITLE:3-Deoxy-3-thia-1a,25-dihydroxyvitamin D3 and Its 1b-Epimer : Synthesis and Biological Evaluation.
JOURNAL:J. Org. Chem.
VOL:57 PAGE : 3846-3854 (1992)

[0282]
AUTHOR:Ishizuka, S., and Norman, A. W.
TITLE:The difference of biological activity among four diastereoisomers of 1 alpha,25-dihydroxycholecalciferol-26,23-lactone PubMed ID:3022075
JOURNAL:J Steroid Biochem.
VOL:25 PAGE : 505-510 (1986)

[0283]
AUTHOR:Dauben, W. G.; Ollmann, Jr. R. R.; Funhoff, A. S.; Leung, S. S.; Norman, A. W.; Bishop, J. E.
TITLE:25-Phosphorus Analogs of Vitamin D3.
JOURNAL:Tetrahedron Lett.
VOL:32 PAGE : 4643-4646 (1991)

[0284]
AUTHOR:Calverley, M. J.; Binderup, E.; Binderup, L.; (1991) Gene Regulation, Structure-Function Analysis and Clinical Application. Proceedings of the Eighth Workshop on Vitamin D Paris, France July 5-10. The 20-Epi Modification in The Vitamin D Series : Selective Enhancement of 'Non-Classical' Receptpr-Mediated Effects. (Norman, A. W.; Bouillon, R.; Thomasset, M.; eds), pp163-164, Walter de Gruyter Berlin New York
TITLE:
JOURNAL:
VOL: PAGE : - ()

[0285]
AUTHOR:Bretting, C.; Calverley, M. J.; Binderup, L.; (1991) Gene Regulation, Structure-Function Analysis and Clinical Application. Proceedings of the Eighth Workshop on Vitamin D Paris, France July 5-10. Synthesis and Biological Activity of 1a-Hydroxylated Vitamin D3 Analogues with Hydroxylated Side Chains, Multi-Homologated in The 24- or 24,26,27-Positions. (Norman, A. W.; Bouillon, R.; Thomasset, M.; eds), pp159-160, Walter de Gruyter Berlin
TITLE:
JOURNAL:
VOL: PAGE : - ()

[0286]
AUTHOR:Lythgoe, B.; Moran, T. A.; Nambudiry, M. E. N.; Tideswell, J.; Wright, P. W.
TITLE:Calciferol and its Relatives. Part 22. A Direct Total Synthesis of Vitamin D2 and Vitamin D3.
JOURNAL:J. C. S. Perkin I
VOL: PAGE : 590-595 (1978)

[0287]
AUTHOR:Kobayashi, Y.; Taguchi, T.; Mitsuhashi, S.; Eguchi, T.; Ohshima, E.; Ikekawa, N.
TITLE:Studies on Organic Fluorine Compounds. XXXIX. Studies on Steroids. LXXIX. Synthesis of 1a,25-Dihydroxy-26,26,26,27,27,27-hexafluoro vitamin D3.
JOURNAL:Chem. Pharm. Bull.
VOL:30 PAGE : 4297-4303 (1982)

[0288]
AUTHOR:Binderup, E.; Calverley, M. J.; Binderup, L.; (1991) Gene Regulation, Structure-Function Analysis and Clinical Application. Proceedings of the Eighth Workshop on Vitamin D Paris, France July 5-10. Synthesis and Biological Activity of 1a-hydroxylated Vitamin D Analogues with Poly-unsaturated Side Chains. (Norman, A. W.; Bouillon, R.; Thomasset, M.; eds), pp192-193, Walter de Gruyter Berlin New York
TITLE:
JOURNAL:
VOL: PAGE : - ()

[0289]
AUTHOR:Calverley, M. J.
TITLE:Synthesis of MC 903, A Biologically Active Vitamin D Metabolite Analogue.
JOURNAL:Tetrahedron
VOL:43 PAGE : 4609-4619 (1987)

[0290]
AUTHOR:Askew, F. A.; Bourdillon, R. B.; Bruce, H. M.; Callow, R. K.; Philpot, J. St. L.; Webster, T. A.
TITLE:Crystalline Vitamin D.
JOURNAL:Proc. Roy. Soc. (London)
VOL:109 PAGE : 488-506 (1932)

[0291]
AUTHOR:Wovkulich, P. M.; Barcelos, F.; Batcho, A. D.; Sereno, J. F.; Baggiolini, E. G.; Hennessy, B. M.; Uskokovic, M. R.
TITLE:Stereoselective Total Synthesis of 1a,25S,26-Trihydroxycholecalciferol.
JOURNAL:Tetrahedron
VOL:40 PAGE : 2283-2296 (1984)

[0292]
AUTHOR:Calverley, M. J.; Binderup, L.
TITLE:Synthesis and Biological Evaluation of MC 1357, A New 20-Epi-23-oxa-1a,25-dihydroxy-vitamin D3 Analogue with Potent Non-Classical Effects.
JOURNAL:Bioorg. Med. Chem. Lett.
VOL:3 PAGE : 1845-1848 (1993)

[0293]
AUTHOR:Bretting, C.; Hansen, C. M.; Andersen, N. R.; (1994) Vitamin D A Pluripotent Steroid Hormone : Structural Studies, Molecular Endocrinology and Clinical Applications. Proceedings of the Ninth Workshop on Vitamin D Orlando, Florida (USA) May 28-June 2. Chemistry and Biology of 22,23-Yne Analogs of Calcitriol. (Norman, A. W.; Bouillon, R.; Thomasset, M.; eds), pp73-74, Walter de Gruyter Berlin New York
TITLE:
JOURNAL:
VOL: PAGE : - ()

[0294]
AUTHOR:Wilhelm, F., Dauben, W. G., Kohler, B., Roesle, A., and Norman, A. W.
TITLE:6-Fluoro-vitamin D3: a new antagonist of the biological actions of vitamin D3 and its metabolites which interacts with the intestinal receptor for 1 alpha,25(OH)2-vitamin D3 PubMed ID:6087739
JOURNAL:Arch Biochem Biophys.
VOL:233 PAGE : 127-132 (1984)

[0295]
AUTHOR:Dauben, W. G.; Kohler, B.; Roesle, A.
TITLE:Synthesis of 6-Fluorovitamin D3.
JOURNAL:J, Org, Chem.
VOL:50 PAGE : 2007-2010 (1985)

[0296]
AUTHOR:Paaren, H. E., Fivizzani, M. A., Schnoes, H. K., and De Luca, H. F.
TITLE:1 alpha, 25-difluorovitamin D3: an inert vitamin D analog PubMed ID:6271060
JOURNAL:Arch Biochem Biophys.
VOL:209 PAGE : 579-583 (1981)

[0297]
AUTHOR:Wovkulich, P. M.; Batcho, A. D.; Baggiolini, E. G.; Boris, A.; Truitt, G.; Uskokovic, M. R.; (1985) Vitamin D Chemical, Biochemical and Clinical Update. Proceedings of the Sixth Workshop on Vitamin D Merano, Italy, March. Synthesis of 1a,25S,26-Trihydroxy-D22-cholecalciferol, A Potent Inducer of Cell Differentiation. (Norman, A. W.; Schaefer, K.; Grigoleit, H. G.; v. Herrath, D.;
TITLE:
JOURNAL:
VOL: PAGE : - ()

[0298]
AUTHOR:Halkes, S. J.; Van Vliet, N. P.
TITLE:Investigations on Sterols. XXXV. Synthesis of 25-Hydroxycholecalciferol.
JOURNAL:Recueil
VOL:88 PAGE : 1080-1083 (1969)

[0299]
AUTHOR:Steinmeyer, A.; Haberey, M.; Kirsch, G.; Neef, G.; Schwarz, K.; Thieroff-Ekerdt, R.; Wiesinger, H.; (1994) Vitamin D A Pluripotent Steroid Hormone : Structural Studies, Molecular Endocrinology and Clinical Applications. Proceedings of the Ninth Workshop on Vitamin D Orlando, Florida (USA) May 28-June 2. Synthesis and Biological Activity of 23-Oxa Vitamin D Analogues. (Norman, A. W.; Bouillon, R.; Thomasset, M.; eds), pp93-94, Walter de Gruyter Berlin New York
TITLE:
JOURNAL:
VOL: PAGE : - ()

[0300]
AUTHOR:Neef, G.; Steinmeyer, A.
TITLE:Synthesis of 23-Oxa-Calcitriol Derivatives.
JOURNAL:Tetrahedron Lett.
VOL:32 PAGE : 5073-5076 (1991)

[0301]
AUTHOR:Nakada, M., Tanaka, Y., DeLuca, H. F., Kobayashi, Y., and Ikekawa, N.
TITLE:Biological activities and binding properties of 23,23-difluoro-25-hydroxyvitamin D3 and its 1 alpha-hydroxy derivative PubMed ID:3839644
JOURNAL:Arch Biochem Biophys.
VOL:241 PAGE : 173-178 (1985)

[0302]
AUTHOR:Colston, K. W., Mackay, A. G., James, S. Y., Binderup, L., Chander, S., and Coombes, R. C.
TITLE:EB1089: a new vitamin D analogue that inhibits the growth of breast cancer cells in vivo and in vitro PubMed ID:1472092
JOURNAL:Biochem Pharmacol.
VOL:44 PAGE : 2273-2280 (1992)

[0303]
AUTHOR:Yamada, S.; Ohmori, M.; Takayama, H.
TITLE:Synthesis of 24,24-Difluoro-25-hydroxyvitamin D3.
JOURNAL:Tetrahedron Lett.
VOL:21 PAGE : 1859-1862 (1979)

[0304]
AUTHOR:Perlman, K. L.; Darwish, H. M.; DeLuca, H. F.
TITLE:20-Oxopregnacalciferols : Vitamin D Compounds That Bind The Progesterone Receptor.
JOURNAL:Tetrahedron Lett.
VOL:35 PAGE : 2295-2298 (1994)

[0305]
AUTHOR:Tanaka, Y., Pahuja, D. N., Wichmann, J. K., De Luca, H. F., Kobayashi, Y., Taguchi, T., and Ikekawa, N.
TITLE:25-hydroxy-26, 26,26,27,27,27-hexafluorovitamin D3: biological activity in the rat PubMed ID:7149723
JOURNAL:Arch Biochem Biophys.
VOL:218 PAGE : 134-141 (1982)

[0306]
AUTHOR:Muralidharan, K. R., Rowland-Goldsmith, M., Lee, A. S., Park, G., Norman, A. W., Henry, H. L., and Okamura, W. H.
TITLE:Inhibitors of 25-hydroxyvitamin D3-1alpha-hydroxylase: thiavitamin D analogs and biological evaluation PubMed ID:9366500
JOURNAL:J Steroid Biochem Mol Biol.
VOL:62 PAGE : 73-78 (1997)

[0307]
AUTHOR:Hara, N., Eguchi, T., Ikekawa, N., Ishizuka, S., and Sato, J.
TITLE:Synthesis and biological activity of (22E,25R)- and (22,25S)-22-dehydro- 1 alpha,25-dihydroxy-26-methylvitamin D3 PubMed ID:2163469
JOURNAL:J Steroid Biochem.
VOL:35 PAGE : 655-664 (1990)

[0308]
AUTHOR:Koizumi, T., Nakao, Y., Ishizuka, S., Oshida, J., Hara, N., Ikekawa, N., and Fijita, T.
TITLE:Novel vitamin D3 derivatives, 26-homo-delta 22-dehydro-1 alpha,25(S)-dihydroxyvitamin D3 and 26-homo-delta 22-dehydro-1 alpha,25(R)-dihydroxyvitamin D3: preferential activity in c-myc mRNA production and in induction of phenotypic differentiation of HL-60 cells PubMed ID:2407190
JOURNAL:Arch Biochem Biophys.
VOL:276 PAGE : 310-316 (1990)

[0309]
AUTHOR:Binderup, L., and Bramm, E.
TITLE:Effects of a novel vitamin D analogue MC903 on cell proliferation and differentiation in vitro and on calcium metabolism in vivo PubMed ID:2830885
JOURNAL:Biochem Pharmacol.
VOL:37 PAGE : 889-895 (1988)

[0310]
AUTHOR:Okamura, W. H., Mitra, M. N., Procsal, D. A., and Norman, A. W.
TITLE:Studies on vitamin D and its analogs. VIII. 3-Deoxy-1alpha, 25-dihydroxyvitamin D3, a potent new analog of 1alpha, 25-(OH) 2-D3 PubMed ID:167766
JOURNAL:Biochem Biophys Res Commun.
VOL:65 PAGE : 24-30 (1975)

[0311]
AUTHOR:Gill, H. S., Londowski, J. M., Corradino, R., and Kumar, R.
TITLE:Synthesis, biologic activity, and protein binding characteristics of a new vitamin D analog, 22-hydroxyvitamin D3 PubMed ID:3041108
JOURNAL:J Steroid Biochem.
VOL:28 PAGE : 147-153 (1987)

[0312]
AUTHOR:Gill, H. S., Londowski, J. M., Corradino, R. A., Zinsmeister, A. R., and Kumar, R.
TITLE:The synthesis and biological activity of 25-hydroxy-26,27-dimethylvitamin D3 and 1,25-dihydroxy-26,27-dimethylvitamin D3: highly potent novel analogs of vitamin D3 PubMed ID:3404985
JOURNAL:J Steroid Biochem.
VOL:31 PAGE : 147-160 (1988)

[0313]
AUTHOR:Valles, M. J.; Castedo, L.; Mourino, A.
TITLE:Functionalization of Vitamin D Metabolites at C-18 and Application to The Synthesis of 1a,18,25-Trihydroxyvitamin D3 and 18,25-Dihydroxyvitamin D3.
JOURNAL:Tetrahedron Lett.
VOL:33 PAGE : 1503-1506 (1992)

[0314]
AUTHOR:Maynard, D. F., Trankle, W. G., Norman, A. W., and Okamura, W. H.
TITLE:14-epi stereoisomers of 25-hydroxy- and 1 alpha,25-dihydroxyvitamin D3: synthesis, isomerization to previtamins, and biological studies PubMed ID:8057286
JOURNAL:J Med Chem.
VOL:37 PAGE : 2387-2393 (1994)

[0315]
AUTHOR:Martinez-Perez, J. A.; Sarandeses, L.; Granja, J.; Palenzuela, J. A.; Mourino, A.
TITLE:Design and Synthesis of 1a,25-Dihydroxyvitamin D3 Analogues with Fixed Torsion Angle C(16-17-20-22).
JOURNAL:Tetrahedron Lett.
VOL:39 PAGE : 4725-4728 (1998)

[0316]
AUTHOR:Sala, G. D.; Izzo, I.; De Riccardis, F.; Sodano, G.
TITLE:Synthesis of Calicoferol E and Astrogorgiadiol, Two Marine 9,10-Secosteroids.
JOURNAL:Tetrahedron Lett.
VOL:39 PAGE : 4741-4744 (1998)

[0317]
AUTHOR:Faulkner, D. J.
TITLE:Marine Natural Product.
JOURNAL:Nat. Prod. Rep.
VOL:14 PAGE : 259-302 (1997)

[0318]
AUTHOR:Ochi, M.; Yamada, K.; Kotsuki, H.; Shibata, K.
TITLE:Calicoferols A and B, Two Novel Secosterols Possessing Brine-Shrimp Lethality from the Gorgonian Calicogorgia sp.
JOURNAL:Chem. Lett.
VOL: PAGE : 427-430 (1991)

[0319]
AUTHOR:Fusetani, N.; Nagata, H.; Hirota, H.; Tsuyuki, T.
TITLE:Astrogorgiadiol and Astrogorgin, Inhibitors of Cell Division in Fertilized Starfish Eggs, from a Gorgonian Astrogorgia sp.
JOURNAL:Tetrahedron Lett.
VOL:30 PAGE : 7079-7082 (1989)

[0320]
AUTHOR:Seo, Y., Shin, J., and Song, J. I.
TITLE:New secosteroids from an undescribed gorgonian of the genus Muricella PubMed ID:7595595
JOURNAL:J Nat Prod.
VOL:58 PAGE : 1291-1295 (1995)

[0321]
AUTHOR:Calverley, M. J.; Grue-Sorensen, G.; Bretting, C.; Binderup, L.; (1994) Vitamin D A Pluripotent Steroid Hormone : Structural Studies, Molecular Endocrinology and Clinical Applications. Proceedings of the Ninth Workshop on Vitamin D Orlando, Florida (USA) May 28-June 2. Chemistry and Biology of Highly Active 22-Oxy Analogs of 20-Epi Calcitriol with very low Binding Affinity to the Vitaamin D Receptor. (Norman, A. W.; Bouillon, R.; Thomasset, M.; eds), pp85-86, Walter de Gruyter Berlin New York
TITLE:
JOURNAL:
VOL: PAGE : - ()

[0322]
AUTHOR:Masuda, S., Strugnell, S., Calverley, M. J., Makin, H. L., Kremer, R., and Jones, G.
TITLE:In vitro metabolism of the anti-psoriatic vitamin D analog, calcipotriol, in two cultured human keratinocyte models PubMed ID:8106449
JOURNAL:J Biol Chem.
VOL:269 PAGE : 4794-4803 (1994)

[0323]
AUTHOR:Masuda, S., Byford, V., Kremer, R., Makin, H. L., Kubodera, N., Nishii, Y., Okazaki, A., Okano, T., Kobayashi, T., and Jones, G.
TITLE:In vitro metabolism of the vitamin D analog, 22-oxacalcitriol, using cultured osteosarcoma, hepatoma, and keratinocyte cell lines PubMed ID:8621502
JOURNAL:J Biol Chem.
VOL:271 PAGE : 8700-8708 (1996)

[0324]
AUTHOR:Dilworth, F. J., Calverley, M. J., Makin, H. L., and Jones, G.
TITLE:Increased biological activity of 20-epi-1,25-dihydroxyvitamin D3 is due to reduced catabolism and altered protein binding PubMed ID:8147918
JOURNAL:Biochem Pharmacol.
VOL:47 PAGE : 987-993 (1994)

[0325]
AUTHOR:Schonecker, B., Reichenbacher, M., Gliesing, S., Gonschior, M., Griebenow, S., Scheddin, D., and Mayer, H.
TITLE:Synthesis and biological activities of 2 alpha-chloro-1-epicalcitriol and 1-epicalcitriol PubMed ID:9437792
JOURNAL:Steroids.
VOL:63 PAGE : 28-36 (1998)

[0326]
AUTHOR:Shankar, V. N., Dilworth, F. J., Makin, H. L., Schroeder, N. J., Trafford, D. J., Kissmeyer, A. M., Calverley, M. J., Binderup, E., and Jones, G.
TITLE:Metabolism of the vitamin D analog EB1089 by cultured human cells: redirection of hydroxylation site to distal carbons of the side-chain PubMed ID:9113099
JOURNAL:Biochem Pharmacol.
VOL:53 PAGE : 783-793 (1997)

[0327]
AUTHOR:Kragballe, K., Gjertsen, B. T., De Hoop, D., Karlsmark, T., van de Kerkhof, P. C., Larko, O., Nieboer, C., Roed-Petersen, J., Strand, A., and Tikjob, G.
TITLE:Double-blind, right/left comparison of calcipotriol and betamethasone valerate in treatment of psoriasis vulgaris PubMed ID:1670840
JOURNAL:Lancet.
VOL:337 PAGE : 193-196 (1991)

[0328]
AUTHOR:Zhou, J. Y., Norman, A. W., Chen, D. L., Sun, G. W., Uskokovic, M., and Koeffler, H. P.
TITLE:1,25-Dihydroxy-16-ene-23-yne-vitamin D3 prolongs survival time of leukemic mice PubMed ID:2339131
JOURNAL:Proc Natl Acad Sci U S A.
VOL:87 PAGE : 3929-3932 (1990)

[0329]
AUTHOR:Uskokovic, M. R.; Baggiolini, E.; Batcho, A.; Shiuey, S. J.; Wovkulich, P.; Horst, R. L.; (1988) Vitamin D Molecular, Cellular and Clinical Endocrinology. Proceeding of the Vitamin D Rancho Mirage, California, USA April. Synthesis of 26,27-Hexadeutero and Epimeric 26-Trideutero 1,25-Dihydroxycholecalciferols. (Norman, A. W.; Schaefer, K.; Grigoleit, H. G.; v. Herrath, D.; eds), pp22-24, Walter de Gruyter Berlin New York
TITLE:
JOURNAL:
VOL: PAGE : - ()

[0330]
AUTHOR:Barrack, S. A.; Gibbs, R. A.; Okamura, W. H.
TITLE:Potential Inhibitors of Vitamin D Metabolism : An Oxa Analogue of Vitamin D.
JOURNAL:J. Org. Chem.
VOL:53 PAGE : 1790-1796 (1988)

[0331]
AUTHOR:Yamada, S.; Suzuki, T.; Takayama, H.; Miyamoto, K.; Matsunaga, I.; Nawata, Y.
TITLE:Stereoselective Synthesis of (5E)- and (5Z)-Vitamin D3 19-Alkanoic Acids via Vitamin D3-Sulfur Dioxide Adducts.
JOURNAL:J. Org. Chem.
VOL:48 PAGE : 3483-3488 (1983)

[0332]
AUTHOR:Yamada, S., Shimizu, M., Fukushima, K., Niimura, K., and Maeda, Y.
TITLE:Syntheses of 24R,25-dihydroxy-[6,19,19-3H]vitamin D3 and 24R,25-dihydroxy-[6,19,19-2H]vitamin D3 PubMed ID:2588294
JOURNAL:Steroids.
VOL:54 PAGE : 145-157 (1989)

[0333]
AUTHOR:Data in papers in preparation : Shimizu, M.; Iwasaki, Y.; Ohno, A.; Yamada, S.; Institute for Medical and Dental Engineering, Tokyo Medical and Dental University.
TITLE:
JOURNAL:
VOL: PAGE : - ()

[0334]
AUTHOR:Shimizu, M.; Iwasaki, Y.; Ishida, H.; Yamada, S.
TITLE:Determination of 25-Hydroxyvitamin D3 in Human Plasma Using a Non-radioactive Tetranorvitamin D Analogue as an Internal Standard. PubMed ID:8590938
JOURNAL:J. Chromat. B
VOL:672 PAGE : 63-71 (1995)

[0335]
AUTHOR:Yamada, S.; Nakayama, K.; Takayama, H.; Itai, A.; Iitaka, Y.
TITLE:Studies of Vitamin D Oxidation. 3. Dye-Sensitized Photooxidation of Vitamin D and Chemical Behavior of Vitamin D 6,19-Epidioxides.
JOURNAL:J. Org. Chem.
VOL:48 PAGE : 3477-3483 (1983)

[0336]
AUTHOR:Moriuchi, S., Tsuruki, F., Otawara, Y., Hosoya, N., Yamada, S., Nakayama, K., and Takayama, H.
TITLE:Biological activity of the endoperoxides derived from vitamin D derivatives by dye-sensitized photo-oxidation PubMed ID:232156
JOURNAL:J Nutr Sci Vitaminol (Tokyo).
VOL:25 PAGE : 455-458 (1979)

[0337]
AUTHOR:Yamada, S.; Nakayama, K.; Takayama, H.
TITLE:Synthesis of 6,19-Epidioxy-9,10-secoergosta-5(10),7,22-trien-3b-ols from Vitamin D Derivatives by Oxidation with singlet Oxygen.
JOURNAL:Tetrahedron Lett.
VOL:49 PAGE : 4895-4898 (1978)

[0338]
AUTHOR:Yamada, S.; Nakayama, K.; Takayama, H.; Itai, A.; Iitaka, Y.
TITLE:Structure of the Endoperoxides derived from Vitamin D Derivatives by Dye Sensitized Photo-oxidation : X-Ray Crystal Structure of 6,19-Epidioxy-9,10-seco-5(10),7,22-ergostatrien-3b-ol Benzoate.
JOURNAL:Chem. Pharm. Bull.
VOL:27 PAGE : 1949-1950 (1979)

[0339]
AUTHOR:Yamada, S., Yamamoto, K., Naito, H., Suzuki, T., Ohmori, M., Takayama, H., Shiina, Y., Miyaura, C., Tanaka, H., Abe, E., et al.
TITLE:Syntheses and differentiating action of vitamin D endoperoxides. Singlet oxygen adducts of vitamin D derivatives in human myeloid leukemia cells (HL-60) PubMed ID:2993611
JOURNAL:J Med Chem.
VOL:28 PAGE : 1148-1153 (1985)

[0340]
AUTHOR:Aberhart, D. J., and Chi-Tung Hsu, A.
TITLE:Studies on the adduct of 4-phenyl-1,2,4-triazoline-3,5-dione with vitamin D3 PubMed ID:180271
JOURNAL:J Org Chem.
VOL:41 PAGE : 2098-2102 (1976)

[0341]
AUTHOR:Reischl, W.; Zbiral, E.
TITLE:Strukturelle Abwandlung am Vitamin D3 via 4-Phenyl-1,2,4-triazolin-3,5-dion-Addukte.
JOURNAL:Ann. Chem.
VOL: PAGE : 745-756 (1978)

[0342]
AUTHOR:Reischl, W.; Altmann, E.; Zbiral, E.
TITLE:Zur gezielten Oxidation der D7-Doppelbindung in den 4-Phenyl-1,2,4-triazolin-3,5-dion-Addekten des Vitamin D3.
JOURNAL:Monatsh. Chem.
VOL:113 PAGE : 427-438 (1982)

[0343]
AUTHOR:Shimizu, M.; Yamazaki, T.; Yamada, S.
TITLE:Fluorescence-Labeling Reaction of Vitamin D Metabolites and Analogs with Fluorescent 1,2,4-Triazoline-3,5-dione (DMEQ-TAD).
JOURNAL:Bioorg. Med. Chem. Lett.
VOL:3 PAGE : 1809-1814 (1993)

[0344]
AUTHOR:Shimizu, M., Kamachi, S., Nishii, Y., and Yamada, S.
TITLE:Synthesis of a reagent for fluorescence-labeling of vitamin D and its use in assaying vitamin D metabolites PubMed ID:1867383
JOURNAL:Anal Biochem.
VOL:194 PAGE : 77-81 (1991)

[0345]
AUTHOR:Shimizu, M.; Iwasaki, Y.; Ohno, A.; Yamada, S.; (1997) Vitamin D Chemistry, Biology and Clinical Applications of the Steroid Hormone. Proceedings of the Tenth Workshop on Vitamin D Strasbourg, France-May. Synthesis of Fluorovitamin D Analogs for Conformational Analysis of Ligand Bound to Vitamin D Receptor. (Norman, A. W.; Bouillon, R.; Thomasset, M.; eds), pp24-25, Printing and Reprographics University of California, Riverside
TITLE:
JOURNAL:
VOL: PAGE : - ()

[0346]
AUTHOR:Iwasaki, Y.; Shimizu, M.; Hirosawa, T.; Yamada, S.
TITLE:Regioselective Synthesis of 19-Fluorovitamin D via Fluorination of Vitamin D-Sulfur Dioxide Adducts.
JOURNAL:Tetrahedron Lett.
VOL:37 PAGE : 6753-6754 (1996)

[0347]
AUTHOR:Perlman, K. L.; Sicinski, R. R.; Schnoes, H. K.; DeLuca, H. F.
TITLE:1a,25-Dihydroxy-19-nor-vitamin D3, A Novel Vitamin D-Related Compound with Potential Therapeutic Activity.
JOURNAL:Tetrahedron Lett.
VOL:31 PAGE : 1823-1824 (1990)

[0348]
AUTHOR:Perlman, K. L.; DeLuca, H. F.
TITLE:1a-Hydroxy-19-nor-vitamin D C-22 Aldehyde. A Valuable Intermediate in the Synthesis of Side Chain Modified 1a,25-Dihydroxy-19-nor-vitamin D3.
JOURNAL:Tetrahedron Lett.
VOL:33 PAGE : 2937-2940 (1992)

[0349]
AUTHOR:Slatopolsky, E.; Stoll, R.; DeLuca, H. F.
TITLE:Biological Activity of 19-Nor(19-Nor-1,25-(OH)2D2):A New Vitamin D Drug for Renal Osteodystrophy.
JOURNAL:?????
VOL: PAGE : 863-865 ()

[0350]
AUTHOR:Mikami, K.; Osaka, A.; Isaka, A.; Sawa, E.; Shimizu, M.; Terada, M.; Kubodera, N.; Nakagawa, K.; Tsugawa, N.; Okano, T.
TITLE:Symmetry in the Synthesis of the A-Ring of a Vitamin D Hybrid Analog with Significant Transactivation Activity: A Combinatorial Sequence of Regioselective Propiolate-Ene, Catalytic Enantioselective Epoxidation and Carbonyl-Ene Cyclization Reactions.
JOURNAL:Tetrahedron Lett.
VOL:39 PAGE : 3359-3362 (1998)

[0351]
AUTHOR:Campbell, M. J., Park, S., Uskokovic, M. R., Dawson, M. I., and Koeffler, H. P.
TITLE:Expression of retinoic acid receptor-beta sensitizes prostate cancer cells to growth inhibition mediated by combinations of retinoids and a 19-nor hexafluoride vitamin D3 analog PubMed ID:9528984
JOURNAL:Endocrinology.
VOL:139 PAGE : 1972-1980 (1998)

[0352]
AUTHOR:Fioravanti, L., Miodini, P., Cappelletti, V., and DiFronzo, G.
TITLE:Synthetic analogs of vitamin D3 have inhibitory effects on breast cancer cell lines PubMed ID:9673393
JOURNAL:Anticancer Res.
VOL:18 PAGE : 1703-1708 (1998)

[0353]
AUTHOR:Sicinski, R. R., Perlman, K. L., and DeLuca, H. F.
TITLE:Synthesis and biological activity of 2-hydroxy and 2-alkoxy analogs of 1 alpha,25-dihydroxy-19-norvitamin D3 PubMed ID:7966133
JOURNAL:J Med Chem.
VOL:37 PAGE : 3730-3738 (1994)

[0354]
AUTHOR:Okano, T., Nakagawa, K., Tsugawa, N., Ozono, K., Kubodera, N., Osawa, A., Terada, M., and Mikami, K.
TITLE:Singly dehydroxylated A-ring analogues of 19-nor-1alpha,25-dihydroxyvitamin D3 and 19-nor-22-oxa-1alpha,25-dihydroxyvitamin D3: novel vitamin D3 analogues with potent transcriptional activity but extremely low affinity for vitamin D receptor PubMed ID:9881643
JOURNAL:Biol Pharm Bull.
VOL:21 PAGE : 1300-1305 (1998)

[0355]
AUTHOR:Sicinski, R. R., Prahl, J. M., Smith, C. M., and DeLuca, H. F.
TITLE:New 1alpha,25-dihydroxy-19-norvitamin D3 compounds of high biological activity: synthesis and biological evaluation of 2-hydroxymethyl, 2-methyl, and 2-methylene analogues PubMed ID:9804706
JOURNAL:J Med Chem.
VOL:41 PAGE : 4662-4674 (1998)

[0356]
AUTHOR:Uskokovic, M. R.; Studzinski, G. P.; Gardner, J. P.; Reddy, S. G.; Campbell, M.. J.; and Koeffller H. P.
TITLE:The 16-Ene Vitamin D Analogs.
JOURNAL:Curr. Pharm. Design
VOL:3 PAGE : 99-123 (1997)

[0357]
AUTHOR:Baggiolini, E. G.; Iacobelli, J. A.; Hennessy, B. M.; Uskokovic, M. R.
TITLE:Stereoselective Total Synthesis of 1a,25-Dihydroxycholecalciferol.
JOURNAL:J. Am. Chem. Soc.
VOL:104 PAGE : 2945-2948 (1982)

[0358]
AUTHOR:Uskokovic, M. R.; Baggiolini, E.; Shiuey, S.-J.; Hennessy, B.; Kiegiel, J.; Daniewski, A. R.; Pizzolato, G.; Courtney, L. F. and Horst, R. L. (1991) The 16-Ene Analogs of 1,25-Dihydroxycholecalciferol. Synthesis and Biological Activity. In Vitamin D Gene Regulation Structure-Function Analysis and Clinical Application (Norman, A.W., Bouillon R. and Thomasset, M., eds), pp 210-213, Walter de Gruyter, Berlin/New York
TITLE:
JOURNAL:
VOL: PAGE : - (1991)

[0359]
AUTHOR:Bouillon, R., Okamura, W. H., and Norman, A. W.
TITLE:Structure-function relationships in the vitamin D endocrine system PubMed ID:7781594
JOURNAL:Endocr Rev.
VOL:16 PAGE : 200-257 (1995)

[0360]
AUTHOR:Onisko, B. L.; Schnoes, H. K.; DeLuca, H. F.
TITLE:Synthesis of Potential Vitamin D Antagonists.
JOURNAL:Tetrahedron Lett.
VOL: PAGE : 1107-1108 (1977)

[0361]
AUTHOR:Havinga, E.; De Kock, R. J.; and Rappoldt, M. P.
TITLE:The Photochemical Interconversions of Provitamin D, Lumisterol, Previtamin D and .
JOURNAL:Tetrahedron
VOL:11 PAGE : 276-284 (1960)

[0362]
AUTHOR:Takahashi, T. and Yamamoto, R.
TITLE:Studies on the Stability of Vitamin D2 Powder Preparations. III. Structure of a New Isomer of Vitamin D2. PubMed ID:5307139
JOURNAL:Yakugaku Zasshi
VOL:89 PAGE : 919-924 (1969)

[0363]
AUTHOR:Yamada, S.; Shiraishi, M.; Ohmori, M. and Takayama, H.
TITLE:Facile and Stereoselective Synthesis of 25-Hydroxyvitamin D2.
JOURNAL:Tetrahedron Lett.
VOL:25 PAGE : 3347-3350 (1984)

[0364]
AUTHOR:Bishop, J. E.; Henry, H. L.; Okamura, W. H.; Koeffler, H. P. and Norman, A. W. (1991) Arocalciferols: A New Class of Side-Chain Analogs of 1,25-(OH)2 D3. In Vitamin D Gene Regulation Structure-Function Analysis and Clinical Application (Norman, A.W., Bouillon R. and Thomasset, M., eds), pp 165-166, Walter de Gruyter, Berlin/New York
TITLE:
JOURNAL:
VOL: PAGE : - (1991)

[0365]
AUTHOR:Nilsson, K.; Valles, M. J.; Castedo, L.; and Mourino, A.
TITLE:Synthesis and Biological Evaluation of 18-Substituted Analogs of 1a,25-Dihydroxyvitamin D3.
JOURNAL:Bioorg. Med. Chem. Lett.
VOL:3 PAGE : 1855-1858 (1993)

[0366]
AUTHOR:De Clercq, P..J.; De Wilde, H.; D'Halleweyn, C.; Zucker, P.; Van Hijfte, L.; Mijngheer, R.; Van Haver, D. and Vandewallle, M. (1991) Total Synthesis of (C-11)-Substituted Analogues of 1,25-Dihydroxyvitamin D3. In Vitamin D Gene Regulation Structure-Function Analysis and Clinical Application (Norman, A.W., Bouillon R. and Thomasset, M., eds), pp 165-166, Walter de Gruyter, Berlin/New York
TITLE:
JOURNAL:
VOL: PAGE : - (1991)

[0367]
AUTHOR:Partridge J. J.; Shiuey, S. J.; Boris, A.;, Mallon, J. and Uskokovic, M. R. Synthesis and biological activity of 24R-hydroxy-25-fluoro-cholecalciferol and 1a,24-dihydroxy-25-fluorocholecalciferol. In Vitamin D, Basic Research and its Clinical Application (Norman, A. W.; Schaefer, K.; v Herrath, D.; et al., eds), pp 445-458, Walter de Gruyter, Berlin/New York
TITLE:
JOURNAL:
VOL: PAGE : - ()

[0368]
AUTHOR:Windaus, A. and Trautmann, G.
TITLE:
JOURNAL:Hoppe-Seyler's Z Physiol. Chem.
VOL:247 PAGE : 185- (1937)

[0369]
AUTHOR:Ruigh, W. L.
TITLE:
JOURNAL:J. Am. Chem. Soc.
VOL:64 PAGE : 1900- (1942)

[0370]
AUTHOR:Linsert, O.
TITLE:
JOURNAL:Hoppe-Seyler's Z Physiol. Chem.
VOL:241 PAGE : 125- (1936)

[0371]
AUTHOR:Wunderlich, W.
TITLE:
JOURNAL:Hoppe-Seyler's Z Physiol. Chem.
VOL:241 PAGE : 116- (1936)

[0372]
AUTHOR:Perlman, K. L.; Swenson, R. E.; Paaren, H. E.; Schnoes, H. K.; DeLuca, H. F.
TITLE:Novel Synthesis of 19-Nor-vitamin D Compounds.
JOURNAL:Tetrahedron Lett.
VOL:32 PAGE : 7663-7666 (1991)

[0373]
AUTHOR:Manabe, K.; Ishizuka, S.; Tanaka, H.; Gao, Q.; Furuya, M.; Tomimori, K.; Sakuma, Y.; and Hazato, A. (1997) Synthesis and Biological Activity of Novel Vitamin D3-Lactone Analogues. In Vitamin D Chemistry, Biology and Clinical Applications of the Steroid Hormone. (Norman, A. W.; Bouillon, R.; Thomasset, M.; eds), pp79-80, Printing and Reprographics University of California, Riverside
TITLE:
JOURNAL:
VOL: PAGE : - (1997)

[0374]
AUTHOR:Scheddin, D., Mayer, H., Schonecker, B., Gliesing, S., and Reichenbacher, M.
TITLE:Synthesis and biological activities of 2 beta-chloro-, 2 beta-fluoro-, and 2 beta-methoxy-1 alpha,25-dihydroxyvitamin D3 PubMed ID:9870260
JOURNAL:Steroids.
VOL:63 PAGE : 633-643 (1998)